PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Borg, JP; Straight, SW; Kaech, SM; de Taddeo-Borg, M; Kroon, DE; Karnak, D; Turner, RS; Kim, SK; Margolis, B				Borg, JP; Straight, SW; Kaech, SM; de Taddeo-Borg, M; Kroon, DE; Karnak, D; Turner, RS; Kim, SK; Margolis, B			Identification of an evolutionarily conserved heterotrimeric protein complex involved in protein targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ELEGANS VULVAR INDUCTION; C-ELEGANS; CAENORHABDITIS-ELEGANS; RECEPTOR LOCALIZATION; DOMAIN; MOTIF; INSULIN; ENCODES; FAMILY	In Caenorhabditis elegans, lin-2, lin-7, and lin-IO genetically interact to control the trafficking of the Let-23 growth factor receptor to the basolateral surface of body epithelia. The human homologue of the lin-10 gene has recently been identified as a member of the X11 gene family. The X11 proteins contain one phosphotyrosine binding (PTB) and two PSD-95.Dlg.ZO-1 (PDZ) domains as well as an extended amino terminus. We have previously shown that the PTB domain of X11 alpha (also known as Mint1) can bind to the amyloid precursor protein (APP) in a phosphotyrosine-independent fashion and can markedly inhibit the processing of APP to the amyloid beta (A beta) peptide. Here, we report that X11 alpha directly binds to the mammalian homologue of Lin-2 (mLin-2), also known as CASK. This binding is mediated by direct interaction between the Calmodulin Kinase II (CKII)-like domain of mLin-2 and the amino terminus of X11 alpha. Furthermore, we can detect direct interactions between mLin-2 and mammalian Lin-7 (mLin-7). In mouse brain, we have identified a heterotrimeric complex that contains mLin-2, mLin-7, and X11 alpha and that is likely important for the localization of proteins in polarized cells. This complex may play an important role in the trafficking and processing of APP in neurons.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, GRECC, Ann Arbor, MI 48105 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University	Margolis, B (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Rm 4570,MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Turner, Raymond Scott/G-2263-2011; Borg, Jean-Paul/AAX-8096-2020	Turner, Raymond Scott/0000-0001-7534-2935; Borg, Jean-Paul/0000-0001-8418-3382	NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG008671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hata Y, 1996, J NEUROSCI, V16, P2488; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; McLoughlin DM, 1996, FEBS LETT, V397, P197; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	30	158	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31633	31636		10.1074/jbc.273.48.31633	http://dx.doi.org/10.1074/jbc.273.48.31633			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822620	hybrid			2022-12-25	WOS:000077207000002
J	Skala, H; Porteu, A; Thomas, M; Szajnert, MF; Okazawa, H; Kahn, A; Phan-Dinh-Tuy, F				Skala, H; Porteu, A; Thomas, M; Szajnert, MF; Okazawa, H; Kahn, A; Phan-Dinh-Tuy, F			Upstream elements involved in vivo in activation of the brain-specific rat aldolase C gene - Role of binding sites for POU and winged helix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BRN-2; NEURON-SPECIFIC ENHANCER; TRANSGENIC MICE; SYNERGISTIC INTERACTIONS; REGIONAL EXPRESSION; REGULATORY ELEMENTS; CHROMATIN STRUCTURE; DOMAIN FAMILY; PROMOTER; MOUSE	The rat aldolase C gene encodes a glycolytic enzyme strongly expressed in adult brain. We previously reported that a 115-base pair (bp) promoter fragment was able to ensure the brain-specific expression of the chloramphenicol acetyltransferase (CAT) reporter gene in transgenic mice, but only at a low level (Thomas, M., Makeh, I., Briand, P., Kahn, A, and Skala, H. (1993) fur. J. Biochem. 218, 143-151). Here we show that in vivo activation of this promoter at a high level requires cooperation between an upstream 0.6-kilobase pair (kb) fragment and far upstream sequences. In the 0.6-kb region, a 28-bp DNA element is shown to include overlapping in vitro binding sites for POU domain regulatory proteins and for the Winged Helix hepatocyte nuclear factor-3 beta factor. An hepatocyte nuclear factor-3 beta-binding site previously described in the short proximal promoter fragment is also shown to interact in vitro with POU proteins, although with a lower affinity than the 28-bp motif. Additional binding sites for POU factors were detected in the upstream 0.6-kb sequences. Progressive deletion in this region resulted in decreased expression levels of the transgenes in mice, suggesting synergistic interactions between these multiple POU-binding sites. We propose that DNA elements characterized by a dual binding specificity for both POU domain and Winged Helix transcription factors could play an essential role in the brain-specific expression of the aldolase C gene and other neuronal genes.	Univ Paris 05, U129, Inst Cochin Genet Mol, INSERM, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Skala, H (corresponding author), Univ Paris 05, U129, Inst Cochin Genet Mol, INSERM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	skala@cochin.inserm.fr						ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Arai Y, 1997, J BIOCHEM-TOKYO, V122, P927, DOI 10.1093/oxfordjournals.jbchem.a021854; ARAI Y, 1994, EUR J BIOCHEM, V221, P253, DOI 10.1111/j.1432-1033.1994.tb18736.x; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BLANCHARD V, 1994, MOL BRAIN RES, V22, P29, DOI 10.1016/0169-328X(94)90029-9; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; BUONO P, 1990, EUR J BIOCHEM, V192, P805, DOI 10.1111/j.1432-1033.1990.tb19294.x; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EISEN T, 1995, ONCOGENE, V11, P2157; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOGAN B, 1996, MANIPULATING MOUSE E, P219; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; Lacorte JM, 1996, BIOCHEM J, V318, P681, DOI 10.1042/bj3180681; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; MAKEH I, 1994, J BIOL CHEM, V269, P4194; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MUKAI T, 1991, BIOCHEM BIOPH RES CO, V174, P1035, DOI 10.1016/0006-291X(91)91523-F; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PIETTE J, 1985, EMBO J, V4, P2675, DOI 10.1002/j.1460-2075.1985.tb03987.x; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POPOVICI T, 1990, FEBS LETT, V268, P189, DOI 10.1016/0014-5793(90)81005-9; Raynal JF, 1998, MOL BRAIN RES, V56, P227, DOI 10.1016/S0169-328X(98)00048-5; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THOMAS M, 1995, J BIOL CHEM, V270, P20316, DOI 10.1074/jbc.270.35.20316; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; THOMPSON RJ, 1982, BRAIN RES, V232, P489, DOI 10.1016/0006-8993(82)90294-3; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walther EU, 1998, P NATL ACAD SCI USA, V95, P2615, DOI 10.1073/pnas.95.5.2615; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	67	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31806	31814		10.1074/jbc.273.48.31806	http://dx.doi.org/10.1074/jbc.273.48.31806			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822647	Green Published, hybrid			2022-12-25	WOS:000077207000029
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			Affinity of yeast nucleotide excision repair factor 2, consisting of the Rad4 and Rad23 proteins, for ultraviolet damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; ESCHERICHIA-COLI; GENE; NUCLEASE; RECONSTITUTION; RECOGNITION; COMPLEX; ENCODES	Saccharomyces cerevisiae Rad4 and Rad23 proteins are required for the nucleotide excision repair of UV light-damaged DNA, Previous studies have indicated that these two DNA repair proteins are associated in a tight complex, which we refer to as nucleotide excision repair factor 2 (NEF2). In a reconstituted nucleotide excision repair reaction, incision of UV-damaged DNA is dependent on NEF2, indicating a role of NEF2 in an early step of the repair process. NEF2 does not, however, possess an enzymatic activity, and its function in the damage-specific incision reaction has not yet been defined, Here we use a DNA mobility shift assay to demonstrate that NEF2 binds specifically to UV-damaged DNA. Elimination of cyclobutane pyrimidine dimers from the UV-damaged DNA by enzymatic photoreactivation has little effect on the affinity of NEF2 far the DNA, suggesting that NEF2 recognizes the 6-(1,2)-dihydro-2-oxo-4-pyrimidinyl)-5 -methyl-5-methyl-2,4-(1H,3H)-pyrimidinedione photoproducts in the damaged DNA. These results highlight the intricacy of the DNA damage-demarcation reaction during nucleotide excision repair in eukaryotes.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech ST, Galveston, TX 77555 USA.		Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA41261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA041261, R01CA041261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; FLEER R, 1987, J BACTERIOL, V169, P4884, DOI 10.1128/jb.169.11.4884-4892.1987; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; MATSUTANI C, 1994, EMBO J, V13, P1831; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mueller JP, 1996, MOL CELL BIOL, V16, P2361; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SPIVAK G, 1988, MUTAT RES, V193, P97, DOI 10.1016/0167-8817(88)90040-5; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	24	101	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31541	31546		10.1074/jbc.273.47.31541	http://dx.doi.org/10.1074/jbc.273.47.31541			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813069	hybrid			2022-12-25	WOS:000077136900097
J	Krieser, RJ; Eastman, A				Krieser, RJ; Eastman, A			The cloning and expression of human deoxyribonuclease II - A possible role in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CALCIUM-DEPENDENT ENDONUCLEASE; HAMSTER OVARY CELLS; INTRACELLULAR ACIDIFICATION; DNA FRAGMENTATION; RAT THYMOCYTES; CATHEPSIN-D; CAENORHABDITIS-ELEGANS; INVOLVEMENT; ACTIVATION	We have previously implicated deoxyribonuclease II (DNase II) as an endonuclease responsible for DNA digestion during apoptosis, The fall-length human cDNA has now been cloned. The cDNA contains an open reading frame of 1078 bases coding for a 40-kDa protein. This protein is 10 kDa larger than commercially supplied enzyme, which has been proteolytically cleaved at an internal aspartate residue. The gene is located at chromosome 19p13.2, and has no significant homology to other human proteins, but has >30% identity to three predicted genes in Caenorhabditis elegans. To determine whether overexpression of DNase II induces apoptosis in Chinese hamster ovary cells, the cDNA was cotransfected with a plasmid encoding green fluorescent protein. Within 24 h, a significant proportion of green fluorescent protein-positive cells contained condensed chromatin, whereas vector-only controls remained viable, Considering that DNase II is normally active only at low pH, it was surprising that transfection induced chromatin condensation. To confirm that transfection was not activating another endonuclease, cells were incubated with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-(O-methyl)-fluoromethylketone; this failed to inhibit chromatin condensation induced by DNase II. These results demonstrate that DNase II acts downstream of caspase activation and that it may be activated by an as yet unknown mechanism to induce DNA digestion during apoptosis.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Eastman, A (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [P30CA023108, R01CA050224, T32CA009658, R55CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108, CA50224, CA09658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZAI N, 1995, BLOOD, V86, P917; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BROOK JD, 1984, HUM GENET, V68, P282, DOI 10.1007/BF00292584; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COHEN JJ, 1984, J IMMUNOL, V132, P38; Eastman A, 1994, Cell Death Differ, V1, P7; ELLIS RE, 1991, GENETICS, V129, P79; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hughes F M Jr, 1994, Cell Death Differ, V1, P11; Hughes FM, 1997, CELL DEATH DIFFER, V4, P200; IMOTO T, 1987, J BIOCHEM-TOKYO, V101, P575, DOI 10.1093/jb/101.3.575; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LIAO TH, 1985, J BIOL CHEM, V260, P708; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; OFFERMANN MK, 1983, BIOCHEM J, V211, P529, DOI 10.1042/bj2110529; Peitsch M C, 1994, Cell Death Differ, V1, P1; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; POLZAR B, 1993, EUR J CELL BIOL, V62, P397; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; Reynolds JE, 1997, INT J ONCOL, V11, P1241; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shiokawa D, 1997, BIOCHEM J, V326, P675, DOI 10.1042/bj3260675; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TANUMA S, 1994, BIOCHEM BIOPH RES CO, V203, P789, DOI 10.1006/bbrc.1994.2252; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TORRIGLIA A, 1995, J BIOL CHEM, V270, P28579, DOI 10.1074/jbc.270.48.28579; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; VORBRODT A, 1974, CELL NUCLEUS, V3, P309; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YANAGISAWASHIOTA F, 1995, ANTICANCER RES, V15, P259; Yasuda T, 1998, J BIOL CHEM, V273, P2610, DOI 10.1074/jbc.273.5.2610; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	47	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30909	30914		10.1074/jbc.273.47.30909	http://dx.doi.org/10.1074/jbc.273.47.30909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812984	hybrid			2022-12-25	WOS:000077136900012
J	Myles, T; Church, FC; Whinna, HC; Monard, D; Stone, SR				Myles, T; Church, FC; Whinna, HC; Monard, D; Stone, SR			Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; PRO-ARG CHLOROMETHYLKETONE; NEXIN PROTEASE NEXIN-1; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; PROTEINASE-INHIBITORS; CRYSTAL-STRUCTURE; C INHIBITOR; SITE; IDENTIFICATION	Site-directed mutagenesis was used to investigate the role of basic residues in the thrombin anion-binding exosite-I during formation of thrombin-antithrombin III (ATIII), thrombin-protease nexin 1 (PN1), and thrombin-heparin cofactor II (HCII) inhibitor complexes, in the absence and presence of glycosaminoglycans, In the absence of glycosaminoglycan, association rate constant (k(on)) values for the inhibition of the mutant thrombins (R35Q, H36Q, R67Q, R73Q, R75Q, R77(a)Q, H81Q, K109Q, K110Q, and K149(e)Q) by ATIII and PN1 were similar to wild-type recombinant thrombin (rIIa), whereas k(on) values were decreased 2-3-fold for HCII against the majority of the exosite-I mutants. The exosite-I mutants did not have a significant effect on heparin-accelerated inhibition by ATIII with maximal k(on) values similar to rIIa, A small effect was seen for PN1/heparin inhibition of the exosite-I mutants R35Q, R67Q, R73Q, R75Q, and R77(a)Q, where k(on) values were decreased 2-4-fold, compared with rIIa, For HCII/heparin, k(on) values far inhibition of the exosite-I mutants (except R67Q, R73Q, and K149(e)Q) were 2-3-fold lower than rIIa. Larger decreases in It,, values for HCII/heparin were found for R67Q and R73Q thrombins with 441- and 14-fold decreases, respectively, whereas K149(e)Q was unchanged. For HCII/dermatan sulfate, R67Q and R73Q had k(on) values reduced 720- and 48-foId, respectively, whereas the remaining mutants were decreased 3-7-fold relative to rIIa, The results suggest that ATIII has no major interaction with exosite-I of thrombin with or without heparin, PN1 bound to heparin uses exosite-I to some extent, possibly by utilizing the positive electrostatic field of exosite-I to enhance orientation and thrombin complex formation. The larger effects of the thrombin exosite-I mutants for HCII inhibition with heparin and dermatan sulfate indicate its need for exosite I, presumably through contact of the "hirudin-like" domain of HCII with exosite-I of thrombin.	Univ Cambridge, Ctr Mrc, Dept Haematol, Cambridge CB2 2QH, England; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Cambridge; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Friedrich Miescher Institute for Biomedical Research	Myles, T (corresponding author), Univ Cambridge, Ctr Mrc, Dept Haematol, Hills Rd, Cambridge CB2 2QH, England.	myles@fmi.ch; fchurch@email.unc.edu			NHLBI NIH HHS [5-T32-HL-07149, HL-32656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007149, R01HL032656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Ciaccia AV, 1997, PROTEIN PEPTIDE LETT, V4, P215; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1989, J BIOL CHEM, V264, P4743; EVANS DL, 1990, NATO ADV SCI I A-LIF, V191, P69; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MYLES T, 1993, THROMB HAEMOSTASIS, V69, P1239; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; RAGG H, 1990, J BIOL CHEM, V265, P5211; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WALLACE A, 1989, BIOCHEM J, V257, P191, DOI 10.1042/bj2570191; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WHINNA HC, 1993, J PROTEIN CHEM, V12, P677, DOI 10.1007/BF01024926	45	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31203	31208		10.1074/jbc.273.47.31203	http://dx.doi.org/10.1074/jbc.273.47.31203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813026	hybrid			2022-12-25	WOS:000077136900054
J	Rindler, MJ				Rindler, MJ			Carboxypeptidase E, a peripheral membrane protein implicated in the targeting of hormones to secretory granules, Co-aggregates with granule content proteins at acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOGRANIN-A; CPE(FAT)/CPE(FAT) MICE; DEPENDENT AGGREGATION; CPE(FAT) MICE; ATT-20 CELLS; E MUTATION; PATHWAY; PROINSULIN; COMPARTMENT; CALCIUM	Carboxypeptidase E (CPE) is a prohormone-processing enzyme and peripheral membrane protein of endocrine/neuroendocrine secretory granules. CPE has been shown to bind to an amino-terminal peptide of pro-opiomelanocortin (N-POMC) at pH 5.5 and hypothesized to be critically involved in the targeting of hormones such as POMC to the regulated secretory pathway [Cool, D. R., Normant, E., Shen, F., Chen, H. C., Pannell, L., Zhang, Y., and Loh, Y. P. (1997) Cell 88, 73-83], To further explore the possibility that CPE serves to mediate the association of content proteins with the membrane during granule biogenesis, the binding of CPE to granule content proteins was investigated using an in vitro aggregation assay in which the selective precipitation of granule content proteins is induced by titration of the pH to <6.0. CPE was observed to co-aggregate efficiently with pituitary and chromaffin granule content proteins at concentrations well below those that promote its self-aggregation. In addition, CPE co-precipitated at pH 5.8 with purified prolactin and with insulin, which homophillically self-aggregate yet are structurally distinct from N-POMC, N-POMC when added to the assays did not inhibit the aggregation of CPE with prolactin or insulin, indicating that these interactions do not involve a binding site for N-POMC. The data show that CPE interacts at acidic pH with a variety of different content proteins, resembling in this regard other granule membrane proteins. The results support the idea that coaggregation of abundant membrane proteins with content proteins is an important general mechanism for the sorting and retention of secretory granule proteins during granule maturation.	NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Rindler, MJ (corresponding author), NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA.				NIDDK NIH HHS [DK44238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; FREEDMAN SD, 1993, EUR J CELL BIOL, V61, P229; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1990, ANAL BIOCHEM, V184, P21, DOI 10.1016/0003-2697(90)90005-T; GORR SU, 1988, BONE MINER, V4, P17; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HENOMATSU N, 1993, EUR J CELL BIOL, V62, P127; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; JACOB M, 1992, BIOCH CELL BIOL, V70, P1005; JAMIESON JD, 1971, J CELL BIOL, V48, P503, DOI 10.1083/jcb.48.3.503; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; MAINS RE, 1988, J BIOL CHEM, V263, P7887; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PALMER DJ, 1992, J BIOL CHEM, V267, P19806; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; VONZASTROW M, 1989, J BIOL CHEM, V264, P6566; WINKLER H, 1993, J ANAT, V183, P237; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1991, J BIOL CHEM, V266, P7740	38	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31180	31185		10.1074/jbc.273.47.31180	http://dx.doi.org/10.1074/jbc.273.47.31180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813022	hybrid			2022-12-25	WOS:000077136900050
J	Missy, K; Van Poucke, V; Raynal, P; Viala, C; Mauco, G; Plantavid, M; Chap, H; Payrastre, B				Missy, K; Van Poucke, V; Raynal, P; Viala, C; Mauco, G; Plantavid, M; Chap, H; Payrastre, B			Lipid products of phosphoinositide 3-kinase interact with rad GTPase and stimulate GDP dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR-1; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACTIVATION; PROTEIN; RHO; KINASE; INVOLVEMENT	A number of reports suggest that under different conditions leading to cytoskeleton reorganization the GTPase Rad and possibly RhoA are downstream targets of phosphoinositide 3-kinase (PI S-kinase). In order to gain more insight into this particular signaling pathway, we have addressed the question of a possible direct interaction of PI 3-kinase products with the Rho family GTPases RhoA, Rad, and Cdc42. Using recombinant proteins, we found that Rad and, to a lesser extent, RhoA but not Cdc42 were capable to selectively bind to phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) in a mixture of crude brain phosphoinositides. Nucleotide-depleted Rad was the most efficient, but the GDP- and GTP-bound forms retained significant PtdIns(3,4,5)P-3 binding activity. This protein-lipid association involved electrostatic as well as hydrophobic interactions, since both phosphate groups located at specific positions of the inositol ring and fatty-acyl chains were absolutely required. Based on the sequence of Rac1, two potential binding sites were identified, one at the C terminus and one in the extra alpha-helical domain. Deletion of these two domains resulted in a complete loss of binding to PI 3-kinase products. Finally, PtdIns(3,4,5)P-3 strongly stimulated GDP dissociation from Rad. in a dose-dependent manner. In agreement, data obtained in intact cells suggest that PtdIns(3,4,5)P-3 might target Rac1 to peculiar membrane domains, allowing formation of specific clusters containing not only small GTPases but other partners bearing pleckstrin homology domains such as specific exchange factors required for Rad and RhoA activation.	Ctr Hosp Univ Toulouse, Hop Purpan, INSERM, Unite Phospholipides Membranaires Signalisat Cell, F-31059 Toulouse, France; Univ Toulouse 3, Inst Fed Rech Immunol Cellulaire & Mol, F-31059 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Payrastre, B (corresponding author), Ctr Hosp Univ Toulouse, Hop Purpan, INSERM, Unite Phospholipides Membranaires Signalisat Cell, F-31059 Toulouse, France.		Mauco, Gerard/A-3164-2016; Raynal, Patrick/O-1926-2018	Mauco, Gerard/0000-0003-2998-2397; Raynal, Patrick/0000-0002-6731-3007; , Bernard/0000-0002-8693-0190				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Gong MC, 1997, MOL BIOL CELL, V8, P279, DOI 10.1091/mbc.8.2.279; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lu PJ, 1997, J BIOL CHEM, V272, P466; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TERUI T, 1994, J BIOL CHEM, V269, P28130; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	43	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30279	30286		10.1074/jbc.273.46.30279	http://dx.doi.org/10.1074/jbc.273.46.30279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804788	hybrid			2022-12-25	WOS:000077008100035
J	Shieh, WM; Ame, JC; Wilson, MV; Wang, ZQ; Koh, DW; Jacobson, MK; Jacobson, EL				Shieh, WM; Ame, JC; Wilson, MV; Wang, ZQ; Koh, DW; Jacobson, MK; Jacobson, EL			Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLISM; MICE; NAD	Poly(ADP-ribose) polymerase (PARP) (EC 2.4.2.30), the only enzyme known to synthesize ADP-ribose polymers from NAD(+), is activated in response to DNA strand breaks and functions in the maintenance of genomic integrity. Mice homozygous for a disrupted gene encoding PARP are viable but have severe sensitivity to gamma-radiation and alkylating agents. We demonstrate here that both 3T3 and primary embryo cells derived from PARP(-/-) mice synthesized ADP-ribose polymers following treatment with the DNA-damaging agent, N-methyl-N'-nitro-N-nitrosoguanidine, despite the fact that no PARP protein was detected in these cells. ADP-ribose polymers isolated from PARP(-/-) cells were indistinguishable from that of PARP(+/+) cells by several criteria. First, they bound to a boronate resin selective for ADP-ribose polymers. Second, treatment of polymers with snake venom phosphodiesterase and alkaline phosphatase yielded ribosyladenosine, a nucleoside diagnostic for the unique ribosyl-ribosyl linkages of ADP-ribose polymers. Third, they were digested by treatment with recombinant poly(ADP-ribose) glycohydrolase, an enzyme highly specific for ADP-ribose polymers, Collectively, these data demonstrate that ADP-ribose polymers are formed in PARP(-/-) cells in a DNA damage-dependent manner. Because the PARP gene has been disrupted, these results suggest the presence of a previously unreported activity capable of synthesizing ADP-ribose polymers in PARP(-/-) cells.	Univ Kentucky, Dept Clin Sci, Lexington, KY 40506 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40506 USA; Univ Kentucky, Coll Pharm, Lexington, KY 40506 USA; Univ Kentucky, Adv Sci & Technol Commercializat Ctr, Lexington, KY 40506 USA; Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon 08, France	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; World Health Organization; International Agency for Research on Cancer (IARC)	Jacobson, EL (corresponding author), Univ Kentucky, Dept Clin Sci, A323A ASTeCC Bldg, Lexington, KY 40506 USA.		Koh, David/AAI-6850-2020	Koh, David/0000-0002-1847-4330	NATIONAL CANCER INSTITUTE [R01CA043894, R01CA065579] Funding Source: NIH RePORTER; NCI NIH HHS [CA43894, CA65579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOULELA N, 1988, ANAL BIOCHEM, V174, P239, DOI 10.1016/0003-2697(88)90541-6; AME JC, 1998, IN PRESS MOL CELL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Jacobson EL, 1997, METHOD ENZYMOL, V280, P221; JACOBSON EL, 1983, J BIOL CHEM, V258, P103; JACOBSON EL, 1998, IN PRESS MOL CELL BI; JACOBSON MK, 1980, CANCER RES, V40, P1797; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Maniatis T., 1982, MOL CLONING LAB MANU, V2; Masutani M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P473; NDUKA N, 1980, EUR J BIOCHEM, V105, P525, DOI 10.1111/j.1432-1033.1980.tb04528.x; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SIMS JL, 1980, ANAL BIOCHEM, V106, P296, DOI 10.1016/0003-2697(80)90524-2; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITACRE CM, 1995, CANCER RES, V55, P3697; WIELCKENS K, 1982, J BIOL CHEM, V257, P2872	22	248	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30069	30072		10.1074/jbc.273.46.30069	http://dx.doi.org/10.1074/jbc.273.46.30069			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804757	hybrid			2022-12-25	WOS:000077008100004
J	Yu, B; Simon, MI				Yu, B; Simon, MI			Interaction of the xanthine nucleotide binding Go alpha mutant with G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; PHOSPHOLIPASE-C; SUBUNITS; CELLS; ACTIVATION; SIGNALS	We constructed a double mutant version of the cu sub unit of Go that was regulated by xanthine nucleotides instead of guanine nucleotides (Go alpha X). We investigated the interaction between Go alpha X and G protein-coupled receptors in vitro, First, we found that the activated ma muscarinic cholinergic receptor (MAChR) could facilitate the exchange of XTP gamma S for XDP in the Go alpha X beta gamma heterotrimer. Second, the Go alpha X beta gamma complex was able to induce the high affinity ligand-binding state in the N-formyl peptide receptor (NFPR). These experiments demonstrated that Goc alpha X was able to interact effectively with G protein-coupled receptors, Third, we found that the empty form of Goc alpha X, lacking a bound nucleotide and beta gamma, formed a stable complex with the m2 muscarinic cholingeric receptor associated with the plasma membrane. Finally, we investigated the interaction of Go alpha X with receptor in COS-7 cells. The empty form of Go alpha X bound tightly to the receptor and was not activated because XTP was not available intracellularly. We tested the ability of Go alpha X to inhibit the activities of several different G protein-coupled receptors in transfected COS-7 cells and found that Go alpha X specifically inhibited Go-coupled receptors. Thus the modified G proteins may act as dominant-negative mutants to trap and inactivate specific subsets of receptors.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Yu, B (corresponding author), CALTECH, Div Biol, 147-75, Pasadena, CA 91125 USA.							ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GRAND RJA, 1996, BIOCHEM J, V313, P356; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P97; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARKER EM, 1991, J BIOL CHEM, V266, P519; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; QUICK MW, 1994, J BIOL CHEM, V269, P30164; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015	21	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30183	30188		10.1074/jbc.273.46.30183	http://dx.doi.org/10.1074/jbc.273.46.30183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804774	Green Accepted, hybrid			2022-12-25	WOS:000077008100021
J	Zhang, ZG; Clawson, A; Rechsteiner, M				Zhang, ZG; Clawson, A; Rechsteiner, M			The proteasome activator 11 S regulator or PA28 - Contribution by both alpha and beta subunits to proteasome activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20-S PROTEASOME; PROTEIN-DEGRADATION; 20S PROTEASOME; REG-ALPHA; THERMOPLASMA-ACIDOPHILUM; MULTICATALYTIC PROTEASE; HOMOLOGOUS SUBUNITS; CELL-CYCLE; UBIQUITIN; PURIFICATION	The proteasome 11 S regulator (REG) consists of two homologous subunits, REG alpha and REG beta. Each subunit is capable of activating the proteasome, and when combined, they form superactive REG alpha/REG beta complexes. We have previously shown that a highly conserved loop in the REG alpha crystal structure is critical for proteasome activation. We now show that hetero-oligomers formed from REG alpha activation loop mutants and wild-type REG beta or vice versa are partially active. By contrast, heterooligomers bearing mutations in the activation loops of REG alpha and REG beta subunits are inactive, demonstrating that both alpha and beta subunits contribute to proteasome activation. We have also characterized REG proteins with mutations near or at their C termini. Partially active REG alpha(Y249C) and REG alpha(M247V) and an inactive REG alpha subunit bearing five additional C-terminal amino acids formed active hetero-oligomers with REG beta. REG beta subunits lacking 1, 2, or 9 C-terminal amino acids did not bind or activate the proteasome, but each of these mutants formed partially active hetero-oligomers with the monomer REG alpha(N50Y). However, hetero-oligomers formed from REG subunits lacking the last 14 amino acids were unable to bind the proteasome. Thus, C-terminal regions of both alpha and beta subunits are required for hetero-oligomers to bind the proteasome.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Rechsteiner, M (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	rechsteiner@medschool.med.Utah.edu			NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; Johnston SC, 1997, PROTEIN SCI, V6, P2469; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; KOPP F, 1995, J MOL BIOL, V248, P264; Kuehn L, 1996, FEBS LETT, V394, P183, DOI 10.1016/0014-5793(96)00946-5; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; MOTT JD, 1994, J BIOL CHEM, V269, P31466; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; Zhang ZG, 1998, J BIOL CHEM, V273, P9501, DOI 10.1074/jbc.273.16.9501; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30660	30668		10.1074/jbc.273.46.30660	http://dx.doi.org/10.1074/jbc.273.46.30660			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804839	hybrid			2022-12-25	WOS:000077008100086
J	Magee, TR; Cai, Y; El-Houseini, ME; Locker, J; Wan, YJY				Magee, TR; Cai, Y; El-Houseini, ME; Locker, J; Wan, YJY			Retinoic acid mediates down-regulation of the alpha-fetoprotein gene through decreased expression of hepatocyte nuclear factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC TRANSCRIPTION; RESPONSE ELEMENT; NEGATIVE REGULATION; PROMOTER ELEMENTS; BINDING PROTEIN; THYROID-HORMONE; MESSENGER-RNA; ALBUMIN GENE; X RECEPTOR; BETA-GENE	alpha-Fetoprotein (AFP), a protein highly induced during fetal liver development, is down-regulated by retinoids in the human hepatoma cell line Hep3B, in contrast to up-regulation observed in other cell types. Previously, we have documented that such up-regulation involves direct effects through cis-retinoid X receptor-binding sites in the AFP enhancer. In this report, we show a distinctive effect of all-trans-retinoic acid (RA) in Hep3B cells. RA caused a marked decrease in AFP transcripts. Deletion analysis of the upstream regulatory region of the AFP gene revealed that cis-acting sites required for down-regulation resided near the promoter. Gel mobility shift assays for factors binding to key elements in the AFP promoter region demonstrated that hepatocyte nuclear factor (HNF) 1 binding was diminished in nuclear extracts from RA-treated cells. In addition, HNF4, which is not known to bind to the AFP promoter but does regulate HNF1, was also diminished. The levels of HNF1 and HNF4 mRNA were also decreased following RA treatment. AFP promoter-chloramphenicol acetyltransferase transient transfection assays demonstrated that the level of HNF1 had a direct impact on basal transcription as well as RA-mediated down-regulation of the AFP gene, and that co-transfection of HNF1 and HNF4, but not transfection of either factor alone, reversed the RA-mediated inhibition. Taken together these data point to an interaction among the RA, HNF1, and HNF4 signals, which is reflected in decreased expression of AFP.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, Torrance, CA 90509 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wan, YJY (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA.	agarose@ucla.edu		El-Houseini, Motawa/0000-0003-4873-8429	NATIONAL CANCER INSTITUTE [R01CA068440, R29CA053596, R01CA053596] Funding Source: NIH RePORTER; NCI NIH HHS [CA53596, CA68440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; BarreraHernandez G, 1996, J BIOL CHEM, V271, P9969, DOI 10.1074/jbc.271.17.9969; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIRMONT A, 1994, CANCER RES, V54, P1319; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEUTSCH HF, 1991, ADV CANCER RES, V56, P253; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HATANO M, 1992, BIOCHEM BIOPH RES CO, V189, P385, DOI 10.1016/0006-291X(92)91570-G; Henriette MF, 1997, FOLIA BIOL-PRAGUE, V43, P5; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hsu SL, 1996, CANCER LETT, V99, P79, DOI 10.1016/0304-3835(95)04040-4; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Li C, 1996, DNA CELL BIOL, V15, P955, DOI 10.1089/dna.1996.15.955; LIU Y, 1994, BIOCHEM BIOPH RES CO, V205, P700, DOI 10.1006/bbrc.1994.2722; LIU Y, 1994, NUCLEIC ACIDS RES, V22, P1079, DOI 10.1093/nar/22.6.1079; LIU Y, 1994, MOL CELL ENDOCRINOL, V103, P149; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCVEY JH, 1993, HUM MOL GENET, V2, P379, DOI 10.1093/hmg/2.4.379; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MIURA N, 1993, NUCLEIC ACIDS RES, V21, P3731, DOI 10.1093/nar/21.16.3731; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NAKAO K, 1990, MOL CELL BIOL, V10, P1461, DOI 10.1128/MCB.10.4.1461; NAKAO K, 1991, BIOCHEM BIOPH RES CO, V174, P1294, DOI 10.1016/0006-291X(91)91562-Q; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Power SC, 1996, MOL CELL BIOL, V16, P778; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395; Zaret Kenneth S., 1994, P53; ZHANG DE, 1991, J BIOL CHEM, V266, P21179; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	60	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30024	30032		10.1074/jbc.273.45.30024	http://dx.doi.org/10.1074/jbc.273.45.30024			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792724	hybrid			2022-12-25	WOS:000076798300101
J	Mazzocchi, G; Rossi, GP; Neri, G; Malendowicz, LK; Albertin, G; Nussdorfer, GG				Mazzocchi, G; Rossi, GP; Neri, G; Malendowicz, LK; Albertin, G; Nussdorfer, GG			11 beta-Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex	FASEB JOURNAL			English	Article						steroidogenesis; cortisone; 11-dehydrocorticosterone; ACTH; angiotensin II; aminoglutethimide; cyanoketone; metyrapone	APPARENT MINERALOCORTICOID EXCESS; MESSENGER-RIBONUCLEIC-ACID; GENE-EXPRESSION; RAT; CELLS; LOCALIZATION; SECRETION; PROTEINS; ENZYMES; TISSUES	Although oxidation of cortisol or corticosterone by 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) represents the physiological mechanism conferring specificity for aldosterone on the mineralocorticoid receptor in mineralocorticoid target tissues, little attention has been paid until now to the expression and activity of this enzyme in human adrenals. We have shown that human adrenal cortex expresses 11 beta-HSD type 2 (11 beta-HSD2) gene, and found a marked 11 beta-HSD2 activity in microsomal preparations obtained from slices of decapsulated normal human adrenal cortices. Under basal conditions, adrenal slices secreted, in addition to cortisol and corticosterone (B), sizeable amounts of cortisone and 11-dehydrocorticosterone (DH-B), the inactive forms to which the former glucocorticoids are converted by 11 beta-HSD. Addition of the 11 beta-HSD inhibitor glycyrrhetinic acid elicited a moderate rise in the production of cortisol and B and suppressed that of cortisone and DH-B. ACTH and angiotensin II evoked a marked rise in the secretion of cortisol and B, but unexpectedly depressed the release of cortisone and DH-B. ACTH also lowered the capacity of adrenal slices to convert [H-3]cortisol to [H-3]cortisone. This last effect of ACTH was concentration-dependently abolished by both aminoglutethimide and cyanoketone, which blocks early steps of steroid synthesis, but not by metyrapone, an inhibitor of 11 beta-hydroxylase. Collectively, these findings indicate that the human adrenal cortex possesses an active 11 beta-HSD2 engaged in the inactivation of newly formed gluco corticoids. The activity of this enzyme is negatively modulated by the main agonists of glucocorticoid secretion through an indirect mechanism, probably involving the rise in the intra-adrenal concentration of non-11 beta-hydroxylated steroid hormones.	Univ Padua, Dept Anat, I-35121 Padua, Italy; Univ Padua, Dept Clin & Expt Med, I-35121 Padua, Italy; Sch Med, Dept Histol & Embryol, PL-60781 Poznan, Poland	University of Padua; University of Padua	Nussdorfer, GG (corresponding author), Univ Padua, Dept Anat, Via Gabelli 65, I-35121 Padua, Italy.	ggnanat@ipdunidx.unipd.it						BAYLEY E, 1969, ACTA ENDOCRINOL-COP, V62, P339; DAZORD A, 1972, J CLIN ENDOCR METAB, V35, P24, DOI 10.1210/jcem-35-1-24; Diederich S, 1996, EUR J ENDOCRINOL, V134, P301, DOI 10.1530/eje.0.1340301; FARESE RV, 1991, NEW ENGL J MED, V325, P1225; Funder JW, 1996, EUR J ENDOCRINOL, V134, P267, DOI 10.1530/eje.0.1340267; Funder JW, 1995, TRENDS ENDOCRIN MET, V6, P248, DOI 10.1016/1043-2760(95)95219-U; HANUKOGLU I, 1992, J STEROID BIOCHEM, V43, P779, DOI 10.1016/0960-0760(92)90307-5; Latif SA, 1997, STEROIDS, V62, P230, DOI 10.1016/S0039-128X(96)00208-5; LATIF SA, 1994, STEROIDS, V59, P352, DOI 10.1016/0039-128X(94)90001-9; LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V78, P1212, DOI 10.1210/jc.78.5.1212; Li KXZ, 1996, MOL CELL ENDOCRINOL, V120, P67, DOI 10.1016/0303-7207(96)03822-1; MACKINNON M, 1977, J LAB CLIN MED, V90, P1096; MCNICOL AM, 1992, ADRENAL GLAND, P1; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MONDER C, 1991, BIOCHIM BIOPHYS ACTA, V1115, P23, DOI 10.1016/0304-4165(91)90006-3; Musajo F, 1996, LIFE SCI, V59, P1401, DOI 10.1016/0024-3205(96)00467-5; Neri G, 1996, J CLIN ENDOCR METAB, V81, P169, DOI 10.1210/jc.81.1.169; Roland BL, 1996, ENDOCRINOLOGY, V137, P1123, DOI 10.1210/en.137.3.1123; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; Shimojo M, 1996, J MOL ENDOCRINOL, V17, P121, DOI 10.1677/jme.0.0170121; Shimojo M, 1997, ENDOCRINOLOGY, V138, P1305, DOI 10.1210/en.138.3.1305; Smith RE, 1997, ENDOCRINOLOGY, V138, P540, DOI 10.1210/en.138.2.540; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SZALAY KS, 1981, ACTA PHYSIOL HUNG, V57, P225; TRAPNELL BC, 1993, AM J PHYSIOL, V264, pL199, DOI 10.1152/ajplung.1993.264.3.L199; WALKER BR, 1992, CLIN ENDOCRINOL, V37, P483, DOI 10.1111/j.1365-2265.1992.tb01478.x; WALKER BR, 1994, J ENDOCRINOL, V141, P467, DOI 10.1677/joe.0.1410467; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P529, DOI 10.1210/jc.80.2.529; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Whorwood C. B., 1995, Journal of Endocrinology, V144, pP183; WHORWOOD CB, 1993, ENDOCRINOLOGY, V132, P2287, DOI 10.1210/en.132.6.2287; WILLIAMS AC, 1992, J ENDOCRINOLOGY S, V132, P111; YANG K, 1994, J ENDOCRINOL, V143, P121, DOI 10.1677/joe.0.1430121; YANG K, 1995, MOL CELL ENDOCRINOL, V111, pR19, DOI 10.1016/0303-7207(95)03574-Q; ZHOU MY, 1995, ENDOCRINOLOGY, V136, P3729, DOI 10.1210/en.136.9.3729	36	86	86	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1533	1539		10.1096/fasebj.12.14.1533	http://dx.doi.org/10.1096/fasebj.12.14.1533			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806762				2022-12-25	WOS:000076749500012
J	Dempsey, LA; Hanakahi, LA; Maizels, N				Dempsey, LA; Hanakahi, LA; Maizels, N			A specific isoform of hnRNP D interacts with DNA in the LR1 heterodimer: Canonical RNA binding motifs in a sequence-specific duplex DNA binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWITCH-REGION SEQUENCES; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RECOMBINATION; TRANSCRIPTION; CELLS; NUCLEOLIN; GLYCINE; END	The B cell-specific, sequence-specific duplex DNA-binding protein LR1 is a transcriptional activator and may also function in heavy chain class switch recombination. LR1 is composed of two polypeptides, a 106-kDa subunit that is nucleolin, and a 45-kDa subunit that we now show to be a specific isoform of hnRNP D. hnRNP D and nucleolin both contain canonical RNA binding domains (RBDs also called RRMs) and Arg-Gly-Gly (RGG) motifs. Although these motifs are not commonly associated with sequence-specific recognition of duplex DNA, nonetheless LR1 binds duplex DNA with high affinity (K-D = 1.8 nm) and clear sequence specificity. Two RBD-RGG proteins can therefore combine to produce a sequence-specific duplex DNA-binding protein.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Maizels, N (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.			Dempsey, Laurie/0000-0002-3304-796X	NATIONAL CANCER INSTITUTE [T32CA009159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039799, F32GM015948] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09159] Funding Source: Medline; NIGMS NIH HHS [GM15948, R01 GM39799, R01 GM039799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; BULFONEPAUS S, 1995, P NATL ACAD SCI USA, V92, P8293, DOI 10.1073/pnas.92.18.8293; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DANIELS GA, 1995, P NATL ACAD SCI USA, V92, P5625, DOI 10.1073/pnas.92.12.5625; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LEUNG H, 1994, MOL CELL BIOL, V14, P1450, DOI 10.1128/MCB.14.2.1450; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; Li MJ, 1997, MOL IMMUNOL, V34, P201, DOI 10.1016/S0161-5890(97)00028-X; LI MJ, 1996, METH MOL G, V8, P375; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WILLIAMS M, 1993, J BIOL CHEM, V268, P13731	26	77	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29224	29229		10.1074/jbc.273.44.29224	http://dx.doi.org/10.1074/jbc.273.44.29224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786934	hybrid			2022-12-25	WOS:000076691800095
J	Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ				Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ			Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents	ONCOGENE			English	Article						gadd45; myc; transcriptional repression	C-MYC; REPRESSES TRANSCRIPTION; INDUCED APOPTOSIS; RAT FIBROBLASTS; CELL-GROWTH; P53; ACTIVATION; PROMOTER; RADIATION; PATHWAY	The growth arrest and DNA damage inducible (gadd) genes are induced by various genotoxic and nongenotoxic stresses such as serum starvation, ultraviolet irradiation and treatment with alkylating agents. Their coordinate induction is a growth arrest signal which may play an important role in the response of cells to DNA damage. Conversely, c-myc is a strong proliferative signal, and overexpression of Myc is frequently observed in cancer cells, We have found that ectopic expression of v-myc in RAT-I cells results in an attenuated induction of the three major gadd transcripts by methyl methanesulfonate (MMS), and almost completely blocks the response to ultraviolet (UV) radiation. Myc acts in part by reducing the stress-responsiveness of the gadd45 promoter, as a c-myc expression vector strongly suppressed activation of gadd-reporter constructs. This activity of Myc localizes to a recently described CC-rich binding site within the gadd45 promoter. These results indicate that a coordinate down-regulation of the gadd gene response is one mechanism by which Myc can circumvent growth arrest and contribute to the neoplastic phenotype.	NCI, NIH, Bethesda, MD 20892 USA; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fornace, AJ (corresponding author), NCI, NIH, 37 Convent Dr,Bldg,37 Room 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Chen CH, 1996, ONCOGENE, V13, P1659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; WANG ZY, 1995, ONCOGENE, V10, P1243; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	28	77	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2149	2154		10.1038/sj.onc.1202136	http://dx.doi.org/10.1038/sj.onc.1202136			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811446				2022-12-25	WOS:000076698200001
J	Larrucea, S; Gonzalez-Rubio, C; Cambronero, R; Ballou, B; Bonay, P; Lopez-Granados, E; Bouvet, P; Fontan, G; Fresno, M; Lopez-Trascasa, M				Larrucea, S; Gonzalez-Rubio, C; Cambronero, R; Ballou, B; Bonay, P; Lopez-Granados, E; Bouvet, P; Fontan, G; Fresno, M; Lopez-Trascasa, M			Cellular adhesion mediated by factor J, a complement inhibitor - Evidence for nucleolin involvement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; BINDING-PROTEIN; RHEUMATOID-ARTHRITIS; SURFACE ANTIGENS; EPITHELIAL-CELLS; FACTOR FAMILY; IDENTIFICATION; PHOSPHORYLATION; RECEPTORS; SEQUENCE	Factor J (FJ) is a complement inhibitor that acts on the classical and the alternative pathways. We demonstrated FJ-cell interactions in fluid phase by flow cytometry experiments using the cell lines Jurkat, K562, JY, and peripheral blood lymphocytes. FJ bound to plastic plates was able to induce in vitro adhesion of these cells with potency equivalent to fibronectin. As evidence for the specificity of this reaction, the adhesion was blocked by MAJ2, an anti-FJ monoclonal antibody, and by soluble FJ. Attachment of the cells required active metabolism and cytoskeletal integrity. The glycosaminoglycans heparin, heparan sulfate, or chondroitin sulfates A, B, and C inhibited to varying degrees the binding of FJ to cells, as did treatment with chondroitinase ABC. In the search for a putative receptor, a protein of 110 kDa was isolated by affinity chromatography, and microsequence analysis identified this protein as nucleolin. Confocal microscopy evidenced the presence of nucleolin in cell membrane by immunofluorescence with monoclonal (D3) and polyclonal. anti-nucleolin antibodies in Jurkat cells. The interaction FJ-nucleolin was evidenced by Western blot and enzyme-linked immunosorbent assay. Furthermore, purified nucleolin and D3 inhibited adhesion of Jurkat cells to immobilized FJ, suggesting that the interaction was specific and that nucleolin mediated the binding.	Hosp La Paz, Unidad Inmunol, Madrid 28046, Spain; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; CNRS, Inst Biol Cellulaire & Genet, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Hospital Universitario La Paz; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Lopez-Trascasa, M (corresponding author), Hosp La Paz, Unidad Inmunol, Paseo de la Castellana 261, Madrid 28046, Spain.		López-Trascasa, Margarita/L-2699-2014; , Bouvet/AAC-8779-2020; Larrucea, Susana/E-4743-2012	López-Trascasa, Margarita/0000-0001-8594-282X; Fresno Escudero, Manuel/0000-0002-9223-5477; Larrucea, Susana/0000-0002-4019-2751; Bouvet, Philippe/0000-0003-4524-2233				ARMSTRONG E, 1992, CANCER RES, V52, P2004; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; Ballou B, 1996, P SOC PHOTO-OPT INS, V2680, P124, DOI 10.1117/12.237600; BALLOU BT, 1993, FASEB J, V7, pA1308; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BUGLER B, 1987, J BIOL CHEM, V262, P10922; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DENG JS, 1993, J INVEST DERMATOL, V100, P527; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DiScipio RG, 1998, J IMMUNOL, V160, P4057; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gillery P, 1996, BIOCHEM BIOPH RES CO, V228, P94, DOI 10.1006/bbrc.1996.1621; Gonzalez-Rubio C, 1997, IMMUNOPHARMACOLOGY, V38, P159, DOI 10.1016/S0162-3109(97)00078-7; GONZALEZRUBIO C, 1994, J BIOL CHEM, V269, P26017; Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JIMENEZCLAVERO MA, 1995, J IMMUNOL, V155, P2143; JIMENEZCLAVERO MA, 1994, CLIN BIOCHEM, V27, P169, DOI 10.1016/0009-9120(94)90051-5; JIMENEZCLAVERO MA, 1994, IMMUNOL LETT, V42, P185, DOI 10.1016/0165-2478(94)90084-1; Jordan P, 1996, MOL BIOL REP, V22, P63, DOI 10.1007/BF00996307; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; KINCH MS, 1993, J IMMUNOL, V151, P4552; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LISCHWE MA, 1979, LIFE SCI, V25, P701, DOI 10.1016/0024-3205(79)90512-5; LOPEZTRASCASA M, 1989, J BIOL CHEM, V264, P16214; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; NICHOLSONWELLER A, 1990, UCLA SYM BI, V121, P201; OCHS RL, 1984, EXP CELL RES, V152, P260, DOI 10.1016/0014-4827(84)90251-9; OLSON MOJ, 1981, EXP CELL RES, V135, P259, DOI 10.1016/0014-4827(81)90161-0; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; POSTIGO AA, 1992, J CLIN INVEST, V89, P1445, DOI 10.1172/JCI115734; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	67	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31718	31725		10.1074/jbc.273.48.31718	http://dx.doi.org/10.1074/jbc.273.48.31718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822633	hybrid			2022-12-25	WOS:000077207000015
J	Andley, UP; Song, Z; Wawrousek, EF; Bassnett, S				Andley, UP; Song, Z; Wawrousek, EF; Bassnett, S			The molecular chaperone alpha A-crystallin enhances lens epithelial cell growth and resistance to UVA stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; ULTRAVIOLET-RADIATION; INCLUSION-BODIES; EYE LENS; PHOSPHORYLATION; DEATH; EXPRESSION; GENE; THERMORESISTANCE	alpha A-Crystallin (alpha A) is a member of the small heat shock protein (sHSP) family and has the ability to prevent denatured proteins from aggregating in vitro. Lens epithelial cells express relatively low levels of alpha A, but in differentiated fiber cells, alpha A is the most abundant soluble protein. The lenses of alpha A-knock-out mice develop opacities at an early age, implying a critical role for alpha A in the maintenance of fiber cell transparency. However, the function of alpha-crystallin in the lens epithelium is unknown. To investigate the physiological function of alpha A in lens epithelial cells, we used the following two systems: alpha A knock-out (alpha A(-/-)) mouse lens epithelial cells and human lens epithelial cells that overexpress cuk The growth rate of alpha A(-/-) mouse lens epithelial cells was reduced by 50% compared with wild type cells. Cell cycle kinetics, measured by fluorescence-activated cell. sorter analysis of propidium iodide-stained cells, indicated a relative deficiency of alpha A(-/-) cells in the G(2)/M phases. Exposure of mouse lens epithelial cells to physiological levels of WA resulted in an increase in the number of apoptotic cells in the cultures. Four hours after irradiation the fraction of apoptotic cells in the alpha A(-/-) cultures was increased 40-fold over wild type. In cells lacking alpha A, WA exposure modified F-actin, but actin was protected in cells expressing alpha A Stably transfected cell lines overexpressing human alpha A were generated by transfecting extended life span human lens epithelial cells with the mammalian expression vector construct pCI-neo alpha A Cells overexpressing alpha A were resistant to WA stress, as determined by clonogenic survival. alpha A remained cytoplasmic after exposure to either WA or thermal stress indicating that, unlike other sHSPs, the protective effect of alpha A was not associated with its relocalization to the nucleus. These results indicate that alpha A has important cellular functions in the lens over and above its well characterized role in refraction.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@seer.wustl.edu	Wawrousek, Eric/A-4547-2008	Andley, Usha/0000-0001-7049-7591; Bassnett, Steven/0000-0002-8337-2760	NATIONAL EYE INSTITUTE [R01EY009852, R01EY005681, P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY09852, R01-EY05681, EY02687, P30 EY002687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P367; ANDLEY UP, 1990, CURR EYE RES, V9, P1099, DOI 10.3109/02713689008997583; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Borkman RF, 1996, EXP EYE RES, V62, P141, DOI 10.1006/exer.1996.0018; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRUNO S, 1992, LEUKEMIA, V6, P1113; CHIESA R, 1989, CURR EYE RES, V8, P151, DOI 10.3109/02713688908995186; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; ELLIS RJ, 1996, CHAPERONINS; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; Godar D E, 1994, Cell Death Differ, V1, P59; Guay J, 1997, J CELL SCI, V110, P357; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Huot J, 1996, CANCER RES, V56, P273; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRISHNA CM, 1991, PHOTOCHEM PHOTOBIOL, V54, P51, DOI 10.1111/j.1751-1097.1991.tb01984.x; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; PEAK MJ, 1986, BIOL EFFECTS UVA RAD, P42; RAFFERTY NS, 1993, CELL MOTIL CYTOSKEL, V26, P40, DOI 10.1002/cm.970260105; RAMAKRISHNAN N, 1993, INT J RADIAT BIOL, V63, P693, DOI 10.1080/09553009314552091; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VOORTER CEM, 1992, FEBS LETT, V309, P111, DOI 10.1016/0014-5793(92)81075-W; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Wawrousek EF, 1997, INVEST OPHTH VIS SCI, V38, P2733; ZAMANSKY GB, 1992, CELL MOTIL CYTOSKEL, V22, P296, DOI 10.1002/cm.970220409; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZIGMAN S, 1995, MOL CELL BIOCHEM, V143, P35, DOI 10.1007/BF00925924; ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723; Zigman S, 1995, OPTOMETRY VISION SCI, V72, P899, DOI 10.1097/00006324-199512000-00008	44	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31252	31261		10.1074/jbc.273.47.31252	http://dx.doi.org/10.1074/jbc.273.47.31252			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813033	hybrid			2022-12-25	WOS:000077136900061
J	Reeve, AM; Breazeale, SD; Townsend, CA				Reeve, AM; Breazeale, SD; Townsend, CA			Purification, characterization, and cloning of an S-adenosylmethionine-dependent 3-amino-3-carboxypropyltransferase in nocardicin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; AMINOPROPYLTRANSFERASE SPERMIDINE SYNTHASE; CRYSTAL-STRUCTURE; DNA METHYLTRANSFERASE; A BIOSYNTHESIS; CODON USAGE; AFFINITY-CHROMATOGRAPHY; N-METHYLTRANSFERASE; BASE COMPOSITION; SEQUENCE MOTIFS	S-Adenosylmethionine:nocardicin 3-amino-3-carboxypropyltransferase catalyzes the biosynthetically rare transfer of the 3-amino-3-carboxypropyl moiety from S-adenosylmethionine to a phenolic site in the beta-lactam substrates nocardicin E, F, and G, a late step of the biosynthesis of the monocyclic beta-lactam antibiotic nocardicin A. Whereas a number of conventional methods were ineffective in purifying the transferase, it was successfully obtained by two complementary affinity chromatography steps that took advantage of the two substrate-two product reaction scheme. S-Adenosylhomocysteine-agarose selected enzymes that utilize S-adenosylmethionine, and a second column, nocardicin A-agarose, specifically bound the desired transferase to yield the enzyme as a single band of 38 kDa on a silver stained SDS-polyacrylamide gel. The transferase is active as a monomer and exhibits sequential kinetics, Further kinetic characterization of this protein is described and its role in the biosynthesis of nocardicin A discussed. The gene encoding this transferase was cloned from a sublibrary of Nocardia uniformis DNA, Translation gave a protein of deduced mass 32,386 Da which showed weak homology to small molecule methyltransferases, However, three correctly disposed signature motifs characteristic of these enzymes were observed.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Johns Hopkins University	Townsend, CA (corresponding author), Johns Hopkins Univ, Dept Chem, 3400 N Charles St, Baltimore, MD 21218 USA.	Townsend@jhunix.hcf.jhu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014937, R56AI014937, R01AI014937] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01934, RR02318] Funding Source: Medline; NIAID NIH HHS [AI 14937] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADYE J, 1964, BIOCHIM BIOPHYS ACTA, V86, P418, DOI 10.1016/0304-4165(64)90077-7; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AOKI H, 1976, J ANTIBIOT, V29, P492, DOI 10.7164/antibiotics.29.492; Arigoni D., 1978, CIBA FDN S, P243; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; CACCIAPUOTI G, 1983, B MOL BIOL MED, V8, P199; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Cleland W W, 1979, Methods Enzymol, V63, P103; COQUE JJR, 1993, FEMS MICROBIOL LETT, V110, P91, DOI 10.1111/j.1574-6968.1993.tb06300.x; COWARD JK, 1983, METHOD ENZYMOL, V94, P286; COWARD JK, 1974, J MED CHEM, V17, P1286, DOI 10.1021/jm00258a011; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; FLOHE L, 1970, Biochimica et Biophysica Acta, V220, P469, DOI 10.1016/0005-2744(70)90278-0; FLOSS HG, 1993, ACCOUNTS CHEM RES, V26, P116, DOI 10.1021/ar00027a007; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3505, DOI 10.1016/0031-9422(90)85265-H; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; FUJII I, 1982, CHEM PHARM BULL, V30, P2283; GOLDING BT, 1985, J CHEM SOC PERK T 1, P2017, DOI 10.1039/p19850002017; GOLDING BT, 1982, J AM CHEM SOC, V104, P5815, DOI 10.1021/ja00385a057; GURANOWSKI AB, 1981, EUR J BIOCHEM, V114, P293, DOI 10.1111/j.1432-1033.1981.tb05148.x; HAN CH, 1993, BIOCHEMISTRY-US, V32, P13974, DOI 10.1021/bi00213a030; HARA M, 1995, PHYTOCHEMISTRY, V38, P1131, DOI 10.1016/0031-9422(94)00802-Z; HASHIMOTO M, 1976, J ANTIBIOT, V29, P890, DOI 10.7164/antibiotics.29.890; HASHIMOTO M, 1976, J AM CHEM SOC, V98, P3023, DOI 10.1021/ja00426a063; HIBASAMI H, 1980, BIOCHEM J, V187, P419, DOI 10.1042/bj1870419; HIGUCHI K, 1995, IRON NUTR SOILS PLAN, P29; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOSODA J, 1977, AGR BIOL CHEM TOKYO, V41, P2013, DOI 10.1080/00021369.1977.10862799; HOSODA J, 1977, AGR BIOL CHEM TOKYO, V41, P2007, DOI 10.1080/00021369.1977.10862798; IHARA M, 1986, BIOCHIM BIOPHYS ACTA, V881, P135, DOI 10.1016/0304-4165(86)90106-6; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5873, DOI 10.1073/pnas.90.12.5873; KIM S, 1978, ANAL BIOCHEM, V84, P415, DOI 10.1016/0003-2697(78)90059-3; KINOSHITA T, 1981, J CHROMATOGR, V210, P77, DOI 10.1016/S0021-9673(00)91182-8; KURITA M, 1976, J ANTIBIOT, V29, P1243, DOI 10.7164/antibiotics.29.1243; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LOWE CR, 1984, METHOD ENZYMOL, V104, P97; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MATHER MW, 1993, METHOD ENZYMOL, V218, P695; MAXWELL CA, 1992, ARCH BIOCHEM BIOPHYS, V293, P158, DOI 10.1016/0003-9861(92)90379-B; McGuire SM, 1996, BIOCHEMISTRY-US, V35, P11470, DOI 10.1021/bi960924s; Moore DD, 1995, GLOB MOB SURV; MUNCH HJ, 1975, FEBS LETT, V51, P257, DOI 10.1016/0014-5793(75)80900-8; NISHIMURA S, 1974, BIOCHEM BIOPH RES CO, V57, P702, DOI 10.1016/0006-291X(74)90603-2; ORR GR, 1988, J AM CHEM SOC, V110, P5971; PAJULA RL, 1983, BIOCHEM J, V215, P669, DOI 10.1042/bj2150669; PANKASKIE M, 1980, J MED CHEM, V23, P121, DOI 10.1021/jm00176a004; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1983, METHOD ENZYMOL, V94, P294; PEGG AE, 1983, METHOD ENZYMOL, V94, P260; RAGIONE ED, 1985, BIOCHEM J, V232, P335, DOI 10.1042/bj2320335; RAINA A, 1983, METHOD ENZYMOL, V94, P257; RAINA A, 1984, BIOCHEM J, V219, P991, DOI 10.1042/bj2190991; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RINA M, 1993, GENE, V133, P91, DOI 10.1016/0378-1119(93)90229-V; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; SALITURO GM, 1990, J AM CHEM SOC, V112, P760, DOI 10.1021/ja00158a040; SAMEJIMA K, 1983, METHOD ENZYMOL, V94, P270; SAMEJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V216, P213, DOI 10.1016/0003-9861(82)90206-5; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SEGEL IH, 1975, ENZYME KINETICS, P18; SHOJIMA S, 1990, PLANT PHYSIOL, V93, P1497, DOI 10.1104/pp.93.4.1497; SHOJIMA S, 1989, PLANT CELL PHYSIOL, V30, P673; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SZILAK L, 1992, EUR J BIOCHEM, V209, P391, DOI 10.1111/j.1432-1033.1992.tb17301.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TANG KC, 1980, BIOCHEM BIOPH RES CO, V96, P1371, DOI 10.1016/0006-291X(80)90102-3; TANG KC, 1981, J MED CHEM, V24, P1277, DOI 10.1021/jm00143a003; TAYA Y, 1978, FEBS LETT, V89, P326, DOI 10.1016/0014-5793(78)80247-6; TOWNSEND CA, 1981, J AM CHEM SOC, V103, P2873, DOI 10.1021/ja00400a069; TOWNSEND CA, 1982, J AM CHEM SOC, V104, P1748, DOI 10.1021/ja00370a056; TOWNSEND CA, 1988, J AM CHEM SOC, V110, P3320, DOI 10.1021/ja00218a063; TOWNSEND CA, 1984, J CHEM SOC CHEM COMM, P1631, DOI 10.1039/c39840001631; TOWNSEND CA, 1983, J AM CHEM SOC, V105, P913, DOI 10.1021/ja00342a046; TOWNSEND CA, 1988, J CHEM SOC CHEM COMM, P1579, DOI 10.1039/c39880001579; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WATANABE K, 1983, J ANTIBIOT, V36, P321, DOI 10.7164/antibiotics.36.321; WILSON BA, 1988, J AM CHEM SOC, V110, P8238, DOI 10.1021/ja00232a047; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; Wright LS, 1996, J BIOL CHEM, V271, P12737, DOI 10.1074/jbc.271.22.12737; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483; ZAPPIA V, 1980, J BIOL CHEM, V255, P7276	90	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30695	30703		10.1074/jbc.273.46.30695	http://dx.doi.org/10.1074/jbc.273.46.30695			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804844	hybrid			2022-12-25	WOS:000077008100091
J	Wei, L; Zhou, W; Croissant, JD; Johansen, FE; Prywes, R; Balasubramanyam, A; Schwartz, RJ				Wei, L; Zhou, W; Croissant, JD; Johansen, FE; Prywes, R; Balasubramanyam, A; Schwartz, RJ			RhoA signaling via serum response factor plays an obligatory role in myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; ALPHA-ACTIN GENE; C-FOS GENE; TRANSCRIPTIONAL ACTIVATION; FOCAL ADHESIONS; TYROSINE PHOSPHORYLATION; ADP-RIBOSYLATION; SKELETAL-MUSCLE; STRESS FIBERS; KINASE FAMILY	Serum response factor (SRF) plays a central role during myogenesis, being required for the expression of striated alpha-actin genes. As shown here, the small GTPase RhoA dependent activation of SRF results in the expression of muscle specific genes, thereby promoting myogenic differentiation in myoblast cell lines. Co-expression of activated V14-RhoA and SRF results in an approximately 10-fold activation of the skeletal alpha-actin promoter in replicating myoblasts, while SRFpm1, a dominant negative SRF mutant, blocks RhoA dependent skeletal alpha-actin promoter activity. Serum withdrawal further potentiates RhoA- and SRF-mediated activation of alpha-actin promoter to about 30-fold in differentiated myotubes. In addition, the proximal SRE1 in the skeletal alpha-actin promoter is sufficient to mediate RhoA signaling via SRF. Furthermore, SRFpm1 and to a lesser extent dominant negative N19-RhoA inhibit myoblast fusion, postreplicative myogenic differentiation, and expression of direct SRF targets such as skeletal alpha-actin and indirect targets such as myogenin and alpha-myosin heavy chain. Moreover, RhoA also stimulates the autoregulatable murine SRF gene promoter in myoblasts, and the expression level of SRF is reduced in myoblasts overexpressing N19-RhoA Our study supports the concept that RhoA signaling via SRF serves as an obligatory muscle differentiation regulatory pathway.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Div Endocrinol, Houston, TX 77030 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Scripps Res Inst, Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Cardiol, Nashville, TN 37232 USA	Baylor College of Medicine; Baylor College of Medicine; Columbia University; Scripps Research Institute; Vanderbilt University	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza,Room 145E, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL50422, P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Groisman R, 1996, J BIOL CHEM, V271, P5258; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERFLIER A, 1995, FEBS LETT, V369, P340, DOI 10.1016/0014-5793(95)00814-P; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG J, 1993, J BIOL CHEM, V268, P22251	55	139	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30287	30294		10.1074/jbc.273.46.30287	http://dx.doi.org/10.1074/jbc.273.46.30287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804789	hybrid			2022-12-25	WOS:000077008100036
J	Yamashita, H; Xu, J; Erwin, RA; Farrar, WL; Kirken, RA; Rui, H				Yamashita, H; Xu, J; Erwin, RA; Farrar, WL; Kirken, RA; Rui, H			Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser(725) of Stat5a and Ser(730) of Stat5b in prolactin-sensitive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE STAT1; DNA-BINDING; TYROSINE PHOSPHORYLATION; SUBSTRATE RECOGNITION; HORMONE ACTIVATION; INTERFERON-ALPHA; GENE-EXPRESSION; KINASE-ACTIVITY; PROTEIN-KINASE; T-LYMPHOCYTES	Transcription factors of the Stat family are controlled by protein kinases, Phosphorylation of a positionally conserved tyrosine residue is obligatory for Stat dimerization, nuclear translocation, and specific DNA binding. Studies of Stat1 and Stat3 have suggested that serine phosphorylation may also regulate function. We now identify serine residues located in a conserved PSP motif of Stat5a (Ser(725)) and Stat5b (Ser(730)) as major phosphorylation sites, using mutagenesis, phosphoamino acid analysis, and site-specific anti-Stat5-phosphoserine antibodies. Unexpectedly, phosphorylation control of this PSP motif differed between the highly homologous Stat5a and Stat5b proteins. Whereas Ser(725) of Stat5a was constitutively phosphorylated both in COS-7 cells and Nb2 lymphocytes, phosphorylation of Ser(730) of Stat5b was markedly stimulated by prolactin. The data also suggested the existence of a second major serine phosphorylation site in Stat5a. Interestingly, constitutive phosphorylation of the PSP motif was suppressed by PD98059 but not by staurosporine under conditions in which both agents inhibited mitogen-activated protein kinases. Furthermore, pretreatment of cells with staurosporine, PD98059, H7, or wortmannin did not prevent either Stat5a or Stat5b from becoming maximally serine-phosphorylated after prolactin exposure. We propose that two pathways regulate Stat5 serine phosphorylation, one that is prolactin-activated and PD98059-resistant and one that is constitutively active and PD98059-sensitive and preferentially targets Stat5a, Finally, phosphorylation of the PSP motif of Stat5a or Stat5b was not essential for DNA binding: or transcriptional activation of a beta-casein reporter gene in COS-7 cells, suggesting that serine kinase control of Stat5 activity differs from that of Stat1 and Stat3.	Uniformed Serv Univ Hlth Sci, Dept Pathol, Sch Med, Bethesda, MD 20814 USA; Univ Texas, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA; NIH, Intramural Res Support Program, Sci Applicat Int Corp Frederick, Frederick, MD 21702 USA; NCI, Div Basic Sci, Mol Immunoregulat Lab, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA	Uniformed Services University of the Health Sciences - USA; University of Texas System; National Institutes of Health (NIH) - USA; Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Rui, H (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	hrui@usuhs.mil			NIDDK NIH HHS [R01 DK52013-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052013] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pericle F, 1997, J IMMUNOL, V159, P2580; Pericle F, 1998, J IMMUNOL, V160, P28; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RUI H, 1994, J BIOL CHEM, V269, P5364; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Shuai K, 1996, ONCOGENE, V13, P247; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	39	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30218	30224		10.1074/jbc.273.46.30218	http://dx.doi.org/10.1074/jbc.273.46.30218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804779	hybrid			2022-12-25	WOS:000077008100026
J	Goodwin, GW; Taylor, CS; Taegtmeyer, H				Goodwin, GW; Taylor, CS; Taegtmeyer, H			Regulation of energy metabolism of the heart during acute increase in heart work	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; FATTY-ACID OXIDATION; MALONYL-COA LEVELS; PYRUVATE-DEHYDROGENASE; SUBSTRATE UTILIZATION; GLYCOGEN; EXERCISE; LACTATE; LIVER; PHOSPHORYLASE	We determined the contribution of all major energy substrates (glucose, glycogen, lactate, oleate, and triglycerides) during an acute increase in heart work (1 mu M epinephrine, afterload increased by 40%) and the involvement of key regulatory enzymes, using isolated working rat hearts exhibiting physiologic values for contractile performance and oxygen consumption. We accounted for oxygen consumption quantitatively from the rates of substrate oxidation, measured on a minute-to-minute basis. Total beta-oxidation (but not exogenous oleate oxidation) was increased by the work jump, consistent with a decrease in the level of malonyl-CoA. Glycogen and lactate were important buffers for carbon substrate when heart work was acutely increased. Three mechanisms contributed to high respiration from glycogen: 1) carbohydrate oxidation was increased selectively; 2) stimulation of glucose oxidation was delayed at glucose uptake; and 3) glycogen-derived pyruvate behaved differently from pyruvate derived from extracellular glucose. Despite delayed activation of pyruvate dehydrogenase relative to phosphorylase, glycogen-derived pyruvate was more tightly coupled to oxidation. Also, glycogen-derived lactate plus pyruvate contributed to an increase in the relative efflux of lactate versus pyruvate, thereby regulating the redox. Glycogen synthesis resulted from activation of glycogen synthase late in the protocol but was timed to minimize futile cycling, since phosphorylase a became inhibited by high intracellular glucose.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA	University of Texas System	Goodwin, GW (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007676] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAINARD JR, 1989, BIOCHEMISTRY-US, V28, P9766, DOI 10.1021/bi00451a033; CAREY EM, 1970, BIOCHIM BIOPHYS ACTA, V210, P371, DOI 10.1016/0005-2760(70)90033-0; COLLINSNAKAI RL, 1994, AM J PHYSIOL-HEART C, V267, pH1862, DOI 10.1152/ajpheart.1994.267.5.H1862; CRASS MF, 1969, AM J PHYSIOL, V216, P1569; DEVOS P, 1979, EUR J BIOCHEM, V99, P161, DOI 10.1111/j.1432-1033.1979.tb13242.x; Doenst T, 1997, CIRCULATION, V96, P3873; DRAKE AJ, 1980, CARDIOVASC RES, V14, P65, DOI 10.1093/cvr/14.2.65; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLAIM SF, 1979, J APPL PHYSIOL, V46, P302, DOI 10.1152/jappl.1979.46.2.302; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOLDFARB AH, 1986, J APPL PHYSIOL, V60, P1268, DOI 10.1152/jappl.1986.60.4.1268; Goodwin GW, 1998, AM J PHYSIOL-HEART C, V274, pH1239, DOI 10.1152/ajpheart.1998.274.4.H1239; Goodwin GW, 1996, J CLIN INVEST, V97, P1409, DOI 10.1172/JCI118561; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; HALL JL, 1995, CARDIOVASC RES, V30, P351, DOI 10.1016/S0008-6363(95)00052-6; Hall JL, 1996, CARDIOVASC RES, V32, P879, DOI 10.1016/S0008-6363(96)00153-8; HARRIS RA, 1989, J BIOL CHEM, V264, P14674; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; HIRAOKA T, 1980, J BIOL CHEM, V255, P7604; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; LAUGHLIN MR, 1992, AM J PHYSIOL, V262, pE875, DOI 10.1152/ajpendo.1992.262.6.E875; LAURENT D, 1998, AM J PHYSIOL, V37, pE130; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; MASSIE BM, 1994, CIRC RES, V74, P64, DOI 10.1161/01.RES.74.1.64; MCCORMACK JG, 1981, BIOCHEM J, V194, P639, DOI 10.1042/bj1940639; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NEELY JR, 1976, CIRC RES, V38, P22; NEELY JR, 1969, AM J PHYSIOL, V216, P804; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Skurat AV, 1997, EUR J BIOCHEM, V245, P147, DOI 10.1111/j.1432-1033.1997.t01-1-00147.x; STALMANS W, 1971, EUR J BIOCHEM, V18, P2851; STARNES JW, 1985, AM J PHYSIOL, V249, pH799, DOI 10.1152/ajpheart.1985.249.4.H799; STATEN MA, 1987, AM J PHYSIOL, V253, pE322, DOI 10.1152/ajpendo.1987.253.3.E322; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VILLARPALASI C, 1960, ARCH BIOCHEM BIOPHYS, V86, P270, DOI 10.1016/0003-9861(60)90417-3; WILLIAMS BJ, 1966, MOL PHARMACOL, V2, P454; WILLIAMSON JR, 1964, J BIOL CHEM, V239, P2721	45	224	227	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29530	29539		10.1074/jbc.273.45.29530	http://dx.doi.org/10.1074/jbc.273.45.29530			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792661	hybrid			2022-12-25	WOS:000076798300038
J	Goulet, CC; Volk, KA; Adams, CM; Prince, LS; Stokes, JB; Snyder, PM				Goulet, CC; Volk, KA; Adams, CM; Prince, LS; Stokes, JB; Snyder, PM			Inhibition of the epithelial Na+ channel by interaction of Nedd4 with a PY motif deleted in Liddle's syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; BETA-SUBUNIT; MISSENSE MUTATION; WW DOMAIN; RECEPTOR; EXPRESSION; PROTEINS; IDENTIFICATION; HYPERTENSION; ENDOCYTOSIS	The epithelial Na+ channel (ENaC) plays a critical role in Na+ absorption in the kidney and other epithelia, Mutations in the C terminus of the beta or gamma ENaC subunits increase renal Na+ absorption, causing Liddle's syndrome, an inherited form of hypertension. These mutations delete or disrupt a PY motif that was recently shown to interact with Nedd4, a ubiquitin-protein ligase expressed in epithelia, We found that Nedd4 inhibited ENaC when they were coexpressed in Xenopus oocytes. Liddle's syndrome-associated mutations that prevent the interaction between Nedd4 and ENaC abolished inhibition, suggesting that a direct interaction is required for inhibition by Nedd4. Inhibition also required activity of a ubiquitin ligase domain within the C terminus of Nedd4, Nedd4 had no detectable effect on the single channel properties of ENaC, Rather, Nedd4 decreased cell surface expression of both ENaC and a chimeric protein containing the C terminus of the beta subunit, Decreased surface expression resulted from an increase in the rate of degradation of the channel complex. Thus, interaction of Nedd4 with the C terminus of ENaC inhibits Na+ absorption, and loss of this interaction may play a role in the pathogenesis of Liddle's syndrome and other forms of hypertension.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200K EMRB, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu		Adams, Christopher/0000-0002-5795-7212				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHUENG M, 1997, J GEN PHYSIOL, V109, P289; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	34	150	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30012	30017		10.1074/jbc.273.45.30012	http://dx.doi.org/10.1074/jbc.273.45.30012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792722	hybrid			2022-12-25	WOS:000076798300099
J	Mukhopadhyay, S; Webster, CRL; Anwer, MS				Mukhopadhyay, S; Webster, CRL; Anwer, MS			Role of protein phosphatases in cyclic AMP-mediated stimulation of hepatic Na+/Taurocholate cotransport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PLASMA-MEMBRANE VESICLES; OKADAIC ACID; FUNCTIONAL EXPRESSION; GLUCOSE-TRANSPORTER; NA+/H+ EXCHANGER; PHOSPHORYLATION; LIVER; INSULIN; CELLS	Cyclic AMP has been proposed to stimulate Na+/taurocholate (TC) cotransport in hepatocytes by translocating Na+/TC cotransport polypeptide (Ntcp) to the plasma membrane and to induce Ntcp dephosphorylation, Whether protein phosphatases 1 and 2A (PP1/2A) are involved in the regulation of Na+/TC cotransport by cAMP was investigated in the present study. Okadaic acid and tautomycin, inhibitors of PP1/2A, inhibited cAMP-mediated increases in TC uptake and cytosolic [Ca2+], and only tautomycin inhibited basal TC uptake. Removal of cAMP reversed cAMP-mediated increases in TC uptake and plasma membrane Ntcp mass. Okadaic acid alone increased Ntcp phosphorylation without affecting Ntcp mass in plasma membranes and homogenates. In the presence of okadaic acid, cAMP failed to increase plasma membrane Ntcp mass, induce Ntcp dephosphorylation, and decrease endosomal Ntcp mass, Phosphorylated Ntcp was detectable in endosomes isolated from okadaic acid-treated hepatocytes but not in endosomes from control and cAMP-treated hepatocytes, PPI was found to be enriched in plasma membranes, whereas PP2A was mostly in the cytosol, Cyclic AMP did not activate either PP1 or PP2A, whereas okadaic acid inhibited primarily PP2A, These results suggest that 1) the effect of cAMP on Na+/TC cotransport is not mediated via either PP1 or PP2A; rather, cAMP-mediated signaling pathway is maintained by PP2A and inhibition of PP2A overrides cAMP-mediated effects, and 2) okadaic acid, by inhibiting PP2A, inhibits cAMP-mediated increases in Na+/TC cotransport by decreasing the ability of cAMP to increase cytosolic [Ca2+]. It is proposed that cAMP-mediated dephosphorylation of Ntcp leads to an increased retention of Ntcp in the plasma membrane, and okadaic acid, by inhibiting PP2A, inhibits cAMP-mediated stimulation of Na+/TC cotransport by reversing the ability of cAMP to increase cytosolic [Ca2+] and to induce Ntcp dephosphorylation.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA	Tufts University	Anwer, MS (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	sanwer@infonet.tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002721, R01DK033436] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033436, K08 DK002721-01, DK-33436] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1988, HEPATOLOGY, V8, P887, DOI 10.1002/hep.1840080430; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; CHRISTOFFERSEN J, 1994, CANCER RES, V54, P2245; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; EPPING RJ, 1984, BIOCHEM J, V223, P733, DOI 10.1042/bj2230733; EVANS WH, 1985, METHOD ENZYMOL, V109, P246; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; GRUNE S, 1993, J BIOL CHEM, V268, P17734; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HammAlvarez SF, 1996, AM J PHYSIOL-CELL PH, V271, pC929, DOI 10.1152/ajpcell.1996.271.3.C929; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAKUBOWSKI J, 1990, EUR J BIOCHEM, V193, P541, DOI 10.1111/j.1432-1033.1990.tb19370.x; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LIU Y, 1995, AM J PHYSIOL-GASTR L, V268, pG11, DOI 10.1152/ajpgi.1995.268.1.G11; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; MUKHOPADHYAY S, 1998, IN PRESS HEPATOLOGY; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; Wallach D. F. H., 1966, METHOD ENZYMOL, V8, P164	37	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30039	30045		10.1074/jbc.273.45.30039	http://dx.doi.org/10.1074/jbc.273.45.30039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792726	hybrid			2022-12-25	WOS:000076798300103
J	Song, CZ; Siok, TE; Gelehrter, TD				Song, CZ; Siok, TE; Gelehrter, TD			Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4; MAD PROTEINS; GENE; RECEPTOR; CELLS; DNA	The transforming growth factor-beta (TGF-beta) family of cytokines mediates multiple biological effects by regulating the expression of target genes. The Smad family proteins function as intracellular signal transducers downstream of the receptors to transmit the TGF-beta signal from cell membrane to nucleus. The mechanisms by which Smads mediate transcriptional activation of target genes is largely unknown. Here we report the identification of a novel TGF-beta-responsive element in the human type 1 plasminogen activator inhibitor promoter that is required for mediating strong transcriptional activation of this gene by TGF-beta. Smad3 and Smad4 are incorporated into a TGF-beta inducible complex formed on this element following TGF-beta stimulation of human hepatoma cells. Both Smads and Smad4 bind directly to this TGF-beta-responsive element through their conserved MH1 domains. These results indicate that Smad3 and Smad4 mediate TGF-beta signaling by directly interacting with a specific response element in a physiological target gene.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Song, CZ (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA22729] Funding Source: Medline; NIDDK NIH HHS [DK46010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HEALY AM, 1994, J BIOL CHEM, V269, P19095; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	29	126	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29287	29290		10.1074/jbc.273.45.29287	http://dx.doi.org/10.1074/jbc.273.45.29287			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792626	hybrid			2022-12-25	WOS:000076798300003
J	Yang, XY; Gabuzda, D				Yang, XY; Gabuzda, D			Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VIF; MAP KINASE; IN-VITRO; SUBSTRATE RECOGNITION; VIRION INCORPORATION; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; DNA-SYNTHESIS; GAG PROTEINS	The human immunodeficiency virus type 1 (HIV-1) Vif protein plays a critical role in virus replication and infectivity. Here we show that Vif is phosphorylated and regulated by p44/42 mitogen-activated protein kinase (MAPK). Vif phosphorylation by MAPK was demonstrated in vitro as well as in vivo and was shown to occur on serine and threonine residues. Two-dimensional tryptic phosphopeptide mapping indicated that Vif is phosphorylated by MAPK on the same sites in vitro and in vivo. Radioactive peptide sequencing identified two phosphorylation sites, Thr(96) and Ser(165). These phosphorylation sites do not correspond to the known optimum consensus sequences for phosphorylation by MAPK (PX(S/T)P) nor to the minimum consensus sequence ((S/ T)P), indicating that MAPK can phosphorylate proteins at sites other than those containing the PX(SPT)P or (S/T)P motifs. Synthetic Vif peptides corresponding to the local sequences of the phosphorylation sites were not phosphorylated by MAPK, suggesting that recognition of these sites by MAPK is likely to require structural determinants outside the phosphorylation site. Mutations of the Thr96 site, which is conserved among Vif sequences from HIV-1, HIV-2, and SIV, resulted in significant loss of Vif activity and inhibition of HIV-1 replication. These results suggest that MAPK plays a direct role in regulating HIV-1 replication and infectivity by phosphorylating Vif and identify a novel mechanism for activation of HIV-1 replication by mitogens and other extracellular stimuli.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gabuzda, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF 712,44 Binney St, Boston, MA 02115 USA.	dana_gabuzda@dfci.harvard.edu			NIAID NIH HHS [AI28691, AI36186, AO6514] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, R01AI036186] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDRES JC, 1994, VIROLOGY, V201, P157, DOI 10.1006/viro.1994.1278; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; Bouyac M, 1997, J VIROL, V71, P2473, DOI 10.1128/JVI.71.3.2473-2477.1997; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COCHRANE AW, 1989, J VIROL, V63, P4438, DOI 10.1128/JVI.63.10.4438-4440.1989; Cohen PS, 1997, MOL MED, V3, P339, DOI 10.1007/BF03401812; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P333, DOI 10.1089/aid.1994.10.333; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; Luo TC, 1997, J VIROL, V71, P2535, DOI 10.1128/JVI.71.3.2535-2539.1997; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	59	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29879	29887		10.1074/jbc.273.45.29879	http://dx.doi.org/10.1074/jbc.273.45.29879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792705	hybrid			2022-12-25	WOS:000076798300082
J	Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H				Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H			Regulation of NGF responsiveness in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; trkA; differentiation	NERVE GROWTH-FACTOR; HUMAN NEURO-BLASTOMA; RETINOIC ACID; CELL-LINE; NEUROTROPHIN RECEPTOR; TRK PROTOONCOGENE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HIGH-AFFINITY	Functional nerve growth factor (NGF) responsiveness was investigated in human neuroblastoma (NB) cell lines in vitro and retinoic acid (RA) was found to transcriptionally enhance expression of the trkA, but not the trkB gene in GOTO cells, while the reverse was found in HTLA230 NE cells. Ciliary neurotrophic factor (CNTF) specifically induced trkA gene transcription in both cell lines. Transcriptional activation of the trkA gene increased total trkA protein and surface bound receptor, which was tyrosine phosphorylated upon NGF stimulation inducing immediate early response gene transcription (i.e. c-fos, Egr-1). Newly synthesized trkA protein had a molecular weight of 110 kDa and was post-translationally modified. Rapid down regulation of the receptor protein occurred upon NGF stimulation, despite the presence of high levels of trkA mRNA, due to an increased rate of receptor degradation. Transient DNA synthesis and cell proliferation upon NGF treatment occurred in GOTO cells with elevated trkA expression. In contrast, NGF induced neuronal differentiation in HTLA230 cells expressing the endogenous trkA receptor gene, despite the lack of p75 expression. Hence, transcriptional activation of trkA gene expression can be achieved by different signal pathways in human NE cells, but NGF can act either as mitogen or inducer of cell differentiation, depending on the tumor from which cells are derived.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Jikei Univ, Sch Med, Inst DNA Med, Dept Pediat,Minato Ku, Tokyo 105, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Gene Therapy,Minato Ku, Tokyo 105, Japan	Children's Hospital Los Angeles; Jikei University; Jikei University	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034940] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS34940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOGENMANN E, 1995, ONCOGENE, V10, P1915; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; Seeger Robert C., 1993, P2172; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Torres M, 1996, ONCOGENE, V12, P77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435	64	23	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2367	2376		10.1038/sj.onc.1202160	http://dx.doi.org/10.1038/sj.onc.1202160			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811468				2022-12-25	WOS:000076723300011
J	Sun, GQ; Sharma, AK; Budde, RJA				Sun, GQ; Sharma, AK; Budde, RJA			Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation	ONCOGENE			English	Article						Src and Yes regulation; Csk; protein tyrosine phosphatase 1B; autophosphorylation	PROTEIN-TYROSINE KINASE; HUMAN COLORECTAL-CANCER; C-SRC; EXPRESSION SYSTEM; PP60(C-SRC) ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMAN-PLACENTA; PP60C-SRC; PURIFICATION	Csk phosphorylates Src family protein tyrosine kinases on a tyrosine residue near their C-terminus and down-regulates their activity. We previously observed that this regulation requires a stoichiometric ratio of Csk:Src in a time-independent manner. In this report we examined this unusual kinetic behavior and found it to be caused by Src autophosphorylation, First, pre-incubation of Src with ATP-Mg led to time-dependent autophosphorylation of Src, activation of its kinase activity and loss of its ability to be inactivated by Csk, However, the autophosphorylated Src can still be phosphorylated by Csk. The SH2 binding site for phospho-Tyr of this hyperactive and doubly phosphorylated form of Src is not accessible. Second, dephosphorylation of autophosphorylated Src by protein tyrosine phosphatase 1B allowed Src to be inactivated by Csk, Third, protein tyrosine phosphatase 1B preferentially dephosphorylates the Src autophosphorylation site and allows for Src regulation by Csk, Finally, Yes, another member of the Src family, was also only partially inactivated when a sub-stoichiometric amount of Csk was used. Mutation of the tyrosine autophosphorylation site of Yes to a phenylalanine resulted in a mutant Yes enzyme that can be fully inactivated by a sub-stoichiometric amount of Csk in a time-dependent manner. These results demonstrate that Csk phosphorylation inactivates Src and Yes only when they are not previously autophosphorylated and Src autophosphorylation can block the inactivation by Csk phosphorylation, This conclusion suggests a dynamic model for the regulation of the Src family protein tyrosine kinases, which is discussed in the context of previously reported observations on the regulation of Src family protein tyrosine kinases.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Budde, RJA (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Box 316, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, U19CA053617, U01CA053617] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA53617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BOLEN JB, 1987, ONCOGENE RES, V1, P149; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BUDDE RJA, 1993, PREP BIOCHEM, V23, P493, DOI 10.1080/10826069308544572; Chappel J, 1997, J CELL BIOCHEM, V67, P432, DOI 10.1002/(SICI)1097-4644(19971215)67:4<432::AID-JCB2>3.0.CO;2-T; Chedin M, 1997, CARCINOGENESIS, V18, P1463, DOI 10.1093/carcin/18.8.1463; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1989, ONCOGENE RES, V5, P49; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Levitzki A, 1996, ANTI-CANCER DRUG DES, V11, P175; Li SL, 1996, CELL BIOL INT, V20, P723; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OETKEN C, 1994, ONCOGENE, V9, P1625; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J, 1989, MOL CLONING; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V345, P135, DOI 10.1006/abbi.1997.0236; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P194, DOI 10.1006/abbi.1997.0156; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WATANABE N, 1995, JPN J CLIN ONCOL, V25, P5; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	74	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1587	1595		10.1038/sj.onc.1202076	http://dx.doi.org/10.1038/sj.onc.1202076			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794236				2022-12-25	WOS:000076089900011
J	Briones, E; Briones, C; Remacha, M; Ballesta, JPG				Briones, E; Briones, C; Remacha, M; Ballesta, JPG			The GTPase center protein L12 is required for correct ribosomal stalk assembly but not for Saccharomyces cerevisiae viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACIDIC PHOSPHOPROTEINS; MONOCLONAL-ANTIBODIES; GENE DISRUPTIONS; CROSS-LINKING; RNA; YEAST; BINDING; DOMAIN; BIOGENESIS	Protein L12, together with the P0/P1/P2 protein complex, forms the protein moiety of the GTPase domain in the eukaryotic ribosome. In Saccharomyces cerevisiae protein L12 is encoded by a duplicated gene, rpL12A and rpL12B. Inactivation of both copies has been performed and confirmed by Southern and Western analyses. The resulting strains are viable but grow very slowly. Growth rate is recovered upon transformation with an intact copy of the L12 gene. Ribosomes hom the disrupted strain lack protein L12 but are able to carry out translation in vitro at about one fourth of the control rate. The L12-deficient ribosomes have also a defective stalk containing standard amounts of the 12-kDa acidic proteins P1 beta and P2 alpha, but proteins P1 alpha and P2 beta are drastically reduced. Moreover, the affinity of PO is reduced in the defective ribosomes. Footprinting of the 26 S rRNA GTPase domain indicates that protein L12 protects in different extent residues G1235, G1242, A1262, A1270, and A1272 from chemical modification. The results in this report indicate that protein L12 is not essential for cell viability but has a relevant role in the structure and stability of the eukaryotic ribosomal stalk.	CSIC, Ctr Mol Biol, E-28049 Madrid, Spain; Univ Autonoma Madrid, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid	Ballesta, JPG (corresponding author), CSIC, Ctr Mol Biol, Plaza Murillo 2, E-28049 Madrid, Spain.	jpgballesta@cbm.uam.es	Briones, Carlos/G-3689-2016; Remacha, Miguel/G-1250-2016	Briones, Carlos/0000-0003-2213-8353; 				Agalarov SC, 1998, P NATL ACAD SCI USA, V95, P999, DOI 10.1073/pnas.95.3.999; Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; BARONASLOWELL DM, 1990, MOL CELL BIOL, V10, P5235, DOI 10.1128/MCB.10.10.5235; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; CUNDLIFFE E, 1979, J MOL BIOL, V132, P235, DOI 10.1016/0022-2836(79)90393-0; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JUANVIDALES F, 1983, EUR J BIOCHEM, V136, P275, DOI 10.1111/j.1432-1033.1983.tb07738.x; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; MARQUIS DM, 1981, J MOL BIOL, V150, P121, DOI 10.1016/0022-2836(81)90327-2; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; Payo JM, 1995, BIOCHEMISTRY-US, V34, P7941; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; Rose MD., 1990, METHODS YEAST GENETI; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANTOS C, 1993, BIOCHEMISTRY-US, V32, P4231, DOI 10.1021/bi00067a010; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STOFFLER G, 1980, J BIOL CHEM, V255, P517; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1985, J BIOL CHEM, V260, P5675; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Zambrano R, 1997, BIOCHEMISTRY-US, V36, P14439, DOI 10.1021/bi971494o; Zurdo J, 1997, BIOCHEMISTRY-US, V36, P9625, DOI 10.1021/bi9702400	52	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31956	31961		10.1074/jbc.273.48.31956	http://dx.doi.org/10.1074/jbc.273.48.31956			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822666	hybrid			2022-12-25	WOS:000077207000048
J	Hauses, M; Tonjes, RR; Grez, M				Hauses, M; Tonjes, RR; Grez, M			The transcription factor spl regulates the myeloid-specific expression of the human hematopoietic cell kinase (HCK) gene through binding to two adjacent GC boxes within the HCK promoter-proximal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FC-GAMMA-RI; SP1-MEDIATED TRANSCRIPTION; CHICKEN LYSOZYME; CD11B PROMOTER; LEUKEMIA-VIRUS; FAMILY MEMBERS; STEM-CELLS; ACTIVATION; RECEPTOR	The human hemopoietic cell kinase (HCK) is a member of the src family of protein tyrosine kinases specifically expressed in myeloid cells and to a minor extent in B-lymphoid cells. HCK expression is up-regulated at the transcriptional level during myeloid differentiation of hematopoietic cells. To elucidate the molecular basis of the differential HCK: gene expression, the genomic region containing the HCK promoter was isolated and functionally characterized. A DNA fragment containing 101 base pairs of the 5'-flanking sequence showed strong promoter activity in the macrophage cell line RAW264 but was inactive in the non-monocytic cell lines HUT-78 and NIH-3T3. Site-directed mutagenesis of the proximal promoter region showed that two GC-rich sequence elements are essential for transcriptional activity in myeloid cells. Electrophoretic mobility shift analysis using nuclear extracts obtained from RAW264 cells and from the promonocytic cell line U-937 revealed the formation of at least three distinct protein-DNA complexes at each of these sites, one of which was found to contain the transcription factor Spl. Expression of a reporter gene linked to the -101 HCK promoter region was up-regulated by Spl, but not by other members of the Spl family of transcription factors, in Drosophila Schneider cells. A synergistic effect on HCK promoter activity was observed at high concentrations of Spl. Our results show that Spl plays an essential role in the regulation of the differential gene expression of the HCK gene.	Mol Virol Lab, D-60596 Frankfurt, Germany; Paul Ehrlich Inst, D-63225 Langen, Germany	Paul Ehrlich Institute	Grez, M (corresponding author), Mol Virol Lab, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.							AHNE B, 1994, J BIOL CHEM, V269, P17794; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BASU A, 1993, J BIOL CHEM, V268, P4188; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BIONDI A, 1991, EUR J IMMUNOL, V21, P843, DOI 10.1002/eji.1830210348; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOULET I, 1992, ONCOGENE, V7, P703; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Featherstone C, 1997, SCIENCE, V275, P1066, DOI 10.1126/science.275.5303.1066; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; PAWSON T, 1997, NATURE, P585; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; POPOVIC M, 1984, LANCET, V2, P1472; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Ye JP, 1996, MOL CELL BIOL, V16, P157; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, p373P; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZIEGLER SF, 1991, ONCOGENE, V6, P283; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	69	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31844	31852		10.1074/jbc.273.48.31844	http://dx.doi.org/10.1074/jbc.273.48.31844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822652	hybrid			2022-12-25	WOS:000077207000034
J	Hung, JJ; Cheng, TJ; Lai, YK; Chang, MDT				Hung, JJ; Cheng, TJ; Lai, YK; Chang, MDT			Differential activation of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinases confers cadmium-induced HSP70 expression in 9L rat brain tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; HEAT-SHOCK; MAP KINASE; CYTOKINE BIOSYNTHESIS; FACTOR-I; PHOSPHORYLATION; STRESS; INHIBITOR; CASCADE; INTERLEUKIN-1	We have reported that treatment with CdCl2 at 40-100 mu M induces the heat shock proteins (HSPs) in 9L rat brain tumor cells, during which the activation of heat shock factor (HSF) is essentially involved. By exploiting protein kinase inhibitors, we further analyzed the possible participation of specific protein kinases in the above processes. It was found that induction of HSP70 in cells treated with a high concentration of cadmium (i.e. 100 mu M) is preceded by the phosphorylation and activation of p38 mitogen-activated protein kinase (p38(MAPK)), while that in cells treated with a low concentration (60 mu M) is accompanied by the phosphorylation and activation of extracellular-regulated protein kinases 1 and 2 (ERK1/2). In 100 mu M cadmium-treated cells, both HSP70 induction and HSF1 activation are eliminated in the presence of SB203580, a specific inhibitor of p38(MAPK). By contrast, in 60 mu M cadmium-treated cells, the processes are not affected by SB203580 but are significantly suppressed by PD98059, which indirectly inhibits ERK1/2 by acting on MAPK-ERK kinase. Taken together, we demonstrate that p38(MAPK) and ERK1/2 can be simultaneously or independently activated under different concentrations of cadmium and that the signaling pathways participate in the induction of HSP70 by acting on the inducible phosphorylation of HSF1. We thus provide the first evidence that both p38(MAPK) and ERK signaling pathways can differentially participate in the activation of HSF1, which leads to the induction of HSP70 by cadmium.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan	National Tsing Hua University	Lai, YK (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan.		HUNG, Jan-Jong/G-7872-2011	Cheng, Rachel/0000-0003-4297-018X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOJ A, 1994, EMBO J, V13, P2617; Hung JJ, 1998, J CELL BIOCHEM, V71, P21; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	45	95	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31924	31931		10.1074/jbc.273.48.31924	http://dx.doi.org/10.1074/jbc.273.48.31924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822662	hybrid			2022-12-25	WOS:000077207000044
J	Lin, FT; Daaka, Y; Lefkowitz, RJ				Lin, FT; Daaka, Y; Lefkowitz, RJ			beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; EGF-RECEPTOR; ACTIVATION; PHOSPHORYLATION; CELLS; SHC; INTERNALIZATION; DESENSITIZATION; SEQUESTRATION	beta-Arrestins mediate agonist-dependent desensitization of G protein-coupled receptors and target the receptors to clathrin-coated pits for internalization. Here we report an expanded role of beta-arrestins in promoting clathrin-mediated endocytosis of a tyrosine kinase growth factor receptor, ie. the insulin-like growth factor I (IGF-1) receptor. beta-Arrestins bind to the ligand-occupied IGF-1 receptors, promote their endocytosis, and enhance IGF-l-dependent mitogen-activated protein kinase phosphorylation and DNA synthesis. Our results suggest a role for beta-arrestins in regulating mitogenic signaling and clathrin-mediated endocytosis of receptors not classically coupled to G proteins.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CARPENTIER JL, 1994, DIABETOLOGIA, V37, P117; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAVIES PJA, 1984, DIABETES CARE, V7, P35; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1	31	157	160	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31640	31643		10.1074/jbc.273.48.31640	http://dx.doi.org/10.1074/jbc.273.48.31640			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822622	hybrid			2022-12-25	WOS:000077207000004
J	Marshall, NF; Dahmus, GK; Dahmus, ME				Marshall, NF; Dahmus, GK; Dahmus, ME			Regulation of carboxyl-terminal domain phosphatase by HIV-1 Tat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; SUBUNIT-IIA; P-TEFB; ELONGATION; TRANSCRIPTION; PHOSPHORYLATION; PURIFICATION; INITIATION; PROMOTER	The phosphorylation state of the carboxyl-terminal domain (CTD) of RNA polymerase (RNAP) II is directly linked to the phase of transcription being carried out by the polymerase, Enzymes that affect CTD phosphorylation can thus play a major role in the regulation of transcription. A previously characterized HeLa CTD phosphatase has been shown to processively dephosphorylate RNAP II and to be stimulated by the 74-kDa subunit of TFIIF. This phosphatase is shown to be comprised of a single 180-kDa subunit by the reconstitution of catalytic activity from a SDS-polyacrylamide gel electrophoresis purified protein. This subunit has been previously cloned and shown to interact with the LW Tat protein. To determine whether this interaction has functional consequences, the effect of Tat on CTD phosphatase was investigated. Full-length Tat-l protein (Tat 86R) strongly inhibits the activity of CTD phosphatase. Point mutations in the activation domain of Tat 86R, which reduce the ability of Tat to transactivate in vivo, diminish its ability to inhibit CTD phosphatase. Furthermore, a deletion mutant missing most of the activation domain is unable to inhibit CTD phosphatase activity. The ability of Tat to transactivate in vitro also correlates with the strength of inhibition of CTD phosphatase. These results are consistent with the hypothesis that Tat-dependent suppression of CTD phosphatase is part of the transactivation function of Tat.	Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Dahmus, ME (corresponding author), Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300, F32GM018952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18952, GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KANG ME, 1993, J BIOL CHEM, V268, P25033; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; REINES D, 1992, J BIOL CHEM, V267, P3795; RHIM H, 1994, NUCLEIC ACIDS RES, V22, P4405, DOI 10.1093/nar/22.21.4405; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	42	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31726	31730		10.1074/jbc.273.48.31726	http://dx.doi.org/10.1074/jbc.273.48.31726			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822634	hybrid			2022-12-25	WOS:000077207000016
J	Kroetz, DL; Yook, P; Costet, P; Bianchi, P; Pineau, T				Kroetz, DL; Yook, P; Costet, P; Bianchi, P; Pineau, T			Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	10th International Symposium on Microsomes and Drug Oxidations	JUL 21-24, 1996	LOS ANGELES, CALIFORNIA				TISSUE-SPECIFIC REGULATION; RAT RENAL MICROSOMES; FATTY-ACIDS; ARACHIDONIC-ACID; OMEGA-HYDROXYLATION; GENE-EXPRESSION; GROWTH-HORMONE; LAURIC ACID; CYTOCHROME-P450 ISOZYMES; HYPOLIPIDEMIC DRUGS	The hepatic CYP4A enzymes are important fatty acid and prostaglandin omega-hydroxylases that are highly inducible by fibric acid hypolipidemic agents and other peroxisome proliferators. Induction of the CYP4A enzymes by peroxisome proliferators is mediated through the nuclear peroxisome proliferator-activated receptor alpha (PPAR alpha), Fatty acids have recently been identified as endogenous ligands of PPAR alpha, and this receptor has been implicated in the regulation of lipid homeostasis. In the present report we characterized the induction of the hepatic CYP4A genes in rats during the altered lipid metabolism associated with starvation and diabetes. The mRNA levels of CYP4A1, CYP4A2, and CYP4A3 were induced 7-17-fold in the livers of fasted animals and 3-8-fold in the livers of diabetic animals. This was accompanied by corresponding changes in CYP4A protein levels and arachidonic and lauric acid omega-hydroxylase activity. Interestingly, feeding animals after the fasting period caused as much as an 80% suppression of CYP4A mRNA levels, whereas CYP4A protein levels and functional activity returned to control values. A second PPAR alpha-responsive gene, acyl-CoA oxidase, was also induced in rat liver by diabetes and fasting. By using PPAR alpha-deficient mice, we unambiguously demonstrated that PPAR alpha is strictly required for hepatic CYP4A induction by starvation and diabetes. Similarly, induction of hepatic thiolase and bifunctional enzyme also required expression of PPAR alpha. This represents the first evidence for the pathophysiologically induced activation of a nuclear receptor.	Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Ctr Liver, San Francisco, CA 94143 USA; INRA, Lab Pharmacol & Toxicol, F-31931 Toulouse, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; INRAE	Kroetz, DL (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, 513 Parnassus,Box 0446, San Francisco, CA 94143 USA.		costet, philippe/A-5314-2010		NHLBI NIH HHS [HL53994] Funding Source: Medline; NIDDK NIH HHS [DK26743] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053994, R29HL053994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1990, J LIPID RES, V31, P1477; Ausbel FM, 1994, CURRENT PROTOCOLS MO; BACHER MA, 1988, CHEM-BIOL INTERACT, V65, P145, DOI 10.1016/0009-2797(88)90051-8; BARNETT CR, 1993, BIOCHEM PHARMACOL, V45, P313, DOI 10.1016/0006-2952(93)90066-6; BARNETT CR, 1992, XENOBIOTICA, V22, P1441, DOI 10.3109/00498259209056694; BARNETT CR, 1990, BIOCHEM J, V268, P765, DOI 10.1042/bj2680765; BARNETT CR, 1988, BIOCHIM BIOPHYS ACTA, V967, P250, DOI 10.1016/0304-4165(88)90016-5; ESPANDIARI P, 1995, FUND APPL TOXICOL, V26, P85, DOI 10.1006/faat.1995.1077; FELBER JP, 1995, METABOLISM, V44, P4, DOI 10.1016/0026-0495(95)90201-5; FERGUSON NL, 1993, DRUG METAB DISPOS, V21, P745; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HEUBI JE, 1987, HEPATOLOGY, V7, P155, DOI 10.1002/hep.1840070130; HU Y, 1995, BIOCHEM PHARMACOL, V50, P155; IMAOKA S, 1993, BIOCHEM PHARMACOL, V46, P2197, DOI 10.1016/0006-2952(93)90609-Z; IMAOKA S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P209, DOI 10.1016/0304-4165(91)90063-M; IMAOKA S, 1990, ARCH BIOCHEM BIOPHYS, V278, P168, DOI 10.1016/0003-9861(90)90245-T; IMAOKA S, 1989, BIOCHEM INT, V18, P731; IMAOKA S, 1990, BIOCHIM BIOPHYS ACTA, V1036, P18, DOI 10.1016/0304-4165(90)90208-E; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JOHNSON EF, 1996, FASEB J, V10, P1; KARARA A, 1993, J BIOL CHEM, V268, P13565; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kroetz DL, 1997, MOL PHARMACOL, V52, P362, DOI 10.1124/mol.52.3.362; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MA XL, 1993, HEPATOLOGY, V18, P1247; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V710, P477, DOI 10.1016/0005-2760(82)90132-1; NAKAMURA M, 1994, BIOCHEM PHARMACOL, V48, P1743, DOI 10.1016/0006-2952(94)90460-X; OCKNER RK, 1993, HEPATOLOGY, V18, P669, DOI 10.1002/hep.1840180327; OKITA JR, 1993, J BIOCHEM TOXICOL, V8, P135, DOI 10.1002/jbt.2570080305; Okita JR, 1997, DRUG METAB DISPOS, V25, P1008; Rahman M, 1997, AM J HYPERTENS, V10, P356, DOI 10.1016/S0895-7061(96)00381-0; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; Saloranta C, 1996, DIABETES METAB REV, V12, P15, DOI 10.1002/(SICI)1099-0895(199603)12:1&lt;15::AID-DMR153&gt;3.0.CO;2-0; Schoonjans K, 1996, J LIPID RES, V37, P907; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; SHIMOJO N, 1993, BIOCHEM PHARMACOL, V46, P621, DOI 10.1016/0006-2952(93)90547-A; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SONG BJ, 1989, J BIOL CHEM, V264, P3568; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; THUMMEL KE, 1990, MOL PHARMACOL, V37, P119; Webb SJ, 1996, MOL PHARMACOL, V49, P276; WU HQ, 1989, CANCER RES, V49, P2337; YAMAZOE Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P567, DOI 10.1016/0003-9861(89)90324-X	54	179	183	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31581	31589		10.1074/jbc.273.47.31581	http://dx.doi.org/10.1074/jbc.273.47.31581			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813074	hybrid			2022-12-25	WOS:000077136900102
J	Sharpe, MA; Cooper, CE				Sharpe, MA; Cooper, CE			Interaction of peroxynitrite with mitochondrial cytochrome oxidase - Catalytic production of nitric oxide and irreversible inhibition of enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; C-OXIDASE; NEURODEGENERATIVE DISEASES; SUPEROXIDE-DISMUTASE; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN; CYCLOSPORINE-A; CALCIUM EFFLUX; STEADY-STATE; OXYGEN	Purified mitochondrial cytochrome c oxidase catalyzes the conversion of peroxynitrite to nitric oxide (NO), This reaction is cyanide-sensitive, indicating that the binuclear heme a(3)/Cu-B center is the catalytic site. NO production causes a reversible inhibition of turnover, characterized by formation of the cytochrome a, nitrosyl complex. In addition, peroxynitrite causes irreversible inhibition of cytochrome oxidase, characterized by a decreased V-max and a raised K-m for oxygen. Under these conditions, the redox state of cytochrome a is elevated, indicating inhibition of electron transfer and/or oxygen reduction reactions subsequent to this center. The lipid bilayer is no barrier to these peroxynitrite effects, as NO production and irreversible enzyme inhibition were also observed in cytochrome oxidase proteoliposomes. Addition of 50 mu M peroxynitrite to 10 mu M fully oxidized enzyme induced spectral changes characteristic of the formation of ferryl cytochrome a,, partial reduction of cytochrome a, and irreversible damage to the Cu-A site. Higher concentrations of peroxynitrite (250 mu M) cause heme degradation. In the fully reduced enzyme, peroxynitrite causes a red shift in the optical spectrum of both cytochromes a and a(3), resulting in a symmetrical peak in the visible region, Therefore, peroxynitrite can both modify and degrade the metal centers of cytochrome oxidase.	Univ Essex, Dept Sci Biol, Colchester CO4 3SQ, Essex, England	University of Essex	Cooper, CE (corresponding author), Univ Essex, Dept Sci Biol, Cent Campus,Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.	ccooper@essex.ac.uk	Cooper, Chris/AAK-9729-2020; Sharpe, Martyn/V-8789-2019	Cooper, Chris/0000-0003-0381-3990; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper C, 1997, ADV EXP MED BIOL, V428, P449; COOPER CE, 1993, BIOCHEM J, V290, P139, DOI 10.1042/bj2900139; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P1534, DOI 10.1021/bi00005a009; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; KELM M, 1996, METHODS NITRIC OXIDE, P557; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUBOYAMA M, 1972, J BIOL CHEM, V247, P6375; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIZASOAIN L, 1996, BIOCHEM J, V246, P737; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; MORGAN JE, 1991, BIOCHEMISTRY-US, V30, P948, DOI 10.1021/bi00218a010; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V275, P279, DOI 10.1016/0005-2728(72)90208-3; Packer MA, 1996, BIOCHEM MOL BIOL INT, V40, P527; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PACKER MA, 1995, EUR J BIOCHEM, V234, P231, DOI 10.1111/j.1432-1033.1995.231_c.x; PETERSEN LC, 1974, BIOCHEM J, V142, P247, DOI 10.1042/bj1420247; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Scorza G, 1998, BIOCHEM J, V329, P405, DOI 10.1042/bj3290405; Sharpe M, 1996, BIOCHEM J, V320, P557, DOI 10.1042/bj3200557; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SQUADRITO GL, 1995, ARCH BIOCHEM BIOPHYS, V322, P53, DOI 10.1006/abbi.1995.1435; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; VANZYL JM, 1994, BIOCHEM PHARMACOL, V48, P2033, DOI 10.1016/0006-2952(94)90502-9; Verkhovsky MI, 1996, NATURE, V380, P268, DOI 10.1038/380268a0; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WILSON MT, 1997, BIOCHEM SOC T, V25, P827; WRIGGLESWORTH JM, 1990, BIOCHEM J, V270, P109, DOI 10.1042/bj2700109; WRIGGLESWORTH JM, 1987, BIOCHEM J, V246, P737, DOI 10.1042/bj2460737; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YONETANI T, 1972, J BIOL CHEM, V247, P2447; ZHAO XJ, 1995, BIOCHEM BIOPH RES CO, V212, P1054, DOI 10.1006/bbrc.1995.2076; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	53	117	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30961	30972		10.1074/jbc.273.47.30961	http://dx.doi.org/10.1074/jbc.273.47.30961			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812992	hybrid			2022-12-25	WOS:000077136900020
J	Anderberg, SJ; Newton, GL; Fahey, RC				Anderberg, SJ; Newton, GL; Fahey, RC			Mycothiol biosynthesis and metabolism - Cellular levels of potential intermediates in the biosynthesis and degradation of mycothiol in Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MOLECULAR-WEIGHT THIOLS; FLUORESCENT	Mycothiol (MSH; 1-D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-alpha-D-glucopyranoside (AcCys-GlcN-Ins)) is a novel thiol produced at millimolar levels by mycobacteria and other actinomycetes that do not make glutathione. We developed methods to determine the major components of MSH (AcCys, Cys-GlcN, AcCys-GlcN, Cys-GlcN-Ins, GlcN-Ins) in cell extracts. Mycobacterium smegmatis was shown to produce measurable levels (nmol/g of residual dry weight) of AcCys (similar to 30), Cys-GlcN-Ins (similar to 8), and GlcN-Ins (similar to 100) but not Cys-GlcN (<3) or AcCys-GlcN (<80) during exponential growth in Middlebrook 7H9 medium. The level of GlcN-Ins declined 10-fold in stationary phase and similar to 5-fold in 7H9 medium lacking glucose. Incubation in 10 mM AcCys produced 50- and 1000-fold increases in cellular Cys and AcCys levels, respectively, a 10-fold decrease in GlcN-Ins and a transient 3-fold increase in Cys-GlcN-Ins. These results exclude Cys-GlcN and AcCys-GlcN as intermediates in MSH biosynthesis and implicate GlcN-Ins and Cys-GlcN-Ins as key intermediates. Assay of GlcN-Ins/ATP-dependent ligase activity with Cys and AcCys as substrates revealed that Cys was at least an order of magnitude better substrate. Based on the cellular measurements, MSH biosynthesis involves assembly of GlcN-Ins, ligation with Cys to produce Cys-GlcN-Ins, and acetylation of the latter to produce MSH.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Fahey, RC (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIAAA NIH HHS [AA11393] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011393] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bornemann C, 1997, BIOCHEM J, V325, P623, DOI 10.1042/bj3250623; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; KOSOWER NS, 1979, P NATL ACAD SCI USA, V76, P3382, DOI 10.1073/pnas.76.7.3382; MAEHR H, 1980, J ANTIBIOT, V33, P1431, DOI 10.7164/antibiotics.33.1431; MissetSmits M, 1997, FEBS LETT, V409, P221, DOI 10.1016/S0014-5793(97)00510-3; NEWTON GL, 1995, METHOD ENZYMOL, V251, P148, DOI 10.1016/0076-6879(95)51118-0; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NEWTON GL, 1993, J BACTERIOL, V175, P2734, DOI 10.1128/JB.175.9.2734-2742.1993; SAKUDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P1347, DOI 10.1271/bbb.58.1347; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; Unson MD, 1998, J IMMUNOL METHODS, V214, P29, DOI 10.1016/S0022-1759(98)00034-9	14	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30391	30397		10.1074/jbc.273.46.30391	http://dx.doi.org/10.1074/jbc.273.46.30391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804803	hybrid			2022-12-25	WOS:000077008100050
J	Hsu, SY; Hsueh, AJW				Hsu, SY; Hsueh, AJW			A splicing variant of the Bcl-2 member Bok with a truncated BH3 domain induces apoptosis but does not dimerize with antiapoptotic Bcl-2 proteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; MAMMALIAN-CELLS; FAMILY MEMBERS; X-L; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; MEMBRANE PROTEIN; HOMOLOG BAK; ION-CHANNEL	Bok ((B) under bar cl-2-related (o) under bar varian (k) under bar iller) is a proapoptotic Bcl-2 family protein identified in the ovary based on its dimerization with the antiapoptotic protein Mcl-1. In addition to the Bcl-2 homology (BH) domains 1 and 2 and the transmembrane sequence, Bok also has a BH3 domain believed to be important for dimerization with selective antiapoptotic Bcl-2 proteins and cell killing. We identified a splicing variant of Bok mRNA with a deletion of 43 residues from the full length protein (Bok L), leading to the fusion of the N-terminal-half of its BH3 domain to the C-terminal-half of the BH1 domain. Genomic analysis indicated that the Bok has five exons, and the short form of Bok (Bok-S) represents the splicing out of exon three during transcription. Although Bok-S retains the apoptosis-inducing activity in transfected cells, it has lost the ability to dimerize with anti apoptotic proteins in vitro. Additional BH3 domain mutations of Bok-L also led to defective heterodimerization without affecting its proapoptotic action. Furthermore, similar deletions for the related channel-forming proapoptotic Bar and Bak did not impair their cell killing ability. Thus, the naturally occurring Bok-S variant represents a new form of proapoptotic protein that induces cell killing without heterodimerization with antiapoptotic Bcl-2 proteins. This variant appears to contain the minimal module spanning BH1 and BH2 domains and the transmembrane sequence for apoptosis induction by channel-forming Bcl-2 proteins.	Stanford Univ, Med Ctr, Sch Med, Div Reprod Biol,Dept Gynecol & Obstet, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Med Ctr, Sch Med, Div Reprod Biol,Dept Gynecol & Obstet, Stanford, CA 94305 USA.				NICHD NIH HHS [HD-31566] Funding Source: Medline; NIDDK NIH HHS [T32 DK07217] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007217] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Han J, 1996, MOL CELL BIOL, V16, P5857; Herberg JA, 1998, GENE, V211, P87, DOI 10.1016/S0378-1119(98)00101-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30139	30146		10.1074/jbc.273.46.30139	http://dx.doi.org/10.1074/jbc.273.46.30139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804769	hybrid			2022-12-25	WOS:000077008100016
J	Li, J; Peet, GW; Pullen, SS; Schembri-King, J; Warren, TC; Marcu, KB; Kehry, MR; Barton, R; Jakes, S				Li, J; Peet, GW; Pullen, SS; Schembri-King, J; Warren, TC; Marcu, KB; Kehry, MR; Barton, R; Jakes, S			Recombinant I kappa B kinases alpha and beta are direct kinases of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; ACTIVATION; COMPLEX; SIGNAL; SITE	Activation of the transcription factor NF-kappa B is regulated by the phosphorylation and subsequent degradation of its inhibitory subunit, I kappa B. A large multiprotein complex, the I kappa B kinase (IKK), catalyzes the phosphorylation of I kappa B. The two kinase components of the IKK complex, IKK alpha and IKK beta, were overexpressed in insect cells and purified to homogeneity. Both purified IKK alpha and IKK beta specifically catalyzed the phosphorylation of the regulatory serine residues of I kappa B alpha. Hence, IKK alpha and IKK beta were functional catalytic subunits of the IKK complex. Purified IKK alpha and IKK beta also preferentially phosphorylated serine as opposed to threonine residues of I kappa B alpha, consistent with the substrate preference of the IKK complex. Kinetic analysis of purified IKK alpha and IKK beta revealed that the kinase activity of IKK beta on I kappa B alpha is 50-60-fold higher than that of IKK alpha. The primary difference between the two activities is the K-m for I kappa B alpha. The kinetics of both IKK alpha and IKK beta followed a sequential Bi Bi mechanism. No synergistic effects on I kappa B alpha phosphorylation were detected between IKK alpha and IKK beta. Thus, in vitro, IKK alpha and IKK beta are two independent kinases of I kappa B alpha.	Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Boehringer Ingelheim; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Li, J (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Biol, 90 E Ridge Rd, Ridgefield, CT 06877 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COPELAND RA, 1996, ENZYMES, P265; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; LAVILLE ER, 1993, BIOTECHNOLOGY, V11, P187; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NOVY R, 1995, NOVATIONS, V3, P9; Possee RD., 1992, BACULOVIRUS EXPRESSI; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	22	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30736	30741		10.1074/jbc.273.46.30736	http://dx.doi.org/10.1074/jbc.273.46.30736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804849	hybrid			2022-12-25	WOS:000077008100096
J	Valenzuela, JG; Charlab, R; Galperin, MY; Ribeiro, JMC				Valenzuela, JG; Charlab, R; Galperin, MY; Ribeiro, JMC			Purification, cloning, and expression of an apyrase from the bed bug Cimex lectularius - A new type of nucleotide-binding enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; ECTO-ATP-DIPHOSPHOHYDROLASE; TOXOPLASMA-GONDII; CD39; PROTEIN; IDENTIFICATION; ARTHROPODS; DATABASE; BRAIN	An enzyme that hydrolyzes the phosphodiester bonds of nucleoside tri- and diphosphates, but not monophosphates, thus displaying apyrase (EC 3.6.1.5) activity, was purified from salivary glands of the bed bug, Cimex lectularius. The purified C. lectularius apyrase was an acidic protein with a pI of 5.1 and molecular mass of similar to 40 kDa that inhibited ADP-induced platelet aggregation and hydrolyzed platelet agonist ADP with specific activity of 379 units/mg protein, Amplification of C. lectularius cDNA corresponding to the N-terminal sequence of purified apyrase produced a probe that allowed identification of a 1.3 kilobase pair cDNA clone coding for a protein of 364 amino acid residues, the first 35 of which constituted the signal peptide. The processed form of the protein was predicted to have a molecular mass of 37.5 kDa and pI of 4.95. The identity of the product of the cDNA clone with native C. lectularius apyrase was proved by immunological testing and by expressing the gene in a heterologous host. Immune serum made against a synthetic peptide with sequence corresponding to the C-terminal region of the predicted cDNA clone recognized both C. lectularius apyrase fractions eluted from a molecular sieving high pressure liquid chromatography and the apyrase active band from chromatofocusing gels. Furthermore, transfected COS-7 cells secreted a Ca2+-dependent apyrase with a pI of 5.1 and immunoreactive material detected by the anti-apyrase serum, C. lectularius apyrase has no significant sequence similarity to any other known apyrases, but homologous sequences have been found in the genome of the nematode C, elegans and in mouse and human expressed sequence tags from fetal and tumor EST libraries.	NIAID, Med Entomol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Ribeiro, JMC (corresponding author), NIAID, Med Entomol Sect, Parasit Dis Lab, NIH, Bldg 4,Rm 126,4 Ctr Dr,MSC 0425, Bethesda, MD 20892 USA.	JRibeiro@atlas.niaid.nih.gov	Galperin, Michael Y./B-5859-2013	Galperin, Michael Y./0000-0002-2265-5572; Ribeiro, Jose/0000-0002-9107-0818				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BEDNAR B, 1995, THROMB RES, V77, P453, DOI 10.1016/0049-3848(95)93881-Y; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Champagne Donald E., 1996, P85; CHRISTOFORIDIS S, 1995, EUR J BIOCHEM, V234, P66, DOI 10.1111/j.1432-1033.1995.066_c.x; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; HUANG XQ, 1992, COMPUT APPL BIOSCI, V8, P155; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; Nagy AK, 1998, J BIOL CHEM, V273, P16043, DOI 10.1074/jbc.273.26.16043; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PLESNER L, 1995, INT REV CYTOL, V158, P141; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Rost B, 1996, METHOD ENZYMOL, V266, P525; SARKIS JJF, 1986, BIOCHEM J, V233, P885, DOI 10.1042/bj2330885; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; Valenzuela JG, 1996, INSECT BIOCHEM MOLEC, V26, P557, DOI 10.1016/S0965-1748(96)00041-0; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Woodhouse EC, 1998, BIOCHEM BIOPH RES CO, V246, P888, DOI 10.1006/bbrc.1998.8714	40	117	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30583	30590		10.1074/jbc.273.46.30583	http://dx.doi.org/10.1074/jbc.273.46.30583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804829	hybrid			2022-12-25	WOS:000077008100076
J	Wu, Y; Dowbenko, D; Lasky, LK				Wu, Y; Dowbenko, D; Lasky, LK			PSTPIP 2, a second tyrosine phosphorylated, cytoskeletal-associated protein that binds a PEST-type protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; PTP-PEST; ACTIN REORGANIZATION; SIGNALING PATHWAY; TRANSFORMED-CELLS; COILED COILS; LIGHT-CHAIN; SH3 DOMAIN	Although cytoskeletal regulation is critical to cell function during interphase and mitosis, the components of the cytoskeleton involved with its control are only beginning to be elucidated. Recently, we reported the identification of a cytoskeletal-associated protein, proline-serine-threonine phosphatase-interacting protein (PSTPIP), whose level of tyrosine phosphorylation was controlled by PEST-type protein-tyrosine phosphatases (PTPs) bound to a novel protein interaction site in the PSTPIP predicted coiled-coil domain. We also showed that the PSTPIP SH3 domain interacts with the Wiskott-Aldrich syndrome protein (WASP), a cytoskeletal regulatory protein, in a manner modulated by tyrosine phosphorylation. Here we describe the identification of PSTPIP 2, a widely expressed protein that is related to PSTPIP, PSTPIP 2 lacks an SH3 domain but contains a region predicted to bind to PEST-type PTPs, and structure-function analyses demonstrate that PSTPIP 2 interacts with the proline-rich C terminus of the PEST-type PTP hematopoietic stem cell factor in a manner similar to that previously demonstrated for PSTPIP. Confocal microscopy revealed that PSTPIP 2 colocalizes with PSTPIP in F actin-rich regions. PSTPIP 2 was found to be efficiently phosphorylated in v-Src-transfected or pervanadate-treated cells at two tyrosines conserved in PSTPIP, but in contrast to PSTPIP, tyrosine phosphorylated PSTPIP 2 was only weakly dephosphorylated in the presence of PTP HSCF, Finally, analysis of oligomer formation demonstrated that PSTPIP and PSTPIP 2 formed homo- but not heterodimers. These data suggest that a family of tyrosine phosphorylated, PEST PTP binding proteins may be implicated in cytoskeletal regulation.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Lasky, LK (corresponding author), Genentech Inc, Dept Mol Oncol, 460 Pt San Bruno Blvd, San Francisco, CA 94080 USA.	lal@gene.com						Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; BENNETT PA, 1993, J CELL SCI, V106, P891; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; Flinn HM, 1996, J CELL SCI, V109, P1133; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KREIS T, 1994, GUIDEBOOK CYTOSKELET, P1; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MABUCHI I, 1990, DEV GROWTH DIFFER, V32, P549; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PATCH LA, 1995, J CELL SCI, V108, P1371; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YANG Q, 1993, J BIOL CHEM, V268, P6622	60	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30487	30496		10.1074/jbc.273.46.30487	http://dx.doi.org/10.1074/jbc.273.46.30487			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804817	hybrid			2022-12-25	WOS:000077008100064
J	Mori, K; Maeda, Y; Kitaura, H; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Mori, K; Maeda, Y; Kitaura, H; Taira, T; Iguchi-Ariga, SMM; Ariga, H			MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; E-BOX; ORNITHINE DECARBOXYLASE; GENE; TARGET; PRODUCT; GROWTH; P107; DNA; TRANSACTIVATION	We have isolated the cDNA encoding a novel c-Myc-binding protein, MM-1, by the yeast two-hybrid screening of a human HeLa cell cDNA library. The protein deduced from the cDNA comprises 167 amino acids and was localized in the nucleus of introduced COS-I cells. The MM-1 mRNA was highly expressed in human pancreas and skeletal muscle and moderately in other tissues. As for the c-Myc binding, glutathione S-transferase MM-1 expressed in Escherichia coli bound in vitro to c-Myc translated in reticulocyte lysate, and almost whole, the MM-1 molecule was necessary for the binding in the yeast two-hybrid system. The mammalian two-hybrid assays in hamster CHO cells revealed that MM-1 interacts in vivo with the N-terminal domain covering the myc box 2, a transcription-activating domain, of Myc. Furthermore, MM-1 repressed the activation of E-box-dependent transcription by c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 060, Japan	Hokkaido University; Hokkaido University	Ariga, H (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 060, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; 				ADNANE J, 1995, ONCOGENE, V10, P381; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; Jones RM, 1996, MOL CELL BIOL, V16, P4754; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; NEGISHI Y, 1994, ONCOGENE, V9, P1133; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4	30	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29794	29800		10.1074/jbc.273.45.29794	http://dx.doi.org/10.1074/jbc.273.45.29794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792694	hybrid			2022-12-25	WOS:000076798300071
J	Shen, BQ; Lee, DY; Gerber, HP; Keyt, BA; Ferrara, N; Zioncheck, TF				Shen, BQ; Lee, DY; Gerber, HP; Keyt, BA; Ferrara, N; Zioncheck, TF			Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; CELL GROWTH; PARACRINE REGULATION; VEGF RECEPTORS; NITRIC-OXIDE; HYPOXIA; FLT-1; BINDING; ANGIOGENESIS	We investigated the possibility that vascular endothelial growth factor (VEGF) treatment could regulate KDR/Flk-1 receptor expression in endothelial cells. Bovine adrenal cortex endothelial cells were incubated with 200 pM rhVEGF(165) for 0-7 days, Western blot analysis showed a 3-5-fold increase in total KDR protein following 4-day VEGF treatment, Scatchard analysis revealed that VEGF induced a 2-3-fold increase in high affinity receptor number (5.0 x 10(4)/cell versus 2.4 x 10(4)/ cell) without significantly affecting receptor binding affinity (K-d 76 pM versus 72 pM), Quantitative polymerase chain reaction analysis demonstrated a 3-fold increase in KDR mRNA levels following VEGF exposure. VEGF-induced KDR expression primarily occurred at the transcriptional level as demonstrated by a luciferase reporter assay system. Receptor selective mutants with wild-type KDR binding and decreased Flt-1 binding also induced KDR up-regulation; in contrast, mutants with decreased KDR binding and wild-type Flt-1 binding did not, suggesting that KDR receptor signaling mediated the increase in KDR expression. Inhibition of tyrosine kinase, Src tyrosine kinase, protein kinase C, and mitogen-activated protein kinase activities all blocked VEGF-induced KDR up-regulation. Finally, co-incubation of nitric-oxide synthase inhibitors with VEGF had no significant effect on KDR expression, but 100 mu M sodium nitroprusside, a NO donor, significantly inhibited VEGF-induced KDR up-regulation, indicating that NO negatively regulates KDR expression. In conclusion, our data demonstrate that VEGF binding to the KDR receptor tyrosine kinase results in an increase in KDR receptor gene transcription and protein expression. Thus, KDR up-regulation induced by VEGF may represent an important positive feedback mechanism for VEGF action in tumor and ischemia-induced angiogenesis.	Genentech Inc, Dept Metab & Pharmacokinet, San Francisco, CA 94080 USA; Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Zioncheck, TF (corresponding author), Genentech Inc, Dept Metab & Pharmacokinet, MS 70,1 DNA Way, San Francisco, CA 94080 USA.	zioncheck.tom@gene.com						Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; Barleon B, 1997, CANCER RES, V57, P5421; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; Breuss JM, 1998, FASEB J, V12, pA105; BROCK TA, 1991, AM J PATHOL, V138, P213; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, AM J PATHOL, V143, P1255; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HASHIMOTO E, 1904, AM J PHYSIOL, V267, pH1948; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kremer C, 1997, CANCER RES, V57, P3852; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; MUSON PJ, 1980, ANAL BIOCHEM, V107, P220; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pepper MS, 1998, EXP CELL RES, V241, P414, DOI 10.1006/excr.1998.4072; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Belle E, 1998, CIRCULATION, V97, P381; vanderZee R, 1997, CIRCULATION, V95, P1030; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	62	185	196	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29979	29985		10.1074/jbc.273.45.29979	http://dx.doi.org/10.1074/jbc.273.45.29979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792718	hybrid			2022-12-25	WOS:000076798300095
J	Patel, N; Padera, R; Sanders, GHW; Cannizzaro, SM; Davies, MC; Langer, R; Roberts, CJ; Tendler, SJB; Williams, PM; Shakesheff, KM				Patel, N; Padera, R; Sanders, GHW; Cannizzaro, SM; Davies, MC; Langer, R; Roberts, CJ; Tendler, SJB; Williams, PM; Shakesheff, KM			Spatially controlled cell engineering on biodegradable polymer surfaces	FASEB JOURNAL			English	Article						tissue engineering; neurite extension; integrins; patterning	PERIPHERAL-NERVE REGENERATION; SELF-ASSEMBLED MONOLAYERS; RECOGNITION SEQUENCES; AXONAL REGENERATION; SIGNAL-TRANSDUCTION; LIGAND-BINDING; ADHESION; ATTACHMENT; NETWORKS; RGD	Controlling receptor-mediated interactions between cells and template surfaces is a central principle in many tissue engineering procedures (1-3). Biomaterial surfaces engineered to present cell adhesion ligands undergo integrin-mediated molecular interactions with cells (1, 4, 5), stimulating cell spreading, and differentiation (6-8). This provides a mechanism for mimicking natural cell-to-matrix interactions. Further sophistication in the control of cell interactions can be achieved by fabricating surfaces on which the spatial distribution of ligands is restricted to micron-scale pattern features (9-14). Patterning technology promises to facilitate spatially controlled tissue engineering with applications in the regeneration of highly organized tissues. These new applications require the formation of ligand patterns on biocompatible and biodegradable templates, which control tissue regeneration processes, before removal by metabolism. We have developed a method of generating micron-scale patterns of any biotinylated ligand on the surface of a biodegradable block copolymer, polylactide-poly(ethylene glycol). The technique achieves control of biomolecule deposition with nanometer precision. Spatial control over cell development has been observed when using these templates to culture bovine aortic endothelial cells and PC12 nerve cells. Furthermore, neurite extension on the biodegradable polymer surface is: directed by pattern features composed of peptides containing the IKVAV sequence (15, 16), suggesting that directional control over nerve regeneration on biodegradable biomaterials can be achieved.	Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	University of Nottingham; Massachusetts Institute of Technology (MIT)	Shakesheff, KM (corresponding author), Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.	kevin.shakesheff@nottingham.ac.uk	Roberts, Clive J/C-6970-2009; Williams, Philip M/C-6947-2009; Shakesheff, Kevin/AAR-6603-2021; Shakesheff, Kevin/O-6371-2018	Roberts, Clive J/0000-0001-9443-3445; Williams, Philip M/0000-0002-1822-2133; Davies, Martyn/0000-0001-7695-0596; Shakesheff, Kevin/0000-0003-3236-2439				BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; Brecknell JE, 1996, BIOL REV, V71, P227, DOI 10.1111/j.1469-185X.1996.tb00748.x; CANNIZZARO SM, 1998, IN PRESS BIOTECHNOL; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CIMA LG, 1993, CHEM ENG PROG    JUN, P46; Cook AD, 1997, J BIOMED MATER RES, V35, P513; Decherchi P, 1996, BRAIN RES, V726, P181, DOI 10.1016/0006-8993(96)00331-9; Delamarche E, 1997, ADV MATER, V9, P741, DOI 10.1002/adma.19970090914; DEROSE JA, 1991, SURF SCI, V256, P102, DOI 10.1016/0039-6028(91)91204-B; DRUMHELLER PD, 1994, ANAL BIOCHEM, V222, P380, DOI 10.1006/abio.1994.1506; EVANS PJ, 1994, PROG NEUROBIOL, V43, P187, DOI 10.1016/0301-0082(94)90001-9; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Han DK, 1996, MACROMOLECULES, V29, P5233, DOI 10.1021/ma9601070; HICKMAN JJ, 1994, J VAC SCI TECHNOL A, V12, P607, DOI 10.1116/1.578844; HO SP, 1994, ADV MATER, V6, P130, DOI 10.1002/adma.19940060205; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Ide C, 1996, NEUROSCI RES, V25, P101; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Larue L, 1996, DEVELOPMENT, V122, P3185; LEE JS, 1993, BIOMATERIALS, V14, P958, DOI 10.1016/0142-9612(93)90139-S; Lhoest JB, 1996, J BIOMAT SCI-POLYM E, V7, P1039, DOI 10.1163/156856296X00534; Li SM, 1996, MACROMOLECULES, V29, P57, DOI 10.1021/ma950531l; Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minuth WW, 1998, CELL TISSUE RES, V291, P1; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775; Nicholls J, 1996, TRENDS NEUROSCI, V19, P229, DOI 10.1016/0166-2236(96)10021-7; OCHI M, 1994, EXP NEUROL, V128, P216, DOI 10.1006/exnr.1994.1130; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; POLLOCK M, 1995, CURR OPIN NEUROL, V8, P354, DOI 10.1097/00019052-199510000-00005; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; RANIERI JP, 1994, INT J DEV NEUROSCI, V12, P725, DOI 10.1016/0736-5748(94)90052-3; RANIERI JP, 1995, J BIOMED MATER RES, V29, P779, DOI 10.1002/jbm.820290614; Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHIBUYA Y, 1995, NEUROSCIENCE, V67, P253, DOI 10.1016/0306-4522(95)00015-B; SPARGO BJ, 1994, P NATL ACAD SCI USA, V91, P11070, DOI 10.1073/pnas.91.23.11070; Tamayo J, 1996, LANGMUIR, V12, P4430, DOI 10.1021/la960189l; TASKINEN HS, 1995, ACTA NEUROPATHOL, V89, P144; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zhao XM, 1997, J MATER CHEM, V7, P1069, DOI 10.1039/a700145b; 1996, J VACUUM SCI TECHNOL, V7	51	210	225	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1447	1454		10.1096/fasebj.12.14.1447	http://dx.doi.org/10.1096/fasebj.12.14.1447			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806753				2022-12-25	WOS:000076749500003
J	Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM				Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM			FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells	ONCOGENE			English	Article						FGF-3; FGF-4; mammary tumors; myoepithelial cells	FIBROBLAST GROWTH-FACTOR; E-CADHERIN EXPRESSION; SMOOTH-MUSCLE ACTIN; HUMAN BREAST-CANCER; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; FACTOR FAMILY; NUDE-MICE; IN-VITRO	Fibroblast Growth Factors 3 (FGF-3) and 4 (FGF-4) mere compared for the effects they each exert on EF43 mouse cells. This non-transformed mammary cell line appears to be myoepithelial mainly because it expresses cc-smooth muscle actin, The EF43 cells were infected with similar vectors that carry either the short fgf-3 sequence (the product of which goes into the secretory pathway), fgf-4 or the selection gene only as control, In syngeneic animals, EF43,fgf-3 cells were tumorigenic only when orthotopically implanted whereas EF43.fgf-4 cells invariably gave rise to aggressive tumors. However, both tumor types were metastatic as evidenced by the blue micrometastases observed when the implanted cells expressed lacZ. In vitro, the FGF-3 producing cells were strongly invasive in matrigel coated chambers whereas the EF43.fgf-4 cells only were invasive in type I-collagen gels, Interestingly, FGF-3 production greatly stimulated the synthesis of pro-MMP-9 (Matrix Metalloprotease-9) and, to a lesser extent, that of pro-MMP-2, FGF-3 also up-regulated the production of plasminogen activators. In contrast, FGF-4 had no effect on these secretions and the medium conditioned by the EF43.fgf-4 cells displayed the largest plasminogen activator-inhibitor activity, These results show that FGF-3 and FGF-4 have distinct mechanisms of action on myoepithelial cells.	Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Med Chem Lab, B-4000 Liege, Belgium; State Univ Ghent, Expt Cancerol Lab, B-9000 Ghent, Belgium	University of Liege; University of Liege; University of Liege; Ghent University	Calberg-Bacq, CM (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B23, B-4000 Liege, Belgium.			Hajitou, Amin/0000-0003-1119-5686; Bajou, Khalid/0000-0002-5529-9228				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ADAMS LM, 1987, CANCER RES, V47, P4425; ANDERSSON LA, 1994, EXP CELL RES, V219, P389; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BARAMOVA EN, 1994, ANTICANCER RES, V14, P841; BARRACLOUGH R, 1990, J CELL PHYSIOL, V144, P333, DOI 10.1002/jcp.1041440220; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; FERNIG DG, 1995, INTERCELLULAR SIGNAL, P336; FOIDART JM, 1980, LAB INVEST, V42, P336; FRANKE WW, 1980, J CELL BIOL, V84, P633, DOI 10.1083/jcb.84.3.633; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GOMM JJ, 1991, CANCER RES, V51, P4685; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAJITOU A, 1995, INT J CANCER, V63, P702, DOI 10.1002/ijc.2910630516; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; KE Y, 1993, J CELL SCI, V100, P135; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEPRINCE P, 1989, ANAL BIOCHEM, V177, P341, DOI 10.1016/0003-2697(89)90063-8; LIN WC, 1990, CANCER RES, V50, P2808; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Miyake H, 1996, CANCER RES, V56, P2440; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; NAVARRO P, 1993, J CELL SCI, V105, P923; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RIES C, 1995, BIOL CHEM H-S, V376, P345; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SATO H, 1992, ONCOGENE, V7, P77; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SMALLEY M, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P99; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; Spieker N, 1995, EUR J CELL BIOL, V68, P427; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; VAKAET L, 1991, INVAS METAST, V11, P249; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Warburton MJ, 1996, EXP CELL RES, V228, P76, DOI 10.1006/excr.1996.0301; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	63	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2059	2071		10.1038/sj.onc.1202126	http://dx.doi.org/10.1038/sj.onc.1202126			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798677				2022-12-25	WOS:000076540900005
J	Barnard, D; Diaz, B; Clawson, D; Marshall, M				Barnard, D; Diaz, B; Clawson, D; Marshall, M			Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms	ONCOGENE			English	Article						oncogene; Ras; Raf; PKC; Src; EGF	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; IN-VITRO; RAS; C-RAF-1; DOMAIN; IDENTIFICATION; ASSOCIATION	We have uniformly examined the regulatory steps required by oncogenic Ras, Src, EGF and phorbol 12-myristate 13-acetate (PMA) to activate Raf-1. Specifically, we determined the role of Ras binding and the phosphorylation of serines 338/339, tyrosines 340/341 and the activation loop (491-508) in response to these stimuli in COS-7 cells. An intact Ras binding domain was found to be essential for Raf-1 kinase activation by each stimulus, including PMA, Brief treatment of COS-7 cells with PMA was found to rapidly promote accumulation of the active, GTP-bound form of Ras. Furthermore, loss of the serine 338/339 and tyrosine 340/341 phosphorylation sites also blocked Raf-1 activation by all stimuli tested. Loss of the serine 497 and serine 499 PKC alpha phosphorylation sites failed to significantly reduce Raf-1 activation by any stimulus including PMA. Alanine substitution of all other potential phosphorylation sites within the Raf-1 activation loop had little or no effect on kinase regulation by Ras[V12] or vSrc although some mutants were less responsive to PMA. These results suggest that in mammalian cells, Raf-1 can be regulated by a variety of different stimuli through a common mechanism involving association with Ras-GTP and multiple phosphorylations of the amino-terminal region of the catalytic domain. Phosphorylation of the activation loop does not appear to be a significant mechanism of Raf-1 kinase regulation in COS-7 cells.	Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Marshall, M (corresponding author), Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, 1044 W Walnut St, Indianapolis, IN 46202 USA.							Arai H, 1996, MOL PHARMACOL, V50, P522; Barnard D, 1995, ONCOGENE, V10, P1283; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1996, ONCOGENE, V12, P609; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1539	1547		10.1038/sj.onc.1202061	http://dx.doi.org/10.1038/sj.onc.1202061			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794231				2022-12-25	WOS:000076089900006
J	Glathe, S; Kervinen, J; Nimtz, M; Li, GH; Tobin, GJ; Copeland, TD; Ashford, DA; Wlodawer, A; Costa, J				Glathe, S; Kervinen, J; Nimtz, M; Li, GH; Tobin, GJ; Copeland, TD; Ashford, DA; Wlodawer, A; Costa, J			Transport and activation of the vacuolar aspartic proteinase phytepsin in barley (Hordeum vulgare L.)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; PROCATHEPSIN-D; ACTIVE-SITE; PURIFICATION; EXPRESSION; MATURATION; DISTINCT; CLEAVAGE; VARIANTS; CELLS	The primary translation product of barley aspartic proteinase, phytepsin (EC 3.4.23.40), consists of a signal sequence, a propart, and mature enzyme forms. Here, we describe post-translational processing and activation of phytepsin during its transport to the vacuole in roots, as detected by using metabolic labeling and immunoprecipitation. After removal of the signal sequence, the glycosylated precursor of 53 kDa (P53) was produced and further processed to polypeptides of 31 and 15 kDa (P31 + P15) and, subsequently, to polypeptides of 26 and 9 kDa (P26 + P9), 45 min and 24 h after synthesis, respectively. The processing occurred in a late-Golgi compartment or post-Golgi compartment, because brefeldin A inhibited the processing, and P53 acquired partial endoglycosidase H resistance 30 min after synthesis, whereas P15 was completely resistant. The N-glycosylation inhibitor tunicamycin had no effect on transport, but the absence of glycans on P53 accelerated the proteolytic processing. Phytepsin was also expressed in baculovirus-infected insect cells. The recombinant prophytepsin underwent autoproteolytic activation in vitro and showed enzymatic properties similar to the enzyme purified from grains. However, a comparison of the in vitro/in vivo processing sites revealed slight differences, indicating that additional proteases are needed for the completion of the maturation in vivo.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, IBET, P-2780 Oeiras, Portugal; NCI, Lab Cell & Mol Struct Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Univ York, Dept Biol, Glycobiol Res & Analyt Facil, York YO1 5DD, N Yorkshire, England; Univ Algarve, Unidad Ciencias Exactas & Humanas, P-8000 Faro, Portugal	Universidade Nova de Lisboa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of York - UK; Universidade do Algarve	Costa, J (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, IBET, Apartado 12, P-2780 Oeiras, Portugal.	jcosta@itqb.unl.pt	Costa, Júlia C/B-7131-2008	Costa, Júlia C/0000-0001-7782-6319				ASAKURA T, 1995, EUR J BIOCHEM, V232, P77, DOI 10.1111/j.1432-1033.1995.tb20783.x; Barrett Alan J., 1997, European Journal of Biochemistry, V250, P1; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CORDEIRO MC, 1994, PLANT MOL BIOL, V24, P733, DOI 10.1007/BF00029855; Costa J, 1997, EUR J BIOCHEM, V243, P695, DOI 10.1111/j.1432-1033.1997.t01-1-00695.x; Costa J, 1997, J BIOL CHEM, V272, P11613; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; KERVINEN J, 1998, HDB PROTEOLYTIC ENZY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; MANNINEN I, 1993, PLANT MOL BIOL, V22, P829, DOI 10.1007/BF00027369; MARTTILA S, 1995, PHYSIOL PLANTARUM, V93, P317, DOI [10.1034/j.1399-3054.1995.930217.x, 10.1111/j.1399-3054.1995.tb02235.x]; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RICHO GR, 1994, J BIOL CHEM, V269, P14806; Runeberg-Roos P, 1998, PLANT J, V15, P139, DOI 10.1046/j.1365-313X.1998.00187.x; RUNEBERGROOS P, 1994, PLANT PHYSIOL, V105, P321, DOI 10.1104/pp.105.1.321; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; SARKKINEN P, 1992, PLANTA, V186, P317, DOI 10.1007/BF00195311; SatiatJeunemaitre B, 1996, J MICROSC-OXFORD, V181, P162, DOI 10.1046/j.1365-2818.1996.112393.x	27	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31230	31236		10.1074/jbc.273.47.31230	http://dx.doi.org/10.1074/jbc.273.47.31230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813030	hybrid			2022-12-25	WOS:000077136900058
J	Hodge, C; Liao, JF; Stofega, M; Guan, KL; Carter-Su, C; Schwartz, J				Hodge, C; Liao, JF; Stofega, M; Guan, KL; Carter-Su, C; Schwartz, J			Growth hormone stimulates phosphorylation and activation of Elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; TERNARY COMPLEX FACTORS; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; RAT ADIPOCYTES; 3T3-F442A PREADIPOCYTES; SERINE PHOSPHORYLATION	Growth hormone (GR), a major regulator of normal body growth and metabolism, regulates cellular gene expression. The transcription factors Elk-1 and Serum Response Factor are necessary for GH-stimulated transcription of c-fos through the Serum Response Element (SRE), GH stimulates the serine phosphorylation of Elk-1, thereby enabling Elk-1 to mediate transcriptional activation. The contribution of the Ras/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway to Elk-1-mediated transcriptional activation of the c-fos SRE in response to GH: was examined. The MEK inhibitor PD098059 attenuated GH-induced expression of the endogenous SRE-regulated genes c-fos, egr-1, and junB as well as transcriptional activation mediated by the c-fos promoter. The MEK inhibitor blocked GH-stimulated activation of MEK, phosphorylation of ERK1/ERK2, and MAP kinase activity in 3T3-F442A cells. Blocking MEK activation prevented GH-induced phosphorylation of Elk-1, as well as the ability of Elk-1 to mediate transcriptional activation in response to GH, Overexpression of dominant-negative Ras or the ERK-specific phosphatase, mitogen-activated protein kinase phosphatase-1, blocked the Ras/MEK/ERK. pathway and abrogated GH-induced phosphorylation of Elk-1, GH failed to stimulate phosphorylation or activation of Jun N-terminal kinase under the conditions used. GH slightly increased p38-mediated mitogen-activated protein kinase-activated protein (MAP-KAP) kinase-2 activity, but the p38 inhibitor SB203580 did not attenuate GH-promoted Elk-1 phosphorylation. Wortmannin, which inhibited GH-induced ERK phosphorylation, also attenuated transcriptional activation of c-fos by GH, Taken together, these data suggest that GH-dependent activation of the Ras/MEK/ERK pathway and subsequent serine phosphorylation of Elk-1 contribute to GH-stimulated c-fos expression through the SRE.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK 46072, DK 34171, R01 DK046072, R01 DK034171] Funding Source: Medline; NIGMS NIH HHS [R01 GM051586, GM51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171, R01DK046072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1995, BIOCHEM SOC T, V23, pS197, DOI 10.1042/bst023197s; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BILLESTRUP N, 1994, P SOC EXP BIOL MED, V206, P205; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; CHEN SY, 1994, ONCOGENE, V9, P2691; Cohen DM, 1996, P NATL ACAD SCI USA, V93, P11242, DOI 10.1073/pnas.93.20.11242; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; COX AD, 1994, J BIOL CHEM, V269, P19203; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Holt KH, 1996, MOL CELL BIOL, V16, P577; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIU SH, 1993, J BIOL CHEM, V268, P21147; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMANTRAN VN, 1992, ENDOCRINOLOGY, V130, P2016, DOI 10.1210/en.130.4.2016; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YOON JB, 1987, J BIOL CHEM, V262, P4284; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	80	222	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31327	31336		10.1074/jbc.273.47.31327	http://dx.doi.org/10.1074/jbc.273.47.31327			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813041	hybrid			2022-12-25	WOS:000077136900069
J	Li, J; Tsuji, K; Komori, T; Miyazono, K; Wrana, JL; Ito, Y; Nifuji, A; Noda, M				Li, J; Tsuji, K; Komori, T; Miyazono, K; Wrana, JL; Ito, Y; Nifuji, A; Noda, M			Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; MAD-RELATED PROTEIN; DNA-BINDING PROTEIN; GROWTH-FACTOR-BETA; OSTEOCALCIN GENE; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE PRODUCT; SIGNALING PATHWAYS; PROMOTER ACTIVITY; BONE-FORMATION	Mothers against decapentaplegic-related proteins (Smads) are essential intracellular components for the signal transduction of transforming growth factor-beta (TGF-beta) family members. Smad1 mediates bone morphogenetic protein (BMP) signals, whereas Smad2 functions downstream of TGF-beta. TGF-beta is expressed in osteoblastic cells and acts as an autocrine and/or paracrine factor in regulation of osteoblastic functions. In this study, we examined the levels and functions of Smad2 in osteoblastic cells. Smad2 mRNA expression was hardly detectable by Northern blot analysis in an osteoblast-like cell line, ROS17/2.8, as well as in primary rat calvaria (PRC) cells, Overexpression of Smad2 gene enhanced endogenous Smad4 gene expression in both ROS17/2.8 and PRC cells, while Smads levels were not altered. Smad2 overexpression suppressed osteocalcin mRNA expression in ROS17/2.8 cells. Furthermore, Smad2 overexpression also suppressed transcriptional activity of the 1-kilobase pair osteocalcin gene promoter, which was linked to chloramphenicol acetyltransferase reporter gene in both ROS and PRC cells. Since core binding factor A1 (CBFA1) is involved in osteocalcin gene expression, we further examined CBFA1 expression in the Smad2-overexpressing ROS17/2.8 and PRC cells. The levels of CBFA1 mRNA were suppressed by the overexpression of Smad2 by about 50% in both ROS17/2.8 and PRC cells. TGF-beta treatment enhanced Smad4 expression in PRC cells, and this TGF-beta effect was blocked by the cotreatment with EMP, indicating that TGF-beta signaling pathway is interfered by BMP. These data indicate that Smad2 regulates Smad4 specifically and that CBFA1 gene is one of the downstream targets of Smad2.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 101, Japan; Osaka Univ, Dept Med 3, Sch Med, Suita, Osaka 565, Japan; Inst Canc Res, Dept Biochem, Toshima Ku, Tokyo 170, Japan; Hosp Sick Children, Program Dev Biol, Div Gastroenterol, Toronto, ON M5G 1X8, Canada; Kyoto Univ, Inst Virus Res, Lab Cell Regulat, Dept Viral Oncol,Sakyo Ku, Kyoto 606, Japan	Tokyo Medical & Dental University (TMDU); Osaka University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Kyoto University	Noda, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, 3-10 Kanda Surugadai 2-Chome, Tokyo 101, Japan.	noda.mph@mri.tmd.ac.jp	Wrana, Jeffrey/F-8857-2013; Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380; Li, Jinghong/0000-0003-2497-9295				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BORTELL R, 1993, P NATL ACAD SCI USA, V90, P2300, DOI 10.1073/pnas.90.6.2300; BREEN EC, 1994, J CELL PHYSIOL, V160, P323, DOI 10.1002/jcp.1041600214; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HAUSCHKA PV, 1986, HAEMOSTASIS, V16, P258; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schutte M, 1996, CANCER RES, V56, P2527; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; YOON K, 1988, BIOCHEMISTRY-US, V27, P8521, DOI 10.1021/bi00423a003; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	52	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31009	31015		10.1074/jbc.273.47.31009	http://dx.doi.org/10.1074/jbc.273.47.31009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812998	hybrid			2022-12-25	WOS:000077136900026
J	Crish, JF; Zaim, TM; Eckert, RL				Crish, JF; Zaim, TM; Eckert, RL			The distal regulatory region of the human involucrin promoter is required for expression in epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC EXPRESSION; CROSS-LINKED ENVELOPE; CORNIFIED CELL-ENVELOPE; MOUSE LORICRIN GENE; TRANSGENIC MICE; TERMINAL DIFFERENTIATION; PROXIMAL PROMOTER; HUMAN KERATIN-1; RETINOIC ACID; AP-1 ELEMENT	Human involucrin (hINV) is a precursor of the keratinocyte cornified envelope that is specifically expressed in the suprabasal layers of stratifying squamous epithelia. The promoter distal (DRR) and proximal regulatory regions (PRR) are required for optimal in vitro expression (Welter, J, F,, Crish, J. F., Agarwal, C., and Eckert, R. L, (1995) J. Biol. Chem. 270, 12614-12622; and Banks, E. B., Crish, J. F., Welter, J. F,, and Eckert, R. L. (1998) Biochem. J. 331, 61-68). We now present the complete sequence of these regions and evaluate their ability to drive in vivo transcription. Transgenes containing 5000 or 2473 base pairs of upstream regulatory region drive tissue- and differentiation-appropriate expression in stratifying surface epithelia, In contrast, transgenes containing 1953, 1333, 986, or 41 base pairs of upstream regulatory region are not expressed in surface epithelia, indicating that loss of the DRR (nucleotides -2474/-1953) results in loss of expression. Fusing the isolated DRR region directly to the hINV minimal promoter restores surface epithelial expression. Sequences downstream of the transcribed gene are not required for appropriate expression. The -1953/-41 segment influences the pattern of differentiation-dependent expression. The -986/-41 region, which includes the PRR, drives expression in internal epithelia.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BERNARD HU, 1994, ARCH DERMATOL, V130, P210, DOI 10.1001/archderm.130.2.210; BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CRIPE T P, 1990, New Biologist, V2, P450; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ECKERT RL, 1987, GENE, V51, P247, DOI 10.1016/0378-1119(87)90313-1; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; HOGAN B, 1986, MANIPULATING MOUSE E; HU L, 1994, J BIOL CHEM, V269, P183; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STEVEN AC, 1994, J CELL SCI, V107, P693; Sun TT, 1984, CANCER CELLS, V1, P169; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WARHOL MJ, 1985, J HISTOCHEM CYTOCHEM, V33, P141, DOI 10.1177/33.2.2578499; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223; Yoneda Kozo, 1992, Journal of Dermatology (Tokyo), V19, P761	54	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30460	30465		10.1074/jbc.273.46.30460	http://dx.doi.org/10.1074/jbc.273.46.30460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804813	hybrid			2022-12-25	WOS:000077008100060
J	Lee, DY; Clayton, DA				Lee, DY; Clayton, DA			Initiation of mitochondrial DNA replication by transcription and R-loop processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADING-STRAND ORIGIN; RNASE MRP; DROSOPHILA EMBRYOS; PURIFIED PROTEINS; RIBOSOMAL-RNA; POLYMERASE; BACTERIOPHAGE-T7; PRIMER; SITE; ENDORIBONUCLEASE	The mitochondrial genome of eukaryotic cells is maintained by a mechanism distinct from that employed in the nucleus. Mitochondrial DNA replication at the leading-strand origin is coupled to transcription through the formation of an RNA-RNA hybrid known as an R-loop. In vivo and in vitro evidence has implicated an RNA processing enzyme, RNase MRP, in primer maturation. In our investigation of mammalian RNase MRP, we have analyzed its specific endoribonuclease activity on model R-loops. We demonstrate here that human RNase MRP cleaves this distinctly configured substrate at virtually all of the major DNA replication sites previously mapped in vivo. We further show that the processed RNA products remain stably base-paired to the template DNA strand and are functional for initiating DNA synthesis on a closed circular plasmid. Thus, in vitro initiation of leading-strand mtDNA synthesis requires only the actions of RNA polymerase and RNase MRP for the generation of replication primers.	Stanford Univ, Med Ctr, Sch Med, Dept Dev Biol,Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA	Stanford University	Clayton, DA (corresponding author), Howard Hughes Med Inst, 4000 Jones Bridge Rd, Chevy Chase, MD 20815 USA.				NIGMS NIH HHS [GM07365-19, R37-GM33088-27] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN GG, 1986, J MOL BIOL, V192, P503, DOI 10.1016/0022-2836(86)90272-X; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1994, P NATL ACAD SCI USA, V91, P4615, DOI 10.1073/pnas.91.11.4615; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; HUANG L, 1994, J BIOL CHEM, V269, P25922; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275; KORNBERG A, 1992, DNA REPLICATION, P209; Lee DY, 1996, J BIOL CHEM, V271, P24262, DOI 10.1074/jbc.271.39.24262; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; ROMANO LJ, 1981, P NATL ACAD SCI-BIOL, V78, P4107, DOI 10.1073/pnas.78.7.4107; SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x	31	112	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30614	30621		10.1074/jbc.273.46.30614	http://dx.doi.org/10.1074/jbc.273.46.30614			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804833	hybrid			2022-12-25	WOS:000077008100080
J	Ma, HW; Sprecher, HW; Kolattukudy, PE				Ma, HW; Sprecher, HW; Kolattukudy, PE			Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPAR gamma-expressing tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; BIOCHEMICAL-MECHANISMS; ARACHIDONIC-ACID; PROSTAGLANDIN-D2; METABOLISM; ALPHA; 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2; 9-ALPHA,11-BETA-PROSTAGLANDIN-F2; DELTA-12-PROSTAGLANDIN-J2; THIAZOLIDINEDIONE	Peroxisome proliferation has been associated with carcinogenesis in the liver, and estrogen intake has been associated with increased risk of cancer in the hormone target tissues. Estrogen-induced peroxisome proliferation has been observed in an estrogen target tissue, the uropygial gland in the duck. To elucidate the molecular mechanism of this process, we previously isolated the cDNA of peroxisome proliferator-activated receptor gamma 1 (PPAR gamma 1) from the duck uropygial gland and found that its expression was high exclusively in this tissue of duck. However, the nature of the ligand for PPAR gamma 1 and how estrogen might enhance PPAR gamma 1-regulated gene expression were not known. Here we dem onstrate that estrogen treatment of animals enhanced the metabolism of arachidonic acid in the uropygial gland. Conversion of prostaglandin D-2 to a metabolite was induced by estradiol treatment preceding peroxisome proliferation, High performance liquid chromatography and TLC analyses showed that the metabolite behaved chromatographically similar to prostaglandin J(2) and Delta(12)-prostaglandin J(2). Gas chromatography/mass spectrometry revealed a striking similarity of the metabolite to Delta(12)-prostaglandin J(2), the only form among the J(2) series whose natural occurrence has been detected. Furthermore, this metabolite was able to activate duck PPAR gamma 1 to the same extent as the same concentrations of Delta(12)-prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2), whereas under the same conditions, prostaglandin D-2 was not effective. The results suggest that estrogen treatment induced the formation of a prostaglandin D-2 metabolite that activated duck PPAR gamma 1, causing the induction of peroxisome proliferation in the duck uropygial gland.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kolattukudy, PE (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, 206 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	kolattukudy.2@osu.edu	kolattukudy, pappachan e/A-1350-2012		NCI NIH HHS [CA58035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHNET S, 1991, J BIOL CHEM, V266, P9795; CHAUD M, 1994, PROSTAG LEUKOTR ESS, V51, P47, DOI 10.1016/0952-3278(94)90177-5; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FAYARD JM, 1994, EUR J ENDOCRINOL, V131, P205, DOI 10.1530/eje.0.1310205; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYBERGER A, 1989, J STEROID BIOCHEM, V33, P473, DOI 10.1016/0022-4731(89)90339-7; FUKUSHIMA M, 1982, BIOCHEM BIOPH RES CO, V109, P626, DOI 10.1016/0006-291X(82)91986-6; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; HAM EA, 1975, P NATL ACAD SCI USA, V72, P1420, DOI 10.1073/pnas.72.4.1420; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HOULT JRS, 1988, BIOCHEM PHARMACOL, V37, P3591, DOI 10.1016/0006-2952(88)90389-9; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Kilgore MW, 1997, MOL CELL ENDOCRINOL, V129, P229, DOI 10.1016/S0303-7207(97)04057-4; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; Ma HW, 1998, FEBS LETT, V434, P394, DOI 10.1016/S0014-5793(98)01017-5; MAHMUD I, 1984, PROSTA LEUKOTR MED, V16, P131, DOI 10.1016/0262-1746(84)90066-0; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; PAKRASI PL, 1984, PROSTA LEUKOTR MED, V14, P365, DOI 10.1016/0262-1746(84)90120-3; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; RAO MS, 1987, CARCINOGENESIS, V8, P631; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROBINSON C, 1988, BIOCHIM BIOPHYS ACTA, V963, P151, DOI 10.1016/0005-2760(88)90276-7; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1997, BIOCHIMIE, V79, P95, DOI 10.1016/S0300-9084(97)81497-6; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TAWFIK OW, 1987, PROSTAGLANDINS, V34, P805, DOI 10.1016/0090-6980(87)90062-1; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WATANABE K, 1986, P NATL ACAD SCI USA, V83, P1583, DOI 10.1073/pnas.83.6.1583; WILSON L, 1984, PROSTAGLANDINS, V28, P104; WOLFE LS, 1989, J NEUROCHEM, V53, P64, DOI 10.1111/j.1471-4159.1989.tb07295.x	50	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30131	30138		10.1074/jbc.273.46.30131	http://dx.doi.org/10.1074/jbc.273.46.30131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804768	hybrid			2022-12-25	WOS:000077008100015
J	Masuda, Y; Bennett, RAO; Demple, B				Masuda, Y; Bennett, RAO; Demple, B			Rapid dissociation of human apurinic endonuclease (Ape1) from incised DNA induced by magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; COLI EXONUCLEASE-III; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; APYRIMIDINIC ENDONUCLEASE; ENZYME HAP1; SUBSTRATE; MUTAGENESIS; SITES; IDENTIFICATION	Repair of apurinic/apyrimidinic (AP) sites is initiated by AP endonucleases, such as the human Ape1 protein (also called Hap1, Apex, and Ref1). This and related enzymes show strong dependence on divalent cations, particularly magnesium, Here we explore the role of this metal in different stages of the Ape1 reaction: substrate binding, cleavage, and product release. We examined DNA binding using an electrophoretic approach and DNA cleavage in single-turnover and steady-state reactions. Magnesium at low to moderate concentrations accelerated both substrate and product release by wildtype Ape1 protein. For a mutant Ape1 protein with an aspartate to alanine substitution at residue 308, substrate in preformed protein-DNA complexes was more efficiently cleaved before release in contrast to wildtype Ape1, whereas product release was accelerated dramatically. The magnesium dependence of steady-state AP endonuclease reactions was sigmoidal for both wild-type and the aspartate 308 to alanine protein but was not sigmoidal for an aspartate 283 to alanine derivative of Ape1. These results show that magnesium affects both DNA interactions with and phosphodiester cleavage by Ape1 and can change the rate-limiting step of the reaction. Structural studies will need to be interpreted in the context of these diverse effects of the metal.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu	Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988	NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993] Funding Source: Medline; NIEHS NIH HHS [ES03926] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; KANE CM, 1981, J BIOL CHEM, V256, P3405; KOW YW, 1989, BIOCHEMISTRY-US, V28, P3280, DOI 10.1021/bi00434a024; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Rothwell DG, 1996, NUCLEIC ACIDS RES, V24, P4217, DOI 10.1093/nar/24.21.4217; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WEISS B, 1976, J BIOL CHEM, V251, P1896; Wilson DM, 1998, CONT CANC RES, P29; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; YAJKO DM, 1975, P NATL ACAD SCI USA, V72, P688, DOI 10.1073/pnas.72.2.688	30	82	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30360	30365		10.1074/jbc.273.46.30360	http://dx.doi.org/10.1074/jbc.273.46.30360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804799	hybrid			2022-12-25	WOS:000077008100046
J	Yeung, YG; Soldera, S; Stanley, ER				Yeung, YG; Soldera, S; Stanley, ER			A novel macrophage actin-associated protein (MAYP) is tyrosine-phosphorylated following colony stimulating factor-1 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; FACTOR-I; CELL-LINE; PHOSPHATASE; CSF-1; RECEPTOR; BAC1.2F5; CLEAVAGE	An similar to 37-kDa cytoplasmic protein is rapidly tyrosine-phosphorylated in the response of mouse BAC1.2F5 macrophages to colony stimulating factor-1 (CSF-1). pp37 was purified from the cytosolic fraction by anti-Tyr(P) affinity chromatography, size exclusion chromatography, and C-4 reverse phase high pressure liquid chromatography. The sequences of four peptides derived from the purified protein matched portions of an expressed sequence tag (EST) sequence, and the EST clone was used to obtain cDNA clones encoding the pp37 protein, which shares sequence similarity with the PST PIP (proline, serine, threonine phosphatase interacting protein)/CDC15 family of protein-tyrosine phosphatase substrates. pp37 is predicted to contain a Fes/CIP4 homology (FCH) domain and an actin-binding domain-like sequence. It is expressed selectively in macrophages, macrophage cell lines, and at low levels in macrophage-containing tissues. pp37 is predominantly found in the cytosol, where it is associated with actin. However, similar to 4% resides in the membrane fraction, and the trace amount in the cytoskeletal fraction is increased by CSF-1 stimulation. Termed macrophage actin-associated tyrosine-phosphorylated protein (MAYP), p37 is the major F-actin-associated protein that is tyrosine-phosphorylated in macrophages and is likely to play a role in regulating the CSF-1-induced reorganization of the actin cytoskeleton.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, ER (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NCI NIH HHS [CA 26504, CA 32551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026504, R01CA026504, R01CA032551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Baccarini M, 1991, Receptor, V1, P243; BOOCOCK CA, 1989, J CELL SCI, V93, P447; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Dosil M, 1996, BLOOD, V88, P4510, DOI 10.1182/blood.V88.12.4510.bloodjournal88124510; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MAGE MG, 1998, METHODS ENZYMOL A, V70, P142; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Pollard JW., 1996, ADV D BIOCH, V4, P153; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; STANLEY ER, 1994, CYTOKINE HDB, P387; STANLEY ER, 1990, METHOD MOL BIOL, P299; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; Webb SE, 1996, J CELL SCI, V109, P793; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	25	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30638	30642		10.1074/jbc.273.46.30638	http://dx.doi.org/10.1074/jbc.273.46.30638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804836	hybrid			2022-12-25	WOS:000077008100083
J	Hu, SM; Snipas, SJ; Vincenz, C; Salvesen, G; Dixit, VM				Hu, SM; Snipas, SJ; Vincenz, C; Salvesen, G; Dixit, VM			Caspase-14 is a novel developmentally regulated protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DOMAIN-CONTAINING RECEPTOR; CELL-DEATH; CYSTEINE PROTEASES; INDUCED APOPTOSIS; FAMILY; PROTEINS; MEMBER; FLICE; IDENTIFICATION	Caspases are a family of cysteine proteases related to interleukin-1 converting enzyme (ICE) and represent the effector arm of the cell death pathway. The zymogen form of all caspases is composed of a prodomain plus large and small catalytic subunits. Herein we report the characterization of a novel caspase, MICE (for mini-ICE), also designated caspase-14, that possesses an unusually short prodomain and is highly expressed in embryonic tissues but absent from all adult tissues examined. In contrast to the other short prodomain caspases (caspase-3, caspase-6, and caspase-7), MICE preferentially associates with large prodomain caspases, including caspase-1, caspase-2, caspase-4, caspase-8, and caspase-10. Also unlike the other short prodomain caspases, MICE was not processed by multiple death stimuli including activation of members of the tumor necrosis factor receptor family and expression of proapoptotic members of the bcl-2 family. Surprisingly, however, overexpression of MICE itself induced apoptosis in MCF7 human breast cancer cells, which was attenuated by traditional caspase inhibitors.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Burnham Inst, La Jolla, CA 92037 USA	Roche Holding; Genentech; University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Rm 290, San Francisco, CA 94080 USA.	dixit@gene.com	Hu, Shimin/H-3427-2019; dixit, vishva m/A-4496-2012	Hu, Shimin/0000-0001-7110-3814; dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [AG13671] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CRAEN MV, 1997, FEBS LETT, V403, P61; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	29	128	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29648	29653		10.1074/jbc.273.45.29648	http://dx.doi.org/10.1074/jbc.273.45.29648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792675	hybrid			2022-12-25	WOS:000076798300052
J	Kapitskaya, MZ; Dittmer, NT; Deitsch, KW; Cho, WL; Taylor, DG; Leff, T; Raikhel, AS				Kapitskaya, MZ; Dittmer, NT; Deitsch, KW; Cho, WL; Taylor, DG; Leff, T; Raikhel, AS			Three isoforms of a hepatocyte nuclear factor-4 transcription factor with tissue- and stage-specific expression in the adult mosquito	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; LYSOSOMAL ASPARTIC PROTEASE; DNA-BINDING-DOMAIN; HORMONE-RECEPTOR; FAT-BODY; VITELLOGENIN GENE; ECDYSONE RECEPTOR; ORPHAN RECEPTOR; AEDES-AEGYPTI; FACTOR HNF-4	We cloned three isoforms of hepatocyte nuclear factor-4 (HNF-4) from the mosquito Aedes aegypti, designated AaHNF-4a, AaHNF-4b, and AaHNF-4c. AaHNF-4a and AaHNF-4b are typical members of the HNF-4 subfamily of nuclear receptors with high amino acid conservation. They differ in N-terminal regions and exhibit distinct developmental profiles in the female mosquito fat body, a metabolic tissue functionally analogous to the vertebrate liver. The AaHNF-4b mRNA is predominant during the previtellogenic and vitellogenic phases, while the AaHNF-4a mRNA is predominant during the termination phase of vitellogenesis, coinciding with the onset of lipogenesis. The third isoform, AaHNF-4c, lacks part of the A/B and the entire C (DNA-binding) domains. The AaHNF-4c transcript found in the fat body during the termination of vitellogenesis may serve as a transcriptional inhibitor. Both AaHNF-4a and AaHNF-4b bind to the cognate DNA recognition site in electrophoretic mobility shift assay. Dimerization of AaHNF-4c with other mosquito HNF-4 isoforms or with mammalian HNF-4 prevents binding to the HNF-4 response element. In transfected human 293T cells, AaHNF-4c significantly reduced the transactivating effect of the human HNF-4 alpha 1 on the apolipoprotein CIII promoter. Electrophoretic mobility shift assay confirmed the presence of HNF-4 binding sites upstream of A. aegypti vg and vcp, two yolk protein genes expressed in the female mosquito fat body during vitellogenesis. Therefore, HNF-4, an important regulator of liver-specific genes, plays a critical role in the insect fat body.	Michigan State Univ, Genet Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA; Natl Yang Ming Univ, Dept Parasitol, Taipei 112, Taiwan; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Cell Biol, Ann Arbor, MI 48105 USA	Michigan State University; Michigan State University; National Yang Ming Chiao Tung University; Pfizer	Raikhel, AS (corresponding author), Michigan State Univ, Genet Program, E Lansing, MI 48824 USA.	araikhel@pilot.msu.edu	Leff, Todd/U-9084-2018	Leff, Todd/0000-0001-6923-3900	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; ABEL T, 1993, DEVELOPMENT, V119, P623; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOSE SG, 1988, BIOCHEM BIOPH RES CO, V155, P436, DOI 10.1016/S0006-291X(88)81105-7; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHO WL, 1992, J BIOL CHEM, V267, P21823; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DARLING DS, 1993, J BIOL CHEM, V268, P10221; Deitsch K.W., 1993, Insect Molecular Biology, V2, P205, DOI 10.1111/j.1365-2583.1994.tb00140.x; Dittmer NT, 1997, INSECT BIOCHEM MOLEC, V27, P323, DOI 10.1016/S0965-1748(97)00007-6; Drewes T, 1996, MOL CELL BIOL, V16, P925; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HATA S, 1995, BBA-GENE STRUCT EXPR, V1260, P55, DOI 10.1016/0167-4781(94)00177-5; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jindra M, 1997, INSECT MOL BIOL, V6, P41, DOI 10.1046/j.1365-2583.1997.00153.x; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; Kapitskaya M, 1996, MOL CELL ENDOCRINOL, V121, P119, DOI 10.1016/0303-7207(96)03847-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEA ARDEN O., 1964, J MED ENTOMOL, V1, P40, DOI 10.1093/jmedent/1.1.40; LEFF T, 1989, J BIOL CHEM, V264, P16132; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Raikhel A.S., 1992, Advances in Disease Vector Research, V9, P1; RAIKHEL AS, 1998, IN PRESS AM ZOOLOGIS; ROMANS P, 1995, INSECT BIOCHEM MOLEC, V25, P939, DOI 10.1016/0965-1748(95)00037-V; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, TRANSCRIPTIONAL REGU, P207; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; Swevers L, 1998, MECH DEVELOP, V72, P3, DOI 10.1016/S0925-4773(97)00180-9; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Taraviras S, 1997, EUR J BIOCHEM, V244, P883, DOI 10.1111/j.1432-1033.1997.00883.x; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VanHeusden MC, 1997, ARCH INSECT BIOCHEM, V34, P301, DOI 10.1002/(SICI)1520-6327(1997)34:3<301::AID-ARCH5>3.0.CO;2-X; Wyatt G.R., 1980, P201; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	56	9	9	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29801	29810		10.1074/jbc.273.45.29801	http://dx.doi.org/10.1074/jbc.273.45.29801			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792695	hybrid			2022-12-25	WOS:000076798300072
J	Lawson, JA; Li, HW; Rokach, J; Adiyaman, M; Hwang, SW; Khanapure, SP; FitzGerald, GA				Lawson, JA; Li, HW; Rokach, J; Adiyaman, M; Hwang, SW; Khanapure, SP; FitzGerald, GA			Identification of two major F-2 isoprostanes, 8,12-iso- and 5-epi-8,12-iso-isoprostane F-2 alpha-VI, in human urine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS IN-VIVO; OXIDANT STRESS; 8-EPI-PROSTAGLANDIN F2-ALPHA; CORONARY REPERFUSION; LIPID-PEROXIDATION; METABOLISM; RAT; F-2-ISOPROSTANES; LEUKOTRIENE-E4; EXCRETION	Isoprostanes (iPs) are nonenzymatic, free radical-derived compounds isomeric with enzymatically formed eicosanoids such as prostaglandins, leukotrienes, and thromboxanes. One group formed by the auto-oxidation of arachidonic acid, the F-2-iPs, consists of four classes of isomers of prostaglandin F-2 alpha (PGF(2 alpha)), They are relatively abundant in human urine. This fact, along with their chemical stability and excellent characteristics for quantitation by gas chromatography/mass spectrometry, has made them attractive indices of oxidative stress in humans. We developed a specific assay using gas chromatography/mass spectrometry for the first identified F-2-iP, iPF(2 alpha)-III (previously called 8-iso-PGF(2 alpha) or 8-epi-PGF(2 alpha)), which demonstrated the utility of monitoring a specific isomer, Recently, we described an assay for another isomer, iPF(2 alpha)-VI, which is present in urine in greater concentration than iPF(2 alpha)-III and which is particularly amenable to quantitation, We now describe the identification in human urine of two more isomers, 8,12-iso-iPF(2 alpha)-Vl and 5-epi-8,12-iso-iPF(2 alpha)-VI, using high performance liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry, These compounds are each present in similar to 5-fold greater concentrations than iPF(2 alpha)-VI (similar to 20-fold greater than iPF(2 alpha)-III), They share the unique chemical characteristics of class VI compounds, which make them attractive targets for quantitation by gas chromatography/mass spectrometry and immunoassay development.	Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54500] Funding Source: Medline; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; FOSTER A, 1987, BIOCHIM BIOPHYS ACTA, V921, P486, DOI 10.1016/0005-2760(87)90076-2; Iuliano L, 1997, BLOOD, V90, P3931, DOI 10.1182/blood.V90.10.3931; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; REILLY M, 1998, IN PRESS CIRCULATION; Reilly MP, 1997, CIRCULATION, V96, P3314; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; ROKACH J, 1990, J ALLERGY CLIN IMMUN, V868, P211; SALA A, 1990, J BIOL CHEM, V265, P21771; STENE DO, 1988, J BIOL CHEM, V263, P2773; TAGARI P, 1989, PROSTAG OTH LIPID M, V37, P629, DOI 10.1016/0090-6980(89)90101-9; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; WENDELBORN DF, 1988, P NATL ACAD SCI USA, V85, P304, DOI 10.1073/pnas.85.2.304	25	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29295	29301		10.1074/jbc.273.45.29295	http://dx.doi.org/10.1074/jbc.273.45.29295			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792628	hybrid			2022-12-25	WOS:000076798300005
J	Leong, P; MacLennan, DH				Leong, P; MacLennan, DH			The cytoplasmic loops between domains II and III and domains III and IV in the skeletal muscle dihydropyridine receptor bind to a contiguous site in the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; MALIGNANT-HYPERTHERMIA; CA2+ RELEASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CDNA; CAFFEINE; MUTATION; CELLS	Excitation-contraction coupling in skeletal muscle is a result of the interaction between the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor or RyR1) and the skeletal muscle L-type Ca2+ channel (dihydropyridine receptor or DHPR), Interactions between RyR1 and DHPR are critical for the depolarization-induced activation of Ca2+ release from the sarcoplasmic reticulum, enhancement of DHPR Ca2+ channel activity, and repolarization induced inactivation of RyR1. The DHPR III-IV loop was fused to glutathione S-transferase (GST) or His-peptide and used as a protein affinity column for S-35-labeled, in vitro translated fragments from the N-terminal three-fourths of RyR1, RyR1 residues Leu(922)-Asp(1112) bound specifically to the DHPR III-IV loop column, but the corresponding fragment from the cardiac ryanodine receptor (RyR2) did not. Construction of chimeras between RyR1 and RyR2 showed that amino acids Lys(954)- Asp(1112) retained full binding activity, whereas Leu(922)- Phe(1075) had no binding activity. The RyR1 sequence Arg(1076)-Asp(1112), previously shown to interact with the DHPR II-III loop (Leong, P,, and MacLennan, D,, H. (1998) J, Biol, Chem. 273, 7791-7794), bound to DHPR III-IV loop columns, but with only half the efficiency of binding of the longer RyR1 sequence, Lys(954)-Asp(1112) These data suggest that the site of DHPR III-TV loop interaction contains elements from both the Lys(954)-Phe(1075) and Arg(1076)-Asp(1112) fragments. The presence of 4 +/- 0.4 mu M GST-DHPR II-III or 5 +/- 0.1 mu M His-peptide-DHPR III-IV was required for half-maximal co-purification of S-35-labeled RyR1 Leu(922)-Asp(1112) On glutathione-Sepharose or Ni2+-nitrilotriacetic acid. Dose-dependent inhibition of S-35-labeled RS RI Leu(922)-Asp(1112) binding to GST-DHPR II-III and GST-DHPR III-IV by His(10)-DHPR II-III and His-peptide-DHPR III-IV was observed. These studies indicate that the DHPR II-III and III-IV loops bind to contiguous and possibly overlapping sites on RyR1 between Lys(954) and Asp(1112).	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Catterall WA, 1996, J BIOENERG BIOMEMBR, V28, P219, DOI 10.1007/BF02110697; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Kozak M, 1979, Methods Enzymol, V60, P360; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; LYTTON J, 1992, HEART CARDIOVASCULAR, V2, P1203; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MELZER W, 1987, BIOPHYS J, V51, P849, DOI 10.1016/S0006-3495(87)83413-6; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; Monnier N, 1997, AM J HUM GENET, V60, P1316, DOI 10.1086/515454; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; OTSU K, 1994, J BIOL CHEM, V269, P9413; OTSU K, 1990, J BIOL CHEM, V265, P13472; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; SUDA N, 1995, J PHYSIOL-LONDON, V486, P105, DOI 10.1113/jphysiol.1995.sp020794; Suda N, 1996, PFLUG ARCH EUR J PHY, V432, P948, DOI 10.1007/s004240050221; SUDA N, 1994, P NATL ACAD SCI USA, V91, P5725, DOI 10.1073/pnas.91.12.5725; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	39	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29958	29964		10.1074/jbc.273.45.29958	http://dx.doi.org/10.1074/jbc.273.45.29958			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792715	hybrid			2022-12-25	WOS:000076798300092
J	Schrader, M; Reuber, BE; Morrell, JC; Jimenez-Sanchez, G; Obie, C; Stroh, TA; Valle, D; Schroer, TA; Gould, SJ				Schrader, M; Reuber, BE; Morrell, JC; Jimenez-Sanchez, G; Obie, C; Stroh, TA; Valle, D; Schroer, TA; Gould, SJ			Expression of PEX11 beta mediates peroxisome proliferation in the absence of extracellular stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BIOGENESIS DISORDERS; MEMBRANE-PROTEIN; RECEPTOR; SUPERFAMILY; INDUCTION; MEMBER; DRUGS; PIP2P; HEPG2	Mammalian cells typically contain hundreds of peroxisomes but can increase peroxisome abundance further in response to extracellular stimuli, We report here the identification and characterization of two novel human peroxisomal membrane proteins, PEX11 alpha and PEX11 beta, Overexpression of the human PEX11 beta gene alone was sufficient to induce peroxisome proliferation, demonstrating that proliferation can occur in the absence of extracellular stimuli and may be mediated by a single gene. Time course studies indicated that PEX11 beta induces peroxisome proliferation through a multistep process involving peroxisome elongation and segregation of PEX11 beta from other peroxisomal membrane proteins, followed by peroxisome division. Overexpression of PEX11 alpha also induced peroxisome proliferation but at a much lower frequency than PEX11 beta in our experimental system, The patterns of PEX11 alpha and PEX11 beta expression were examined in the rat, the animal in which peroxisome proliferation has been examined most extensively, Levels of PEX11 beta mRNA were similar in all tissues examined and were unaffected by peroxisome-proliferating agents. Conversely, PEX11 alpha mRNA levels varied widely among different tissues, were highest in tissues that are sensitive to peroxisome-proliferating agents, and were induced more than 10-fold in response to the peroxisome proliferators clofibrate and di(2-ethylhexyl) phthalate, Taken together, these data implicate PEX11 beta in the constitutive control of peroxisome abundance and suggest that PEX11 alpha may regulate peroxisome abundance in response to extracellular stimuli.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Schroer, Trina/0000-0002-5065-1835; Schrader, Tina A./0000-0003-1652-9956	NIDDK NIH HHS [DK45787] Funding Source: Medline; NIGMS NIH HHS [R01 GM044589] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FITZPATRICK DR, 1995, GENOMICS, V27, P457, DOI 10.1006/geno.1995.1077; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schrader M, 1996, EUR J CELL BIOL, V69, P24; Schrader M, 1998, EUR J CELL BIOL, V75, P87, DOI 10.1016/S0171-9335(98)80051-4; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	21	200	209	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29607	29614		10.1074/jbc.273.45.29607	http://dx.doi.org/10.1074/jbc.273.45.29607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792670	hybrid			2022-12-25	WOS:000076798300047
J	Balasubramanian, K; Schroit, AJ				Balasubramanian, K; Schroit, AJ			Characterization of phosphatidylserine-dependent beta(2)-glycoprotein I macrophage interactions - Implications for apoptotic cell clearance by phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LOW-DENSITY-LIPOPROTEIN; ANTICARDIOLIPIN ANTIBODIES; PHOSPHOLIPID ANALOGS; BLOOD-CELLS; RECOGNITION; BETA-2-GLYCOPROTEIN-I; PROTEIN; LIPOSOMES; SURFACE	The binding and uptake of phosphatidylserine (PS)-expressing cells appears to involve multiple receptor-mediated systems that recognize the lipid either directly or indirectly through intermediate proteins that form a molecular bridge between the cells. Here we show that beta(2)-glycoprotein I (beta(2)GPI), a 50-kDa serum glycoprotein, binds PS-containing vesicles and serves as an intermediate for the interaction of these vesicles with macrophages. Chemical modification of lysines and cysteines abolished beta(2)GPI-dependent PS uptake by inhibiting the binding of PS to beta(2)GPI and the binding of PS.beta(2)GPI complex to macrophages, respectively, Recognition was mediated by beta(2)GPI and not by the lipid because antibodies to beta(2)GPI inhibited binding of the complex to macrophages. These results indicate that human (THP-l-derived) macrophages bind beta(2)GPI only after it is bound to its lipid ligand, Competition experiments with monosaccharides that inhibit lectin-dependent interactions, and PS.beta(2)GPI binding experiments using deglycosylated beta(2)GPI, suggested that carbohydrate residues were not required for macrophage recognition of the complex. Antibodies to putative macrophage PS receptors (CD36, CD68, and CD14) did not inhibit uptake of the complex. These data suggest that beta(2)GPI can bind cells that fail to maintain membrane lipid asymmetry and generate a specific bridging moiety that is recognized for clearance by a phagocyte receptor that is distinct from CD36, CD68, and CD14.	Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schroit, AJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDDK NIH HHS [DK 41714] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BORCHMAN D, 1995, CLIN EXP IMMUNOL, V102, P373; Brighton TA, 1996, BRIT J HAEMATOL, V93, P185, DOI 10.1046/j.1365-2141.1996.446981.x; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; COHNEN G, 1969, J LAB CLIN MED, V75, P212; CONNOR J, 1992, J BIOL CHEM, V267, P19412; DAEMEN FJM, 1974, BIOCHEMISTRY-US, V13, P2865, DOI 10.1021/bi00711a014; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; FADOK VA, 1992, J IMMUNOL, V148, P2207; FLORA PK, 1994, EUR J IMMUNOL, V24, P2625, DOI 10.1002/eji.1830241109; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; HAGIHARA Y, 1995, J BIOCHEM-TOKYO, V118, P129, DOI 10.1093/oxfordjournals.jbchem.a124867; HUNT J, 1994, J IMMUNOL, V152, P653; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MATSUURA E, 1994, J EXP MED, V179, P457, DOI 10.1084/jem.179.2.457; Mehdi H, 1996, VIROLOGY, V217, P58, DOI 10.1006/viro.1996.0093; POLTZ E, 1979, FEBS LETT, V102, P183; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Price BE, 1996, J IMMUNOL, V157, P2201; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHOUSBOE I, 1979, BIOCHIM BIOPHYS ACTA, V579, P396, DOI 10.1016/0005-2795(79)90067-9; SCHROIT AJ, 1983, BIOCHEMISTRY-US, V22, P3617, DOI 10.1021/bi00284a012; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; STEINKASSERER A, 1991, BIOCHEM J, V277, P387, DOI 10.1042/bj2770387; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	33	116	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29272	29277		10.1074/jbc.273.44.29272	http://dx.doi.org/10.1074/jbc.273.44.29272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786940	hybrid			2022-12-25	WOS:000076691800101
J	Kothny-Wilkes, G; Kulms, D; Poppelmann, B; Luger, TA; Kubin, M; Schwarz, T				Kothny-Wilkes, G; Kulms, D; Poppelmann, B; Luger, TA; Kubin, M; Schwarz, T			Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; DEATH DOMAIN; RECEPTOR; FAMILY; MEMBER; ALPHA; IDENTIFICATION; MITOCHONDRIA; INHIBITION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family. It induces apoptosis primarily of transformed but not of normal cells and may therefore be a promising anti-cancer drug. Studying the role of TRAIL in apoptosis of keratinocytes, we detected TRAIL transcripts and protein in both normal human keratinocytes and transformed keratinocyte cell lines HaCaT and KB. Although normal keratinocytes were resistant to TRAIL, HaCaT and RB cells underwent apoptosis following TRAIL exposure. When HaCaT and KB cells were pretreated with the pro-inflammatory cytokine interleukin-1 (IL-l), cells became resistant to TRAIL-induced apoptosis. IL-1 significantly induced activation of the transcription factor NF kappa B in transformed keratinocytes. Moreover, the proteasome inhibitor MG132, which inhibits IL-l-induced NF kappa B activation, completely prevented the protective effect of IL-1. Thus, IL-1 appears to protect transformed keratinocytes from the cytotoxic effect of TRAIL via activation of NF kappa B. These data suggest that NF kappa B activation may protect cells from TRAIL-induced apoptosis and indicate a TRAIL receptor-independent pathway, which allows cells to escape the cytotoxic effect of TRAIL. Because IL-1 is secreted by a variety of tumor cells and is also released by inflammatory cells participating in the tumor-host immune response, tumors under these conditions could become resistant to TRAIL.	Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Dept Dermatol, D-48149 Munster, Germany; Immunex Res & Dev Corp, Seattle, WA 98101 USA	University of Munster	Schwarz, T (corresponding author), Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Dept Dermatol, Von Esmarchstr 56, D-48149 Munster, Germany.	schwtho@uni-muenster.de	Kulms, Dagmar/H-1653-2014					Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DURUM SK, 1990, IMMUNOPHYSIOLOGY ROL, P210; GOLSTEIN P, 1997, CURR BIOL, V7, P750; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRIFFITH TS, 1998, IN PRESS J IMMUNOL; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAEMER KH, 1997, P NATL ACAD SCI USA, V94, P1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LUGER TA, 1992, PHARM SKIN, P283; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schwarz A, 1998, J IMMUNOL, V160, P4262; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	41	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29247	29253		10.1074/jbc.273.44.29247	http://dx.doi.org/10.1074/jbc.273.44.29247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786937	hybrid			2022-12-25	WOS:000076691800098
J	Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S				Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S			pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F	ONCOGENE			English	Article						retinoblastoma protein; pRB; E2F; phosphorylation; checkpoint control; cell cycle	RETINOBLASTOMA-SUSCEPTIBILITY GENE; CELL-CYCLE CONTROL; RESTRICTION POINT; PROTEIN; PRODUCT; BINDING; EXPRESSION; TRANSCRIPTION; APOPTOSIS; RB	Progression of cells into S phase is controlled by the retinoblastoma protein (pRB) and relies on the functional inactivation of this tumour suppressor in late G1 via protein phosphorylation. We provide evidence here that, besides controlling entry of cells into S phase, pRB can operate to inhibit S phase completion. Differential arrays of phosphorylation appear to regulate these different events, suggesting that cycle progression at these two stages of the cell cycle may be achieved via activation of distinct downstream pRB effector pathways. In agreement with this hypothesis, pRB's ability to prevent S phase entry, but not its ability to inhibit S phase completion, correlates with repression of E2F-regulated promoters. Furthermore, ectopic expression of E2F or the E2F-regulated cyclin E gene promote S phase entry in cells expressing phosphorylation-defective pRB but neither is sufficient to trigger completion of S phase. Our findings raise the possibility that pRB, in addition to its web-established role in controlling a checkpoint in late G1, could be involved in the control of a further checkpoint operating during S phase and that implementation of this checkpoint relies on an as yet unidentified PRE effector distinct from E2F.	Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; GAUTSCHI JR, 1973, J MOL BIOL, V80, P393, DOI 10.1016/0022-2836(73)90411-7; Geng Y, 1996, ONCOGENE, V12, P1173; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iliakis G, 1997, SEMIN ONCOL, V24, P602; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YAVUZER U, 1995, ONCOGENE, V10, P123; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	74	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2177	2186		10.1038/sj.onc.1202443	http://dx.doi.org/10.1038/sj.onc.1202443			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811449				2022-12-25	WOS:000076698200004
J	Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT				Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT			Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes	ONCOGENE			English	Article						HPV E7 protein; p21cip1 protein induction; post-transcription regulation; inhibition of DNA synthesis	CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; UP-REGULATION; REPLICATION; P53; P21; PROLIFERATION	Productive infection by human papillomaviruses (HPVs) occurs only in differentiated squamous epithelial cells in papillomas, condylomata, and low grade intraepithelial neoplasias, Host DNA replication is reactivated in a fraction of terminally differentiated keratinocytes in benign human lesions and in organotypic raft cultures of primary human keratinocytes (PHKs) transduced with retroviruses expressing HPV-18 E7 oncogene from its native upstream regulatory region (URR), Thus the natural function of E7 protein, which inactivates pRB family proteins, is to induce host genes essential to support viral DNA replication in post-mitotic cells, Using this raft culture model system, we show that HPV-18 URR-E7 induces the universal cyclin-dependent kinase inhibitor p21cip1 protein in a fraction of differentiated PHKs, Induction is mediated by posttranscriptional mechanisms independent of p53, Double immunofluorescence studies demonstrate that, in raft cultures and in laryngeal papillomas, p21cip1 induction and reactivated host DIVA synthesis take place in a mutually exclusive manner in PCNA-positive, differentiated keratinocytes, We suggest that p21cip1 induction effectively blocks unscheduled DNA synthesis reactivated by E7, These results begin to explain the inverse relationship between p21cip1 induction and HPV activities previously observed in a spectrum of benign lesions regardless of HPV types present.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 1918 Univ Blvd,Room 508, Birmingham, AL 35294 USA.				NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline; NIAID NIH HHS [AI34674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chow Louise T., 1997, P267; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEMETER LM, 1994, HUM PATHOL, V25, P343, DOI 10.1016/0046-8177(94)90141-4; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Harper JW, 1997, CANCER SURV, V29, P91; HEALY E, 1995, J INVEST DERMATOL, V105, P274, DOI 10.1111/1523-1747.ep12318430; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Inohara S, 1996, BRIT J DERMATOL, V135, P717; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KUO SR, 1994, J BIOL CHEM, V269, P24058; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsuta M, 1997, J DERMATOL SCI, V14, P233, DOI 10.1016/S0923-1811(96)00579-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Palazzo JP, 1997, HUM PATHOL, V28, P60, DOI 10.1016/S0046-8177(97)90280-X; PARKER JN, 1997, CELL GROWTH DIFFER, V8, P75; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHEVCHUK MM, 1982, CANCER, V49, P489, DOI 10.1002/1097-0142(19820201)49:3<489::AID-CNCR2820490316>3.0.CO;2-U; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; STOLER MH, 1986, HUM PATHOL, V17, P1250, DOI 10.1016/S0046-8177(86)80569-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Zeng YX, 1996, ONCOGENE, V12, P1557; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	60	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2027	2038		10.1038/sj.onc.1202142	http://dx.doi.org/10.1038/sj.onc.1202142			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798674				2022-12-25	WOS:000076540900002
J	Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M				Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M			Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor	ONCOGENE			English	Article						rat; metastasis; phosphatidyl-inositol anchor; matrix degradation	UROKINASE PLASMINOGEN-ACTIVATOR; CELL-SURFACE RECEPTOR; COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CANCER METASTASIS; GLYCOSYL-PHOSPHATIDYLINOSITOL; SIGNAL TRANSDUCTION; LAMININ DEGRADATION; ADHESION MOLECULES	We have described recently a panel of metastasis-associated antigens expressed on a rat pancreatic tumor. One of these molecules, recognized by the monoclonal antibody C4.4 and named accordingly C4.4A, was under physiological conditions expressed only in the gravid uterus and on epithelial of the upper gastrointestinal tract. The cDNA of the antigen has been isolated and cloned. The 1,637 b cDNA codes for a 352 amino acid long glycosylphosphatidy-inositol (GP) anchored molecule, whose molecular weight varies in different cells between 94-98 kD according to the degree of N- and O-glycosylation. Data base searches have revealed a low degree of homology to the receptor for the plasminogen activator (uPAR). After intrafootpad and intravenous application of C4.4A transfected and mocktransfected tumor cells, an increased number of lung nodules was detected with the former, whereby the individual metastatic nodules amalgamated without any encapsulation of the tumor tissue. Furthermore, C4.4A is involved in adhesion to laminin and, although transfection of a non-metastasizing tumor line with the molecule was not sufficient, constitutively C4.4A-positive tumor cells penetrated through matrigel. This process could be completely prevented by C4.4. Finally, we could demonstrate that uPA, albeit weakly, bound to the C4.4A molecule. In view of the observed influence of C4.4A on metastasis formation and matrix penetration it is tempting to speculate that this newly described metastasis-associated molecule may exert functional activity similar to the uPAR, i.e. via activation of matrix degrading enzymes. By the very restricted expression of the molecule in the adult organism, modulation of C4.4A could well be of therapeutic interest.	German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany; Univ Karlsruhe, Dept Appl Genet, D-78000 Karlsruhe, Germany; Univ Hosp, Dept Dermatol, D-66424 Homburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Universitatsklinikum des Saarlandes	Zoller, M (corresponding author), German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany.							Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURGLE M, 1997, BIOL CHEM, V378, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claas C, 1996, CELL GROWTH DIFFER, V7, P663; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; COOK RG, 1992, CELL IMMUNOL, V144, P367, DOI 10.1016/0008-8749(92)90252-K; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dasgupta A, 1996, BIOCHEM BIOPH RES CO, V227, P110, DOI 10.1006/bbrc.1996.1475; De Clerck Yves A., 1993, P121; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DURLIAT M, 1992, BRIT J CANCER, V66, P51, DOI 10.1038/bjc.1992.215; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; EVANS CW, 1992, CELL BIOL INT REP, V16, P1, DOI 10.1016/S0309-1651(06)80150-5; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FERGUSON RM, 1988, CLIN TRANSPLANT, V2, P285; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLINSKY GV, 1993, CRIT REV ONCOL HEMAT, V14, P229, DOI 10.1016/1040-8428(93)90011-R; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBE M, 1994, EUR J IMMUNOL, V24, P731; Jardi M, 1996, THROMB HAEMOSTASIS, V76, P1009; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KHOKHA R, 1993, J NEUROONCOL, V18, P123; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1983, LAB INVEST, V49, P636; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; Mareel M. M., 1991, MECH INVASION METAST; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; MOLLER LB, 1992, FEBS LETT, V301, P493; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Nagase H, 1997, BIOL CHEM, V378, P151; NazihSanderson F, 1997, BBA-LIPID LIPID MET, V1346, P45, DOI 10.1016/S0005-2760(97)00017-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PLOUG M, 1991, J BIOL CHEM, V266, P1926; REISSER D, 1993, INT J CANCER, V53, P651, DOI 10.1002/ijc.2910530421; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLECHTE JW, 1990, CANCER COMMUN, V2, P261, DOI 10.3727/095535490820874245; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SORDAT BC, 1995, INVAS METAST, V14, P223; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; SUH TT, 1994, J BIOL CHEM, V269, P25992; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYGVASSON K, 1989, INFLUENCE TUMOR DEV, P72; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; ZOLLER M, 1978, BRIT J CANCER, V37, P61, DOI 10.1038/bjc.1978.9; ZOLLER M, 1992, J NUCL MED, V33, P1366; Zoller M, 1996, CURR TOP MICROBIOL, V213, P215	76	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1989	2002		10.1038/sj.onc.1202079	http://dx.doi.org/10.1038/sj.onc.1202079			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788443				2022-12-25	WOS:000076423500013
J	Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN				Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN			Quiescence versus apoptosis: Myc abundance determines pathway of exit from the cell cycle	ONCOGENE			English	Article						apoptosis; c-Myc; cdk2; cell cycle control; quiescence; tetracycline	DEPENDENT PROTEIN-KINASES; C-MYC; GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-REPLICATION; MESSENGER-RNA; GROWTH; FIBROBLASTS	When exposed to diverse growth conditions in vitro, cells can respond by entering states of proliferation, quiescence, differentiation or apoptosis, While the choices among these states can be influenced by proto-oncogene expression, how these disparate outcomes are achieved remains poorly understood. To address these issues, we have generated rodent fibroblast cell lines that harbor a human c-myc gene under the control of a tetracycline-regulated promoter, When Myc-induced cells are deprived of serum growth factors, they rapidly become apoptotic with the onset of apoptosis preceded by a large, transient increase in cdk2 kinase activity that is associated with the induction of cdc25A phosphatase and the later accumulation of p27(Kip1) kinase inhibitor, Surprisingly, serum starvation in the absence of myc overexpression, (which leads to quiescence instead of apoptosis) also causes a marked transient elevation in cdk2 kinase activity, an induction of cdc25A and a delayed increase in p27(Kip1), Transient elevations in cdk2 kinase activity and cdc25A abundance are required for cell cycle progression, but it is evident that these changes also precede entry to either apoptosis or quiescence in serum-starved cells. These findings suggest that the pathways to both quiescence and apoptosis share regulatory machinery with cell cycle control mechanisms. In addition, the abundance of MSc protein can be critical in the choices among these cellular states.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Johnston, RN (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Johnston, Randal/B-9247-2009	Helbing, Caren/0000-0002-8861-1070				ASKEW DS, 1991, ONCOGENE, V6, P1915; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREEMAN RS, 1994, NEURON, V12, P3443; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GIBSON AW, 1992, BIOCHEM CELL BIOL, V70, P998, DOI 10.1139/o92-143; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HASS R, 1994, CRIT REV ONCOGENESIS, V5, P359, DOI 10.1615/CritRevOncog.v5.i4.20; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Helbing C, 1996, DEV GENET, V18, P223, DOI 10.1002/(SICI)1520-6408(1996)18:3<223::AID-DVG3>3.3.CO;2-T; Helbing CC, 1997, CANCER RES, V57, P1255; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LEE WH, 1995, ANN NY ACAD SCI, V752, P432, DOI 10.1111/j.1749-6632.1995.tb17453.x; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mueller Rolf, 1993, Biochimica et Biophysica Acta, V1155, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1993, ONCOGENE, V8, P1593; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATERS CM, 1991, ONCOGENE, V6, P797; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	77	22	22	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1491	1501		10.1038/sj.onc.1202241	http://dx.doi.org/10.1038/sj.onc.1202241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794226				2022-12-25	WOS:000076089900001
J	Fronsdal, K; Engedal, N; Slagsvold, T; Saatcioglu, F				Fronsdal, K; Engedal, N; Slagsvold, T; Saatcioglu, F			CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ACTIVATION FUNCTION AF-2; TRANSCRIPTIONAL COACTIVATOR; DEPENDENT ACTIVATION; THYROID-HORMONE; MOLECULAR MECHANISMS; ESTROGEN-RECEPTOR; CO-REPRESSOR; IN-VIVO; CBP	Androgens are critical in the development and maintenance of the male reproductive system and important in the progression of prostate cancer. The effects of androgens are mediated through the androgen receptor (AR), which is a ligand-modulated transcription factor that belongs to the nuclear receptor superfamily, In addition to its ability to activate transcription from androgen response elements, AR can inhibit activator protein-1 (AP-1) activity, composed of Jun and Fos oncoproteins, in a ligand-dependent manner. Conversely, when activated, AP-1 can block AR activity. We found that CREB (cAMP response element-binding protein) binding protein (CBP) had a direct role in both of these activities of AR. CBP significantly increased the ability of endogenous AR in LNCaP cells to activate transcription from an AR-dependent reporter construct. On the other hand, repression of AR activity by treatment of LNCaP cells with an activator of AP-1 was largely relieved when CBP was ectopically expressed. AR and CBP can physically interact in vitro as was shown in glutathione S-transferase pulldown assays. Whereas both the N terminus and ligand-binding domain of AR can interact with CBP, a short region in the N terminus of CBP is required for these interactions. As opposed to the interaction of CBP with other nuclear receptors studied so far, CBP-AR interactions were not affected by ligand binding to AR in vitro, These data suggest that CBP is a coactivator for AR in vivo and that the transcriptional interference between AR and AP-I is the result of competition for limiting amounts of CBP in the cell.	Univ Oslo, Inst Clin Med, Ctr Biotechnol, N-0371 Oslo, Norway; Univ Oslo, Dept Biol, Ctr Biotechnol, N-0371 Oslo, Norway; Univ Oslo, Dept Biochem, Ctr Biotechnol, N-0371 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Inst Clin Med, Ctr Biotechnol, Gaustadalleen 21, N-0371 Oslo, Norway.		Engedal, Nikolai/AAJ-8951-2020	Engedal, Nikolai/0000-0003-3718-3464				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Eckner R, 1996, BIOL CHEM, V377, P685; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LINDZEY J, 1994, VITAM HORM, V49, P383; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; ONATE SA, 1995, SCIENCE, V270, P1354; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	39	176	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31853	31859		10.1074/jbc.273.48.31853	http://dx.doi.org/10.1074/jbc.273.48.31853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822653	hybrid			2022-12-25	WOS:000077207000035
J	Oei, SL; Griesenbeck, J; Schweiger, M; Ziegler, M				Oei, SL; Griesenbeck, J; Schweiger, M; Ziegler, M			Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribosyl)ation of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 PROTEIN; DNA-REPAIR; IN-VITRO; BINDING; YY1; PURIFICATION; TRANSFERASE; INITIATION; INVITRO	Poly(ADP-ribosyl) transferase (ADPRT) is a nuclear protein that modifies proteins by forming and attaching to them poly(ADP-ribose) chains. Poly(ADP-ribosyl)ation represents an event of major importance in perturbed cell nuclei and participates in the regulation of fundamental processes including DNA repair and transcription. Although ADPRT serves as a positive cofactor of transcription, initiation of its catalytic activity may cause repression of RNA polymerase II-dependent transcription. It is demonstrated here that ADPRT-dependent silencing of transcription involves ADP-ribosylation of the TATA-binding protein. This modification occurs only if poly(ADP-ribosyl)ation is initiated before TATA-binding protein has bound to DNA and thereby prevents formation of active transcription complexes. Specific DNA binding of other transcription factors including Yin Yang 1, p53, NF kappa B, Spl, and CREB but not c-Jun or AP-2 is similarly affected. After assembly of transcription complexes initiation of poly(ADP-ribosyl)ation does not influence DNA binding of transcription factors. Accordingly, if bound to DNA, transcription factors are inaccessible to poly(ADP-ribosyl)ation. Thus, poly(ADP-ribosyl)ation prevents binding of transcription factors to DNA, whereas binding to DNA prevents their modification. Considering its ability to detect DNA strand breaks and stimulate DNA repair, it is proposed that ADPRT serves as a molecular switch between transcription and repair of DNA to avoid expression of damaged genes.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Free University of Berlin	Oei, SL (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	lity@chemie.fu-berlin.de		Ziegler, Mathias/0000-0001-6961-2396; Griesenbeck, Joachim/0000-0002-7817-6095				BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MATSUI T, 1980, J BIOL CHEM, V255, P1992; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oei SL, 1996, FEBS LETT, V397, P17, DOI 10.1016/S0014-5793(96)01137-4; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353	30	104	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31644	31647		10.1074/jbc.273.48.31644	http://dx.doi.org/10.1074/jbc.273.48.31644			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822623	hybrid			2022-12-25	WOS:000077207000005
J	Osanai, T; Kamada, T; Fujiwara, N; Katoh, T; Takahashi, K; Kimura, M; Satoh, K; Magota, K; Kodama, S; Tanaka, T; Okumura, K				Osanai, T; Kamada, T; Fujiwara, N; Katoh, T; Takahashi, K; Kimura, M; Satoh, K; Magota, K; Kodama, S; Tanaka, T; Okumura, K			A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2); ATP SYNTHASE; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; BOVINE MITOCHONDRIA; EXPRESSION CLONING; BROMOENOL LACTONE; MOLECULAR-CLONING; ESCHERICHIA-COLI; MECHANISM	The possible presence of an unknown prostacyclin synthesis inhibitory substance has been reported in some strains of rats. We purified the inhibitory substance from the heart of spontaneously hypertensive rats by collecting active fractions after gel-filtration column chromatography and two steps of reverse-phase high performance liquid chromatography. The amino acid composition and automated gas-phase sequencing of the full-length substance and fragments cleaved by AspN indicated that the prostacyclin-inhibitory peptide was identical to coupling factor 6. Recombinant rat coupling factor 6, which was synthesized using a cleavable fusion protein strategy, attenuated base-line and bradykinin (10(-6) M)-induced prostacyclin synthesis and [H-3]arachidonic acid (AA) release in human umbilical vein endothelial cells in a dose-dependent manner (10(-9)-10(-7) M). Exogenous AA- and prostaglandin H-2-induced prostacyclin synthesis were unchanged even after treatment with 10(-7) M recombinant coupling factor 6. Base-line and bradykinin-induced [H-3]AA release were suppressed by arachidonyltrifluoromethyl ketone, a relatively specific inhibitor of cytosolic phospholipase A(2) at 40 mu M, and simultaneous administration of coupling factor 6 showed no further effect. Neither oleyloxyethyl phosphorylcholine at 1 mu M nor bromoenol lactone at 1 mu M affected AA release. Preincubation (1 min) with 10(-7) M recombinant coupling factor 6 had no influence on adenosine diphosphate- and collagen-induced platelet aggregations. We conclude that coupling factor 6 possesses a novel function of prostacyclin synthesis inhibition in endothelial cells via suppression of Ca2+-dependent cytosolic phospholipase A(2), although it is unclear whether coupling factor 6 functions in normal conditions or only in pathophysiological states.	Hirosaki Univ, Sch Med, Dept Internal Med 2, Hirosaki, Aomori 0368562, Japan; Suntory Inst Biomed Res, Pharmaceut Res Labs, Osaka 6188503, Japan	Hirosaki University; Suntory Holdings Ltd	Osanai, T (corresponding author), Hirosaki Univ, Sch Med, Dept Internal Med 2, Zaifu Cho 5, Hirosaki, Aomori 0368562, Japan.							ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Byron KL, 1996, CIRC RES, V78, P813, DOI 10.1161/01.RES.78.5.813; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; COLLINSON IR, 1994, J MOL BIOL, V242, P408; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FALARDEAU P, 1985, PROSTAG OTH LIPID M, V29, P621, DOI 10.1016/0090-6980(85)90085-1; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HIGUTI T, 1991, BIOCHEM BIOPH RES CO, V178, P793, DOI 10.1016/0006-291X(91)90178-A; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; KAGAWA Y, 1966, J BIOL CHEM, V241, P2475; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KNOWLES AF, 1971, J BIOL CHEM, V246, P2672; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MORI H, 1979, J CHEM ENG JPN, V12, P313, DOI 10.1252/jcej.12.313; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; OSANAI T, 1990, JPN CIRC J, V54, P507, DOI 10.1253/jcj.54.507; OSANAI T, 1994, HYPERTENS RES, V17, P227; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; UEHARA Y, 1986, HYPERTENSION, V8, P180; UEHARA Y, 1987, HYPERTENSION, V9, P6; UEMURA T, 1987, J JPN ATHEROSCLER SO, V15, P767; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YABUTA M, 1995, APPL MICROBIOL BIOT, V42, P703; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591	37	40	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31778	31783		10.1074/jbc.273.48.31778	http://dx.doi.org/10.1074/jbc.273.48.31778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822642	hybrid			2022-12-25	WOS:000077207000024
J	Kim, HJ; Chang, WT; Meima, M; Gross, JD; Schaap, P				Kim, HJ; Chang, WT; Meima, M; Gross, JD; Schaap, P			A novel adenylyl cyclase detected in rapidly developing mutants of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DEPENDENT PROTEIN-KINASE; EXTRACELLULAR CAMP; CYCLIC-AMP; DISCOIDEUM; AGGREGATION; CELLS; ACTIVATION; GENES; PURIFICATION	Disruption of either the RDEA or REGA genes leads to rapid development in Dictyostelium. The RDEA gene product displays homology to certain H2-type phosphotransferases, while REGA encodes a cAMP phosphodiesterase with an associated response regulator. It has been proposed that RDEA activates REGA in a multistep phosphorelay, To test this proposal, we examined cAMP accumulation in rdeA and regA null mutants and found that these mutants show a pronounced accumulation of cAMP at the vegetative stage that is not observed in wild-type cells. This accumulation was due to a novel adenylyl cyclase and not to the known Dictyostelium adenylyl cyclases, aggregation stage adenylyl cyclase (ACA) or germination stage adenylyl cyclase (ACG), since it occurred in an acaA/rdeA double mutant and, unlike ACG, was inhibited by high osmolarity, The novel adenylyl cyclase was not regulated by G-proteins and was relatively insensitive to stimulation by Mn2+ ions. Addition of the cAMP phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX) permitted detection of the novel adenylyl cyclase activity in lysates of an acaA/acgA double mutant. The fact that disruption of the RDEA gene as well as inhibition of the REGA-phosphodiesterase by IBMX permitted detection of the novel AC activity supports the hypothesis that RDEA activates REGA.	Leiden Univ, Cell Biol Sect, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Leiden University; Leiden University - Excl LUMC; University of Oxford	Schaap, P (corresponding author), Leiden Univ, Cell Biol Sect, Inst Mol Plant Sci, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.		Schaap, Pauline/M-5355-2019; Schaap, Pauline/A-3682-2009	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; BARBER R, 1980, J CYCLIC NUCL PROT, V6, P3; BLAIR SS, 1995, NATURE, V373, P656, DOI 10.1038/373656a0; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; Chang WT, 1998, EMBO J, V17, P2809, DOI 10.1093/emboj/17.10.2809; COUKELL MB, 1980, FEBS LETT, V110, P39, DOI 10.1016/0014-5793(80)80017-2; DASILVEIRA JF, 1977, BIOCHIM BIOPHYS ACTA, V481, P722, DOI 10.1016/0005-2744(77)90306-0; DEGUNZBURG J, 1984, BIOCHEMISTRY-US, V23, P3805, DOI 10.1021/bi00312a003; Endl I, 1996, MOL BIOL CELL, V7, P17, DOI 10.1091/mbc.7.1.17; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; HENDERSON EJ, 1975, J BIOL CHEM, V250, P4730; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; Kawabe J, 1996, J BIOL CHEM, V271, P20132, DOI 10.1074/jbc.271.33.20132; Loomis WF, 1997, J CELL SCI, V110, P1141; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; SCHULKES C, 1995, FEBS LETT, V368, P377; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SOMKUTI SG, 1982, J BIOL CHEM, V257, P6387; STEINER AL, 1972, J BIOL CHEM, V247, P1106; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; vanEs S, 1996, J BIOL CHEM, V271, P23623, DOI 10.1074/jbc.271.39.23623; VANHAASTERT PJM, 1984, J GEN MICROBIOL, V130, P2559; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; YANG JK, 1983, J BIOL CHEM, V258, P3750	33	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30859	30862		10.1074/jbc.273.47.30859	http://dx.doi.org/10.1074/jbc.273.47.30859			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812977	hybrid			2022-12-25	WOS:000077136900005
J	Lang, M; Apt, KE; Kroth, PG				Lang, M; Apt, KE; Kroth, PG			Protein transport into "Complex" diatom plastids utilizes two different targeting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST TRANSIT PEPTIDES; NUCLEOTIDE-SEQUENCE; ODONTELLA-SINENSIS; ENDOPLASMIC-RETICULUM; EUGLENA-GRACILIS; BINDING PROTEIN; GAMMA-SUBUNIT; CDNA CLONE; PRECURSOR; PRESEQUENCE	The plastids found in diatoms and other chromophytic algae are completely enclosed by four membranes in contrast to chloroplasts of higher plants, which are surrounded by only two membranes. The bipartite targeting sequence of diatom nuclear-encoded plastid proteins contains an endoplasmic reticulum signal sequence and, based on sequence comparison, a transit peptide-like domain similar to that which targets proteins into the plastids of higher plants, By performing heterologous import experiments using the precursor of the gamma subunit of the chloroplast ATPase from the diatom Odontella sinensis we were able to show that protein import into diatom plastids is at least a two step event. We demonstrate that the first step involves co-translational transport through endoplasmic reticulum membranes and that there is an additional targeting step which is similar to the import of precursor proteins into chloroplasts of higher plants and green algae indicating that the transit peptide-like domain of the diatom precursor is functionally equivalent to the respective targeting signal of higher plants. Our results suggest that the transit peptide depending targeting mechanism in plastids has apparently remained relatively unchanged over the course of evolution, with only the peptidase cleavage site significantly modified.	Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany; Martek Biosci, Columbia, MD 21045 USA	Heinrich Heine University Dusseldorf	Kroth, PG (corresponding author), Univ Dusseldorf, Inst Biochem Pflanzen, Universitatsstr 1, D-40225 Dusseldorf, Germany.	Peter.Kroth@uni-duesseldorf.de	Kroth, Peter G/A-9728-2008	Kroth, Peter G/0000-0003-4734-8955				APT KE, 1993, J BIOL CHEM, V268, P16208; Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; APT KE, 1995, MOL GEN GENET, V246, P455, DOI 10.1007/BF00290449; APT KE, 1995, PLANT PHYSIOL, V109, P339; BHATYA D, 1991, MOL GEN GENET, V229, P400; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 1995, BIODIVERSITY EVOLUTI, P75; CAVALIERSMITH T, 1986, PROGR PHYCOLOGICAL R, P309; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Dunahay TG, 1995, J PHYCOL, V31, P1004, DOI 10.1111/j.0022-3646.1995.01004.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GIBBS SP, 1979, J CELL SCI, V35, P253; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GIBBS SP, 1981, INT REV CYTOL, V72, P49, DOI DOI 10.1016/S0074-7696(08)61194-8; GROSSMAN A, 1990, MOL GEN GENET, V224, P91, DOI 10.1007/BF00259455; Heins L, 1998, TRENDS PLANT SCI, V3, P56, DOI 10.1016/S1360-1385(97)01161-8; Kermode AR, 1996, CRIT REV PLANT SCI, V15, P285, DOI 10.1080/713608135; KISHORE R, 1993, P NATL ACAD SCI USA, V90, P11845, DOI 10.1073/pnas.90.24.11845; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KOZAK M, 1983, MICROBIOL REV, V47, P1; KROTHPANCIC PG, 1995, PLANT MOL BIOL, V27, P825, DOI 10.1007/BF00020236; Liaud MF, 1997, J MOL EVOL, V44, pS28, DOI 10.1007/PL00000050; LUDWIG M, 1985, PROTOPLASMA, V127, P9, DOI 10.1007/BF01273697; MCFADDEN G, 1995, TRENDS ECOL EVOL, V10, P12, DOI 10.1016/S0169-5347(00)88954-5; MCFADDEN GI, 1995, ARCH PROTISTENKD, V145, P231, DOI 10.1016/S0003-9365(11)80318-0; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; NORRIS BJ, 1994, PLANT MOL BIOL, V24, P673, DOI 10.1007/BF00023563; OSAFUNE T, 1991, EXP CELL RES, V193, P320, DOI 10.1016/0014-4827(91)90103-2; PALMER JD, 1993, NATURE, V364, P762, DOI 10.1038/364762a0; PANCIC PG, 1990, BOT ACTA, V103, P274; PANCIC PG, 1993, FEBS LETT, V320, P61, DOI 10.1016/0014-5793(93)81658-M; REITH M, 1995, ANNU REV PLANT PHYS, V46, P549, DOI 10.1146/annurev.arplant.46.1.549; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SHIGEMORI Y, 1994, PLANT MOL BIOL, V24, P209, DOI 10.1007/BF00040587; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SULLI C, 1995, J BIOL CHEM, V270, P13084, DOI 10.1074/jbc.270.22.13084; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1995, BIOESSAYS, V17, P25, DOI 10.1002/bies.950170107; WHATLEY JM, 1979, PROC R SOC SER B-BIO, V204, P165, DOI 10.1098/rspb.1979.0020; Wittpoth C, 1998, PLANTA, V206, P79, DOI 10.1007/s004250050376	46	93	95	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30973	30978		10.1074/jbc.273.47.30973	http://dx.doi.org/10.1074/jbc.273.47.30973			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812993	hybrid			2022-12-25	WOS:000077136900021
J	Li, JF; Qu, XQ; Schmidt, AM				Li, JF; Qu, XQ; Schmidt, AM			Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; NEURITE OUTGROWTH; BINDING-PROTEINS; OXIDANT STRESS; DIABETIC COMPLICATIONS; ADHESION MOLECULE-1; POTENTIAL MECHANISM; NERVOUS-SYSTEM; VESSEL WALL; RECEPTOR	Receptor for AGE (RAGE) and the polypeptide amphoterin are highly expressed and co-localized in neurons of the developing central nervous system of the rat. In vitro, the interaction of amphoterin with neuronal RAGE induces neurite outgrowth. We tested the hypothesis that interaction of amphoterin with neuronal cells enhances RAGE expression, thereby providing a mechanism by which amphoterin-mediated regulation of RAGE might contribute to promotion of neurite growth and spreading. Incubation of cultured neuroblastoma cells with amphoterin resulted in increased transcription and translation of RAGE, a process largely inhibited in the presence of anti-RAGE IgG but not by nonimmune IgG. To begin to delineate molecular mechanisms underlying these findings, we identified multiple putative binding elements within the 5'-flanking region of the RAGE gene for Sp1, a transcription factor that has been critically Linked to the process of normal development. DNase I footprinting and electrophoretic mobility shift assays demonstrated multiple functional Spl-binding sites within the region -245 to -40 of the RAGE promoter. Transient transfection of cultured SK-N-SH neuroblastoma cells with chimeric 5'-deletion constructs linked to luciferase reporter revealed that the region containing Spl-binding elements did not contribute uniquely to basal expression of the RAGE gene. Simultaneous mutation of the multiple Spl-binding elements in this region did not affect basal promoter function; however, promoter responsiveness to amphoterin was markedly attenuated. These results point to Sp1-dependent mechanisms underlying amphoterin-mediated increases in RAGE expression in neuroblastoma cells and further link amphoterin-RAGE interaction to development of the nervous system.	Columbia Univ Coll Phys & Surg, Div Surg Sci, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, Div Surg Sci, Dept Surg, 630 W 168th St,P&S 17-501, New York, NY 10032 USA.	ams11@columbia.edu	li, tao/B-2402-2008		NIA NIH HHS [AG00602] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662; BIEDLER JL, 1973, CANCER RES, V33, P2643; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schmidt AM, 1996, J PERIODONTAL RES, V31, P508, DOI 10.1111/j.1600-0765.1996.tb01417.x; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	33	69	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30870	30878		10.1074/jbc.273.47.30870	http://dx.doi.org/10.1074/jbc.273.47.30870			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812979	hybrid			2022-12-25	WOS:000077136900007
J	Lischke, A; Moriggl, R; Brandlein, S; Berchtold, S; Kammer, W; Sebald, W; Groner, B; Liu, XW; Hennighausen, L; Friedrich, K				Lischke, A; Moriggl, R; Brandlein, S; Berchtold, S; Kammer, W; Sebald, W; Groner, B; Liu, XW; Hennighausen, L; Friedrich, K			The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common gamma-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; COLONY-STIMULATING FACTOR; MAMMARY-GLAND FACTOR; HUMAN IL-4 RECEPTOR; SIGNAL-TRANSDUCTION; ALPHA-CHAIN; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; GENE-EXPRESSION	Interleukin (IL)-4 signaling proceeds via cytoplasmic activation of the Janus kinases JAK1 and JAK3 and the signal transducer and activator of transcription STAT6. We show that the IL-4 receptor, like other cytokine receptor systems utilizing the common receptor gamma-chain (gamma c), is also connected to a signaling pathway that involves STATE. Both STAT5a and STAT5b become tyrosine-phosphorylated and acquire specific DNA-binding properties in response to IL-4 receptor stimulation in the murine pro-B cell line Ba/F3. In preactivated human T cells, STATE became activated in an IL-4-dependent fashion as assayed by IL-Li-induced STATE translocation from the cytoplasm to the cell nucleus and by binding to cognate DNA. Moreover, stimulation of preactivated human T cells by IL-4 led to specific transcriptional upregulation of STATE target genes. IL-4 receptor-mediated STATE activation is dependent on the presence of gamma c and JAK3 within the receptor complex. In COS-7 cells, the JAK/STAT pathway leading from the IL-4 receptor to STATE-dependent regulation of a reporter gene relied largely on coexpression of JAK3. In Ba/F3 cells, studies on signal transduction evoked by directed specific receptor homo- or heterodimerization revealed that STATE activation can be triggered exclusively by IL-4R heterodimers containing gamma c.	Theodor Boveri Inst Biowissensch, Biozentrum, D-97074 Wurzburg, Germany; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany; NIDDK, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liu, XW (corresponding author), Theodor Boveri Inst Biowissensch, Biozentrum, Hubland, D-97074 Wurzburg, Germany.		Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463; Hennighausen, Lothar/0000-0001-8319-9841				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BONSCH D, 1995, J BIOL CHEM, V270, P8452, DOI 10.1074/jbc.270.15.8452; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DEUTSCH HHJ, 1995, J IMMUNOL, V154, P3696; Duschl A, 1996, EUR CYTOKINE NETW, V7, P37; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HARADA N, 1992, J BIOL CHEM, V267, P22752; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAHLER I, 1994, FEBS LETT, V345, P187; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moriggl R, 1998, EUR J BIOCHEM, V251, P25, DOI 10.1046/j.1432-1327.1998.2510025.x; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; PAUL WE, 1991, BLOOD, V77, P1859; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	62	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31222	31229		10.1074/jbc.273.47.31222	http://dx.doi.org/10.1074/jbc.273.47.31222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813029	hybrid			2022-12-25	WOS:000077136900057
J	Persson, AL; Sahlin, M; Sjoberg, BM				Persson, AL; Sahlin, M; Sjoberg, BM			Cysteinyl and substrate radical formation in active site mutant E441Q of Escherichia coli class I ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE EVIDENCE; PROTEIN R1; MECHANISM; 5'-DIPHOSPHATE; INACTIVATION; ENZYMES; R2	AU classes of ribonucleotide reductase are proposed to have a common reaction mechanism involving a transient cysteine thiyl radical that initiates catalysis by abstracting the 3'-hydrogen atom of the substrate nucleotide. In the class Ia ribonucleotide reductase system of Escherichia coli we recently trapped two kinetically coupled transient radicals in a reaction involving the engineered E441Q R1 protein, wild-type R2 protein, and substrate (Persson, A. L., Eriksson, R2, Katterle, B., Potsch, S., Sahlin, M., and Sjoberg, B.-M. (1997) J. Biol. Chem. 272, 31533-31541). Using isotopically labeled R1 protein or substrate, we now demonstrate that the early radical intermediate is a cysteinyl radical, possibly in weak magnetic interaction with the diiron site of protein R2, and that the second radical intermediate is a carbon-centered substrate radical with hyperfine coupling to two almost identical protons. This is the first report of a cysteinyl free radical in ribonucleotide reductase that is a kinetically coupled precursor of an identified substrate radical. We suggest that the cysteinyl radical is localized to the active site residue, Cys(439) which is conserved in all classes of ribonucleotide reductase, and which, in the three-dimensional structure of protein R1, is positioned to abstract the 3'-hydrogen atom of the substrate. We also suggest that the substrate radical is localized to the 3'-position of the ribose moiety, the first substrate radical intermediate in the postulated reaction mechanism.	Stockholm Univ, Dept Biol Mol, S-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Biol Mol, S-10691 Stockholm, Sweden.			Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; BERNHARD WA, 1989, J MAGN RESON, V82, P156, DOI 10.1016/0022-2364(89)90176-5; Coves J, 1996, BIOCHEMISTRY-US, V35, P8595, DOI 10.1021/bi960355o; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Gerfen GJ, 1998, J AM CHEM SOC, V120, P3823, DOI 10.1021/ja972166e; JONESMOR.MC, 1968, BIOCHEM J, V110, P589, DOI 10.1042/bj1100589; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KERTESZ JC, 1973, J MAGN RESON, V10, P22, DOI 10.1016/0022-2364(73)90230-8; Lakkaraju PS, 1998, J CHEM SOC PERK T 2, P1119, DOI 10.1039/a800341f; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NELSON DJ, 1977, J CHEM SOC PERK T 2, P2005, DOI 10.1039/p29770002005; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Reddy SG, 1998, BIOCHEMISTRY-US, V37, P558, DOI 10.1021/bi972086n; RIORDAN C, 1977, PROC R SOC SER B-BIO, V198, P401, DOI 10.1098/rspb.1977.0105; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sjoberg BM, 1997, STRUCT BOND, V88, P139; STUBBE J, 1983, J BIOL CHEM, V258, P1625; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; vanderDonk WA, 1996, BIOCHEMISTRY-US, V35, P8381, DOI 10.1021/bi960190j; WEHRLI WE, 1965, J AM CHEM SOC, V87, P2265, DOI 10.1021/ja01088a028	29	39	39	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31016	31020		10.1074/jbc.273.47.31016	http://dx.doi.org/10.1074/jbc.273.47.31016			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812999	hybrid			2022-12-25	WOS:000077136900027
J	Shen, L; Shah, AM; Dahlback, B; Nelsestuen, GL				Shen, L; Shah, AM; Dahlback, B; Nelsestuen, GL			Enhancement of human protein C function by site-directed mutagenesis of the gamma-carboxyglutamic acid domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT PROTEINS; CLOTTING FACTOR-X; PHOSPHOLIPID-VESICLES; MEMBRANE-BINDING; ANTICOAGULANT ACTIVITY; BLOOD-COAGULATION; FACTOR VA; RESIDUES; PHOSPHATIDYLETHANOLAMINE; PROTHROMBIN	This study reports properties of site-directed mutants of human protein C that display enhanced calcium and/or membrane binding properties. Mutants containing the S11G modification all showed increased affinity for membranes at saturating calcium concentration. Ser-ll is unique to human protein C, whereas all other vitamin R-dependent proteins contain glycine, This site is located in a compact region of the protein, close to a suggested membrane contact site. Additional changes of H10Q or S12N resulted in proteins with lower calcium requirement for membrane contact but without further increase in membrane affinity at saturating calcium. Mutations Q32E and N33D did not, by themselves, alter membrane affinity to a significant degree. These mutations were included in other mutant proteins and may contribute somewhat to higher function in these mutants. This family of mutants helped discriminate events that are necessary for protein-membrane binding. These include calcium binding to the free protein and subsequent protein-membrane contact. Depending on conditions of the assay used, the mutants displayed increased activity of the corresponding activated protein C (APC) derivatives, The degree of enhanced activity (up to 10-fold) was dependent on the concentration of phospholipid and quality of phospholipid (+/- phosphatidylethanolamine) used in the assay. This was expected, because APC is active in its membrane-associated form, which can be regulated by changes in either the protein or phospholipid. As expected, the largest impact of the mutants occurred at low phospholipid concentration and in the absence of phosphatidylethanolamine. The anticoagulant activity of all proteins was stimulated by protein S, with the greatest impact on the enhanced mutants. Whereas plasma containing Factor V:R506Q was partially resistant to all forms of APC, the enhanced variants were more active than normal APC, Protein C variants with enhanced function present new reagents for study of coagulation and may offer improved materials for biomedical applications.	Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA; Malmo Gen Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Lund, S-20502 Malmo, Sweden	University of Minnesota System; University of Minnesota Twin Cities; Lund University	Nelsestuen, GL (corresponding author), Univ Minnesota, Dept Biochem, 1479 Gortner Ave, St Paul, MN 55108 USA.			Dahlback, Bjorn/0000-0003-1546-0328	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60859] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P8082, DOI 10.1021/bi00025a014; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P14993, DOI 10.1021/bi00254a007; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; Gale AJ, 1997, PROTEIN SCI, V6, P132; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; HASHIMOTO T, 1988, Patent No. 1085096; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; Jalbert LR, 1996, BIOCHEMISTRY-US, V35, P7093, DOI 10.1021/bi960290p; KIM JY, 1994, J BIOL CHEM, V269, P28214; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; NELSESTUEN GL, 1973, P NATL ACAD SCI USA, V70, P3366, DOI 10.1073/pnas.70.12.3366; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NELSESTUEN GL, 1978, FED PROC, V37, P2621; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; PLAGER DA, 1994, BIOCHEMISTRY-US, V33, P13239, DOI 10.1021/bi00249a010; PLETCHER CH, 1983, J BIOL CHEM, V258, P1086; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; Shah AM, 1998, P NATL ACAD SCI USA, V95, P4229, DOI 10.1073/pnas.95.8.4229; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Thariath A, 1997, BIOCHEM J, V322, P309, DOI 10.1042/bj3220309; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1994, J BIOL CHEM, V269, P3590; ZHANG L, 1992, BLOOD, V80, P942	36	20	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31086	31091		10.1074/jbc.273.47.31086	http://dx.doi.org/10.1074/jbc.273.47.31086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813008	hybrid			2022-12-25	WOS:000077136900036
J	Yamane, Y; Furuichi, M; Song, R; Van Nguyen, T; Mulcahy, RT; Ishikawa, T; Kuo, MT				Yamane, Y; Furuichi, M; Song, R; Van Nguyen, T; Mulcahy, RT; Ishikawa, T; Kuo, MT			Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; HUMAN GLIOMA-CELLS; MRP GENE; S-CONJUGATE; BUTHIONINE SULFOXIMINE; GLUTATHIONE METABOLISM; INCREASED SENSITIVITY; LIGHT SUBUNITS; HEAVY SUBUNIT; INDUCTION	Expression of the MRP1 gene encoding the GS-X pump and of the gamma-GCSh gene encoding the heavy (catalytic) subunit of the gamma-glutamylcysteine synthetase is frequently elevated in many drug-resistant cell lines and can be co-induced by many cytotoxic agents. However, mechanisms that regulate the expression of these genes remain to be elucidated. We report here that like gamma-GCSh, the expression of MRP1 can be induced in cultured cells treated with pro-oxidants such as tert-butylhydroquinone, 2,3-dimethoxy-1,4-naphthoquinone, and menadione. Intracellular reactive oxygen intermediate (ROI) levels were increased in hepatoma cells treated with tert-butylhydroquinone for 2 h as measured by flow cytometry using an ROI-specific probe, dihydrorhodamine 123. Elevated GSH levels in stably gamma-GCSh-transfected cell lines down-regulated endogenous MRP1 and gamma-GCSh expression. ROI levels in these transfected cells were lower than those in the untransfected control. In the cell lines in which depleting cellular GSH pools did not affect the expression of the MRP1 and gamma-GCSh genes, only minor increased intracellular levels of ROIs were observed. These results suggest that intracellular ROI levels play an important role in the regulation of MRP1 and gamma-GCSh expression. Our data also suggest that elevated intracellular GSH levels not only facilitate substrate transport by the MRP1/GS-X pump as previously demonstrated, but also suppress MRP1 and gamma-GCSh expression.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Hematol & Therapy, Houston, TX 77030 USA; Univ Wisconsin, Dept Human Oncol, Madison, WI 53792 USA; Pfizer Inc, Cent Res, Med Biol Lab, Aichi 4702393, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Wisconsin System; University of Wisconsin Madison; Pfizer	Kuo, MT (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, POB 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tkuo@notes.mdacc.tmc.edu			NCI NIH HHS [CA 72404, CA 60586, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404, R01CA060586, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AliOsman F, 1996, MOL PHARMACOL, V49, P1012; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; Cimino F, 1997, CURR TOP CELL REGUL, V35, P123, DOI 10.1016/S0070-2137(97)80005-2; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Gomi A, 1997, CANCER RES, V57, P5292; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; ISHIKAWA T, 1989, GLUTATHIONE CHEM B B, V3, P85; JEDITSCHKY G, 1994, CANCER RES, V54, P4833; JEVTOVICTODOROVIC V, 1992, BIOCHEM PHARMACOL, V44, P1383, DOI 10.1016/0006-2952(92)90540-Y; Kuo MT, 1996, CANCER RES, V56, P3642; Kuo MT, 1998, BIOCHEM PHARMACOL, V55, P605, DOI 10.1016/S0006-2952(97)00494-2; KUROKAWA H, 1995, BIOCHEM BIOPH RES CO, V216, P258, DOI 10.1006/bbrc.1995.2618; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; LEO DW, 1996, EUR J CANCER, V32, P945; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; LOE DW, 1996, J BIOL CHEM, V271, P983; Lorico A, 1997, CANCER RES, V57, P5238; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2; ODwyer PJ, 1996, J CLIN ONCOL, V14, P249, DOI 10.1200/JCO.1996.14.1.249; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Rappa G, 1997, CANCER RES, V57, P5232; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SHERTZER HG, 1994, CHEM RES TOXICOL, V7, P358, DOI 10.1021/tx00039a013; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; THOMAS M, 1995, BRIT J CANCER, V72, P45, DOI 10.1038/bjc.1995.275; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZHANG JG, 1993, BIOCHEM PHARMACOL, V45, P2215; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZHU QC, 1994, CANCER RES, V54, P4488	54	142	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31075	31085		10.1074/jbc.273.47.31075	http://dx.doi.org/10.1074/jbc.273.47.31075			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813007	hybrid			2022-12-25	WOS:000077136900035
J	Alzola, E; Perez-Etxebarria, A; Kabre, E; Fogarty, DJ; Metioui, M; Chaib, N; Macarulla, JM; Matute, C; Dehaye, JP; Marino, A				Alzola, E; Perez-Etxebarria, A; Kabre, E; Fogarty, DJ; Metioui, M; Chaib, N; Macarulla, JM; Matute, C; Dehaye, JP; Marino, A			Activation by P2X(7) agonists of two phospholipases A(2) (PLA(2)) in ductal cells of rat submandibular gland - Coupling of the calcium-independent PLA(2) with kallikrein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; PURINERGIC RECEPTOR ACTIVATION; ARACHIDONIC-ACID RELEASE; PERITONEAL MAST-CELLS; PROTEIN-KINASE-C; EXTRACELLULAR ATP; P-2X RECEPTOR; CA2+-INDEPENDENT PHOSPHOLIPASE-A2; PHOSPHATIDATE PHOSPHOHYDROLASE; ADENOSINE 5'-TRIPHOSPHATE	Isolated ductal cells of rat submandibular gland phospholipid pools were labeled with [H-3]arachidonic acid (AA). The tracer was incorporated preferentially to phosphatidylcholine (46% of the lipidic fraction). Extracellular ATP induced the release of [H-3]AA to the extracellular medium in a time- and dose-dependent manner (EC50 = 220 mu M). Among other agents tested, only 2',3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate (Bz-ATP) was able to mimic the effect of ATP (EC50 = 15 mu M), without activation of phospholipase C. The purinergic antagonists oxidized ATP, suramin, and Coomassie Blue partly inhibited the response to 1 mM ATP and 100 mu M Bz-ATP; the response was also blocked by the addition of Mg2+ or Ni2+. Expression of P2X(7) receptor mRNA in these cells was confirmed by reverse transcription-polymerase chain reaction. In the presence of extracellular calcium, the phospholipase A(2) inhibitor 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid (a nonspecific in hibitor), arachidonyl trifluoromethylketone (AACOCF(3), an inhibitor of the calcium-dependent cytosolic PLA(2) (cPLA(2))), and bromoenol lactone tan inhibitor of the calcium-independent PLA(2) (iPLA(2))) inhibited the release of [H-3]AA induced by ATP and Bz-ATP. In the absence of extracellular calcium, the release of [H-3]AA in response to the purinergic agonists was still observed; this response was not affected by AACOCF(3) and completely blocked by bromoenol lactone. ATP and Bz-ATP stimulated a calcium-independent secretion of kallikuein, which could be blocked by EEL but which was enhanced by AACOCF(3). It is concluded that the P2X(7) receptor in ductal cells is coupled to kallikrein secretion through a calcium-dependent cPLA(2) and a calcium-independent iPLA(2).	Univ Basque Country, Fac Med & Odontol, Dept Neurosci, Leioa 48940, Spain; Univ Basque Country, Fac Sci, Dept Biochem & Mol Biol, Leioa 48940, Spain; Free Univ Brussels, Lab Biochim Gen & Humaine, Inst Pharm, B-1050 Brussels, Belgium	University of Basque Country; University of Basque Country; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Alzola, E (corresponding author), Univ Basque Country, Fac Ciencias, Dept Bioquim & Biol Mol, Euskal Herriko Unibertsitates, Apdo 644, E-48080 Bilbao, Spain.	gbbalece@lg.ehu.es	Matute, Carlos/N-5559-2014; Fogarty, David J./AAN-7674-2020; Fogarty, David/C-7046-2011	Matute, Carlos/0000-0001-8672-711X; Fogarty, David J./0000-0002-3103-1657; Fogarty, David/0000-0002-3103-1657; MARINO SANCHEZ, AIDA LUISA/0000-0003-3208-0677				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Amsallem H, 1996, AM J PHYSIOL-CELL PH, V271, pC1546, DOI 10.1152/ajpcell.1996.271.5.C1546; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung HC, 1995, PFLUG ARCH EUR J PHY, V431, P161, DOI 10.1007/BF00410187; Collo G, 1996, J NEUROSCI, V16, P2495; Coutinho-Silva R, 1997, AM J PHYSIOL-CELL PH, V273, pC1793, DOI 10.1152/ajpcell.1997.273.6.C1793; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; ELMOATASSIM C, 1990, EUR J PHARMACOL, V181, P111, DOI 10.1016/0014-2999(90)90251-Z; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Eriksson G., 1979, Analytica Chimica Acta, Computer Techniques and Optimization, V112, P375, DOI 10.1016/S0003-2670(01)85035-2; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; GALLACHER DV, 1982, NATURE, V296, P83, DOI 10.1038/296083a0; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hurley TW, 1996, J CELL PHYSIOL, V168, P229, DOI 10.1002/(SICI)1097-4652(199608)168:2<229::AID-JCP1>3.3.CO;2-8; ISHIMOTO T, 1994, EUR J BIOCHEM, V219, P401, DOI 10.1111/j.1432-1033.1994.tb19952.x; JONES KT, 1994, EXP CELL RES, V212, P409, DOI 10.1006/excr.1994.1161; KUROSAWA M, 1992, INT ARCH ALLERGY IMM, V97, P226, DOI 10.1159/000236123; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Loo RW, 1997, J BIOL CHEM, V272, P19214, DOI 10.1074/jbc.272.31.19214; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; Metioui M, 1996, J CELL PHYSIOL, V168, P462, DOI 10.1002/(SICI)1097-4652(199608)168:2<462::AID-JCP25>3.0.CO;2-3; MIZUNO M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P21, DOI 10.1016/0005-2760(91)90050-R; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NAGAO T, 1995, BIOCHEM J, V307, P563, DOI 10.1042/bj3070563; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; Park MK, 1997, AM J PHYSIOL-CELL PH, V272, pC1388, DOI 10.1152/ajpcell.1997.272.4.C1388; PERRIN DD, 1983, STABILITY CONSTANT A, V22; PERRIN DD, 1983, STABILITY CONSTANT B, V22; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; PURKISS J, 1992, BIOCHEM PHARMACOL, V43, P1235, DOI 10.1016/0006-2952(92)90497-7; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; SIGEL H, 1987, INORG CHEM, V26, P2149, DOI 10.1021/ic00260a028; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takuma T, 1997, J BIOCHEM-TOKYO, V121, P1018; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THAYSEN JH, 1954, AM J PHYSIOL, V178, P155, DOI 10.1152/ajplegacy.1954.178.1.155; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; Ugur M, 1997, J PHYSIOL-LONDON, V498, P427, DOI 10.1113/jphysiol.1997.sp021869; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Weisman GA, 1996, J PHARMACOL EXP THER, V277, P1; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227	64	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30208	30217		10.1074/jbc.273.46.30208	http://dx.doi.org/10.1074/jbc.273.46.30208			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804778	hybrid			2022-12-25	WOS:000077008100025
J	Bhullar, IS; Li, YS; Miao, H; Zandi, E; Kim, M; Shyy, JYJ; Chien, S				Bhullar, IS; Li, YS; Miao, H; Zandi, E; Kim, M; Shyy, JYJ; Chien, S			Fluid shear stress activation of I kappa B kinase is integrin-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-ENDOTHELIAL-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ALPHA PROTEOLYSIS; INDUCED APOPTOSIS; JNK PATHWAY; T-CELLS; PHOSPHORYLATION; ADHESION	Vascular endothelial cells (ECs), forming a boundary between the circulating blood and the vessel wall, are constantly subjected to fluid shear stress due to blood flow. The aim of this study was to determine the role of the recently identified I kappa B kinases (IKKs) in shear stress activation of NF-kappa B and to elucidate the upstream signaling mechanism that mediates IKK activation. Our results demonstrate that IKKs in ECs are activated by shear stress in a rapid and transient manner. This IKK activation is followed by I kappa B degradation and NF-kappa B translocation into the nucleus. Transfection of plasmids encoding catalytic inactive mutants of IKKs, i.e. hemagglutinin (HA)-IKK alpha(K44M) and HA-IKK beta(K44A), inhibits shear stress-induced NF-kappa B translocation, In addition, constructs encoding antisense IKKs, i.e. HA-IKK alpha(AS) and HA-IKK beta(AS), attenuate shear stress induction of a promoter driven by the kappa B enhancer element. Preincubation of the EC monolayer with a monoclonal anti-alpha(v)beta(3) integrin antibody (clone LM609) attenuates shear stress induction of IKK. Inhibition of tyrosine kinases by genistein causes a similar down-regulating effect. These results suggest that the integrin-mediated signaling pathway regulates NP-kappa B through IKKs in ECs in response to shear stress.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Biomed Engn, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Chien, S (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NHLBI NIH HHS [HL-44174, HL-19454, HL-43026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043026, R01HL019454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLAKE DR, 1994, ANN NY ACAD SCI, V723, P308, DOI 10.1111/j.1749-6632.1994.tb36736.x; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Faure E, 1996, CELL MOL BIOL, V42, P811; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCGILVRAY ID, 1997, J BIOL CHEM, V272, P10258; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PARSONS JT, 1994, J CELL SCI, P109; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Rosales C, 1996, CANCER RES, V56, P2302; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shyy JYJ, 1995, J BIOMECH, V28, P1451, DOI 10.1016/0021-9290(95)00093-3; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tardy Y, 1997, ARTERIOSCL THROM VAS, V17, P3102, DOI 10.1161/01.ATV.17.11.3102; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Udagawa T, 1996, J IMMUNOL, V157, P1965; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	116	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30544	30549		10.1074/jbc.273.46.30544	http://dx.doi.org/10.1074/jbc.273.46.30544			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804824	hybrid			2022-12-25	WOS:000077008100071
J	Frendo, JL; Xiao, GZ; Fuchs, S; Franceschi, RT; Karsenty, G; Ducy, P				Frendo, JL; Xiao, GZ; Fuchs, S; Franceschi, RT; Karsenty, G; Ducy, P			Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; BONE-FORMATION; DNA-BINDING; COL1A1 PROMOTER; MAMMALIAN-CELLS; PROTEIN; MUTATIONS	Osteocalcin gene expression is initiated perinatally and is restricted to mature osteoblasts and odontoblasts. Because their pattern of expression is highly restricted, the osteocalcin genes are excellent tools to study osteoblast-specific gene expression. To define the mechanisms of osteocalcin cell-specific gene expression in vivo, we generated transgenic mice harboring deletion mutants of the promoter region of OG2, one of the mouse osteocalcin genes. We show here that only 647 base pairs of this promoter are sufficient to confer cell-specific and time-specific expression to a reporter gene in vivo, This promoter fragment contains two copies of OSE2, This osteoblast-specific cis-acting element binds Osf2, a recently characterized osteoblast-specific transcription factor (Ducy, P,, Zhang, R,, Geoffroy, V,, Ridall, A. L,, and Karsenty, G, (1997) Cell 89, 747-754), We also demonstrate that the proximal OSE2 element is critical to confer an osteoblast-specific, developmentally regulated pattern of expression to a reporter gene. The other OSE2 element, located more upstream and presenting a lower affinity for Osf2, affects only weakly OG2 promoter activity. These data demonstrate the crucial role of Osf2 in controlling osteocalcin gene expression. Since osteocalcin synthesis is a hallmark of the differentiated osteoblast phenotype, these results suggest that, beyond its developmental function, Osf2 is also required for the maintenance of the osteoblast phenotype postnatally.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Michigan, Dept Periodont Prevent & Geriatr & Biol Chem, Ann Arbor, MI 48109 USA	Baylor College of Medicine; University of Michigan System; University of Michigan	Ducy, P (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,630E, Houston, TX 77030 USA.		Frendo, Jean-Louis/M-2546-2019; Frendo, Jean-Louis/AAX-2676-2020	Frendo, Jean-Louis/0000-0003-0118-5556	NIDCR NIH HHS [DE-11290] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aubin Jane E., 1993, P1; Ausubel FM, 1995, CURRENT PROTOCOL MOL; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BONNEROT C, 1993, GUIDE TECHNIQUES MOU, V225; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BYERS PH, 1988, AM J HUM GENET, V42, P237; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eriebacher Adrian, 1995, Cell, V80, P371; Frenkel B, 1997, ENDOCRINOLOGY, V138, P2109, DOI 10.1210/en.138.5.2109; HARRIS SE, 1994, J BONE MINER RES, V9, P389; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KESTERSON RA, 1993, MOL ENDOCRINOL, V7, P462, DOI 10.1210/me.7.3.462; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; MARIE PJ, 1991, J CLIN INVEST, V88, P1167, DOI 10.1172/JCI115418; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MERIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PRICE PA, 1987, CALCIUM REGULATION B, P142; RAISZ LG, 1983, NEW ENGL J MED, V309, P29, DOI 10.1056/NEJM198307073090107; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103	36	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30509	30516		10.1074/jbc.273.46.30509	http://dx.doi.org/10.1074/jbc.273.46.30509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804819	hybrid			2022-12-25	WOS:000077008100066
J	Heath, RJ; Yu, YT; Shapiro, MA; Olson, E; Rock, CO				Heath, RJ; Yu, YT; Shapiro, MA; Olson, E; Rock, CO			Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; REDUCTASE FABI; BIOSYNTHESIS; ELONGATION; TRICLOSAN; ENVM; NADH	The broad spectrum antibacterial properties of 2-hydroxydiphenyl ethers have been appreciated for decades, and their use in consumer products is rapidly increasing. We identify the enoyl-acyl carrier protein reductase (fabI) component of the type II fatty acid synthase system as the specific cellular target for these antibacterials. Biologically active 8-hydroxydiphenyl ethers effectively inhibit fatty acid synthesis in vivo and FabI activity in vitro. Resistant mechanisms include upregulation of fabI expression and spontaneously arising missense mutations in the fabI gene. These results contradict the view that these compounds directly disrupt membranes and suggest that their widespread use will. select for resistant bacterial populations.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI 48105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Pfizer; Pfizer; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.			Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BALDWIN JE, 1992, BIOORG MED CHEM LETT, V2, P633; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; EGAN AF, 1973, GENET RES, V21, P3603; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; REGOS J, 1979, DERMATOLOGICA, V158, P72, DOI 10.1159/000250746; REGOS J, 1974, ZBL BAKT-INT J MED M, V226, P390; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VISCHER WA, 1974, ZBL BAKT-INT J MED M, V226, P376; WEBSTER J, 1992, J HOSP INFECT, V21, P137, DOI 10.1016/0195-6701(92)90033-I	23	302	320	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30316	30320		10.1074/jbc.273.46.30316	http://dx.doi.org/10.1074/jbc.273.46.30316			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804793	hybrid			2022-12-25	WOS:000077008100040
J	Nagano, F; Orita, S; Sasaki, T; Naito, A; Sakaguchi, G; Maeda, M; Watanabe, T; Kominami, E; Uchiyama, Y; Takai, Y				Nagano, F; Orita, S; Sasaki, T; Naito, A; Sakaguchi, G; Maeda, M; Watanabe, T; Kominami, E; Uchiyama, Y; Takai, Y			Interaction of Doc2 with tctex-1, a light chain of cytoplasmic dynein - Implication in dynein-dependent vesicle transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX; MOLECULAR-CLONING; MESSENGER-RNA; PROTEINS; BRAIN; BINDING; DOMAINS; GENE; RABPHILIN-3A; FAMILY	Doca has one Munc13-interacting domain at the N-terminal region and two CS-like domains interacting with Ca2+ and phospholipid at the C-terminal region. Doc2 consists of two isoforms, Doc2 alpha and -beta. Doc2 alpha is specifically expressed in neuronal cells and implicated in Ca2+-dependent neurotransmitter release, whereas Doc2 beta is ubiquitously expressed and its function is unknown. We show here that both Doc2 alpha and -beta interact with rat tctex-1, a light chain of cytoplasmic dynein, in both cell-free and intact cell systems. Overexpression of the N-terminal fragment of Doc2 containing the tctex-1-interacting domain induces changes in the intracellular localization of cation-independent mannose 6-phosphate receptor and its ligand, cathepsin D, which are transported from trans-Golgi network to late endosomes. Overexpression of the C-terminal fragment containing two C2-like domains shows the similar effect, but to a lesser extent, whereas overexpression of full-length Doc2 or the C-terminal fragment of rabphilin3 containing two CS-like domains does not show this effect. Because dynein is a minus-end-directed microtubule-based motor protein, these results suggest that Doc2, especially Doc2 beta, plays a role in dynein-dependent intracellular vesicle transport.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Anat 1, Suita, Osaka 5650871, Japan; Shionogi Inst Med Sci, Settsu 5660022, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1130033, Japan	Osaka University; Osaka University; Shionogi & Company Limited; Juntendo University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.		Kominami, Eiki/D-3802-2009	Watanabe, Tsuyoshi/0000-0002-6094-7728				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J.H., 1972, EXPT MOL GENETICS; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	27	58	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30065	30068		10.1074/jbc.273.46.30065	http://dx.doi.org/10.1074/jbc.273.46.30065			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804756	hybrid			2022-12-25	WOS:000077008100003
J	Nalca, A; Rangnekar, VM				Nalca, A; Rangnekar, VM			The G(1)-phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED G(1) ARREST; CYCLIN-DEPENDENT KINASES; WILD-TYPE P53; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; P53-INDEPENDENT PATHWAY; HUMAN CANCERS; TUMOR; APOPTOSIS; INDUCTION	Interleukin-1 (IL-1) causes G(1)-phase growth arrest of A375-C6 human melanoma cells by hypophosphorylation of the retinoblastoma susceptibility gene product Rb. Because p53 and p21/WAF1 proteins are key components of growth arrest pathways involving Rb hypophosphorylation, we tested the functional role of these two proteins in IL-1 action. Exposure to IL-1 caused induction of both p53 and p21/WAF1 proteins. However, inhibition of p53 function by the KI mutant of SV40-T antigen or by m175 (Arg to His) dominant-negative mutant of p53 did not result in abrogation of IL-1 action, suggesting that p53 function is not required for growth arrest by IL-1. Studies aimed at testing the role of p21/WAF1 in IL-1 action indicated that IL-1 induced p21/WAF1 expression independently of the p53 status of the cells. However, inhibition of p21/WAF1 expression resulted in only a marginal rescue from the growth-arresting action of IL-1. These findings imply that despite their induction, neither wild-type p53 nor p21 can fully account for the growth arrest by IL-1. Thus, a p53- and p21-independent pathway(s) mediates IL-1 action.	Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Div Urol, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Microbiol & Immunol, Combs Res Bldg,Rm 303,800 Rose St, Lexington, KY 40536 USA.	vmrang01@pop.uky.edu	Nalca, Aysegul/L-8149-2019	Nalca, Aysegul/0000-0001-8581-7535	NCI NIH HHS [CA60872, CA52837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052837, R01CA060872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BOOKSTEIN R, 1993, CANCER-AM CANCER SOC, V71, P1179, DOI 10.1002/1097-0142(19930201)71:3+<1179::AID-CNCR2820711442>3.0.CO;2-B; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DelSal G, 1996, ONCOGENE, V12, P177; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DINARELLO CA, 1991, BLOOD, V77, P1627; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDO Y, 1988, J IMMUNOL, V141, P2342; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAKS T, 1994, CURR BIOL, V4, P1; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINGSTON RE, 1995, SHORT PROTOCOLS MOL, P255; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; SELLS SF, 1995, MOL CELL BIOL, V15, P682; Shiohara M, 1997, ONCOGENE, V15, P1605, DOI 10.1038/sj.onc.1201315; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHRIVASTAVA S, 1990, NATURE, V348, P747; Smith ML, 1996, AM J PATHOL, V148, P1019; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	59	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30517	30523		10.1074/jbc.273.46.30517	http://dx.doi.org/10.1074/jbc.273.46.30517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804820	hybrid			2022-12-25	WOS:000077008100067
J	Ponnampalam, SN; Elsen, S; Bauer, CE				Ponnampalam, SN; Elsen, S; Bauer, CE			Aerobic repression of the Rhodobacter capsulatus bchC promoter involves cooperative interactions between CrtJ bound to neighboring palindromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PHAGE REPRESSOR; GENE-EXPRESSION; BINDING; BACTERIOCHLOROPHYLL; SPHAEROIDES; BIOSYNTHESIS; MUTAGENESIS; SEQUENCES; PROTEIN; OXYGEN	Previous studies demonstrated that bacteriochlorophyll, carotenoid, and light harvesting gene expression in Rhodobacter capsulatus is repressed under aerobic growth conditions by the repressor CrtJ. Isolated CrtJ is known to bind to the palindrome TGTN(12)ACA, which is present in two copies in the bchC promoter, one of which spans the -35 and the other the -10 sigma-70 recognition sequences. In this study, we demonstrate that CrtJ binds to the two palindromic sites in the bchC promoter in a cooperative manner. The level of cooperativity of CrtJ binding to the -35 palindrome was shown to be 26-fold. A distance of 8 base pairs between the two palindromic sites was shown to be critical for cooperative binding, as evidenced by the disruption of binding that resulted when +6 and +11 base pairs were inserted between the palindromes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Biochem Program, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.			Elsen, Sylvie/0000-0003-4611-4719	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040941, R01GM040941, K04GM000618, R01GM053940] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM00618, GM53940, R01 GM040941, R37 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; Elsen S, 1998, J BIOL CHEM, V273, P30762, DOI 10.1074/jbc.273.46.30762; GAUGH JA, 1983, J MOL BIOL, V166, P1; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; Nickens DG, 1998, J BACTERIOL, V180, P4270, DOI 10.1128/JB.180.16.4270-4277.1998; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Ptashne M., 1987, GENETIC SWITCH; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	24	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30757	30761		10.1074/jbc.273.46.30757	http://dx.doi.org/10.1074/jbc.273.46.30757			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804852	hybrid			2022-12-25	WOS:000077008100099
J	Rao, PV; Garrow, TA; John, F; Garland, D; Millian, NS; Zigler, JS				Rao, PV; Garrow, TA; John, F; Garland, D; Millian, NS; Zigler, JS			Betaine-homocysteine methyltransferase is a developmentally regulated enzyme crystallin in rhesus monkey lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE METABOLISM; EYE LENS; PURIFICATION; PROTEIN; RAT; MAMMALS; GENE; CHROMATOGRAPHY; CYSTATHIONINE; QUANTITATION	We describe herein the characterization of a major 45-kDa protein from the soluble beta H-crystallin fraction of rhesus monkey (Macaca mulatta) lens. Based on partial peptide sequence, immunoreactivity, and enzymatic activity, this protein has been identified as betaine-homocysteine S-methyltransferase (BHMT: EC 2.1.1.5), an enzyme that catalyzes the methylation of homocysteine using either betaine or thetins as methyl donors. This protein was found to be expressed abundantly in the nuclear region of the monkey lens, reaching similar to 10% of the total nuclear protein, but was barely detectable in the epithelium and cortex regions of the lens. Because the nucleus represents the early embryonic and fetal stages of lens development, we infer that BHMT expression in the lens of the eye is developmentally regulated. By virtue of its high abundance, BHMT can be considered an enzyme crystallin (psi-crystallin). This is the first enzyme crystallin to be found in primate lenses.	NEI, Lab Mech Ocular Dis, NIH, Bethesda, MD 20892 USA; Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Illinois System; University of Illinois Urbana-Champaign	Zigler, JS (corresponding author), NEI, Lab Mech Ocular Dis, NIH, 6 Ctr Dr,MSC 2735,Bldg 6,Rm 237, Bethesda, MD 20892 USA.	szigler@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052501, R29DK052501] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W; BAGCHI KALYAN, 1959, INDIAN JOUR MED RES, V47, P437; BERGAD PL, 1986, OPHTHALMIC RES, V28, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DURELL J, 1957, BIOCHIM BIOPHYS ACTA, V26, P270, DOI 10.1016/0006-3002(57)90005-7; DURELL J, 1959, BIOCHIM BIOPHYS ACTA, V35, P515, DOI 10.1016/0006-3002(59)90401-9; Emmert JL, 1996, J NUTR, V126, P2050; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2102, DOI 10.3891/acta.chem.scand.14-2102; FINKELSTEIN JD, 1967, J BIOL CHEM, V242, P873; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1983, J NUTR, V113, P519, DOI 10.1093/jn/113.3.519; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1978, TRANSMETHYLATION, P49; Garland DL, 1996, EXP EYE RES, V62, P285, DOI 10.1006/exer.1996.0034; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; GELLER AM, 1986, EXP EYE RES, V43, P997, DOI 10.1016/0014-4835(86)90077-1; GONZALEZ P, 1995, MOL BIOL EVOL, V12, P773; Harding JJ, 1984, EYE B, V1b, P207; JIMENEZASENSIO J, 1995, BIOCHEM BIOPH RES CO, V209, P796, DOI 10.1006/bbrc.1995.1570; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KLEE WA, 1961, BIOCHIM BIOPHYS ACTA, V54, P157, DOI 10.1016/0006-3002(61)90948-9; KLEE WA, 1960, BIOCHIM BIOPHYS ACTA, V45, P545, DOI 10.1016/0006-3002(60)91492-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KH, 1992, ARCH BIOCHEM BIOPHYS, V292, P77, DOI 10.1016/0003-9861(92)90053-Y; MAR MH, 1995, J NUTR BIOCHEM, V6, P392, DOI 10.1016/0955-2863(95)80008-Z; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; REDDY VN, 1973, EXP EYE RES, V16, P105, DOI 10.1016/0014-4835(73)90305-9; REED DJ, 1995, METHOD ENZYMOL, V252, P92; Roll B, 1996, J BIOL CHEM, V271, P10437; RUSAKOW LS, 1993, J APPL PHYSIOL, V74, P989, DOI 10.1152/jappl.1993.74.3.989; SATO S, 1985, EXP EYE RES, V41, P323, DOI 10.1016/S0014-4835(85)80023-3; SKIBA WE, 1982, J BIOL CHEM, V257, P4944; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; Wada K, 1995, EUR J PHARMACOL, V294, P377, DOI 10.1016/0014-2999(95)00558-7; Wada K, 1996, EUR J PHARMACOL, V296, P335, DOI 10.1016/0014-2999(95)00717-2; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Wistow G, 1995, MOL BIOL EVOLUTION C; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1989, INVEST OPHTH VIS SCI, V30, P2195; ZIGLER JS, 1981, TRENDS BIOCHEM SCI, V6, P133; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	49	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30669	30674		10.1074/jbc.273.46.30669	http://dx.doi.org/10.1074/jbc.273.46.30669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804840	hybrid			2022-12-25	WOS:000077008100087
J	Scatena, CD; Stewart, ZA; Mays, D; Tang, LJ; Keefer, CJ; Leach, SD; Pietenpol, JA				Scatena, CD; Stewart, ZA; Mays, D; Tang, LJ; Keefer, CJ; Leach, SD; Pietenpol, JA			Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL-INDUCED APOPTOSIS; CYTOCHROME-C; PROTEIN-KINASES; TYROSINE KINASE; CDC25 PROTEIN; ION-CHANNEL; HUMAN WEE1; ACTIVATION; DEATH; BAX	There is increasing evidence that prolonged mitotic arrest initiates apoptosis; however, little is known about the signaling pathways involved. Several studies have associated deregulated Cdc2 activity with apoptosis. Herein, we report that the anti-apoptotic protein, Bcl-2, undergoes cell cycle-dependent phosphorylation during mitosis when there is elevated Cdc2 activity. We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death. The Taxol-induced BcI-2 phosphorylation was dose-dependent. Furthermore, phosphorylated Bcl-2 remained complexed with Bax in Taxol-treated cells undergoing apoptosis. Immunoprecipitation experiments revealed a Bcl-2-associated kinase capable of phosphorylating histone H1 in vitro. However, the kinase was likely not cyclin B1/Cdc2, since cyclin B1/Cdc2 was not detectable in Bcl-2 immunoprecipitates, nor was recombinant Bcl-2 phosphorylated in vitro by cyclin B1/Cdc2. The results of this study further define a link between mitotic kinase activation and the apoptotic machinery in the cell. However, the role, if any, of prolonged Bcl-2 phosphorylation in Taxol-mediated apoptosis awaits further definition of Bcl-2 mechanism of action. Taxol may increase cellular susceptibility to apoptosis by amplifying the normal downstream events associated with mitotic kinase activation.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Surg, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Canc Ctr, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 652 Med Res Bldg 2, Nashville, TN 37232 USA.	pietenpol@toxicology.mc.vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIEHS NIH HHS [ES07028] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; CohenFix O, 1997, CURR OPIN CELL BIOL, V9, P800, DOI 10.1016/S0955-0674(97)80080-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; Decaudin D, 1997, CANCER RES, V57, P62; Draetta GF, 1997, CURR BIOL, V7, pR50, DOI 10.1016/S0960-9822(06)00020-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fang GF, 1998, CANCER RES, V58, P3202; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Leach SD, 1998, CANCER RES, V58, P3231; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Otter I, 1998, J BIOL CHEM, V273, P6110, DOI 10.1074/jbc.273.11.6110; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; TANG C, 1994, LEUKEMIA, V8, P1960; WANG HG, 1994, ONCOGENE, V9, P2751; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yao SL, 1996, CANCER RES, V56, P4551; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	64	206	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30777	30784		10.1074/jbc.273.46.30777	http://dx.doi.org/10.1074/jbc.273.46.30777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804855	hybrid			2022-12-25	WOS:000077008100102
J	Alfonzo, JD; Thiemann, OH; Simpson, L				Alfonzo, JD; Thiemann, OH; Simpson, L			Purification and characterization of MAR1 - A mitochondrial associated ribonuclease from Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; MESSENGER-RNA; KINETOPLASTID MITOCHONDRIA; DIRECTED ENDONUCLEASE; ESCHERICHIA-COLI; DNA; EXPRESSION; MOLECULES; SEQUENCE; GENE	A relatively thermostable 22-kDa endoribonuclease (MAR1) was purified more than 10,000-fold from a mitochondrial extract of Leishmania tarentolae and the gene closed. The purified nuclease has a K-m of 100-145 +/- 33 nM and a V-max of 1.8-2.9 +/- 2 nmol/min, depending on the RNA substrate, and yields a 3'-OH and a 5'-phosphate. Cleavage was limited to several specific sites in the substrate RNAs tested, but cleavage of pre-edited RNAs was generally independent of the addition of cognate guide RNA. The MAR1 gene was expressed in Escherichia coli or in L. tarentolae cells, and the recombinant protein was affinity-purified. The cleavage specificity of the recombinant enzyme from L. tarentolae was identical to that of the native enzyme. The single copy MAR1 gene maps to an 820-kilobase pair chromosome and contains an open reading frame of 579 nucleotides. The 18-amino acid N-terminal sequence shows characteristics of an uncleaved mitochondrial targeting sequence. Data base searching revealed two homologues of MAR1 corresponding to unidentified open reading frames in Caenorhabditis elegans (GenBank(TM) accession number Z69637) and Archaeoglobus fulgidus (GenBank(TM) accession number AE000943). The function of MAR1 in mitochondrial RNA metabolism in L. tarentolae remains to be determined.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.		Thiemann, Otavio H/D-9767-2012		NIAID NIH HHS [AI09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CAMPBELL AG, 1993, P NATL ACAD SCI USA, V90, P9350, DOI 10.1073/pnas.90.20.9350; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; DANG YL, 1993, J BIOL CHEM, V268, P19791; Dombrowski S, 1997, EMBO J, V16, P5069, DOI 10.1093/emboj/16.16.5069; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; Hajduk SL, 1997, TRENDS MICROBIOL, V5, P1, DOI 10.1016/S0966-842X(96)30039-5; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; Hesslein DGT, 1997, MOL BIOCHEM PARASIT, V86, P121, DOI 10.1016/S0166-6851(97)90014-1; Koslowsky DJ, 1997, MOL BIOCHEM PARASIT, V90, P81, DOI 10.1016/S0166-6851(97)00133-3; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIU XQ, 1989, J BIOL CHEM, V264, P16100; MICHELOTTI EF, 1992, MOL BIOCHEM PARASIT, V54, P31, DOI 10.1016/0166-6851(92)90092-X; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; Piller KJ, 1997, RNA, V3, P279; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; READ LK, 1992, J BIOL CHEM, V267, P1123; Rieger KJ, 1997, CURR GENET, V32, P163, DOI 10.1007/s002940050262; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Sambrook J., 2002, MOL CLONING LAB MANU; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; VANDERPLOEG LHT, 1989, NUCLEIC ACIDS RES, V17, P3217, DOI 10.1093/nar/17.8.3217	32	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30003	30011		10.1074/jbc.273.45.30003	http://dx.doi.org/10.1074/jbc.273.45.30003			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792721	hybrid			2022-12-25	WOS:000076798300098
J	Fanning, AS; Jameson, BJ; Jesaitis, LA; Anderson, JM				Fanning, AS; Jameson, BJ; Jesaitis, LA; Anderson, JM			The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELLS; POSTSYNAPTIC DENSITY; MEMBRANE-PROTEIN; PARACELLULAR PERMEABILITY; PHYSIOLOGICAL REGULATION; PERIPHERAL COMPONENT; ZONULA OCCLUDENS-1; CYTOCHALASIN-D; HUMAN HOMOLOG	The tight junction protein ZO-1 belongs to a family of multidomain proteins known as the membrane-associated guanylate kinase homologs (MAGUKs). ZO-1 has been demonstrated to interact with the transmembrane protein occludin, a second tight junction-specific MAGUK, ZO-2, and F-actin, although the nature and functional significance of these interactions is poorly understood. To further elucidate the role of ZO-1 within the epithelial tight junction, we have introduced epitope-tagged fragments of ZO-1 into cultured MDCK cells and identified domains critical for the interaction with ZO-2, occludin, and F-actin. A combination of in vitro and in vivo binding assays indicate that both ZO-2 and occludin interact with specific domains within the N-terminal (MAGUK-like) half of ZO-1, whereas the unique proline-rich C-terminal half of ZO-1 cosediments with F-actin. Consistent with these observations, we found that a construct encoding the N-terminal half of ZO-1 is specifically associated with tight junctions, whereas the unique C-terminal half of ZO-1 is distributed over the entire lateral surface of the plasma membrane and other actin-rich structures. In addition, we have identified a 244-amino acid domain within the N-terminal half of ZO-1, which is required for the stable incorporation of ZO-1 into the junctional complex of polarized MDCK cells. These observations suggest that one functional role of ZO-1 is to organize components of the tight junction and link them to the cortical actin cytoskeleton.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Yale University; Yale University; University of California System; University of California Berkeley	Fanning, AS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,POB 208019, New Haven, CT 06520 USA.	alan.fanning@yale.edu		Anderson, James/0000-0003-2765-7996	NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK045134] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NIDDK NIH HHS [DK45134, DK34989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; ANDERSON JM, 1996, CURR BIOL, V6, P326; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BENTZEL CJ, 1980, AM J PHYSIOL, V239, pC75, DOI 10.1152/ajpcell.1980.239.3.C75; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CEREIJIDO M, TIGHT JUNCTIONS, P1; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V269, pC1057, DOI 10.1152/ajpcell.1995.269.4.C1057; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; Fanning AS, 1996, CURR TOP MEMBR, V43, P211; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; FARQUHAR MG, 1963, J CELL BIOL, V17, P412; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; Hoskins R, 1996, DEVELOPMENT, V122, P97; HOWARTH AG, 1992, AM J PHYSIOL, V262, pC461, DOI 10.1152/ajpcell.1992.262.2.C461; HOWARTH AG, 1995, CELL MOTIL CYTOSKEL, V31, P323, DOI 10.1002/cm.970310408; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; KELLER TCS, 1982, J CELL BIOL, V95, P943, DOI 10.1083/jcb.95.3.943; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LUE R, 1995, P NATL ACAD SCI USA, V91, P9818; MADARA JL, 1992, ANN NY ACAD SCI, V664, P47, DOI 10.1111/j.1749-6632.1992.tb39748.x; MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McCarthy KM, 1996, J CELL SCI, V109, P2287; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nybom P, 1996, BIOSCIENCE REP, V16, P313, DOI 10.1007/BF01855015; PAPPENHEIMER JR, 1987, J MEMBRANE BIOL, V100, P136; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Sheth B, 1997, DEVELOPMENT, V124, P2027; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1994, J CELL SCI, V107, P367; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; TURNER JR, 1995, GASTROENTEROLOGY, V109, P1391, DOI 10.1016/0016-5085(95)90605-3; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YONEMURA S, 1995, J CELL SCI, V108, P127; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	76	1051	1078	2	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29745	29753		10.1074/jbc.273.45.29745	http://dx.doi.org/10.1074/jbc.273.45.29745			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792688	hybrid			2022-12-25	WOS:000076798300065
J	Goumon, Y; Lugardon, K; Kieffer, B; Lefevre, JF; Van Dorsselaer, A; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Lugardon, K; Kieffer, B; Lefevre, JF; Van Dorsselaer, A; Aunis, D; Metz-Boutigue, MH			Characterization of antibacterial COOH-terminal proenkephalin-A-derived peptides (PEAP) in infectious fluids - Importance of enkelytin, the antibacterial PEAP(209-237) secreted by stimulated chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PREPROENKEPHALIN MESSENGER-RNA; ENKEPHALIN-CONTAINING PEPTIDES; BOVINE ADRENAL-MEDULLA; ANTIMICROBIAL PEPTIDES; STAPHYLOCOCCUS-AUREUS; GENE-EXPRESSION; MET-ENKEPHALIN; XENOPUS-LAEVIS; DIFFERENTIAL EXPRESSION	Proenkephalin-A (PEA) and its derived peptides (PEAP) have been described in neural, neuroendocrine tissues and immune cells. The processing of PEA has been extensively studied in the adrenal medulla chromaffin cell showing that maturation starts with the removal of the carboxyl-terminal PEAP(209-239). In 1995, our laboratory has shown that antibacterial activity is present within the intragranular chromaffin granule matrix and in the extracellular medium following exocytosis, More recently, we have identified an intragranular peptide, named enkelytin, corresponding to the bisphosphorylated PEAP(209-237), that inhibits the growth of Micro coccus luteus (Goumon, Y., Strub, J. M., Moniatte, M., Nullans, G., Poteur, L., Hubert, P., Van Dorsselaer, A., Aunis, D., and Metz-Boutigue, M. H. (1996) Eur. J. Biochem. 235, 516-525). As a continuation of this previous study, in order to characterize the biological function of antibacterial PEAP, we have here examined whether this COOH-terminal fragment is released from stimulated chromaffin cells and whether it could be detected in wound fluids and in polymorphonuclear secretions following cell stimulation. The antibacterial spectrum shows that enkelytin is active against several Grampositive bacteria including Staphylococcus aureus, but it is unable to inhibit the Gram-negative bacteria growth. In order to relate the antibacterial activity of enkelytin with structural features, various synthetic enkelytin-derived peptides were tested. We also propose a computer model of synthetic PEAP(209-237) deduced from H-1 NMR analysis, in order to relate the antibacterial activity of enkelytin with the three-dimensional structure. Finally, we report the high phylogenetic conservation of the COOH-terminal PEAP, which implies some important biological function and we discuss the putative importance of enkelytin in the defensive processes.	INSERM, U338, Unite Biol Commun Cellulaire, F-67084 Strasbourg, France; CNRS, UPR 9003, Illkirch Graffenstaden, France; CNRS, URA 31, Lab Spect Masse Bioorgan Chim Organ Subst Nat, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Metz-Boutigue, MH (corresponding author), INSERM, U338, Unite Biol Commun Cellulaire, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Kieffer, Bruno/AAE-8999-2019; Dominique, Aunis/W-1419-2019	Kieffer, Bruno/0000-0002-2033-4679				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; BEHAR O, 1994, ENDOCRINOLOGY, V134, P475, DOI 10.1210/en.134.1.475; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; Brogden KA, 1997, ANTIMICROB AGENTS CH, V41, P1615, DOI 10.1128/AAC.41.7.1615; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BULET P, 1993, J BIOL CHEM, V268, P14893; COLIN DA, 1994, INFECT IMMUN, V62, P3184, DOI 10.1128/IAI.62.8.3184-3188.1994; COMB M, 1982, NATURE, V295, P663, DOI 10.1038/295663a0; DAlagni M, 1996, EUR J BIOCHEM, V240, P540, DOI 10.1111/j.1432-1033.1996.0540h.x; Das KP, 1997, J NEUROIMMUNOL, V73, P37, DOI 10.1016/S0165-5728(96)00165-8; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; Dobner T, 1991, DNA Seq, V1, P409, DOI 10.3109/10425179109020799; DSOUZA NB, 1988, J BIOL CHEM, V263, P2548; FAITH RE, 1987, ANN NY ACAD SCI, V496, P137, DOI 10.1111/j.1749-6632.1987.tb35756.x; FINCKBARBANCON V, 1993, BIOCHIM BIOPHYS ACTA, V1182, P275, DOI 10.1016/0925-4439(93)90069-D; FORIS G, 1987, ANN NY ACAD SCI, V496, P151, DOI 10.1111/j.1749-6632.1987.tb35758.x; FRANK RW, 1990, J BIOL CHEM, V265, P18871; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; HOWELLS RD, 1984, P NATL ACAD SCI-BIOL, V81, P7651, DOI 10.1073/pnas.81.23.7651; HOWELLS RD, 1986, P NATL ACAD SCI USA, V83, P1960, DOI 10.1073/pnas.83.6.1960; JANKOVIC BD, 1987, ANN NY ACAD SCI, V496, P115, DOI 10.1111/j.1749-6632.1987.tb35754.x; KESHET E, 1989, EMBO J, V8, P2917, DOI 10.1002/j.1460-2075.1989.tb08441.x; KEW D, 1990, MOL ENDOCRINOL, V4, P337, DOI 10.1210/mend-4-2-337; KIEFFER B, 1998, IN PRESS J BIOL CHEM, V273; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; KOJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V215, P638, DOI 10.1016/0003-9861(82)90125-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORGE KS, 1995, MOL CELL BIOL, V15, P2080; LINDBERG I, 1986, BIOCHEM BIOPH RES CO, V139, P1024, DOI 10.1016/S0006-291X(86)80280-7; LINNER KM, 1991, ENDOCRINOLOGY, V128, P717, DOI 10.1210/endo-128-2-717; LINNER KM, 1995, J IMMUNOL, V154, P5049; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LIU TJ, 1987, NUCLEIC ACIDS RES, V15, P3023, DOI 10.1093/nar/15.7.3023; MARIC D, 1987, ANN NY ACAD SCI, V496, P126, DOI 10.1111/j.1749-6632.1987.tb35755.x; MARTENS GJM, 1984, NATURE, V310, P251, DOI 10.1038/310251a0; MARTIN J, 1987, J NEUROSCI RES, V18, P82, DOI 10.1002/jnr.490180114; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MEUNIER O, 1995, CYTOMETRY, V21, P241, DOI 10.1002/cyto.990210304; MILON A, 1990, BIOCHEMISTRY-US, V29, P65, DOI 10.1021/bi00453a009; MUFFLY KE, 1988, MOL ENDOCRINOL, V2, P979, DOI 10.1210/mend-2-10-979; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; NODA M, 1982, NATURE, V297, P431, DOI 10.1038/297431a0; OLESON D R, 1988, Brain Behavior and Immunity, V2, P171, DOI 10.1016/0889-1591(88)90020-7; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PITTIUS CW, 1985, EMBO J, V4, P1257, DOI 10.1002/j.1460-2075.1985.tb03769.x; Plotnikoff NP, 1997, CLIN IMMUNOL IMMUNOP, V82, P93, DOI 10.1006/clin.1996.4287; PLOTNIKOFF NP, 1983, INT J IMMUNOPHARMACO, V5, P437, DOI 10.1016/0192-0561(83)90020-6; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROMEO D, 1988, J BIOL CHEM, V263, P9573; ROSEN H, 1989, J IMMUNOL, V143, P3703; ROSTOVTSEV AP, 1994, MOL CELL ENDOCRINOL, V101, P277, DOI 10.1016/0303-7207(94)90244-5; Salzet M, 1997, BRAIN RES, V768, P224, DOI 10.1016/S0006-8993(97)00646-X; SALZET M, 1998, IN PRESS J IMMUNOL; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; STEFANO GB, 1990, BRAIN BEHAV IMMUN, V4, P323, DOI 10.1016/0889-1591(90)90035-O; Stefano GB, 1998, IMMUNOL TODAY, V19, P265, DOI 10.1016/S0167-5699(98)01268-7; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STERN AS, 1981, P NATL ACAD SCI-BIOL, V78, P1962, DOI 10.1073/pnas.78.3.1962; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; TERZI E, 1992, FEBS LETT, V309, P413, DOI 10.1016/0014-5793(92)80819-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHL GR, 1988, J NEUROSCI, V8, P4755; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; WATKINSON A, 1988, J NEUROCHEM, V51, P1252, DOI 10.1111/j.1471-4159.1988.tb03094.x; WATKINSON A, 1989, J BIOL CHEM, V264, P3061; WONG M, 1991, MOL BRAIN RES, V11, P197, DOI 10.1016/0169-328X(91)90028-V; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZHU YS, 1994, DNA CELL BIOL, V13, P25, DOI 10.1089/dna.1994.13.25; ZURAWSKI P, 1908, SCIENCE, V232, P772	88	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29847	29856		10.1074/jbc.273.45.29847	http://dx.doi.org/10.1074/jbc.273.45.29847			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792701	hybrid			2022-12-25	WOS:000076798300078
J	Lamprecht, G; Weinman, EJ; Yun, CHC				Lamprecht, G; Weinman, EJ; Yun, CHC			The role of NHERF and E3KARP in the cAMP-mediated inhibition of NHE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BORDER NA+/H+ EXCHANGER; CELL-LINE; PARATHYROID-HORMONE; REGULATORY SUBUNIT; ANCHORING PROTEIN; H+ EXCHANGER; EZRIN; PHOSPHORYLATION; IDENTIFICATION	NHE3 is the apically located Na+/H+ exchanger in the gut and in the renal proximal tubule, Acute inhibition of this transporter by cAMP requires the presence of either of two NHE3-associated proteins, NHERF or E3KARP, It has been suggested that these proteins either directly regulate MHE3 activity after being phosphorylated by protein kinase A (PKA) or that they may serve as adapters that localize PKA near NHE3, We studied the role of NHERF and E3KARP in opossum kidney cells, which endogenously express NHE3, NHERF, and ezrin and display cAMP-dependent inhibition of NHE3, In vivo phosphorylation studies showed that NHERF is a phosphoprotein under basal conditions, but does not change its phosphorylation state after 8-bromo-cAMP treatment, and that E3KARP is not phosphorylated at all. Co-immunoprecipitation showed that NHERF and E3KARP bind both NHE3 and ezrin, Using cAMP analogs it was demonstrated that NHE3 activity, measured as sodium-dependent recovery of the intracellular pH after intracellular acidification, is inhibited by PKA type II. Because others have shown that ezrin binds PKA type II and that NHE3 is phosphorylated by PKA we suggest that NHERF and E3KARP are adapters that link NHE3 to ezrin, thereby localizing PKA near NHE3 to allow NHE3 phosphorylation.	Johns Hopkins Univ, Sch Med, Dept Med, Gastroenterol Div,GI Unit, Baltimore, MD 21205 USA; W Virginia Univ, Sch Med, Dept Med, Morgantown, WV 26506 USA; Dept Vet Affairs Med Ctr, Clarksburg, WV 26301 USA	Johns Hopkins University; West Virginia University	Yun, CHC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Gastroenterol Div,GI Unit, 918 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037319, P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44484, DK-37319] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambuhl P, 1998, J CLIN INVEST, V101, P170, DOI 10.1172/JCI62; Aronson PS, 1996, KIDNEY INT, V49, P1665, DOI 10.1038/ki.1996.243; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CARR DW, 1992, J BIOL CHEM, V267, P13376; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; KOLB CH, 1990, PFLUGERS ARCH, V415, P461; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MONTROSE MH, 1990, AM J PHYSIOL, V259, pC121, DOI 10.1152/ajpcell.1990.259.1.C121; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; OGREID D, 1989, EUR J BIOCHEM, V181, P19; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Robinson ML, 1996, ARCH BIOCHEM BIOPHYS, V330, P181, DOI 10.1006/abbi.1996.0240; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SEGAL JH, 1990, J CLIN INVEST, V86, P1442, DOI 10.1172/JCI114860; SHENOLIKAR S, 1988, SEC MESS PHOSPHOPROT, V12, P95; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1998, IN PRESS MIN ELECT M; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	38	184	185	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29972	29978		10.1074/jbc.273.45.29972	http://dx.doi.org/10.1074/jbc.273.45.29972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792717	hybrid, Green Submitted			2022-12-25	WOS:000076798300094
J	Lin, RZ; Chen, J; Hu, ZW; Hoffman, BB				Lin, RZ; Chen, J; Hu, ZW; Hoffman, BB			Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha(1) adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BETA-GAMMA-SUBUNITS; C-FOS TRANSCRIPTION; RAT CEREBRAL-CORTEX; GENE-EXPRESSION; ADENYLYL-CYCLASE; EARLY REPRESSOR; NUCLEAR FACTOR; FACTOR CREB; KINASE	Activation of alpha(1) adrenergic receptors not only stimulates smooth muscle contraction but also modifies gene expression. We wondered if alpha(1) adrenergic receptors could activate transcription of genes regulated by the cAMP response element-binding protein (CREB). Using Rat1 cells stably transfected with each of the three cloned human alpha(1) adrenergic receptor subtypes, norepinephrine strongly stimulated CREB phosphorylation in alpha(1A) and alpha(1B) but more weakly in alpha(1D)-transfected cells, Norepinephrine increased the activity of a somatostatin cAMP-regulated enhancer-chloramphenicol acetyltransferase reporter in these cells, alpha(1) adrenergic receptors are known to activate protein kinase C (PKC) and increase [Ca2+](i). Nonetheless, neither GF109203X a PKC inhibitor, nor BAPTA-AM, a calcium chelator, blocked phosphorylation of CREB induced by norepinephrine, In addition, alpha(1) adrenergic receptor-induced CREB phosphorylation was not mediated via the mitogen-activated protein kinase pathway because norepinephrine did not stimulate mitogen-activated protein kinase activity in these cells. Activation of alpha(1) adrenergic receptors increased cAMP accumulation in these cells. Norepinephrine-induced cAMP-regulated enhancer-chloramphenicol acetyltransferase activity was inhibited either by expression of the PKA inhibitory peptide or a dominant negative PKA regulatory subunit mutant. These results demonstrate that alpha(1) adrenergic receptors activate the transcription factor CREB by a PKA-dependent pathway.	Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Hoffman, BB (corresponding author), Vet Adm Med Ctr, GRECC 182B, 3801 Miranda Ave, Palo Alto, CA 94304 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NHLBI NIH HHS [HL41315] Funding Source: Medline; NIGMS NIH HHS [GM07065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINS S, 1990, J BIOL CHEM, V265, P19330; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1989, J BIOL CHEM, V264, P19506; HORIE K, 1995, MOL PHARMACOL, V48, P392; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Jiang L, 1996, BIOCHEMISTRY-US, V35, P13136, DOI 10.1021/bi960844o; JONES DJ, 1980, J NEUROCHEM, V34, P467, DOI 10.1111/j.1471-4159.1980.tb06622.x; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; LLAHI S, 1992, J BIOL CHEM, V267, P3679; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; MORGAN NG, 1983, J BIOL CHEM, V258, P5103; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; PERKINS JP, 1973, J PHARMACOL EXP THER, V185, P371; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Tsu RC, 1996, J NEUROSCI, V16, P1317; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	38	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30033	30038		10.1074/jbc.273.45.30033	http://dx.doi.org/10.1074/jbc.273.45.30033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792725	hybrid			2022-12-25	WOS:000076798300102
J	Rodgers, AJW; Capaldi, RA				Rodgers, AJW; Capaldi, RA			The second stalk composed of the b- and delta-subunits connects F-0 to F-1 via an alpha-subunit in the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; TERMINAL DOMAIN; CATALYTIC SITES; CROSS-LINKING; PROTON-ATPASE; POLAR LOOP; H+-ATPASE; F1; EPSILON; BINDING	The b- and delta-subunits of the Escherichia coli ATP synthase are critical for binding ECF1 to the F-0 part, and appear to constitute the stator necessary for holding the alpha(3)beta(3) hexamer as the c-epsilon-gamma domain rotates during catalysis. Previous studies have determined that the b- subunits are dimeric for a large part of their length, and interact with the F-1 part through the delta-subunit (Rodgers, A. J. W., Wilkens, S., Aggeler, R, Morris, M. B., Howitt, S. M., and Capaldi, R. A. (1997) J. Biol. Chem. 272, 31058-31064). To further study b-subunit interactions, three mutants were constructed in which Ser-84, Ala-144, and Leu-156, respectively, were replaced by Cys. Treatment of purified ECF1F0 from all three mutants with CuCl2 induced disulfide formation resulting in b-subunit dimer cross-link products. In addition, the mutant bL156C formed a cross-link from a b-subunit to an alpha-subunit via alpha Cys90. Neither b-b nor b-alpha cross-linking had significant effect on ATPase activities in any of the mutants. Proton pumping activities were measured in inner membranes from the three mutants. Dimerization of the b-subunit did not effect proton pumping in mutants bS84C or bA144C. In the mutant bL156C, CuCI2 treatment reduced proton pumping markedly, probably because of uncoupling caused by the b-alpha cross-link formation. The results show that the alpha-subunit forms part of the binding site on ECF1 for the b(2)delta domain and that the b-subunit extends all the way from the membrane to the top of the F-1 structure. Some conformational flexibility in the connection between the second stalk and F-1 appears to be required for coupled catalysis.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.		Rodgers, Andrew/H-3527-2013; Rodgers, Andrew/AAT-8756-2021	Rodgers, Andrew/0000-0002-8897-6221; Rodgers, Andrew/0000-0003-2063-4521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58671] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OGILVIE I, 1998, IN PRESS ACTA PHYSL; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	31	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29406	29410		10.1074/jbc.273.45.29406	http://dx.doi.org/10.1074/jbc.273.45.29406			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792643	hybrid			2022-12-25	WOS:000076798300020
J	Sable, CL; Filippa, N; Filloux, C; Hemmings, BA; Van Obberghen, E				Sable, CL; Filippa, N; Filloux, C; Hemmings, BA; Van Obberghen, E			Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; SIGNALING MOLECULES; AKT PROTOONCOGENE; SER/THR KINASE; GROWTH-FACTOR; PHOSPHORYLATION; SURVIVAL; ADIPOCYTES	Involvement of the pleckstrin homology (PR) domain in the insulin-stimulated activation of protein kinase B (PKB) was investigated in human embryonic kidney 293 cells. Different PKB constructs that contain mutations or deletions in the PH domain were transfected into cells, and the results on the basal and insulin-induced kinase activities were analyzed. Deletion of the entire PH domain (Delta PH-PKB) did not impair the kinase activity; in contrast, the basal activity was elevated with respect to wild-type PKB. In addition, Delta PH-PKB was responsive to insulin, and as for wild-type PKB, this was dependent on phosphoinositide 3-kinase. By contrast, a point mutation within the PH domain that impairs phospholipid binding (R25C) resulted in a construct that was not responsive to insulin. However, this defect was overcome by mutations that mimic the phosphorylation state of the active kinase. The increase in the basal activity of Delta PH-PKB was shown to be due to an elevation in the level of phosphorylation of this construct. In addition, the subcellular localization of Delta PH-PKB, as determined by both immunofluorescence and fractionation, was predominately cytosolic, and Delta PH-PKB was present in the plasma membrane at much lower levels compared with wild-type PKB. These data show that phosphorylation is the major factor regulating the activity of PKB and that either removal of the PH domain or binding of phospholipids is required to permit this phosphorylation. In addition, membrane localization does not appear to be required for the activation process, but instead, binding of PKB to membrane phospholipids permits a conformational change in the molecule that allows for phosphorylation.	Fac Med Nice, INSERM, U145, F-06107 Nice 2, France; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Friedrich Miescher Institute for Biomedical Research	Van Obberghen, E (corresponding author), Fac Med Nice, INSERM, U145, Ave Valombrose, F-06107 Nice 2, France.							Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Whiteford CC, 1996, BIOCHEM J, V319, P851, DOI 10.1042/bj3190851; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	46	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29600	29606		10.1074/jbc.273.45.29600	http://dx.doi.org/10.1074/jbc.273.45.29600			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792669	hybrid			2022-12-25	WOS:000076798300046
J	Subtil, A; Rocca, A; Dautry-Varsat, A				Subtil, A; Rocca, A; Dautry-Varsat, A			Molecular characterization of the signal responsible for the targeting of the interleukin 2 receptor beta chain toward intracellular degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; DI-LEUCINE MOTIF; T-CELL LINE; CYTOPLASMIC DOMAIN; GAMMA-CHAIN; INTERNALIZATION SIGNAL; MEDIATED ENDOCYTOSIS; RAPID ENDOCYTOSIS; MEMBRANE-PROTEINS; SORTING SIGNALS	During receptor-mediated endocytosis, most growth factor receptors are transported to late endocytic compartments and degraded. This process is important to control their expression on the cell surface and requires sorting in early endocytic compartments. Little is known about the mechanisms and the signals involved. We have studied the signal involved in targeting the interleukin 2 receptor beta chain (IL2R beta), a member of the cytokine receptor superfamily, toward degradation after internalization. We show that a motif of 8 amino acids in the cytosolic tail of IL2R beta is sufficient to target a normally recycling receptor toward degradation. Deletion of this signal strongly impairs IL2R beta degradation. Further molecular characterization of the motif shows that it does not resemble the well documented tyrosine and dileucine families of trafficking signals.	Inst Pasteur, CNRS, URA 1960, Unite Biol Interact Cellulaires, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Dautry-Varsat, A (corresponding author), Inst Pasteur, CNRS, URA 1960, Unite Biol Interact Cellulaires, 25 Rue Dr Roux, F-75724 Paris 15, France.		Subtil, Agathe/C-7464-2017	Subtil, Agathe/0000-0002-7481-4846				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG CP, 1993, J BIOL CHEM, V268, P19312; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HEMAR A, 1994, EUR J IMMUNOL, V24, P1951, DOI 10.1002/eji.1830240902; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Morelon E, 1998, J BIOL CHEM, V273, P22044, DOI 10.1074/jbc.273.34.22044; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; RUBIN LA, 1985, J IMMUNOL, V135, P3172; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Subtil A, 1998, EUR J BIOCHEM, V253, P525, DOI 10.1046/j.1432-1327.1998.2530525.x; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; SUBTIL A, 1994, J CELL SCI, V107, P3461; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WHITNEY JA, 1995, CELL, V83, P703; WILDE A, 1994, J BIOL CHEM, V269, P7131; WILEY HS, 1982, J BIOL CHEM, V257, P4222	55	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29424	29429		10.1074/jbc.273.45.29424	http://dx.doi.org/10.1074/jbc.273.45.29424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792646	hybrid			2022-12-25	WOS:000076798300023
J	Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN				Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN			Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification	ONCOGENE			English	Article						cyclin D1; tumorigenesis; dysregulated expression; amplification; FISH; immunohistochemistry	SQUAMOUS-CELL CARCINOMAS; CHROMOSOME 11Q13 REGION; G1 PHASE PROGRESSION; PREMALIGNANT LESIONS; INSITU HYBRIDIZATION; TUMOR PROGRESSION; AMPLIFIED REGION; CANCER; OVEREXPRESSION; PROTEIN	Cyclin D1 proto-oncogene is a key regulator of the mammalian cell-cycle acting at the restriction point in late G1, Amplification of the cyclin D1 locus, located on chromosome 11q13, as well as cyclin D1 protein overexpression have been reported in several human malignancies. The purpose of this study was to evaluate cyclin D1 gene copy status and protein expression during the multistep process of head and neck tumorigenesis, using a combination of fluorescence in situ hybridization and immunohistochemistry techniques. From 29 selected patients presenting with head and neck squamous carcinoma and whose tumor cytospins had been previously screened for presence (16 cases) or absence (13 cases) of amplification at the 11q13 band, we analysed 46 paraffin-embedded tissue specimens that demonstrated, besides the primary tumor, the presence of contiguous adjacent normal tissue and/or premalignant lesions. Of the 16 amplified cases, nine demonstrated a continuous progression from premalignant to invasive carcinoma and seven (77.7%) of these cases showed cyclin D1 gene amplification in premalignant lesions prior to development of invasive carcinoma. Increased cyclin D1 protein expression was observed in all 16 amplified tumors' and five of the 13 (38.4%) nonamplified tumors. Interestingly, dysregulated cyclin D1 expression was also found in the premalignant lesions adjacent to all 16 amplified tumors, and it appeared to precede cyclin D1 gene amplification. In contrast no dysregulated expression was detected in the premalignant lesions of the non-amplified tumors. In conclusion, these findings provide strong evidence for early dysregulation of cyclin D1 expression during the tumorigenesis process and suggest that dysregulated increased expression precedes and possibly enables gene amplification.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hittelman, WN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, 1515 holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA-16672, CA-52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOHR VA, 1988, J CELL SCI, V91, P175; BOYLE JO, 1993, CANCER RES, V53, P4477; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; Califano J, 1996, CANCER RES, V56, P2488; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; ELNAGGAR AK, 1995, CYTOMETRY, V21, P47, DOI 10.1002/cyto.990210110; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Farber E, 1996, ADV CANCER RES, V70, P21, DOI 10.1016/S0065-230X(08)60870-2; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HINDS PW, 1994, P NATL ACAD SCI USA, V87, P6281; Izzo J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P361; JARES P, 1994, CANCER RES, V54, P4813; JIAN W, 1993, ONCOGENE, V8, P2159; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LAMMIE GA, 1991, ONCOGENE, V6, P439; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUTZ S, 1992, J PATHOL, V167, P279, DOI 10.1002/path.1711670304; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAWROZ H, 1994, CANCER RES, V54, P1152; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roh H. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P117; SAUTER G, 1995, INT J CANCER, V64, P99, DOI 10.1002/ijc.2910640205; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN DM, 1994, CANCER RES, V54, P3153; SHIN DM, 1993, J NATL CANCER I, V85, P971, DOI 10.1093/jnci/85.12.971; SHIN DM, 1994, CANCER RES, V54, P321; SODER AI, 1995, CANCER RES, V55, P5030; SOMERS KD, 1990, ONCOGENE, V5, P915; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TAM SW, 1994, ONCOGENE, V9, P2663; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TLSTY TD, 1993, COLD SPRING HARB SYM, V58, P645, DOI 10.1101/SQB.1993.058.01.072; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Uhlman DL, 1996, CANCER RES, V56, P2199; VORAVUD N, 1993, CANCER RES, V53, P2874; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zhou P, 1996, CANCER RES, V56, P36	55	103	109	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2313	2322		10.1038/sj.onc.1202153	http://dx.doi.org/10.1038/sj.onc.1202153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811462				2022-12-25	WOS:000076723300005
J	Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N				Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N			Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells	ONCOGENE			English	Article						merlin; schwannomin; actin; Rho; Rac; C3 transferase; adenovirus	NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; NERVE SHEATH TUMORS; ERM FAMILY MEMBERS; FIBRILLARY ACIDIC-PROTEIN; ACTIN-BASED CYTOSKELETONS; GERM-LINE MUTATIONS; PERIPHERAL-NERVE; GENE-PRODUCT; FOCAL ADHESIONS; TYPE-2 GENE	Schwannomas are peripheral nerve tumors that typically have mutations in the NF2 tumor suppressor gene. We compared cultured schwannoma cells with Schwann cells from normal human peripheral nerves (NHSC). Both cell types expressed specific antigenic markers, interacted with neurons, and proliferated in response to glial growth factor, confirming their identity as Schwann cells. Schwannoma cells frequently had elevated basal proliferation compared to NHSC. Schwannoma cells also showed spread areas 5-7-fold greater than NHSC, aberrant membrane ruffling and numerous, frequently disorganized stress fibers. Dominant negative Rac inhibited schwannoma cell ruffling but had no apparent effect on NHSC. Schwannoma cell stress fibers were inhibited by C3 transferase, tyrphostin A25, or dominant negative RhoA. These data suggest that the Rho and Rac pathways are abnormally activated in schwannoma cells. Levels of ezrin and moesin, proteins related to the NF2 gene product, merlin, were unchanged in schwannoma cells compared to NHSC. Our findings demonstrate for the first time that cell proliferation and actin organization are aberrant in schwannoma cells. Because NF2 is mutant in most or all human schwannomas, we postulate that loss of NF2 contributes to the cell growth and cytoskeletal dysfunction reported here.	Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Miami, Miami Project, Miami, FL 33136 USA; Cambridge Neurosci, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Miami	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA.			RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10133, NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARON P, 1991, ACTA NEUROPATHOL, V81, P491, DOI 10.1007/BF00310128; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P141, DOI 10.1007/BF00692502; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P116, DOI 10.1007/BF00692501; DARDENNE AJ, 1984, J CLIN PATHOL, V37, P895, DOI 10.1136/jcp.37.8.895; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hitotsumatsu T, 1997, ACTA NEUROPATHOL, V93, P225, DOI 10.1007/s004010050608; Huynh DP, 1996, ONCOGENE, V13, P73; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JAASKELAINEN J, 1994, J NEUROSURG, V80, P541, DOI 10.3171/jns.1994.80.3.0541; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHNSON MD, 1988, ARCH PATHOL LAB MED, V112, P155; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARKWELL MA, 1978, ANAL BIOCHEM, V82, P206; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; MCCOMB RD, 1985, J NEUROPATH EXP NEUR, V44, P242, DOI 10.1097/00005072-198505000-00003; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; NANCE WE, 1993, ARCH NEUROL-CHICAGO, V45, P575; NOBES CD, 1995, J CELL SCI, V108, P225; Parry DM, 1996, AM J HUM GENET, V59, P529; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Raabe TD, 1996, J NEUROSCI RES, V46, P263; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; Rosenbaum T, 1997, NEUROSCIENTIST, V3, P412, DOI 10.1177/107385849700300614; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTKOWSKI JL, 1992, ANN NEUROL, V31, P580, DOI 10.1002/ana.410310603; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; SOBEL RA, 1993, J NEUROPATH EXP NEUR, V52, P106, DOI 10.1097/00005072-199303000-00002; StemmerRachamimov AO, 1997, AM J PATHOL, V151, P1649; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TIKOO A, 1994, J BIOL CHEM, V269, P1; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WECHSLER W., 1965, BEITR PATHOL ANAT ALLG PATHOL, V132, P319; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	82	103	120	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2195	2209		10.1038/sj.onc.1202141	http://dx.doi.org/10.1038/sj.onc.1202141			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811451				2022-12-25	WOS:000076698200006
J	Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT				Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT			EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI1; RDA; cell cycle; transformation; E2-C	EWINGS-SARCOMA; DNA-BINDING; FUSION GENE; TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; SISTER CHROMATIDS; PROTEIN; TRANSLOCATION; PROTEOLYSIS; SEPARATION	The EWS/FLI1 fusion gene found in Ewing's sarcoma and primitive neuroectodermal tumor, is able to transform certain cell lines by acting as an aberrant transcription factor, The ability of EWS/FLI1 to modulate gene expression in cells transformed and resistant to transformation by EWS/FLI1, was assessed by Representational Difference Analysis (RDA), We found that the cyclin selective ubiquitin conjugase murine E2-C, was up regulated in NIH3T3 cells transformed by EWS/FLI1 but not in a nontransformed NIH3T3 clone expressing EWS/FLI1, We also found that mn-C is upregulated in NIH3T3 cells transformed by other genes including activated cdc42, v-ABL and c-myc, We demonstrated that expression of mn-C in both the EWS/FLI1 transformed and parent NIH3T3 lines varies with the cell cycle. Finally, dominant-negative mE2-C, created by changing a catalytic cysteine to serine, inhibits the in vitro ubiquitination and degradation of cyclin B in human HeLa cell extracts. These data suggest that part of the biologic effect of EWS/FLI1 could be, to transcriptionally modulate genes involved in cell cycle regulation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Expt Pathol Lab Med, Los Angeles, CA USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Denny, CT (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NCI NIH HHS [CA09056, CA32737] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BRAUN BS, 1997, THESIS; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; LESSNICK SL, 1995, ONCOGENE, V10, P423; LESSNICK SL, 1994, THESIS; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHNO T, 1993, CANCER RES, V53, P5859; ORMEROD MG, 1996, FLOW CYTOMETRY PRACT, P75; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RON D, 1995, P NATL ACAD SCI USA, V92, P2016; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; Thompson AD, 1996, ONCOGENE, V13, P2649; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	31	75	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2039	2045		10.1038/sj.onc.1202129	http://dx.doi.org/10.1038/sj.onc.1202129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798675				2022-12-25	WOS:000076540900003
J	von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK				von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK			Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q	ONCOGENE			English	Article						tylosis; loss of heterozygosity; oesophageal cancer	ESOPHAGEAL CANCER; PALMOPLANTAR KERATODERMA; P53 GENE; CARCINOMA; ALLELOTYPE; MUTATIONS	From the genotyping of UK and US tylotic families with a high risk of oesophageal cancer we have previously localized the tylosis-associated cancer susceptibility gene (TOC gene, tylosis oesophageal cancer gene) to a 1 cM region on the long arm of chromosome 17 (Kelsell et al,, 1996), In the present study we investigated loss of heterozygosity (LOH) patterns of 35 sporadic squamous cell carcinomas of the oesophagus using six polymorphic microsatellite markers encompassing this locus. Twenty-four of the 35 cases (69%) revealed LOH at one or more loci. Deletion was most frequently observed with the marker D17S801 (64% LOH, informative cases), which shows significant linkage to the TOC locus. The LOH analysis in sporadic oesophageal cancer we report here is thus consistent with the hypothesis that the tylosis oesophageal cancer susceptibility gene is also involved in the pathogenesis of a proportion of sporadic squamous cell carcinomas of the oesophagus.	Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Deutsch Krebsforschungszentrum, German Canc Res Ctr, D-69120 Heidelberg, Germany; NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 4TA, Merseyside, England	University of Liverpool; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Field, JK (corresponding author), Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BENNETT WP, 1991, ONCOGENE, V6, P1779; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; *J HOPK U, 1990, GDBTM HUM GEN DAT VE; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; MORI T, 1994, CANCER RES, V54, P1638; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; vonBrevern MC, 1996, CANCER RES, V56, P4917	17	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2101	2105		10.1038/sj.onc.1202139	http://dx.doi.org/10.1038/sj.onc.1202139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798681				2022-12-25	WOS:000076540900009
J	Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G				Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G			Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; p15; Smad4; Smad2; TGF beta-RII; CDC25A	TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; DPC4 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; ADENOCARCINOMA; MUTATIONS; CARCINOMA; DELETION; PHOSPHATASES	Resistance to TGF-beta 1 occurred in pancreatic cancer cells suggesting that inactivation of TGF-beta inhibitory signaling pathways may play an important role in human pancreatic cancer. The aim of our study was to determine the presence of alterations in the main putative components of the TGF-beta inhibitory signaling pathways (p15, Smad4, Smad2, TGF beta-RII, CDC25A). A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines, Additional aberrations in these genes were acquired during in vivo perpetuation and distal dissemination. Paradoxically, TGF beta-RII overexpression and a decrease in CDC25A protein levels were found in all tumors and cell lines. In one cell line, resistance to TGF-beta 1 occurred in the absence of alterations in the genes analysed so far. We conclude that all human pancreatic tumor cells analysed herein have non-functional TGF-beta pathways. The majority of cells harbor alterations in at least one of the putative components of TGF-beta pathways, mainly in p15 and Smad4 genes. These results suggest that inactivation of TGF-beta signaling pathways plays an important role in human pancreatic tumorigenesis.	Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain; Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona	Capella, G (corresponding author), Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain.		Villalonga, Priam/K-4350-2014; Capella, Gabriel/I-1879-2015; Agell, Neus/E-9640-2016	Villalonga, Priam/0000-0002-7190-6884; Capella, Gabriel/0000-0002-4669-7320; Agell, Neus/0000-0002-1205-6074; Lluis, Felix/0000-0002-4770-0923				Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Barrett MT, 1996, CANCER RES, V56, P4351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRIESS H, 1993, CANCER RES, V53, P2704; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Huang LY, 1996, CANCER RES, V56, P1137; IVARAONE A, 1997, NATURE, V87, P417; JEN J, 1994, CANCER RES, V54, P6353; Kim IY, 1996, CANCER RES, V56, P44; Kim SK, 1996, CANCER RES, V56, P2519; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATO E, 1993, J PINEAL RES, V15, P43, DOI 10.1111/j.1600-079X.1993.tb00508.x; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Reyes G, 1996, CANCER RES, V56, P5713; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Riggins GJ, 1997, CANCER RES, V57, P2578; SCARPA A, 1994, INT J CANCER, V57, P167; Schutte M, 1996, CANCER RES, V56, P2527; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsubari M, 1997, CANCER RES, V57, P2966; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	41	165	173	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1969	1978		10.1038/sj.onc.1202118	http://dx.doi.org/10.1038/sj.onc.1202118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788440				2022-12-25	WOS:000076423500010
J	Wang, YC; Blandino, G; Oren, M; Givol, D				Wang, YC; Blandino, G; Oren, M; Givol, D			Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs	ONCOGENE			English	Article						inducible p53; senescence; anti-cancer drugs; p21(waf1)	WILD-TYPE P53; HUMAN-DIPLOID FIBROBLASTS; P53-DEFICIENT MICE; MUTANT P53; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; TUMOR SUPPRESSION; IN-VIVO; GROWTH; GENE	The p53-null human lung cancer cell line H1299 was used in order to generate clones with ecdysone-inducible p53 as well as ecdysone-inducible p21(waf1). Induced expression of p53 resulted in irreversible cell growth arrest with characteristics of replicative senescence, suggesting that p53 can prevent immortalization by activating a senescence program. The effect of induced p53 and p21(waf1) expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed. Whereas p21(waf1) overexpression conferred increased resistance to killing by either drug, p53 overexpression enhanced the cytotoxic effect of cisplatin but protected against etoposide cytotoxicity. These results imply that the impact of p53 on susceptibility to chemotherapy may depend greatly on the particular drug and type of DNA damage. Moreover, these data demonstrate the importance of using isogenic cell lines to address this issue.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BODNER SM, 1992, ONCOGENE, V7, P743; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; CHEDID M, 1994, ONCOGENE, V9, P3021; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OConnor PM, 1997, CANCER RES, V57, P4285; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Sambrook J., 2002, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TSUKADA T, 1993, ONCOGENE, V8, P3313; VIKHANSKAYA F, 1995, INT J CANCER, V61, P397, DOI 10.1002/ijc.2910610320; Vikhanskaya F, 1996, EXP CELL RES, V227, P380, DOI 10.1006/excr.1996.0288; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; ZAKUT R, 1995, ONCOGENE, V11, P393	43	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1923	1930		10.1038/sj.onc.1202113	http://dx.doi.org/10.1038/sj.onc.1202113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788435	Bronze			2022-12-25	WOS:000076423500005
J	Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG				Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG			Loss of imprinting and allele switching of p73 in renal cell carcinoma	ONCOGENE			English	Article						p73; imprinting; allelic expression; renal cell carcinoma	TUMOR-SUPPRESSOR; WILMS-TUMOR; CANCER; GENE; EXPRESSION; P53; NEUROBLASTOMA; METHYLATION; H19	p73, a protein that has substantial structural and functional similarity to p53, has recently been identified. It was found to be monoallelically expressed in all cell lines and normal individuals tested, To elucidate its role in cancer development and as a potential imprinted tumor suppressor, we investigated the allele-specific expression of the human p73 gene in 28 cases of renal cell carcinoma and its imprinting status in fetal pancreatic and thymic tissues. Of 12 informative pairs of renal cell carcinoma and matched normal tissues identified by StyI restriction fragment length polymorphism (RFLP) in exon 2, p73 showed monoallelic expression in 11 out of 12 normal tissues but biallelic expression in 8/12 and switched allele expression in 2/12 of the matched corresponding cancers. An imprinting study of the p73 gene in two families using a newly identified exonic BanI RFLP indicated that expression of p73 was limited to the maternal allele in RNA from fetal pancreas and thymus, demonstrating that p73 is imprinted in at least these two tissues. These findings strongly suggest that loss of imprinting or switching of allelic expression of the p73 gene is associated with the development of renal cell carcinoma.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol Res, Rochester, MN 55905 USA; McGill Univ, Dept Pediat, Div Endocrinol, Montreal, PQ H3H 1P3, Canada	Mayo Clinic; Mayo Clinic; McGill University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA.		Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Hibi K, 1996, CANCER RES, V56, P480; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; McBride G, 1997, J NATL CANCER I, V89, P1256; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Svensson K, 1998, DEVELOPMENT, V125, P61; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson JS, 1996, CANCER RES, V56, P5723; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Watanabe D, 1996, GENES CELLS, V1, P795, DOI 10.1046/j.1365-2443.1996.d01-276.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113	18	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1739	1741		10.1038/sj.onc.1202099	http://dx.doi.org/10.1038/sj.onc.1202099			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796703				2022-12-25	WOS:000076200100012
J	Acharya, S; Rodriguez, IR; Moreira, EF; Midura, RJ; Misono, K; Todres, E; Hollyfield, JG				Acharya, S; Rodriguez, IR; Moreira, EF; Midura, RJ; Misono, K; Todres, E; Hollyfield, JG			SPACR, a novel interphotoreceptor matrix glycoprotein in human retina that interacts with hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CHONDROITIN SULFATE; ROD PHOTORECEPTORS; SEQUENCE-ANALYSIS; DERMATAN SULFATE; BINDING-PROTEINS; PROTEOGLYCAN; GLYCOSAMINOGLYCAN; CALCIUM; DOMAINS	SPACR (sialoprotein associated with cones and rods), is the major 147-150-kDa glycoprotein present in the insoluble interphotoreceptor matrix of the human retina. Immunocytochemistry localizes SPACR to the matrix surrounding rods and cones (Acharya, S., Rayborn, M. E., and Hollyf'ield, J. G. (1998) Glycobiology 8, 997-1006), From affinity-purified SPACR, we obtained seven peptide sequences showing 100% identity to the deduced sequence of IMPG1, a purported chondroitin 6-sulfate proteoglycan core protein, which binds peanut agglutinin and is localized to the interphotoreceptor matrix. We show here that SPACR is the most prominent 147-150-kDa band present in the interphotoreceptor matrix and is the gene product of IMPG1. SPACR is not a chondroitin sulfate proteoglycan, since it is not a product of chondroitinase ABC digestion and does not react to a specific antibody for chondroitin B-sulfate proteoglycan. Moreover, the deduced amino acid sequence reveals no established glycosaminoglycan attachment site. One hyaluronan binding motif is present in the predicted sequence of SPACR. We present evidence that SPACR has a functional hyaluronan binding domain, suggesting that interactions between SPACR and hyaluronan may serve to form the basic macromolecular scaffold, which comprises the insoluble interphotoreceptor matrix.	Cleveland Clin Fdn, Inst Eye, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; NEI, NIH, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Acharya, S (corresponding author), Cleveland Clin Fdn, Inst Eye, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL EYE INSTITUTE [R01EY002362] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02362] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; BLANKS JC, 1988, J COMP NEUROL, V270, P288, DOI 10.1002/cne.902700209; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; GOLD GH, 1986, P NATL ACAD SCI USA, V83, P1150, DOI 10.1073/pnas.83.4.1150; GOLD GH, 1980, P NATL ACAD SCI-BIOL, V77, P5557, DOI 10.1073/pnas.77.9.5557; Goodstone NJ, 1998, ARCH BIOCHEM BIOPHYS, V350, P26, DOI 10.1006/abbi.1997.0472; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HAGEMAN GS, 1987, CURR EYE RES, V6, P639, DOI 10.3109/02713688709025225; HAGEMAN GS, 1991, PROGR RETINAL RES, V10, P207; HAGEMAN GS, 1990, INVEST OPHTHALMOL  S, V30, P489; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; HOLLYFIELD JG, 1990, EXP EYE RES, V50, P335, DOI 10.1016/0014-4835(90)90220-O; HOLLYFIELD JG, 1990, EXP EYE RES, V50, P107; IWASAKI M, 1992, J COMP NEUROL, V319, P277, DOI 10.1002/cne.903190207; JOHNSON L V, 1989, Investigative Ophthalmology and Visual Science, V30, P490; JOHNSON LV, 1986, INVEST OPHTH VIS SCI, V27, P129; Kelsell RE, 1998, AM J HUM GENET, V63, P274, DOI 10.1086/301905; KIRCHOFF M A, 1990, Investigative Ophthalmology and Visual Science, V31, P153; Kuehn MH, 1997, INVEST OPHTH VIS SCI, V38, P2788; KUEHN MH, 1993, INVEST OPHTHALMOL  S, V34, P2443; KUEHN MH, 1995, INVEST OPHTHALMOL  S, V36, P3264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MANN DM, 1990, J BIOL CHEM, V265, P5317; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; NOVENBERG U, 1992, NEURON, V8, P849; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6; Sambrook J., 1989, MOL CLONING, V1; Sauer CG, 1997, J MED GENET, V34, P961, DOI 10.1136/jmg.34.12.961; SCHOEN TJ, 1995, BIOCHEM BIOPH RES CO, V213, P181, DOI 10.1006/bbrc.1995.2114; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SCOTT J E, 1973, Biochemical Society Transactions, V1, P787; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; TIEN LF, 1992, EXP EYE RES, V55, P297, DOI 10.1016/0014-4835(92)90194-W; VARNER HH, 1987, EXP EYE RES, V44, P633, DOI 10.1016/S0014-4835(87)80135-5; Wang X, 1996, MOL BRAIN RES, V41, P269, DOI 10.1016/0169-328X(96)00107-6; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YHANG B, 1993, J BIOL CHEM, V268, P8617	46	48	51	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31599	31606		10.1074/jbc.273.47.31599	http://dx.doi.org/10.1074/jbc.273.47.31599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813076	hybrid			2022-12-25	WOS:000077136900104
J	Adzuma, K				Adzuma, K			No sliding during homology search by RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION-DRIVEN MECHANISMS; REPRESSOR-OPERATOR INTERACTION; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; FACILITATED DIFFUSION; NUCLEIC-ACIDS; RNA-POLYMERASE; ATP HYDROLYSIS; RAD51 PROTEIN; LAC REPRESSOR	The RecA protein of Escherichia coli is a prototype of the RecA/Rad51 family of proteins that exist in virtually all the organisms. In a process called DNA synapsis, RecA first polymerizes onto a single-stranded DNA (ssDNA) molecule; the resulting RecA-ssDNA complex then searches for and binds to a double-stranded DNA (dsDNA) molecule containing the almost identical, or "homologous," sequence. The RecA-ssDNA complex thus can be envisioned as a sequence-specific binding entity. How does the complex search for its target buried within nonspecific sequences? One possible mechanism is the sliding mechanism, in which the complex first binds to a dsDNA molecule nonspecifically and then linearly diffuses, or slides, along the dsDNA To understand the mechanism of homology search by RecA, this sliding model was tested. A plasmid containing four homologous targets in tandem was constructed and used as the dsDNA substrate in the synapsis reaction. If the sliding is the predominant search mode, the two outermost targets should act as more efficient targets than the inner targets. No such positional preference was observed, indicating that a long range sliding of the RecA-ssDNA complex does not occur. These and other available data can be adequately explained by a simple three-dimensional random collision mechanism.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Adzuma, K (corresponding author), Rockefeller Univ, 1230 York Ave,Box 256, New York, NY 10021 USA.				NIGMS NIH HHS [R01 GM052862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BALIGA R, 1995, P NATL ACAD SCI USA, V92, P10393, DOI 10.1073/pnas.92.22.10393; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bazemore LR, 1997, J BIOL CHEM, V272, P14672, DOI 10.1074/jbc.272.23.14672; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P1183; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GOLUB EI, 1992, NUCLEIC ACIDS RES, V20, P3121, DOI 10.1093/nar/20.12.3121; GONDA DK, 1986, J BIOL CHEM, V261, P3087; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10215, DOI 10.1021/bi00200a001; JULIN DA, 1986, J BIOL CHEM, V261, P1025; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; Lapham J, 1997, J BIOMOL NMR, V10, P255, DOI 10.1023/A:1018310702909; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; PODYMINOGIN MA, 1995, BIOCHEMISTRY-US, V34, P13098, DOI 10.1021/bi00040a022; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RICCHETTI M, 1988, P NATL ACAD SCI USA, V85, P4610, DOI 10.1073/pnas.85.13.4610; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; YANCEYWRONA JE, 1995, CURR BIOL, V5, P1149, DOI 10.1016/S0960-9822(95)00231-4; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	50	38	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31565	31573		10.1074/jbc.273.47.31565	http://dx.doi.org/10.1074/jbc.273.47.31565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813072	hybrid			2022-12-25	WOS:000077136900100
J	Delgado, M; Munoz-Elias, EJ; Kan, YQ; Gozes, I; Fridkin, M; Brenneman, DE; Gomariz, RP; Ganea, D				Delgado, M; Munoz-Elias, EJ; Kan, YQ; Gozes, I; Fridkin, M; Brenneman, DE; Gomariz, RP; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN MONOCYTIC CELLS; MURINE T-LYMPHOCYTES; C-JUN; CYTOKINE PRODUCTION; GENE-EXPRESSION; MESSENGER-RNA; CYCLIC-AMP; PRIMARY MACROPHAGES; TERMINAL KINASE	Tumor necrosis factor alpha (TNF alpha) an early cytokine produced by activated macrophages, plays an essential role in normal and pathological inflammatory reactions. The excessive production of TNF alpha is prevented by the so-called "macrophage-deactivating factors." This study examines the role of two structurally related neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating peptide (PACAP), as inhibitors of TNF alpha. Both VIP and PACAP inhibit TNF alpha production from lipopolysaccharide-stimulated RAW 246.7 cells in a dose- and time-dependent manner. Although the activated cells express mRNA for all three VIP/PACAP receptors, agonist and antagonist studies indicate that the major receptor involved is VIP1R. VIP/PACAP inhibit TNF alpha gene expression by affecting both NF-kB binding and the composition of the cAMP responsive element binding complex (CREB/c-Jun). Two transduction pathways, a cAMP-dependent and a cAMP-independent pathway, are involved in the inhibition of TNF alpha gene expression and appear to differentially regulate the transcriptional factors involved. Because TNF alpha plays a central role in various inflammatory diseases such as endotoxic shock, multiple sclerosis, cerebral malaria, and various autoimmune conditions, the down-regulatory effect of VIP/PACAP may have a significant therapeutic potential.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Univ Complutense Madrid, Dept Biol Celular, E-28040 Madrid, Spain; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; NICHD, Sect Dev & Mol Pharmacol, Dev Neurobiol Lab, NIH, Bethesda, MD 20895 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Complutense University of Madrid; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.		Delgado, Mario/P-1524-2016; Gomariz, Rosa P./H-2470-2017	Delgado, Mario/0000-0003-1893-5982; Gomariz, Rosa P./0000-0003-2839-1923	NIAID NIH HHS [AI 41786-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041786, R21AI041786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1997, ENDOCRINOLOGY, V138, P1930, DOI 10.1210/en.138.5.1930; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DelaFuente M, 1996, ADV NEUROIMMUNOL, V6, P75, DOI 10.1016/S0960-5428(96)00002-2; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; Delgado M, 1996, REGUL PEPTIDES, V62, P161, DOI 10.1016/0167-0115(96)00024-9; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; DOKTER WHA, 1993, BLOOD, V81, P337; DROUET C, 1991, J IMMUNOL, V147, P1694; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; GOZES I, 1995, J PHARMACOL EXP THER, V273, P161; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hashimoto H, 1996, BBA-BIOMEMBRANES, V1281, P129, DOI 10.1016/0005-2736(96)00056-9; Hernanz A, 1996, J NEUROIMMUNOL, V71, P25, DOI 10.1016/S0165-5728(96)00118-X; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; Johnson MC, 1996, J NEUROIMMUNOL, V68, P109, DOI 10.1016/0165-5728(96)00085-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Martinez C, 1996, J IMMUNOL, V156, P4128; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591, DOI 10.1002/jlb.63.5.591; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Muchamuel T, 1997, J IMMUNOL, V158, P2898; Muller A, 1998, J NEUROCHEM, V70, P1431; MUROI M, 1993, J BIOL CHEM, V268, P19534; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; Ohishi S, 1996, EUR J PHARMACOL, V300, P255, DOI 10.1016/0014-2999(96)00005-2; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pozo D, 1997, BBA-MOL CELL RES, V1359, P250, DOI 10.1016/S0167-4889(97)00104-3; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RENZ H, 1988, J IMMUNOL, V141, P2388; Romano MF, 1996, J IMMUNOL, V156, P2119; Schomerus C, 1996, CELL TISSUE RES, V286, P305; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGURA JJ, 1991, REGUL PEPTIDES, V33, P133, DOI 10.1016/0167-0115(91)90208-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TREDE NS, 1995, J IMMUNOL, V155, P902; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; West MA, 1997, SURGERY, V122, P204, DOI 10.1016/S0039-6060(97)90010-6; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; XIN ZC, 1994, J NEUROIMMUNOL, V54, P59, DOI 10.1016/0165-5728(94)90231-3; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	64	159	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31427	31436		10.1074/jbc.273.47.31427	http://dx.doi.org/10.1074/jbc.273.47.31427			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813054	hybrid			2022-12-25	WOS:000077136900082
J	Li, SM; Zhou, WT; Doglio, L; Goldberg, E				Li, SM; Zhou, WT; Doglio, L; Goldberg, E			Transgenic mice demonstrate a testis-specific promoter for lactate dehydrogenase, LDHC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERMATOGENESIS; CELL APOPTOSIS; IN-VITRO; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION; ELEMENTS; SEQUENCE; REGION	The mammalian genome encodes a family of lactate dehydrogenase (LDH) isozymes. Two of these, ldha and ldhb, are expressed ubiquitously. The ldhc gene is active only in the germinal epithelium during spermatogenesis. In our analysis of ldhc gene regulation, we found that a 60-base pair promoter sequence was sufficient for testis-specific expression in an in vitro transcription assay. To confirm these findings, a genomic fragment containing 100 base pairs overlapping the transcription start site was isolated and linked to the Escherichia coli lacZ gene. We report that this genomic fragment drives testis-specific expression in transgenic mice. We conclude that transcription of the transgene and possibly of the endogenous ldhc gene is restricted to leptotene/pachytene primary spermatocytes.	Northwestern Univ, Dept BM BCB, Evanston, IL 60208 USA	Northwestern University	Goldberg, E (corresponding author), Northwestern Univ, Dept BM BCB, 2153 N Campus Dr, Evanston, IL 60208 USA.				NICHD NIH HHS [HD05863] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albanesi C, 1996, DEVELOPMENT, V122, P1291; ALCIVAR AA, 1991, BIOL REPROD, V44, P527, DOI 10.1095/biolreprod44.3.527; BLANCO A, 1991, ACAD NAC CIENC CORDO, V84, P1; Bonny C, 1998, BIOL REPROD, V58, P754, DOI 10.1095/biolreprod58.3.754; COOKER LA, 1993, BIOL REPROD, V48, P1309, DOI 10.1095/biolreprod48.6.1309; Ewulonu UK, 1997, DNA CELL BIOL, V16, P645, DOI 10.1089/dna.1997.16.645; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; Furuchi T, 1996, DEVELOPMENT, V122, P1703; Goldberg E, 1996, J ANDROL, V17, P628; Grimes SR, 1997, MOL BIOL REP, V24, P175, DOI 10.1023/A:1006807716339; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; Markert CL, 1998, J EXP ZOOL, V282, P171, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;171::AID-JEZ19&gt;3.0.CO;2-X; OBrien DA, 1996, MOL REPROD DEV, V43, P236, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;236::AID-MRD13&gt;3.0.CO;2-1; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; SALEHIASHTIANI K, 1995, MOL ENDOCRINOL, V9, P17862; THOMAS K, 1990, DEVELOPMENT, V109, P483; Yang J, 1997, NUCLEIC ACIDS RES, V25, P2213, DOI 10.1093/nar/25.11.2213; Zhou WT, 1996, BIOL REPROD, V54, P84, DOI 10.1095/biolreprod54.1.84; ZHOU WT, 1994, BIOL REPROD, V51, P425, DOI 10.1095/biolreprod51.3.425; ZINN SA, 1991, J BIOL CHEM, V266, P23860	21	55	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31191	31194		10.1074/jbc.273.47.31191	http://dx.doi.org/10.1074/jbc.273.47.31191			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813024	hybrid			2022-12-25	WOS:000077136900052
J	Pronin, AN; Carman, CV; Benovic, JL				Pronin, AN; Carman, CV; Benovic, JL			Structure-function analysis of G protein-coupled receptor kinase-5 - role of the carboxyl terminus in kinase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; BETA-GAMMA-SUBUNITS; RHODOPSIN KINASE; MEMBRANE PHOSPHOLIPIDS; DEPENDENT PHOSPHORYLATION; C SUBSTRATE; FAMILY; GRK5; ACTIVATION; ISOPRENYLATION	Many G protein-coupled receptors are phosphorylated and regulated by a distinct family of G protein-coupled receptor kinases (GRKs) that specifically target the activated form of the receptor. Recent studies have revealed that the GRKs are also subject to post-translational regulation. For example, GRK5 activity is strongly inhibited by protein kinase C phosphorylation and by Ca2+-calmodulin binding. Ca2+-calmodulin binding also promotes GRK5 autophosphorylation, which further contributes to kinase inhibition. In this study we identify two important structural domains in GRK5, a phospholipid binding domain (residues 552-562) and an autoinhibitory domain (residues 563-590), that significantly contribute to GRK5 localization and function. We demonstrate that the C-terminal region of GRK5 (residues 563-590) contains residues autophosphorylated in the presence of calmodulin as well as the residues phosphorylated by protein kinase C. Deletion of this domain increases the apparent affinity of GRK5 for receptor substrates 3-4-fold but has no effect on nonreceptor substrates. These findings define residues 563-590 of GRK5 as an autoinhibitory domain with efficacy that is regulated by phosphorylation. Another C-terminal domain in GRK5 that appears to be functionally important is found between residues 552 and 562. Deletion of this region significantly inhibits kinase phosphorylation of membrane-bound receptor substrates but has no effect on soluble substrates. Additional studies reveal that this domain is critical for GRK5 interaction with phospholipids and for the intracellular localization of the kinase. Interestingly, similar regions in GRK4 and GRK6 appear to be palmitoylated (and involved in membrane interaction), suggesting evolutionary conservation of the function of this domain.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Immunol & Microbiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu	Carman, Christopher V./AAX-8995-2020; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANT JS, 1992, BIOCHEM BIOPH RES CO, V183, P468, DOI 10.1016/0006-291X(92)90505-F; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, RECEPTOR, V3, P39; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; SHICHI H, 1978, J BIOL CHEM, V253, P7040; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197	35	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31510	31518		10.1074/jbc.273.47.31510	http://dx.doi.org/10.1074/jbc.273.47.31510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813065	hybrid			2022-12-25	WOS:000077136900093
J	Trinh, KY; O'Doherty, RM; Anderson, P; Lange, AJ; Newgard, CB				Trinh, KY; O'Doherty, RM; Anderson, P; Lange, AJ; Newgard, CB			Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; INSULIN-RECEPTOR SUBSTRATE-1; OBESE ZUCKER RATS; GENE-EXPRESSION; MICROSOMAL GLUCOSE-6-PHOSPHATASE; DIABETES-MELLITUS; MESSENGER-RNA; FATTY RAT; GLUCOSE; MICE	The terminal step in hepatic gluconeogenesis is catalyzed by glucose-6-phosphatase, an enzyme activity residing in the endoplasmic reticulum and consisting of a catalytic subunit (glucose-6-phosphatase (G6Pase)) and putative accessory transport proteins. We show that Zucker diabetic fatty rats (fa/fa), which are known to exhibit impaired suppression of hepatic glucose output, have 2.4-fold more glucose-6-phosphatase activity in liver than lean controls. To define the potential contribution of increased hepatic G6Pase to development of diabetes, we infused recombinant adenoviruses containing the G6Pase cDNA (AdCMV-G6Pase) or the beta-galactosidase gene into normal rats. Animals were studied by one of three protocols as follows: protocol I, fed ad libitum for 7 days; protocol 2, fed ad libitum for 5 days, fasted overnight, and subjected to an oral glucose tolerance test; protocol 3, fed ad libitum for 4 days, fasted for 48 h, subjected to oral glucose tolerance test, and then allowed to refeed overnight. Hepatic glucose-6-phosphatase enzymatic activity was increased by 1.6-3-fold in microsomes isolated from AdCMV-G6Pase-treated animals in all three protocols, and the resultant metabolic profile was similar in each case. AdCMV-GGPase-treated animals exhibited several of the abnormalities associated with early stage non-insulin-dependent diabetes mellitus, including glucose intolerance, hyperinsulinemia, decreased hepatic glycogen content, and increased peripheral (muscle) triglyceride stores, These animals also exhibited significant decreases in circulating free fatty acids and triglycerides, changes not normally associated with the disease. Our studies show that overexpression of G6Pase in liver is sufficient to perturb whole animal glucose and lipid homeostasis, possibly contributing to the development of metabolic abnormalities associated with diabetes.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, 5323 Harry Hines Blvd,Rm Y8-212, Dallas, TX 75235 USA.				PHS HHS [P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CHANG MLW, 1976, J NUTR, V106, P136, DOI 10.1093/jn/106.1.136; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; SANCHEZGUTIERREZ JC, 1994, ENDOCRINOLOGY, V134, P1868, DOI 10.1210/en.134.4.1868; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; TRISCARI J, 1979, METABOLISM, V28, P183, DOI 10.1016/0026-0495(79)90084-2	38	153	158	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31615	31620		10.1074/jbc.273.47.31615	http://dx.doi.org/10.1074/jbc.273.47.31615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813078	hybrid			2022-12-25	WOS:000077136900106
J	Yamabhai, M; Hoffman, NG; Hardison, NL; McPherson, PS; Castagnoli, L; Cesareni, G; Kay, BK				Yamabhai, M; Hoffman, NG; Hardison, NL; McPherson, PS; Castagnoli, L; Cesareni, G; Kay, BK			Intersectin, a novel adaptor protein with two Eps15 homology and five Src homology 3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; TERMINAL DOMAIN; NERVE-TERMINALS; SH3 DOMAINS; EH-DOMAIN; BINDING; ENDOCYTOSIS; IDENTIFICATION	We screened a Xenopus laevis oocyte cDNA expression library with a Src homology 3 (SH3) class LT. peptide ligand and identified a 1270-amino acid-long protein containing two Eps15 homology (EH) domains, a central coiled-coil region, and five SH3 domains. We named this protein Intersectin, because it potentially brings together EH and SH3 domain-binding proteins into a macromolecular complex. The ligand preference of the EH domains were deduced to be asparajine-proline-phenylalanine (NPF) or cyclized NPF (CX1-2NPFXXC), depending on the type of phage-displayed combinatorial peptide library used. Screens of a mouse embryo cDNA library with the EH domains of Intersectin yielded clones for the Rev-associated binding/Rev-interacting protein (RAB/Rip) and two novel proteins, which we named Intersectin-binding proteins (lbps) 1 and 2. All three proteins contain internal and C-terminal NPF peptide sequences, and Ibp1 and Ibp2 also contain putative clathrin-binding sites. Deletion of the C-terminal sequence, NPFL-COOH, from RAB/Rip eliminated EH domain binding, whereas fusion of the same peptide sequence to glutathione S-transferase generated strong binding to the EH domains of Intersectin, Several experiments support the conclusion that the free carboxylate group contributes to binding of the NPFL motif at the C terminus of RAB/Rip to the EH domains of Intersectin, Finally, affinity selection experiments with the SR3 domains of Intersectin identified two endocytic proteins, dynamin and synaptojanin, as potential interacting proteins. We propose that Intersectin is a component of the endocytic machinery.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ N Carolina, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Roma Tor Vergata, Dept Biol, Enrico Calef, I-00173 Rome, Italy	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; Duke University; McGill University; University of Rome Tor Vergata	Kay, BK (corresponding author), Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA.	bkkay@facstaff.wisc.edu		Castagnoli, Luisa/0000-0001-5283-8671				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GLUCKSMAN MJ, 1992, J MOL BIOL, V226, P455, DOI 10.1016/0022-2836(92)90960-R; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; JONES H, 1997, PLANT PHYSIOL, V113, P663; KISHCHENKO G, 1994, J MOL BIOL, V241, P208, DOI 10.1006/jmbi.1994.1489; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Petrenko VA, 1996, PROTEIN ENG, V9, P797, DOI 10.1093/protein/9.9.797; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sparks Andrew B., 1996, P227, DOI 10.1016/B978-012402380-2/50015-0; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Tang HY, 1996, MOL CELL BIOL, V16, P4897; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040	58	230	242	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31401	31407		10.1074/jbc.273.47.31401	http://dx.doi.org/10.1074/jbc.273.47.31401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813051	Green Published, hybrid			2022-12-25	WOS:000077136900079
J	Elsen, S; Ponnampalam, SN; Bauer, CE				Elsen, S; Ponnampalam, SN; Bauer, CE			CrtJ found to distant binding sites interacts cooperatively to aerobically repress photopigment biosynthesis and light harvesting II gene expression in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOCHLOROPHYLL BIOSYNTHESIS; CAROTENOID BIOSYNTHESIS; ESCHERICHIA-COLI; LACTOSE PROMOTER; LAC REPRESSOR; PROTEIN; OPERON; SPHAEROIDES; IDENTIFICATION; TRANSCRIPTION	Expression of light harvesting II genes and of bacteriochlorophyll and carotenoid biosynthesis genes in Rhodobacter capsulatus is repressed under aerobic growth conditions by the transcription factor CrtJ. In this study, we demonstrate that the crtA-crtI intergenic region contains divergent promoters that initiate transcription 116 base pairs apart, based on primer extension analyses. DNase I protection assays demonstrate that purified CrtJ binds to one palindrome that overlaps the crtA -10 promoter recognition sequence as well as to a second palindrome that overlaps the -35 crtI promoter recognition sequence. Similar analyses also show that the puc promoter region contains two distant CrtJ palindromes, with one near the -35 promoter recognition sequence and the other located 240 base pairs upstream. Gel mobility shift and filter retention assays indicate that CrtJ binds in a cooperative manner to these distantly separated palindromes. In vivo expression assays with puc and crtI promoter reporter plasmids further demonstrate that aerobic repression of puc and crtI expression requires both CrtJ palindromes. These in vitro and in vivo results indicate that aerobic repression of puc, crtA, and crtI expression involves cooperative interactions between CrtJ bound to distant palindromes. A DNA looping model is discussed.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Biochem Program, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.			Elsen, Sylvie/0000-0003-4611-4719	NIGMS NIH HHS [GM00618, R37 GM040941, R01 GM040941, GM53940] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040941, R01GM040941, R01GM053940, K04GM000618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ARMSTRONG GA, 1990, J BIOL CHEM, V265, P8329; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1993, J GEN MICROBIOL, V139, P897, DOI 10.1099/00221287-139-5-897; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ELSEN S, 1993, J BACTERIOL, V175, P7404, DOI 10.1128/JB.175.22.7404-7412.1993; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; GIULIANO G, 1986, J BIOL CHEM, V261, P2925; HUBNER P, 1991, J BACTERIOL, V173, P2993; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; Jiang ZY, 1997, J BACTERIOL, V179, P5712, DOI 10.1128/jb.179.18.5712-5719.1997; KOCABIYIK S, 1995, BIOTECHNIQUES, V18, P570; KUOADIO JL, 1997, THESIS INDIANA U; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; Miller J.H., 1972, EXPT MOL GENETICS; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; Nickens DG, 1998, J BACTERIOL, V180, P4270, DOI 10.1128/JB.180.16.4270-4277.1998; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHMIDT A, 1989, EUR J BIOCHEM, V184, P375, DOI 10.1111/j.1432-1033.1989.tb15029.x; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; Vossen KM, 1996, J MOL BIOL, V255, P44, DOI 10.1006/jmbi.1996.0005; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUNG DA, 1992, FEMS MICROBIOL LETT, V95, P213	46	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30762	30769		10.1074/jbc.273.46.30762	http://dx.doi.org/10.1074/jbc.273.46.30762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804853	hybrid			2022-12-25	WOS:000077008100100
J	Goto, JJ; Gralla, EB; Valentine, JS; Cabelli, DE				Goto, JJ; Gralla, EB; Valentine, JS; Cabelli, DE			Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studied by pulse radiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-M; MUTATIONS; PROTEIN; MICE; GENE; MECHANISM; BEHAVIOR; DISEASE; ENZYME; SITES	Mutations in copper-zinc superoxide dismutase (CuZn-SOD) have been implicated in the familial form of the motor neuron disease amyotrophic lateral sclerosis (Lou Gehrig's disease). We have expressed and purified recombinant human wild type (hWT) and G93A (hG93A) CuZn-SOD, and we have used pulse radiolysis to measure their superoxide dismutase activities and their rates of deactivation upon exposure to hydrogen peroxide or heat. Both hG93A and hWT CuZn-SOD were found to have high SOD activities in their copper and zinc containing as-isolated forms as well as when remetallated entirely with copper (CuCu). Rates of deactivation by hydrogen peroxide of the as-isolated hWT and hG93A enzymes were determined and were found to be similar, suggesting that the FALS mutant enzyme is not inactivated at a higher rate than wild type by generation of and subsequent reaction with hydroxyl radical, (OH)-O-., when it is in the CuZn form. However, rates of deactivation by hydrogen peroxide of the CuCu derivatives of both hWT and hGr93A were significantly greater than those of the copper and zinc containing as-isolated enzymes. Rates of thermal deactivation were also similar for the mutant and hWT as-isolated CuZn forms but were greater for the CuCu derivatives of both enzymes. Reactions of hydrogen peroxide with the Cu(II)Cu(II) derivative of the WT enzyme demonstrate that the copper ion in the copper site is reduced much more rapidly than the copper in the zinc site, leading to the conclusion that reaction of hydrogen peroxide with Cu(I) in the copper site is the source of deactivation in the CuCu as well as the CuZn enzymes.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	University of California System; University of California Los Angeles; United States Department of Energy (DOE); Brookhaven National Laboratory	Valentine, JS (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1971, METHODS ENZYMOLOGY; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEEM KM, 1977, BIOCHEMISTRY-US, V16, P1930, DOI 10.1021/bi00628a027; BRAY R C, 1973, Biochemical Society Transactions, V1, P1067; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; FEE JA, 1975, BIOCHIM BIOPHYS ACTA, V400, P439, DOI 10.1016/0005-2795(75)90200-7; FEE JA, 1986, J BIOL CHEM, V261, P3000; FIELDEN E M, 1973, Biochemical Society Transactions, V1, P52; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1997, J NEUROL, V244, pS15, DOI 10.1007/BF03160575; Hart PJ, 1998, PROTEIN SCI, V7, P545; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; KLUG D, 1972, J BIOL CHEM, V247, P4839; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; SYMONYAN MA, 1972, FEBS LETT, V28, P22, DOI 10.1016/0014-5793(72)80667-7; VALENTINE JS, 1981, COPPER PROTEINS, P292; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	39	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30104	30109		10.1074/jbc.273.46.30104	http://dx.doi.org/10.1074/jbc.273.46.30104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804764	hybrid			2022-12-25	WOS:000077008100011
J	Ingham, RJ; Holgado-Madruga, M; Siu, C; Wong, AJ; Gold, MR				Ingham, RJ; Holgado-Madruga, M; Siu, C; Wong, AJ; Gold, MR			The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CROSS-LINKING; SH3 DOMAIN; KINASE; CRK; ACTIVATION; STIMULATION	Gab1 is a member of the docking/scaffolding protein family which includes IRS-1, IRS-2, c-Cbl, p130(cas), and p62(dok). These proteins contain a variety of protein-protein interaction motifs including multiple tyrosine residues that when phosphorylated can act as binding sites for Src homology 2 (SH2) domain-containing signaling proteins. We show in the RAMOS human B cell line that Gab1 is tyrosine-phosphorylated in response to B cell antigen receptor (BCR) engagement. Moreover, tyrosine phosphorylation of Gab1 correlated with the binding of several SH2-containing signaling proteins to Gab1 including Shc, Grb2, phosphatidylinositol 3-kinase, and the SHP-2 tyrosine phosphatase, Far Western analysis showed that the SH2 domains of Shc, SHP-2, and the p85 subunit of phosphatidylinositol 3-kinase could bind directly to tyrosine-phosphorylated Gab1 isolated from activated RAMOS cells. In contrast, the Grb2 SH2 domain did not bind directly to Gab1 but instead to the Shc and SHP-2 associated with Gab1, We also show that Gab1 is present in the membrane-enriched particulate fraction of RAMOS cells and that Gab1/signaling protein complexes are found in this fraction after BCR engagement. Thus, tyrosine-phosphorylated Gab1 may recruit cytosolic signaling proteins to cellular membranes where they can act on membrane-bound targets. This may be a critical step in the activation of multiple BCR signaling pathways.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of British Columbia; Jefferson University	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@unixg.ubc.ca	Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191	NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; CASE RD, 1994, J BIOL CHEM, V269, P10467; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DAmbrosio D, 1996, EUR J IMMUNOL, V26, P1960, DOI 10.1002/eji.1830260842; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1994, J IMMUNOL, V152, P42; GOLD MR, 1995, INT REV CYTOL, V157, P181, DOI 10.1016/S0074-7696(08)62159-2; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KAPSTEIN JS, 1996, J BIOL CHEM, V271, P18875; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAXTON TM, 1994, J IMMUNOL, V153, P623; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WENG WK, 1994, J BIOL CHEM, V269, P32514; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	39	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30630	30637		10.1074/jbc.273.46.30630	http://dx.doi.org/10.1074/jbc.273.46.30630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804835	hybrid			2022-12-25	WOS:000077008100082
J	Mangel, L; Ternes, T; Schmitz, B; Doerfler, W				Mangel, L; Ternes, T; Schmitz, B; Doerfler, W			New 5 '-(CGG)(n)-3 ' repeats in the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1A)-VOLTAGE-DEPENDENT CALCIUM-CHANNEL; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEATS; MUSCULAR-DYSTROPHY; REDUCES EXPRESSION; MOLECULAR-BASIS; TRIPLET REPEAT; FRAGILE SITES; DNA; EXPANSION	We identified new, potentially unstable loci in the human genome containing 5'-(CGG)(n)-3' trinucleotide repeats by screening a human subgenomic Library as well as a chromosome 16 library with a 5'-(CGG)(17)-3' oligodeoxyribonucleotide probe. Five different clones were isolated, two from the chromosome 16 library and three from the subgenomic library. Determinations of the nucleotide sequences have revealed that the E7 clone displayed, in addition to the 5'-(CGG)(n)-3' trinucleotide repeat, a 5'-(CAG)(n)-3' and a 5'-(CCT)(n)-3' trinucleotide repeat. Two clones, CL16-1 and P5-5, had homologies to known genes, the human casein kinase II alpha' subunit (chromosome 16) and the human calcium-activated potassium channel (chromosome 10), respectively. Clones E7 and P4 were assigned to chromosome 6, whereas CL16-8 mapped to chromosome 16. Their potential coding capacities were assessed by RNA transfer (Northern blotting) experiments. Four different transcripts were identified by using the E7 clones as hybridization probes, three of them being brain-specific. The P4 clone was expressed in placenta and skeletal muscle. Minor polymorphisms within the repeats were observed in normal and in fragile X individuals. Lung and colon carcinoma cell lines in which some microsatellites were shown to be unstable were also investigated. Expansions of the 5'-(CGG)n-3' repeats were not found.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.			Mangel, Laurence/0000-0002-6750-2270				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BEHNKRAPPA A, 1991, GENOMICS, V11, P1, DOI 10.1016/0888-7543(91)90095-V; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; COLINS C, 1991, GENOMICS, V11, P997; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Goellner GM, 1997, AM J HUM GENET, V60, P879; IMBERT G, 1996, NAT GENET, V14, P185; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Koshy BT, 1997, BRAIN PATHOL, V7, P927, DOI 10.1111/j.1750-3639.1997.tb00894.x; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; Matsuyama Z, 1997, HUM MOL GENET, V6, P1283, DOI 10.1093/hmg/6.8.1283; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; Naom IS, 1997, J MED GENET, V34, P99, DOI 10.1136/jmg.34.2.99; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Oostra B. A., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P93; PARSA NZ, 1994, GENE CHROMOSOME CANC, V9, P13, DOI 10.1002/gcc.2870090104; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; Riess O, 1997, HUM MOL GENET, V6, P1289, DOI 10.1093/hmg/6.8.1289; Saito S, 1996, CANCER RES, V56, P5586; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; YANGFENG T, 1994, GENOMICS, V9, P173; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	38	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30466	30471		10.1074/jbc.273.46.30466	http://dx.doi.org/10.1074/jbc.273.46.30466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804814	hybrid			2022-12-25	WOS:000077008100061
J	Robert, V; De Giorgi, F; Massimino, ML; Cantini, M; Pozzan, T				Robert, V; De Giorgi, F; Massimino, ML; Cantini, M; Pozzan, T			Direct monitoring of the calcium concentration in the sarcoplasmic and endoplasmic reticulum of skeletal muscle myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED RECOMBINANT AEQUORIN; JUNCTIONAL TERMINAL CISTERNAE; CA2+ CONCENTRATION; RELEASE CHANNEL; RYANODINE; CELLS; DIFFERENTIATION; HOMEOSTASIS; EXPRESSION; RECEPTOR	Direct monitoring of the free Ca2+ concentration in the sarcoplasmic reticulum (SR) was carried out in rat skeletal myotubes transfected with a specifically targeted aequorin chimera (srAEQ). Myotubes were also transfected with a chimeric aequorin (erAEQ) that we have demonstrated previously is retained in the endoplasmic reticulum (ER). Immunolocalization analysis showed that although both recombinant proteins are distributed in an endomembrane network identifiable with immature SR, the erAEQ protein was retained also in the perinuclear membrane. The difficulty of measuring [Ca2+] in 100-1000 mu M range was overcome with the use of the synthetic coelenterazine analogue, coelenterazine n. We demonstrate that the steady state levels of [Ca2+] measured with srAEQ is around 300 mu M, whereas that measured with erAEQ is significantly lower, i.e. around 200 mu M. The effects of caffeine, high KCl, and nicotinic receptor stimulation, in the presence or absence of external calcium or after blockade of the Ca-ATPase, were investigated with both chimeras. The kinetics of [Ca2+] changes revealed by the erAEQ were similar, but not identical, neither quantitatively nor qualitatively, to those monitored with the srAEQ, indicating that at this stage of muscle development, differences exist between SR and ER in their mechanisms of Ca2+ handling. The functional implications of these findings are discussed.	Univ Padua, CNR, Ctr Biomembranes, Dept Biomed Sci, I-35121 Padua, Italy; Ctr Ric Interdipartimentale Biotecnol & Informat, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua	Robert, V (corresponding author), Univ Padua, CNR, Ctr Biomembranes, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	pozzan@civ.bio.unipd.it	Massimino, Maria Lina/AAX-8773-2020	De Giorgi, Francesca/0000-0003-4850-3582	Telethon [845] Funding Source: Medline	Telethon(Fondazione Telethon)		BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; CANTINI M, 1994, IN VITRO CELL DEV-AN, V30A, P131; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7540; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; CHU A, 1986, BIOCHEMISTRY-US, V25, P8315, DOI 10.1021/bi00373a028; COGNARD C, 1992, PFLUG ARCH EUR J PHY, V422, P207, DOI 10.1007/BF00370424; EZERMAN EB, 1967, J CELL BIOL, V35, P405, DOI 10.1083/jcb.35.2.405; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLUCHER BE, 1991, J CELL BIOL, V115, P1345, DOI 10.1083/jcb.115.5.1345; FLUCHER BE, 1993, J CELL BIOL, V123, P1161, DOI 10.1083/jcb.123.5.1161; FLUCHER BE, 1992, DEV BIOL, V154, P245, DOI 10.1016/0012-1606(92)90065-O; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HRYSHKO LV, 1989, AM J PHYSIOL, V257, pH1369, DOI 10.1152/ajpheart.1989.257.5.H1369; HUXLEY AF, 1971, PROC R SOC SER B-BIO, V178, P1, DOI 10.1098/rspb.1971.0049; KAWAI M, 1994, CELL CALCIUM, V16, P123, DOI 10.1016/0143-4160(94)90007-8; LEVITSKY DO, 1981, J MOL CELL CARDIOL, V13, P785, DOI 10.1016/0022-2828(81)90236-4; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Shannon TR, 1997, BIOPHYS J, V73, P1524, DOI 10.1016/S0006-3495(97)78184-0; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	32	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30372	30378		10.1074/jbc.273.46.30372	http://dx.doi.org/10.1074/jbc.273.46.30372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804801	hybrid			2022-12-25	WOS:000077008100048
J	Sampson, MJ; Ross, L; Decker, WK; Craigen, WJ				Sampson, MJ; Ross, L; Decker, WK; Craigen, WJ			A novel isoform of the mitochondrial outer membrane protein VDAC3 via alternative splicing of a 3-base exon - Functional characteristics and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; CREATINE-KINASE; SITE SELECTION; YEAST; PORIN; EXPRESSION; INTRON; RECOGNITION; HEXOKINASE; RETICULUM	Voltage-dependent anion channels (VDACs) are poreforming proteins found in the outer mitochondrial membrane of all eucaryotes. VDACs are the major pathway for metabolites through the outer mitochondrial membrane and, in mammals, bind several cytosolic carbohydrate kinases. Whereas yeast contain a single VDAC (YVDAC), to date three isoforms have been described in the mouse that constitute a gene family. We have observed an additional isoform of VDAC3 that appears to be generated via the tissue-specific alternative splicing of a 3-base exon (ATG), The exon is predicted to introduce a methionine 39 amino acids downstream of the amino terminus of the polypeptide. Between exons 3 and 4 is an intronic sequence that potentially encodes the exon, with flanking splice enhancer elements. Expression of this alternative form in the mouse is limited to brain, heart, and skeletal muscle. Complementation of YVDAC-deficient yeast by the two isoforms and with other sequence variants of VDAC3 suggests this residue is an important modulator of VDAC3 function. In transfected mammalian cells both isoforms localize to mitochondria. A similar variant is present in humans.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Craigen, WJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, S821,1 Baylor Plaza, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823] Funding Source: NIH RePORTER; NICHD NIH HHS [1P30-HD27823] Funding Source: Medline; NIGMS NIH HHS [R01 GM05517-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ANDREADIS A, 1995, NUCLEIC ACIDS RES, V23, P3585, DOI 10.1093/nar/23.17.3585; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1989, J BIOENERG BIOMEMBR, V21, P471, DOI 10.1007/BF00762519; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; Carlo T, 1996, RNA, V2, P342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; DEVEREUX J, 1994, WISCONSIN PACKAGE PR; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; ELKELES A, 1995, PLANT MOL BIOL, V29, P109, DOI 10.1007/BF00019123; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; Huizing M, 1996, PEDIATR RES, V39, P760, DOI 10.1203/00006450-199605000-00003; JURGENS L, 1995, BIOL CHEM H-S, V376, P685; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE AC, 1994, J BIOL CHEM, V269, P30974; Moore M., 1993, RNA WORLD, P303; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; RUBY SW, 1991, TRENDS GENET, V7, P79; Sampson MJ, 1996, GENOMICS, V36, P192, DOI 10.1006/geno.1996.0445; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; THOMAS N, 1988, ANAL BIOCHEM, V170, P393, DOI 10.1016/0003-2697(88)90650-1; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZHANG SP, 1991, GENE, V105, P61, DOI 10.1016/0378-1119(91)90514-C; ZIZI M, 1994, J BIOL CHEM, V269, P1614	42	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30482	30486		10.1074/jbc.273.46.30482	http://dx.doi.org/10.1074/jbc.273.46.30482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804816	hybrid			2022-12-25	WOS:000077008100063
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; PROLIFERATION; RECEPTOR; PHOSPHORYLATION; DIFFERENTIATION; RESISTANCE; LINES; PKR	The molecular signaling events involved in the inhibition of breast cancer cell growth by retinoic acid and interferon-alpha were investigated. All-trans-retinoic acid and interferon-alpha acted synergistically to inhibit growth of both the estrogen receptor-positive breast cancer cell line MCF-7 and the estrogen receptor-negative line BT-20. In MCF-7 cells, all-trans-retinoic acid potentiated the effects of interferon-alpha by up-regulating the expression of the RNA-dependent protein kinase (PKR). Consequently, the synergism between all-trans-retinoic acid and interferon-alpha down-regulated the expression of c-Myc, but not its functional partner, Max. Transfection of MCF-7 cells with a dominant-negative mutant of PKR relieved c-Myc down-regulation and cell growth inhibition, indicating that PKR is directly involved in c-Myc down-regulation and that c-Myc down-regulation is responsible for the inhibition of cell growth. Corresponding with c-Myc down-regulation, c-Myc Max heterodimers bound to their consensus DNA sequence were undetectable in cells treated with all-trans-retinoic acid and interferon-alpha, indicating diminished c-Myc functionality. When c-Myc was overexpressed ectopically via a c-Myc expression vector, MCF-7 cells became resistant to growth inhibition by all-trans-retinoic acid plus interferon-alpha. These experiments define the following pathway as a major pathway in the synergistic growth inhibition of MCF-7 cells by all-trans-retinoic acid plus interferon-alpha all-trans-retinoic acid + interferon-alpha --> up arrow double-stranded RNA-dependent protein kinase --> down arrow c-Myc --> cell growth inhibition.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; FONTANA JA, 1990, CANCER RES, V50, P1977; GARCIA I, 1989, CANCER RES, V49, P6675; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; HIGUCHI T, 1991, CANCER RES, V51, P3958; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Lippman SM, 1997, INT J CANCER, V70, P481, DOI 10.1002/(SICI)1097-0215(19970207)70:4<481::AID-IJC20>3.0.CO;2-H; Mangelsdorf David J., 1994, P319; MARTH C, 1984, BIOCHEM PHARMACOL, V33, P2217, DOI 10.1016/0006-2952(84)90657-9; MARTH C, 1986, J NATL CANCER I, V77, P1197; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Samuel CE, 1997, INT J HEMATOL, V65, P227; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WAKELING AE, 1989, J STEROID BIOCHEM, V34, P183, DOI 10.1016/0022-4731(89)90081-2; Watson PH, 1996, CURR TOP MICROBIOL, V213, P267; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	30	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30608	30613		10.1074/jbc.273.46.30608	http://dx.doi.org/10.1074/jbc.273.46.30608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804832	hybrid			2022-12-25	WOS:000077008100079
J	Green, VJ; Kokkotou, E; Ladias, JAA				Green, VJ; Kokkotou, E; Ladias, JAA			Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC AMINO-ACIDS; RNA-POLYMERASE-II; BINDING PROTEIN; TERMINAL DOMAIN; HISTONE ACETYLTRANSFERASE; ALPHA-HELIX; RECEPTOR; VP16; P53; CLONING	The nuclear receptor hepatocyte nuclear factor 4 (HNF-4) is an important regulator of several genes involved in diverse metabolic and developmental pathways. Mutations in the ANF-4A gene are responsible for the maturity-onset diabetes of the young type 1. Recently, we showed that the 24 N-terminal residues of HNF-4 function as an acidic transcriptional activator, termed AF-1 (Hadzopoulou-Cladaras, M., Kistanova, E., Evagelopoulou, C., Zeng, S., Cladaras C., and Ladias, J. A. A. (1997) J. Biol. Chem. 272, 539-550). To identify the critical residues for this activator, we performed an extensive genetic analysis using site-directed mutagenesis. We showed that the aromatic and bulky hydrophobic residues Tyr(6), Tyr(14), Phe(19), Lys(10), and Lys(17) are essential for AF-1 function. To a lesser degree, five acidic residues are also important for optimal activity. Positional changes of Tyr(6) and Tyr(14) reduced AF-1 activity, underscoring the importance of primary structure for this activator. Our analysis also indicated that AF-1 is bipartite, consisting of two modules that synergize to activate transcription. More important, AF-1 shares common structural motifs and molecular targets with the activators of the tumor suppressor protein p53 and NF-kappa B-p65, suggesting similar mechanisms of action. Remarkably, AF-1 interacted specifically with multiple transcriptional targets, including the TATA-binding protein; the TATA-binding protein-associated factors TAF(II)31 and TAF(II)80; transcription factor IIB; transcription factor IIH-p62; and the coactivators cAMP-responsive element-binding protein-binding protein, ADA2, and PC4. The interaction of AF-1 with proteins that regulate distinct steps of transcription may provide a mechanism for synergistic activation of gene expression by AF-1.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Expt Med,Gene Regulat Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Expt Med,Macromol Crystallog Unit, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ladias, JAA (corresponding author), Harvard Inst Med, Gene Regulat Lab, Rm 354,4 Blackfan Circle, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52666] Funding Source: Medline; NIAID NIH HHS [AI34270] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P182; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FOLKERS GE, 1995, J BIOL CHEM, V270, P23552, DOI 10.1074/jbc.270.40.23552; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	39	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29950	29957		10.1074/jbc.273.45.29950	http://dx.doi.org/10.1074/jbc.273.45.29950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792714	hybrid			2022-12-25	WOS:000076798300091
J	Langford, JK; Stanley, MJ; Cao, DJ; Sanderson, RD				Langford, JK; Stanley, MJ; Cao, DJ; Sanderson, RD			Multiple heparan sulfate chains are required for optimal syndecan-1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; CHONDROITIN SULFATE; MOLECULAR-CLONING; EPITHELIAL-CELLS; I COLLAGEN; EXPRESSION; GLYCOSAMINOGLYCANS; ADHESION; SITES	Syndecans have three highly conserved sites available for heparan sulfate attachment. To determine if all three sites are required for normal function, a series of mutated syndecans having two, one, or no heparan sulfate chains were expressed in ARH-77 cells. Previously, we demonstrated that expression of wild-type syndecan-1 on these myeloma cells mediates cell-matrix and cell-cell adhesion and inhibits cell invasion into collagen gels. Here we show that to optimally mediate each of these activities, all three sites of heparan sulfate attachment are required. Generally, an increasing loss of syndecan-1 function occurs as the number of heparan sulfate attachment sites decreases. This loss of function is Plot the result of a decrease in either the total amount of cell surface heparan sulfate or syndecan-1 core protein. In regard to cell invasion, cells expressing syndecan-1 bearing a single heparan sulfate attachment site exhibit a hierarchy of function based upon the position of the site within the core protein; the presence of an available attachment site at serine 47 confers the greatest level of activity, while serine 37 contributes little to syndecan-1 function. However, when all three heparan sulfate chains are present, significantly greater biological activity is observed than is predicted by the sum of the activities occurring when the chains act individually, This synergy provides a functional basis for the evolutionary conservation of the three heparan sulfate attachment sites on syndecans and supports the idea that molecular heterogeneity, which is characteristic of proteoglycans, contributes to their functional diversity.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Anat, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Dept Pathol, Slot 517,4301 W Markham, Little Rock, AR 72205 USA.				NCI NIH HHS [CA 71145, CA 68494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071145, R01CA068494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACIU PC, 1994, J BIOL CHEM, V269, P696; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1997, BIOCHEM J, V327, P1; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RIDLEY RC, 1993, BLOOD, V81, P767; ROSENBLUM ND, 1995, BIOCHEM J, V309, P69, DOI 10.1042/bj3090069; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	23	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29965	29971		10.1074/jbc.273.45.29965	http://dx.doi.org/10.1074/jbc.273.45.29965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792716	hybrid			2022-12-25	WOS:000076798300093
J	Piovesan, B; Pennell, N; Berinstein, NL				Piovesan, B; Pennell, N; Berinstein, NL			Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity	ONCOGENE			English	Article						apoptosis; mutated p53; cisplatin; lymphoblastoid cell lines	WILD-TYPE P53; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; HUMAN B-CELLS; THYMOCYTE APOPTOSIS; UV IRRADIATION; IN-VIVO; MUTATIONS; LYMPHOMA	Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or gamma-radiation and observed for changes in the cell cycle arrest and apoptosis, We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246(val) or 135(ser)) exhibited decreased apoptosis in response to gamma-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Interestingly the cells expressing mutant p53(135(ser)) protein were less resistant to cisplatin-induced apoptosis than the p53(246(val))-bearing cell line. A significant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. No increase in basal levels of Bc12 protein in wild type or mutant p53 expressing cells was observed in response to cisplatin or irradiation. Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53.	Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Berinstein, NL (corresponding author), Univ Toronto, Dept Med, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Pennell, Nancy/0000-0002-1556-3506				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FARRUGIA MM, 1994, BLOOD, V83, P191; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang TS, 1996, ONCOGENE, V13, P625; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LI CCH, 1995, LEUKEMIA, V9, P650; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; Perego P, 1996, CANCER RES, V56, P556; Pocard M, 1996, ONCOGENE, V12, P875; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; RODRIGUEZ MA, 1995, J CLIN ONCOL, V13, P1734, DOI 10.1200/JCO.1995.13.7.1734; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SUGIMOTO K, 1991, BLOOD, V77, P1153; TWEEDDALE ME, 1987, BLOOD, V69, P1307; VAZIRI H, 1997, EMBO J, V16, P6818; VELASQUEZ WS, 1988, BLOOD, V71, P117; VOELKERDING KV, 1995, ONCOGENE, V10, P515; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhang N, 1996, ONCOGENE, V13, P655; ZINZANI PL, 1994, AM J HEMATOL, V47, P301, DOI 10.1002/ajh.2830470410	45	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2339	2350		10.1038/sj.onc.1202147	http://dx.doi.org/10.1038/sj.onc.1202147			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811465				2022-12-25	WOS:000076723300008
J	Piotrowicz, RS; Hickey, E; Levin, EG				Piotrowicz, RS; Hickey, E; Levin, EG			Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration	FASEB JOURNAL			English	Article						lamellipodia; F-actin; vascular endothelial growth factor; HSP27; wounding	ACTIN MICROFILAMENT DYNAMICS; POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR CHAPERONES; ORGANIZATION; GROWTH; POLYMERIZATION; FILAMENTS; HSP27; REORGANIZATION; DICTYOSTELIUM	The effects of enhanced HSP27 expression or expression of a nonphosphorylatable form of HSP27 on the migration of bovine arterial endothelial cells was assessed. Expression of the wildtype protein enhanced migration by twofold compared to control transfectants, whereas expression of the mutant protein retarded migration by 40%, Since homologs of the small heat shock protein inhibit F-actin polymerization in vitro and may alter basolateral F-actin content in vivo, it was postulated that the 27 kDa heat shock protein affects microfilament extension essential for cell motility. Expression of the wild type protein promoted the generation of long cellular extensions, whereas expression of the dominant negative mutant protein resulted in a marked reduction of lamellipodia and generated aberrant microfilament morphology at the wound edge, Immunofluorescence combined with phalloidin staining demonstrated the colocalization of the HSP27 gene products with lamellipodial microfilament structures. These data suggest that the 27 kDa heat shock protein regulates migration by affecting the generation lamellipodia microfilaments.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Scripps Research Institute; Scripps Research Institute; Nevada System of Higher Education (NSHE); University of Nevada Reno	Levin, EG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop SBR13,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	glevin@scripps.edu			NATIONAL CANCER INSTITUTE [R29CA077670] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NCI NIH HHS [CA77670-01] Funding Source: Medline; NHLBI NIH HHS [HL40435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLERS A, 1994, MOL PHARM, V4, P1077; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DiNubile MJ, 1997, BBA-MOL CELL RES, V1358, P261, DOI 10.1016/S0167-4889(97)00076-1; Garrido C, 1997, CANCER RES, V57, P2661; GEIGER B, 1984, J CELL BIOL, V99, P83; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; Guay J, 1997, J CELL SCI, V110, P357; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUOT J, 1995, EUR J BIOCHEM, V227, P418; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee TYJ, 1996, J VASC RES, V33, P13, DOI 10.1159/000159127; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; OESTERREICH S, 1993, CANCER RES, V53, P4443; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SHOLLEY MM, 1977, LAB INVEST, V36, P18; Small J V, 1988, Electron Microsc Rev, V1, P155; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1994, ADV EXP MED BIOL, V358, P133; WATTS RG, 1993, BLOOD, V81, P2750; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; WONG MKK, 1990, ARTERIOSCLEROSIS, V10, P76, DOI 10.1161/01.ATV.10.1.76	39	113	114	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1481	1490		10.1096/fasebj.12.14.1481	http://dx.doi.org/10.1096/fasebj.12.14.1481			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806757	Green Submitted			2022-12-25	WOS:000076749500007
J	Chen, JK; Falck, JR; Reddy, KM; Capdevila, J; Harris, RC				Chen, JK; Falck, JR; Reddy, KM; Capdevila, J; Harris, RC			Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; ARACHIDONIC-ACID; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; EPOXYGENASE METABOLITE; SIGNAL-TRANSDUCTION; NA+/H+ EXCHANGE; MESANGIAL CELLS	In our present studies utilizing a well characterized proximal tubule cell line, LLCPKc14, we determined that all four EET regioisomers (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) stimulated [H-3]thymidine incorporation, with 14,15-EET being the most potent. In contrast, no mitogenic effects were seen with arachidonic acid, other cP450 arachidonate metabolites (12R-hydroxyeicosatetraenoic acid (12R-HETE), 14,15-dihydroxyeicosatrienoic acid (14,15-DHET), or 20-HETE), or lipoxygenase metabolites (5S-HETE, leukotriene B-4, or lipoxin A4). We found that their metabolically more stable sulfonimide (SI) analogs (11,12-EET-SI and 14,15-EET-SI) were also potent mitogens. In addition 14,15-EET-SI also increased cell proliferation as well as expression of both c-fos and egr-1 mRNA. The protein kinase C and A inhibitors, H-7 and H-8, or the cyclooxygenase inhibitor, indomethacin, had no effect upon 14,15-EET-induced [H-3]thymidine incorporation, but the selective tyrosine kinase inhibitor, genistein, significantly inhibited it. Immunoprecipitation and immunoblotting demonstrated increased tyrosine phosphorylation of PIS-kinase and epidermal growth factor receptor (EGFR) within 1 min of EET administration. EETs also stimulated association of PI3-kinase with EGFR. PI3-kinase inhibitors, wortmannin and LY 294002, markedly inhibited 14,15-EET-SI-stimulated [H-3]thymidine incorporation. In addition, 14,15-EET-SI administration stimulated tyrosine phosphorylation of src homologous and collagen-like protein (SHC) and association of SHC with both growth factor receptor-binding protein (GRB2) and EGFR. Mitogen-activated protein kinase was also activated within 5 min. Pretreatment of the cells with the mitogen-activated protein kinase kinase inhibitor, PD98059, inhibited the 14,15-EET-SI-stimulated [H-3]thymidine incorporation. Moreover, immunoblotting indicated that 14,15-EET stimulated tyrosine phosphorylation of the specific pp60(c-src) substrate p120 and c-Src association with EGFR. 14,15-EET increased src kinase activity within 1 min. Our data indicate that EETs are potent mitogens for renal epithelial cells, and the mitogenic effects of the EETs are mediated, at least in part, by the activation of Src kinase and initiation of a tyrosine kinase phosphorylation cascade.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Texas SW, Dept Biochem, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S 3322,MCN, Nashville, TN 37232 USA.			Falck, John/0000-0002-9219-7845	NIDDK NIH HHS [DK38226] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENDOU H, 1983, JPN J PHARMACOL, V33, P423, DOI 10.1254/jjp.33.423; ESCALANTE BA, 1995, ADV PROSTAG THROMB L, V23, P207; FALCK JR, 1990, METHOD ENZYMOL, V187, P385; Fukao M, 1997, BRIT J PHARMACOL, V120, P439, DOI 10.1038/sj.bjp.0700932; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; Houillier P, 1996, KIDNEY INT, V50, P1496, DOI 10.1038/ki.1996.464; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Li PL, 1997, CIRC RES, V80, P877; Lin FM, 1995, AM J PHYSIOL-RENAL, V269, pF806, DOI 10.1152/ajprenal.1995.269.6.F806; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Sato SB, 1996, J BIOCHEM, V119, P887; SAWAI T, 1993, BIOCHEM BIOPH RES CO, V195, P264, DOI 10.1006/bbrc.1993.2039; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEKI K, 1992, BIOCHEM J, V281, P185, DOI 10.1042/bj2810185; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; SHEU HL, 1995, ADV PROSTAG THROMB L, V23, P211; STAUDINGER R, 1994, J CELL PHYSIOL, V160, P69, DOI 10.1002/jcp.1041600109; Stoltz RA, 1997, J OCUL PHARMACOL TH, V13, P191, DOI 10.1089/jop.1997.13.191; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VandeVoorde J, 1997, J CARDIOVASC PHARM, V29, P827, DOI 10.1097/00005344-199706000-00018; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WONG PYK, 1993, J LIPID MEDIATOR, V6, P199; Wong PYK, 1997, J LIPID MEDIAT CELL, V16, P155, DOI 10.1016/S0929-7855(97)00005-9	56	120	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29254	29261		10.1074/jbc.273.44.29254	http://dx.doi.org/10.1074/jbc.273.44.29254			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786938	hybrid			2022-12-25	WOS:000076691800099
J	Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR				Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR			Deficient post-translational processing of Rap 1A in variant HL-60 cells	ONCOGENE			English	Article						Rap 1A; HL-60 cells; post-translational processing	DEPENDENT PROTEIN-KINASE; GTP-BINDING PROTEINS; PROMYELOCYTIC LEUKEMIA-CELLS; INDUCED DIFFERENTIATION; HUMAN-PLATELETS; GRANULOCYTIC DIFFERENTIATION; PHOSPHORYLATION SITE; CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; KINETIC MECHANISM	Variant HL-60 cells resistant to differentiation induced by nitroprusside and cGMP analogs have normal guanylate cyclase and cGMP-dependent protein kinase (G-kinase) activity (J, Biol. Chem. 269, 32155-32161, 1994). We found decreased phosphorylation of a low molecular weight protein (pp23) in the variant cells and by co-migration on two-dimensional polyacrylamide gels, phosphopeptide mapping, immunoprecipitation and immunoblotting, we showed that pp23 was one of three post-translationally modified forms of Rap 1A expressed in HL-60 cells. Using an in vitro transcription/ translation system, rye studied each of the posttranslational processing steps of Rap 1A and we showed that pp23 represented fully processed Rap 1A. By immunoprecipitation, immunoblotting and S-35-methionine/cysteine incorporation, we showed that the variant cells were deficient in pp23, and thus in fully processed Rap 1A, but that these cells did express normal amounts of completely unprocessed Rap 1A and geranylgeranylated Rap 1A; the lack of Rap 1A processing beyond geranylgeranylation in the variant cells was not secondary to a change in Rap 1A's amino acid sequence, The variant cells had normal carboxyl methyltransferase activity suggesting they are deficient in proteolytic cleavage of Rap 1A, The deficient post-translational processing of Rap 1A had no effect on Rap 1A's subcellular distribution and we found no evidence for altered post-translational processing of H-Ras.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NIGMS NIH HHS [GM49360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1991, FEBS LETT, V283, P173, DOI 10.1016/0014-5793(91)80581-M; GALLAGHER R, 1979, BLOOD, V54, P713; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P60; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINZ FJ, 1992, EUR J BIOCHEM, V207, P207, DOI 10.1111/j.1432-1033.1992.tb17039.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MA YT, 1993, FEBS LETT, V332, P105, DOI 10.1016/0014-5793(93)80493-E; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1994, J BIOL CHEM, V269, P32155; PILZ RB, 1990, J BIOL CHEM, V265, P8880; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1998, IN PRESS MOL CELL BI; SHI YQ, 1992, J BIOL CHEM, V267, P9547; STUDZINSKI GP, 1987, LAB INVEST, V56, P499; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	57	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2211	2223		10.1038/sj.onc.1202137	http://dx.doi.org/10.1038/sj.onc.1202137			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811452				2022-12-25	WOS:000076698200007
J	Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A				Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A			CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells	ONCOGENE			English	Article						interleukin 6; STAT; JAK; tyrosine kinase; regulation	GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; INHIBITORY FACTOR; DNA-DAMAGE; C-MYC; RECEPTOR; PATHWAYS; PROTEIN; FAMILY	We have reported JAK-signaling modulators, CIS1 (cytokine-inducible SH2 protein-1), CIS3 and JAB (JAK2 binding protein), which are structurally related. In M1 myeloid leukemia cells, CIS3 was induced by neither interleukin 6 (IL6) nor interferon gamma (IFN gamma), while JAB was induced strongly by IFN gamma and slightly by IL6 and leukemia inhibitory factor (ILF), Forced expression of CIS3 and JAB in Mi cells prevented IL6- or LIF-induced growth arrest and differentiation, even when their expression levels were comparable to endogenous ones in several cell lines such as HEL, UT-7, IFN gamma-treated Mi, and CTLL2 cells, Pretreatment of parental Mi cells with IFN gamma but not IFN beta resulted in suppression of LIF-induced STAT3 activation and differentiation, further supporting that physiological level of JAB is sufficient to inhibit LIF-signaling. However, unlike JAB, CIS3 did not inhibit IFN gamma-induced growth arrest, suggesting a difference in cytokine specificity between CIS3 and JAB. CIS3 inhibited STAT3 activation with slower kinetics than JAB and allowed rapid c-fos induction and partial Fc gamma RI expression in response to IL6, In 293 cells, CIS3 as well as JAB bound to JAK2 tyrosine kinase domain (JH1), and inhibited its kinase activity, however, the effect of CIS3 an tyrosine kinase activity was weaker than that of JAB, indicating that CIS3 possesses lower affinity to JAK kinases than JAB, These findings suggest that CIS3 is a weaker inhibitor than JAB against JAK signaling, and JAB and CIS3 possess different regulatory roles in cytokine signaling.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kurume University; Kurume University	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.			Sasaki, Atsuo/0000-0003-2963-4501				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	26	77	79	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2271	2278		10.1038/sj.onc.1202143	http://dx.doi.org/10.1038/sj.onc.1202143			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811457				2022-12-25	WOS:000076698200012
J	Cobellis, G; Missero, C; Di Lauro, R				Cobellis, G; Missero, C; Di Lauro, R			Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation	ONCOGENE			English	Article						thyroid; Rac; MEK; Ras; differentiation; transformation	MAP KINASE KINASE; ACTIN STRESS FIBERS; PROTEIN-KINASE; MAMMALIAN-CELLS; THYROGLOBULIN PROMOTER; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; CYCLE PROGRESSION; GENE-EXPRESSION; CDC42 GTPASES	Activating point mutations in the Ras oncogene occur in a large number of human tumors, especially of epithelial origin. In thyroid follicular cells, ectopic expression of oncogenic H-Ras results in growth factor-independent proliferation, loss of differentiation and tumor formation in nude mice. In fibroblasts concomitant activation of the MAP kinase cascade and the small GTPase Rac-1 leads to full malignant transformation. We have tested the effects of these key downstream mediators of Pas in thyroid epithelial cells, by stably expressing either a constitutively active form of MEK-1 (MEKDelta N3/S218E/S222D), a constitutively active form of Rac-1 (Val12-Rac), or both. While the activation of one molecule or the other results in a weak phenotype, concomitant activation of both MEK-1 and Rac-1 in thyroid cells leads to growth factor-independent proliferation, morphological transformation and anchorage-independent growth. However, in contrast to Pas-transformed thyroid cells, the ones expressing the constitutively active forms of MEK-1 and Rac-1 maintain their differentiate phenotype and fail to form tumors when injected into nude mice. Thus, in thyroid epithelial cells, concomitant activation of MEK-1 and Rac-1 can reproduce only a subset of the Ras-induced effects and is not sufficient to cause full malignant transformation. Significantly, Pas-mediated increased proliferation and loss of differentiation can be dissociated in these cells.	Staz Zool Anton Dohrn, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, I-80121 Naples, Italy.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Cobellis, Gilda/0000-0003-2687-2272; Missero, Caterina/0000-0003-0905-5123	Telethon [E.0406] Funding Source: Medline	Telethon(Fondazione Telethon)		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANGECARTER CA, 1995, METH ENZIMOL, V255; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARIAIS R, 1993, CELL, V73, P391; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mascia A, 1997, BBA-GENE STRUCT EXPR, V1354, P171, DOI 10.1016/S0167-4781(97)00127-9; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSERO C, 1997, IN PRESS MOL CELL EN; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rochefort P, 1996, ONCOGENE, V12, P111; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAUREZ HG, 1990, ONCOGENE, V5, P565; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE P, 1993, NATURE, V36, P352; WESTWICK JK, 1995, METH ENZIMOL; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	76	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2047	2057		10.1038/sj.onc.1202130	http://dx.doi.org/10.1038/sj.onc.1202130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798676				2022-12-25	WOS:000076540900004
J	Wang, Q; Zhang, HT; Kajino, K; Greene, MI				Wang, Q; Zhang, HT; Kajino, K; Greene, MI			BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells	ONCOGENE			English	Article						BRCA1; breast cancer; c-Myc; transcription; transformation	ORNITHINE DECARBOXYLASE GENE; EPIDERMAL GROWTH-FACTOR; NUCLEAR PHOSPHOPROTEIN; EMBRYO FIBROBLASTS; PROTEIN COMPLEX; TRANSGENIC MICE; BREAST-CANCER; IN-VIVO; EXPRESSION; CYCLE	c-Myc, a proto-oncogene that is implicated in tumorigenesis, embryonic development and apoptosis, can physically associate with BRCA1. We have found that BRCA1 interacts with c-Myc in yeast, in in vitro assays and in mammalian cells. Endogenous interactions between BRCA1 and c-Myc were also observed. Efficient BRCA1-Myc association requires the intact helix-loop-helix region of c-Myc, a motif involved in Myc-Max dimerization. BRCA1 does not however bind to Max. Our studies revealed that BRCA1 represses Myc-mediated transcription while having no effect on some other transcriptional activities. Furthermore, BRCA1 reverses the phenotype of embryonic fibroblasts transformed by the activation of Myc and Ras, but only minimally affects the transformed phenotype induced by SV40 virus. These data indicate that BRCA1 may function as a tumor suppressor by regulating the behavior of c-Myc and provide a molecular explanation for some of the effects of the BRCA1 gene product.	Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.		Kajino, Kiichi/F-6873-2012; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EASTON DF, 1995, AM J HUM GENET, V56, P265; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GREENE MI, 1982, J IMMUNOL, V128, P732; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hou XY, 1996, CANCER RES, V56, P2616; KARN J, 1989, ONCOGENE, V4, P773; KIRKLAND JL, 1992, ENDOCRINOLOGY, V130, P3223, DOI 10.1210/en.130.6.3223; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMAITRE JM, 1996, ADV CANC RES, V70; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MOSHIER JA, 1995, CANCER RES, V55, P5358; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rao VN, 1996, ONCOGENE, V12, P523; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANDGREN EP, 1995, CANCER RES, V55, P3915; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu SJ, 1996, ONCOGENE, V12, P621; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140	71	179	182	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1939	1948		10.1038/sj.onc.1202403	http://dx.doi.org/10.1038/sj.onc.1202403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788437				2022-12-25	WOS:000076423500007
J	Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK				Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK			Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression	ONCOGENE			English	Article						glioma; PTEN; DMBT; mutation; tumour suppressor; 10q24-26	GERMLINE MUTATIONS; HUMAN GLIOMAS; HEREDITARY RETINOBLASTOMA; BRAIN-TUMORS; CHROMOSOME-10; HETEROZYGOSITY; PHOSPHATASE; REGIONS; LOCI	The transition from low grade astrocytoma to glioblastoma multiforme is almost always accompanied by the loss of genetic markers from chromosome 10. Recently two genes, PTEN/MMAC1/TEP1 and DMBT, have been isolated from chromosome 10q. We have analysed these two genes for mutations in 21 primary glioblastomas, An exon by exon screen of the PTEN gene using SSCP failed to identify any mutations in this tumour series, In contrast, 38% of tumours showed intragenic homozygous deletions in the DMBT gene, The fact that the majority of gliomas do not carry mutations in either of these genes suggests that there may still be other genes on chromosome 10 which are important in the development of glioblastoma multiforme.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Somerville, RPT (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.			Eng, Charis/0000-0002-3693-5145; Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CHERNOVA O, 1998, IN PRESS CANC GENET; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOGG A, 1992, ONCOGENE, V7, P1444; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; LI J, 1997, SCIENCE, V275, P1945; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Louis David N., 1997, P2013; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WANG SI, 1997, CANCER RES, V57, P4138	28	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1755	1757		10.1038/sj.onc.1202066	http://dx.doi.org/10.1038/sj.onc.1202066			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796706				2022-12-25	WOS:000076200100015
J	Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T				Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T			Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells	ONCOGENE			English	Article						Smad; TGF-beta; apoptosis; down-regulation; lung	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; IN-VIVO ALTERATIONS; SIGNAL-TRANSDUCTION; RECEPTOR; 18Q21; GENES; SUPERFAMILY; CANCERS; DPC4	Small family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities, Two highly homologous molecules, Smad2 and Smad3, have so far been identified as receptor-activated Smads for TGF-beta signaling and have become the focus of intensive studies, However, no definite differences in regulation or function have been established between these TGF-beta signaling molecules. In the present study, we show that the expression of Smad3, but not its close relative, Smad2, is down-regulated by TGF-beta mediated signals themselves in human lung epithelial cells. This down-regulation of Smad3 by TGF-beta treatment did not appear to result from shortening of the half-life of Smad3 mRNA, Constitutive expression of Smad3 in the presence of TGF-beta induced apoptotic cell death, with an adverse effect on the cell growth of human lung epithelial cells, Apoptotic cell death could also be induced by forced expression of Smad2 in the presence of TGF-beta, but less efficiently than by that of Smad3. These findings clearly define the distinctions between Smad2 and Smad3 for the first time in that a qualitative difference was observed with regard to the regulation of their expression in response to TGF-beta, while Smad2 and Smad3 appeared to have quantitatively different capabilities regarding the induction of apoptotic cell death in human lung epithelial cells.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Nagoya Univ, Sch Med, Showa Ku, Nagoya, Aichi 466, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Kondo, Masashi/I-7378-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Nagatake M, 1996, CANCER RES, V56, P2718; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	26	140	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1743	1747		10.1038/sj.onc.1202052	http://dx.doi.org/10.1038/sj.onc.1202052			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796704				2022-12-25	WOS:000076200100013
J	Groysman, M; Nagano, M; Shaanan, B; Katzav, S				Groysman, M; Nagano, M; Shaanan, B; Katzav, S			Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation	ONCOGENE			English	Article						vav; SH3; Zyxin; hnRNP-K	AMINO-ACID SUBSTITUTIONS; TYROSINE KINASE-ACTIVITY; PROLINE-RICH PEPTIDES; GTP EXCHANGE FACTOR; PROTOONCOGENE PRODUCT; C-SRC; SIGNAL-TRANSDUCTION; T-CELL; BINDING-PROTEIN; GENE	The vav proto-oncogene encodes a protein with multiple modulae domains that enable it to function as a mediator, linking tyrosine signaling to downstream events in hematopoietic cells, Circumstantial evidence suggests that protein-protein interactions exerted by two of these domains, the Src homology 2 (SH2) and the Src homology 3 (SH3), play an important role in the regulation of Vav activity, To study the relevance of the SH3 domain for the function of vav as a transforming gene, we have created several mutations in the SH3 domain located at its carboxy region. Substitution of the non-conserved aspartic acid 797 (to asparagine, D797N) retained the transforming potential of the vav oncogene, whereas substitutions of five highly conserved amino-acids: alanine 789 (to asparagine, A789N), leucine 801 (to arginine, L801R), tryptophan 821 (to arginine, W821R), glycine 830 (to valine, G830V) and valine 837 (to glutamic acid, V837E) greatly reduced its transforming potential. The mutant proteins resemble Vav in many biochemical properties; however, while the transforming mutant protein (D797N) associates with several unidentified proteins in a manner similar to that of Vav, the non-transforming mutant Vav proteins react very poorly with these proteins, Among the known Vav-interacting proteins, hnRNP-K associates with all mutant proteins except A789N and V837E whereas binding of Zyxin to any of the mutant proteins is not affected. Taken together, our results clearly demonstrate that the SH3 domain has a positive effect on vav activity and is needed for vav transformation, The vavSH3C associating protein(s) that are crucial for its activity as a transforming gene have probably not Set been identified.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.		Shaanan, Boaz/F-1202-2012	Shaanan, Boaz/0000-0001-8925-4362; Sherman, Maya/0000-0002-7421-9844				ADAMS JM, 1992, ONCOGENE, V7, P611; BOUGSKI MS, 1993, NATURE, V366, P643; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Morton CJ, 1996, STRUCTURE, V4, P705, DOI 10.1016/S0969-2126(96)00076-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Romero F, 1996, MOL CELL BIOL, V16, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	59	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1597	1606		10.1038/sj.onc.1202074	http://dx.doi.org/10.1038/sj.onc.1202074			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794237				2022-12-25	WOS:000076089900012
J	Choy, L; Derynck, R				Choy, L; Derynck, R			The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSLATION INITIATION-FACTOR-3; SIGNALING PATHWAYS; WD-REPEATS; SACCHAROMYCES-CEREVISIAE; TRANSFERASE-ALPHA; CRYSTAL-STRUCTURE; DOMAIN PROTEIN; SMAD PROTEINS; SUBUNIT; COMPLEX	The transforming growth factor-beta (TGF-beta) receptor interacting protein TRIP-1 was originally identified as a WD40 repeat-containing protein that has the ability to associate with the TGF-beta type II receptor and is phosphorylated by it (1). However, its function was not known. We now show that TRIP-1 expression represses the ability of TGF-beta to induce transcription from the plasminogen activator inhibitor-1 promoter, a common reporter of the TGF-beta-induced gene expression response, but does not affect the ability of TGF-beta to inhibit cyclin A transcription. TRIP-1 can also inhibit the plasminogen activator inhibitor-1 expression induced by Smads as well as activated TGF-beta type I receptors. Its inhibitory effect is exerted by a combination of receptor-dependent and receptor-independent mechanisms. Deletion mutational analysis revealed that two distinct regions, which do not contain recognizable WD40 repeats, are required for the ability of TRIP-I to inhibit the gene expression response. Expression of other segments of TRIP-I increased the TGF-beta-induced gene expression response and therefore may exert a dominant negative phenotype. We conclude that TRIP-1 acts as a modulator of the TGF-beta response.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER; NCI NIH HHS [CA63101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Derynck Rik, 1998, P593; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	44	102	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31455	31462		10.1074/jbc.273.47.31455	http://dx.doi.org/10.1074/jbc.273.47.31455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813058	hybrid			2022-12-25	WOS:000077136900086
J	Favre, CJ; Ufret-Vincenty, CA; Stone, MR; Ma, HT; Gill, DL				Favre, CJ; Ufret-Vincenty, CA; Stone, MR; Ma, HT; Gill, DL			Ca2+ pool emptying stimulates Ca2+ entry activated by S-nitrosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THAPSIGARGIN-RESISTANT CELLS; CAPACITATIVE CALCIUM-ENTRY; NUCLEOTIDE-GATED CHANNEL; NITRIC-OXIDE; ARACHIDONIC-ACID; DEPLETION; GROWTH; INFLUX; DERIVATIVES; MECHANISM	The entry of Ca2+ following Ca2+ pool release is a major component of Ca2+ signals; yet despite intense study, how "store-operated" entry channels are activated is unresolved. Because S-nitrosylation has become recognized as an important regulatory modification of several key channel proteins, its role in Ca2+ entry was investigated. A novel class of lipophilic NO donors activated Ca2+ entry independent of the well defined NO target, guanylate cyclase. Strikingly similar entry of Ca2+ induced by cell permeant alkylators indicated that this Ca2+ entry process was activated through thiol modification Significantly, Ca2+ entry activated by either NO donors or alkylators was highly stimulated by Ca2+ pool depletion, which increased both the rate of Ca2+ release and the sensitivity to thiol modifiers. The results indicate that S-nitrosylation underlies activation of an important store-operated Ca2+ entry mechanism.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dgill@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Clementi E, 1997, TRENDS PHARMACOL SCI, V18, P266; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; GILON P, 1995, BIOCHEM J, V311, P649, DOI 10.1042/bj3110649; Graber MN, 1997, J BIOL CHEM, V272, P29546, DOI 10.1074/jbc.272.47.29546; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; Kankaanranta H, 1996, BRIT J PHARMACOL, V117, P401, DOI 10.1111/j.1476-5381.1996.tb15204.x; Kosonen O, 1997, EUR J PHARMACOL, V337, P55, DOI 10.1016/S0014-2999(97)01266-1; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; MOORE GA, 1987, FEBS LETT, V224, P31; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SCHMIDT MJ, 1985, J PHARMACOL EXP THER, V232, P764; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; XU X, 1994, J BIOL CHEM, V269, P12645	36	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30855	30858		10.1074/jbc.273.47.30855	http://dx.doi.org/10.1074/jbc.273.47.30855			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812976	hybrid			2022-12-25	WOS:000077136900004
J	Hann, CL; Carlberg, AL; Bjornsti, MA				Hann, CL; Carlberg, AL; Bjornsti, MA			Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; CAMPTOTHECIN RESISTANCE; SACCHAROMYCES-CEREVISIAE; CATALYTIC ACTIVITY; MUTATIONAL ANALYSIS; SHUTTLE VECTORS; POINT MUTATION; YEAST; IDENTIFICATION; GENE	Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA topology and is the cellular target of the antitumor drug camptothecin (Cpt). Mutation of several conserved residues in yeast top1 mutants is sufficient to induce cell lethality in the absence of camptothecin. Despite tremendous differences in catalytic activity, the mutant proteins Top1T722Ap and Top1R517Gp cause cell death via a mechanism similar to that of Cpt, ie. stabilization of the covalent enzyme-DNA intermediate. To establish the interdomainal interactions required for the catalytic activity of Top1p and how alterations in enzyme structure contribute to the cytotoxic activity of Cpt or specific DNA topoisomerase I mutants, we initiated a genetic screen for intragenic suppressors of the top1T722A-lethal phenotype, Nine single amino acid substitutions were defined that map to the conserved central and C-terminal domains of Top1p as well as the nonconserved linker domain of the protein. All reduced the catalytic activity of the enzyme over 100-fold, However, detailed biochemical analyses of three suppressors, top1C273Y,T722A, top1G295V,T722A, and top1G369D,T722A, revealed this was accomplished via a mechanism of reduced affinity for the DNA substrate. The mechanistic implications of these results are discussed in the context of the known structures of yeast and human DNA topoisomerase I.	Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University	Bjornsti, MA (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, 233 S 10th St, Philadelphia, PA 19107 USA.	bjornsti@lac.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORCK A, 1994, BIT, V34, P1; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FUJIMORI A, 1995, CANCER RES, V55, P1339; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LEVIN NA, 1993, GENETICS, V133, P799; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; Shen HG, 1996, J BIOL CHEM, V271, P11844, DOI 10.1074/jbc.271.20.11844; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q	48	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31519	31527		10.1074/jbc.273.47.31519	http://dx.doi.org/10.1074/jbc.273.47.31519			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813066	hybrid			2022-12-25	WOS:000077136900094
J	Kunkele, KP; Juin, P; Pompa, C; Nargang, FE; Henry, JP; Neupert, W; Lill, R; Thieffry, M				Kunkele, KP; Juin, P; Pompa, C; Nargang, FE; Henry, JP; Neupert, W; Lill, R; Thieffry, M			The isolated complex of the translocase of the outer membrane of mitochondria - Characterization of the cation-selective and voltage-gated preprotein-conducting pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SENSITIVE CHANNEL; PROTEIN IMPORT RECEPTOR; PRECURSOR PROTEINS; ENDOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; LIPID BILAYERS; YEAST; BIOGENESIS; PRESEQUENCE; BINDING	The complex of the translocase mitochondrial outer membrane (TOM), mediates recognition, unfolding, and translocation of preproteins, We have used a combination of biochemical and electrophysiological methods to study the properties of the preprotein-conducting pore of the purified TOM complex. The pore is cation-selective and voltage-gated. It shows three main conductance levels with characteristic slow and fast kinetics transitions to states of lower conductance following application of transmembrane voltages. These electrical properties distinguish it from the mitochondrial voltage-dependent anion channel (porin) and are identical to those of the previously described peptide-sensitive channel. Binding of antibodies to the C terminus of Tom40 on the intermembrane space side of the outer membrane modifies the channel properties and allows determination of the orientation of the channel within the lipid bilayer. Mitochondrial presequence peptides specifically interact with the pore and decrease the ion flow through the channel in a voltage-dependent manner,We propose that the presequence-induced closures of the pore are related to structural alterations of the TOM complex observed during the various stages of preprotein movement across the mitochondrial outer membrane.	Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany; Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, D-80336 Munich, Germany; Inst Biol Physicochim, Unite Neurobiol Physicochim, F-75005 Paris, France; CNRS, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	Philipps University Marburg; University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Alberta	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol, Robert Koch Str 5, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de	JUIN, Philippe/Q-1338-2019; Nargang, Frank/A-2669-2014; JUIN, Philippe P/H-3636-2014	JUIN, Philippe/0000-0002-4997-3888; Nargang, Frank/0000-0002-1383-4720; JUIN, Philippe P/0000-0002-4997-3888; Lill, Roland/0000-0002-8345-6518				AUSTIN B, 1990, GENE, V93, P157, DOI 10.1016/0378-1119(90)90152-H; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; CHIEH JF, 1991, EUR J BIOCHEM, V196, P29; Colombini M, 1996, Ion Channels, V4, P169; Court DA, 1996, MOL CELL BIOL, V16, P4035; COURT DA, 1995, CAN J BOT, V73, pS193; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EHRLICH BE, 1992, METHOD ENZYMOL, V207, P463; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; FEVRE F, 1994, BIOPHYS J, V66, P1887, DOI 10.1016/S0006-3495(94)80982-8; FEVRE F, 1990, FEBS LETT, V262, P201, DOI 10.1016/0014-5793(90)80189-P; GAIKWAD AS, 1994, J BIOL CHEM, V269, P6437; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Henry JP, 1996, J BIOENERG BIOMEMBR, V28, P101, DOI 10.1007/BF02110639; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MICHEJDA J, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P225; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAPAPORT D, 1998, MOL CELL BIOL, V18, P5256; PATTUS F, 1981, BIOCHIM BIOPHYS ACTA, V647, P29, DOI 10.1016/0005-2736(81)90292-3; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; SZABO I, 1995, BBA-BIOMEMBRANES, V1235, P115, DOI 10.1016/0005-2736(94)00306-A; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0; THIEFFRY M, 1994, MOL BIOL MITOCHONDRI, P209	52	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31032	31039		10.1074/jbc.273.47.31032	http://dx.doi.org/10.1074/jbc.273.47.31032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813001	hybrid			2022-12-25	WOS:000077136900029
J	Matthew, JD; Khromov, AS; Trybus, KM; Somlyo, AP; Somlyo, AV				Matthew, JD; Khromov, AS; Trybus, KM; Somlyo, AP; Somlyo, AV			Myosin essential light chain isoforms modulate the velocity of shortening propelled by nonphosphorylated cross-bridges	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; LASER-FLASH-PHOTOLYSIS; VERTEBRATE MUSCLE; FORCE MAINTENANCE; PHOSPHORYLATION; ACTOMYOSIN; KINETICS; MGADP; RELAXATION; CONTRACTION	The differential effects of essential light chain isoforms (LC17a and LC17b) on the mechanical properties of smooth muscle were determined by exchanging recombinant for endogenous LC17 in permeabilized smooth muscle treated with trifluoperazine (TFP). Go-precipitation with endogenous myosin heavy chain verified that 40-60% of endogenous LC17a could be exchanged for recombinant LC17a or LC17b. Upon addition of MgATP in Ca2+-free solution, recombinant LC17 exchange induced slow contractions unaccompanied by regulatory light chain (RLC) phosphorylation only in TFP-treated, but not in untreated, permeabilized smooth muscle; the shortening velocity and rate of force development were approximately 1.5 and 2 times faster, respectively, in response to LC17a than LC17b. Additional incubation with recombinant, thiophosphorylated RLC increased the shortening velocity, independent of the LC17 isoform exchanged. The LC17-induced contractions of TFP-treated muscles were abolished by prior addition of nonphosphorylated RLC. We suggest that LC17 stiffens the lever arm of myosin and, in the absence of regulation by RLC, permits cross-bridge cycling without requiring RLC phosphorylation. Our results are compatible with nonphosphorylated RLC acting as a repressor and with LC17 isoforms modulating the MgADP affinity and, consequently, rate of cooperative cycling of nonphosphorylated cross-bridges.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Vermont, Dept Mol Physiol, Burlington, VT 05405 USA	University of Virginia; University of Vermont	Somlyo, AV (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA.	avs5u@virginia.edu			NHLBI NIH HHS [P01-HL48807, P01-HL19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807, P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMER A, 1985, J PHYSIOL-LONDON, V360, P347; ARNER A, 1982, PFLUG ARCH EUR J PHY, V395, P277, DOI 10.1007/BF00580790; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; Eden D, 1997, BIOPHYS J, V73, P952, DOI 10.1016/S0006-3495(97)78127-X; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; FUGLSANG A, 1993, J MUSCLE RES CELL M, V14, P666, DOI 10.1007/BF00141563; GREGELY J, 1967, J GEN PHYSIOL, V50, P168; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HASEGAWA Y, 1992, J BIOCHEM-TOKYO, V111, P804, DOI 10.1093/oxfordjournals.jbchem.a123840; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IKEBE M, 1987, J BIOL CHEM, V262, P13828; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Khromov A, 1995, BIOPHYS J, V69, P2611, DOI 10.1016/S0006-3495(95)80132-3; Khromov AS, 1996, J PHYSIOL-LONDON, V492, P669, DOI 10.1113/jphysiol.1996.sp021336; Khromov AS, 1998, J PHYSIOL-LONDON, V512, P345, DOI 10.1111/j.1469-7793.1998.345be.x; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; Malmqvist U, 1997, P NATL ACAD SCI USA, V94, P7655, DOI 10.1073/pnas.94.14.7655; MALMQVIST U, 1991, PFLUG ARCH EUR J PHY, V418, P523, DOI 10.1007/BF00370566; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; ROMANOFF AL, 1960, AVIAN EMBRYO, P1081; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; SIEGMAN MJ, 1980, J GEN PHYSIOL, V76, P609, DOI 10.1085/jgp.76.5.609; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SOBIESZEK A, 1986, ELECTROPHORESIS, V7, P417, DOI 10.1002/elps.1150070906; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1993, J MUSCLE RES CELL M, V14, P557, DOI 10.1007/BF00141552; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WARSHAW DM, 1991, J BIOL CHEM, V266, P24339; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	42	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31289	31296		10.1074/jbc.273.47.31289	http://dx.doi.org/10.1074/jbc.273.47.31289			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813037	hybrid			2022-12-25	WOS:000077136900065
J	Richer, JK; Lange, CA; Manning, NG; Owen, G; Powell, R; Horwitz, KB				Richer, JK; Lange, CA; Manning, NG; Owen, G; Powell, R; Horwitz, KB			Convergence of progesterone with growth factor and cytokine signaling in breast cancer - Progesterone receptors regulate signal transducers and activators of transcription expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GENE-EXPRESSION; MAMMARY-GLANDS; MESSENGER-RNA; EGF-RECEPTOR; FACTOR-ALPHA; MOUSE; KINASE; INDUCTION; PROLACTIN	STATS (signal transducers and activators of transcription) are latent transcription factors activated in the cytoplasm by diverse cell surface signaling molecules. Like progesterone receptors (PR), Stat5a and 5b are required for normal mammary gland growth and differentiation. These two proteins are up-regulated during pregnancy, a period dominated by high levels of progesterone. me now show that progestin treatment of breast cancer cells regulates Stat5a and 5b, Stat3, and Stat1 protein levels in a PR-dependent manner. In addition, progestin treatment induces translocation of Stat5 into the nucleus, possibly mediated by the association of PR and Stat5. Last, progesterone pretreatment enhances the phosphorylation of Stat5 on tyrosine 694 induced by epidermal growth factor. Functional data show that progestin pretreatment of breast cancer cells enhances the ability of prolactin to stimulate the transcriptional activity of Stat5 on a beta-casein promoter. Progesterone and epidermal growth factor synergize to control transcription from p21(WAF1) and c-fos promoters. These data demonstrate the convergence of progesterone and growth factor/cytokine signaling pathways at multiple levels, and suggest a mechanism for coordination of PR and Stat5-mediated proliferative and differentiative events in the mammary gland.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Richer, JK (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80262 USA.	richer_j@defiance.uchsc.edu		Horwitz, Kathryn/0000-0001-7402-6455; Lange, Carol/0000-0003-2751-3976	NCI NIH HHS [CA268969] Funding Source: Medline; NIDDK NIH HHS [DK 48238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHALBOS D, 1990, REV ESP FISIOL, V46, P43; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; Guthridge CJ, 1997, MOL CELL BIOL, V17, P1118, DOI 10.1128/MCB.17.3.1118; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KRUSEKOPF S, 1991, J STEROID BIOCHEM, V40, P239, DOI 10.1016/0960-0760(91)90188-B; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lechner J, 1997, IMMUNOBIOLOGY, V198, P112, DOI 10.1016/S0171-2985(97)80032-0; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Miller MM, 1997, J CLIN ENDOCR METAB, V82, P2956, DOI 10.1210/jc.82.9.2956; MURPHY LC, 1988, BIOCHEM BIOPH RES CO, V150, P192, DOI 10.1016/0006-291X(88)90504-9; MURPHY LJ, 1986, CANCER RES, V46, P728; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SARTORIUS CA, 1994, CANCER RES, V54, P3668; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; Xie W, 1997, ANTICANCER RES, V17, P2627; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	52	168	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31317	31326		10.1074/jbc.273.47.31317	http://dx.doi.org/10.1074/jbc.273.47.31317			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813040	hybrid			2022-12-25	WOS:000077136900068
J	Yang, RJ; Chun, KT; Wek, RC				Yang, RJ; Chun, KT; Wek, RC			Mitochondrial respiratory mutants in yeast inhibit glycogen accumulation by blocking activation of glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ADENYLATE-CYCLASE PATHWAY; SACCHAROMYCES-CEREVISIAE; S-CEREVISIAE; NUTRIENT LIMITATION; STRUCTURAL GENE; RAS PROTEINS; WILD-TYPE; METABOLISM; CDC25	Control of glycogen synthase activity by protein phosphorylation is important for regulating the synthesis of glycogen, In this report, we describe a regulatory linkage between the ability of yeast cells to respire and activation of glycogen synthase. Strains containing respiration-deficient mutations in genes such as COQ3, required for the synthesis of coenzyme Q, were reduced in their ability to accumulate glycogen in response to Limiting glucose, This lowered glycogen accumulation results from inactivation of the rate-determining enzyme, glycogen synthase (Gsy2p). Reduced glycogen synthase activity is coincident with lowered glucose B-phosphate and ATP levels in the respiration-deficient cells deprived of glucose. Alanine substitutions of three previously characterized phosphorylation sites in Gsy2p, Ser-650, Ser-654, or Thr-667, each suppressed the glycogen defect in cells unable to respire, suggesting that inactivation of this enzyme is mediated by phosphorylation of these residues. Inactivation of glycogen synthase requires the RAS signaling pathway that controls cAMP-dependent protein kinase and is independent of Pho85p previously identified as a Gsy2p kinase, These results suggest that yeast cells unable to shift from a fermentative to a respiratory metabolic regimen block accumulation of glycogen by inactivating Gsy2p through protein phosphorylation.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Wek, RC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	rwek@iupui.edu			NIGMS NIH HHS [GM49164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049164, R01GM049164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams H., 1963, METHOD ENZYMAT AN, P539; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; Chun KT, 1996, GENETICS, V142, P39; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DESCHENES RJ, 1989, ADV CANCER RES, V54, P79; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; FRANCOIS J, 1991, J BIOL CHEM, V266, P6174; Francois J., 1997, YEAST SUGAR METABOLI, P285; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Huang DQ, 1997, J BIOL CHEM, V272, P22495, DOI 10.1074/jbc.272.36.22495; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Ma PS, 1997, MICROBIOL-SGM, V143, P3451, DOI 10.1099/00221287-143-11-3451; MATSUMOTO K, 1984, J BACTERIOL, V157, P277, DOI 10.1128/JB.157.1.277-282.1984; PENG ZY, 1990, J BIOL CHEM, V265, P13871; PETITJEAN A, 1990, GENETICS, V124, P797; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Timblin BK, 1996, GENETICS, V143, P57; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6	45	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31337	31344		10.1074/jbc.273.47.31337	http://dx.doi.org/10.1074/jbc.273.47.31337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813042	hybrid			2022-12-25	WOS:000077136900070
J	Fleck, O; Kunz, C; Rudolph, C; Kohli, J				Fleck, O; Kunz, C; Rudolph, C; Kohli, J			The high mobility group domain protein Cmb1 of Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FIDELITY; TRANSCRIPTION FACTOR; COLON-CANCER; DNA-REPAIR; HMG-BOX; CELLS; RECOMBINATION; HETERODIMER; CISPLATIN; GENOME	The mismatch-binding activity Cmb1 of Schizosaccharomyces pombe was enriched from wild type cells, and N-terminal sequencing enabled cloning of the respective gene. The deduced amino acid sequence of cmb1(+) contains a high mobility group domain, a motif that is common to a heterogeneous family of DNA-binding proteins. In crude protein extracts of a cmb1 gene-disruption strain, specific binding to C/T, C/A, and C/Delta was abolished. Weak binding to C/C revealed the presence of a second mismatch-binding activity, Cmb2. Cmb1, enriched from S. pombe and purified from Escherichia coli, bound specifically to C/C, C/T, C/A, T/T, and C/Delta but showed little or no affinity to other mismatches and small loops. Cmb1 recognizes 1,2 GpG intrastrand crosslinks, produced by the chemotherapeutic drug cisplatin, when two cytosines are opposite the cross-linked guanines but not when other bases are present. Consistently, O-6-methylguanine:C but not O-6-methylguanine/T lesions were bound. Thus, cytosines in mismatches and opposite chemically modified guanines are the preferred target of Cmb1 recognition. cmb1 mutant cells are more sensitive to cisplatin than wild type cells, indicating a role of Cmb1 in repair of cisplatin-induced DNA damage.	Univ Bern, Inst Gen Microbiol, CH-3012 Bern, Switzerland	University of Bern	Fleck, O (corresponding author), Univ Bern, Inst Gen Microbiol, Baltzer Str 4, CH-3012 Bern, Switzerland.			Fleck, Oliver/0000-0003-0550-6513; Kunz, Christophe/0000-0002-0511-3915				Alani E, 1996, MOL CELL BIOL, V16, P5604; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BOISSONNEAULT G, 1993, MOL CELL BIOL, V13, P4323, DOI 10.1128/MCB.13.7.4323; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BURKE JD, 1994, MOL GEN GENET, V242, P169, DOI 10.1007/BF00391010; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FLECK O, 1994, NUCLEIC ACIDS RES, V22, P5289, DOI 10.1093/nar/22.24.5289; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P191; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LAUX T, 1991, NUCLEIC ACIDS RES, V19, P4769, DOI 10.1093/nar/19.17.4769; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORegan NE, 1996, J BIOL CHEM, V271, P1789, DOI 10.1074/jbc.271.3.1789; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; VANHUFFEL C, 1992, EUR J BIOCHEM, V205, P33; WU W, 1995, ANAL BIOCHEM, V229, P350, DOI 10.1006/abio.1995.1425; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	41	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30398	30405		10.1074/jbc.273.46.30398	http://dx.doi.org/10.1074/jbc.273.46.30398			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804804	hybrid			2022-12-25	WOS:000077008100051
J	Kihara, A; Ito, K				Kihara, A; Ito, K			Translocation, folding, and stability of the HflKC complex with signal anchor topogenic sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; CYTOPLASMIC MEMBRANE; RECOGNITION PARTICLE; SECRETORY PROTEINS; PHAGE-LAMBDA; LEADER PEPTIDE; DEGP PROTEASE	HflK and HflC are plasma membrane proteins of Escherichia coli, each having a large C-terminal domain exposed to the periplasmic space and an N-terminally located transmembrane segment, which should act as a signal anchor sequence for their biogenesis. They form a complex, HflKC. We studied in vivo processes of biogenesis of this pair of membrane proteins. Translocation of the C-terminal domains across the membrane, as assessed by their accessibility to externally added protease, was completed within 1 min after the synthesis in wild-type cells as web as in the secB mutant cells or in the FtsY-depleted cells. In contrast, translocation of these domains was retarded markedly when sodium azide was added to inhibit SecA ATPase and blocked almost completely in secY- or secD-defective mutant cells. Thus, although targeting of these membrane proteins depends neither on the SecB chaperone nor on the SRP pathway, their translocation occurs exclusively via the Sec translocase complex. Translocated HflK molecules were then folded into a partially protease-resistant conformation, taking a few minutes, and this folding was induced upon association with HflC. Singly expressed HflK and HflC were unstable in vivo and periplasmic proteases DegP and Pre were involved in the degradation of the HflK subunit. We characterized several hflA alleles isolated in early studies; they alter the HflK or the HflC sequence and destabilize the HflKC complex.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BANUETT F, 1986, J MOL BIOL, V187, P213, DOI 10.1016/0022-2836(86)90229-9; BANUETT F, 1987, J BACTERIOL, V169, P4076, DOI 10.1128/jb.169.9.4076-4085.1987; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BELFORT M, 1971, BACTERIOPHAGE LAMBDA, P739; Bost S, 1997, J BIOL CHEM, V272, P4087, DOI 10.1074/jbc.272.7.4087; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHENG HH, 1988, P NATL ACAD SCI USA, V85, P7882, DOI 10.1073/pnas.85.21.7882; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Connolly L, 1997, GENE DEV, V11, P2012, DOI 10.1101/gad.11.15.2012; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Davis R., 1980, ADV BACTERIAL GENETI; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Duong F, 1998, EMBO J, V17, P696, DOI 10.1093/emboj/17.3.696; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; Hara H, 1996, MICROB DRUG RESIST, V2, P63, DOI 10.1089/mdr.1996.2.63; Homma T, 1997, FEBS LETT, V408, P11, DOI 10.1016/S0014-5793(97)00376-1; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; Ito K, 1996, GENES CELLS, V1, P337, DOI 10.1046/j.1365-2443.1996.34034.x; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; Kihara A, 1997, P NATL ACAD SCI USA, V94, P5544, DOI 10.1073/pnas.94.11.5544; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE JI, 1992, J BIOL CHEM, V267, P938; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; Missiakas D, 1997, EMBO J, V16, P1670, DOI 10.1093/emboj/16.7.1670; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; NOBLE JA, 1993, P NATL ACAD SCI USA, V90, P10866, DOI 10.1073/pnas.90.22.10866; OLIVER DB, 1985, J BACTERIOL, V161, P285, DOI 10.1128/JB.161.1.285-291.1985; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; STADER J, 1989, GENE DEV, V3, P1045, DOI 10.1101/gad.3.7.1045; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	75	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29770	29775		10.1074/jbc.273.45.29770	http://dx.doi.org/10.1074/jbc.273.45.29770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792691	hybrid			2022-12-25	WOS:000076798300068
J	Walter, DM; Paul, KS; Waters, MG				Walter, DM; Paul, KS; Waters, MG			Purification and characterization of a novel 13 S hetero-oligomeric protein complex that stimulates in vitro Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; MEMBRANE-FUSION; VESICLE FUSION; SACCHAROMYCES-CEREVISIAE; N-ACETYLGLUCOSAMINE; SECRETORY PATHWAY; ENDOSOME FUSION; SNARE COMPLEXES; YEAST VACUOLES	Intracellular protein traffic involves a tightly regulated series of events in which a membrane-bounded vesicles bud from one compartment and are specifically targeted to the next compartment, where they dock and fuse. A cell-free system that reconstitutes vesicle trafficking between the cis and medial Golgi cisternae has been used previously to identify several proteins involved in vesicular transport (N-ethylmaleimide-sensitive fusion protein, soluble N-ethylmaleimide-sensitive fusion protein attachment proteins, p115, and p16); however, these factors are insufficient to drive the transport reaction. We have used a modified version of this in vitro intra-Golgi transport assay to guide purification of a new transport-stimulating activity. The active component is a 13 S hetero-oligomeric complex consisting of at least five polypeptides (approximately 110, 109, 90, 82, and 71 kDa), which we term Golgi transport complex (GTC). Hydrodynamic properties suggest that GTC is approximately 800 kDa and nonglobular, We obtained peptide sequence information from the 90-kDa subunit (GTC-90) that allowed us to identify a number of GTC-90 cDNAs, Comparison of these cDNAs with one another and with the genomic sequence suggests that the GTC-90 mRNA is alternatively spliced. Anti-GTC-90 antibodies inhibit the in vitro Golgi transport assay, confirming the functionality of the purified complex. Subcellular fractionation indicates that GTC-90 exists in both membrane and cytosolic pools, with the cytosolic pool associated exclusively with the GTC complex. The membrane-associated pool of GTC-90 is localized to the Golgi apparatus.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Waters, MG (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Paul, Kimberly/AAO-4275-2020		NATIONAL CANCER INSTITUTE [T32CA009528] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA9528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ANTONY C, 1992, J CELL SCI, V103, P785; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; COLOMBO MI, 1991, J BIOL CHEM, V266, P23438; DAmbraCabry K, 1995, AM J DERMATOPATH, V17, P560, DOI 10.1097/00000372-199512000-00006; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fell D., 1997, UNDERSTANDING CONTRO; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P731; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Paul KS, 1998, FEBS LETT, V431, P91, DOI 10.1016/S0014-5793(98)00722-4; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Puthalakath H, 1996, J BIOL CHEM, V271, P27818, DOI 10.1074/jbc.271.44.27818; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	74	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29565	29576		10.1074/jbc.273.45.29565	http://dx.doi.org/10.1074/jbc.273.45.29565			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792665	hybrid			2022-12-25	WOS:000076798300042
J	Woodfolk, JA; Wheatley, LM; Piyasena, RV; Benjamin, DC; Platts-Mills, TAE				Woodfolk, JA; Wheatley, LM; Piyasena, RV; Benjamin, DC; Platts-Mills, TAE			Trichophyton antigens associated with IgE antibodies and delayed type hypersensitivity - Sequence homology to two families of serine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC DERMATOPHYTE INFECTIONS; DIPEPTIDYL PEPTIDASE-IV; T-CELLS; IMMUNE-RESPONSES; SINGLE PROTEIN; TINEA-CAPITIS; EXPRESSION; IMMEDIATE; ALLERGEN; IDENTIFICATION	The dermatophyte fungus Trichophyton exhibits unique immunologic properties by its ability to cause both immediate and delayed type hypersensitivity. An 83-kDa Trichophyton tonsurans allergen (Tri t 4) was previously shown to elicit distinct T lymphocyte cytokine profiles in vitro, The homologous protein, Tri r 4, was cloned from a Trichophyton rubrum cDNA library, and the recombinant protein was expressed in Pichia pastoris, This 726-amino acid protein contained an arrangement of catalytic triad residues characteristic of the prolyl oligopeptidase family of serine proteinases (Ser-Asp-His). In addition, a novel Trichophyton allergen, encoding 412 amino acids, was identified by its human IgE antibody-binding activity. Sequence similarity searches showed that this allergen, designated Tri r 2, contained all of the conserved residues characteristic of the class D subtilase subfamily (41-58% overall sequence identity). Forty-two percent of subjects with immediate hypersensitivity skin test reactions to a Trichophyton extract exhibited IgE antibody binding to a recombinant glutathione S-transferase fusion protein containing the carboxyl-terminal 289 amino acids of Tri r 2, Furthermore, this antigen was capable of inducing delayed type hypersensitivity skin test reactions. Our results define two distinct antigens derived from the dermatophyte Trichophyton that serve as targets for diverse immune responses in humans.	Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Internal Med, POB 225, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI 34607, AI 01416, AI 30840] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001416, R01AI030840, U01AI034607, U19AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1994, J AM ACAD DERMATOL, V31, pS21, DOI 10.1016/S0190-9622(08)81262-5; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; Bachrach G, 1997, INFECT IMMUN, V65, P267, DOI 10.1128/IAI.65.1.267-271.1997; BAJORATH J, 1988, BIOCHIM BIOPHYS ACTA, V954, P176, DOI 10.1016/0167-4838(88)90069-6; Biagini RE, 1996, J APPL TOXICOL, V16, P139, DOI 10.1002/(SICI)1099-1263(199603)16:2<139::AID-JAT321>3.0.CO;2-P; CLARE JJ, 1991, BIO-TECHNOL, V9, P455, DOI 10.1038/nbt0591-455; DEUELL B, 1991, J IMMUNOL, V147, P96; FRIEDEN IJ, 1994, J AM ACAD DERMATOL, V31, pS42, DOI 10.1016/S0190-9622(08)81266-2; GREENBERG M, 1971, BRIT MED J, V2, P629; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HAY RJ, 1982, BRIT J DERMATOL, V106, P191, DOI 10.1111/j.1365-2133.1982.tb00928.x; HAY RJ, 1982, BRIT J DERMATOL, V106, P1, DOI 10.1111/j.1365-2133.1982.tb00895.x; HEGEN M, 1993, CELL IMMUNOL, V146, P249, DOI 10.1006/cimm.1993.1024; Hu ZX, 1996, J BIOL CHEM, V271, P3375; HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x; JONES HE, 1974, ARCH DERMATOL, V110, P369, DOI 10.1001/archderm.110.3.369; JONES HE, 1973, ARCH DERMATOL, V108, P61, DOI 10.1001/archderm.108.1.61; JUTEL M, 1995, CLIN EXP ALLERGY, V25, P1108, DOI 10.1111/j.1365-2222.1995.tb03258.x; KAAMAN T, 1979, ACTA DERM-VENEREOL, V59, P229; KAAMAN T, 1981, ACTA DERM-VENEREOL, V61, P119; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; Kemp M, 1996, IMMUNOL TODAY, V17, P13, DOI 10.1016/0167-5699(96)80562-7; KIVITY S, 1992, CLIN EXP ALLERGY, V22, P498, DOI 10.1111/j.1365-2222.1992.tb00153.x; Lambkin I, 1996, FEMS IMMUNOL MED MIC, V13, P131, DOI 10.1111/j.1574-695X.1996.tb00226.x; LEGENDRE NM, 1993, PRACTICAL GUIDE PROT; Leibovici V, 1995, CLIN EXP DERMATOL, V20, P390, DOI 10.1111/j.1365-2230.1995.tb01355.x; MOSER M, 1994, INFECT IMMUN, V62, P936, DOI 10.1128/IAI.62.3.936-942.1994; MUNK ME, 1995, EUR RESPIR J, V8, pS668; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ODOM R, 1995, J AM ACAD DERMATOL, V28, pS2; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PLATTSMILLS TAE, 1992, CLIN EXP ALLERGY, V22, P427, DOI 10.1111/j.1365-2222.1992.tb00142.x; RASMUSSEN JE, 1978, ARCH DERMATOL, V114, P371, DOI 10.1001/archderm.114.3.371; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Romani L, 1996, CHEM IMMUNOL, V63, P115; SALGAME P, 1992, CHEM IMMUNOL, V54, P44; Slunt JB, 1996, J IMMUNOL, V157, P5192; STAHL D, 1982, ACTA DERM-VENEREOL, V62, P289; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; WARD GW, 1989, LANCET, V1, P859; WARD GW, 1994, J ALLERGY CLIN IMMUN, V93, P261; WEARY PE, 1967, ARCH DERMATOL, V95, P400, DOI 10.1001/archderm.95.4.400; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Wise F, 1930, J AMER MED ASSOC, V95, P1504, DOI 10.1001/jama.1930.27210200002011a; Woodfolk JA, 1996, J IMMUNOL, V156, P1695	47	81	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29489	29496		10.1074/jbc.273.45.29489	http://dx.doi.org/10.1074/jbc.273.45.29489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792655	hybrid			2022-12-25	WOS:000076798300032
J	Yue, DX; Weiner, AM; Maizels, N				Yue, DX; Weiner, AM; Maizels, N			The CCA-adding enzyme has a single active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; DNA-POLYMERASE-BETA; COMPLETE GENOME SEQUENCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PRIMER BINDING; METHANOCOCCUS-JANNASCHII; REVERSE-TRANSCRIPTASE; MUTATIONAL ANALYSIS; CATALYTIC DOMAIN	The CCA-adding enzyme (tRNA nucleotidyltransferase) synthesizes and repairs the 3'-terminal CCA sequence of tRNA. The eubacterial, eukaryotic, and archaeal CCA-adding enzymes all share a single active-site signature motif, which identifies these enzymes as belonging to the nucleotidyltransferase superfamily, Here we show that mutations at Asp-53 or Asp-55 of the Sulfolobus shibatae signature sequence abolish addition of both C and A, demonstrating that a single active site is responsible for addition of both nucleotides. Mutations at Asp-106 (and to a lesser extent, at Glu-173 and Asp-215) selectively impaired addition of A, but not C, We have previously demonstrated that the tRNA acceptor stem remains fixed on the surface of the CCA-adding enzyme during C and A addition (Shi, P.-Y., Maizels, N., and Weiner, A. M. (1998) EMBO J, 17, 3197-3206). Taken together with this new evidence that there is a single active site for catalysis, our data suggest that specificity of nucleotide addition is determined by a process of collaborative templating: as the single active site catalyzes addition of each nucleotide, the growing 3'-end of the tRNA would progressively refold to create a binding pocket for addition of the next nucleotide.	Yale Univ, Dept Mol Biophys & Biochem, Sch Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Maizels, N (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Sch Med, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	nancy.maizels@yale.edu						BLASCO MA, 1995, J BIOL CHEM, V270, P2735, DOI 10.1074/jbc.270.6.2735; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; DONG Q, 1993, J BIOL CHEM, V268, P24175; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MASIAKOWSKI P, 1980, J BIOL CHEM, V255, P1233; MASIAKOWSKI P, 1980, J BIOL CHEM, V255, P1240; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; OSUMIDAVIS PA, 1994, J MOL BIOL, V237, P5, DOI 10.1006/jmbi.1994.1205; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; SAKON J, 1993, BIOCHEMISTRY-US, V32, P11977, DOI 10.1021/bi00096a006; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; SHORTLE D, 1985, GENETICS, V110, P539; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Thurlow DL, 1997, J MOL EVOL, V44, P686, DOI 10.1007/PL00013143; Veenstra DL, 1997, PROTEIN ENG, V10, P789, DOI 10.1093/protein/10.7.789; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; Yue DX, 1996, RNA, V2, P895; ZHU L, 1986, J BIOL CHEM, V261, P4875; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	44	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29693	29700		10.1074/jbc.273.45.29693	http://dx.doi.org/10.1074/jbc.273.45.29693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792681	hybrid			2022-12-25	WOS:000076798300058
J	Juompan, L; Lambin, P; Zouali, M				Juompan, L; Lambin, P; Zouali, M			Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection	FASEB JOURNAL			English	Article						B cell death; immunoglobulin isotypes; disease progression	B-CELL ACTIVATION; IMMUNODEFICIENCY-VIRUS TYPE-1; CIRCULATING IMMUNE-COMPLEXES; HUMAN MONOCLONAL-ANTIBODIES; MOLECULAR CHARACTERIZATION; GENE-PRODUCTS; PROTEIN-A; SERUM; AIDS; IGG	HIV infection is characterized by accelerated apoptosis and progressive loss of B cells. To see whether these abnormalities are related to the property of gp120 to act as a superantigen for V-H(3+) B cells, we probed the temporal development of V-H(3+) antibodies in HTV-1-infected subjects over a 7-year period. We found that VH3+ antibodies specific for the gp120 superantigen binding site are deficient, Since V-H(3+) antibodies impart protective responses to infectious agents, we quantified V-H(3+) antibodies in serum samples from HIV-seropositive slow progressors and from patients who progressed to AIDS-related manifestations, We found that paucity in V-H(3+) antibodies is a marker of rapid clinical decline. Remarkably, anti-gp160 V-H(3+) antibodies showed a gradual decrease in progressors and, with time, varied depending on the viral load. We conclude that disease aggravation is associated with a decrease of the magnitude of the humoral response, that V-H(3+) antibodies play an important role in protection, and that their underexpression may accelerate disease progression. We propose that vaccine preparations able to trigger V-H(3+) antibodies might confer a better protection against HIV infection, This work also represents a novel mechanism of humoral deficiency resulting from the capacity of a viral antigen to affect an important subset of the B cell repertoire and to induce B cell death by apoptosis.	Inst Pasteur, Dept Immunol, F-75015 Paris, France; INTS, Unite Immunol Transfus, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zouali, M (corresponding author), Inst Pasteur, Dept Immunol, 28 Rue Dr Roux, F-75015 Paris, France.			Zouali, Moncef/0000-0002-8225-456X				AMADORI A, 1989, J IMMUNOL, V143, P2146; AMADORI A, 1991, J IMMUNOL, V146, P57; AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; ANDRIS JS, 1993, MOL IMMUNOL, V30, P1601, DOI 10.1016/0161-5890(93)90452-H; BERBERIAN L, 1991, BLOOD, V78, P175; BERBERIAN L, 1994, J ACQ IMMUN DEF SYND, V7, P641; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; BROWN AE, 1995, J INFECT DIS, V172, P1091, DOI 10.1093/infdis/172.4.1091; Clerici M, 1996, AIDS RES HUM RETROV, V12, P1053, DOI 10.1089/aid.1996.12.1053; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; CROWLEY JJ, 1990, MOL IMMUNOL, V27, P87, DOI 10.1016/0161-5890(90)90063-6; DAVID D, 1995, IMMUNOL LETT, V47, P107, DOI 10.1016/0165-2478(95)00078-J; Ditzel HJ, 1996, J IMMUNOL, V157, P739; Ditzel HJ, 1997, J MOL BIOL, V267, P684, DOI 10.1006/jmbi.1997.0912; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; GOODGLICK L, 1995, J IMMUNOL, V155, P5151; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; IBRAHIM S, 1993, SCAND J IMMUNOL, V37, P257, DOI 10.1111/j.1365-3083.1993.tb01764.x; JANOFF EN, 1991, J IMMUNOL, V147, P2130; JANOFF EN, 1995, J INFECT DIS, V172, P855, DOI 10.1093/infdis/172.3.855; Karray S, 1997, P NATL ACAD SCI USA, V94, P1356, DOI 10.1073/pnas.94.4.1356; KARRAY S, 1998, IN PRESS J IMMUNOL; KOZLOWSKI PA, 1995, J IMMUNOL, V154, P6163; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MARASCO WA, 1992, J CLIN INVEST, V90, P1467, DOI 10.1172/JCI116014; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; MULLER S, 1993, SCAND J IMMUNOL, V38, P327, DOI 10.1111/j.1365-3083.1993.tb01734.x; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Ng VL, 1997, AIDS RES HUM RETROV, V13, P135, DOI 10.1089/aid.1997.13.135; PROCACCIA S, 1987, CLIN EXP IMMUNOL, V67, P236; QUESNEL A, 1993, CLIN EXP IMMUNOL, V91, P237; Rump JA, 1996, AIDS RES HUM RETROV, V12, P757, DOI 10.1089/aid.1996.12.757; SASSO EH, 1991, J IMMUNOL, V147, P1877; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SEBIRE G, 1993, J IMMUNOL, V150, P1517; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Silverman GJ, 1997, IMMUNOL TODAY, V18, P379, DOI 10.1016/S0167-5699(97)01101-8; SWEET SP, 1995, AIDS, V9, P1288, DOI 10.1097/00002030-199511000-00014; TAKEDA T, 1994, J IMMUNOL, V153, P4573; TownsleyFuchs J, 1996, J CLIN INVEST, V98, P1794, DOI 10.1172/JCI118979; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZOUALI M, 1995, IMMUNOL TODAY, V16, P399, DOI 10.1016/0167-5699(95)80009-3; ZOUALI M, 1994, NAT GENET, V7, P118, DOI 10.1038/ng0694-118	46	26	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1473	1480		10.1096/fasebj.12.14.1473	http://dx.doi.org/10.1096/fasebj.12.14.1473			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806756				2022-12-25	WOS:000076749500006
J	Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK				Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK			Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability	ONCOGENE			English	Article						chTRF1; identity; localization	END ASSOCIATIONS; CELLS; TRF1; SEQUENCES; TELOBOX; LENGTH; YEAST	Chinese hamster cells frequently have altered karyotypes, To investigate the basis of recent observations that karyotypic alterations are related to telomeric fusions, we asked whether these alterations are due to lack of telomere repeat binding factor/s, Further, Chinese hamster chromosomes contain large blocks of interstitial telomeric repeats, which are preferentially involved in chromosome breakage and exchange, rendering it an interesting model for such studies. Here, we report on the cloning and the chromosomal localization of the Chinese hamster telomere repeat binding factor, chTRF1, The sequence analysis revealed, similar to human TRF1 (hTRF1), an N-terminal acidic domain, a TRF1 specific DNA binding motif and a C-terminal Myb type domain, Unlike mouse TRF1 (mTRF1), chTRF1 shows 97.5% identity to hTRF1, chTRF1 gene was localized on the long arm of chromosome 5. In vitro translation of chTRF1 resulted in protein product similar in molecular weight to hTRF1, Immunostaining of Chinese hamster ovary cells (CHO) with anti-TRF1 antibody revealed punctate nuclear staining. At metaphase, antibodies failed to detect TRF1 on most of the chromosome ends and the interstitial telomeric repeat bands. These studies suggest that chTRF1 does not bind the interstitial telomeric repeats, and its presence at the metaphase chromosome ends is limited. The later could be a factor contributing to frequent karyotypic alterations observed in Chinese hamster cells.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21205 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOUFFLER S, 1993, GENE CHROMOSOME CANC, V6, P98, DOI 10.1002/gcc.2870060206; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEAVEN LL, 1973, CHROMOSOMA, V41, P129, DOI 10.1007/BF00319690; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KAO FT, 1969, J CELL PHYSIOL, V74, P245, DOI 10.1002/jcp.1040740305; KATINKA MD, 1992, EMBO J, V11, P725, DOI 10.1002/j.1460-2075.1992.tb05105.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; SHEN M, 1997, P NATL ACAD SCI USA, V98, P13618; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zakian VA, 1996, TRENDS CELL BIOL, V6, P29, DOI 10.1016/0962-8924(96)81035-X; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2137	2142		10.1038/sj.onc.1202138	http://dx.doi.org/10.1038/sj.onc.1202138			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798685				2022-12-25	WOS:000076540900013
J	Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA				Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA			Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers	ONCOGENE			English	Article						microsatellite instability; p53; BAX; colorectal cancer	WILD-TYPE P53; MICROSATELLITE MUTATOR PHENOTYPE; II RECEPTOR GENE; DNA-DAMAGE; GASTROINTESTINAL TUMORS; GENOMIC INSTABILITY; SOMATIC MUTATIONS; GASTRIC-CANCER; CELL-LINES; EXPRESSION	Though most colorectal cancers show allelic losses, a subset of colorectal cancers (microsatellite instability or MSI-positive cancers) develop numerous small insertion and deletion mutations in repetitive DNA, Some of these sequences occur in coding regions of cancer related genes which, when targeted by frameshift mutations, produce truncations in their protein product, Such a gene is the proapoptotic tumor suppressor, BAX, mutated by frameshifts within a polyG sequence in approximately 50% of MSI-positive colorectal cancers. BAX is directly transactivated by p53, a gene commonly mutated in colorectal cancers but not often in MSI-positive lesions. Here we sought to characterize the relationship between BAX and p53 by simultaneously analysing a selected series of 65 colorectal tumors for mutations in the entire coding regions of both genes. The tumors comprised 19 MSI-high, 12 MSI-low and 34 MSI-null cancers. Eight of 19 MSI-high sporadic colorectal cancers (42%) contained insertions and deletions at the polyG tract in the BAX gene, In addition, three somatic BAX missense mutations were identified in two tumors. A single missense mutation was detected in an MSI-high tumor that also contained a frameshift microdeletion, and two missense mutations were identified in an MSI-null tumor wild-type for p53, p53 mutations were detected in 5/12 MSI-low tumors (42%) and 12/34 MSI-null tumors (35%), Of significance, no p53 mutations were detected in MSI-high tumors. This study demonstrates that a reciprocal relationship exists between p53 and BAX in sporadic colorectal cancers, and further supports the hypothesis that MSI-low tumors are biologically similar to MSI-null tumors.	Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Gastroenterol, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Herston, Qld 4006, Australia; Univ Maryland, Sch Med, Dept Pathol & Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Simms, LA (corresponding author), Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia.		Radford-Smith, Graham L/G-5749-2017; Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Radford-Smith, Graham/H-2792-2013; Leggett, Barbara A/D-3579-2011; Cummings, Margaret/B-5747-2011	Radford-Smith, Graham L/0000-0002-2047-6239; Radford-Smith, Graham/0000-0002-2047-6239; Cummings, Margaret/0000-0002-7657-0240; Simms, Lisa/0000-0002-5387-7397; Leggett, Barbara/0000-0003-2062-7380	NATIONAL CANCER INSTITUTE [R01CA067497, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chou D, 1996, CANCER GENET CYTOGEN, V88, P136, DOI 10.1016/0165-4608(95)00341-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gallagher WM, 1997, ONCOGENE, V14, P185; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hanski C, 1996, CANCER LETT, V103, P163, DOI 10.1016/0304-3835(96)04208-5; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTHE RA, 1993, CANCER RES, V53, P5849; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; PARSONS R, 1995, CANCER RES, V55, P5548; Perego P, 1996, CANCER RES, V56, P556; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; RHYU MG, 1994, ONCOGENE, V9, P29; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SMITH ML, 1995, ONCOGENE, V10, P1053; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Souza RF, 1997, CANCER RES, V57, P2350; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Watatani M, 1996, CANCER, V77, P1688, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1688::AID-CNCR16>3.0.CO;2-U; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; ZHAN QM, 1994, ONCOGENE, V9, P3743	57	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2003	2008		10.1038/sj.onc.1202109	http://dx.doi.org/10.1038/sj.onc.1202109			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788444				2022-12-25	WOS:000076423500014
J	Richardson, N; Navaratnam, N; Scott, J				Richardson, N; Navaratnam, N; Scott, J			Secondary structure for the apolipoprotein B mRNA editing site - AU-binding proteins interact with a stem loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CATALYTIC SUBUNIT; SEQUENCE REQUIREMENTS; PLANT-MITOCHONDRIA; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; APOBEC-1; ENZYME; EXPRESSION; INVITRO	The C to U editing of apolipoprotein B (apoB) mRNA converts a glutamine codon in apoB100 mRNA into a stop translation codon thereby generating apoB48. The catalytic subunit of the editing enzyme, APOBEC-1, is an RNA-binding cytidine deaminase that requires auxiliary factors for the editing of apoB mRNA. Computer modeling and ribonuclease probing of the wild-type and mutant apoB RNA substrates reveal a stem loop at the editing site. This structure incorporates the essential sequence motifs required for editing. The localization of the edited cytidine within the loop suggests how it could be presented to the active site of APOBEC-1 for deamination. We have identified 43/45 kDa proteins from chick enterocytes and show evidence for their involvement in auxiliary editing activity. p43/45 demonstrates preferential binding to AU-rich RNA and to the Caauuug motif that forms the loop and proximal stem of the apoB mRNA.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Div Natl Heart & Lung Inst, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Ctr Clin Sci,MRC Mol Med Grp, London W12 0NN, England	Imperial College London; Imperial College London	Scott, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Div Natl Heart & Lung Inst, Du Cane Rd, London W12 0NN, England.	jscott@rpms.ac.uk						Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; ANANT S, 1995, NUCL ACIDS S SER, V33, P99; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; Borner GV, 1996, EMBO J, V15, P5949, DOI 10.1002/j.1460-2075.1996.tb00981.x; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GOTT JM, 1993, J BIOL CHEM, V268, P25483; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HOCH B, 1991, NATURE, V353, P178, DOI 10.1038/353178a0; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Laforest MJ, 1997, NUCLEIC ACIDS RES, V25, P626, DOI 10.1093/nar/25.3.626; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; LEE MC, 1985, J BIOL CHEM, V260, P3108; LONERGAN KM, 1993, SCIENCE, V259, P812, DOI 10.1126/science.8430334; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Malek O, 1996, EMBO J, V15, P1403, DOI 10.1002/j.1460-2075.1996.tb00482.x; MARECHALDROUARD L, 1993, NUCLEIC ACIDS RES, V21, P4909, DOI 10.1093/nar/21.21.4909; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; NAGAI K, 1994, RNA PROTEIN INTERFAC; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith HC, 1996, TRENDS GENET, V12, P418, DOI 10.1016/0168-9525(96)10042-1; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Wakasugi T, 1996, P NATL ACAD SCI USA, V93, P8766, DOI 10.1073/pnas.93.16.8766; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; YOKOBORI S, 1995, P NATL ACAD SCI USA, V92, P10432, DOI 10.1073/pnas.92.22.10432; Yoshinaga K, 1996, NUCLEIC ACIDS RES, V24, P1008, DOI 10.1093/nar/24.6.1008; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	60	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31707	31717		10.1074/jbc.273.48.31707	http://dx.doi.org/10.1074/jbc.273.48.31707			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822632	hybrid			2022-12-25	WOS:000077207000014
J	Treuner, K; Eckerich, C; Knippers, R				Treuner, K; Eckerich, C; Knippers, R			Chromatin association of replication protein a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; XENOPUS EGG EXTRACTS; BINDING-PROTEIN; CELL-CYCLE; POLYMERASE-ALPHA; PHOSPHORYLATION; INITIATION; CENTERS; KINASE; SITES	Replication protein A (RPA) is the major single strand-specific DNA-binding protein in eukaryotic cells. We have investigated the distribution of RPA in nuclei of proliferating HeLa cells and found that only one-third of the detectable RPA appeared to be bound to DNA in chromatin, whereas the remainder was free in the nucleosol. This distribution did not significantly change when cells were released from a double thymidine block into the S phase of the cell cycle. Single strand-specific endonucleases failed to mobilize RPA bound to chromatin in G(1), phase and S phase HeLa cells. In contrast, brief treatments with pancreatic DNase I or with micrococcal nuclease sufficed to release RPA from its chromatin-binding sites. Sucrose gradient analysis of soluble micrococcal nuclease digests showed that the released RPA sedimented free of mono- or oligonucleosomal chromatin fragments, possibly indicating that most of the detectable RPA may be associated with chromatin sites, which are more open to nuclease attack than bulk chromatin. The surprising conclusion is that the majority of the detectable RPA is, either directly or indirectly, associated with double-stranded DNA regions in chromatin from HeLa cells in G(1), phase and in S phase.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Treuner, K (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Kai.Treuner@uni-konstanz.de						ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ADAM SA, 1992, METHOD ENZYMOL, V219, P97; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; HANCOCK R, 1974, J MOL BIOL, V86, P649, DOI 10.1016/0022-2836(74)90187-9; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OHYASHIKI JH, 1988, CANCER GENET CYTOGEN, V34, P159, DOI 10.1016/0165-4608(88)90255-5; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHLAEGER EJ, 1982, BIOCHEMISTRY-US, V21, P3167, DOI 10.1021/bi00256a021; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YAN H, 1995, SCIENCE, V269, P1883, DOI 10.1126/science.7569932	43	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31744	31750		10.1074/jbc.273.48.31744	http://dx.doi.org/10.1074/jbc.273.48.31744			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822637	hybrid			2022-12-25	WOS:000077207000019
J	Brodie, C; Bogi, K; Acs, P; Lorenzo, PS; Baskin, L; Blumberg, PM				Brodie, C; Bogi, K; Acs, P; Lorenzo, PS; Baskin, L; Blumberg, PM			Protein kinase C delta (PKC delta) inhibits the expression of glutamine synthetase in glial cells via the PKC delta regulatory domain and its tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER-INDUCED TRANSLOCATION; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; NEURONAL DEGENERATION; CATALYTIC DOMAIN; RETINAL TISSUE; ACTIVATION; RECEPTOR; GROWTH; DIFFERENTIATION	Protein kinase C (PKC) plays an important role in the proliferation and differentiation of glial cells. In a recent study we found that overexpression of PKC delta reduced the expression of the astrocytic marker glutamine synthetase (GS). In this study we explored the mechanisms involved in the inhibitory effect of PRC delta on the expression of glutamine synthetase. Using PHC chimeras we first examined the role of the catalytic and regulatory domains of PKC delta on the expression of glutamine synthetase. We found that cells stably transfected with chimeras between the regulatory domain of PKC delta and the catalytic domains of PKC alpha or epsilon inhibited the expression of GS, similar to the inhibition exerted by overexpression of PKC delta itself. In contrast, no significant effects were observed in cells transfected with the reciprocal PKC chimeras between the regulatory domains of PKC alpha or epsilon and the catalytic domain of PKC delta. PKC delta has been shown to undergo tyrosine phosphorylation in response to various activators. Tyrosine phosphorylation of PKC delta in response to phorbol 12-myristate 13-acetate and platelet derived growth factor occurred only in chimeras which contained the PKC delta regulatory domain. Cells transfected with a PKC delta mutant (PKC delta 5), in which the five putative tyrosine phosphorylation sites were mutated to phenylalanine, showed markedly diminished tyrosine phosphorylation in response to phorbol 12-myristate 13-acetate and platelet-derived growth factor and normal levels of GS. Our results indicate that the regulatory domain of PKC delta mediates the inhibitory effect of this isoform on the expression of GS. Phosphorylation of PKC delta on tyrosine residues in the regulatory domain is implicated in this inhibitory effect.	NCI, Mol Mech Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bar Ilan University	Brodie, C (corresponding author), NCI, Mol Mech Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 3A01,37 Convent Dr, Bethesda, MD 20892 USA.							Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; BATTAGLIOLI G, 1991, NEUROCHEM RES, V16, P151, DOI 10.1007/BF00965703; Belin MF, 1997, GLIA, V21, P154, DOI 10.1002/(SICI)1098-1136(199709)21:1<154::AID-GLIA17>3.0.CO;2-R; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; Bhat NR, 1995, DEV NEUROSCI-BASEL, V17, P267, DOI 10.1159/000111296; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; BRODIE C, 1991, GLIA, V4, P269, DOI 10.1002/glia.440040304; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Gorovits R, 1996, MOL BRAIN RES, V43, P321, DOI 10.1016/S0169-328X(96)00213-6; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACKSON MJ, 1995, NEUROCHEM RES, V20, P201, DOI 10.1007/BF00970545; JAKEN S, 1996, CURR OPIN CELL BIOL, V8, P18; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; MEAROW KM, 1990, GLIA, V3, P385, DOI 10.1002/glia.440030510; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; SCHOUSBOE A, 1993, DEV NEUROSCI-BASEL, V15, P359, DOI 10.1159/000111356; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Szallasi Z, 1996, CANCER RES, V56, P2105; THOLEY G, 1986, J NEUROCHEM, V47, P1490, DOI 10.1111/j.1471-4159.1986.tb00783.x; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76	43	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30713	30718		10.1074/jbc.273.46.30713	http://dx.doi.org/10.1074/jbc.273.46.30713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804846	hybrid			2022-12-25	WOS:000077008100093
J	Shome, K; Nie, YM; Romero, G				Shome, K; Nie, YM; Romero, G			ADP-ribosylation factor proteins mediate agonist-induced activation of phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SWISS 3T3 CELLS; BREFELDIN-A; GUANINE-NUCLEOTIDE; PHOSPHATIDIC-ACID; PHOSPHATIDYLCHOLINE BREAKDOWN; GROWTH-FACTORS; KINASE-C; ARF; RHO	The role of small G proteins of the ADP-ribosylation factor (ARF) and Rho families on the activation of phospholipase D (PLD) by platelet-derived growth factor (PDGF) and phorbol esters (PMA) has been investigated. The activation of PLD by PDGF and PMA was blocked by brefeldin A (BFA), an inhibitor of ARF activation, but not by Clostridiun botulinum C3 exotoxin, an inhibitor of the activity of Rho. PDGF and PMA, in the presence of GTP gamma S, promoted the association of ARF and RhoA with cell membranes. Cells depleted of ARF and Rho by digitonin permeabilization showed a significant reduction of the activity of phospholipase D. Recombinant ARF was sufficient to restore agonist-induced PLD activity to digitonin-permeabilized, cytoplasm-depleted cells. In contrast, isoprenylated recombinant RhoA had no effects in this reconstitution assay. HIRcB cells were transiently transfected with wild-type and dominant-negative mutants of ARF1 and ARF6. Neither wt-ARF1 nor wt-ARF6 had any effects on agonist-dependent PLD activity. However, dominant-negative ARF1 and ARF6 mutants blocked the stimulation of PLD by PDGF but only partially inhibited the effects of PMA. These results demonstrate that ARF rather than Rho proteins mediate the activation of PLD by PDGF and phorbol esters in HIRcB fibroblasts.	Univ Pittsburgh, Dept Pharmacol, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Dept Pharmacol, Sch Med, W1345 BST, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [DK51183, DK02465] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051183, K02DK002465] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MALCOLM KC, 1996, J BIOL CHEM, V271, P1315; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; Ohguchi K, 1997, BBA-LIPID LIPID MET, V1346, P301, DOI 10.1016/S0005-2760(97)00043-X; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SHOME K, 1995, FEBS LETT, V357, P109, DOI 10.1016/0014-5793(94)01310-W; Singer WD, 1996, J BIOL CHEM, V271, P4504; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Vasudevan C, 1998, J CELL SCI, V111, P1277; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	35	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30836	30841		10.1074/jbc.273.46.30836	http://dx.doi.org/10.1074/jbc.273.46.30836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804862	hybrid			2022-12-25	WOS:000077008100109
J	Zhao, JK; Hoye, E; Boylan, S; Walsh, DA; Trewhella, J				Zhao, JK; Hoye, E; Boylan, S; Walsh, DA; Trewhella, J			Quaternary structures of a catalytic subunit-regulatory subunit dimeric complex and the holoenzyme of the cAMP-dependent protein kinase by neutron contrast variation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGLE-SCATTERING-DATA; ADENOSINE 3'-5'-MONOPHOSPHATE; CONFORMATIONAL-CHANGES; INHIBITOR PEPTIDE; INTERACTION SITES; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; BINDING DOMAINS; TROPONIN-C; A-KINASE	Chimeric molecules of the cAMP-dependent protein kinase (PKA) holoenzyme (R2C2) and of Delta(1-91)RC dimer were reconstituted using deuterated regulatory (R) and protiated catalytic (C) subunits. Small angle scattering with contrast variation has revealed the shapes and dispositions of R and C in the reconstituted complexes, leading to low resolution models for both forms. The crystal structures of C and a truncation mutant of R fit well within the molecular boundaries of the RC dimer model. The area of interaction between R and C is small, seemingly poised for dissociation upon a conformational transition within R induced by cAMP binding. Within the RC dimer, C has a "closed" conformation similar to that seen for C with a bound pseudosubstrate peptide. The model for the PKA holoenzyme has an extended dumbbell shape. The interconnecting bar is formed from the dimerization domains of the R subunits, arranged in an antiparallel configuration, while each lobe contains the cAMP-binding domains of one R interacting with one C. Our studies suggest that the PKA structure may be flexible via a hinge movement of each dumbbell lobe with respect to the dimerization domain. Sequence comparisons suggest that this hinge might be a property of the R, PICA isoforms.	Univ Calif Los Alamos Natl Lab, Chem Sci & Technol Div, Los Alamos, NM 87545 USA; Univ Calif Davis, Dept Biol Chem, Livermore, CA 95616 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Davis	Trewhella, J (corresponding author), Univ Calif Los Alamos Natl Lab, Chem Sci & Technol Div, POB 1663, Los Alamos, NM 87545 USA.	jtrewhella@lanl.gov	Zhao, Jinkui/B-7872-2013	Zhao, Jinkui/0000-0002-7756-1952; Trewhella, Jill/0000-0002-8555-6766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013613] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13613] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; CHAU V, 1980, BIOCHEMISTRY-US, V19, P924, DOI 10.1021/bi00546a016; COX S, 1994, J BIOL CHEM, V269, P22614; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HAMMOUDA B, 1996, SMALL ANGLE SCATTERI; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JOHNSON DA, 1993, BIOCHEMISTRY-US, V32, P6402, DOI 10.1021/bi00076a013; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sahara S, 1996, FEBS LETT, V384, P138, DOI 10.1016/0014-5793(96)00302-X; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5186; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TSUZUKI J, 1978, BIOCHEMISTRY-US, V17, P2961, DOI 10.1021/bi00608a004; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	40	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30448	30459		10.1074/jbc.273.46.30448	http://dx.doi.org/10.1074/jbc.273.46.30448			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804812	hybrid			2022-12-25	WOS:000077008100059
J	Fernandez-Busquets, X; Gerosa, D; Hess, D; Burger, MM				Fernandez-Busquets, X; Gerosa, D; Hess, D; Burger, MM			Accumulation in marine sponge grafts of the mRNA encoding the main proteins of the cell adhesion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MICROCIONA-PROLIFERA; AGGREGATION FACTOR; IMMUNOGLOBULIN SUPERFAMILY; GEODIA-CYDONIUM; IMMUNE-SYSTEM; RECOGNITION; ACID; BINDING; DOMAINS	Specific cell adhesion in the marine sponge Microciona prolifera is mediated by an extracellular aggregation factor complex, whose main protein component, termed MAFp3, is highly polymorphic. We have now identified MAFp4, an similar to 400-kDa protein, from the aggregation factor that is translated from the same mRNA as MAFp3. The existence of multiple potential sites for N-glycosylation and calcium binding suggests a direct involvement of MAFp4 in the species-specific aggregation of sponge cells. The deduced partial polypeptide consists of a 16-fold reiterated motif that shows significant similarity to a repeat in an endoglucanase from the symbiontic bacterium Azorhizobium caulinodans and to the intracellular loop of mammalian Na+-Ca2+ exchangers. Restriction fragment length polymorphism analysis indicated that the genomic variability of MAFp4 is high and comparable to that of MAFp3. Their combined polymorphism correlates with allogeneic responses studied in a population of 23 sponge individuals. Peptide mass fingerprinting of tryptic digests of the polymorphic MAFp3 bands observed on polyacrylamide gels after chemical deglycosylation of the Microciona aggregation factor revealed that the variability detected on Southern blots at least partially reflects the individual variability of aggregation factor protein components. Polyclonal antibodies raised against MAFp3 strongly crossreacted with a 68-kDa protein localized in sponge cell membranes. Immunohistochemical use of the anti-MAFp3 antibodies strongly stained a cell layer along the line of contact in allogeneic grafts. We show that the transcription level of the MAFp3/MAFp4 mRNA in sponge allo- and isografts is clearly increased in comparison with non-grafted tissue. These data are discussed with respect to a possible evolutionary relationship between cell adhesion and histocompatibility systems.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Marine Biol Lab, Woods Hole, MA 02543 USA	Friedrich Miescher Institute for Biomedical Research; Marine Biological Laboratory - Woods Hole	Fernandez-Busquets, X (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	fernande@fmi.ch	Fernàndez-Busquets, Xavier/K-1323-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631				BERGQUIST PR, 1978, SPONGES, P49; CARROLL SB, 1983, J BIOL CHEM, V258, P24; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS ASG, 1979, BIOL SYSTEMATICS COL, P39; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DESUTTER D, 1979, DEV COMP IMMUNOL, V3, P389, DOI 10.1016/S0145-305X(79)80036-1; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; FernandezBusquets X, 1997, J BIOL CHEM, V272, P27839, DOI 10.1074/jbc.272.44.27839; FernandezBusquets X, 1996, J BIOL CHEM, V271, P23558, DOI 10.1074/jbc.271.38.23558; Fritz J, 1997, J STRUCT BIOL, V119, P165, DOI 10.1006/jsbi.1997.3887; GEELEN D, 1995, APPL ENVIRON MICROB, V61, P3304, DOI 10.1128/AEM.61.9.3304-3310.1995; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; HUMASON GL, 1979, ANIMAL TISSUE TECHNI, P495; HUMPHREYS T, 1994, ANN NY ACAD SCI, V712, P342, DOI 10.1111/j.1749-6632.1994.tb33590.x; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; Landon, 1977, Methods Enzymol, V47, P145; LEITH A, 1979, BIOL BULL, V156, P212, DOI 10.2307/1541044; Lipke P.N., 1996, Progress in Molecular and Subcellular Biology, V17, P119; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MORRIS PJ, 1993, EVOLUTION, V47, P152, DOI 10.1111/j.1558-5646.1993.tb01206.x; NEIGEL JE, 1984, SCIENCE, V224, P413, DOI 10.1126/science.224.4647.413; Pancer Z, 1998, GENE, V207, P227, DOI 10.1016/S0378-1119(97)00631-8; Pancer Z, 1996, CELL ADHES COMMUN, V4, P327, DOI 10.3109/15419069609010776; PIGOTT R, 1993, ADHESION MOL FACTS B, P6; RINKEVICH B, 1993, BIOL BULL, V184, P79, DOI 10.2307/1542381; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaecke Heike, 1994, Journal of Molecular Recognition, V7, P273, DOI 10.1002/jmr.300070406; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Van de Vyver G., 1975, Transactions Congr int Un Game Biol, V10, P123; VANDEVYVER G, 1983, J EXP ZOOL, V227, P1, DOI 10.1002/jez.1402270102; WEINBAUM G, 1973, NATURE, V244, P510, DOI 10.1038/244510a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yin CQ, 1996, BIOL BULL, V191, P159, DOI 10.2307/1542919	41	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29545	29553		10.1074/jbc.273.45.29545	http://dx.doi.org/10.1074/jbc.273.45.29545			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792663	hybrid			2022-12-25	WOS:000076798300040
J	Mottahedeh, J; Marsh, R				Mottahedeh, J; Marsh, R			Characterization of 101-kDa transglutaminase from Physarum polycephalum and identification of LAV1-2 as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; MOLECULAR-CLONING; CROSS-LINKING; KERATINOCYTE TRANSGLUTAMINASE; PROTEIN; BINDING; GTP; PURIFICATION; ENZYMES; PROSTATE	Plasmodial transglutaminase of Physarum polycephalum was purified by anion exchange and hydrophobic chromatography. Gel filtration and SDS-polyacrylamide gel electrophoresis indicate that it is a monomer of 96-101 kDa. It is Ca2+-dependent, with half-maximal activity at 0.7 mM Ca2+. Optimal activity occurs at pH 7.5 and at 50 mM KCl. Inactivation by N-ethylmaleimide indicates that it is a thiol enzyme. With N,N-dimethylcasein as substrate, the K-m for monodansylcadaverine is 33.9 +/- 1.8 mu M. Damage of plasmodia by brief treatment with 15% ethanol activates the transglutaminase, with rapid accumulation of cross-linked proteins unable to enter gels during SDS-polyacrylamide gel electrophoresis. Added monodansylcadaverine is conjugated principally to LAV1-2, a plasmodia-specific 40-kDa protein with four EF-hand sequences believed to bind Ca2+. Actin is seen as an additional substrate only in plasmodial homogenates. Immunoblots show that upon ethanol treatment, a portion of LAV1-2 is modified quickly and shifts to 36 kDa; another portion is cross-linked to itself or other proteins. The modification of LAV1-2 may lead to localized release of Ca2+ and activation of transglutaminase for walling off damaged areas of plasmodia. No significant increase in amount of the transglutaminase occurs during starvation-induced differentiation of plasmodia to form spherules, but a 50% reduction in the amount of total protein leads to a doubling in the specific mass of the TGase. Neither the transglutaminase nor LAV1-2 is found in the ameboid form of the organism.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Marsh, R (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.	rmarsh@utdallas.edu						ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Adany Roza, 1996, Seminars in Thrombosis and Hemostasis, V22, P399, DOI 10.1055/s-2007-999038; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERGAMINI CM, 1987, BIOCHIM BIOPHYS ACTA, V916, P149, DOI 10.1016/0167-4838(87)90222-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKHART PP, 1983, ANAL BIOCHEM, V128, P202, DOI 10.1016/0003-2697(83)90364-0; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; Daniel J. W., 1964, METHOD CELL PHYSIOL, P9; DeCorte V, 1996, BIOCHEMISTRY-US, V35, P5472, DOI 10.1021/bi952237r; DEE J, 1960, NATURE, V185, P780, DOI 10.1038/185780a0; GASSNER D, 1983, CELL BIOL INT REP, V7, P905, DOI 10.1016/0309-1651(83)90209-6; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GROSS M, 1977, J BIOL CHEM, V252, P3752; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; KANAJI T, 1993, J BIOL CHEM, V268, P11565; KIM HC, 1990, J BIOL CHEM, V265, P21971; KLEIN JD, 1992, J BACTERIOL, V174, P2599, DOI 10.1128/jb.174.8.2599-2605.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; LAROCHE A, 1989, NUCLEIC ACIDS RES, V17, P10502, DOI 10.1093/nar/17.24.10502; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LOEWY AG, 1981, BIOCHIM BIOPHYS ACTA, V668, P167, DOI 10.1016/0005-2795(81)90160-4; LORAND L, 1986, ANN NY ACAD SCI, V485, P144, DOI 10.1111/j.1749-6632.1986.tb34577.x; Lorand L., 1970, METHOD ENZYMOL, V19, P770; MARTINET N, 1988, J BIOL CHEM, V263, P4236; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NATIONS C, 1987, J CELL PHYSIOL, V133, P181, DOI 10.1002/jcp.1041330124; Nemes Z, 1996, EUR J CELL BIOL, V70, P125; PALLOTTA D, 1986, BIOCHEM CELL BIOL, V64, P1294, DOI 10.1139/o86-170; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SAUER HW, 1982, MOL BIOL PHYSARUM PO, P1; SINGER MA, 1992, DEV BIOL, V154, P143, DOI 10.1016/0012-1606(92)90055-L; SLIFE CW, 1985, ARCH BIOCHEM BIOPHYS, V241, P329, DOI 10.1016/0003-9861(85)90554-5; TOKUNAGA F, 1993, J BIOL CHEM, V268, P252; VEKRIS A, 1994, NUCLEIC ACIDS RES, V22, P4842, DOI 10.1093/nar/22.22.4842; WENDELBERGERSCHIEWEG G, 1978, ARCH MICROBIOL, V117, P27, DOI 10.1007/BF00689347; WONG S, 1992, MOL GEN GENET, V233, P225, DOI 10.1007/BF00587583; ZAAR K, 1979, BIOCHIM BIOPHYS ACTA, V582, P21, DOI 10.1016/0304-4165(79)90285-X	44	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29888	29895		10.1074/jbc.273.45.29888	http://dx.doi.org/10.1074/jbc.273.45.29888			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792706	hybrid			2022-12-25	WOS:000076798300083
J	Lubec, B; Hermon, M; Hoeger, H; Lubec, G				Lubec, B; Hermon, M; Hoeger, H; Lubec, G			Aromatic hydroxylation in animal models of diabetes mellitus	FASEB JOURNAL			English	Article						hydroxyl radical; streptozotocin; db/db mouse; BB rat; KK mouse; o-tyrosine; glycoxidation; pentosidine; carboxymethyllysine; malondialdehyde; lipid peroxidation	N-EPSILON-CARBOXYMETHYLLYSINE; MAILLARD REACTION-PRODUCTS; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; BB RAT; COLLAGEN ACCUMULATION; SKIN COLLAGEN; O-TYROSINE; STREPTOZOTOCIN; PENTOSIDINE	Although the involvement of oxidative stress is well documented in the diabetic state, the individual active oxygen species generated have mot been demonstrated in animal models of diabetes currently used. Since streptozotocin-induced diabetes mellitus in animals still serves as an animal model of diabetes mellitus, but streptozotocin induces diabetes and generates oxidative stress per se, we decided to study whether aromatic hydroxylation reflecting hydroxyl radical attack was found in three animal models of diabetes mellitus without streptozotocin induction or in streptozotocin-induced diabetes only, For this purpose, we compared lipid peroxidation, aromatic hydroxylation of phenylalanine, glycoxidation in genetically determined diabetic mouse strains db/db and kk, and the diabetic BE rat to these parameters in the streptozotocin-treated rat. Kidney malondialdehyde concentrations, reflecting lipid peroxidation, pentosidine, and N-epsilon-caboxymethyllysine concentrations, reflecting glycoxidation, were significantly elevated in all diabetic groups as compared to their nondiabetic mates, Aromatic hydroxylation was significantly elevated in the streptozotocin-induced diabetic state exclusively. We conclude that biochemical, pathophysiological, and treatment studies in the streptozotocin model of diabetes mellitus may be confounded by the presence of products, reactions, and tissue damage generated by aromatic hydroxylation reflecting hydroxyl radical attack. We suggest it is not the diabetic state but streptozotocin that generates the hydroxyl radical, as reflected by aromatic hydroxylation in this model.	Univ Vienna, Dept Pediat, A-1090 Vienna, Austria; Univ Vienna, Dept Neonatol & Intens Care, A-1090 Vienna, Austria; Univ Vienna, Inst Anim Breeding, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Lubec, G (corresponding author), Univ Vienna, Dept Pediat, Waehringer Guertel 18 A, A-1090 Vienna, Austria.	gert.lubec@akh-wien.ac.at	YAMAMOTO, MASAHIRO/F-9094-2011; Hermon, Michael/H-9495-2019	YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Lubec, Gert/0000-0002-6333-9461				AWATA T, 1995, ENDOCRINOLOGY, V136, P5731, DOI 10.1210/en.136.12.5731; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BENNETT RA, 1981, CANCER RES, V41, P2786; CAMERON NE, 1993, DIABETOLOGIA, V36, P299, DOI 10.1007/BF00400231; CARUBELLI R, 1995, FREE RADICAL BIO MED, V18, P265, DOI 10.1016/0891-5849(94)E0134-5; Coleman D L, 1967, Diabetologia, V3, P238, DOI 10.1007/BF01222201; CROUCH R, 1978, DIABETOLOGIA, V15, P53, DOI 10.1007/BF01219329; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Frischer T, 1997, FREE RADICAL BIO MED, V22, P201, DOI 10.1016/S0891-5849(96)00292-4; FU MX, 1992, DIABETES, V41, P42, DOI 10.2337/diab.41.2.S42; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GANDY SE, 1982, J CLIN INVEST, V70, P650, DOI 10.1172/JCI110659; Halliwell B., 1991, FREE RADICALS BIOL M; Hardmeier R, 1997, P NATL ACAD SCI USA, V94, P7572, DOI 10.1073/pnas.94.14.7572; HIRAMOTO K, 1993, MUTAT RES, V285, P191, DOI 10.1016/0027-5107(93)90106-P; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HUNT JV, 1991, FREE RADICAL RES COM, V12-3, P115, DOI 10.3109/10715769109145775; ISHIMITSU S, 1986, J CHROMATOGR, V378, P222, DOI 10.1016/S0378-4347(00)80716-1; JAIN SK, 1990, METABOLISM, V39, P971, DOI 10.1016/0026-0495(90)90310-9; JUNOD A, 1967, P SOC EXP BIOL MED, V126, P201; KARAM LR, 1991, FREE RADICAL RES COM, V12-3, P11, DOI 10.3109/10715769109145762; KELLY FJ, 1995, PEDIATR RES, V38, P286, DOI 10.1203/00006450-199509000-00003; KHAIDAR A, 1994, CIRCULATION, V90, P479, DOI 10.1161/01.CIR.90.1.479; KRAJNIK P, 1995, Z NATURFORSCH A, V50, P864, DOI 10.1515/zna-1995-0912; LIARDON R, 1987, J AGR FOOD CHEM, V35, P427, DOI 10.1021/jf00075a035; LUBEC B, 1993, J PEDIATR-US, V123, P748, DOI 10.1016/S0022-3476(05)80852-2; Lubec B, 1997, FREE RADICAL BIO MED, V22, P355, DOI 10.1016/S0891-5849(96)00386-3; Lubec B, 1997, NEPHRON, V75, P213, DOI 10.1159/000189534; Lubec B, 1996, FREE RADICAL BIO MED, V21, P219, DOI 10.1016/0891-5849(96)00018-4; LUBEC G, 1994, FASEB J, V8, P1166, DOI 10.1096/fasebj.8.14.7958623; Lubec G, 1996, J INVEST MED, V44, P324; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MARLISS EB, 1982, DIABETOLOGIA, V22, P225, DOI 10.1007/BF00281296; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; NONODA K, 1993, JPN HEART J, V34, P591; OHKUWA T, 1995, LIFE SCI, V56, P1789, DOI 10.1016/0024-3205(95)00150-5; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; PITKANEN OM, 1992, LIFE SCI, V50, P335, DOI 10.1016/0024-3205(92)90434-Q; POUSSIER P, 1982, ENDOCRINOLOGY, V110, P1825, DOI 10.1210/endo-110-5-1825; RERUP C C, 1970, Pharmacological Reviews, V22, P485; ROBBINS MJ, 1980, DIABETOLOGIA, V18, P55, DOI 10.1007/BF01228303; SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; SHAH G, 1994, LIFE SCI, V55, P1343, DOI 10.1016/0024-3205(94)00767-5; SLONIM AE, 1976, DIABETES, V25, P216, DOI 10.2337/diabetes.25.3.216; SLONIM AE, 1977, DIABETES, V26, P417; TAKAHASHI M, 1993, DIABETOLOGIA, V36, P664, DOI 10.1007/BF00404078; TOMINO Y, 1991, NEPHRON, V59, P632, DOI 10.1159/000186656; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; WENINGER M, 1992, NEPHRON, V62, P80, DOI 10.1159/000187000; WONG SHY, 1987, CLIN CHEM, V33, P214; YAGUCHI Y, 1990, NEPHRON, V54, P368, DOI 10.1159/000185904	58	23	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1581	1587		10.1096/fasebj.12.14.1581	http://dx.doi.org/10.1096/fasebj.12.14.1581			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806767				2022-12-25	WOS:000076749500017
J	McLeod, SJ; Ingham, RJ; Bos, JL; Kurosaki, T; Gold, MR				McLeod, SJ; Ingham, RJ; Bos, JL; Kurosaki, T; Gold, MR			Activation of the Rap1 GTPase by the B cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; EXCHANGE FACTOR; GENE-PRODUCT; PROTEIN; CRK; INHIBITION; COMPLEXES; KINASE; C3G	The B cell antigen receptor (BCR) activates Ras, a GTPase that promotes cell proliferation by activating the Raf-1/REK/ERK signaling module and other signaling enzymes. In its active GTP-bound form, the Rap1 GTPase may act as a negative regulator of Ras-mediated signaling by sequestering Ras effecters (e.g., Raf-1) and preventing their activation. In this report, we show that BCR engagement activates Rap1 and that this is dependent on production of diacylglycerol (DAG) by phospholipase C-gamma. Activation of Rap1 by the BCR was greatly reduced in phospholipase C-gamma-deficient B cells, whereas both a synthetic DAG and phorbol dibutyrate could activate Rap1 in B cells. We had previously shown that C3G, an activator of Rap1, associates with the Crk adaptor proteins in B cells and that BCR engagement causes Crk to bind to the Cas and Cbl docking proteins. However, the DAG-dependent pathway by which the BCR activates Rap1 apparently does not involve Crk signaling complexes since phorbol dibutyrate could activate Rap1 without inducing the formation of these complexes. Thus, the BCR activates Rap1 via a novel DAG-dependent pathway.	Univ British Columbia, Dept Immunol & Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Kansai Med Univ, Dept Mol Genet, Inst Hepat Res, Moriguchi, Osaka 570, Japan	University of British Columbia; Utrecht University; Kansai Medical University	Gold, MR (corresponding author), Univ British Columbia, Dept Immunol & Microbiol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@unixg.ubc.ca	Gold, Michael/AAF-2081-2021; Kurosaki, Tomohiro/D-1306-2009	Gold, Michael/0000-0003-1222-3191; Kurosaki, Tomohiro/0000-0002-6352-304X				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOS JL, 1989, CANCER RES, V49, P4682; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GOLD MR, 1995, INT REV CYTOL, V157, P181, DOI 10.1016/S0074-7696(08)62159-2; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAGE DM, 1988, J IMMUNOL, V140, P3717; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAXTON TM, 1994, J IMMUNOL, V153, P623; SIRINIAN MI, 1993, ONCOGENE, V8, P157; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	37	71	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29218	29223		10.1074/jbc.273.44.29218	http://dx.doi.org/10.1074/jbc.273.44.29218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786933	hybrid			2022-12-25	WOS:000076691800094
J	Bates, S; Ryan, KM; Phillips, AC; Vousden, KH				Bates, S; Ryan, KM; Phillips, AC; Vousden, KH			Cell cycle arrest and DNA endoreduplication following p21(Waf1/Cip1) expression	ONCOGENE			English	Article						p21(Waf1/Cip1); cell cycle arrest; cyclin dependent kinase; endoreduplication; senescence	DEPENDENT-KINASE INHIBITOR; P53-MEDIATED G(1) ARREST; HUMAN CANCER-CELLS; WILD-TYPE P53; S-PHASE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CDK INHIBITORS; GROWTH ARREST; IN-VIVO	p21(Waf1/Cip1) is a major transcriptional target of p53 and has been shown to be one of the principal mediators of the p53 induced G1 cell cycle arrest. We show that in addition to the G1 block, p21(Waf1/Cip1) can also contribute to a delay in G2 and expression of p21(Waf1/Cip1) gives rise to cell cycle profiles essentially indistinguishable from those obtained following p53 expression. Arrest of cells in G2 likely reflects an inability to induce cyclin B1/cdc2 kinase activity in the presence of p21(Waf1/Cip1), although the inefficient association of p21(Waf1/cip1) and cyclin B1 suggests that the mechanism of inhibition is indirect. Cells released from an S-phase block were not retarded in their ability to progress through S-phase by the presence of p21(Waf1/Cip1), despite efficient inhibition of cyclin E, A and B1 dependent kinase activity, suggesting that p2l(Waf1/Cip1) is inefficient at inhibiting replicative DNA synthesis in vivo. Interestingly, significant numbers of cells released from the p21(Waf1/Cip1) activated G2 block undergo endoreduplication, passing through another S-phase before undergoing mitosis, This supports a function of the mitotic kinases in both entry into mitosis, and also in preventing re-replication of DNA following S-phase and suggests a role for p21(Waf1/Cip1) in coupling DNA synthesis and mitosis, Unlike p53, which induces apoptosis in these cells, extended expression of p21(Waf1/Cip1) resulted in the expression of a senescent-like phenotype in these p53 null, pRB null tumor cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.			Ryan, Kevin M./0000-0002-1059-9681				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BOND JA, 1995, CANCER RES, V55, P2404; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Stern B, 1996, TRENDS GENET, V12, P345; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	62	145	149	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1691	1703		10.1038/sj.onc.1202104	http://dx.doi.org/10.1038/sj.onc.1202104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796698				2022-12-25	WOS:000076200100007
J	Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF				Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF			Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2	ONCOGENE			English	Article						medulloblastoma; stem cells; FGF; proliferation; differentiation; signal transduction	CENTRAL-NERVOUS-SYSTEM; FIBROBLAST GROWTH-FACTOR; STEM-CELLS; HUMAN MEDULLOBLASTOMA; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; FACTOR RECEPTORS; CEREBRAL-CORTEX; HUMAN HOMOLOG; BRAIN-TUMORS	Primitive neuroectodermal tumours (PNET) are thought to derive from the malignant transformation of pluripotent CNS precursors although this hypothesis has yet to be tested in vitro. Here we show that cells of a human PNET cell line 'Dev' express functional fibroblast growth factor (FGF) receptors (FGFR) and respond to FGF2 as multipotent CNS precursors. FGF2 induces tyrosine phosphorylation of FGFR-1 and FGFR-2 and many cellular substrates including MAP kinases and stimulates proliferation. Cells detach from plastic substrates and proliferate to form large clusters of undifferentiated cells. After adhesion to polylysine, cells migrate out from the clusters and differentiate. The majority of differentiated cells express neuronal phenotypes but distinct subpopulations express oligodendrocytic and astrocytic markers. Mature neural differentiation markers are not otherwise detected in Del cells in defined medium. Identical results were obtained with 12 monoclonal subclones as well as the parent cell line, confirming that Dev cells are multipotent, This extends evidence that multipotent CNS precursors are the cellular substrate from which certain PNET develop and shows that FGF2 is a potent proliferation and differentiation inducer for PNET cells in vitro, suggesting that FGF2 may also modulate the evolution of PNET in vivo. Finally our results suggest that PNET cell lines may provide models to elucidate the biology of human multipotent CNS precursors.	Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, F-69003 Lyon, France; Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, UMR 49, F-69364 Lyon 07, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON)	Derrington, EA (corresponding author), Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, Bvd Pinel, F-69003 Lyon, France.		Derrington, Ed/G-9478-2017	RUDKIN, Brian B./0000-0003-3700-1982				BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Billon N, 1996, ONCOGENE, V13, P2047; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; Dubois PM, 1996, J IMMUNOL, V156, P1356; DUFAY N, 1994, EUR J NEUROSCI, V6, P1633, DOI 10.1111/j.1460-9568.1994.tb00554.x; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P1; GIRAUDON P, 1993, NEUROSCIENCE, V52, P1069, DOI 10.1016/0306-4522(93)90553-R; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Gritti A, 1996, J NEUROSCI, V16, P1091; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KILPATRICK TJ, 1995, J NEUROSCI, V15, P3653; Kleihues P, 1993, HISTOLOGICAL TYPING; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MCKAY R, 1993, CR ACAD SCI III-VIE, V316, P1452; MIYAKE A, 1995, MOL BRAIN RES, V31, P95, DOI 10.1016/0169-328X(95)00039-U; PACKER RJ, 1984, J NEUROSURG, V61, P296, DOI 10.3171/jns.1984.61.2.0296; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PIETSCH T, 1994, CANCER RES, V54, P3278; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; REID CB, 1995, NEURON, V15, P299, DOI 10.1016/0896-6273(95)90035-7; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; SHAOUL E, 1995, ONCOGENE, V10, P1553; Smits A, 1996, LAB INVEST, V74, P188; Stemple DL, 1997, NEURON, V18, P1, DOI 10.1016/S0896-6273(01)80018-0; TOHYAMA T, 1992, LAB INVEST, V66, P303; TROJANOWSKI JQ, 1994, MOL CHEM NEUROPATHOL, V21, P219, DOI 10.1007/BF02815352; VALTZ NLM, 1991, NEW BIOL, V3, P364; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1	40	14	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1663	1672		10.1038/sj.onc.1202025	http://dx.doi.org/10.1038/sj.onc.1202025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796695				2022-12-25	WOS:000076200100004
J	Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S				Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S			Transcriptional regulation of osteopontin gene in vivo by PEBP2 alpha A/CBFA1 and ETS1 in the skeletal tissues	ONCOGENE			English	Article						osteopontin; PEBP2 alpha A/CBFA1; ETS1; synergistic transactivation; osteogenesis	LEUKEMIA-VIRUS ENHANCERS; CORE-BINDING-FACTOR; GM-CSF PROMOTER; RUNT DOMAIN; MESSENGER-RNA; RESPONSE ELEMENT; RECEPTOR-DELTA; BONE-FORMATION; NUCLEAR FACTOR; IN-VIVO	Osteopontin (Opn) and polyoma enhancer-binding protein (PEBP) 2 alpha A/core binding factor (CBFA) 1 have been suggested to play important roles in ossification, The overlapping localization of opn and PEBP2 alpha A/CBFA1 mRNA, and the marked decrease of opn mRNA expression in PEBP2 alpha A knockout mice, indicated that the transcription of opn gene was controlled by PEBP2 alpha A. In the present study, we determined the direct regulation of PEBP2 alpha A on the opn promoter activity, Opn promoter activity was markedly enhanced by PEBP2 alpha A and ETS1 in a synergistic manner, The synergistic effect was diminished when either the PEBP2 alpha A or ETS1 binding site was mutated, or the spatial arrangement of these sites was mutated by a 4-nt insertion. The distance between these sites was important for transactivation but not protein-DNA binding. The direct interaction between PEBP2 alpha A and ETS1 was depended on protein-DNA binding. These results suggested that the specific spatial arrangement of both sites and direct interaction between PEBP2 alpha A and ETS1, were essential for promoter function. Furthermore, endogenous opn mRNA was decreased with the introduction of dominant negative PEBP2 alpha A to MC3T3/E1 cells expressing endogenous PEBP2 alpha A, ETS1 and opn, These findings suggest that PEBP2 alpha A and ETS1 cooperate iii vivo to regulate expression of the opn gene in the skeletal tissue, Cell type-specific regulation of Opn gene expression will also be discussed.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Orthopaed Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 5650871, Japan; Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 4678601, Japan; Kyoto Univ, Sch Med, Inst Virus Res, Dept Viral Oncol, Kyoto 6068397, Japan	Osaka University; Osaka University; Osaka University; Nagoya City University; Kyoto University	Nomura, S (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan.		YASUI, Takahiro/E-6401-2018	YASUI, Takahiro/0000-0003-2197-2477				AUBIN JE, 1996, J BONE MINER RES, V11, pS102; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BROWN LF, 1994, AM J PATHOL, V145, P610; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, AM J PATHOL, V143, P1003; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KOHRI K, 1993, J BIOL CHEM, V268, P15180; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oates AJ, 1996, ONCOGENE, V13, P97; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PAGANO M, 1992, ONCOGENE, V7, P1681; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SATO M, IN PRESS J BONE MINE; SINGH RP, 1991, J EXP MED, V171, P1931; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKEMURA T, 1994, HEARING RES, V79, P99, DOI 10.1016/0378-5955(94)90131-7; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YAMADA T, 1995, EUR J IMMUNOL, V25, P2710, DOI 10.1002/eji.1830250947; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	57	183	185	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1517	1525		10.1038/sj.onc.1202064	http://dx.doi.org/10.1038/sj.onc.1202064			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794229				2022-12-25	WOS:000076089900004
J	Krukonis, ES; Dersch, P; Eble, JA; Isberg, RR				Krukonis, ES; Dersch, P; Eble, JA; Isberg, RR			Differential effects of integrin alpha chain mutations on invasin and natural ligand interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; PLATELET INTEGRIN; BINDING-SITE; GPIIB-IIIA; G-PROTEIN; RECEPTOR; SUBUNIT; DOMAIN; IDENTIFICATION; FIBRONECTIN	To determine if recognition of the Yersinia pseudotuberculosis invasin protein and natural substrates requires identical integrin residues, a region of the human alpha(3) integrin chain predicted to be involved in substrate adhesion was targeted for mutation. One point mutation located in a region of the third N-terminal repeat of the alpha(3) chain, alpha(3)-W220A, failed to promote adhesion to the natural alpha(3)beta(1) substrate epiligrin but maintained near wild type levels of adhesion to invasin, A second nearby mutation, alpha(3)-Y218A, which showed no detectable adhesion to epiligrin, was only partially attenuated for invasin binding as well as invasin-mediated bacterial uptake. A third substitution, alpha(3)-D154A, predicted to be in the second N-terminal repeat not known to be implicated in cell adhesion, was competent for invasin-promoted adhesion events and appeared to encode a receptor of increased activity, as it had a higher efficiency than wild type receptor for adhesion to epiligrin, Cell lines expressing this derivative were not recognized by a function blocking anti-alpha(3) antibody, indicating that the second and third repeats of the alpha(3) chain are either closely linked in space or the second repeat can modulate activity of the third. Differential effects on substrate adhesion do not appear to be associated with all integrin alpha chain mutations, as alpha(4) chain mutations affecting the divalent cation binding domains depressed adhesion to invasin to a significant extent.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Howard Hughes Med Inst, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Tufts University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, 136 Harrison Ave M&V 409, Boston, MA 02111 USA.	risberg@opal.tufts.edu		Dersch, Petra/0000-0001-8177-3280	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007422, R01AI023538] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI23538, T32-AI07422] Funding Source: Medline; NIDDK NIH HHS [1 P30DK39428] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DRANSFIELD I, 1990, IMMUNOL REV, V114, P29, DOI 10.1111/j.1600-065X.1990.tb00560.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; Saltman LH, 1996, J BIOL CHEM, V271, P23438, DOI 10.1074/jbc.271.38.23438; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31837	31843		10.1074/jbc.273.48.31837	http://dx.doi.org/10.1074/jbc.273.48.31837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822651	hybrid			2022-12-25	WOS:000077207000033
J	Ertesvag, H; Hoidal, HK; Skjak-Braek, G; Valla, S				Ertesvag, H; Hoidal, HK; Skjak-Braek, G; Valla, S			The Azotobacter vinelandii mannuronan C-5-epimerase AlgE1 consists of two separate catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; EXPRESSION; SEQUENCE; VECTORS; CLONING; GENE	The Azotobacter vinelandii enzyme AlgE1 is a member of a family of secreted mannuronan C-5-epimerases. These enzymes convert beta-n-mannuronic acid residues (M) to alpha-L-guluronic acid residues (G) at the polymer level in the industrially important polysaccharide alginate, leading to altered physical and immunological properties of the polymer. The reaction product of AIgE1 was found to be a mixture of blocks of continuous G residues (G-blocks) and blocks containing alternating M and G residues (MG-blocks), The enzyme is dependent on Ca2+ for activity, and only Sr2+ of those tested was able to replace Ca2+. Zn2+ blocked the activity even at low concentrations. algE1 has been divided into two parts based on the modular type of structure previously reported to be a characteristic of the secreted epimerases, and each part has been expressed in Escherichia coli, These experiments showed that AlgE1 contains two catalytic domains, AlgE1-1, which introduces both G-blocks and MG-blocks, and AlgE1-2, which only introduces MG-blocks, AlgE1-1 has a much lower specific activity than both AlgE1-2 and AlgE1, However, the two halves of AlgE1 seem to cooperate in such a way that they contribute approximately equally to the overall epimerization reaction.	Norwegian Univ Sci & Technol, UNIGEN Ctr Mol Biol, N-7005 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Biotechnol, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Ertesvag, H (corresponding author), Norwegian Univ Sci & Technol, UNIGEN Ctr Mol Biol, N-7005 Trondheim, Norway.			Ertesvag, helga/0000-0001-9437-9469				AMANN L, 1988, GENE AMST, V69, P301; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COTE GL, 1988, CARBOHYD RES, V181, P143, DOI 10.1016/0008-6215(88)84030-8; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GORIN PAJ, 1966, CAN J CHEMISTRY, V44, P993, DOI 10.1139/v66-147; GOVAN JRW, 1981, J GEN MICROBIOL, V125, P217; GRASDALEN H, 1979, CARBOHYD RES, V68, P23, DOI 10.1016/S0008-6215(00)84051-3; HAUG A, 1971, CARBOHYD RES, V17, P297, DOI 10.1016/S0008-6215(00)82537-9; LINKER A, 1964, NATURE, V204, P187, DOI 10.1038/204187a0; MURAYAMA K, 1984, J BIOCH, V95, P511; Onsoyen E, 1996, CARBOHYDR EUR, V46, P26; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; SADOFF HL, 1975, BACTERIOL REV, V39, P516, DOI 10.1128/MMBR.39.4.516-539.1975; Sambrook J., 2002, MOL CLONING LAB MANU; Skjak-Braek G, 1991, SEAWEED RESOURCES EU, P219; Skjak-Braek G, 1996, CARBOHYDR EUR, V14, P19; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Smidsrod O., 1996, CARBOHYDR EUR, V14, P6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	37	38	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30927	30932		10.1074/jbc.273.47.30927	http://dx.doi.org/10.1074/jbc.273.47.30927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812987	hybrid			2022-12-25	WOS:000077136900015
J	Heinrichs, DE; Yethon, JA; Amor, PA; Whitfield, C				Heinrichs, DE; Yethon, JA; Amor, PA; Whitfield, C			The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli - The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTAN-I; GENE-CLUSTER; SALMONELLA-TYPHIMURIUM; MONOCLONAL-ANTIBODIES; GLYCOSYL TRANSFERASES; POLYACRYLAMIDE GELS; RHIZOBIUM-MELILOTI; MOLECULAR ANALYSIS; BIOSYNTHESIS; REGION	The major core oligosaccharide biosynthesis operons from prototype Escherichia coli strains displaying R1 and R4 lipopolysaccharide core types were polymerase chain reaction-amplified and analyzed. Comparison of deduced products of the open reading frames between the two regions indicate that all but two share total similarities of 94% or greater. Core oligosaccharide structures resulting from nonpolar insertion mutations in each gene of the core OS biosynthesis operon in the R1 strain allowed assignment of all of the glycosyltransferase enzymes required for outer core assembly. The difference between the R1 and R4 core oligosaccharides results from the specificity of the WaaV protein (a beta 1,3-glucosyltransferase) in R1 and WaaX (a beta 1,4-galactosyltransferase) in R4. Complementation of the waaV mutant of the R1 prototype strain with the waaX gene of the R4 strain converted the core oligosaccharide from an R1- to an R4-type lipopolysaccharide core molecule. Aside from generating core oligosaccharide specificity, the unique beta-linked glucopyranosyl residue of the R1 core plays a crucial role in organization of the lipopolysaccharide. This residue provides a novel attachment site for lipid A-core-linked polysaccharides and distinguishes the R1-type LPS from existing models for enterobacterial lipopolysaccharides.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Guelph	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Heinrichs, David/ABD-5702-2021	Heinrichs, David/0000-0002-7217-2456				Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; APPELMELK BJ, 1994, MICROBIOL-UK, V140, P1119, DOI 10.1099/13500872-140-5-1119; Brade L, 1996, J ENDOTOXIN RES, V3, P39, DOI 10.1177/096805199600300105; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; FEIGE U, 1977, BIOCHEM BIOPH RES CO, V79, P88, DOI 10.1016/0006-291X(77)90064-X; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GIBB AP, 1992, J INFECT DIS, V166, P1051, DOI 10.1093/infdis/166.5.1051; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLST O, 1992, BACTERIAL ENDOTOXIC, V1, P134; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; KLENA JD, 1992, J BACTERIOL, V174, P7297, DOI 10.1128/jb.174.22.7297-7307.1992; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MULLER E, 1972, J BIOL CHEM, V247, P2614; NIKAIDO H, 1969, J BIOL CHEM, V244, P2835; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PRADEL E, 1992, J BACTERIOL, V174, P4736, DOI 10.1128/JB.174.14.4736-4745.1992; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAINA S, 1991, NUCLEIC ACIDS RES, V19, P3811, DOI 10.1093/nar/19.14.3811; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SAWARDEKER JH, 1967, ANAL CHEM, V39, P1602; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHMIDT G, 1969, EUR J BIOCHEM, V10, P501, DOI 10.1111/j.1432-1033.1969.tb00717.x; SCHMIDT P, 1974, ECONOMETRICA, V42, P303, DOI 10.2307/1911980; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; vanKranenburg R, 1997, MOL MICROBIOL, V24, P387, DOI 10.1046/j.1365-2958.1997.3521720.x; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310	47	78	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29497	29505		10.1074/jbc.273.45.29497	http://dx.doi.org/10.1074/jbc.273.45.29497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792656	hybrid			2022-12-25	WOS:000076798300033
J	Johansson, E; Hjortsberg, K; Thelander, L				Johansson, E; Hjortsberg, K; Thelander, L			Two YY-1-binding proximal elements regulate the promoter strength of the TATA-less mouse ribonucleotide reductase R1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; PHASE-SPECIFIC EXPRESSION; C-MYC; TRANSCRIPTIONAL INITIATOR; BINDING PROTEIN; DNA-DAMAGE; YY1; ASSOCIATION; SUBUNIT; ENHANCER	Ribonucleotide reductase is essential for DNA synthesis. In mammalian cells, the enzyme consists of two nonidentical subunits, proteins R1 and R2. The expression of the mouse R1 and R2 genes is strictly correlated to S phase. Using promoter-reporter gene constructs, we have defined a region of the TATA-less mouse ribonucleotide reductase R1 gene promoter that correlates reporter gene expression to S phase. This is demonstrated in stably transformed cells both synchronized by serum starvation and separated by centrifugal elutriation, suggesting that the R1 gene expression during the cell cycle is mainly regulated at the transcriptional level. The region contains four protein-binding DNA elements, beta (nucleotides -189 to -167), alpha (-98 to -76), Inr (-4 to +16), and gamma (+34 to +61), together regulating promoter activity. The nearly identical upstream elements, alpha and beta, each form three DNA-protein complexes in gel shift assays. We have identified YY1 as a component in at least one of the complexes using supershift antibodies and a yeast one-hybrid screening of a mouse cDNA library using the alpha element as a target. Transient transfection assays demonstrate that the alpha and beta elements are mainly important for the R1 promoter strength and suggest that YY1 functions as an activator.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Thelander, L (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.			Johansson, Erik/0000-0002-8526-6224				BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KINGSTON RE, 1990, CURRENT PROTOCOLS S, V14; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MANN GJ, 1988, CANCER RES, V48, P5151; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANGINKEL PR, 1997, J BIOL CHEM, V272, P16754; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	29	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29816	29821		10.1074/jbc.273.45.29816	http://dx.doi.org/10.1074/jbc.273.45.29816			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792697	hybrid			2022-12-25	WOS:000076798300074
J	Piotrowski, M; Morsomme, P; Boutry, M; Oecking, C				Piotrowski, M; Morsomme, P; Boutry, M; Oecking, C			Complementation of the Saccharomyces cerevisiae plasma membrane H+-ATPase by a plant H+-ATPase generates a highly abundant fusicoccin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMELINA-COMMUNIS; YEAST; PROTEINS; RECEPTORS; VESICLES; GROWTH; GENE; BMH1	Accumulating evidence suggests that the H+-ATPase of the plant plasma membrane is activated by a direct, reversible interaction with 14-3-3 proteins involving the displacement of the C-terminal autoinhibitory domain of the enzyme, The fungal phytotoxin fusicoccin (FC) appears to stabilize this H+-ATPase 14-3-3 complex, thus leading to a persistent activation of the H+-ATPase in vivo. In this study we show that functional replacement of the Saccharomyces cerevisiae H+-ATPase genes by a Nicotiana plumbaginifolia H+-ATPase (pma2) results in the generation of a high affinity fusicoccin binding site that is exceptionally abundant. Acquisition of FC binding capacity is accompanied by a significant increase in the amount of plasma membrane-associated yeast 14-3-3 homologs, The existence of a (plant) PMA2. (yeast)14-3-3 complex was demonstrated using two-dimensional gel systems (native/denaturing). After expression of PMA2 lacking most of its C-terminal region, neither H+-ATPase 14-3-3 complex formation nor FC binding activity could be observed. Furthermore, we obtained direct biochemical evidence for a minimal FC binding complex consisting of the C-terminal PMA2 domain and yeast 14-3-3 homologs, Thus we demonstrated unambiguously the relevance of this regulatory ATPase domain for 14-3-3 interaction as well as its requirement for FC binding.	Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44780 Bochum, Germany; Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Ruhr University Bochum; Universite Catholique Louvain	Oecking, C (corresponding author), Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44780 Bochum, Germany.	Claudia.Oecking@ruhr-uni-bochum.de	Piotrowski, Markus/F-5419-2010; Morsomme, Pierre/AAD-9600-2019	Piotrowski, Markus/0000-0002-6347-3337; Morsomme, Pierre/0000-0001-7780-7230; Boutry, Marc/0000-0002-2315-6900				ADUCCI P, 1995, J EXP BOT, V46, P1463, DOI 10.1093/jxb/46.10.1463; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; FEYERABEND M, 1988, PLANTA, V174, P115, DOI 10.1007/BF00394883; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GRAF P, 1989, PHYSIOL PLANTARUM, V75, P469, DOI 10.1111/j.1399-3054.1989.tb05611.x; HODGES TK, 1974, METHOD ENZYMOL, V32, P292; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; KORTHOUT HAAJ, 1994, PLANT CELL, V6, P1681, DOI 10.1105/tpc.6.11.1681; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFERMEIJER FC, 1994, PLANT PHYSIOL, V104, P1277, DOI 10.1104/pp.104.4.1277; MARRA M, 1994, PLANT PHYSIOL, V106, P1497, DOI 10.1104/pp.106.4.1497; MEYER C, 1993, Z NATURFORSCH C, V48, P595; MEYER C, 1989, PLANT PHYSIOL, V89, P692, DOI 10.1104/pp.89.2.692; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; OECKING C, 1994, FEBS LETT, V352, P163, DOI 10.1016/0014-5793(94)00949-X; OECKING C, 1991, EUR J BIOCHEM, V199, P685, DOI 10.1111/j.1432-1033.1991.tb16171.x; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olivari C, 1998, PLANT PHYSIOL, V116, P529, DOI 10.1104/pp.116.2.529; PALMGREN MG, 1991, PHYSIOL PLANTARUM, V83, P314, DOI 10.1111/j.1399-3054.1991.tb02159.x; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PALMGREN MG, 1990, J BIOL CHEM, V265, P13423; PARETSSOLER A, 1990, PLANT PHYSIOL, V93, P1654, DOI 10.1104/pp.93.4.1654; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SERRANO R, 1993, EUR J BIOCHEM, V212, P737, DOI 10.1111/j.1432-1033.1993.tb17712.x; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341	36	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30018	30023		10.1074/jbc.273.45.30018	http://dx.doi.org/10.1074/jbc.273.45.30018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792723	hybrid			2022-12-25	WOS:000076798300100
J	Boizard, M; Le Liepvre, X; Lemarchand, P; Foufelle, F; Ferre, P; Dugail, I				Boizard, M; Le Liepvre, X; Lemarchand, P; Foufelle, F; Ferre, P; Dugail, I			Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; ADIPOCYTE DIFFERENTIATION; STIMULATES TRANSCRIPTION; CHOLESTEROL-METABOLISM; TRANSGENIC MICE; CULTURED-CELLS; HAMSTER LIVER; ZUCKER RATS; PROMOTER	Elevated lipogenesis is a key determinant of exaggerated fat deposition in adipose tissue of obese Zucker rats. We previously delineated a region in the fatty-acid synthase promoter, which was responsible for obesity-related overexpression of the fatty-acid synthase (FAS) gene, by negatively regulating the activity of the downstream promoter in lean but not obese rat fat cells, The present study aimed to identify the transcriptional factors acting on this target region. First, functional analysis of mutated FAS promoter constructs in transiently transfected lean and obese rat adipocytes showed that the activity of the obesity-related region relied on the presence of a transcriptionally inactive sterol regulatory element at -150, which counteracted activation through the downstream F-box, Adenovirus-mediated overexpression of a dominant negative form of adipocyte determination and differentiation factor 1 (ADD1) was used to neutralize endogenous ADD1/sterol regulatory element-binding protein (SREBP) transcriptional activity in fat cells, by producing inactive dimers unable to bind target DNA, With this system, we observed that overexpression of FAS in obese rat adipocytes was ADD1/SREBP-dependent. SREBP isoforms expression was assessed in lean and obese rat fat cells and showed no differences in the level of ADD1/SREBP1 mRNA, In addition, equivalent amounts of immunoreactive ADD1/SREBP1 were found in nuclear extracts from lean and obese rat fat cells. In contrast, immunoreactive SREBP2, which was very low in nuclear extracts from lean rats, was induced in obese rat fat cells, Finally, using in vitro binding studies, we showed that SREBP2 was able to displace ADD1/SREBP1 binding from the sterol regulatory element (SRE) site. Thus, we propose a mechanism for obesity-related overexpression of FAS gene in rat adipocyte, ADD1/SREBP1-activated transcription proceeding from the E-box motif is counterbalanced by a negative SRE site acting by limiting the availability of ADD1/SREBP1 in normal fat cells. The negative effect of this site is abolished in obese rat adipocyte nuclei where SREBP2 is induced and can substitute for ADD1/SREBP1 binding to the inactive SRE, These results provide evidence for the implication of SREBPs in the dysregulation of adipocyte metabolism characteristic of the obese state.	Inst Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Hop Necker Enfants Malad, INSERM, Fac Med, U25, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dugail, I (corresponding author), Inst Biomed Cordeliers, INSERM, U465, 15 Rue Ecole Med, F-75006 Paris, France.	idugail@infobiogen.fr	lemarchand, patricia/C-3247-2011; Dugail, Isabelle/L-1567-2017; Ferré, Pascal/K-1250-2013	lemarchand, patricia/0000-0002-5330-2008; Dugail, Isabelle/0000-0003-3631-2252; Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BAZIN R, 1982, J LIPID RES, V23, P839; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY G, 1998, PHYSIOL REV, V59, P719; BRIQUETLAUGIER V, 1994, AM J PHYSIOL, V267, pF439; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Emtage PCR, 1998, J IMMUNOL, V160, P2531; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GUERREMILLO M, 1994, LIPIDS, V29, P205, DOI 10.1007/BF02536730; GUICHARD C, 1992, J LIPID RES, V33, P679; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KRAUSE BR, 1984, J LIPID RES, V25, P97; Lafont A, 1997, HUM GENE THER, V8, P1033, DOI 10.1089/hum.1997.8.9-1033; LAVAU M, 1977, P SOC EXP BIOL MED, V156, P251, DOI 10.3181/00379727-156-39916; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; OUALIKENE W, 1995, J VIROL, V69, P6518, DOI 10.1128/JVI.69.10.6518-6524.1995; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WEISS GH, 1980, J BIOL CHEM, V255, P4751; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	42	106	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29164	29171		10.1074/jbc.273.44.29164	http://dx.doi.org/10.1074/jbc.273.44.29164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786926	hybrid			2022-12-25	WOS:000076691800087
J	Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS				Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS			Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity	ONCOGENE			English	Article						Bcl-2; apoptosis; GL331; poly(ADP-ribose)polymerase	NICOTINAMIDE ADENINE-DINUCLEOTIDE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; CHINESE-HAMSTER CELLS; LEUKEMIA HL-60 CELLS; MITOCHONDRIAL PERMEABILITY; DNA FRAGMENTATION; ADP-RIBOSYLATION; POLYMERASE; ACTIVATION	Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme responsible for DNA strand breaks, has been recently suggested to be crucial for apoptosis induced by a number chemotherapeutic drugs, In this study, we demonstrated that the PARP activity could be evidently elevated with a peak at 6 h when HL-60 cells were treated with a new anticancer drug GL331, Coincident with the peak of PARP activity, an apparent DNA fragmentation and apoptotic morphology were observed in cells treated with GL331. The subsequent apoptotic DNA fragmentation induced by GL331 could be completely blocked by transfecting cells with anti-sense PARP retroviral vector or by treating cells with PARP inhibitor, 3-aminobenzamide (3-AB). This blocking effect thus suggests that activation of PARP was critically involved in GL331-induced apoptosis, The fact that Bcl-2 has been found to antagonize cell death induced by a wide variety of agents, accounts for why we examined whether if Bcl-2 could antagonize GL331 effects, Interestingly, ectopic overexpression of Bcl-2 in either HL-60 or U937 cells caused in resistance towards GL331-elicited DNA fragmentation and cytotoxic effect. Additionally, Bcl-2 also attenuated the poly(ADP-ribosyl)ation of PARP itself as well as Histone H1 at the early period of drug treatment. However, Bcl-2 did not influence the extent of DNA strand breaks induced by GL331 in either control or Bcl-2-overexpressing cells. In addition, analysis of basal PARP activity in control and several Bcl-2 overexpressing clones revealed that Bcl-2 down-regulated PARP activity under the condition without DNA damages, Above findings suggest that poly(ADP-ribosyl)ation of nuclear targets is important for apoptosis induced by DNA-reactive anticancer drugs.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Dept Oncol, Taipei, Taiwan; Natl Hlth Res Inst, Canc Res Div, Cooperat Lab, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan.		Chuang, Shuang-En/D-2080-2010; Huang, Tze-Sing/E-3667-2010; Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/C-9361-2013	Huang, Tze-Sing/0000-0001-8736-4330; KUO, MIN-LIANG/0000-0002-7139-0144; Yang, James Chih-Hsin/0000-0002-5586-5138; Cheng, Ann-Lii/0000-0002-9152-6512				ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; CHU G, 1994, J BIOL CHEM, V269, P787; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Eymin B, 1997, CANCER RES, V57, P686; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; FAIRBAIRN LJ, 1994, MOL CARCINOGEN, V11, P49, DOI 10.1002/mc.2940110109; FERRO AM, 1984, J BIOL CHEM, V259, P547; FRITZ G, 1994, MUTAT RES, V308, P127, DOI 10.1016/0027-5107(94)90147-3; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HAHN GM, 1973, RADIAT RES, V55, P280, DOI 10.2307/3573683; Huang TS, 1996, CANCER LETT, V110, P77, DOI 10.1016/S0304-3835(96)04464-3; HUANG TS, 1997, CANCER RES, V57, P2914; Hyde H, 1997, BLOOD, V89, P2453, DOI 10.1182/blood.V89.7.2453; Ibrado AM, 1996, CANCER RES, V56, P4743; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Marchetti P, 1996, J IMMUNOL, V157, P4830; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; MEISTERERNST M, 1997, P NATL ACAD SCI USA, V75, P12; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIYASHITA T, 1993, BLOOD, V81, P151; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Sokolove PM, 1996, J BIOENERG BIOMEMBR, V28, P199, DOI 10.1007/BF02110651; SOLVEIG WSA, 1984, CARCINGOENESIS, V5, P319; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takahashi T, 1996, J BIOCHEM-TOKYO, V119, P256; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VAN GL, 1997, EUR J BIOCHEM, V244, P15; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1990, J MED CHEM, V33, P2660, DOI 10.1021/jm00171a050; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZEREZ CR, 1987, BLOOD, V69, P999	61	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2225	2234		10.1038/sj.onc.1202133	http://dx.doi.org/10.1038/sj.onc.1202133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811453				2022-12-25	WOS:000076698200008
J	Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA				Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA			Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor	ONCOGENE			English	Article						Drosophila; AP-2 transcription factor; development regulation; functional conservation	MOUSE EMBRYOGENESIS; REGULATORY ELEMENTS; MAMMARY-CARCINOMA; RETINOIC ACID; GENE; CELLS; EXPRESSION; ACTIVATION; PROMOTER; BINDING	The AP-2 family of transcription factors (AP-2 alpha, AP-2 beta and AP-2 gamma) is temporally and spatially regulated in mammals and has also been implicated in oncogenesis. Here we report the isolation of genomic and cDNA clones encoding the Drosophila homologue of AP-2, designated DAP-2. The predicted amino acid sequence exhibits 42-45% overall identity with the vertebrate AP-2 proteins, A sequence of 107 amino acids within the DNA binding and dimerization domain of the vertebrate AP-2 proteins is highly conserved (90-92%) with the DAP-2 homologue. An in vitro translation product of DAP-2 cDNA binds specifically to AP-2 consensus binding sites. DAP-2 was also shown to be functionally conserved in vivo because transient transfection of a DAP-2 expression plasmid activated transcription through AP-2 binding sites in both mammalian and Drosophila cell lines. DAP-2 is expressed during early embryogenesis and DAP-2 transcripts are also detected in the adult. Whole-mount in situ hybridizations demonstrated that DAP-2 is expressed initially at stage 9 of Drosophila embryonic development and that DAP-2 transcripts are detected in regions of the brain, eye-antennal disc, optical lobe, antenno-maxillary complex, and in a subset of cells of the ventral nerve cord. The cloning of DAP-2 and the identification of the DAP-2 expression pattern during embryogenesis provides a starting point to address the function of AP-2 during differentiation and development in a well understood model system.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tainsky, MA (corresponding author), Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA.			Tainsky, Michael/0000-0002-0261-831X; Mattox, William/0000-0001-8084-9677	NCI NIH HHS [R01-CA53475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; Bisgrove DA, 1997, MOL CELL BIOL, V17, P5935, DOI 10.1128/MCB.17.10.5935; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAYETTE B, 1994, NEURON, V12, P977; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CHUNG YT, 1990, MOL CELL BIOL, V10, P6172, DOI 10.1128/MCB.10.12.6172; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hall B. K., 1988, NEURAL CREST; HOLLAND P, 1994, J MAR BIOL ASSOC UK, V75, P49; JAN YN, 1994, CURR OPIN NEUROBIOL, V4, P13; KANNAN P, 1994, GENE DEV, V12, P1258; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; LEWIS RA, 1980, GENETICS, V95, P383; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Maniatis T., 1989, MOL CLONING LAB MANU; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOUNT SM, 1993, ATLAS DROSOPHILA GEN, P333; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SKINNER A, 1993, ONCOGENE, V8, P3393; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YounossiHartenstein A, 1996, J COMP NEUROL, V370, P313, DOI 10.1002/(SICI)1096-9861(19960701)370:3<313::AID-CNE3>3.0.CO;2-7	41	24	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1911	1922		10.1038/sj.onc.1202114	http://dx.doi.org/10.1038/sj.onc.1202114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788434				2022-12-25	WOS:000076423500004
J	Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H				Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H			Induction of cell transformation by mutated 16K vacuolar H+-ATPase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells	ONCOGENE			English	Article						gap junction; connexins; 16 K protein; ductin; cell transformation	GROWTH-CONTROL; E5 ONCOPROTEIN; POTENTIAL ROLE; PROTON PUMP; HELA-CELLS; SRC GENE; PROTEIN; CHANNEL; COMPONENT; CARCINOGENESIS	The 16 K subunit of the vacuolar H+-ATPase (ductin) has been suggested to also play a role in gap junction channels. Since mutated 16 K subunits have transforming ability when transfected into NIH3T3 cells and since aberrant gap junctional intercellular communication (GJIC) is a hallmark of cancer cells, we hypothesized that mutated 16 K subunits might transform these cells via alteration of GJIC, When GJIC was measured by the dye-transfer assay, NIH3T3 cells transfected with the mutant 16 K protein genes (deletion of the fourth transmembrane domain or a point mutation at codon 143 from glutamic acid to arginine) showed significantly lower levels of GJIC than those transfected with the vector alone or with the wild-type 16 K subunit gene. GJIC levels of NIH3T3 cells transformed by v-ras and v-src were not significantly decreased, suggesting that low GJIC levels are not necessarily the result of cell transformation pel se. NIH3T3 cells express Cx 43 as a major connexin gene. Although cells transfected with mutated 16 K subunits showed a level of Cx 43 protein expression similar to non-transfectants, their Cx43 protein was localized aberrantly, i.e. intracytoplasmically, These results indicate that mutant 16 K subunits with transforming ability translocate Cx43 proteins, thus inhibiting GJIC of NIH3T3 cells.	Int Agcy Res Canc, Unit Multistage Carcinogenesis, F-69372 Lyon 08, France; Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA; Hiroshima Univ, Sch Med, Inst Hlth Sci, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Anat, Minami Ku, Hiroshima 734, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Georgetown University; Hiroshima University; Hiroshima University	Yamasaki, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, S1,W16, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [R01/CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; FINBOW ME, 1983, EMBO J, V2, P1479, DOI 10.1002/j.1460-2075.1983.tb01611.x; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; KRUTOVSKIKH VA, 1995, LAB INVEST, V72, P571; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MESNIL M, 1995, CANCER RES, V55, P629; MESNIL M, 1994, CELL ADHES COMMUN, V2, P377, DOI 10.3109/15419069409004449; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; NELSON N, 1992, J EXP BIOL, V172, P19; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TROSKO JE, 1983, J AM COLL TOXICOL, V2, P5, DOI 10.3109/10915818309140689; XU HX, 1994, J BIOL CHEM, V269, P22875; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	49	44	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1673	1680		10.1038/sj.onc.1202092	http://dx.doi.org/10.1038/sj.onc.1202092			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796696				2022-12-25	WOS:000076200100005
J	Boudreault, A; Gauthier, D; Lazure, C				Boudreault, A; Gauthier, D; Lazure, C			Proprotein convertase PC1/3-related peptides are potent slow tight-binding inhibitors of murine PC1/3 and Hfurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-ACTIVITY; PRO-SEQUENCE; CATHEPSIN-B; PROPEPTIDE; SUBTILISIN; FURIN; CLEAVAGE; 7B2; PROTEASES; CELLS	The proprotein convertase PC1/3 belongs to the subtilisin/kexin-like endoprotease family and is synthesized as a preproenzyme. To investigate the function of its propeptide, murine proPC1/3 and preproPC1/3 were isolated from the inclusion bodies of recombinant preproPC1/3 baculovirus-infected insect cells, rendered soluble with 6 M guanidine HCl and 20 mM dithiothreitol, and purified by gel filtration and metal-binding affinity chromatography. Two NH2-terminal fragments containing the complete propeptide 1-84 region were obtained after CNBr cleavage, purified, and chemically characterized, Progress curve kinetic analysis with enzymatically active murine 71-kDa PC1/3 or 50-kDa human furin demonstrated that both fragments were potent slow tight-binding inhibitors of either enzyme with K-i in the low nanomolar range. Additional cleavages at Trp residues yielded fragment(9-71), which no longer represents a potent inhibitor, Upon incubation at pH 5.5 in the presence of excess 71-kDa murine PC1/3, NH2-terminal fragment(1-98) is cleaved at two sites, as revealed through Western blotting using NH2-terminal-directed PC1/3 antibodies. Finally, murine PC2 is inhibited by the proPC1/3(1-98) peptide, albeit at a much lesser extent with a micromolar Ki and in a strictly competitive manner. These results suggest that the proregion of PC1/3 is an important feature in regulating its activity.	Univ Montreal, Inst Rech Clin Montreal, Lab Neuropeptides Struct & Metab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Inst Rech Clin Montreal, Prot Engn Network Ctr Excellence, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Lazure, C (corresponding author), Univ Montreal, Inst Rech Clin Montreal, Lab Neuropeptides Struct & Metab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BASAK A, 1995, IN PRESS P 14 AM PEP; Boudreault A, 1996, J NEUROCHEM, V66, P2596; BOUDREAULT A, 1998, IN PRESS PROTEIN EXP; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Hu ZX, 1996, J BIOL CHEM, V271, P3375; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Khan AR, 1998, PROTEIN SCI, V7, P815; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; PAQUET L, 1994, J BIOL CHEM, V269, P19279; Powner D, 1998, MOL CELL BIOL, V18, P400, DOI 10.1128/MCB.18.1.400; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	34	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31574	31580		10.1074/jbc.273.47.31574	http://dx.doi.org/10.1074/jbc.273.47.31574			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813073	hybrid			2022-12-25	WOS:000077136900101
J	Branstrom, R; Leibiger, IB; Leibiger, B; Corkey, BE; Berggren, PO; Larsson, O				Branstrom, R; Leibiger, IB; Leibiger, B; Corkey, BE; Berggren, PO; Larsson, O			Long chain coenzyme A esters activate the pore-forming subunit (Kir6.2) of the ATP-regulated potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SENSITIVE K+ CHANNELS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; ACYL-COA; DIAZOXIDE; CLONING; KATP; ADP	The ATP-dependent potassium (K-ATP) channel in the pancreatic P-cell is a complex of two proteins, the pore-forming Kir6.2 and the sulfonylurea receptor type 1 (SUR1), Both subunits are required for functional KATP channels because expression of Kir6.2 alone does not result in measurable currents. However, truncation of the last 26 or 36 amino acids of the C terminus of Kir6.2 enables functional expression of the pore forming protein in the absence of SUR1, Thus, by using the truncated form of Kir6.2, expressed in the absence and presence of SUR1, it has been shown that the site at which ATP mediates channel inhibition is likely to be situated on Kir6.2. We have now examined the effects of long chain acyl-CoA (LC-CoA) esters on the C-terminally truncated mouse Kir6.2 Delta 365-390 (Kir6.2 Delta C26) in inside-out patches isolated from Xenopus laevis oocytes, LC-CoA esters, saturated (C14:0, C16:0) and unsaturated (C18:1), increased Kir6.2 Delta C26 currents, whereas short and medium chain CoA esters (C3:0, C8:0, C12:0) were unable to affect channel activity. The LC-CoA esters were also able to counteract the blocking effect of ATP on Kir6.2 Delta C26. The stimulatory effect of the esters could be explained by the induction of a prolonged open state of Kir6.2 Delta C26. In the presence of the esters, channel open time was increased approximately 3-fold, which is identical to what was obtained in the native mouse K-ATP channel. Coexpression of SUR1 together with Kir6.2 Delta C26 did not further increase the ability of LC-CoA esters to stimulate channel activity, We conclude that Kir6.2 is the primary target for LC-CoA esters to activate the K-ATP channel and that the esters are likely to induce a conformational change by a direct interference with the pore-forming subunit,leading to openings of long duration.	Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Boston Univ, Med Ctr, Diabet & Metab Unit, Evans Dept Med, Boston, MA 02118 USA	Karolinska Institutet; Boston University	Larsson, O (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, L1-02, S-17176 Stockholm, Sweden.		; Corkey, Barbara/E-7712-2015	Berggren, Per-Olof/0000-0001-8991-413X; Branstrom, Robert/0000-0001-6245-7223; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [DK50662, DK35914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R01DK050662, R56DK035914, R37DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Suzuki M, 1997, DIABETES, V46, P1440, DOI 10.2337/diabetes.46.9.1440; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	17	88	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31395	31400		10.1074/jbc.273.47.31395	http://dx.doi.org/10.1074/jbc.273.47.31395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813050	hybrid			2022-12-25	WOS:000077136900078
J	Lange, CA; Richer, JK; Shen, TJ; Horwitz, KB				Lange, CA; Richer, JK; Shen, TJ; Horwitz, KB			Convergence of progesterone and epidermal growth factor signaling in breast cancer - Potentiation of mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; FACTOR RECEPTOR; GENE-EXPRESSION; CARCINOMA-CELLS; PC12 CELLS; MEK KINASE; PHOSPHORYLATION; TYROSINE; RAS; EGF	During late stages of breast cancer progression, tumors frequently acquire steroid hormone resistance with concurrent amplification of growth factor receptors; this alteration predicts a poor prognosis. We show here that following treatment with the progestin, R5020, breast cancer cells undergo a "biochemical shift" in the regulation of epidermal growth factor (EGF)-stimulated signaling pathways: R5020 potentiates the effects of EGF by up-regulating EGFR, c-ErbB2 and c-ErbB3 receptors, and by enhancing EGF-stimulated tyrosine phosphorylation of signaling molecules known to associate with activated type I receptors. Independently of EGF, R5020 increases Stat5 protein levels, association of Stat5 with phosphotyrosine-containing proteins, and tyrosine phosphorylation of JAK2 and Shc. Furthermore, progestins "prime" breast cancer cells for growth signals by potentiating EGF-stimulated p42/p44 mitogen-activated protein kinase (MAPK), p38 MAP kinase, and JNK activities. Although the levels of cyclin D1, cyclin E, and p21(WAF1), are up-regulated by R5020 alone, they are synergistically up-regulated by EGF in the presence of R5020. Up-regulation of cell cycle proteins by EGF is blocked by inhibition of p42/p44 MAPK only in the presence of R5020, supporting a shift in the regulation of these cell cycle mediators from MAPK-independent to MAPK-dependent pathways. In summary, progesterone selectively increases the sensitivity of key kinase cascades to growth factors, thereby priming cells for stimulation by latent growth signals. These data support a model in which breast cancer cell growth switches from steroid hormone to growth factor dependence.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Lange, CA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Campus Box B151, Denver, CO 80262 USA.			Horwitz, Kathryn/0000-0001-7402-6455; Lange, Carol/0000-0003-2751-3976	NCI NIH HHS [CA26869] Funding Source: Medline; NIDDK NIH HHS [DK53825, DK48238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026869, R01CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053825, R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALDI E, 1995, TRENDS ENDOCRIN MET, V265, P1376; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DICKSON RB, 1992, CELLULAR MOL BIOL BR; DITTADI R, 1993, BRIT J CANCER, V67, P7, DOI 10.1038/bjc.1993.2; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELLEDGE RM, 1992, SEMIN ONCOL, V19, P244; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Giordano V, 1997, J IMMUNOL, V158, P4097; Gompel A, 1996, BREAST CANCER RES TR, V38, P227, DOI 10.1007/BF01806677; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Gullick WJ, 1996, CANCER SURV, V27, P339; HASLAM SZ, 1993, J CELL PHYSIOL, V155, P72, DOI 10.1002/jcp.1041550110; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KIENHUIS CBM, 1993, BREAST CANCER RES TR, V26, P289, DOI 10.1007/BF00665807; KRUSEKOPF S, 1991, J STEROID BIOCHEM, V40, P239, DOI 10.1016/0960-0760(91)90188-B; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Liu Y, 1996, CANCER RES, V56, P31; LU S, 1998, BREAST PROSTATE CANC, V219, P42; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; Meyer C, 1998, STEROIDS, V63, P111, DOI 10.1016/S0039-128X(97)00143-8; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MODIANO JF, 1991, J CELL BIOCHEM, V45, P196, DOI 10.1002/jcb.240450211; Moore MR, 1997, J STEROID BIOCHEM, V62, P243, DOI 10.1016/S0960-0760(97)00036-8; MURPHY LC, 1988, CANCER RES, V48, P4555; MURPHY LJ, 1986, CANCER RES, V46, P728; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARUP JC, 1988, CANCER RES, V48, P5071; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN J, 1996, NATURE, V381, P804; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; TURNER KO, 1995, BIOCHEM BIOPH RES CO, V213, P774, DOI 10.1006/bbrc.1995.2197; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALDEGGER S, 1995, BBA-MOL CELL RES, V1266, P186, DOI 10.1016/0167-4889(94)00236-8; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xie W, 1997, ANTICANCER RES, V17, P2627; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	75	166	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31308	31316		10.1074/jbc.273.47.31308	http://dx.doi.org/10.1074/jbc.273.47.31308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813039	hybrid			2022-12-25	WOS:000077136900067
J	Austin, RC; Sood, SK; Dorward, AM; Singh, G; Shaughnessy, SG; Pamidi, S; Outinen, PA; Weitz, JI				Austin, RC; Sood, SK; Dorward, AM; Singh, G; Shaughnessy, SG; Pamidi, S; Outinen, PA; Weitz, JI			Homocysteine-dependent alterations in mitochondrial gene expression, function and structure - Homocysteine and H2O2 act synergistically to enhance mitochondrial damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL INJURY; PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; OXIDATIVE INJURY; BINDING-ACTIVITY; MECHANISM; ARTERIOSCLEROSIS; INVITRO; ATHEROSCLEROSIS; HOMOCYSTINURIA	Mitochondrial abnormalities have been identified in hepatocytes of patients with hyperhomocysteinemia and in endothelial cells from the aortas of rats with diet-induced hyperhomocysteinemia. However, the mechanism by which homocysteine affects mitochondria is unknown. In this report, homocysteine-induced expression of the mitochondrial electron transport chain gene, cytochrome c oxidase III/ATPase 6,8 (CO3/ATPase 6,8), was identified in a human megakaryocytic cell line DAMI using mRNA differential display. Steady-state mRNA levels of CO3/ATPase 6,8, as well as other mitochondrial transcripts, were increased in DAMI cells by homocysteine in a concentration- and time-dependent manner. Despite an increase in mitochondrial RNA levels and changes in mitochondrial ultrastructure, no effect on either cell growth or mitochondrial respiration rates was observed in DAMI cells exposed to homocysteine at concentrations up to 1 mM. In contrast, 1 mM homocysteine in the presence of Cu2+, which is known to generate H2O2, significantly decreased mitochondrial RNA levels, caused gross morphological changes in mitochondrial ultrastructure, and inhibited both cell growth and mitochondrial respiration rates. However, precursors of cellular glutathione and preexposure to heat shock blocked the decrease in mitochondrial RNA levels caused by homocysteine and Cu2+. The observations that (i) homocysteine and H2O2, but not H2O2, alone, caused a decrease in mitochondrial RNA levels, (ii) intracellular levels of H2O2 were significantly increased in the presence of homocysteine and Cu2+, and (iii) catalase, but not free radical scavengers, prevented a decrease in mitochondrial RNA levels, provide evidence that homocysteine and H2O2 act synergistically to cause mitochondrial damage. Furthermore, our findings suggest that intracellular glutathione and heat shock proteins play a role in protecting mitochondria against the adverse effects elicited by homocysteine and H2O2.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada	McMaster University; McMaster University; McMaster University	Austin, RC (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Singh, Gurmit/C-6744-2014; Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blundell G, 1996, ATHEROSCLEROSIS, V122, P163, DOI 10.1016/0021-9150(95)05730-7; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; FORTIN LJ, 1995, CLIN BIOCHEM, V28, P155, DOI 10.1016/0009-9120(94)00073-5; Fukai T, 1998, J CLIN INVEST, V101, P2101, DOI 10.1172/JCI2105; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; HLADOVEC J, 1979, BLOOD VESSELS, V16, P202; HULTBERG B, 1995, BBA-MOL CELL RES, V1269, P6, DOI 10.1016/0167-4889(95)00094-9; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; MCCULLY KS, 1997, HOMOCYSTEINE REVOLUT; MUDD SH, 1981, AM J HUM GENET, V33, P883; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; POLLAK JK, 1980, TRENDS BIOCHEM SCI, V5, P23, DOI 10.1016/S0968-0004(80)80073-9; Sambrook J., 2002, MOL CLONING LAB MANU; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Sie H, 1991, AM J MED, V9, P31, DOI DOI 10.1016/0002-9343(91)90281-2; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; TOBOREK M, 1995, ATHEROSCLEROSIS, V115, P217, DOI 10.1016/0021-9150(94)05516-L; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; UELAND PM, 1989, J LAB CLIN MED, V114, P473; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WHITFIELD CD, 1990, J BIOL CHEM, V265, P18852; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30808	30817		10.1074/jbc.273.46.30808	http://dx.doi.org/10.1074/jbc.273.46.30808			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804859	hybrid			2022-12-25	WOS:000077008100106
J	Beard, WA; Bebenek, K; Darden, TA; Li, L; Prasad, R; Kunkel, TA; Wilson, SH				Beard, WA; Bebenek, K; Darden, TA; Li, L; Prasad, R; Kunkel, TA; Wilson, SH			Vertical-scanning mutagenesis of a critical tryptophan in the minor groove binding track of HIV-1 reverse transcriptase - Molecular nature of polymerase-nucleic acid interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; TEMPLATE-PRIMER; DNA-SYNTHESIS; CRYSTAL-STRUCTURE; THUMB SUBDOMAIN; REACTION PH; FIDELITY; POLYMERIZATION; SITE	While sequence-specific DNA-binding proteins interact predominantly in the DNA major groove, DNA polymerases bind DNA through interactions in the minor groove that are sequence nonspecific. Through functional analyses of alanine-substituted mutant enzymes that were guided by molecular dynamics modeling of the human immunodeficiency virus type I reverse transcriptase and DNA complex, we previously identified a structural element in reverse transcriptase, the minor groove binding track (MGBT), The MGBT is comprised of five residues (Ile(94), Gln(258), Gly(262), Trp(266), and Gln(269)) which interact 2-6 base pahs upstream from the polymerase active site in the DNA minor groove and are important in DNA binding, processivity, and frameshift fidelity. These residues do not contribute equally; functional analysis of alanine mutants suggests that Trp(266) contributes the most to binding. To define the molecular interactions between Trp(266) and the DNA minor groove, we have analyzed the properties of eight mutants, each with an alternate side chain at this position. A refined molecular dynamics model was used to calculate relative binding free energies based on apolar surface area buried upon complex formation. In general, there was a strong correlation between the relative calculated binding free energies for the alternate residue 266 side chains and the magnitude of the change in the properties which reflect template-primer interactions (template-primer dissociation rate constant, K-i,K-AZTTP, processivity, and frameshift fidelity). This correlation suggests that hydrophobic interactions make a major contribution to the stability of the polymerase-DNA complex. Additionally, tyrosine and arginine substitutions resulted in mutant enzymes with DNA binding properties better than predicted by buried surface area alone, suggesting that hydrogen bonding could also play a role in DNA binding at this position.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019; Li, Leping/F-6497-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293; Li, Leping/0000-0003-4208-0259				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECKERT KA, 1993, NUCLEIC ACIDS RES, V21, P5212, DOI 10.1093/nar/21.22.5212; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Janin J, 1997, STRUCTURE, V5, P473, DOI 10.1016/S0969-2126(97)00204-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Wells R.D., 1998, GENETIC INSTABILITIE; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682	45	36	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30435	30442		10.1074/jbc.273.46.30435	http://dx.doi.org/10.1074/jbc.273.46.30435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804810	hybrid			2022-12-25	WOS:000077008100057
J	Gimble, FS; Duan, XQ; Hu, DL; Quiocho, FA				Gimble, FS; Duan, XQ; Hu, DL; Quiocho, FA			Identification of Lys-403 in the PI-SceI homing endonuclease as part of a symmetric catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RESTRICTION-ENDONUCLEASE; I-CREI; ESCHERICHIA-COLI; DNA-BINDING; PROTEIN; ECORV; CLEAVAGE; RESIDUES; INTEIN	Superposition of the PI-SceI and I-CreI homing endonuclease three-dimensional x-ray structures indicates general similarity between the I-CreI homodimer and the PI-SceI endonuclease domain. Saddle-shaped structures are present in each protein that are proposed to bind DNA. At the putative endonucleolytic active sites, the superposition reveals that two lysine (Lys-301 and Lys-403 in PI-SceI and Lys-98 and Lys-98' in I-CreI) and two aspartic acid residues (Asp-218 and Asp-326 in PI-SceI and Asp-20 and Asp-20' in I-CreI) are related by 2-fold symmetry. The critical role of Lys-301, Asp-218, and Asp-326 in the PI-SceI reaction pathway was reported previously. Here, we demonstrate the significance of the active-site symmetry by showing that alanine substitution at Lys-403 reduces cleavage activity by greater than 50-fold but has little effect on the DNA binding activity of the mutant enzyme. Substitution of Lys-403 with arginine, which maintains the positive charge, has only a modest effect on activity. Interestingly, even though the Lys-301 and Lys-403 residues display pseudosymmetry, PI-SceI mutant proteins with substitutions at these positions have different behaviors. The presence of similar basic and acidic residues in many LAGLIDADG homing endonucleases suggests that these enzymes use a common reaction mechanism to cleave double-stranded DNA.	Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University System; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Gimble, FS (corresponding author), Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Wood, David W/B-2992-2012		NIGMS NIH HHS [GM50815, GM08280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R29GM050815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal AK, 1998, CURR OPIN STRUC BIOL, V8, P19, DOI 10.1016/S0959-440X(98)80005-5; AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; Grindl W, 1998, NUCLEIC ACIDS RES, V26, P1857, DOI 10.1093/nar/26.8.1857; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LykkeAndersen J, 1996, NUCLEIC ACIDS RES, V24, P3982, DOI 10.1093/nar/24.20.3982; MUELLER JE, 1993, NUCLEASES, P111; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Seligman LM, 1997, GENETICS, V147, P1653; Stahl F, 1996, P NATL ACAD SCI USA, V93, P6175, DOI 10.1073/pnas.93.12.6175; Turmel M, 1997, NUCLEIC ACIDS RES, V25, P2610, DOI 10.1093/nar/25.13.2610; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Wang JS, 1997, NUCLEIC ACIDS RES, V25, P3767, DOI 10.1093/nar/25.19.3767; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	23	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30524	30529		10.1074/jbc.273.46.30524	http://dx.doi.org/10.1074/jbc.273.46.30524			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804821	hybrid			2022-12-25	WOS:000077008100068
J	Mani, RS; Hammond, JR; Marjan, JMJ; Graham, KA; Young, JD; Baldwin, SA; Cass, CE				Mani, RS; Hammond, JR; Marjan, JMJ; Graham, KA; Young, JD; Baldwin, SA; Cass, CE			Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORT; MEMBRANE-GLYCOPROTEINS; PLASMA-MEMBRANES; LEUKEMIA-CELLS; NITROBENZYLTHIOINOSINE; BINDING; EXPRESSION; SITES; ERYTHROCYTES; ADENOSINE	The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells. BeWo cells exhibit large numbers (>10(7)/cell) of NBMPR-binding sites and high es and ei nucleoside transport activities relative to other cell types. In this work, we have demonstrated that proliferating BeWo cells possess (i) mRNA encoding hENT1 and hENT2 and (ii) hENT1-specific immuno-epitopes. We examined NBMPR binding and its inhibition of uridine transport in various BeWo membrane fractions and proteoliposomes derived therefrom to determine if NBMPR binding to intracellular membranes represented interaction with functional es transporters. Unfractionated membranes and fractions enriched 5-fold in plasma membranes relative to postnuclear supernatants exhibited high NBMPR binding activity. Intact nuclei and nuclear envelopes also exhibited abundant quantities of NBMPR-binding sites with affinities similar to those of enriched plasma membranes (K-d = 0.4-0.9 nM). When proteoliposomes were made from octyl glucoside-solubilized membranes, high affinity NBMPR-binding sites were not only observed in crude membrane preparations and plasma membrane-enriched fractions but also in nuclear envelope fractions. Proteoliposomes prepared from either unfractionated membranes or nuclear envelopes exhibited both hENT1-mediated (82-85%) and hENT2-mediated (15-18%) transport of [H-3]uridine. These results provided evidence for the presence of functional es and ei transporters in nuclear membranes and endoplasmic reticulum, suggesting that hENT1 and hENT2 may function in the translocation of nucleosides between the cytosol and the luminal compartments of one or both of these membrane types.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Fac Med, Dept Physiol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Fac Med, Membrane Transport Res Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Fac Med, Mol Biol Membranes Grp, Edmonton, AB T6G 1Z2, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada; Univ Leeds, Dept Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Western University (University of Western Ontario); University of Leeds	Cass, CE (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca	Hammond, James/A-4524-2008	Hammond, James/0000-0002-9006-7529				BARDIN C, 1978, J BIOL CHEM, V253, P1725; BOUMAH CE, 1992, BIOCHEM J, V288, P987, DOI 10.1042/bj2880987; BURRES NS, 1986, J CELL PHYSIOL, V128, P375, DOI 10.1002/jcp.1041280305; BURRES NS, 1992, BIOCHEM J, V288, P987; Camins A, 1996, LIFE SCI, V58, P753, DOI 10.1016/0024-3205(95)02353-4; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1998, IN PRESS MEMBRANE TR; CASS CE, 1994, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; COHEN A, 1979, J BIOL CHEM, V254, P112; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; FRIEDMAN SJ, 1979, CANCER RES, V39, P1960; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1994, J PHARMACOL EXP THER, V271, P906; Hammond JR, 1996, ARCH BIOCHEM BIOPHYS, V332, P313, DOI 10.1006/abbi.1996.0347; HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; JARVIS SM, 1988, ADENOSINE RECEPTORS, P113; JOHNSON PA, 1982, MEMBRANE BIOCHEM, V4, P189, DOI 10.3109/09687688209065431; KAY RR, 1972, EUR J BIOCHEM, V30, P145, DOI 10.1111/j.1432-1033.1972.tb02081.x; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; Loizaga B, 1979, BIOCHEM SOC T, V7, P148, DOI 10.1042/bst0070148; Markwell M A, 1981, Methods Enzymol, V72, P296; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PATERSON ARP, 1987, TOPICS PERSPECTIVES, P89; PATTILLO RA, 1968, CANCER RES, V28, P1231; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PUDDINGTON L, 1985, J BIOL CHEM, V260, P5641; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Thorn JA, 1996, GEN PHARMACOL, V27, P613, DOI 10.1016/0306-3623(95)02053-5; TORRISI MR, 1987, J CELL BIOL, V104, P733, DOI 10.1083/jcb.104.3.733; TSE CM, 1989, BIOCHIM BIOPHYS ACTA, V985, P343, DOI 10.1016/0005-2736(89)90424-0; TSE CM, 1985, J BIOL CHEM, V260, P3506; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	45	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30818	30825		10.1074/jbc.273.46.30818	http://dx.doi.org/10.1074/jbc.273.46.30818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804860	hybrid			2022-12-25	WOS:000077008100107
J	Cohen, I; Kohl, C; McGarry, JD; Girard, J; Prip-Buus, C				Cohen, I; Kohl, C; McGarry, JD; Girard, J; Prip-Buus, C			The N-terminal domain of rat liver carnitine palmitoyltransferase 1 mediates impart into the outer mitochondrial membrane and is essential for activity and malonyl-CoA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-ANCHOR SEQUENCE; FATTY-ACID OXIDATION; PROTEIN IMPORT; SINGLE POLYPEPTIDE; INNER MEMBRANE; ENZYME-SYSTEM; YEAST; EXPRESSION; INSERTION; BINDING	The rat liver carnitine palmitoyltransferase 1 (L-CPT1), an integral outer mitochondrial membrane (OMM) protein, is the key regulatory enzyme of fatty acid oxidation and is inhibited by malonyl-CoA. In vitro import of L-CPT1 into the OMM requires the presence of mitochondrial receptors and is stimulated by ATP but is membrane potential-independent. Its N-terminal domain (residues 1-150), which contains two transmembrane segments, possesses all of the information for mitochondrial targeting and OMM insertion. Deletion of this domain abrogates protein targeting, whereas its fusion to non-OMM-related proteins results in their mitochondrial targeting and OMM insertion in a manner similar to L-CPT1. Functional analysis of chimeric CPTs expressed in Saccharomyces cerevisiae shows that this domain also mediates in vivo protein insertion into the OMM. When the malonyl-CoA-insensitive CPT2 was anchored at the OMM either by a specific OMM signal anchor sequence (pOM29) or by the N-terminal domain of L-CPT1, its activity remains insensitive to malonyl-CoA inhibition. This indicates that malonyl-CoA sensitivity is an intrinsic property of L-CPT1 and that its N-terminal domain cannot confer malonyl-CoA sensitivity to CPT2. Replacement of the N-terminal domain by pOM29 results in a less folded and less active protein, which is also malonyl-CoA-insensitive. Thus, in addition to its role in mitochondrial targeting and OMM insertion, the N-terminal domain of L-CPT1 is essential to maintain an optimal conformation for both catalytic function and malonyl-CoA sensitivity.	CNRS, UPR 1524, F-92190 Meudon, France; Univ Texas, SW Med Ctr, SW Med Sch, Dept Internal Med & Biochem, Dallas, TX 75235 USA	Centre National de la Recherche Scientifique (CNRS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Prip-Buus, C (corresponding author), CNRS, UPR 1524, 9 Rue J Hetzel, F-92190 Meudon, France.	pripbuus@infobiogen.fr	PRIP-BUUS, Carina/P-9084-2017	Prip-Buus, Carina/0000-0002-2153-7857				BROADWAY NM, 1995, BIOCHEM J, V310, P989, DOI 10.1042/bj3100989; BROWN NF, 1991, J BIOL CHEM, V266, P15446; BROWN NF, 1994, J BIOL CHEM, V269, P26438; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; Court DA, 1996, MOL CELL BIOL, V16, P4035; Court DA, 1996, FEBS LETT, V390, P73, DOI 10.1016/0014-5793(96)00629-1; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; EPAND RM, 1986, J BIOL CHEM, V261, P17; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GHADIMINEJAD I, 1990, FEBS LETT, V269, P406, DOI 10.1016/0014-5793(90)81204-2; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; HAMAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P362, DOI 10.1093/oxfordjournals.jbchem.a122474; HERBIN C, 1987, EUR J BIOCHEM, V165, P201, DOI 10.1111/j.1432-1033.1987.tb11212.x; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; ONO H, 1987, EUR J BIOCHEM, V168, P509, DOI 10.1111/j.1432-1033.1987.tb13447.x; PANDE SV, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P165; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SCHLOSSMANN J, 1995, J BIOL CHEM, V270, P27116, DOI 10.1074/jbc.270.45.27116; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SMITH MD, 1995, J BIOL CHEM, V270, P28331; Steenaart NAE, 1997, J BIOL CHEM, V272, P12057, DOI 10.1074/jbc.272.18.12057; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; ZAMMIT VA, 1989, BIOCHEM J, V263, P89, DOI 10.1042/bj2630089	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29896	29904		10.1074/jbc.273.45.29896	http://dx.doi.org/10.1074/jbc.273.45.29896			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792707	hybrid			2022-12-25	WOS:000076798300084
J	Driscoll, MD; Sathya, G; Muyan, M; Klinge, CM; Hilf, R; Bambara, RA				Driscoll, MD; Sathya, G; Muyan, M; Klinge, CM; Hilf, R; Bambara, RA			Sequence requirements for estrogen receptor binding to estrogen response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER TRANSCRIPTION FACTOR; C-FOS PROTOONCOGENE; GENE-EXPRESSION; XENOPUS-LAEVIS; OVALBUMIN GENE; INDUCIBLE ENHANCER; 3'-FLANKING REGION; 5'-FLANKING REGION; DEPENDENT ENHANCER; PROLACTIN GENE	The estrogen receptor (ER) is a transcription factor that binds to a specific DNA sequence found in the regulatory regions of estrogen-responsive genes, called the estrogen response element (ERE), Many genes that contain EREs have been identified, and most of these EREs contain one or more changes from the core consensus sequence, a 13-nucleotide segment with 10 nucleotides forming an inverted repeat, A number of genes have multiple copies of these imperfect EREs, In order to understand why natural EREs have developed in this manner, we have attempted to define the basic sequence requirements for ER binding. To this end, we measured the binding of homodimeric ER to a variety of nonconsensus EREs, We discovered that an ERE containing even a single change from the consensus may be unable to bind ER, However, an ERE with two changes from the consensus may be capable of binding avidly to ER in the context of certain flanking sequences. We found that changes in the sequences flanking a nonconsensus ERE can greatly alter ER-ERE affinity, either positively or negatively. Careful study of sequences flanking a series of EREs made it possible to develop rules that predict whether ER binds to a given natural ERE and also to predict the relative amounts of binding when comparing two EREs.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.		Muyan, Mesut/AAZ-4888-2020	Klinge, Carolyn/0000-0002-3358-4378; Muyan, Mesut/0000-0003-3058-6228	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024459] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24459] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BAUMANN H, 1995, EUR J BIOCHEM, V230, P879, DOI 10.1111/j.1432-1033.1995.tb20631.x; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; DARWISH H, 1991, J BIOL CHEM, V266, P551; Driscoll MD, 1996, J STEROID BIOCHEM, V58, P45, DOI 10.1016/0960-0760(96)00015-5; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORSKI J, 1993, BIOL REPROD, V48, P8, DOI 10.1095/biolreprod48.1.8; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; HYDER SM, 1991, STEROIDS, V56, P498, DOI 10.1016/0039-128X(91)90114-B; HYDER SM, 1992, J BIOL CHEM, V267, P18047; HYDER SM, 1994, J STEROID BIOCHEM, V48, P69, DOI 10.1016/0960-0760(94)90252-6; IKEDA M, 1994, BIOCHEM MOL BIOL INT, V33, P447; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLINGE CM, 1992, CANCER RES, V52, P1073; KLINGE CM, 1997, STEROID BIOCH MOL BI, V63, P283; KOFLER B, 1995, DNA CELL BIOL, V14, P321, DOI 10.1089/dna.1995.14.321; KRAWCZYK Z, 1992, CELL BIOL INT REP, V16, P937, DOI 10.1016/S0309-1651(06)80173-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEE JH, 1995, DNA CELL BIOL, V14, P419, DOI 10.1089/dna.1995.14.419; LIU D, 1995, ENDOCRINOLOGY, V136, P3486, DOI 10.1210/en.136.8.3486; LUDWIG LB, 1990, MOL ENDOCRINOL, V4, P1027, DOI 10.1210/mend-4-7-1027; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAY FEB, 1993, GENE, V134, P277, DOI 10.1016/0378-1119(93)90107-E; MILLER MA, 1985, ENDOCRINOLOGY, V117, P515, DOI 10.1210/endo-117-2-515; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; NAWAZ Z, 1993, MOL CARCINOGEN, V7, P76, DOI 10.1002/mc.2940070204; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; NOWAKOWSKI BE, 1994, MOL ENDOCRINOL, V8, P1742, DOI 10.1210/me.8.12.1742; PAVLIK EJ, 1976, J STEROID BIOCHEM, V7, P357, DOI 10.1016/0022-4731(76)90095-9; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; PEALE FV, 1989, BIOCHEMISTRY-US, V28, P8671, DOI 10.1021/bi00448a001; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552; SABBAH M, 1989, J BIOL CHEM, V264, P2397; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TENG CT, 1994, ADV EXP MED BIOL, V357, P183; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; WAHLI W, 1989, J STEROID BIOCHEM, V34, P17, DOI 10.1016/0022-4731(89)90062-9; WALKER P, 1983, EMBO J, V2, P2271, DOI 10.1002/j.1460-2075.1983.tb01734.x; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1987, J BIOL CHEM, V262, P16080; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231	59	147	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29321	29330		10.1074/jbc.273.45.29321	http://dx.doi.org/10.1074/jbc.273.45.29321			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792632	hybrid			2022-12-25	WOS:000076798300009
J	Le Borgne, R; Alconada, A; Bauer, U; Hoflack, B				Le Borgne, R; Alconada, A; Bauer, U; Hoflack, B			The mammalian AP-3 adaptor-like complex mediates the intracellular transport of lysosomal membrane glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; CASEIN KINASE-II; CLATHRIN-COATED VESICLES; GOLGI NETWORK LOCALIZATION; HIGH-AFFINITY INTERACTION; CYTOPLASMIC TAIL; ASSEMBLY PROTEINS; ACID-PHOSPHATASE; PLASMA-MEMBRANE; SORTING SIGNALS	In mammalian cells, the mannose B-phosphate receptors (MPRs) and the lysosomal glycoproteins, lysosomal-associated membrane protein (LAMP) I, lysosomal integral membrane protein (LIMP) II, are directly transported from the trans-Golgi network to endosomes and lysosomes. While MPR traffic relies on the AP-1 adaptor complex, we report that proper targeting of LAMP I and LIMP II to lysosomes requires the AP-3 adaptor-like complex. Overexpression of these proteins, which contain either a tyrosine- or a di-leucine-based-sorting motif, promotes AP-3 recruitment on membranes. Inhibition of AP-3 function using antisense oligonucleotides leads to a selective misrouting of both LAMP I and LIMP II to the cell surface without affecting MPR trafficking. These results provide evidence that AP-3 functions in the intracellular targeting of transmembrane glycoproteins to lysosomes.	Inst Pasteur, Inst Biol, CNRS, EP 525, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Hoflack, B (corresponding author), Inst Pasteur, Inst Biol, CNRS, EP 525, BP 447,1 Rue Professeur Calmette, F-59021 Lille, France.		HOFLACK, Bernard/AAZ-6668-2020	LE BORGNE, Roland/0000-0001-6892-278X				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KORNER C, 1994, J BIOL CHEM, V269, P16529; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; Lloyd V, 1998, TRENDS CELL BIOL, V8, P257, DOI 10.1016/S0962-8924(98)01270-7; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELMAN I, 1996, ANNU REV CELL DEV BI, V12, P575; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; OGATA S, 1994, J BIOL CHEM, V269, P5210; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1997, EMBO J, V16, P4508; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	64	161	164	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29451	29461		10.1074/jbc.273.45.29451	http://dx.doi.org/10.1074/jbc.273.45.29451			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792650	hybrid			2022-12-25	WOS:000076798300027
J	Deng, J; Xia, WY; Hung, MC				Deng, J; Xia, WY; Hung, MC			Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo	ONCOGENE			English	Article						tumor suppression; apoptosis; adenovirus 5 E1A; murine melanoma	PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; E1A GENE-PRODUCTS; TRANSCRIPTIONAL REPRESSION; ULTRAVIOLET-RADIATION; MURINE MELANOMA; BREAST-CANCER; SOLID TUMORS; RAT-CELLS; EXPRESSION	Disruption of apoptotic pathways is a major factor in the multistep process of tumorigenesis, whereas induction of apoptosis can be important for tumor suppression and cancer therapy. The adenovirus type 5 E1A gene provides a useful tool to study the function of tumor suppression and apoptosis. E1A has been shown to induce apoptosis in different systems in vitro . However, this activity has not been well characterized in vivo. Therefore, the effect of this activity and the link to the in vivo biological function are not clear. To answer these questions, we introduced E1A into murine melanoma cells and characterized the biological features both in vitro and in vivo. Expression of the EIA gene does not affect the proliferation rate of tumor cells in vitro, but inhibits tumor growth in vivo. The in vitro analysis indicated that the E1A-expressing tumor cells are sensitive to serum depletion-induced apoptosis. Importantly, E1A-mediated apoptosis was also identified in vivo, suggesting this activity contributed to the tumor suppressive function. The in vivo apoptotic pattern was unique: most of the apoptotic cells were around the periphery of the tumors, implicating the interaction of these cells with stress stimuli irt vivo. In addition, E1A also rendered the tumor cells susceptible to the cytotoxicity of other anticancer agents, a feature useful for improving the efficacy of cancer therapy. The results provide a functional link between in vitro activity and in vivo effects.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01 CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Boulakia CA, 1996, ONCOGENE, V12, P529; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHEN PW, 1993, J IMMUNOL, V151, P244; CHU G, 1994, J BIOL CHEM, V269, P787; COOK JL, 1989, J IMMUNOL, V142, P4527; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Donawho CK, 1996, J IMMUNOL, V157, P781; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN M, 1995, CANCER RES, V55, P2470; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Jansen B, 1997, CANCER RES, V57, P362; KERBEL RS, 1994, INVAS METAST, V14, P50; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; PIERCEALL WE, 1992, CANCER RES, V52, P3946; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SHIH IM, 1993, J INVEST DERMATOL, V100, P196; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRENT JC, 1996, EMBO J, V15, P4459; TSUJI Y, 1993, J IMMUNOL, V150, P1897; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wu JX, 1996, ANTICANCER RES, V16, P2233; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG YJ, 1995, ONCOGENE, V10, P1947	58	62	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2167	2175		10.1038/sj.onc.1202148	http://dx.doi.org/10.1038/sj.onc.1202148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811448				2022-12-25	WOS:000076698200003
J	Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ				Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ			Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin	ONCOGENE			English	Article						cyclins; cell-cycle; tumor progression; papilloma; squamous cell carcinoma	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITORS; E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; HARVEY-RAS ONCOGENE; D-CDK COMPLEXES; GROWTH SUPPRESSION; SQUAMOUS-CELL; ALTERED EXPRESSION; TRANSGENIC MICE	It is now evident that several genes encoding regulatory activities that control the mammalian cell cycle, particularly some that control the progression of quiescent cells through G1 and into S phase, are targets for alterations that underlie the development of neoplasms. Here, we made a sequential study of alterations in cell cycle protein expression and complex formation among cyclin, cyclin dependent kinases (CDKs) and CDK inhibitors (CKIs) during premalignant progression in SENCAR mouse skin tumors. Changes in the level of expression were observed in positive (cyclin DI, D2, and E2F family members) and negative regulators (p16(Ink4a), p57(Kip2)) Of the cell cycle. Also, we observed the formation of cyclin/CDK/CKI complexes. The amounts of these proteins and complexes increased substantially at specific times during promotion but not during malignant conversion to carcinomas. These data show that deregulation of growth control occurs in benign tumors and that subsequent mutations not involved cell-cycle regulation are probably necessary to induce invasive behavior.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 57596, CA 42157, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, P01CA057596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; BATES S, 1994, ONCOGENE, V9, P1633; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BURNS FJ, 1978, CARCINOGENESIS, V2, P91; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUKUDA M, 1978, CELL TISSUE KINET, V11, P611, DOI 10.1111/j.1365-2184.1978.tb00834.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POTTER VR, 1981, CARCINOGENESIS, V2, P1375, DOI 10.1093/carcin/2.12.1375; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLAGA T J, 1989, P1; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; TENNENBAUM T, 1992, CANCER RES, V52, P2966; VAN DJ, 1991, AM J PATHOL, V138, P1165; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; ZHANG SY, 1994, CANCER RES, V54, P5050	72	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2251	2258		10.1038/sj.onc.1202131	http://dx.doi.org/10.1038/sj.onc.1202131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811455				2022-12-25	WOS:000076698200010
J	Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M				Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M			Relationship between I kappa B alpha constitutive expression, TNF alpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; EBV; TNF alpha	TUMOR-NECROSIS-FACTOR; SIGNAL-BINDING-PROTEIN; VIRUS TRANSFORMING PROTEIN; RBP-J-KAPPA; T-CELL; V-REL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; LYMPHOMA PATIENTS; GENE-EXPRESSION	In order to understand the role of NF-KB in EBV transformation we have established stably transfected I kappa B alpha: into lymphoblastoid cells. Two clones were obtained in which the loss of NF-kappa B binding activity correlated with the constitutive expression of the transgenic I kappa B alpha. Protein latency expression was determined by immunocytochemistry. Expression of surface markers, intracytoplasmic content of cytokines cell cycle analysis after BrdU incorporation and DNA staining with propidium iodide were studied by flow cytometry, Percentage of apoptotic cells was determined by in-situ labelling of DNA strand breaks, No significative changes in EBV latency nor in cell surface marker expression was found. In contrast, intracytoplasmic TNF alpha levels were strongly reduced in transfected clones. Furthermore, 30% of I kappa B alpha transfected cells were apoptotic after 8 h of TNF alpha treatment. This correlated with a strong reduction of BrdU incorporation after 24 h of TNF alpha treatment, No effect was seen with non transfected cells or with cells transfected with a control plasmid, Our results suggest that the TNF: gene could be one of the targets of NF-kappa B in EBV infected cells and that NF-kappa B protects EBV-infected cells from apoptosis induced by TNF alpha, which may favour the proliferative effect of this cytokine.	Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop La Pitie Salpetriere, URA 625, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Feuillard, J (corresponding author), Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France.		Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Coral S, 1997, CELL GROWTH DIFFER, V8, P581; CORDINGLEY FT, 1988, LANCET, V1, P969; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; FEUILLARD J, 1995, INT IMMUNOL, V7, P121, DOI 10.1093/intimm/7.1.121; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; HUEN DS, 1995, ONCOGENE, V10, P549; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JELINEK DF, 1987, J IMMUNOL, V139, P2970; Jochems G J, 1991, Hum Antibodies Hybridomas, V2, P57; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; KIEFF E, 1990, EPSTEINBARR VIRUS IT; Klein SC, 1996, LEUKEMIA RES, V20, P633, DOI 10.1016/0145-2126(96)00029-X; KORNER M, 1990, BIOCHEM J, V265, P547, DOI 10.1042/bj2650547; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macia J, 1996, LEUKEMIA LYMPHOMA, V20, P481, DOI 10.3109/10428199609052433; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Osnes LTN, 1996, THROMB HAEMOSTASIS, V76, P970; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Warzocha K, 1997, J CLIN ONCOL, V15, P499, DOI 10.1200/JCO.1997.15.2.499; Warzocha Krzysztof, 1997, Leukemia (Basingstoke), V11, P441; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	63	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1607	1615		10.1038/sj.onc.1202365	http://dx.doi.org/10.1038/sj.onc.1202365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794238				2022-12-25	WOS:000076089900013
J	Block, KL; Vornlocher, HP; Hershey, JWB				Block, KL; Vornlocher, HP; Hershey, JWB			Characterization of cDNAs encoding the p44 and p35 subunits of human translation initiation factor eIF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; RNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; PRT1 PROTEIN; COMPLEX; YEAST; DIVERSITY; IDENTIFICATION; CONSERVATION	Eukaryotic translation initiation factor 3 (eIF3) is a large multisubunit complex that plays a central role in the initiation of translation. It binds to 40 S ribosomal subunits resulting in dissociation of 80 S ribosomes, stabilizes initiator methionyl-tRNA binding to 40 S subunits, and is required for mRNA binding. eIF3 has an aggregate molecular mass of similar to 600 kDa and comprises at least 10 subunits, The cDNAs encoding eight of the subunits have been cloned previously (p170, pile, p110, p66, p48, p47, p40, and p36), Here we report the cloning and characterization of human cDNAs encoding two more subunits of human eIF3, namely eIF3-p44 and eIF3-p35. These proteins are immunoprecipitated by affinity-purified anti-eIF3-p170 antibodies, indicating they are components of the eIF3 complex. Far Western analysis shows that eIF3-p44 interacts strongly and specifically with the eIF3-p170 subunit, and weakly with p116/p110, p66, p40, and itself. eIF3-p44 contains an RNA recognition motif near its C terminus. Northwestern blotting shows that eIF3-p44 binds 18 S rRNA and beta-globin mRNA. Possession of cloned cDNAs encoding all 10 subunits of eIF3 provides the tools necessary to elucidate the functions of the individual subunits and the structure of the eIF3 complex.	Univ Calif Davis, Sch Med, Dept Biol Chem, Livermore, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Livermore, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHOMCZYNSKI P, 1994, ANAL BIOCHEM, V221, P303, DOI 10.1006/abio.1994.1416; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; GOUMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39, DOI 10.1016/0005-2787(80)90131-8; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; YAO F, 1994, J VIROL, V68, P8158, DOI 10.1128/JVI.68.12.8158-8168.1994; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	34	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31901	31908		10.1074/jbc.273.48.31901	http://dx.doi.org/10.1074/jbc.273.48.31901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822659	hybrid			2022-12-25	WOS:000077207000041
J	Ishii, A; Ohta, M; Watanabe, Y; Matsuda, K; Ishiyama, K; Sakoe, K; Nakamura, M; Inokuchi, J; Sanai, Y; Saito, M				Ishii, A; Ohta, M; Watanabe, Y; Matsuda, K; Ishiyama, K; Sakoe, K; Nakamura, M; Inokuchi, J; Sanai, Y; Saito, M			Expression cloning and functional characterization of human cDNA for ganglioside G(M3) synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LINE HL-60; SPHINGOLIPID SYNTHESIS; G(D3) SYNTHASE; ALPHA-2,3-SIALYLTRANSFERASE; SIALYLTRANSFERASE; GROWTH; DIFFERENTIATION; BIOSYNTHESIS; INHIBITION; PURIFICATION	Ganglioside G(M3) is a major glycosphingolipid in the plasma membrane and is widely distributed in vertebrates. We describe here the isolation of a human cDNA whose protein product is responsible for the synthesis of G(M3). The cloned cDNA spanned 2,359 base pairs, with an open reading frame encoding a protein of 362 amino acids with a predicted molecular mass of 41.7 kDa. The deduced primary structure shows features characteristic of the sialyltransferase family, including a type II transmembrane topology and the sialylmotifs L at the center and S at the C-terminal region. An amino acid substitution hom aspartic acid to histidine was demonstrated at a position invariant in sialylmotif L of all the other sialyltransferases so far cloned. The best acceptor substrate for the gene product was lactosylceramide, and cells transfected with the cloned cDNA clearly exhibited de novo synthesis of G(M3), with a measurable decrease in the precursor lactosylceramide. Despite the ubiquitous distribution of ganglioside G(M3) in human tissues, a major 2.4-kilobase transcript of the gene was found in a tissue-specific manner, with predominant expression in brain, skeletal muscle, and testis, and very low expression in liver.	Natl Canc Ctr, Res Inst, Virol & Glycobiol Div, Chuo Ku, Tokyo 1040045, Japan; Tokyo Metropolitan Med Ctr Geriatr, Itabashi Ku, Tokyo 1730015, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 3290431, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	National Cancer Center - Japan; Tokyo Metropolitan Institute of Medical Science; Jichi Medical University; Hokkaido University	Saito, M (corresponding author), Natl Canc Ctr, Res Inst, Virol & Glycobiol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Inokuchi, Jin-ichi/AAW-9964-2020	Inokuchi, Jin-ichi/0000-0002-0703-5746				BREMER EG, 1984, J BIOL CHEM, V259, P6818; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FURUYA S, 1995, J NEUROCHEM, V65, P1551; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; INOKUCHI J, 1993, CLIN EXP METASTAS, V11, P27, DOI 10.1007/BF00880063; ITO N, 1990, SCIENCE, V247, P324; Kim YJ, 1997, BIOCHEM BIOPH RES CO, V235, P327, DOI 10.1006/bbrc.1997.6725; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MeivarLevy I, 1997, J BIOL CHEM, V272, P1558, DOI 10.1074/jbc.272.3.1558; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Nara K, 1996, EUR J BIOCHEM, V238, P647, DOI 10.1111/j.1432-1033.1996.0647w.x; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1984, BLOOD, V64, P534; PREUSS U, 1993, J BIOL CHEM, V268, P26273; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x	35	121	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31652	31655		10.1074/jbc.273.48.31652	http://dx.doi.org/10.1074/jbc.273.48.31652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822625	hybrid			2022-12-25	WOS:000077207000007
J	Wang, JS; Dong, XW; Reeves, WH				Wang, JS; Dong, XW; Reeves, WH			A model for Ku heterodimer assembly and interaction with DNA - Implications for the function of Ku antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; BINDING; MUTANTS	Ku autoantigen, a heterodimer of 70- and 80-kDa subunits, is a DNA end-binding factor critical for DNA repair. Two domains of p70 mediate DNA binding, one on the C-terminal and one on the N-terminal portion. The latter must dimerize with p80 in order to bind DNA, whereas the former is p80-independent. Both must be intact for end binding activity in gel shift assays. To evaluate the role of p80 in DNA binding, deletion mutants were co-expressed with full-length p70 using recombinant baculoviruses. We show by several criteria that amino acids 371-510 of p80 interact with p70. Both of the p70 dimerization domains bind to the same region of p80, but apparently to separate sites within that region. In DNA immunoprecipitation assays, amino acids 179-510 of p80 were required for p80-dependent DNA binding of p70, whereas in gel shift assays, amino acids 179-732 were necessary. Interestingly, both the p80-dependent and the p80-independent DNA binding sites preferentially bound to DNA ends, suggesting a model in which a single Ku heterodimer may juxtapose two broken DNA ends physically, facilitating their rejoining by DNA ligases.	Univ N Carolina, Div Rheumatol & Immunol, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr,Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Immunol & Microbiol, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Reeves, WH (corresponding author), Univ N Carolina, Div Rheumatol & Immunol, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr,Dept Med, 3330 Thurston Bldg,CB 7280, Chapel Hill, NC 27599 USA.	westley_reeves@unc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007416, R01AR040391] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00046] Funding Source: Medline; NIAMS NIH HHS [R01-AR40391, T32-AR7416] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Errami A, 1996, MOL CELL BIOL, V16, P1519; GRIFFIN W, 1996, NATURE, V380, P265; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1986, J BIOL CHEM, V261, P375; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; Pang DL, 1997, CANCER RES, V57, P1412; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Reeves WH, 1997, ANTIBODIES, P33; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wang JS, 1997, ARTHRITIS RHEUM-US, V40, P1344, DOI 10.1002/1529-0131(199707)40:7<1344::AID-ART20>3.0.CO;2-V; WANG JS, 1994, J CELL SCI, V107, P3223; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; YANEVA M, 1989, J BIOL CHEM, V264, P13407; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	38	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31068	31074		10.1074/jbc.273.47.31068	http://dx.doi.org/10.1074/jbc.273.47.31068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813006	hybrid			2022-12-25	WOS:000077136900034
J	Yukawa, K; Tanaka, T; Tsuji, S; Akira, S				Yukawa, K; Tanaka, T; Tsuji, S; Akira, S			Expressions of CCAAT/enhancer-binding proteins beta and delta and their activities are intensified by cAMP signaling as well as Ca2+/calmodulin kinases activation in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; DEPENDENT LATE-PHASE; GENE-EXPRESSION; TRANSCRIPTION FACTORS; SYNAPTIC PLASTICITY; CREB PHOSPHORYLATION; CORTICAL ASTROCYTES; RESPONSIVE ELEMENT; LEUCINE ZIPPER; C/EBP-BETA	The transcription factor, Aplysia CCAAT enhancer-binding protein (ApC/EBP), plays a crucial role in long term facilitation, a synaptic mechanism of long term memory in Aplysia, To gain a clue to whether the mammalian C/EBP family of transcription factors are also involved in long term memory, we examined how C/EBP activities in hippocampal neurons can be modulated in response to cAMP and Ca2+, crucial inductive signals for memory formation. As a result, stimulation of either cAMP or Ca2+ signals in hippocampal neurons was found to enhance mRNA expressions and DNA binding activities of C/EBP beta and C/EBP delta, Furthermore, it is indicated that CaM kinases have essential roles for increasing the expression and DNA binding activities of C/EBP beta in hippocampal neurons activated by membrane depolarization. Overexpression of constitutively active calcium/calmodulin-dependent kinase TV was found to directly stimulate either C/EBP beta-dependent or C/EBP delta-dependent transcription, reinforcing the evidence that C/EBP family members contribute to Ca2+ dependent transcription. Thus, these results suggest that C/EBP beta and C/EBP delta may be involved in the transcription-dependent phase of memory formation by increasing the expression of both the DNA binding and the transcriptional activities under the direction of cAMP and/or Ca2+ signaling in hippocampal neurons.	Wakayama Med Coll, Dept Physiol 2, Wakayama 6410012, Japan; Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 663, Japan	Wakayama Medical University; Hyogo College of Medicine	Yukawa, K (corresponding author), Wakayama Med Coll, Dept Physiol 2, 811-1 Kimiidera, Wakayama 6410012, Japan.	kazu59@wakayama-med.ac.jp	Tanaka, Takashi/O-8254-2015; Akira, Shizuo/C-3134-2009					Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Baranes D, 1996, P NATL ACAD SCI USA, V93, P4706, DOI 10.1073/pnas.93.10.4706; Barthel F, 1996, NEUROSCIENCE, V70, P1053, DOI 10.1016/0306-4522(95)00411-4; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cardinaux JR, 1996, J NEUROSCI, V16, P919; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Hebb Donald O., 1949, ORG BEHAV; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KUO CF, 1990, DEVELOPMENT, V109, P473; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; Nguyen PV, 1996, J NEUROSCI, V16, P3189; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; THOMAS KL, 1996, CORTICAL PLASTICITY, P103; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TULLY T, 1996, FUNCTION DYSFUNCTION, P207; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XU LX, 1996, CHUNG HUA I HSUEH TS, V76, P20; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yano S, 1996, J BIOL CHEM, V271, P23520, DOI 10.1074/jbc.271.38.23520; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996	54	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31345	31351		10.1074/jbc.273.47.31345	http://dx.doi.org/10.1074/jbc.273.47.31345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813043	hybrid			2022-12-25	WOS:000077136900071
J	Belandia, B; Latasa, MJ; Villa, A; Pascual, A				Belandia, B; Latasa, MJ; Villa, A; Pascual, A			Thyroid hormone negatively regulates the transcriptional activity of the beta-amyloid precursor protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT; ALZHEIMERS-DISEASE; RECEPTOR-BINDING; CO-REPRESSOR; PROMOTER; CELLS; EXPRESSION; REGION; BRAIN; FORMS	The expression of the beta-amyloid precursor protein (APP), which plays a key role in the development of Alzheimer's disease, is regulated by a variety of cellular mediators in a cell-dependent manner. In the present study, we present evidence that thyroid hormones negatively regulate the expression of the APP gene in neuroblastoma cells. Transient transfection studies using plasmids that contain progressive deletions of the 5' region of the gene demonstrate that triiodothyronine (T3), the more active form of the thyroid hormones, represses APP promoter activity by a mechanism that requires binding of the nuclear T3 receptor (TR) to a specific sequence located in the first exon. The unliganded receptor increases promoter activity, and T3 reverses that activity to basal levels. The repressive effect of T3 does not exhibit TR isoform specificity, and it is equally mediated by TR alpha and TRP. Gel mobility shift assays using in vitro synthesized nuclear receptors and nuclear extracts led to the identification of a negative thyroid hormone response element, at nucleotide position +80/+96, that preferentially binds heterodimers of TR with the retinoid X receptor. Insertion of sequences containing this element confers negative regulation by T3 to a heterologous TK promoter, thus indicating the functionality of the element.	CSIC, Inst Invest Biomed, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Pascual, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	apascual@biomed.iib.uam.es	Latasa, Maria-Jesus/M-8704-2014; Belandia, Borja/H-1509-2015	Latasa, Maria-Jesus/0000-0003-2840-8692; Belandia, Borja/0000-0003-2448-206X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HEYMAN A, 1983, ANN NEUROL, V14, P507, DOI 10.1002/ana.410140503; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Latasa MJ, 1998, ENDOCRINOLOGY, V139, P2692, DOI 10.1210/en.139.6.2692; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILICI A, 1990, BIOCHEM BIOPH RES CO, V169, P46, DOI 10.1016/0006-291X(90)91430-Z; MORTIMER JA, 1989, ALZHEIMERS AND PARKINSONS DISEASES /, P85; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; OHYAGI Y, 1993, MOL BRAIN RES, V18, P127, DOI 10.1016/0169-328X(93)90181-N; ORTIZCARO J, 1986, ENDOCRINOLOGY, V119, P2163, DOI 10.1210/endo-119-5-2163; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SUTHERLAND MK, 1992, NEUROBIOL AGING, V13, P301, DOI 10.1016/0197-4580(92)90043-W; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TREJO J, 1994, J BIOL CHEM, V269, P21682; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	45	77	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30366	30371		10.1074/jbc.273.46.30366	http://dx.doi.org/10.1074/jbc.273.46.30366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804800	Green Submitted, hybrid			2022-12-25	WOS:000077008100047
J	Hasler, U; Wang, XY; Crambert, G; Beguin, P; Jaisser, F; Horisberger, JD; Geering, K				Hasler, U; Wang, XY; Crambert, G; Beguin, P; Jaisser, F; Horisberger, JD; Geering, K			Role of beta-subunit domains in the assembly, stable expression, intracellular routing, and functional properties of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; PRIMARY SEQUENCE; XENOPUS-OOCYTES; SIGNAL SEQUENCE; TRANSPORT; OLIGOMERIZATION; (NA+,K+)-ATPASE; TRANSMEMBRANE; INACTIVATION	The beta-subunit of Na,K-ATPase (beta NK) interacts with the catalytic alpha-subunit (alpha NK) in the ectodomain, the transmembrane, and the cytoplasmic domain. The functional significance of these different interactions was studied by expressing alpha NK in Xenopus oocytes along with N-terminally modified beta NK or with chimeric beta NK/ beta H,K-ATPase (beta HK), Complete truncation of the beta NK N terminus allows for cell surface-expressed, functional Na,K-pumps that exhibit, however, reduced apparent K+ and Na+ affinities as assessed by electrophysiological measurements. A mutational analysis suggests that these functional effects are not related to a direct interaction of the beta N terminus with the alpha NK but rather that N-terminal truncation induces a conformational change in another functionally relevant beta domain. Comparison of the functional properties of alpha NK.beta NK, alpha NK.beta HK, or alpha NK.beta NK/beta HK complexes shows that the effect of the beta NK on K+ binding is mainly mediated by its ectodomain. Finally, beta HK/NK containing the transmembrane domain of PHR produces stable but endoplasmic reticulum-retained alpha NK.beta complexes, while alpha NK/beta HK complexes can leave the ER but exhibit reduced ouabain binding capacity and transport function. Thus, interactions of both the transmembrane and the ectodomain of beta NK with alpha NK are necessary to form correctly folded Na,K-ATPase complexes that can be targeted to the plasma membrane and/or become functionally competent. Furthermore, the beta N terminus plays a role in the beta-subunit's folding necessary for correct interactions with the alpha-subunit.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009; Jaisser, Frederic/P-4287-2017	Jaisser, Frederic/0000-0001-9051-1901; Crambert, Gilles/0000-0001-7065-9124				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHOW DC, 1995, J EXP BIOL, V198, P1; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1997, MOL B INT U, P173; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; High S, 1997, TRENDS CELL BIOL, V7, P206; HORISBERGER JD, 1994, NA K ATPASE STRUCTUR, P1; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Lyu RM, 1997, AM J PHYSIOL-CELL PH, V272, pC1717, DOI 10.1152/ajpcell.1997.272.5.C1717; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; Schneider H, 1997, J BIOL CHEM, V272, P16158, DOI 10.1074/jbc.272.26.16158; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; VONHEIJNE G, 1995, BIOESSAYS, V17, P25, DOI 10.1002/bies.950170107; WANG SG, 1997, AM J PHYSIOL, V41, pC923; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241	36	130	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30826	30835		10.1074/jbc.273.46.30826	http://dx.doi.org/10.1074/jbc.273.46.30826			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804861	hybrid			2022-12-25	WOS:000077008100108
J	Barth, H; Preiss, JC; Hofmann, F; Aktories, K				Barth, H; Preiss, JC; Hofmann, F; Aktories, K			Characterization of the catalytic site of the ADP-ribosyltransferase Clostridium botulinum C2 toxin by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFRINGENS-IOTA-TOXIN; NAD-BINDING-SITE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; HEAT-LABILE ENTEROTOXIN; AERUGINOSA EXOTOXIN-A; DIPHTHERIA-TOXIN; CRYSTAL-STRUCTURE; ACTIVE-SITE; PERTUSSIS TOXIN; BINARY TOXIN	The actin ADP-ribosylating Clostridium botulinum C2 toxin is a binary toxin composed of the binding component C2II and the enzyme component C2I. C2I ADP-ribosylates G-actin at arginine 177, resulting in the depolymerization of the actin cytoskeleton. Here, we studied the structure-function relationship of C2I by site-directed mutagenesis. Exchange of Glu(389) to glutamine caused the complete loss of ADP-ribosyltransferase and NAD-glycohydrolase activities of C2I. In contrast, exchange of Glu(387) to glutamine blocked ADP-ribosyltransferase but not NAD-glycohydrolase activity. Whereas photoaffinity labeling of the double mutant E387Q/E389Q C2I with [carbonyl-C-14]NAD was blocked, labeling of the single C2I mutants was reduced (E389Q) or not changed (E387Q). Exchange of the STS motif (amino acid residues 348-350) of C2I caused a decrease in transferase activity by more than 99 (S348A) and 90% (T349V), or did not affect activity (S350A). Exchange of Arg(299) and Arg(300) to lysine reduced transferase activity to <0.1 and similar to 35% of wild-type activity. The data indicate that the amino acid residues Glu(389), Glu(387), Ser(348), and Arg(299), which are conserved in various prokaryotic and eukaryotic arginine-modifying ADP-ribosyltransferases, are essential for ADP-ribosyltransferase activity of the enzyme component of C. botulinum C2 toxin.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	aktories@uni-freiburg.de	Barth, Holger/E-7920-2013; Preiß, Jan/N-4976-2019; Aktories, Klaus/CAJ-5682-2022	Preiß, Jan/0000-0002-0901-1422; Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Bohmer J, 1996, BIOCHEMISTRY-US, V35, P282, DOI 10.1021/bi951784+; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; Fujii N, 1996, BIOCHEM BIOPH RES CO, V220, P353, DOI 10.1006/bbrc.1996.0409; GEIPEL U, 1989, EUR J BIOCHEM, V179, P229, DOI 10.1111/j.1432-1033.1989.tb14545.x; GIERSCHIK P, 1992, HDB EXPT PHARM, P807; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; JOHNSON VG, 1994, J BIOL CHEM, V269, P4349; JUNG M, 1993, J BIOL CHEM, V268, P23215; KochNolte F, 1996, IMMUNOL TODAY, V17, P402, DOI 10.1016/0167-5699(96)30023-6; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; MAUSS S, 1990, EUR J BIOCHEM, V194, P237, DOI 10.1111/j.1432-1033.1990.tb19448.x; Moss J, 1997, J BIOL CHEM, V272, P4342, DOI 10.1074/jbc.272.7.4342; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; OKAZAKI IJ, 1994, MOL CELL BIOCHEM, V138, P177, DOI 10.1007/BF00928460; Perelle S, 1997, INFECT IMMUN, V65, P1402, DOI 10.1128/IAI.65.4.1402-1407.1997; Perelle S, 1996, FEBS LETT, V395, P191, DOI 10.1016/0014-5793(96)01035-6; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SIMPSON LL, 1987, INFECT IMMUN, V55, P118, DOI 10.1128/IAI.55.1.118-122.1987; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; vanDamme J, 1996, FEBS LETT, V380, P291, DOI 10.1016/0014-5793(96)00052-X; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WILLE M, 1992, J BIOL CHEM, V267, P50; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27	44	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29506	29511		10.1074/jbc.273.45.29506	http://dx.doi.org/10.1074/jbc.273.45.29506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792657	hybrid			2022-12-25	WOS:000076798300034
J	Gebauer, M; Melki, R; Gehring, U				Gebauer, M; Melki, R; Gehring, U			The chaperone cofactor Hop/p60 interacts with the cytosolic chaperonin-containing TCP-1 and affects its nucleotide exchange and protein folding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CYTOPLASMIC CHAPERONIN; RETICULOCYTE LYSATE; REFOLDING ACTIVITY; ESCHERICHIA-COLI; BINDING DOMAINS; REACTION CYCLE; BETA-TUBULIN; IN-VITRO; COMPLEX	The folding of protein structures often: requires the presence of molecular chaperones and/or chaperonin complexes. We here investigated the inhibitory effects of the chaperone cofactors Hop/p60 and Hap46. By coimmunoprecipitation, we observed a direct interaction of the eukaryotic chaperonin-containing TCP-1 (CCT) purified from rabbit reticulocyte lysate with Hop/p60. By contrast, Hap46 was not coprecipitated. Binding of Hop/p60 to CCT is dependent on the presence of ATP or ADP and occurs through carboxyl-terminal sequences of Hop/p60. Hop/p60 significantly stimulates nucleotide exchange on CCT but not its ATPase activity, while Hap46 has no effects. We used denatured firefly luciferase as a model protein and found decreased binding to CCT in the presence of Hop/p60 and ATP. This coincides with the inhibitory effect of Hop/p60 on luciferase reactivation in an assay using purified CCT in combination with hsc70 and hsp40. We also observed that an antibody directed against one of the subunits of CCT efficiently inhibits refolding in a system which depends on crude reticulocyte lysate.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Gehring, U (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 501, D-69120 Heidelberg, Germany.							Beissinger M, 1998, BIOL CHEM, V379, P245; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; GEBAUER M, 1998, IN PRESS MOL CELL BI; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Moore DD, 1995, GLOB MOB SURV; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	38	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29475	29480		10.1074/jbc.273.45.29475	http://dx.doi.org/10.1074/jbc.273.45.29475			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792653	hybrid			2022-12-25	WOS:000076798300030
J	Mazumdar, M; Cross, RA				Mazumdar, M; Cross, RA			Engineering a lever into the kinesin neck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; MICROTUBULE MOVEMENT; STRUCTURAL REPEATS; CRYSTAL-STRUCTURE; FORCE GENERATION; SPECTRIN REPEAT; MOLECULAR MOTOR; MYOSIN MOTORS; COILED-COIL; NCD	To probe for a lever arm action in the kinesin stepping mechanism, we engineered a rodlike extension piece into the tail of rat kinesin at various points close to the head-tail junction and measured its effects on the temperature dependence of velocity in microtubule gliding assays. The insert comprised two contiguous alpha-actinin triple coil repeats and was predicted to fold into a stiff rodlike module about 11 nm long. The effects of this module were greater the closer it was placed to the head-tail junction. When inserted distal to the head-tail junction, at Asn(401) in the dimeric K partial derivative 401GST, the insert had no effect. When inserted closer to the heads at Val(376) into K partial derivative 376GST, the insert slowed progress below 22 degrees C but accelerated progress to similar to 125% of wild type above 22 degrees C. The most dramatic effect of the synthetic lever occurred when it was inserted very close to the head-neck junction, at Glu(340) into the single-headed construct K partial derivative 340GST. This construct was immotile without the insert, but motile with it, at about 30% of the velocity of the dimeric control. The alpha-actinin module thus confers some gain of-function when inserted close to the head-neck. junction but not when placed distal to it. The data exclude the presence of a lever arm C-terminal to Val(376) in the kinesin tail but suggest that a short-throw lever arm may be present, N-terminal to Val(376) and contiguous with the head-neck junction at Ala(339).	Marie Curie Res Inst, Mol Motors Grp, Surrey RH8 0TL, England		Cross, RA (corresponding author), Marie Curie Res Inst, Mol Motors Grp, Surrey RH8 0TL, England.		Cross, Robert A/F-1798-2011	Cross, Robert A/0000-0002-0004-7832				Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; BARON MD, 1987, J BIOL CHEM, V262, P2558; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; Block SM, 1998, J CELL BIOL, V140, P1281, DOI 10.1083/jcb.140.6.1281; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; Cross RA, 1997, NATURE, V389, P15, DOI 10.1038/37864; Cross RA, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P317; CROSS RA, 1997, CURR BIOL, V7, P631; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; Flood G, 1997, EUR BIOPHYS J BIOPHY, V25, P431, DOI 10.1007/s002490050057; FLOOD GJ, 1995, BIOCHEM SOC T, V23, pS399, DOI 10.1042/bst023399s; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HOWARD J, 1993, METHOD CELL BIOL, V39, P137, DOI 10.1016/S0091-679X(08)60167-3; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1957, PROGR BIOPHYS BIOPHY, V7, P257; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Morii H, 1997, BIOCHEMISTRY-US, V36, P1933, DOI 10.1021/bi962392l; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Tripet B, 1997, J BIOL CHEM, V272, P8946; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Winkler J, 1997, EUR J BIOCHEM, V248, P193, DOI 10.1111/j.1432-1033.1997.00193.x; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n	47	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29352	29359		10.1074/jbc.273.45.29352	http://dx.doi.org/10.1074/jbc.273.45.29352			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792635	hybrid			2022-12-25	WOS:000076798300012
J	Reed, SH; You, ZY; Friedberg, EC				Reed, SH; You, ZY; Friedberg, EC			The yeast RAD7 and RAD16 genes are required for postincision events during nucleotide excision repair - In vitro and in vivo studies with rad7 and rad16 mutants and purification of a Rad7/Rad16-containing protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE DIMER REMOVAL; ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; DIFFERENTIAL REPAIR; DROSOPHILA EMBRYOS; ESCHERICHIA-COLI; THYMINE DIMERS; ACTIVE GENE; UV DAMAGE	In eukaryotes, nucleotide excision repair (NER) is a complex reaction requiring multiple proteins. In the yeast Saccharomyces cerevisiae, two of these proteins, Rad7 and Rad16, are specifically involved in the removal of lesions from transcriptionally silent regions of the genome in vivo, Extracts prepared from rad7 or rad16 mutant cells are deficient, but not totally defective, in both oligonucleotide excision and repair synthesis of damaged plasmid DNA, We show that these extracts are, however, fully proficient in the incision step of the NER reaction in vitro. Furthermore, using a cdcs mutant to trap incision intermediates, we demonstrate that rad7 and rad16 mutants are proficient in NER-dependent DNA incision in vivo, A purified protein complex containing both Rad7 and Rad16 proteins complements the oligonucleotide excision and repair synthesis defects in rad7 and rad16 mutant extracts. We conclude that the products of the RAD7 and RAD16 genes are involved in a postincision event(s) during NER in yeast.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	friedberg.errol@pathology.svvmed.edu		Reed, Simon/0000-0002-4711-0560	NCI NIH HHS [CA12428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BARKER DG, 1985, MOL GEN GENET, V200, P458, DOI 10.1007/BF00425731; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CAMPBELL I, 1988, YEAST PRACTICAL APPR; FRIEDBERG EC, 1995, PHILOS T ROY SOC B, V347, P63, DOI 10.1098/rstb.1995.0010; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Ordoukhanian P, 1997, NUCLEIC ACIDS RES, V25, P3783, DOI 10.1093/nar/25.19.3783; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sherman F., 1986, METHODS YEAST GENETI; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANHOUTEN B, 1987, J BACTERIOL, V169, P540, DOI 10.1128/jb.169.2.540-545.1987; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Verhage RA, 1996, MOL CELL BIOL, V16, P496; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; Wang ZG, 1996, MUTAT RES-DNA REPAIR, V364, P33, DOI 10.1016/0921-8777(96)00019-5; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668	35	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29481	29488		10.1074/jbc.273.45.29481	http://dx.doi.org/10.1074/jbc.273.45.29481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792654	hybrid			2022-12-25	WOS:000076798300031
J	Wang, D; Baldwin, AS				Wang, D; Baldwin, AS			Activation of nuclear factor-kappa B-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; KINASE; P65; MECHANISM; SUBUNITS; FAMILY; COACTIVATORS; SEQUENCES; EPSILON; MEMBER	Nuclear factor-kappa B (NF-kappa B) is an essential transcription factor in the control of expression of genes involved in immune and inflammatory responses. In unstimulated cells, NF-kappa B complexes are sequestered in the cytoplasm through interactions with I kappa B alpha and other I kappa B proteins. Extracellular stimuli that activate NF-kappa B, such as tumor necrosis factor alpha (TNF alpha), cause rapid phosphorylation of I kappa B alpha at serines 32 and 36. The inducible phosphorylation of I kappa B alpha is followed by its ubiquitination and degradation, allowing NF-kappa B complexes to translocate into the nucleus and to activate gene expression. Previously, it has been shown that TNF alpha as well as other stimuli also lead to the phosphorylation of the RelA/p65 subunit of NF-kappa B. In this report, we demonstrate that the TNF alpha-induced phosphorylation of the RelA/p65 subunit occurs on serine 529, which is in the C-terminal (TA1) transactivation domain. Accordingly, the TNF alpha-induced phosphorylation of Rel/p65 increases NF-kappa B transcriptional activity but does not affect nuclear translocation or DNA binding affinity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	35	308	315	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29411	29416		10.1074/jbc.273.45.29411	http://dx.doi.org/10.1074/jbc.273.45.29411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792644	Green Published, hybrid			2022-12-25	WOS:000076798300021
J	Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M				Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M			Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer	ONCOGENE			English	Article						nitric oxide; glioma; CD 95 ligand; p53	NITRIC-OXIDE SYNTHASE; WILD-TYPE P53; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; TATA-BINDING PROTEIN; GROWTH-FACTOR-BETA; GLIAL-CELLS; ENDOTHELIAL-CELLS; BCL-2 EXPRESSION; L-ARGININE	Nitric oxide (NO) is thought to play an important role in neurotransmission, inflammation, and regulation of cell death in the mammalian brain. Here, we examined the synthesis and biological effects of NO in human malignant glioma cells. Exposure to cytokines such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta and lipopolysaccharide (LPS) induced NO synthesis in rat C6 and A172 human glioma cells, but not in LN-229, T98G or LN-18 human malignant glioma cells. Induced release of NO involved enhanced expression of inducible NO synthase (iNOS). Failure to detect NO release in the latter cell lines was not overcome by neutralization of endogenous TGF-beta or by coexposure to cytokines, LPS, and antioxidants. Apoptosis induced by CD95 ligand (CD95L) did not involve NO formation. Neither NOS inhibitors nor NO donators modulated CD95L-induced apoptosis. Dexamethasone (DEX)-mediated protection of glioma cells from CD95L-induced apoptosis was also independent of DEX effects on NO metabolism. DEX inhibited not only cytokine/ LPS-evoked NO release but also attenuated the toxicity of NO in three of five cell lines. Forced expression of temperature-sensitive p53 val(135) in C6 cells in either mutant or wild-type conformation inhibited cytokine/LPS-induced NO synthesis. Further, accumulation of p53 in both mutant or wild-type conformation protected glioma cells from the toxicity of exogenous NO, consistent with a gain of p53 function associated with p53 accumulation. We conclude that resistance to NO-dependent immune defense mechanisms may contribute to the malignant progression of human cancers with p53 alterations, notably those associated with the accumulation of mutant p53 protein.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany; Univ Tubingen, Sch Med, Dept Neurol, Neuropharmacol Lab, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany.		Heneka, Michael/E-8072-2015	Heneka, Michael/0000-0003-4996-1630; Weller, Michael/0000-0002-1748-174X				ALBINA JE, 1993, J IMMUNOL, V150, P5080; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BERNATOWICZ A, 1995, J NEUROIMMUNOL, V60, P53, DOI 10.1016/0165-5728(95)00053-5; BIANCO FJ, 1995, AM J PATHOL, V146, P75; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Calmels S, 1997, CANCER RES, V57, P3365; COBBS CS, 1995, CANCER RES, V55, P727; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ellie E, 1995, NEUROREPORT, V7, P294, DOI 10.1097/00001756-199512290-00070; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Kawase M, 1996, BRAIN RES, V738, P319, DOI 10.1016/S0006-8993(96)00924-9; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MURATA J, 1995, INT J CANCER, V62, P743, DOI 10.1002/ijc.2910620616; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P597; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TREPEL M, 1997, J NEUROONCOL; TREPEL M, 1997, IN PRESS LEUKEMIA; TREPEL M, 1996, J NEUROONCOL, V30, P95; VAN MEIR EG, 1994, CANCER RES, V54, P649; VIGNE P, 1993, BRAIN RES, V606, P332, DOI 10.1016/0006-8993(93)91003-B; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wagenknecht B, 1997, FEBS LETT, V409, P17, DOI 10.1016/S0014-5793(97)00468-7; WAGENKNECHT B, 1997, CELL PHYSIOL BIOCHEM, V19, P459; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	53	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2323	2332		10.1038/sj.onc.1202154	http://dx.doi.org/10.1038/sj.onc.1202154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811463				2022-12-25	WOS:000076723300006
J	Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA				Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA			p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours	ONCOGENE			English	Article						BRCA1; BRCA2; p53; mutation(s); breast; tumour; familial	WILD-TYPE CHROMOSOME; OVARIAN-CANCER; FAMILIAL BREAST; MICROSATELLITE INSTABILITY; GERMLINE MUTATIONS; POINT MUTATION; CELL-LINES; GENE; CARCINOMA; TUMORS	The status of p53 was investigated in breast tumours arising in germ-line carriers of mutant alleles of BRCA1 and BRCA2 and in a control series of sporadic breast tumours, p53 expression was detected in 20/26 (77%) BRCA1-, 10/22 (45%) BRCA2-associated and 25/72 (35%) grade-matched sporadic tumours, Analysis of p53 sequence revealed that the gene was mutant in 33/50 (66%) BRCA-associated tumours, whereas 7/20 (35%) sporadic grade-matched tumours contained p53 mutation (P<0.05), A number of the mutations detected in the BRCA-associated tumours have not been previously described in human cancer databases, whilst others occur extremely rarely. Analysis of additional genes, p16(INK4), Ki-ras and beta-globin revealed absence or very low incidence of mutations, suggesting that the higher frequency of p53 mutation in the BRCA-associated tumours does not reflect a generalized increase in susceptibility to the acquisition of somatic mutation. Furthermore, absence of frameshift mutations in the polypurine tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies that loss of function of BRCA1 or BRCA2 does not confer a mutator phenotype such as that found in tumours with microsatellite instability (MST), p21(Waf1) was expressed in BRCA-associated tumours regardless of p53 status and, furthermore, some tumours expressing wild-type p53 did not express detectable p21(Waf1). These data do not support, therefore, the simple model based on studies of BRCA-/- embryos, in which mutation of p53 in BRCA-associated tumours results in loss of p21(Waf1) expression and deregulated proliferation, Rather, they imply that proliferation of such tumours will be subject to multiple mechanisms of growth regulation.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009	Yulug, Isik/0000-0002-7577-2502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOS JL, 1989, CANCER RES, V49, P4682; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1996, CANCER RES, V56, P471; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GLEBOV OK, 1994, CANCER RES, V54, P3703; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Visscher DW, 1996, DIAGN MOL PATHOL, V5, P187, DOI 10.1097/00019606-199609000-00007; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; XU L, 1994, CANCER RES, V54, P5262; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; ZHANG SY, 1994, CANCER RES, V54, P5050	44	147	150	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1681	1689		10.1038/sj.onc.1202106	http://dx.doi.org/10.1038/sj.onc.1202106			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796697	Green Published			2022-12-25	WOS:000076200100006
J	Smas, CM; Kachinskas, D; Liu, CM; Xie, XZ; Dircks, LK; Sul, HS				Smas, CM; Kachinskas, D; Liu, CM; Xie, XZ; Dircks, LK; Sul, HS			Transcriptional control of the pref-1 gene in 3T3-L1 adipocyte differentiation - Sequence requirement for differentiation-dependent suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; EPIDERMAL-GROWTH-FACTOR; DNA RESPONSE ELEMENT; ESTROGEN-RECEPTOR; POLYMERASE-II; CELL-CYCLE; EXPRESSION; REPRESSION; ALPHA; ADIPOGENESIS	Preadipocyte factor-1 (Pref-1) is a transmembrane epidermal growth factor-like domain-containing protein highly expressed in 3T3-L1 preadipocytes, but is undetectable in mature fat cells; this down-regulation is required for adipocyte differentiation. We show here that pref-1 transcription is markedly suppressed during adipose conversion and results in decreased Pref-1 RNA levels. Using 3T3-L1 cells stably transfected with Pref-1 5'-deletion constructs truncated at -6000, -2100, -1300, -692, -300, -235, -193, -183, -170, -93, and -45 base pairs, we determined that the -183 to -170 region is responsible for the suppression of the pref-1 gene during adipogenesis, This is distinct from the -93 to -45 sequence important for pref-1 promoter activity in preadipocytes, The placement of a 40-base pair -193 to -154 pref-1 sequence containing the putative SAD (suppression in adipocyte differentiation) element upstream of the SV40 promoter decreased promoter activity by 85% upon adipocyte differentiation, compared with 40% observed with the SV40 promoter alone. The SAD element is therefore sufficient for adipocyte differentiation-dependent down-regulation of a heterologous promoter. A DNA-protein complex was observed when the -193 to -174 sequence was used with 3T3-L1 nuclear extracts in gel mobility shift assays. Competition with oligonucleotides harboring base substitution mutations identified a core sequence of (-183)AAAGA(-179) as crucial for DNA-protein complex formation. UV cross-linking predicts that an similar to 63-kDa protein specifically binds the SAD element.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.		Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [F32 DK09562, DK50828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHN JD, 1995, NATURE, V377, P454; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DJIAN P, 1988, GENE DEV, V2, P1251, DOI 10.1101/gad.2.10.1251; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; INOSTROZA JA, 1992, CELL, V70, P477; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; Jensen CH, 1997, CLIN CHIM ACTA, V268, P1, DOI 10.1016/S0009-8981(97)00152-6; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Smas CM, 1996, INT J OBESITY, V20, pS65; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tang QQ, 1997, P NATL ACAD SCI USA, V94, P13571, DOI 10.1073/pnas.94.25.13571; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	61	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31751	31758		10.1074/jbc.273.48.31751	http://dx.doi.org/10.1074/jbc.273.48.31751			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822638	hybrid			2022-12-25	WOS:000077207000020
J	Falcone, DJ; Khan, KMF; Layne, T; Fernandes, L				Falcone, DJ; Khan, KMF; Layne, T; Fernandes, L			Macrophage formation of angiostatin during inflammation - A byproduct of the activation of plasminogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR; TUMOR-GROWTH; MICE; SUPPRESSION; CARCINOMA; RECEPTOR; CANCER; CELLS; GENE	Angiostatin is a potent inhibitor of tumor angiogenesis and the growth of metastatic foci. Recent studies have indicated that neoplastic cells can generate angiostatin directly or in cooperation with tumor-associated macrophages. In studies reported here, we determined whether angiostatin is generated in mice under non-neoplastic: settings. Utilizing murine RAW264.7 macrophages and thioglycollate-elicited peritoneal macrophages, we demonstrate that angiostatin-like fragments are generated as a byproduct of the proteolytic regulation of membrane-bound plasmin. Plasmin proteolysis and subsequent loss in membrane-bound plasmin activity requires active plasmin but was unaffected by inhibitors of metalloproteinases. Lysine binding fragments of plasmin, isolated from macrophage-conditioned media utilizing affinity chromatography, appeared as a major (48 kDa) and two minor bands (42 and 50 kDa) in SDS-polyacrylamide gel electrophoresis and were immunoreactive with anti-kringle 1-3 IgG. Each peptide begins with Lys(77) and contains the entire sequence of angiostatin. The affinity isolated plasmin fragments inhibited bFGF-induced endothelial cell proliferation. Lavage fluid recovered from the peritoneal cavities of mice previously injected with thioglycollate contained angiostatin-like plasmin fragments similar to those generated in vitro. This is the first demonstration that angiostatin-like plasmin fragments are generated in a non-neoplastic inflammatory setting. Thus, in addition to regulating pericellular plasmin activity, proteolysis of plasmin generates inactive kringle-containing fragments expressing angiostatic properties.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Cornell University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, Rm A678,1300 York Ave, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423, R01HL040819] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40819, T32-HL07423-18] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1994, J BIOL CHEM, V269, P32660; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Sim BKL, 1997, CANCER RES, V57, P1329; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032	25	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31480	31485		10.1074/jbc.273.47.31480	http://dx.doi.org/10.1074/jbc.273.47.31480			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813061	hybrid			2022-12-25	WOS:000077136900089
J	Kuramasu, A; Saito, H; Suzuki, S; Watanabe, T; Ohtsu, H				Kuramasu, A; Saito, H; Suzuki, S; Watanabe, T; Ohtsu, H			Mast cell-/basophil-specific transcriptional regulation of human L-histidine decarboxylase gene by CpG methylation in the promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; CYTOSINE METHYLATION; CHROMATIN STRUCTURE; BINDING-PROTEIN; EXPRESSION; LINE; 5-METHYLCYTOSINE; DEMETHYLATION; LEUKEMIA; ENHANCER	L-Histidine decarboxylase (HDC) catalyzes the formation of histamine from L-histidine, and in hematopoietic cell Lineages the gene is expressed only in mast cells and basophils, We attempted here to discover how HDC gene expression is restricted in these cells. In the cultured cell. lines tested, only the mast cells and basophils strongly transcribed the HDC gene. However, in transient transfection analysis, the reporter constructs with the HDC promoter were active not only in expressing cells but also in nonexpressing cells. Detailed analyses of the HDC promoter region revealed that the GC box is essential for transactivation. Also, the promoter region of the HDC gene proved to be sensitive to DNase I and restriction endonucleases exclusively in HDC-expressing cells, suggesting that the promoter region is readily accessible to trans-acting factor(s), Furthermore, the promoter region in HDC-expressing cell lines was found to be selectively unmethylated, The correlation between HDC expression and hypomethylation was also found in primary human mast cells. Methylation of the HDC promoter in vitro reduced the luciferase reporter activity in transient expression analysis, suggesting that methylation of the promoter region is functionally important for HDC gene expression. These results imply that alteration of DNA methylation is one of the mechanisms regulating cell-specific expression of the HDC gene.	Tohoku Univ, Sch Med, Dept Cellular Pharmacol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Natl Childrens Med Res Ctr, Div Allergy, Setagaya Ku, Tokyo 1548509, Japan	Tohoku University; National Center for Child Health & Development - Japan	Ohtsu, H (corresponding author), Tohoku Univ, Sch Med, Dept Cellular Pharmacol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.			Saito, Hirohisa/0000-0002-6630-8337				ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BURLAND WL, 1982, PHARM HISTAMINE RECE, P436; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUKUDA T, 1987, BLOOD, V70, P612; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HENKEL G, 1992, J IMMUNOL, V149, P3239; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAMUNESATO R, 1992, EUR J BIOCHEM, V209, P533, DOI 10.1111/j.1432-1033.1992.tb17317.x; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nakagawa S, 1997, J BIOCHEM-TOKYO, V121, P935; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OCONNER JL, 1992, BIOTECHNIQUES, V12, P238; Ohtsu H, 1996, J BIOL CHEM, V271, P28439, DOI 10.1074/jbc.271.45.28439; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Saito H, 1996, J IMMUNOL, V157, P343; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; WATANABE T, 1991, HISTAMINE HISTAMINE, P145; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WENG A, 1995, MOL CELL BIOL, V15, P572, DOI 10.1128/MCB.15.1.572; YATSUNAMI K, 1994, J BIOL CHEM, V269, P1554; ZON LI, 1991, J BIOL CHEM, V266, P22948	52	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31607	31614		10.1074/jbc.273.47.31607	http://dx.doi.org/10.1074/jbc.273.47.31607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813077	hybrid			2022-12-25	WOS:000077136900105
J	Dahan-Grobgeld, E; Livneh, Z; Maretzek, AF; Polak-Charcon, S; Eichenbaum, Z; Degani, H				Dahan-Grobgeld, E; Livneh, Z; Maretzek, AF; Polak-Charcon, S; Eichenbaum, Z; Degani, H			Reversible induction of ATP synthesis by DNA damage and repair in Escherichia coli - In vivo NMR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; GENETIC-RECOMBINATION; SOS INDUCTION; RECA PROTEIN; SPECTROSCOPY; CELLS; SYSTEM; RAD51; ENERGETICS; MECHANISM	Early metabolic events in Escherichia coli exposed to nalidixic acid, a topoisomerase II inhibitor and an in ducer of the SOS system, were investigated by in vivo NMR spectroscopy, a technique that permits monitoring of bacteria under controlled physiological conditions. The energetics of AB1157 (wild type) and of its isogenic, SOS-defective mutants, recBC, lexA, and Delta recA, were studied by P-31 and F-19 NMR before, during, and after exposure to nalidixic acid. The content of the NTP in E. coli embedded in agarose beads and perfused at 36 degrees C was found to be 4.3 +/- 1.1 x 10(-18) mol/cell, yielding a concentration of similar to 2.7 +/- 0.7 mM. Nalidixic acid induced in the wild type and mutants a rapid 2-fold increase in the content of the NTP, predominantly ATP. This induction did not involve synthesis of uracil derivatives or breakdown of RNA and caused cell proliferation to stop. Removal of nalidixic acid after 40 min of treatment rescued the cells and resulted in a decrease of ATP to control levels and resumption of proliferation. However, in Delta recA cells, which were more sensitive to the activity of the drug, ATP elevation could not be reversed, and ATP content continued to increase faster than in control cells. The results ruled out association between the elevation of ATP and the induction of the SOS system and suggested involvement of a process reminiscent of apoptosis in the stimulation of ATP synthesis. Thus, the presence of the RecA protein was found to be essential for reversing the ATP increase and cell rescue, possibly by its function in repair of DNA damage.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center	Degani, H (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	cidegani@weizmann.weizmann.ac.il	Eichenbaum, Zehava/A-7627-2009					ALAM KY, 1989, J BACTERIOL, V171, P6213, DOI 10.1128/jb.171.11.6213-6217.1989; BAILONE A, 1985, P NATL ACAD SCI USA, V82, P5973, DOI 10.1073/pnas.82.17.5973; BARBE J, 1986, J BACTERIOL, V167, P1055, DOI 10.1128/jb.167.3.1055-1057.1986; BARBE J, 1983, BIOCHEM BIOPH RES CO, V117, P556, DOI 10.1016/0006-291X(83)91236-6; BECHTEL DB, 1976, J BACTERIOL, V127, P1472, DOI 10.1128/JB.127.3.1472-1481.1976; BENTAL M, 1990, EUR J BIOCHEM, V188, P111, DOI 10.1111/j.1432-1033.1990.tb15377.x; BERGHMANS K, 1992, BIOCHEM BIOPH RES CO, V183, P114, DOI 10.1016/0006-291X(92)91616-X; BRIASCO CA, 1990, BIOTECHNOL BIOENG, V36, P887, DOI 10.1002/bit.260360904; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; Chen G.L, 1986, ANNU REP MED CHEM, V21, P257, DOI [10.1016/S0065-7743(08)61134-3, DOI 10.1016/S0065-7743(08)61134-3]; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COOK TM, 1966, J BACTERIOL, V91, P774, DOI 10.1128/JB.91.2.774-779.1966; DAHANGROBGELD E, 1995, P SOC MAGN RES 3 SCI, P1698; DEJONG S, 1991, BRIT J CANCER, V63, P205, DOI 10.1038/bjc.1991.50; GUERRERO R, 1984, J GEN MICROBIOL, V130, P2247; HILLS DC, 1966, BIOCHEMISTRY-US, V5, P1625, DOI 10.1021/bi00869a025; HOROWITZ J, 1977, J BIOL CHEM, V252, P4418; HUFF AC, 1990, J BIOL CHEM, V265, P20496; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; KAISER II, 1969, BIOCHEMISTRY-US, V8, P231, DOI 10.1021/bi00829a033; KARU AE, 1982, MOL GEN GENET, V185, P275, DOI 10.1007/BF00330798; KORENBERG A, 1992, DNA REPLICATION, P54; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Kupfer G, 1987, NCI Monogr, P37; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; KWOK JBJ, 1992, BRIT J CANCER, V65, P503, DOI 10.1038/bjc.1992.104; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIU J, 1994, P NATL ACAD SCI USA, V91, P4618, DOI 10.1073/pnas.91.11.4618; MARSHALL AG, 1980, BIOCHEMISTRY-US, V19, P5955, DOI 10.1021/bi00567a002; MOUNT DW, 1972, J BACTERIOL, V112, P886, DOI 10.1128/JB.112.2.886-893.1972; NAGATE T, 1990, J CLIN GASTROENTEROL, V12, pS135, DOI 10.1097/00004836-199001001-00023; NEEMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P255, DOI 10.1016/0167-4889(90)90219-4; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; UGURBIL K, 1982, BIOCHEMISTRY-US, V21, P1068, DOI 10.1021/bi00534a038; UGURBIL K, 1979, BIOL APPL MAGNETIC R, P527; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528	44	26	26	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30232	30238		10.1074/jbc.273.46.30232	http://dx.doi.org/10.1074/jbc.273.46.30232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804781	hybrid			2022-12-25	WOS:000077008100028
J	Lombardi, SJ; Truong, A; Spence, P; Rhodes, KJ; Jones, PG				Lombardi, SJ; Truong, A; Spence, P; Rhodes, KJ; Jones, PG			Structure-activity relationships of the K-v beta 1 inactivation domain and its putative receptor probed using peptide analogs of voltage-gated potassium channel alpha- and beta-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ION CHANNELS; K+ CHANNEL; FUNCTIONAL-CHARACTERIZATION; RAT-BRAIN; LIBRARIES; PHAGE; EXPRESSION; DIVERSITY; LIGANDS; SURFACE	Certain beta-subunits exert profound effects on the kinetics of voltage-gated (K-v) potassium channel inactivation through an interaction between the amino-terminal "inactivation domain" of the beta-subunit and a "receptor" located at or near the cytoplasmic mouth of the channel pore. Here we used a bacterial random peptide library to examine the structural requirements for this interaction. To identify peptides that bind K(v)1.1 we screened the library against a synthetic peptide corresponding to the predicted S4-S5 cytoplasmic loop of the K(v)1.1 alpha-subunit (residues 313-328), Among the highest affinity interactors were peptides with significant homology to the amino terminus of K(v)beta 1. We performed a second screen using a peptide from the amino terminus of K(v)beta 1 (residues 2-31) as "bait" and identified peptide sequences with significant homology to the 54-55 loop of K(v)1.1. A series of synthetic peptides containing mutations of the wild-type K(v)beta 1 and K(v)1.1 sequences were examined for their ability to inhibit Kv beta 1/K(v)1.1 binding. Amino acids Arg(20) and Leu(21) in K(v)beta 1 and residues Arg(324) and Leu(328) in K(v)1.1 were found to be important for the interaction. Taken together, these data provide support for the contention that the 54-55 loop of the K(v)1.1 alpha subunit is the likely acceptor for the Kv beta 1 inactivation domain and provide information about residues that may underlie the protein-protein interactions responsible for beta-subunit mediated K-v channel inactivation.	Wyeth Ayerst Res, CNS Disorders, Princeton, NJ 08543 USA	Pfizer	Lombardi, SJ (corresponding author), Wyeth Ayerst Res, CNS Disorders, CN-8000, Princeton, NJ 08543 USA.							CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HILLE B, 1992, CHANNELS EXCITABLE M; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; LATORRE R, 1984, ANNU REV PHYSIOL, V46, P485; Leicher T, 1996, NEUROPHARMACOLOGY, V35, P787, DOI 10.1016/0028-3908(96)00133-5; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MAJUMDER K, 1995, FEBS LETT, V370, P32; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MCMORMACK K, 1995, FEBS LETT, V370, P32; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakamura RL, 1997, J BIOL CHEM, V272, P1011, DOI 10.1074/jbc.272.2.1011; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SHI GY, 1994, J BIOL CHEM, V269, P23204; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	32	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30092	30096		10.1074/jbc.273.46.30092	http://dx.doi.org/10.1074/jbc.273.46.30092			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804762	hybrid			2022-12-25	WOS:000077008100009
J	Safer, JD; Cohen, RN; Hollenberg, AN; Wondisford, FE				Safer, JD; Cohen, RN; Hollenberg, AN; Wondisford, FE			Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; ERBA-BETA GENE; NUCLEAR-RECEPTOR; RETINOIC ACID; CO-REPRESSOR; TRANSCRIPTIONAL ACTIVATION; ONCOGENE PRODUCT; RESPONSE ELEMENT; COACTIVATOR; MUTATION	On positive thyroid hormone response elements (pTREs), thyroid hormone receptor (TR) binding to DNA in the absence of ligand (thyroid hormone, T-3) decreases transcription (silencing). Silencing is due to a family of recently described nuclear corepressor proteins (NCoR and SMRT) which bind to the CoR box in the hinge region of TR. Ligand-dependent activation of TR is associated with displacement of corepressors and recruitment of coactivating proteins. Resistance to thyroid hormone (RTH) is due to mutations in the beta isoform of the thyroid hormone receptor (TR-beta). To date, three RTH mutations reportedly with near-normal T-3 binding (A234T, R243Q, and R243W) have been described in or near the CoR box. To determine the mechanism of RTH caused by these mutants, the interaction of wild type (wt) and mutant TRs with the corepressor, NCoR, and the coactivator, SRC-1, was tested in gel-shift assays. As expected, NCoR bound wt TR in the absence of T-3 and dissociated from TR with increasing T-3 concentration. SRC-1 failed to bind wt TR in the absence of T-3, but bound to TR with increasing avidity as T-3 concentrations rose. At no T-3 concentration did both NCoR and SRC-1 bind to wt TR, indicating that their binding to TR was mutually exclusive. Hinge mutants bound NCoR normally in the absence of T-3; however, dissociation of NCoR and recruitment of SRC-1 was markedly impaired except at very high T-3 concentrations. Importantly, hinge mutant TRs when complexed to DNA bound T-3 poorly despite their near normal T-3 binding in solution. These binding studies correlated with functional assays showing defective transactivation of pTREs by hinge mutants except at high T-3 concentrations. Thus, we describe a novel mechanism of RTH whereby TR hinge mutants selectively affect T-3 binding when complexed to DNA, and prevent NCoR dissociation from TR. Our data also suggest that solution T-3 binding by RTH mutants may not accurately reflect physiologically relevant T binding by TR when bound to DNA.	Beth Israel Deaconess Med Ctr, Dept Med, Thyroid Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wondisford, FE (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Thyroid Unit, Res N,Rm 330C,99 Brookline Ave, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49126, DK-02423, DK-43653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEHR M, 1992, MOL ENDOCRINOL, V6, P1119, DOI 10.1210/me.6.7.1119; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; NAGAYA T, 1993, J CLIN ENDOCR METAB, V77, P982, DOI 10.1210/jc.77.4.982; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; ONATE SA, 1995, SCIENCE, V270, P1354; ONIGATA K, 1995, THYROID, V5, P355, DOI 10.1089/thy.1995.5.355; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; RATINEJAD F, 1995, NATURE, V375, P203; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Yagi H, 1997, J CLIN ENDOCR METAB, V82, P1608, DOI 10.1210/jc.82.5.1608; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	57	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30175	30182		10.1074/jbc.273.46.30175	http://dx.doi.org/10.1074/jbc.273.46.30175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804773	hybrid			2022-12-25	WOS:000077008100020
J	Venema, RC; Venema, VJ; Eaton, DC; Marrero, MB				Venema, RC; Venema, VJ; Eaton, DC; Marrero, MB			Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHOSPHOLIPASE C-GAMMA; DNA-BINDING ACTIVITY; JAK/STAT PATHWAY; CARDIAC MYOCYTES; AT(1) RECEPTOR; JAK2 KINASE; MAP KINASE; SRC; STAT3	Angiotensin II (Ang II) AT(1) receptors on vascular smooth muscle cells (VSMCs) are coupled to the Janus-activated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway. We have shown previously that Ang II stimulation of VSMCs results in the tyrosine phosphorylation of JAK2 and STAT1 and the translocation of STAT1 to the nucleus. In the present study, we demonstrate using specific enzyme inhibitors and antisense oligonucleotides that both JAK2 and p59 Fyn tyrosine kinases are required for the Ang II-induced tyrosine phosphorylation and nuclear translocation of STAT1 in VSMCs, Neither tyrosine kinase, however, appears to function upstream from the other in a phosphorylation cascade. Rather, p59 Fyn functions as an Ang II-activated docking protein for both JAK2 and STAT1, a docking interaction that may facilitate JAK2-mediated STAT1 tyrosine phosphorylation. In this study, we have also identified the nuclear dual-specificity phosphatase mitogen-activated protein kinase phosphatase 1 as the enzyme responsible for STAT1 tyrosine dephosphorylation in VSMCs.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Emory University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.	mmarrero@mail.mcg.edu		Eaton, Douglas/0000-0002-2686-6692	NHLBI NIH HHS [HL57201, HL58129] Funding Source: Medline; NIDDK NIH HHS [P01-DK50268] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; Bittorf T, 1997, CELL SIGNAL, V9, P85, DOI 10.1016/S0898-6568(96)00121-0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin H, 1998, BLOOD, V91, P3734; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dostal DE, 1997, J MOL CELL CARDIOL, V29, P2893, DOI 10.1006/jmcc.1997.0524; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Kodama H, 1998, CIRC RES, V82, P244; LI Y, 1995, J LEUKOCYTE BIOL, V57, P484, DOI 10.1002/jlb.57.3.484; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MARRERO MB, 1998, IN PRESS AM J PHYSL; McWhinney CD, 1998, J MOL CELL CARDIOL, V30, P751, DOI 10.1006/jmcc.1998.0639; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	41	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30795	30800		10.1074/jbc.273.46.30795	http://dx.doi.org/10.1074/jbc.273.46.30795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804857	hybrid			2022-12-25	WOS:000077008100104
J	Choi, JH; Lou, W; Vancura, A				Choi, JH; Lou, W; Vancura, A			A novel membrane-bound glutathione S-transferase functions in the stationary phase of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; CASEIN KINASE-I; MULTIDRUG-RESISTANCE; LIPID-PEROXIDATION; MULTIPLE ALIGNMENT; STRESS CONDITIONS; OXIDATIVE STRESS; CONTROL ELEMENT; ALPHA-CLASS; CTT1 GENE	The glutathione S-transferases (GSTs) represent a significant group of detoxification enzymes that play an important role in drug resistance in all eukaryotic species. In this paper we report an identification and characterization of the two Saccharomyces cerevisiae genes, GTT1 and GTT2 (glutathione transferase 1 and 2), coding for functional GST enzymes. Despite only limited similarity with GSTs from other organisms (similar to 50%), recombinant Gtt1p and Gtt2p exhibit GST activity with l-chloro-2,4-dinitrobenzene as a substrate. Both Gtt1p and Gtt2p are able to form homodimers, as determined by two hybrid assay. Subcellular fractionation demonstrated that Gtt1p associates with the endoplasmic reticulum. Expression of GTT1 is induced after diauxic shift and remains high throughout the stationary phase. Strains deleted for GTT1 and/or GTT2 are viable but exhibit increased sensitivity to heat shock in stationary phase and limited ability to grow at 39 degrees C.	St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	Saint John's University	Vancura, A (corresponding author), St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA.	vancuraa@stjohns.edu		Vancura, Ales/0000-0002-5895-1218				AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; Branum GD, 1998, BIOCHEM J, V330, P73; CASALONE E, 1988, A VAN LEEUW J MICROB, V54, P367, DOI 10.1007/BF00393527; Chaudhuri B, 1997, GENETICS, V145, P75; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DIRR H, 1994, J MOL BIOL, V243, P79; Elliott B, 1996, GENETICS, V144, P923; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MOSCOW JA, 1993, CYTOTECHNOLOGY, V12, P155, DOI 10.1007/BF00744663; MOSIALOU E, 1993, BIOCHEM PHARMACOL, V45, P1645, DOI 10.1016/0006-2952(93)90305-G; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; ROSE M, 1983, METHOD ENZYMOL, V101, P167; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHEEHAN D, 1993, COMP BIOCHEM PHYS B, V104, P7, DOI 10.1016/0305-0491(93)90331-X; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANCURA A, 1994, J BIOL CHEM, V269, P19271; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; Wang XM, 1996, MOL CELL BIOL, V16, P5375; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Wu AL, 1996, J BIOL CHEM, V271, P2914, DOI 10.1074/jbc.271.6.2914	56	117	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29915	29922		10.1074/jbc.273.45.29915	http://dx.doi.org/10.1074/jbc.273.45.29915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792709	hybrid			2022-12-25	WOS:000076798300086
J	Cotte, N; Balestre, MN; Phalipou, S; Hibert, M; Manning, M; Barberis, C; Mouillac, B				Cotte, N; Balestre, MN; Phalipou, S; Hibert, M; Manning, M; Barberis, C; Mouillac, B			Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OXYTOCIN; LIGAND; V-2; SPECIFICITY; DETERMINES; HORMONE; KIDNEY; POTENT; SITE	To improve our understanding of the functional architecture of G protein-coupled receptors, we have taken advantage of differences among mammalian species in ligand binding to search for the rat versus human selectivity determinants of the V2 vasopressin receptor and of its peptide ligands. Our data indicate that residue 2 of species-selective peptide antagonists such as d(CH(2))(5)-[D-Ile(2),Ile(4),Tyr-NH(2)(9)]arginine vasopressin controls their rat versus human selectivity. For species-selective agonists such as desmopressin, residues 1 and 8 modulate the binding selectivity. Among residues different between rat and human V2 receptors, those localized in the upper part of the human V2 receptor have been substituted with their rat V2 homologs. Pharmacological analysis of mutant receptors revealed that residues 202 and 304 fully control the species selectivity of the discriminating antagonists in an independent and additive manner. A third residue (position 100) is necessary to observe an equivalent phenomenon for the discriminating agonists. The substitution of these three residues does not modify the affinity of the nonselective agonists and antagonists. In conclusion, extracellular loops and the top of the transmembrane domains of V2 vasopressin receptors may provide the molecular basis for peptide ligand-binding species selectivity. Very few residues in these regions may control the binding mode of both agonists and antagonists.	CNRS, INSERM, Ctr Pharmacol Endocrinol, Unite 469, F-34094 Montpellier 5, France; Fac Pharm Strasbourg, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mouillac, B (corresponding author), CNRS, INSERM, Ctr Pharmacol Endocrinol, Unite 469, 141 Rue Cardonille, F-34094 Montpellier 5, France.	mouillac@u469.montp.inserm.fr	MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673	NIGMS NIH HHS [GM25280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025280] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ala Y, 1997, EUR J PHARMACOL, V331, P285, DOI 10.1016/S0014-2999(97)01021-2; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; DEROUFFIGNAC C, 1983, AM J PHYSIOL, V244, pF156, DOI 10.1152/ajprenal.1983.244.2.F156; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FONG TM, 1992, J BIOL CHEM, V267, P25668; KINTER LB, 1988, AM J PHYSIOL, V254, pF165, DOI 10.1152/ajprenal.1988.254.2.F165; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; Manning M, 1995, INT CONGR SER, V1098, P21; MANNING M, 1993, ANN NY ACAD SCI, V689, P219, DOI 10.1111/j.1749-6632.1993.tb55550.x; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; MOREL F, 1987, KIDNEY INT, V31, P512, DOI 10.1038/ki.1987.30; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Postina R, 1996, J BIOL CHEM, V271, P31593, DOI 10.1074/jbc.271.49.31593; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Tian Y, 1996, J BIOL CHEM, V271, P20250, DOI 10.1074/jbc.271.34.20250; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x	28	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29462	29468		10.1074/jbc.273.45.29462	http://dx.doi.org/10.1074/jbc.273.45.29462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792651	hybrid			2022-12-25	WOS:000076798300028
J	Heard, TS; Weiner, H				Heard, TS; Weiner, H			A regional net charge and structural compensation model to explain how negatively charged amino acids can be accepted within a mitochondrial leader sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALDEHYDE DEHYDROGENASE; PROTEIN IMPORT; TRANSIT PEPTIDE; SIGNAL PEPTIDE; RAT; PRESEQUENCE; MEMBRANE; YEAST; HELIX; FORM	Mitochondrial leader sequences have been found to be statistically enriched for positively charged residues, with only a few known leader sequences possessing negatively charged residues. Mutational studies that have introduced negatively charged residues into various leader sequences have shown a general, but not absolute, trend toward reduced import. The leader sequence of rat liver aldehyde dehydrogenase has been previously determined by NMR to form a helix-linker-helix structure. A negative charge introduced into this leader did not prevent import, provided that a net positive charge remained in the N-helical segment. When the net charge of the N-terminal helical segment was reduced to zero, import could be recovered by removing the linker, which resulted in a longer, more stable leader. This structural recovery of import was effective enough to compensate for a net charge of zero within the first 10 residues, even when a glutamate is the first charged side chain presented in the sequence.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weiner, H (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.							BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; CHU TW, 1987, J BIOL CHEM, V262, P12806; CHU TW, 1987, J BIOL CHEM, V262, P15759; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; HAMPSEY DM, 1983, P NATL ACAD SCI-BIOL, V80, P1270, DOI 10.1073/pnas.80.5.1270; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HORWICH AL, 1987, J CELL BIOL, V105, P669, DOI 10.1083/jcb.105.2.669; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MILLER DM, 1991, J BIOL CHEM, V266, P4686; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Schleiff E, 1997, FEBS LETT, V404, P314, DOI 10.1016/S0014-5793(97)00145-2; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG Y, 1993, J BIOL CHEM, V268, P4759	20	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29389	29393		10.1074/jbc.273.45.29389	http://dx.doi.org/10.1074/jbc.273.45.29389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792640	hybrid			2022-12-25	WOS:000076798300017
J	Morais, F; Barber, J; Nixon, PJ				Morais, F; Barber, J; Nixon, PJ			The chloroplast-encoded alpha subunit of cytochrome b-559 is required for assembly of the photosystem two complex in both the light and the dark in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; DELETION MUTAGENESIS; NUCLEOTIDE-SEQUENCE; PLASTID CHROMOSOME; ELECTRON-TRANSPORT; AXIAL LIGANDS; PSBF GENES; D1 PROTEIN; LACKING; MUTANT	The role of cytochrome b-559 in the photosystem two (PSII) complex has been investigated through the construction of a psbE null mutant by transformation of the chloroplast genome of the green alga Chlamydomonas reinhardtii, No PSII activity could be detected in this mutant either in oxygen evolution assays or by analysis of variable chlorophyll fluorescence. Immunoblotting experiments showed that the absence of PSII activity in the mutant was due to the loss of the PSII complex in both light-grown and dark-grown cultures. In contrast, the photosystem one reaction center polypeptide, PsaA, was present at wild-type levels in the mutant. RNA gel blot assays confirmed that the transcript levels for the psbA, psbD, and psbP genes were unaffected by disruption of the psbE gene, suggesting a post-transcriptional effect on their expression. Pulse-labeling experiments showed that either synthesis of PSII subunits was impaired in the psbE null mutant or there was extremely rapid degradation of newly synthesized subunits, Interestingly, the PsbE and PsbF subunits accumulated to wild-type levels in a psbA deletion mutant of C, reinhardtii, FuD7, which fails to synthesize D1 and assemble PSII, Our results provide evidence for a role for cytochrome b-559 in the early steps of assembly of the PSII complex, possibly as a redox-controlled nucleation factor that determines the level of PSII within the thylakoid membrane.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Imperial College London	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.			Nixon, Peter/0000-0003-1952-6937				ALIZADEH S, 1994, BBA-BIOENERGETICS, V1188, P439, DOI 10.1016/0005-2728(94)90067-1; ALIZADEH S, 1995, THESIS U LONDON; ALIZADEH S, 1995, PHOTOSYNTHESIS LIGHT, V1, P895; ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; Andronis C, 1998, PLANT PHYSIOL, V117, P515, DOI 10.1104/pp.117.2.515; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Barber J, 1997, PHYSIOL PLANTARUM, V100, P817, DOI 10.1034/j.1399-3054.1997.1000408.x; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; CHAPMAN DJ, 1989, BIOCHEM J, V258, P357, DOI 10.1042/bj2580357; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRMANN RG, 1984, FEBS LETT, V176, P239, DOI 10.1016/0014-5793(84)80949-7; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; LIND LK, 1993, J BIOL CHEM, V268, P1575; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; McNamara VP, 1997, P NATL ACAD SCI USA, V94, P14173, DOI 10.1073/pnas.94.25.14173; MOR TS, 1995, MOL GEN GENET, V246, P600, DOI 10.1007/BF00298966; MORAIS F, 1995, PHOTOSYNTHESIS LIGHT, V1, P791; NILSSON F, 1990, PLANT MOL BIOL, V14, P1051, DOI 10.1007/BF00019402; Nixon P. J., 1990, CURRENT RES PHOTOSYN, VI, P471; OHASHI K, 1992, PLANT CELL PHYSIOL, V33, P371; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; PAKRASI HB, 1990, Z NATURFORSCH C, V45, P423; Rochaix JD, 1995, ANNU REV GENET, V29, P209, DOI 10.1146/annurev.ge.29.120195.001233; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; TAE GS, 1992, BIOCHEMISTRY-US, V31, P4066, DOI 10.1021/bi00131a024; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; vanWijk KJ, 1997, BIOCHEMISTRY-US, V36, P6178, DOI 10.1021/bi962921l; ZHANG ZH, 1993, PHOTOSYNTH RES, V38, P369, DOI 10.1007/BF00046763	47	67	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29315	29320		10.1074/jbc.273.45.29315	http://dx.doi.org/10.1074/jbc.273.45.29315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792631	hybrid			2022-12-25	WOS:000076798300008
J	Saphire, ACS; Bark, SJ; Gerace, L				Saphire, ACS; Bark, SJ; Gerace, L			All four homochiral enantiomers of a nuclear localization sequence derived from c-Myc serve as functional import signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; CHEMICAL SYNTHESIS; PEPTIDES; RETRO; IDENTIFICATION; ANALOGS; TRANSLOCATION; INHIBITION; LOCATION; RECEPTOR	The information that targets a protein to the nucleus often consists of a short cluster of basic amino acids called a nuclear localization sequence (NLS). Since a wide range of sequences rich in basic amino acid residues function as NLSs, we postulated that an NLS-like sequence composed exclusively of D-amino acids might have biological activity. We synthesized peptides corresponding to the c-Myc NLS composed of either all L or D-amino acids, both in the forward and reverse order. We tested these peptides for nuclear import activity in a digitonin-permeabilized cell assay. All four peptide-bovine serum albumin conjugates localized to the nucleus with similar efficiency, and each conjugate competed for import with an SV40 large T antigen-derived NLS conjugate. Cross-linking experiments with free NLS peptides in HeLa cytosol indicated that each peptide bound to a protein that migrated at the molecular weight of importin alpha. Recombinant importin a, importin beta, Ran, and NTF2 alone were sufficient to support the import of both L-form and D-form conjugates in permeabilized cells. This indicates that both D- and L-form NLS peptides use the same import machinery. Although the free D-forms of the NLS were proteolytically resistant in cytosol, the L-forms were rapidly degraded. To our knowledge, this is the first example of an intracellular pathway in which the receptor is insensitive to the chirality of the ligand.	Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), Dept Cell Biol, 10550 N Torrey Pines Rd-IMM 10, La Jolla, CA 92037 USA.	lgerace@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41955] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRADY L, 1994, NATURE, V368, P692, DOI 10.1038/368692a0; CANNE LE, 1995, TETRAHEDRON LETT, V36, P1217, DOI 10.1016/0040-4039(95)00037-D; Carmona AK, 1996, BIOCHEM PHARMACOL, V51, P1051, DOI 10.1016/0006-2952(96)00047-0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOREV M, 1979, SCIENCE, V204, P1210, DOI 10.1126/science.451565; Collas P, 1996, TRANSGENIC RES, V5, P451, DOI 10.1007/BF01980210; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MURAKAMI M, 1991, J PROTEIN CHEM, V10, P469, DOI 10.1007/BF01025474; PAPPENHEIMER JR, 1994, P NATL ACAD SCI USA, V91, P1942, DOI 10.1073/pnas.91.5.1942; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SKERJANC I, 1990, BIOCHEM CELL BIOL, V68, P9, DOI 10.1139/o90-002; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	34	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29764	29769		10.1074/jbc.273.45.29764	http://dx.doi.org/10.1074/jbc.273.45.29764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792690	hybrid			2022-12-25	WOS:000076798300067
J	Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T				Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T			Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization	ONCOGENE			English	Article						p53; transcription; oligomerization	WILD-TYPE P53; DNA-BINDING FUNCTION; PROTEIN-KINASE-C; MONOCLONAL-ANTIBODIES; REPRESSION FUNCTIONS; SUPPRESSOR PROTEIN; ACTIVATION DOMAINS; TYROSINE KINASE; GENE-EXPRESSION; GROWTH	Tumour suppressor protein p53 is the most frequent target of mutations occurring in different types of human cancers. Most of these are point mutations clustered in certain 'hot spots'. Because p53 is a tetramer in solution, it can form heterooligomers when both wild-type and mutant forms of p53 are expressed in the same cell. Inactivation of wt p53 by heterooligomerization has been proposed as a mechanism for dominant negative effect of mutant protein. In this paper we show that other mechanisms can also be involved in the inhibition of transcriptional activity of wt p53 by mutant proteins. In addition to suppressing the wt p53 activity, mutant proteins are also able to suppress the activity of p53 protein unable to oligomerize. Either N- or C-terminus of mutant p53 are needed for this activity. The suppression of transcriptional activity described is restricted to p53-dependent promoters and no effect is seen with the promoter not containing p53 binding site. Point mutants also inhibit the growth suppressing activity of monomeric p53. Our data allow to propose the existence of a cofactor specifically needed for p53-dependent transcription. Depletion of this cofactor could be an alternative mechanism of inactivation of wt p53 by its point mutants.	Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, EE-2400 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GOGA A, 1995, ONCOGENE, V11, P791; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Knippschild U, 1996, ONCOGENE, V13, P1387; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Sambrook J., 2002, MOL CLONING LAB MANU; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2351	2358		10.1038/sj.onc.1202146	http://dx.doi.org/10.1038/sj.onc.1202146			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811466				2022-12-25	WOS:000076723300009
J	Surette, ME; Dallaire, N; Jean, N; Picard, S; Borgeat, P				Surette, ME; Dallaire, N; Jean, N; Picard, S; Borgeat, P			Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B-4 in chemotactic peptide-stimulated human neutrophils	FASEB JOURNAL			English	Article						priming; polymorphonuclear leukocytes; free arachidonic acid; translocation	CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID RELEASE; PLATELET-ACTIVATING-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; COMPLEMENT COMPONENT C5A; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; FACTOR GM-CSF; 5-LIPOXYGENASE ACTIVATION; BACTERIAL LIPOPOLYSACCHARIDE	The goal of this study was to explain the priming effect of lipopolysaccharides (LPS) in human polymorphonuclear leukocytes on leukotriene B-4 (LTB4) biosynthesis after stimulation with the receptor-mediated agonist formyl-methionyl-leucyl-phenylalanine (fMLP), This priming effect for LTB4 biosynthesis was maximal after a 30 min preincubation with LPS but was lost when incubations were extended to 90 min or longer, Priming with LPS resulted in an enhanced maximal activation of 5-lipoxygenase (5- to 15-fold above unprimed cells) as well as a prolonged activation of the enzyme after stimulation with fMLP compared to that measured in unprimed cells. The activation of 5-lipoxygenase was associated with its translocation to the nuclear fraction of the cell, after stimulation of LPS-primed cells but not of unprimed cells, Priming of cells with LPS also resulted in an enhanced capacity (fivefold increase) for arachidonic acid (AA) release after stimulation with fMLP compared to unprimed cells as measured by mass spectrometry, This release of AA was very efficiently blocked in a dose-dependent manner by the 85 kDa cytosolic phospholipase A(2) (PLA(2)) inhibitor MAFP (IC50=10nM) but not by the 14 kDa secretory PLA(2) inhibitor SE 203347 (up to 5 mu M), indicating that the 85 kDa cPLA(2) is the PLA(2) responsible for AA release in response to receptor-mediated agonists, In accord with inhibitor studies, the LPS-mediated phosphorylation of cPLA(2) followed the same kinetics as the priming for AA release, and a measurable fMLP-induced translocation of cPLA(2) was observed only in primed cells, As with AA release and LTB4 biosynthesis, both the phosphorylation and capacity to translocate CPLA(2) were reversed when the preincubation period with LPS was extended to 120 min. These results explain some of the cellular events responsible for the potentiation and subsequent decline of functional responses of human polymorphonuclear leukocytes recruited to inflammatory foci.	CHU Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Surette, ME (corresponding author), CHU Laval, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,Pavillon CHUL, Quebec City, PQ G1V 4G2, Canada.	marc.surette@crchul.ulaval.ca	Surette, Marc/AAW-1078-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; Bauldry SA, 1996, BBA-LIPID LIPID MET, V1299, P223, DOI 10.1016/0005-2760(95)00207-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DIPERSIO JF, 1988, PROSTAGLANDINS, V36, P673, DOI 10.1016/0090-6980(88)90013-5; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; KRUMP E, 1994, BBA-LIPID LIPID MET, V1213, P135, DOI 10.1016/0005-2760(94)90019-1; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MCCOLL SR, 1991, J IMMUNOL, V146, P1204; MCDONALD PP, 1993, J LIPID MEDIATOR, V6, P59; MCDONALD PP, 1991, BIOCHEM J, V280, P379, DOI 10.1042/bj2800379; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Nahas N, 1996, BIOCHEM J, V313, P503, DOI 10.1042/bj3130503; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; Nixon AB, 1997, BBA-LIPID LIPID MET, V1347, P219, DOI 10.1016/S0005-2760(97)00077-5; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; PALMANTIER R, 1994, LAB INVEST, V70, P696; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; QIU ZH, 1993, J BIOL CHEM, V268, P24506; ROSENTHAL MD, 1995, BIOCHEM BIOPH RES CO, V208, P650, DOI 10.1006/bbrc.1995.1388; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Winkler JD, 1997, BBA-LIPID LIPID MET, V1346, P173, DOI 10.1016/S0005-2760(97)00032-5; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; XU XX, 1994, J BIOL CHEM, V269, P31693	62	62	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1521	1531		10.1096/fasebj.12.14.1521	http://dx.doi.org/10.1096/fasebj.12.14.1521			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806761				2022-12-25	WOS:000076749500011
J	Bulygin, VV; Duncan, TM; Cross, RL				Bulygin, VV; Duncan, TM; Cross, RL			Rotation of the epsilon subunit during catalysis by Escherichia coli F0F1-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; ATP SYNTHASE; BETA-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; ALPHA-SUBUNIT; GAMMA-SUBUNIT; MOLECULAR MACHINE; F1 ATPASE; F1-ATPASE	We report evidence for catalysis-dependent rotation of the single epsilon subunit relative to the three catalytic beta subunits of functionally coupled, membrane-bound FOF1-ATP synthase, Cysteines substituted at beta 380 and epsilon 108 allowed rapid formation of a specific beta-epsilon disulfide cross-link upon oxidation, Consistent with a need for epsilon to rotate during catalysis, tethering epsilon to one of the beta subunits resulted in the inhibition of both ATP synthesis and hydrolysis, These activities were fully restored upon reduction of the beta-epsilon cross-link. As a more critical test for rotation, a subunit dissociation/reassociation procedure was used to prepare a beta-epsilon cross-linked hybrid F-1, having epitope-tagged beta D380C subunits (beta(flag)) exclusively in the two noncross-linked positions. This allowed the beta subunit originally aligned with epsilon to form the crosslink to be distinguished from the other two beta s. The cross-linked hybrid was reconstituted with F-O in F-1-depleted membranes. After reduction of the beta-epsilon cross-link and a brief period of catalytic turnover, reoxidation resulted in a significant amount of beta(flag) in the beta-epsilon cross-linked product. In contrast, exposure to ligands that bind to the catalytic site but do not allow catalysis resulted in the subsequent cross-linking of epsilon to the original untagged beta, Furthermore, catalysis dependent rotation of epsilon was prevented by prior treatment of membranes with N,N'-dicyclohexylcarbodiimide to block. proton translocation through F-O, From these results, we conclude that epsilon is part of the rotor that couples proton transport to ATP synthesis.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cross, RL (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.			Duncan, Thomas/0000-0002-6432-4958	NIGMS NIH HHS [GM 23152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023152, R37GM023152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; Dimroth P, 1998, BBA-BIOENERGETICS, V1365, P87, DOI 10.1016/S0005-2728(98)00047-4; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; Duncan TM, 1995, BIOCHEM SOC T, V23, P736, DOI 10.1042/bst0230736; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1982, J BIOL CHEM, V257, P7354; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIK SB, 1994, J BIOL CHEM, V269, P30364; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WISE JG, 1990, J BIOL CHEM, V265, P10403; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	45	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31765	31769		10.1074/jbc.273.48.31765	http://dx.doi.org/10.1074/jbc.273.48.31765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822640	hybrid			2022-12-25	WOS:000077207000022
J	Liao, VHC; Freedman, JH				Liao, VHC; Freedman, JH			Cadmium-regulated genes from the nematode Caenorhabditis elegans - Identification and cloning of new cadmium-responsive genes by differential display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SUPEROXIDE-DISMUTASE GENE; HAMSTER HA-1 CELLS; MESSENGER-RNAS; TRANSCRIPTION FACTORS; OXIDATIVE STRESS; TOPOISOMERASE-II; MAMMALIAN-CELLS; PHORBOL ESTERS; HEPATOMA-CELLS	The transition metal cadmium is a pervasive and persistent environmental contaminant that has been shown to be both a human toxicant and carcinogen. To inhibit cadmium-induced damage, cells respond by increasing the expression of genes encoding stress-response proteins. In most cases, the mechanism by which cadmium affects the expression of these genes remains unknown. It has been demonstrated in several instances that cadmium activates gene transcription through signal transduction pathways, mediated by protein kinase C, cAMP-dependent protein kinase, or calmodulin. A codicil is that cadmium should influence the expression of numerous genes. To investigate the ability of cadmium to affect gene transcription, the differential display technique was used to analyze gene expression in the nematode Caenorhabditis elegans. Forty-nine cDNAs whose steady-state levels of expression change 2-6-fold in response to cadmium exposure were identified. The nucleotide sequences of the majority of the differentially expressed cDNAs are identical to those of C. elegans cosmids, yeast artificial chromosomes, expressed sequence tags, or predicted genes. The translated amino acid sequences of several clones are identical to C. elegans metallothionein-l, HSP70, collagens, and rRNAs. In addition, C. elegans homologues of pyruvate carboxylase, DNA gyrase, P-adrenergic receptor kinase, and human hypothetical protein KIAA0174 were identified. The translated amino acid sequences of the remaining differentially expressed cDNAs encode novel proteins.	Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University; Duke University	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu		Liao, Vivian/0000-0002-4676-9953	NCI NIH HHS [CA 61337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, BBA-GEN SUBJECTS, V1201, P29, DOI 10.1016/0304-4165(94)90147-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMENDOLA R, 1995, FEBS LETT, V371, P209, DOI 10.1016/0014-5793(95)00871-6; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; BRENNER S, 1974, GENETICS, V77, P71; CAGLIERO E, 1991, J BIOL CHEM, V266, P14244; CHIN TA, 1993, TOXICOLOGY, V77, P145, DOI 10.1016/0300-483X(93)90145-I; CHMIELNICKA J, 1986, BIOL TRACE ELEM RES, V10, P243, DOI 10.1007/BF02795623; CHOI HS, 1991, J BIOL CHEM, V266, P11858; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; Ebert RH, 1996, DEV GENET, V18, P131, DOI 10.1002/(SICI)1520-6408(1996)18:2&lt;131::AID-DVG6&gt;3.0.CO;2-A; EDER JP, 1995, CANCER RES, V55, P6109; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; Favello A, 1995, METHOD CELL BIOL, V48, P551; FAY RM, 1997, FOOD CHEM TOXICOL, V34, P1163; Fortoul TI, 1996, ENVIRON HEALTH PERSP, V104, P630, DOI 10.2307/3433092; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; Friberg L., 1986, HDB TOXICOLOGY METAL, P130; GIGLIO AM, 1994, BIOCHEM MOL BIOL INT, V33, P41; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; Gordon S, 1997, DEV BIOL, V181, P47, DOI 10.1006/dbio.1996.8441; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hartman P, 1996, MUTAT RES-DNA REPAIR, V363, P201, DOI 10.1016/0921-8777(96)00012-2; HARTWIG A, 1994, ENVIRON HEALTH PERSP, V102, P45, DOI 10.2307/3431762; HATCHER EL, 1995, FREE RADICAL BIO MED, V19, P805, DOI 10.1016/0891-5849(95)00099-J; HESCHL MFP, 1989, DNA-J MOLEC CELL BIO, V8, P233, DOI 10.1089/dna.1.1989.8.233; HICKSON ID, 1990, INT J RADIAT BIOL, V58, P561, DOI 10.1080/09553009014551921; HIRANUMA K, 1993, BIOCHEM BIOPH RES CO, V194, P531, DOI 10.1006/bbrc.1993.1852; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; Kikuchi Y, 1997, JPN J CANCER RES, V88, P213, DOI 10.1111/j.1349-7006.1997.tb00368.x; KISS T, 1994, PHARMACOL REV, V46, P245; KOSTIC MM, 1993, EUR J HAEMATOL, V51, P86; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LU XY, 1990, J BIOL CHEM, V265, P3293; MANCA D, 1991, TOXICOLOGY, V67, P303, DOI 10.1016/0300-483X(91)90030-5; MCGHEE JD, 1997, C ELEGANS, V2, P147; MERALI Z, 1975, CAN J PHYSIOL PHARM, V53, P174, DOI 10.1139/y75-024; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; OBERDORSTER G, 1986, SCAND J WORK ENV HEA, V12, P523, DOI 10.5271/sjweh.2104; OVELGONNE JH, 1995, TOXICOLOGY, V99, P19, DOI 10.1016/0300-483X(94)02990-C; SALOVSKY P, 1992, HUM EXP TOXICOL, V11, P217, DOI 10.1177/096032719201100310; SALVATO M, 1986, J MOL BIOL, V190, P281, DOI 10.1016/0022-2836(86)90002-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGHAL RL, 1976, FED PROC, V35, P75; SLICE LW, 1990, J BIOL CHEM, V265, P256; STRINGHAM EG, 1994, ENVIRON TOXICOL CHEM, V13, P1211, DOI 10.1897/1552-8618(1994)13[1211:THLSOT]2.0.CO;2; STRINGHAM EG, 1992, GENE, V113, P165, DOI 10.1016/0378-1119(92)90392-3; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; TSUZUKI K, 1994, ENVIRON HEALTH PERSP, V102, P341, DOI 10.2307/3431817; Vogt TMM, 1997, CANCER RES, V57, P3554; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Wang YH, 1996, ARCH BIOCHEM BIOPHYS, V332, P255, DOI 10.1006/abbi.1996.0340; Waterston Robert H., 1997, Cold Spring Harbor Monograph Series, V33, P23; WEBER HW, 1991, MOL CELL BIOCHEM, V104, P201; WESTON K, 1989, NUCLEIC ACIDS RES, V17, P2138, DOI 10.1093/nar/17.5.2138; WIEGANT FAC, 1994, TOXICOLOGY, V94, P143, DOI 10.1016/0300-483X(94)90034-5; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	71	90	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31962	31970		10.1074/jbc.273.48.31962	http://dx.doi.org/10.1074/jbc.273.48.31962			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822667	hybrid, Green Submitted			2022-12-25	WOS:000077207000049
J	Arthur, TM; Burgess, RR				Arthur, TM; Burgess, RR			Localization of a sigma(70) binding site on the N terminus of the Escherichia coli RNA polymerase beta ' subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-70 SUBUNIT; LEUCINE ZIPPER; PROTEIN; MUTANT; IDENTIFICATION; EXPRESSION; FRAGMENTS; CLEAVAGE; AFFINITY; CLONING	The Escherichia coli genome encodes genes for seven different a subunit species while only having single genes for the alpha, beta, and beta' subunits that make up the RNA polymerase core enzyme. The various sigma factors compete for binding to the core enzyme, upon which they confer promoter; DNA-specific transcription initiation to the polymerase. We have mapped a major interaction site between one of the a species, sigma(70), and beta'. Using far-Western blotting analysis of chemically cleaved and genetically engineered protein fragments, we have identified a N-terminal fragment of beta' (residues 60-309) that could bind sigma(70). We were able to more precisely map the interaction domain to amino acid residues 260-309 of beta' using nickel nitrilotriacetic acid co-immobilization assays.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	burgess@oncology.wisc.edu		Arthur, Terrance/0000-0001-9035-0474; Burgess, Richard/0000-0001-9545-3165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline; OHS HRSA HHS [ST32GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bornstein P, 1977, Methods Enzymol, V47, P132; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLASS RE, 1986, MOL GEN GENET, V203, P492, DOI 10.1007/BF00422075; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gross CA, 1996, PHILOS T R SOC B, V351, P475, DOI 10.1098/rstb.1996.0045; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ishihama A, 1981, Adv Biophys, V14, P1; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Jishage M, 1998, P NATL ACAD SCI USA, V95, P4953, DOI 10.1073/pnas.95.9.4953; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; Joo DM, 1998, J BACTERIOL, V180, P1095, DOI 10.1128/JB.180.5.1095-1102.1998; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Luo JY, 1996, GENES CELLS, V1, P819, DOI 10.1046/j.1365-2443.1996.700269.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Rao L, 1996, ANAL BIOCHEM, V241, P173, DOI 10.1006/abio.1996.0395; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SHULER MF, 1995, J BACTERIOL, V177, P3687, DOI 10.1128/jb.177.13.3687-3694.1995; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WALDBURGER C, 1994, J MOL BIOL, V235, P1489, DOI 10.1006/jmbi.1994.1103; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992; ZHOU YN, 1992, J BACTERIOL, V174, P7128, DOI 10.1128/jb.174.22.7128-7137.1992	44	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31381	31387		10.1074/jbc.273.47.31381	http://dx.doi.org/10.1074/jbc.273.47.31381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813048	hybrid			2022-12-25	WOS:000077136900076
J	Josefsson, E; O'Connell, D; Foster, TJ; Durussel, I; Cox, JA				Josefsson, E; O'Connell, D; Foster, TJ; Durussel, I; Cox, JA			The binding of calcium to the B-repeat segment of SdrD, a cell surface protein of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; MAGNESIUM-BINDING; STRUCTURAL BASIS; FIBRONECTIN; DOMAIN; INTERLEUKIN-6; MODULE	In the Sdr family of Staphylococcus aureus cell surface proteins, three recently cloned members (Josefsson, E., McCrea, K., Ni Eidhin, D., O' Connell, D., Cox, J. A, Hook, M., and Foster, T. (1998) Microbiology, in press) display variable numbers of B-repeats, i.e. segments of 110-113 residues that probably make up one folding unit. Each B-repeat contains one conserved EF-hand motif and two acidic stretches. Equilibrium dialysis revealed that segment B1-B5 of SrdD contains 14 Ca2+-binding sites with high affinity ([Ca2+](0.5), 4 mu M), whereas flow dialysis yielded 5 sites of high affinity (class I) and 10 of low affinity (class II). The discrepancy could be explained by the slow induction of high affinity in the class II sites. Kinetic experiments using fluorescent Ca2+ indicators corroborated slow binding of Ca2+ at the latter sites. Circular dichroism and Trp fluorescence showed that, whereas the Ca2+ form is well folded, the metal-free form seems strongly disorganized. The Ca2+-induced conformational changes comprise both fast and slow steps, giving thus a structural support for the induction of class II Ca2+-binding sites. The B-repeats may act as rulers or springs that modulate the distance between the interactive A region and the bacterial cell surface.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland	University of Geneva; Trinity College Dublin	Cox, JA (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	jos.cox@biochem.unige.ch			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; COX JA, 1996, GUIDEBOOK CALCIUM BI, P58; DeFilippis V, 1996, BIOCHEMISTRY-US, V35, P11503, DOI 10.1021/bi9604587; EBERHARD M, 1994, EUR J BIOCHEM, V222, P21, DOI 10.1111/j.1432-1033.1994.tb18836.x; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FOSTER TJ, 1997, MOL ASPECTS HOST PAT, V55, P67; HAMES BD, 1990, GEL ELECTROPHORESIS, P12; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; JOSEFSSON E, 1998, IN PRESS MICROBIOLOG; KRESTINGER RH, 1987, COLD SPRING HARB SYM, V52, P499; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCN; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARTELL AE, 1964, CRITICAL STABILITY C, V1; Matsubara M, 1998, FEBS LETT, V421, P203, DOI 10.1016/S0014-5793(97)01557-3; Maurer P, 1996, CURR OPIN CELL BIOL, V8, P609, DOI 10.1016/S0955-0674(96)80101-3; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nath U, 1997, BIOCHEMISTRY-US, V36, P8602, DOI 10.1021/bi970426z; NIEIDHIN D, 1998, IN PRESS MOL MICROBI, V29; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; PROJAN SJ, 1997, STAPHYLOCOCCI HUMAN, P55; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHECHTE.B, 1971, EUR J BIOCHEM, V20, P301, DOI 10.1111/j.1432-1033.1971.tb01394.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STEVENS ES, 1987, J MOL BIOL, V197, P743, DOI 10.1016/0022-2836(87)90481-5; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SWAN DG, 1987, NATURE, V329, P84, DOI 10.1038/329084a0; VENYAMINOV SY, 1983, EUR J BIOCHEM, V135, P485, DOI 10.1111/j.1432-1033.1983.tb07677.x; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WARD LD, 1993, PROTEIN SCI, V2, P1291, DOI 10.1002/pro.5560020812; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WENDEL M, 1995, J BIOL CHEM, V270, P6125, DOI 10.1074/jbc.270.11.6125; WNUK W, 1979, J BIOL CHEM, V254, P5284; Woody R. W., 1994, CIRCULAR DICHROISM P, P473	43	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31145	31152		10.1074/jbc.273.47.31145	http://dx.doi.org/10.1074/jbc.273.47.31145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813018	hybrid, Green Published			2022-12-25	WOS:000077136900046
J	Kimball, SR; Horetsky, RL; Jefferson, LS				Kimball, SR; Horetsky, RL; Jefferson, LS			Implication of eIF2B rather than eIF4E in the regulation of global protein synthesis by amino acids in L6 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; INITIATION-FACTOR 4E; GLYCOGEN-SYNTHASE KINASE-3; PHAS-I; TRANSLATION INITIATION; ORNITHINE DECARBOXYLASE; PHYSIOLOGICAL STRESSES; PHOSPHORYLATION SITES; 4E-BINDING PROTEIN-1; 3T3-L1 ADIPOCYTES	The present study was designed to investigate the mechanism through which leucine and histidine regulate translation initiation in L6 myoblasts, The results show that both amino acids stimulate initiation and coordinately regulate the activity of eukaryotic initiation factor eIF2B, The changes in eIF2B activity could be explained in part by modulation of the phosphorylation state of the alpha-subunit of eIF2, The activity changes might also be a result of modulation of the phosphorylation state of the eIF2B epsilon-subunit, because deprivation of either amino acid caused a decrease in eIF2B epsilon kinase activity. Leucine, but not histidine, additionally caused a redistribution of eIF4E from the inactive eIF4E.4E-BP1 complex to the active eIF4E.eIF4G complex. The redistribution was a result of increased phosphorylation of 4E-BP1, The changes in 4E-BP1 phosphorylation and eIF4E redistribution associated with leucine deprivation were not observed in the presence of insulin. However, the leucine- and histidine-induced alterations in global protein synthesis and eIF2B activity were maintained in the presence of the hormone, Overall, the results suggest that both leucine and histidine regulate global protein synthesis through modulation of eIF2B activity. Furthermore, under the conditions employed herein, alterations in eIF4E availability are not rate-controlling for global protein synthesis but might be necessary for regulation of translation of specific mRNAs.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	skimball@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; AROOR AR, 1994, BIOCHEMISTRY-US, V33, P3350, DOI 10.1021/bi00177a028; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; Fabian JR, 1998, PROTEIN EXPRES PURIF, V13, P16, DOI 10.1006/prep.1998.0860; Fadden P, 1997, J BIOL CHEM, V272, P10240; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; Flynn A, 1996, CANCER SURV, V27, P293; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; FULKS RM, 1975, J BIOL CHEM, V250, P290; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; JEFFREY IW, 1993, BIOCHIMIE, V75, P791, DOI 10.1016/0300-9084(93)90129-G; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1988, J IMMUNOL METHODS, V106, P217, DOI 10.1016/0022-1759(88)90200-1; KIMBALL SR, 1988, BIOCHEM BIOPH RES CO, V156, P706, DOI 10.1016/S0006-291X(88)80900-8; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; KIMBALL SR, 1991, BIOCHEM BIOPH RES CO, V177, P1082, DOI 10.1016/0006-291X(91)90649-R; Kimball SR, 1998, PROTEIN EXPRES PURIF, V12, P415, DOI 10.1006/prep.1998.0863; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LI JB, 1978, BIOCHIM BIOPHYS ACTA, V544, P351, DOI 10.1016/0304-4165(78)90103-4; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUIKEN JJFP, 1994, BIOCHEM SOC T, V22, P508, DOI 10.1042/bst0220508; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; MELLOR H, 1994, FEBS LETT, V350, P143, DOI 10.1016/0014-5793(94)00756-X; Morley SJ, 1997, RNA, V3, P1085; Morley SJ, 1997, BIOCHEM SOC T, V25, P503, DOI 10.1042/bst0250503; Morris DR, 1997, MOD CELL B, V17, P165; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; Thompson MG, 1996, BBA-MOL CELL RES, V1311, P37, DOI 10.1016/0167-4889(95)00194-8; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; WENG QP, 1995, MOL CELL BIOL, V15, P2333	67	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30945	30953		10.1074/jbc.273.47.30945	http://dx.doi.org/10.1074/jbc.273.47.30945			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812990	hybrid			2022-12-25	WOS:000077136900018
J	Zhao, MM; Abdel-Razek, T; Sun, MF; Gailani, D				Zhao, MM; Abdel-Razek, T; Sun, MF; Gailani, D			Characterization of a heparin binding site on the heavy chain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; ACTIVATED FACTOR-XI; FACTOR-IX; ALPHA-1-PROTEASE INHIBITOR; CONFORMATIONAL CHANGE; SUBCUTANEOUS HEPARIN; ANTITHROMBIN-III; HAGEMAN-FACTOR; THROMBIN; INACTIVATION	The glycosaminoglycan heparin enhances several reactions involving coagulation factor XI (FXI) including activation of FXI by factor XIIa, thrombin, and autoactivation; and inactivation of activated FXI (FXIa) by serine protease inhibitors. We examined the effect of heparin on inhibition of FXIa by the inhibitors C1-inhibitor (C1-INH) and antithrombin LII (ATIII), Second order rate constants for inhibition in the absence of heparin were 1.57 x 10(3) and 0.91 x 10(3) M-1 s(-1) for C1-INH and ATIII, respectively. Therapeutic heparin concentrations (0.1-1.0 units/ml) enhanced inhibition by ATIII 20-55-fold compared with 0.1-7.0-fold for C1-INH. For both inhibitors, the effect of heparin over a wide range of concentrations (10(-1) to 10(5) units/ml) produced bell-shaped curves, demonstrating that inhibition occurs by a template mechanism requiring both inhibitor and protease to bind to heparin, This implies that FXI/XIa contains structural elements that interact with heparin, Human FXI contains a sequence of amino acids (R-250-I-K-K-S-K) in the apple 3 domain of the heavy chain that binds heparin (Ho, D., Badellino, K., Baglia, F., and Walsh, P. (1998) J. Biol. Chem. 273, 16382-16390), To determine the importance of this sequence to heparin-mediated reactions, recombinant FXI molecules with alanine substitutions for basic amino acids were expressed in 293 fibroblasts, and tested in heparin-dependent assays. Inhibition of FXIa by ATIII in the presence of heparin was decreased 4-fold by alanine substitution at Lys(253) (A253), with smaller effects noted for mutants A255 and A252, FXI undergoes autoactivation to FXIa in the presence of heparin, The rate of autoactivation was decreased substantially for A253 with modest decreases for A255 and A252, Substituting all four charged residues in the sequence resulted in a profound decrease in autoactivation, significantly greater than for any single substitution. Relative affinity for heparin was tested by determining the concentration of NaCl required to elute FXIa from heparin-Sepharose. Wild type FXIa eluted from the column at 320 mM NaCl, whereas FXIa with multiple substitutions (A252-254 or A250-255) eluted at 230 mM NaCl, AU proteins with single substitutions in charged amino acids eluted at intermediate NaCl concentrations. The data indicate that FXI/XIa must bind to heparin for optimal inhibition by ATIII and for autoactivation. Lys(253) is the most important amino acid involved in binding, and Lys(255) and Lys(252) also have roles in interactions with heparin.	Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, 538 MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.	dave.gailani@mcmail.vanderbilt.edu			NHLBI NIH HHS [HL02917, HL58837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837, K08HL002917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BEELER DL, 1986, BLOOD, V67, P1488; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHIU HM, 1977, BLOOD, V49, P171; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 1997, BLOOD, V90, P1055, DOI 10.1182/blood.V90.3.1055.1055_1055_1064; GAILANI D, 1993, BLOOD COAGUL FIBRIN, V4, P15, DOI 10.1097/00001721-199304010-00003; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; HEMKER HC, 1992, ADV EXP MED BIOL, V313, P221; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 1996, BLOOD, V88, P1120; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOIDE T, 1977, BIOCHEMISTRY-US, V16, P2279, DOI 10.1021/bi00629a037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURON Y, 1997, THROMB HAEMOST S, P213; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P959, DOI 10.1021/bi00403a018; NAITO K, 1991, J BIOL CHEM, V266, P7353; NISHIKADO H, 1987, THROMB RES, V48, P145, DOI 10.1016/0049-3848(87)90410-5; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SCOTT CF, 1989, BLOOD, V73, P1873; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SOONS H, 1989, BIOCHEMISTRY-US, V26, P4624; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; WALSH PN, 1987, J CLIN INVEST, V80, P1578, DOI 10.1172/JCI113244; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139; Zhao M, 1997, BLOOD, V90, P119	46	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31153	31159		10.1074/jbc.273.47.31153	http://dx.doi.org/10.1074/jbc.273.47.31153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813019	hybrid			2022-12-25	WOS:000077136900047
J	Albury, MS; Affourtit, C; Moore, AL				Albury, MS; Affourtit, C; Moore, AL			A highly conserved glutamate residue (Glu-270) is essential for plant alternative oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE MITOCHONDRIA; COLI RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; INNER MEMBRANE; PROTEIN R2; IRON; SITE; RESPIRATION; CLONING; CHAIN	We have previously demonstrated that expression of a Sauromatum guttatum alternative oxidase in Schizosaccharomyces pombe confers cyanide-resistant respiratory activity on these cells (Albury, M. S., Dudley, P., Watts, F. Z., and Moore, A. L. (1996) J. Biol. Chem. 271, 17062-17066). Using this functional expression system we have investigated the active site of the plant alternative oxidase, which has been postulated to comprise a non-heme binuclear iron center. Mutation of a conserved glutamate (Glu-270), previously postulated to be a bridging ligand within the active site, to asparagine abolishes catalytic activity because mitochondria containing the E270N mutant protein do not exhibit antimycin A-resistant respiration. Western blot analysis, using antibodies specific for the alternative oxidase, revealed that the E270N mutant protein was targeted to and processed by S. pombe mitochondria in a manner similar to that of the wild type protein. It is possible that lack of antimycin A-insensitive respiration observed in mitochondria containing the E270N mutant protein is due to incorrect insertion of the mutant alternative oxidase into the inner mitochondrial membrane. However, Western blot analysis of subfractionated mitochondria shows that both wild-type and E270N alternative oxidase are specifically located in the inner mitochondrial membrane, suggesting that misfolding or lack of insertion is unlikely. These results provide the first experimental evidence to support the structural model in which the active site of the alternative oxidase contains a coupled binuclear iron center.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	Moore, AL (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.		Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943				Albury MS, 1996, J BIOL CHEM, V271, P17062, DOI 10.1074/jbc.271.29.17062; ATTA M, 1992, J BIOL CHEM, V267, P20682; Berthold DA, 1998, BBA-BIOENERGETICS, V1364, P73, DOI 10.1016/S0005-2728(98)00015-2; Brookes PS, 1997, J MEMBRANE BIOL, V155, P167, DOI 10.1007/s002329900168; CHAUDHURI M, 1995, J EUKARYOT MICROBIOL, V42, P467, DOI 10.1111/j.1550-7408.1995.tb05892.x; Chaudhuri M, 1996, MOL BIOCHEM PARASIT, V83, P125, DOI 10.1016/S0166-6851(96)02754-5; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; Finnegan PM, 1997, PLANT PHYSIOL, V114, P455, DOI 10.1104/pp.114.2.455; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAMBERS H, 1982, PHYSIOL PLANTARUM, V55, P478, DOI 10.1111/j.1399-3054.1982.tb04530.x; LENNON AM, 1995, PLANT PHYSIOL, V107, P925, DOI 10.1104/pp.107.3.925; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLAR AH, 1993, FEBS LETT, V329, P259, DOI 10.1016/0014-5793(93)80233-K; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MOORE AL, 1983, ISOLATION MEMBRANES, P153; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; Purvis AC, 1997, PHYSIOL PLANTARUM, V100, P165, DOI 10.1034/j.1399-3054.1997.1000119.x; RASMUSSON AG, 1990, FEBS LETT, V259, P311, DOI 10.1016/0014-5793(90)80034-G; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; Sambrook J., 2002, MOL CLONING LAB MANU; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; Vanlerberghe Greg C., 1997, Plant Physiology (Rockville), V114, P204; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586; WATTS FZ, 1992, PLANT MOL BIOL, V18, P23, DOI 10.1007/BF00018453	33	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30301	30305		10.1074/jbc.273.46.30301	http://dx.doi.org/10.1074/jbc.273.46.30301			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804791	hybrid			2022-12-25	WOS:000077008100038
J	Kessler, E; Safrin, M; Gustin, JK; Ohman, DE				Kessler, E; Safrin, M; Gustin, JK; Ohman, DE			Elastase and the LasA protease of Pseudomonas aeruginosa are secreted with their propeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; ACTIVE-SITE HIS-223; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; EXTRACELLULAR SECRETION; AFFINITY PURIFICATION; CLEAVAGE; PROTEINS; GENE; IDENTIFICATION	Pseudomonas aeruginosa elastase and the LasA protease are synthesized as preproenzymes with long amino-terminal propeptides, The elastase propeptide is cleaved autocatalytically in the periplasm to form a transient, inactive elastase-propeptide complex. In contrast, the processing of proLasA does not involve autoproteolysis. In this study, we analyzed short-term P, aeruginosa cultures under conditions that minimize proteolysis and found that an elastase-propeptide complex is secreted, and then the propeptide is degraded extracellularly, apparently by elastase itself. LasA protease, on the other hand, was found to be secreted in its unprocessed 42-kDa proenzyme form. The processing of proLasA occurred extracellularly, and it involved the transient appearance of a 28-kDa intermediate and the respective 14-kDa LasA propeptide fragment. The processing of proLasA in P, aeruginosa strain FRD740, which does not express elastase, also proceeded via the 28-kDa intermediate, but the rate of processing was greatly reduced. This low rate of proLasA processing was further reduced when the activity of a secreted lysine-specific protease was blocked. Purified secreted proteases of P, aeruginosa (i.e, elastase, the lysine-specific protease, and alkaline proteinase) converted proLasA to the active enzyme. Processing by elastase and the lysine-specific enzyme, but not by alkaline proteinase, proceeded via the 28-kDa intermediate, and both were far more effective than alkaline proteinase in con verting proLasA to the mature enzyme. We conclude that LasA protease and elastase are secreted with their propeptides, which are then degraded by secreted proteases of P. aeruginosa, In addition to their other functions, the propeptides may play a role in targeting their respective enzymes across the outer membrane.	Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel; Univ Tennessee, Dept Microbiol & Immunol, Knoxville, TN 37996 USA; Vet Adm Med Ctr, Memphis, TN 38163 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Tennessee System; University of Tennessee Knoxville; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kessler, E (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026187] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26187] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; EPSTEIN DM, 1988, J BIOL CHEM, V263, P16586; FUJISHIGE A, 1992, J CELL BIOL, V118, P33, DOI 10.1083/jcb.118.1.33; Gustin JK, 1996, J BACTERIOL, V178, P6608, DOI 10.1128/jb.178.22.6608-6617.1996; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; KESSLER E, 1992, FEBS LETT, V299, P291, DOI 10.1016/0014-5793(92)80134-3; KESSLER E, 1993, J BIOL CHEM, V268, P7503; KESSLER E, 1982, INFECT IMMUN, V38, P716, DOI 10.1128/IAI.38.2.716-723.1982; Kessler E, 1997, J BIOL CHEM, V272, P9884; KESSLER E, 1994, J BIOL CHEM, V269, P22726; KESSLER E, 1995, METHOD ENZYMOL, V248, P740; KESSLER E, 1988, J BACTERIOL, V170, P1215, DOI 10.1128/jb.170.3.1215-1219.1988; KESSLER E, 1998, IN PRESS HDB PROTEOL; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Marie-Claire C, 1998, J BIOL CHEM, V273, P5697, DOI 10.1074/jbc.273.10.5697; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; McIver KS, 1995, MOL MICROBIOL, V18, P877, DOI 10.1111/j.1365-2958.1995.18050877.x; MCIVER KS, 1993, J BACTERIOL, V175, P4008, DOI 10.1128/JB.175.13.4008-4015.1993; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OLSON JC, 1992, J BACTERIOL, V174, P4140, DOI 10.1128/jb.174.12.4140-4147.1992; PETERS JE, 1992, MOL MICROBIOL, V6, P1155, DOI 10.1111/j.1365-2958.1992.tb01554.x; Pugsley AP, 1997, GENE, V192, P13, DOI 10.1016/S0378-1119(96)00803-7; SCHAD PA, 1988, J BACTERIOL, V170, P2784, DOI 10.1128/jb.170.6.2784-2789.1988; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; TOMMASSEN J, 1992, FEMS MICROBIOL LETT, V103, P73; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x	34	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30225	30231		10.1074/jbc.273.46.30225	http://dx.doi.org/10.1074/jbc.273.46.30225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804780	hybrid			2022-12-25	WOS:000077008100027
J	Mackay, JP; Kowalski, K; Fox, AH; Czolij, R; King, GF; Crossley, M				Mackay, JP; Kowalski, K; Fox, AH; Czolij, R; King, GF; Crossley, M			Involvement of the N-finger in the self-association of GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; DNA-BINDING DOMAIN; ZINC-FINGER; DEVELOPMENTAL REGULATION; PROTEIN; GENE; HEMATOPOIESIS; ACTIVATION; SP1; DROSOPHILA	Zinc fingers are recognized as small protein domains that bind to specific DNA sequences. Recently however, zinc fingers from a number of proteins, in particular the GATA family of transcription factors, have also been implicated in specific protein-protein interactions. The erythroid protein GATA-1 contains two zinc fingers: the C-finger, which is sufficient for sequence-specific DNA-binding, and the N-finger, which appears both to modulate DNA-binding and to interact with other transcription factors. We have expressed and purified the N-finger domain and investigated its involvement in the self-association of GATA-1. We demonstrate that this domain does not homodimerize but instead makes intermolecular contacts with the C-finger, suggesting that GATA dimers are maintained by reciprocal N-finger-C-finger contacts. Deletion analysis identifies a 25-residue region, C-terminal to the core N-finger domain, that is sufficient for interaction with intact GATA-1. A similar subdomain exists C-terminal to the C-finger, and we show that self-association is substantially reduced when both subdomains are disrupted by mutation. Moreover, mutations that impair GATA-1 self-association also interfere with its ability to activate transcription in transfection studies.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.		Fox, Archa H/H-9219-2014; Mackay, Joel P/D-6834-2011; Crossley, Merlin/D-7888-2011; King, Glenn F/J-5059-2012	Fox, Archa H/0000-0003-1962-270X; Mackay, Joel P/0000-0001-7508-8033; Crossley, Merlin/0000-0003-2057-3642; King, Glenn F/0000-0002-2308-2200				BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; Cotton F. A., 1988, ADV INORGANIC CHEM; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DREVET JR, 1995, J MOL BIOL, V246, P43, DOI 10.1006/jmbi.1994.0064; Elefanty AG, 1996, EMBO J, V15, P319, DOI 10.1002/j.1460-2075.1996.tb00362.x; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Huheey J.E., 1983, INORG CHEM; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; YANG HY, 1995, MOL CELL BIOL, V15, P1353; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	48	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30560	30567		10.1074/jbc.273.46.30560	http://dx.doi.org/10.1074/jbc.273.46.30560			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804826	hybrid			2022-12-25	WOS:000077008100073
J	Xu, CJ; Ahn, YT; Pathania, S; Jayaram, M				Xu, CJ; Ahn, YT; Pathania, S; Jayaram, M			Flp ribonuclease activities - Mechanistic similarities and contrasts to site-specific DNA recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; FUNCTIONAL-ANALYSIS; TYROSINE; CLEAVAGE; PROTEIN; INTEGRASE; COMPLEMENTATION; RESOLUTION; MUTATIONS; SUBSTRATE	The ribonuclease active site harbored by the Flp site-specific recombinase can act on two neighboring phosphodiester bonds to yield mechanistically distinct chain breakage reactions, One of the RNase reactions apparently proceeds via a covalent enzyme intermediate and targets the phosphodiester position involved in DNA recombination (Flp RNase I activity). The second activity (Flp RNase II) targets the phosphodiester immediately to the 3' side but appears not to involve an enzyme-linked intermediate. Flp RNase I is absolutely dependent upon Tyr-343 of Flp and is competitive with respect to the normal strand joining reaction. It can utilize the 2'-hydroxyl group from any one of the four ribonucleotides with comparable efficiencies in the cleavage reaction. On the other hand, the RNase II reaction mediated by Flp(Y343F) is specific for U and cannot utilize the 2'-hydroxyl group from ribo-A, -G, or -C under standard reaction conditions. The RNase II. activity is also sensitive to the 3'-neighboring base. Although dT is functional, the activity is stimulated by U or U-2'-OMe, The Flp RNase II reaction effectively competes with the normal strand cleavage reaction mediated by Tyr-343, even though their phosphodiester targets are not the same.	Univ Texas, Dept Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Jayaram, M (corresponding author), Univ Texas, Dept Microbiol, Austin, TX 78712 USA.	jayaram@almach.cc.utexas.edu						BEAUDRY AA, 1992, SCIENCE, V257, P35; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; Burgin AB, 1997, CELL, V91, P873, DOI 10.1016/S0092-8674(00)80478-X; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; COZZARELLI NR, 1992, P S APPL MATH, V45, P1; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; JAYARAM M, 1994, NUCLEIC ACIDS MOL BI, V8, P268; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; KIMBALL AS, 1993, BIOCHEMISTRY-US, V32, P4698, DOI 10.1021/bi00069a002; Knudsen BR, 1997, J MOL BIOL, V266, P93, DOI 10.1006/jmbi.1996.0767; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LEE J, 1993, J BIOL CHEM, V268, P17564; Lee J, 1996, J MOL BIOL, V257, P532, DOI 10.1006/jmbi.1996.0183; LEE J, 1995, J BIOL CHEM, V270, P23203, DOI 10.1074/jbc.270.39.23203; Nash H, 1996, ESCHERICHIA COLI SAL, V2, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; Sambrook J., 2002, MOL CLONING LAB MANU; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; SERRE MC, 1993, J BIOL CHEM, V268, P455; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Shuman S, 1998, MOL CELL, V1, P741, DOI 10.1016/S1097-2765(00)80073-8; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Wittschieben J, 1998, NUCLEIC ACIDS RES, V26, P490, DOI 10.1093/nar/26.2.490; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Yokochi T, 1996, GENES CELLS, V1, P1069, DOI 10.1046/j.1365-2443.1996.d01-226.x	40	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30591	30598		10.1074/jbc.273.46.30591	http://dx.doi.org/10.1074/jbc.273.46.30591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804830	hybrid			2022-12-25	WOS:000077008100077
J	de Haan, CAM; Roestenberg, P; de Wit, M; de Vries, AAF; Nilsson, T; Vennema, H; Rottier, PJM				de Haan, CAM; Roestenberg, P; de Wit, M; de Vries, AAF; Nilsson, T; Vennema, H; Rottier, PJM			Structural requirements for O-glycosylation of the mouse hepatitis virus membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; EQUINE ARTERITIS VIRUS; ACETYL-D-GALACTOSAMINE; BOVINE UDP-GALNAC; ENDOPLASMIC-RETICULUM; LINKED GLYCOSYLATION; E1 GLYCOPROTEIN; CDNA CLONING; EDMAN DEGRADATION	The mouse hepatitis virus (MHV) membrane (M) protein contains only O-linked oligosaccharides. We have used this protein as a model to study the structural requirements for O-glycosylation, We show that MHV M is modified by the addition of a single oligosaccharide side chain at the cluster of 4 hydroxylamino acids present at its extreme amino terminus and identified Thr at position 5 as the functional acceptor site. The hydroxylamino acid cluster, which is quite conserved among O-glycosylated coronavirus M proteins, is not in itself sufficient for O-glycosylation, Downstream amino acids are required to introduce a functional O-glycosylation site into a foreign protein, In a mutagenic analysis Oglycosylation was found to be sensitive to some particular changes but no unique sequence motif for O-glycosylation could be identified. Expression of mutant M proteins in cells revealed that substitution of any 1 residue was tolerated, conceivably due to the occurrence of multiple UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc transferases). Indeed, MHV M served as a substrate for GalNac-T1, -T2, and -T3, as was demonstrated using an in situ glycosylation assay based on the co-expression of endoplasmic reticulum-retained forms of the GalNAc transferases with endoplasmic reticulum-resident MHV M mutants. The GalNAc transferases were found to have largely overlapping, but distinct substrate specificities. The requirement for a threonine as acceptor rather than a serine residue and the requirement for a proline residue three positions downstream of the acceptor site were found to be distinctive features.	Univ Utrecht, Fac Vet Med, Inst Virol, Dept Immunol & Infect Dis, NL-3584 CL Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CL Utrecht, Netherlands; European Mol Biol Lab, Cell Biol Programme, D-69012 Heidelberg, Germany	Utrecht University; Utrecht University; European Molecular Biology Laboratory (EMBL)	Rottier, PJM (corresponding author), Univ Utrecht, Fac Vet Med, Inst Virol, POB 80-165, NL-3508 TD Utrecht, Netherlands.	P.Rottier@vetmic.dgk.ruu.nl	de Vries, Antoine/ABG-5787-2021	de Haan, Cornelis/0000-0002-4459-9874				ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998; DEREGT D, 1987, J GEN VIROL, V68, P2863, DOI 10.1099/0022-1317-68-11-2863; DEVRIES AAF, 1995, J VIROL, V69, P4668, DOI 10.1128/JVI.69.8.4668-4674.1995; DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HOMBERGER FR, 1994, VIRUS RES, V31, P49; HORTON RM, 1991, DIRECTED MUTAGENESIS; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUNITA S, 1995, VIRUS RES, V35, P277, DOI 10.1016/0168-1702(94)00089-U; LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; MOUNIR S, 1992, J GEN VIROL, V73, P2731, DOI 10.1099/0022-1317-73-10-2731; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PFLEIDERER M, 1986, J INFECT DIS, V154, P443; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987; ROTTIER PJM, 1990, ADV EXP MED BIOL, V276, P127; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SIDDELL S, 1981, J GEN VIROL, V53, P145, DOI 10.1099/0022-1317-53-1-145; STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982; SUGIYAMA K, 1986, ARCHVIROL, V87, P331; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG Y, 1993, J BIOL CHEM, V268, P22979; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884	57	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29905	29914		10.1074/jbc.273.45.29905	http://dx.doi.org/10.1074/jbc.273.45.29905			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792708	hybrid, Green Published			2022-12-25	WOS:000076798300085
J	Neri, LM; Borgatti, P; Capitani, S; Martelli, AM				Neri, LM; Borgatti, P; Capitani, S; Martelli, AM			Nuclear diacylglycerol produced by phosphoinositide-specific phospholipase C is responsible for nuclear translocation of protein kinase C-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; ENVELOPE SIGNAL-TRANSDUCTION; CANINE KIDNEY-CELLS; GROWTH-FACTOR-I; REPLICATIONAL SITES; IGF-I; ACTIVATION; STIMULATION; DIFFERENTIATION; LOCALIZATION	It is well established that an independent inositide cycle is present within the nucleus, where it is involved in the control of cell proliferation and differentiation. Previous results have shown that when Swiss 3T3 cells are treated with insulin-like growth factor-I (IGF-I) a rapid and sustained increase in mass of diacylglycerol (DAG) occurs within the nuclei, accompanied by a decrease in the levels of both phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. However, it is unclear whether or not other lipids could contribute to this prolonged rise in DAG levels. We now report that the IGF-I-dependent increase in nuclear DAG production can be inhibited by the specific phosphatidylinositol phospholipase C inhibitor 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine or by neomycin sulfate but not by the purported phosphatidylcholine-phospholipase C specific inhibitor D609 or by inhibitors of phospholipase D-mediated DAG generation. Treatment of cells with 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine or neomycin sulfate inhibited translocation of protein kinase C-alpha to the nucleus. Moreover, exposure of cells to 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine, but not to D609, dramatically reduced the number of cells entering S-phase upon stimulation with IGF-I. These results suggest that the only phospholipase responsible for generation of nuclear DAG after IGF-I stimulation of 3T3 cells is PI-PLC. When this activity is inhibited, neither DAG rise is seen nor PKC-alpha translocation to the nucleus occurs. Furthermore, this PI-PLC activity appears to be essential for the G(0)/G(1) to S-phase transition.	Univ Trieste, Dipartimento Morfol Umana Normale, I-34138 Trieste, Italy; Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana Normale, I-44100 Ferrara, Italy; Ist Ortoped Rizzoli, CNR, Ist Citomorfol Normale & Patol, I-40137 Bologna, Italy	University of Trieste; University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Rizzoli	Martelli, AM (corresponding author), Univ Trieste, Dipartimento Morfol Umana Normale, Via Manzoni 16, I-34138 Trieste, Italy.		Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017	Neri, Luca Maria/0000-0002-7924-1477; CAPITANI, Silvano/0000-0003-2795-6814				BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARNERO A, 1994, ONCOGENE, V9, P1387; CUADRADO A, 1993, ONCOGENE, V8, P2959; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Manzoli L, 1997, CANCER RES, V57, P2137; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MARTELLI AM, 1991, BIOCHEM BIOPH RES CO, V177, P480, DOI 10.1016/0006-291X(91)92009-9; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1989, EXP CELL RES, V185, P191, DOI 10.1016/0014-4827(89)90048-7; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Mufson RA, 1998, EXP CELL RES, V240, P228, DOI 10.1006/excr.1998.3932; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neri LM, 1997, CELL SIGNAL, V9, P353, DOI 10.1016/S0898-6568(96)00178-7; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; NERI LM, 1992, HISTOCHEMISTRY, V98, P19, DOI 10.1007/BF00716934; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nofer JR, 1997, J BIOL CHEM, V272, P32861, DOI 10.1074/jbc.272.52.32861; PALMER S, 1990, METHODS INOSITIDE RE; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RABEN DM, 1994, J MEMBRANE BIOL, V142, P1; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; Zheng LX, 1997, P NATL ACAD SCI USA, V94, P1573, DOI 10.1073/pnas.94.4.1573	41	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29738	29744		10.1074/jbc.273.45.29738	http://dx.doi.org/10.1074/jbc.273.45.29738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792687	hybrid			2022-12-25	WOS:000076798300064
J	Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG				Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG			Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?	ONCOGENE			English	Article						hypoxia; tumor progression; alternative spliced p53; p53 mutation	ALTERNATIVELY SPLICED P53; DNA-BINDING; MESSENGER-RNA; PROTEIN; CELLS; MICE	Most solid tumors are unable to grow in the ascites form, unless selected by prolonged serial transfer of peritoneal fluid (Klein, 1955), Established ascites tumor cells grow under highly crowded, virtually anoxic conditions (Warburg and Hiepler, 1953), Hypoxia was recently identified as a powerful inducer of p53 dependent apoptosis (Graeber et nl,, 1996), We wished to examine whether the conversion of relatively well-vascularized solid mouse tumors into freely growing ascitic cell variants favors cell with mutated or deleted p53, We have sequenced exons 4-9 of p53 cDNA from two serially transplanted methylcholanthrene induced sarcomas (MCIM and MSWBS) that were available in the original solid and the gradually converted ascites form, We have also examined five additional solid tumors, four carcinomas and one sarcoma and six additional ascites tumors, five carcinomas and one sarcoma, Sequence analysis showed that all solid tumors carried exclusively wild type p53, Among the eight ascites tumors, five carried mutant p53 and three had only the wild type gene. In one of the two isogenic pairs, the original solid tumor line had only wild type, whereas the derived ascites line had only mutant p53, In the second pair, the solid tumor was mild type whereas the ascitic variant was heterozygous, The naturally occurring alternatively spliced p53 (p53as) mRNA was detected in all solid tumors, but not in five of the eight ascites tumors. Our findings indicate that conversion of solid into ascites tumors favors the selection of cell variants with mutated p53 and of cells that lack the alternatively spliced form of p53.	Karolinska Inst, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden; CODE Genet, IS-110 Reykjavik, Iceland; Univ Bari, Dept Anat, I-70124 Bari, Italy	Karolinska Institutet; Universita degli Studi di Bari Aldo Moro	Magnusson, KP (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, S-17177 Stockholm, Sweden.		Magnusson, Kristinn/A-6479-2011; Magnusson, Kristinn P Pétur/X-4907-2019; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn/0000-0003-4528-6826; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X				BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HELLSTROM U, 1978, EUR J CANCER, V14, P1265, DOI 10.1016/0014-2964(78)90234-7; KLEIN E, 1955, EXP CELL RES, V8, P188, DOI 10.1016/0014-4827(55)90056-2; KLEIN E, 1955, EXP CELL RES, V8, P213, DOI 10.1016/0014-4827(55)90057-4; KLEIN G, 1951, CANCER RES, V11, P466; KLEIN G, 1960, CANCER RES, V20, P1561; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; KUZUMAKI N, 1980, EUR J CANCER, V16, P1181, DOI 10.1016/0014-2964(80)90177-2; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LETTRE H, 1950, Z KREBSFORSCH, V57, P1; Provencher DM, 1997, TUMOR BIOL, V18, P167, DOI 10.1159/000218027; PURDOM L, 1958, NATURE, V181, P1586, DOI 10.1038/1811586a0; RINGERTZ N, 1957, J NATL CANCER I, V18, P173; Schumacher U, 1997, EXP MOL PATHOL, V64, P103, DOI 10.1006/exmp.1997.2213; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Wang Q, 1997, J GEN VIROL, V78, P893, DOI 10.1099/0022-1317-78-4-893; WARBURG O, 1952, Z NATURFORSCH B, V7, P193; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x	25	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2333	2337		10.1038/sj.onc.1202149	http://dx.doi.org/10.1038/sj.onc.1202149			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811464				2022-12-25	WOS:000076723300007
J	Ohmori, Y; Hamilton, TA				Ohmori, Y; Hamilton, TA			STAT6 is required for the anti-inflammatory activity of interleukin-4 in mouse peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; MONOCYTIC CELL-LINES; DNA-BINDING FACTOR; GENE-EXPRESSION; INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; IFN-GAMMA; RECEPTOR ANTAGONIST; REGULATES IL-1	Interleukin-4 (IL-4) is an anti-inflammatory cytokine which inhibits many inducible macrophage functions. The present study demonstrates that the ability of IL-4 to inhibit interferon gamma (IFN gamma)-dependent gene transcription is dependent upon STATE. IL-4 suppressed IFN gamma-induced expression of the MIG (monokine Induced by IFN gamma) gene, a C-X-C chemokine, in mouse macrophages. IFN gamma-induced expression of MIG mRNA was abolished in peritoneal macrophages from Stat1-/- mice, and the suppression of MIG mRNA by IL-4 was abolished in macrophages from Stat6-/- mice. Transient transfection assays using a reporter gene containing the MIG gene promoter or the IFN gamma-responsive element (gamma RE) from the MIG gene revealed that the IFN gamma-dependent transcription was suppressed by IL-4, although IL-4 alone had no transactivating function. IFN gamma and IL-4 activated STAT1 and STATE, respectively, and both proteins were able to bind the gamma RE motif. Furthermore, STATE was associated with the co activator CREB-binding protein in RAW264.7 cells. These observations indicate that STATE is necessary for the IL-4-mediated suppression of IFN gamma-induced, STAT1-dependent transcription and suggest that STATE may directly suppress the STAT1-dependent transcription by competing with STAT1 for occupancy of the gamma RE motif and/or by competing with limiting quantities of the transcriptional coactivator.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ohmori, Y (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NN10,9500 Euclid Ave, Cleveland, OH 44195 USA.			Hamilton, Thomas/0000-0002-9817-242X; Ohmori, Yoshihiro/0000-0002-6069-357X	NCI NIH HHS [CA39621, CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039621, P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BERTON MT, 1995, J IMMUNOL, V154, P4513; Bethea JR, 1997, J IMMUNOL, V158, P5815; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CJP, 1995, EUR J IMMUNOL, V25, P2961, DOI 10.1002/eji.1830251037; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Deng WL, 1996, CELL IMMUNOL, V170, P20, DOI 10.1006/cimm.1996.0129; DENG WL, 1994, J IMMUNOL, V153, P2130; DOKTER WHA, 1993, BLOOD, V81, P337; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ESSNER R, 1989, J IMMUNOL, V142, P3857; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; FENTON MJ, 1992, J IMMUNOL, V149, P1283; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, J IMMUNOL, V150, P1944; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mijatovic T, 1997, J BIOL CHEM, V272, P14394, DOI 10.1074/jbc.272.22.14394; Mikita T, 1996, MOL CELL BIOL, V16, P5811; OHMORI Y, 1994, J IMMUNOL, V153, P2204; OHMORI Y, 1994, PHARMACOL THERAPEUT, V63, P235, DOI 10.1016/0163-7258(94)90026-4; Ohmori Y, 1996, J IMMUNOL, V157, P2058; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OPPENHEIM JJ, 1994, FASEB J, V8, P158, DOI 10.1096/fasebj.8.2.8119486; ORINO E, 1992, J IMMUNOL, V149, P925; PAUL WE, 1991, BLOOD, V77, P1859; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RENKONEN R, 1992, SCAND J IMMUNOL, V35, P525; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeshita S, 1996, J IMMUNOL, V156, P2591; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; VELDE AAT, 1990, J IMMUNOL, V144, P3046; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WONG HL, 1993, J EXP MED, V177, P775, DOI 10.1084/jem.177.3.775; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	69	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29202	29209		10.1074/jbc.273.44.29202	http://dx.doi.org/10.1074/jbc.273.44.29202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786931	hybrid			2022-12-25	WOS:000076691800092
J	Munoz, O; Brignone, C; Grenier-Brossette, N; Bonnefoy, JY; Cousin, JL				Munoz, O; Brignone, C; Grenier-Brossette, N; Bonnefoy, JY; Cousin, JL			Binding of anti-CD23 monoclonal antibody to the leucine zipper motif of Fc epsilon RII/CD23 on B cell membrane promotes its proteolytic cleavage - Evidence for an effect on the oligomer/monomer equilibrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY RECEPTOR; FC-EPSILON-RII; HUMAN IGE REGULATION; SOLUBLE CD23; LYMPHOCYTES-B; ANTIGEN; SURFACE; LIGAND; EXPRESSION; MODULATION	In the present study we have compared the binding of two monoclonal antibodies to CD23, EBVCS1 and mAb25, which recognize the stalk and the lectin domain, respectively, on the CD23 molecule. At 4 degrees C, EBVCS1 binds to about 10% of the receptors recognized by mAb25 on the B cell surface, At 37 degrees C, whereas mAb25 reaches its maximal binding within a few seconds, EBVCS1 requires 60 min to bind to the same extent. Stabilization of the oligomeric structure of CD23 with IgE strongly affects in a dose-dependent fashion the number of binding sites seen by EBVCS1 but not the t(1/2) to reach them, suggesting that EBVCS1 binds to the coiled coil region through an allosteric mechanism, EBVCS1 rapidly down-modulates the membrane CD23 expression with a coincident increase of CD23-soluble fragments in the culture medium, an effect that is inhibited by IgE, In contrast, mAb25, as well as IgE, protects CD23 from proteolytic cleavage and stimulates its endocytosis, These results suggest that EBVCS1 unravels the coiled coil structure of CD23, rendering it more susceptible to proteolytic attack. This supports the oligomeric model proposed previously (Gould, H,, Sutton, B,, Edmeades, R,, and Beavil, A. (1991) Monogr. Allergy 29, 28-49), The biological significance of these observations is discussed.	Hop Archet, INSERM, U343, F-06202 Nice 03, France; Fac Med, INSERM, U364, F-06107 Nice 02, France; Glaxo Inst Mol Biol SA, CH-1211 Geneva, Switzerland	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; GlaxoSmithKline	Cousin, JL (corresponding author), Hop Archet, INSERM, U343, BP 79, F-06202 Nice 03, France.	cousin@unice.fr						ARMANT M, 1995, J IMMUNOL, V155, P4868; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BARTLETT WC, 1995, J IMMUNOL, V154, P4240; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7118, DOI 10.1073/pnas.86.18.7118; BOBER LA, 1994, INT ARCH ALLERGY IMM, V105, P26, DOI 10.1159/000236799; BONNEFOY JY, 1995, CURR OPIN IMMUNOL, V7, P355, DOI 10.1016/0952-7915(95)80110-3; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; BONNEFOY JY, 1993, IMMUNOL TODAY, V14, P1, DOI 10.1016/0167-5699(93)90313-A; Bonnefoy JY, 1996, EUR RESPIR J, V9, pS63; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; BOURGET I, 1995, EUR J IMMUNOL, V25, P1872, DOI 10.1002/eji.1830250712; BOURGET I, 1994, J BIOL CHEM, V269, P6927; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; GORDON J, 1987, IMMUNOLOGY, V60, P517; Gould H, 1991, Monogr Allergy, V29, P28; GRABER P, 1992, J IMMUNOL METHODS, V149, P215, DOI 10.1016/0022-1759(92)90253-P; GRENIERBROSSETTE N, 1992, EUR J IMMUNOL, V22, P1573, DOI 10.1002/eji.1830220634; GUY GR, 1987, P NATL ACAD SCI USA, V84, P6239, DOI 10.1073/pnas.84.17.6239; KATIRA A, 1995, ALLERGY, V50, P689, DOI 10.1111/j.1398-9995.1995.tb02587.x; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; LEE WT, 1987, J IMMUNOL, V139, P1191; LETELLIER M, 1989, MOL IMMUNOL, V26, P1105, DOI 10.1016/0161-5890(89)90054-0; LUO HY, 1991, J IMMUNOL, V146, P2122; NOBEN NN, 1994, INT IMMUNOL, V6, P935, DOI 10.1093/intimm/6.7.935; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; SARFATI M, 1988, J IMMUNOL, V141, P2195; SARFATI M, 1987, IMMUNOLOGY, V60, P539; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P333, DOI 10.1016/S0091-6749(05)80096-X; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SHERR E, 1989, J IMMUNOL, V142, P481; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; STIEF A, 1994, J IMMUNOL, V152, P3378; SUGDEN B, 1992, TRENDS BIOCHEM SCI, V17, P239, DOI 10.1016/0968-0004(92)90400-4; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WAKAI M, 1993, HYBRIDOMA, V12, P25, DOI 10.1089/hyb.1993.12.25; YOKOTA A, 1992, P NATL ACAD SCI USA, V89, P5030, DOI 10.1073/pnas.89.11.5030; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	54	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31795	31800		10.1074/jbc.273.48.31795	http://dx.doi.org/10.1074/jbc.273.48.31795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822645	hybrid			2022-12-25	WOS:000077207000027
J	van der Vliet, A; Hristova, M; Cross, CE; Eiserich, JP; Goldkorn, T				van der Vliet, A; Hristova, M; Cross, CE; Eiserich, JP; Goldkorn, T			Peroxynitrite induces covalent dimerization of epidermal growth factor receptors in A431 epidermoid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; CATALYZED OXIDATION; ENDOTHELIAL-CELLS; KINASE-ACTIVITY; CROSS-LINKING; NITRIC-OXIDE; PROTEIN; MECHANISM	Irreversible tyrosine modifications by inflammatory oxidants such as peroxynitrite (ONOO-) can affect sig nal transduction pathways involving tyrosine phosphorylation, The epidermal growth factor receptor (EGFR), a member of the c-ErbB receptor tyrosine kinase family, is involved in regulation of epithelial cell growth and differentiation, and possible modulation of EGER-dependent signaling by ONOO- was studied, Exposure of epidermoid carcinoma A431 cells to 0.1-1.0 mM ONOO- resulted in tyrosine nitration on EGFR and other proteins but did not significantly affect EGFR tyrosine autophosphorylation. A high molecular mass tyrosine-phosphorylated protein (similar to 340 kDa) was detected in A431 cell lysates after exposure to ONOO-, most likely representing a covalently dimerized form of EGFR, based on immunoprecipitation and/or immunoblotting with alpha-EGFR antibodies and co-migration with ligand-induced EGFR dimers cross-linked with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Covalent EGFR dimerization by ONOO- probably involved intermolecular dityrosine cross-linking and was enhanced after receptor activation with epidermal growth factor. Furthermore, irreversibly cross-linked EGFR was more extensively tyrosine-phosphorylated compared with the monomeric form, indicating that ONOO- preferentially cross-links activated EGFR, Exposure of A431 cells to ONOO- markedly reduced the kinetics of tyrosine phosphorylation of a downstream EGFR substrate, phospholipase C-gamma 1, which may be related to covalent alterations in EGFR, Alteration of EGFR signaling by covalent EGFR dimerization by inflammatory oxidants such as ONOO- may affect conditions of increased EGFR activation such as epithelial repair or tumorigenesis.	Univ Calif Davis, Signal Transduct Lab, Dept Internal Med, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA	University of California System; University of California Davis	van der Vliet, A (corresponding author), Univ Calif Davis, Signal Transduct Lab, Dept Internal Med, Ctr Comparat Resp Biol & Med, TB149, Davis, CA 95616 USA.	avandervliet@ucdavis.edu; ttgoldkorn@ucdavis.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057452] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57452] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; COCHET C, 1988, J BIOL CHEM, V263, P3290; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ESTRADA C, 1977, BIOCHEM J, V326, P369; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P6414, DOI 10.1021/bi00369a011; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; GOLDKORN T, 1992, CELL GROWTH DIFFER, V3, P101; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Li XH, 1998, BIOCHEM J, V331, P599, DOI 10.1042/bj3310599; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MACLEOD CL, 1986, J CELL PHYSIOL, V127, P175, DOI 10.1002/jcp.1041270121; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MIERZWA S, 1987, BIOCHEM J, V246, P37, DOI 10.1042/bj2460037; Mondoro TH, 1997, FREE RADICAL BIO MED, V22, P1055, DOI 10.1016/S0891-5849(96)00510-2; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Pietraforte D, 1997, BIOCHEM J, V325, P675, DOI 10.1042/bj3250675; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; Riordan J F, 1972, Methods Enzymol, V25, P515, DOI 10.1016/S0076-6879(72)25048-0; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; vanderVliet A, 1996, METHOD ENZYMOL, V269, P175; VanWinkle LS, 1997, AM J PATHOL, V151, P443; VEALE D, 1989, CANCER RES, V49, P1313; WHITE AC, 1992, AM J RESP CELL MOL, V6, P364, DOI 10.1165/ajrcmb/6.4.364; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801	58	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31860	31866		10.1074/jbc.273.48.31860	http://dx.doi.org/10.1074/jbc.273.48.31860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822654	hybrid			2022-12-25	WOS:000077207000036
J	Cao, WS; Adya, N; Britos-Bray, M; Liu, PP; Friedman, AD				Cao, WS; Adya, N; Britos-Bray, M; Liu, PP; Friedman, AD			The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBF beta-SMMHC are both required to slow cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; TRANSCRIPTION FACTOR; DNA-BINDING; MURINE MYELOPEROXIDASE; FUNCTIONAL DISSECTION; VIRUS ENHANCERS; FUSION GENE; PROTEIN	We have expressed several variants of core binding factor beta (CBF beta)-smooth muscle myosin heavy chain (SMMHC) from the metallothionein promoter in Ba/F3 cells. Deletion of amino acids 2-11 from the CBF beta segment, required for interaction with CBF alpha, prevented CBF beta-SMMHC from inhibiting CBF DNA binding and cell cycle progression. Deletion of 283 carboxyl-terminal residues from the SMMHC domain, required for multimerization, also inactivated CBF beta-SMMHC. Nuclear expression of CBF beta(Delta 2-11)-SMMHC was decreased relative to CBF beta-SMMHC. CBF beta(Delta 2-11)-SMMHC linked to a nuclear localization signal still did not slow cell growth. The ability of each CBF beta-SMMHC variant to inhibit CBF DNA binding and cell proliferation correlated with its ability to inhibit transactivation by an AML1-VP16 fusion protein. Thus, CBF beta-SMMHC slows cell cycle progression from G(1) to S phase by inhibiting CBF DNA binding and transactivation.	Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21287 USA; NHGRI, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Friedman, AD (corresponding author), Johns Hopkins Oncol Ctr, Div Pediat Oncol, Rm 3-109,600 N Wolfe St, Baltimore, MD 21287 USA.		Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADYA N, 1998, IN PRESS MOL CELL BI; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; BAE SC, 1993, ONCOGENE, V8, P809; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BRITOSBRAY M, 1998, IN PRESS BLOOD; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Frank R, 1995, ONCOGENE, V11, P2667; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MILLER JD, 1997, BLOOD, V90, pA41; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG S, 1993, OGAWCELL BIOL, V13, P3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; YANAGISAWA K, 1991, BLOOD, V78, P451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	44	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31534	31540		10.1074/jbc.273.47.31534	http://dx.doi.org/10.1074/jbc.273.47.31534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813068	hybrid			2022-12-25	WOS:000077136900096
J	Champliaud, MF; Burgeson, RE; Jin, W; Baden, HP; Olson, PF				Champliaud, MF; Burgeson, RE; Jin, W; Baden, HP; Olson, PF			cDNA cloning and characterization of sciellin, a LIM domain protein of the keratinocyte cornified envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; CELL-ENVELOPE; MOLECULAR CHARACTERIZATION; EPIDERMAL-CELLS; HUMAN LORICRIN; INVOLUCRIN; EXPRESSION; GENE; TRANSGLUTAMINASE; DIFFERENTIATION	Sciellin is a precursor of the cornified envelopes of mammalian keratinizing tissues. We have cloned the cDNA encoding sciellin by screening a human keratinocyte expression library with a sciellin-specific monoclonal antibody. The composite cDNA of 2.35 kilobase pairs encodes a protein of 75.3 kDa with a pi of 10.09, The translated sequence has a central domain containing 16 repeats of 20 amino acids each that is rich in Gin and Lys residues, which are potential transglutaminase substrates, and a carboxyl domain, which contains a single LIM motif, Sciellin cDNA probes hybridize to bands of 3.4 and 4.4 kilobase pairs on Northern blots of cultured human keratinocyte RNA. The gene was mapped to human chromosome band 13q22 by fluorescence in situ hybridization, Radiation hybrid mapping demonstrated that sciellin is linked to the sequence tagged site marker WI-457 with a logarithm of the odds score of 7.77, In situ hybridization of human foreskin tissue sections demonstrated that sciellin is expressed in the stratum granulosum, Immunofluorescent staining with a polyclonal rabbit antibody made to a recombinant sciellin protein showed peripheral cytoplasmic localization in the upper cell. layers of epidermis and in stratified squamous epithelia such as the oral cavity, esophagus, and vagina. Simple and columnar epithelia, with the exception of the amnion, showed no reaction.	Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Dermatol, Cambridge, MA 02139 USA	Harvard University	Olson, PF (corresponding author), Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Bldg 149,13th St, Cambridge, MA 02139 USA.	pamela_olson@cbrc.mgh.harvard.edu			NIAMS NIH HHS [AR35689] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035689, R37AR035689] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; BADEN HP, 1987, J INVEST DERMATOL, V89, P454, DOI 10.1111/1523-1747.ep12460759; BADEN HP, 1993, J INVEST DERMATOL, V101, pS72, DOI 10.1111/1523-1747.ep12362869; BADEN HP, 1968, J INVEST DERMATOL, V51, P478, DOI 10.1038/jid.1968.158; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; Champliaud MF, 1998, J INVEST DERMATOL, V110, P277, DOI 10.1046/j.1523-1747.1998.00127.x; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; De Viragh Pierre A., 1997, Journal of Investigative Dermatology, V108, P555; DOWNING DT, 1992, J LIPID RES, V33, P301; ELIAS PM, 1975, J CELL BIOL, V65, P180, DOI 10.1083/jcb.65.1.180; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; IshidaYamamoto A, 1997, AM J HUM GENET, V61, P581, DOI 10.1086/515518; Kibar Z, 1996, HUM MOL GENET, V5, P543, DOI 10.1093/hmg/5.4.543; Korge BP, 1997, J INVEST DERMATOL, V109, P604, DOI 10.1111/1523-1747.ep12337534; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KVEDAR JC, 1992, DIFFERENTIATION, V49, P195, DOI 10.1111/j.1432-0436.1992.tb00667.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; POLAKOWSKA RR, 1991, PHYSL BIOCH MOL BIOL, V1, P168; Reichert Uwe, 1993, P107; Robinson NA, 1998, J BIOL CHEM, V273, P2721, DOI 10.1074/jbc.273.5.2721; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SIMON M, 1988, J BIOL CHEM, V263, P18093; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; SUN TT, 1985, ANN NY ACAD SCI, V455, P307, DOI 10.1111/j.1749-6632.1985.tb50419.x; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; Takahashi M, 1996, ARCH BIOCHEM BIOPHYS, V329, P123, DOI 10.1006/abbi.1996.0199; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WU RY, 1994, J BIOL CHEM, V269, P25085; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; Yoneda K., 1996, Journal of Investigative Dermatology, V106, P875	57	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31547	31554		10.1074/jbc.273.47.31547	http://dx.doi.org/10.1074/jbc.273.47.31547			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813070	hybrid			2022-12-25	WOS:000077136900098
J	Ridgway, ND; Lagace, TA; Cook, HW; Byers, DM				Ridgway, ND; Lagace, TA; Cook, HW; Byers, DM			Differential effects of sphingomyelin hydrolysis and cholesterol transport on oxysterol-binding protein phosphorylation and Golgi localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE SPHINGOMYELIN; HAMSTER OVARY CELLS; SHORT-CHAIN CERAMIDE; ENDOPLASMIC-RETICULUM; KINASE-C; CULTURED FIBROBLASTS; IMMUNOCYTOCHEMICAL LOCALIZATION; RAT-BRAIN; CHO CELLS; PHOSPHATASE	The deposition of de novo synthesized and lipoprotein-derived cholesterol at the plasma membrane and trans port to the endoplasmic reticulum is dependent on sphingomyelin (SM) content. Here we show that hydrolysis of plasma membrane SM in Chinese hamster ovary cells by exogenous bacterial sphingomyelinase resulted in enhanced cholesterol esterification at the endoplasmic reticulum and rapid dephosphorylation of the oxysterol-binding protein (OSBP), a cytosolic/Golgi receptor for oxysterols such as 25-hydroxycholesterol. After sphingomyelinase treatment, restoration of OSBP phosphorylation closely paralleled resynthesis of SM and down-regulation of cholesterol ester synthesis. SM hydrolysis activated an okadaic acid-sensitive phosphatase that was not stimulated in Chinese hamster ovary cells by short chain ceramides. Agents that specifically Mocked sphingomyelinase-mediated delivery of cholesterol to acyl-CoA:cholesterol acyltransferase (U18666A) or promoted cholesterol efflux to the medium (cyclodextrin) did not inhibit OSBP dephosphorylation. SM hydrolysis also promoted OSBP translocation from a vesicular compartment to the Golgi apparatus. Cyclodextrin and U18666A also caused OSBP translocation to the Golgi apparatus, suggesting that OSBP movement is coupled to changes in the cholesterol content of the plasma membrane or Golgi apparatus. These results identify OSBP as a potential target of SM turnover and cholesterol mobilization at the plasma membrane and/or Golgi apparatus.	Dalhousie Univ, Clin Res Ctr, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Ridgway, ND (corresponding author), Dalhousie Univ, Clin Res Ctr, Atlantic Res Ctr, Rm C302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	nridgway@is.dal.ca		Ridgway, Neale/0000-0002-0441-6228				BRASAEMLE DL, 1990, J LIPID RES, V31, P103; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHEN H, 1993, J LIPID RES, V34, P2159; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GUPTA AK, 1991, J LIPID RES, V32, P125; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; Jacobs NL, 1997, J LIPID RES, V38, P1973; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKWU AK, 1994, J LIPID RES, V35, P644; PORN MI, 1990, BIOCHEM J, V271, P121, DOI 10.1042/bj2710121; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; RIDGWAY ND, 1997, BIOCHIM BIOPHYS ACTA, V1390, P37; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TABAS I, 1988, J BIOL CHEM, V263, P1266; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; URBANI L, 1990, J BIOL CHEM, V265, P1919; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	50	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31621	31628		10.1074/jbc.273.47.31621	http://dx.doi.org/10.1074/jbc.273.47.31621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813079	hybrid			2022-12-25	WOS:000077136900107
J	Costet, P; Legendre, C; More, J; Edgar, A; Galtier, P; Pineau, T				Costet, P; Legendre, C; More, J; Edgar, A; Galtier, P; Pineau, T			Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; ACYL-COA OXIDASE; GENE-EXPRESSION; TARGETED DISRUPTION; BODY-WEIGHT; FATTY-ACIDS; RAT-LIVER; PPAR-GAMMA; MOUSE; MICE	The alpha-isoform of the peroxisome proliferator-activated receptor (PPAR alpha) is a nuclear transcription factor activated by structurally diverse chemicals referred to as peroxisome proliferators. Activators can be endogenous molecules (fatty acids/steroids) or xenobiotics (fibrate lipid-lowering drugs). Upon pharmacological activation, PPAR alpha modulates target genes encoding lipid metabolism enzymes, lipid transporters, or apolipoproteins, suggesting a role in lipid homeostasis. Transgenic mice deficient in PPAR alpha were shown to lack hepatic peroxisomal proliferation and have an impaired expression and induction of several hepatic target genes. Young adult males show hypercholesterolemia but normal triglycerides. Using a long term experimental set up, we identified these mice as a model of monogenic, spontaneous, late onset obesity with stable caloric intake and a marked sexual dimorphism. Serum triglycerides, elevated in aged animals, are higher in females that develop a more pronounced obesity than males. The latter show a marked and original centrilobular-restricted steatosis and a delayed occurrence of obesity. Fat cells from their liver express substantial levels of PPAR gamma 2 transcripts when compared with lean cells. These studies demonstrate, in rodents, the involvement of PPAR alpha nuclear receptor in lipid homeostasis, with a sexually dimorphic control of circulating lipids, fat storage, and obesity. Characterization of this pathological link may help to delineate new molecular targets for therapeutic intervention and could lead to new insights into the etiology and heritability of mammalian obesity.	INRA, Lab Pharmacol & Toxicol, F-31931 Toulouse 9, France; Labs Fournier SCA, Dept Atherosclerose, F-21121 Daix, France	INRAE	Pineau, T (corresponding author), INRA, Lab Pharmacol & Toxicol, BP 3, F-31931 Toulouse 9, France.	tpineau@toulouse.inra.fr	costet, philippe/A-5314-2010					AIKEN J, 1990, J PEDIATR SURG, V25, P140, DOI 10.1016/S0022-3468(05)80180-0; Auwerx J, 1996, J Atheroscler Thromb, V3, P81; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouchard C, 1996, DIABETOLOGIA, V39, P1532, DOI 10.1007/s001250050610; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96; EDELSTEIN C, 1986, METHOD ENZYMOL, V128, P339; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1996, ANN NY ACAD SCI, V804, P530, DOI 10.1111/j.1749-6632.1996.tb18643.x; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; Gabreels BATF, 1998, J CLIN ENDOCR METAB, V83, P591, DOI 10.1210/jc.83.2.591; Gonzalez FJ, 1997, BIOCHIMIE, V79, P139, DOI 10.1016/S0300-9084(97)81506-4; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HEUBI JE, 1987, HEPATOLOGY, V7, P155, DOI 10.1002/hep.1840070130; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HSU MH, 1995, MOL PHARMACOL, V48, P559; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; INGELMANSUNDBERG M, 1988, BIOCHEM BIOPH RES CO, V157, P55, DOI 10.1016/S0006-291X(88)80010-X; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LARSEN ML, 1994, ATHEROSCLEROSIS, V106, P235, DOI 10.1016/0021-9150(94)90128-7; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LI ZG, 1994, GENOMICS, V24, P259, DOI 10.1006/geno.1994.1614; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morin CL, 1997, J NUTR BIOCHEM, V8, P702, DOI 10.1016/S0955-2863(97)00123-X; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Muls E, 1997, INT J OBESITY, V21, P155, DOI 10.1038/sj.ijo.0800370; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Naggert J, 1997, CURR OPIN GENET DEV, V7, P398, DOI 10.1016/S0959-437X(97)80155-4; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Norman RA, 1996, DIABETES, V45, P1229, DOI 10.2337/diabetes.45.9.1229; Oinonen T, 1996, BIOCHEM PHARMACOL, V51, P1379, DOI 10.1016/0006-2952(96)00064-0; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Puck TT, 1997, P NATL ACAD SCI USA, V94, P1218, DOI 10.1073/pnas.94.4.1218; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Schoonjans K, 1996, J LIPID RES, V37, P907; SHEPHERD J, 1994, ATHEROSCLEROSIS, V110, pS55, DOI 10.1016/0021-9150(94)05380-2; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDENHEUVEL JP, 1993, BIOCHIM BIOPHYS ACTA, V1177, P183, DOI 10.1016/0167-4889(93)90039-R; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	66	335	350	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29577	29585		10.1074/jbc.273.45.29577	http://dx.doi.org/10.1074/jbc.273.45.29577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792666	Green Published, hybrid			2022-12-25	WOS:000076798300043
J	Hendricks, SP; Mathews, CK				Hendricks, SP; Mathews, CK			Differential effects of hydroxyurea upon deoxyribonucleoside triphosphate pools, analyzed with vaccinia virus ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMALL-SUBUNIT; SUBSTRATE CYCLES; MAMMALIAN-CELLS; DNA-SYNTHESIS; PROTEIN R2; REPLICATION; GENE	Hydroxyurea inhibits DNA synthesis by destroying the catalytically essential free radical of class I ribonucleoside diphosphate (rNDP) reductase, thereby blocking the de novo synthesis of deoxyribonucleotides. In mammalian cells, including those infected by vaccinia virus, hydroxyurea treatment causes a differential depletion of the four deoxyribonucleoside triphosphate pools, suggesting that the activities of rNDP reductase are differentially sensitive to hydroxyurea, In the presence of different substrates and allosteric modifiers, we measured rates of free radical destruction in the vaccinia virus-coded rNDP reductase, by following absorbance at 417 nm as a function of time after hydroxyurea addition. Also, we followed enzyme activity directly, by using a recently developed assay that allows simultaneous monitoring of the four activities, in the presence of substrates and effecters at concentrations that approximate the intracellular environment. We found the primary determinant of radical loss to be not the ensemble of allosteric ligands bound but the activity of the enzyme. Nucleoside triphosphate effecters accelerated radical decay, compared with rates seen with the free enzyme. Adding substrate to the holoenzyme, under conditions where the enzymatic reaction is proceeding, further accelerated radical decay, Alternative models are discussed, to account for selective depletion of purine nucleotide pools by hydroxyurea.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@ucs.orst.edu			NIGMS NIH HHS [GM-55234] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; CHIU CS, 1977, J BIOL CHEM, V252, P8603; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; GAO WY, 1995, P NATL ACAD SCI USA, V92, P8333, DOI 10.1073/pnas.92.18.8333; Hendricks SP, 1998, J BIOL CHEM, V273, P29512, DOI 10.1074/jbc.273.45.29512; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; NICANDER B, 1985, J BIOL CHEM, V260, P5376; NICANDER B, 1985, J BIOL CHEM, V260, P9216; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; SLABAUGH M, 1988, J VIROL, V62, P519, DOI 10.1128/JVI.62.2.519-527.1988; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; TENGELSON LA, 1988, VIROLOGY, V164, P7426; THELANDER M, 1985, J BIOL CHEM, V260, P2737	27	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29519	29523		10.1074/jbc.273.45.29519	http://dx.doi.org/10.1074/jbc.273.45.29519			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792659	hybrid			2022-12-25	WOS:000076798300036
J	Lee, YJ; Corry, PM				Lee, YJ; Corry, PM			Metabolic oxidative stress-induced HSP70 gene expression is mediated through SAPK pathway - Role of Bcl-2 and c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR; GROWTH-FACTOR GENE; SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; TRANSCRIPTION FACTOR; DNA-BINDING; HELA-CELLS; ESCHERICHIA-COLI; MCF-7/ADR CELLS	In previous reports we demonstrated that glucose deprivation induces metabolic oxidative stress in drug-resistant human breast carcinoma MCF-7/ADR cells (Lee, Y. J., Galoforo, S. S., Berns, c. M., Chen, J. C., Davis, B. H., Swim, J. E., Corry, P. M., and Spitz, D. R. (1998) J. Biol. Chem. 273, 5294-5299). In the study described here, we investigated intracellular responses to metabolic oxidative stress. Northern blots show an increase in the level of HSP70 and HSP28 mRNA in cells exposed to glucose-free medium for 1 h, One and two-dimensional polyacrylamide gel analyses confirmed that glucose deprivation induced a family of HSPs, particularly an inducible HSP70. Overexpression of bcl-2 suppressed glucose deprivation-induced HSP70 gene expression, heat shock transcription factor-heat shock element binding activity, as well as c-Jun NH2-terminal kinase (JNK1) activation. Expression of a dominant-negative mutant of JNK1 also suppressed glucose deprivation-induced JNK1 activation as well as HSP70 gene expression. Taken together, the stress-activated protein kinase signal transduction pathway is involved in glucose deprivation-induced heat shock gene expression.	William Beaumont Hosp, Dept Radiat Oncol, Res Labs, Royal Oak, MI 48073 USA; Seoul Natl Univ, Coll Nat Sci, Dept Mol Biol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Beaumont Health; Seoul National University (SNU); Seoul National University (SNU)	Lee, YJ (corresponding author), William Beaumont Hosp, Dept Radiat Oncol, Res Labs, 3601 W 13th Mile Rd, Royal Oak, MI 48073 USA.				NCI NIH HHS [CA44550, CA48000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048000, R37CA044550, R01CA044550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bradley TM, 1997, NUCLEIC ACIDS RES, V25, P1469, DOI 10.1093/nar/25.8.1469; BRUCE JL, 1993, CANCER RES, V53, P12; Bunn HF, 1998, J EXP BIOL, V201, P1197; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; CUNNIFF NFA, 1991, MOL CELL BIOL, V11, P3504, DOI 10.1128/MCB.11.7.3504; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gomer CJ, 1996, CANCER RES, V56, P2355; Gordon S, 1997, DEV BIOL, V181, P47, DOI 10.1006/dbio.1996.8441; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HATAYAMA T, 1993, J BIOCHEM-TOKYO, V114, P592, DOI 10.1093/oxfordjournals.jbchem.a124222; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; IWAI SA, 1993, EXP CELL RES, V205, P39, DOI 10.1006/excr.1993.1055; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEE YJ, 1986, RADIAT RES, V106, P98, DOI 10.2307/3576565; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI GC, 1985, CANCER RES, V45, P3816; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Qin SF, 1997, J BIOL CHEM, V272, P2098; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014-5793(93)80561-8; TUSHINSKI RJ, 1977, P NATL ACAD SCI USA, V74, P2357, DOI 10.1073/pnas.74.6.2357; Walker J M, 1984, Methods Mol Biol, V1, P57, DOI 10.1385/0-89603-062-8:57; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	73	60	65	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29857	29863		10.1074/jbc.273.45.29857	http://dx.doi.org/10.1074/jbc.273.45.29857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792702	hybrid			2022-12-25	WOS:000076798300079
J	Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH				Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH			Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression	ONCOGENE			English	Article						BRCA2; tumor suppressor gene; breast cancer; cell cycle	BREAST-CANCER FAMILIES; MUTATIONS; GENE; PROTEIN; ASHKENAZI; MICE; PROLIFERATION; PROGRESSION; PHENOTYPES; 6174DELT	People carrying a mutant BRCA2 gene are susceptible to breast, ovarian, pancreatic and other tumors. Many facets of BRCA2 have been studied, including its mutation in human cancers, its role in mouse embryogenesis and its RNA expression in different tissues and different mouse embryogenesis stages. However, there has been very little characterization of BRCA2 protein. We investigated the biochemical and biological properties of BRCA2 by using a monoclonal antibody we generated against the N-terminal portion of BRCA2, We discovered that the detection of BRCA2 by immunoblot analysis was sensitive to the temperature used to denature the samples before gel electrophoresis. BRCA2 was easily detectable when samples were denatured at low temperature instead of boiling. Although the precise mechanism underlying this observation is not clear yet, this finding mill significantly improve our ability to study BRCA2, We examined the expression of BRCA2 using an immunoblot analysis protocol modified according to this observation. We showed that BRCA2 was presented in every human cell lines examined, including Capan-1, which expressed a truncated BRCA2 due to a BRCA2 frameshift mutation. We also showed that the expression of BRCA2 was cell-cycle regulated. Our results suggest that BRCA2 has an important role in cell growth regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682	NATIONAL CANCER INSTITUTE [R01CA064856, R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 70371, CA 64856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Berman DB, 1996, CANCER RES, V56, P3409; Bertwistle D, 1997, CANCER RES, V57, P5485; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Friedman LS, 1998, CANCER RES, V58, P1338; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang TC, 1996, ARCH BIOCHEM BIOPHYS, V329, P208, DOI 10.1006/abbi.1996.0210; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RON D, 1992, BIOTECHNIQUES, V13, P866; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	18	18	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2377	2381		10.1038/sj.onc.1202162	http://dx.doi.org/10.1038/sj.onc.1202162			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811469				2022-12-25	WOS:000076723300012
J	Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL				Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL			Characterization of a carboxy-terminal BRCA1 interacting protein	ONCOGENE			English	Article						BRCA1 interactor; tumor suppressor; mutation; transcription	CANCER SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; E1A PROTEIN; DNA-REPAIR; RAD51	There are several lines of evidence indicating that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid and in vitro biochemical assays, we show that a protein, CtIP, interacts specifically with the carboxy-terminal segment of human BRCA1 from residues 1602-1863. A germ line truncation mutation, Y1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1, abolishes not only its transcriptional activation function, but also binding to CtIP. The function of CtIP is unknown, but its reported association with a transcriptional repressor CtBP lends further support that it may have a role in transcription. A sequence based screen of a panel of 89 tumor cell line cDNAs for mutations in the CtIP coding region identified five missense variants. In the pancreatic carcinoma cell line, BxPC3, the non-conservative lysine to glutamic acid change at codon 337 is accompanied with apparent loss of heterozygosity or non-expression of the wild type allele. Thus it is plausible that CtIP may itself be a tumor suppressor acting in the same pathway as BRCA1.	Myriad Genet Inc, Salt Lake City, UT 84108 USA	Myriad Genetics, Inc	Wong, AKC (corresponding author), Myriad Genet Inc, 390 Wakara Way, Salt Lake City, UT 84108 USA.							Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PIDDER JD, 1996, TRENDS GENET, V12, P272; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V15, P535; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sobol A, 1996, CANCER RES, V56, P3216; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P4177; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	46	136	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2279	2285		10.1038/sj.onc.1202150	http://dx.doi.org/10.1038/sj.onc.1202150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811458				2022-12-25	WOS:000076723300001
J	Au, WC; Moore, PA; LaFleur, DW; Tombal, B; Pitha, PM				Au, WC; Moore, PA; LaFleur, DW; Tombal, B; Pitha, PM			Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA PROMOTER REGION; VIRUS-INFECTION; MESSENGER-RNA; BETA GENE; FACTOR-I; EXPRESSION; IRF-1; IMMUNODEFICIENCY; IDENTIFICATION; ISGF3-GAMMA	The family of interferon regulatory factors (IRFs) plays an important role in modulating cellular responses to viral infection and cytokines, including IFNs. The transcription factors that are involved in the transcriptional activation of the IFNB gene have been extensively studied. However, the molecular mechanism by which virus activates the expression of the IFNA gene remains to be defined. Recently, we have identified a new IRF-7 isoform, denoted as IRF-7H, which encodes a protein of 514 amino acids and is most closely related to the IRF-3. The expression of IRF-7 is restricted to the lymphoid cell types and is inducible by virus, lipopolysaccharide, and IFNA. The functional characterization of IRF-7H reveals a presence of transactivation domain located carboxyl-terminal to its DNA binding domain. Overexpression of IRF-7H results in an activation of IFNA promoter in transient transfection assay and a strong enhancement of virus-mediated activation of this promoter. Whereas in uninfected cells, overexpressed IRF-7H is present mainly in the cytoplasm, viral infection facilitates the transfer of IRF-7H to the nucleus; overexpression of IRF-3 interferes with the virus-induced translocation of IRF-7H. Thus, IRF-7 exhibits functional similarity to IRF-3; however, the preferential expression of IRF-7 in lymphoid cells (the cell type that expresses IFNA) suggests that IRF-7 may play a critical role in regulating the IFNA gene expression.	Johns Hopkins Univ, Sch Med, Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Oncol Ctr, 418 N Bond St, Baltimore, MD 21231 USA.	parowe@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19737] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Braganca J, 1997, J BIOL CHEM, V272, P22154, DOI 10.1074/jbc.272.35.22154; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; HARADA H, 1994, ONCOGENE, V9, P3313; HISAMARU H, 1988, NUCLEIC ACIDS RES, V16, P6067; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Parker SF, 1997, J VIROL, V71, P2004, DOI 10.1128/JVI.71.3.2004-2012.1997; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	30	229	238	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29210	29217		10.1074/jbc.273.44.29210	http://dx.doi.org/10.1074/jbc.273.44.29210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786932	hybrid			2022-12-25	WOS:000076691800093
J	Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA				Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA			p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro	ONCOGENE			English	Article						hepatitis B virus; apoptosis; X protein; liver; p53	WILD-TYPE P53; MYC-MEDIATED APOPTOSIS; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; LIVER-CANCER; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; CELL-DEATH; HELA-CELLS	The hepatitis B virus protein HBx is a promiscuous transactivator implicated in both cell growth and death and in the development of hepatocellular carcinoma. We recently reported that HBx can potentiate c-myc-induced liver oncogenesis in a transgenic model where low level expression of HBx induces no pathology, To assess if HBx could affect the hepatocyte turnover, we investigated the HBx-elicited apoptotic responses in transgenic livers and in primary hepatocyte cultures. Here we show that transgenic expression of HBx is associated with a twofold increase of spontaneous cell death in the mouse liver, The finding that apoptosis was enhanced to similar extents in HBx mice carrying homozygous p53 null mutations implied that functionally intact p53 was not required to transduce the death signal, A direct, dose-dependent apoptotic function of HBx was demonstrated in transient transfections of liver-derived cell lines. We further show that stable expression of HBx at low, presumably physiological levels in primary hepatocytes, induced cellular susceptibility to diverse apoptotic insults, including growth factor deprivation, treatment with anti-Fas antibodies or doxorubicine and oxidative stress, HBx expression, but not p53 status profoundly affected the commitment of cells to die upon apoptotic stimuli, These data strengthen the notion that HEX may contribute to HBV pathogenesis by enhancing apoptotic death in the chronically infected liver.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France; Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotechnol Cellulari, Fdn Inst Pasteur Cenci Bolognetti, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.		Pollicino, Teresa/K-5790-2016; Pollicino, Teresa/HDN-3708-2022; Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022	Pollicino, Teresa/0000-0001-6602-3035; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOOPER ML, 1994, J CELL SCI, P13; HSU B, 1995, ONCOGENE, V11, P175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lecoeur H, 1997, J IMMUNOL METHODS, V209, P111, DOI 10.1016/S0022-1759(97)00138-5; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, CANCER RES, V57, P5137; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Peterhans E, 1997, J NUTR, V127, pS962, DOI 10.1093/jn/127.5.962S; Petersen J, 1997, J VIROL, V71, P5455, DOI 10.1128/JVI.71.7.5455-5463.1997; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TEODORO JG, 1995, ONCOGENE, V11, P467; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	65	152	158	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2115	2123		10.1038/sj.onc.1202432	http://dx.doi.org/10.1038/sj.onc.1202432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798683				2022-12-25	WOS:000076540900011
J	Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF				Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF			PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate	ONCOGENE			English	Article						PTEN/MMAC1; prostate cancer; allelic loss; mutation; homozygous deletion	TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; COWDEN-DISEASE; MICROSATELLITE INSTABILITY; PTEN GENE; CANCER; DELETION; BREAST; CHROMOSOME; FREQUENT	Deletion of the q23-24 region of human chromosome 10 is one of the most frequent genetic alterations in prostate cancer, suggesting that inactivation of a tumor suppressor gene in this region is involved in the development or progression of this carcinoma. A candidate gene, PTEN/MMAC1, has been identified from this chromosomal region; mutations of this gene have been found in various advanced tumors and cell lines including those of prostate cancer. To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods. Six tumors showed loss of heterozygosity for one of the ten markers analysed, while one tumor showed loss of two markers. None of the markers within PTEN/MMAC1 was lost. Direct sequencing of PCR amplified exons and intron/exon junctions of all 40 tumors revealed three sequence variants, one of which was a point mutation in exon 9, while the other two were polymorphisms. Using multiplex PCR, no homozygous deletions were detected in any of the neoplasms. Our results showing a low frequency of alterations of PTEN/MMAC1 in pT2 and pT3 prostate cancers suggest that this gene plays an insignificant role in the development of most low stage carcinomas of the prostate.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Dong, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA.			Dong, Jin-Tang/0000-0003-2349-5782				*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cairns P, 1997, CANCER RES, V57, P4997; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Murakami YS, 1996, CANCER RES, V56, P2157; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Trybus TM, 1996, CANCER RES, V56, P2263; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Wang SI, 1997, CANCER RES, V57, P4183	34	80	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1979	1982		10.1038/sj.onc.1202119	http://dx.doi.org/10.1038/sj.onc.1202119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788441				2022-12-25	WOS:000076423500011
J	Wang, RX; Brunner, T; Zhang, LY; Shi, YF				Wang, RX; Brunner, T; Zhang, LY; Shi, YF			Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression	ONCOGENE			English	Article						fungal metabolite; c-myc; FasL; apoptosis; T cell hybridoma	T-CELL HYBRIDOMAS; ACTIVATION-INDUCED APOPTOSIS; CHROMOBACTERIUM-VIOLACEUM NO-968; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; LYMPHOCYTES; ANTIGEN; CD95; SENSITIVITY	Activation of T lymphocytes often leads to cellular activation, production of cytokines, entry into cell cycle, and expression of Fas (CD95) and Fas ligand (FasL), Although it is well established that the interaction of Fas and Fast results in apoptosis, mechanisms for regulated expression of Fas and Fast are unclear. Our previous work with antisense oligodeoxynucleotides suggested that the protooncogene c-myc is obligatory for activation-induced apoptosis, To study the relationship between myc and the Fas/FasL expression, we employed the antisense method and a newly identified fungal metabolite, FR901228, which has been shown to specifically inhibit expression of c-myc in fibroblasts, We found that FR901228 could effectively block activation-induced apoptosis in T cell hybridomas and this was correlated with its specific inhibition of c-myc expression, Both FR901228 and antisense oligodeoxynucleotide to c-myc had similar effect in inhibiting Fast expression. These treatments did not affect activation-induced production of IL-2, nor the expression of Fas, In addition, FR901228 inhibited the expression of Fast in 3T3 fibroblasts, but not these transfected with c-myc, supporting a specific role of c-myc in this process. Thus, c-Myc plays a fundamental role in the regulation of the expression of Fast, but not Fas and IL-2, Our data further defined the requirement of c-Myc in activation-induced apoptosis in T cells.	Amer Red Cross, Jerome H Holland Lab, Dept Immunol, Rockville, MD 20855 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	American Red Cross; La Jolla Institute for Immunology	Shi, YF (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Immunol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MERCEP M, 1989, J IMMUNOL, V142, P4085; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1995, CANCER RES, V55, P1982; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUDA T, 1995, J IMMUNOL, V154, P3806; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579; Williams MS, 1996, J IMMUNOL, V157, P2395; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	37	62	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1503	1508		10.1038/sj.onc.1202059	http://dx.doi.org/10.1038/sj.onc.1202059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794227	Green Submitted			2022-12-25	WOS:000076089900002
J	Day, RN; Liu, J; Sundmark, V; Kawecki, M; Berry, D; Elsholtz, HP				Day, RN; Liu, J; Sundmark, V; Kawecki, M; Berry, D; Elsholtz, HP			Selective inhibition of prolactin gene transcription by the ETS-2 repressor factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; CHROMOSOMAL LOCALIZATION; DOMAIN PROTEIN; GROWTH-HORMONE; PIT-1 BINDING; MAP KINASE; CELL-CYCLE; PROMOTER; EXPRESSION; PHOSPHORYLATION	Regulation of prolactin gene transcription requires cooperative interactions between the pituitary-specific POU domain protein Pit-1 and members of the ETS transcription factor family. We demonstrate here that the ETS-S repressor factor (ERF) is expressed in pituitary tumor cells and that overexpression of recombinant ERF inhibits prolactin promoter activity, but not the closely related growth hormone promoter. In non-pituitary cell lines, coexpression of ERF disrupts the cooperative interactions between Pit-1 and ETS-1 and blocks the induction of Pit-1-dependent prolactin promoter activity by cAMP, The potential role of ERF in the inhibitory response of the prolactin promoter to dopamine was examined using pituitary tumor cells stably expressing dopamine D-2 receptors. The inhibitory responses of the prolactin promoter to ERF and dopamine are additive, suggesting that ERF has a complementary role in this hormonal response, A single Pit-1 DNA-binding element from the prolactin promoter is sufficient to reconstitute the inhibitory response to ERF. DNA binding analysis using either a composite Pit-1/ETS protein-binding site or a Pit-1 element with no known affinity for ETS proteins revealed that ERF interferes with Pit-1 binding. Together, these results demonstrate that ERF is a specific inhibitor of basal and hormone-regulated transcription of the prolactin gene and suggest a new level of complexity for the interaction of ETS factors with Pit-1 target genes.	Univ Virginia, Natl Sci Fdn, Ctr Biol Timing, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Natl Sci Fdn, Ctr Biol Timing, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Toronto, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; University of Toronto	Day, RN (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, POB 578, Charlottesville, VA 22903 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043701] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-43701] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DAY RN, 1994, MOL ENDOCRINOL, V8, P12, DOI 10.1210/me.8.1.12; deCastro CM, 1997, GENOMICS, V42, P227, DOI 10.1006/geno.1997.4730; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; HOWARD PW, 1994, J BIOL CHEM, V69, P28662; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; LEW AM, 1995, J BIOL CHEM, V270, P7156, DOI 10.1074/jbc.270.13.7156; LEW AM, 1994, J BIOL CHEM, V269, P12007; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MCCHESNEY R, 1991, MOL CELL ENDOCRINOL, V79, pR1, DOI 10.1016/0303-7207(91)90110-E; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PEERS B, 1991, J BIOL CHEM, V266, P18127; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; VALLAR L, 1990, J BIOL CHEM, V265, P10320; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31909	31915		10.1074/jbc.273.48.31909	http://dx.doi.org/10.1074/jbc.273.48.31909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822660	hybrid			2022-12-25	WOS:000077207000042
J	Tsang, AW; Escalante-Semerena, JC				Tsang, AW; Escalante-Semerena, JC			CobB, a new member of the SIR2 family of eucaryotic regulatory proteins, is required to compensate for the lack of nicotinate mononucleotide : 5,6-dimethylbenzimidazole phosphoribosyltransferase activity in cobT mutants during cobalamin biosynthesis in Salmonella typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TETRACYCLINE RESISTANCE; NUCLEOTIDE LOOP; PROPIONATE CATABOLISM; PRP LOCUS; GENE; OPERON; TRANSDUCTION	The cobB gene of Salmonella typhimurium LT2 has been isolated and genetically and biochemically characterized. cobB was located by genetic means to the 27-centisome region of the chromosome. Genetic crosses established the gene order to be cobB pepT phoQ, and the direction of cobB transcription was shown to be clockwise, The nucleotide sequence of cobB (711 base pairs) predicted a protein of 237 amino acids length with a molecular mass of 26.3 kDa, a mass consistent with the experimentally determined one of similar to 28 kDa, The cobB gene was defined genetically by deletions (10), insertions (5), and point mutations (15), The precise location of a Tn10d(Tc) element within cobB was established by sequencing. DNA sequence analysis of the region flanking cobB located it 81 base pairs 3' of the potABCD operon, with the potABCD operon and cobB being divergently transcribed. cobB was overexpressed to similar to 30% of the total soluble protein using a T7 overexpression system. In vitro activity assays showed that cell-free extracts enriched for CobB catalyzed the synthesis of the cobalamin biosynthetic intermediate N-1-(5-phospho-alpha-D-ribosyl)-5,6-dimethylbenzimidazole (also known as alpha-ribazole-5'-phosphate) from nicotinate mononucleotide and 5,6-dimethylbenzimidazole, the reaction known to be catalyzed by the CobT phosphoribosyltransferase enzyme (EC 2.4.2.21) (Trzebiatowski, J. R. and Escalante-Semerena, J. C. (1997) J. Biol. Chem. 272, 17662-17667), Computer analysis of the primary amino acid sequence of the CobB protein identified the sequences <(GAGIS)under bar>AES<(GI)under bar>RT<(FR)under bar> and <(YTQNID)under bar> which are diagnostic of members of the SIR2 family of eucaryotic transcriptional regulators. Possible roles of CobB as a regulator are discussed within the context of the catabolism of propionate, a pathway known to require cobB function (Tsang, A. W. and Escalante-Semerena, J. C. (1996) J, Bacteriol. 178, 7016-7019).	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [R01 GM040313, GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R37GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; CHEN P, 1995, J BACTERIOL, V177, P1461, DOI 10.1128/jb.177.6.1461-1469.1995; DAVIS RW, 1980, MANUAL GENETIC ENG A, P201; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; Hammelman TA, 1996, FEMS MICROBIOL LETT, V137, P233; HONG JS, 1971, P NATL ACAD SCI USA, V68, P3158, DOI 10.1073/pnas.68.12.3158; Horswill AR, 1997, J BACTERIOL, V179, P928, DOI 10.1128/jb.179.3.928-940.1997; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HUGHES KT, 1985, GENETICS, V109, P263; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO MJ, 1993, J BACTERIOL, V175, P7745, DOI 10.1128/JB.175.23.7745-7746.1993; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MARTINUSSEN J, 1995, J BACTERIOL, V177, P271, DOI 10.1128/jb.177.1.271-274.1995; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; RALEIGH EA, 1989, CURRENT PROTOCOLS MO, V1; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P546; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V100, P378; SCHWARZ JJ, 1989, GENETICS, V121, P635; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TAYLOR RT, 1973, ENZYMES, V9, P121; Tomchick DR, 1998, STRUCTURE, V6, P337, DOI 10.1016/S0969-2126(98)00036-7; Trzebiatowski JR, 1997, J BIOL CHEM, V272, P17662, DOI 10.1074/jbc.272.28.17662; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; TRZEBIATOWSKI JR, 1998, THESIS U WISCONSIN M; Tsang AW, 1996, J BACTERIOL, V178, P7016, DOI 10.1128/jb.178.23.7016-7019.1996; Turner RJ, 1998, J BIOL CHEM, V273, P5932, DOI 10.1074/jbc.273.10.5932; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YOUDERIAN P, 1988, GENETICS, V118, P581	47	116	141	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31788	31794		10.1074/jbc.273.48.31788	http://dx.doi.org/10.1074/jbc.273.48.31788			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822644	hybrid			2022-12-25	WOS:000077207000026
J	Bunemann, M; Hosey, MM				Bunemann, M; Hosey, MM			Regulators of G protein signaling (RGS) proteins constitutively activate G beta gamma-gated potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; RECTIFYING K+ CHANNELS; CGMP PHOSPHODIESTERASE; CALCIUM CHANNELS; TRANSITION-STATE; PHOSPHOLIPASE-C; GTPASE ACTIVITY; ALPHA-SUBUNITS; I-KACH; TRANSDUCIN	Here we report novel effects of regulators of G protein signaling (RGS) on G protein-regulated ion channels. RGS3 and RGS4 induced a substantial increase in currents through the G beta gamma-regulated inwardly rectifying K+ channels, I-K(ACh), in the absence of receptor activation. Concomitantly, the amount of current that could be activated by agonist was reduced. Pretreatment with pertussis toxin or a muscarinic receptor antagonist abolished agonist-induced currents but did not modify RGS effects. Cotransfection of cells with a G beta gamma-binding protein significantly reduced the RGS4-induced basal I-K(ACh) currents. The RGS proteins also modified the properties of another G beta gamma effector, the N-type Ca2+ channels. These observations strongly suggest that RGS proteins increase the availability of G beta gamma in addition to their previously described GTPase-activating function.	Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Northwestern University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave,S-215, Chicago, IL 60611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Clapham DE, 1996, CURR BIOL, V6, P814, DOI 10.1016/S0960-9822(02)00602-4; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Iyengar R, 1997, SCIENCE, V275, P42, DOI 10.1126/science.275.5296.42; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shekter LR, 1997, MOL PHARMACOL, V52, P282, DOI 10.1124/mol.52.2.282; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; Wieland T, 1997, J BIOL CHEM, V272, P8853; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4	45	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31186	31190		10.1074/jbc.273.47.31186	http://dx.doi.org/10.1074/jbc.273.47.31186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813023	hybrid			2022-12-25	WOS:000077136900051
J	Gomez-Escobar, N; Chou, CF; Lin, WW; Hsieh, SL; Campbell, RD				Gomez-Escobar, N; Chou, CF; Lin, WW; Hsieh, SL; Campbell, RD			The G11 gene located in the major histocompatibility complex encodes a novel nuclear serine/threonine protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-III REGION; IDENTIFICATION; PHOSPHORYLATION; TRANSCRIPTION; SPECIFICITY; DOMAINS; FAMILY; C4A	Protein kinases are involved in signal transduction pathways and play fundamental roles in the regulation of cell functions. Here we report that the gene G11 located in the human major histocompatibility complex encodes a novel Ser/Thr protein kinase. The G11 gene products of 41.5 and 30 kDa were expressed in insect cells using the baculovirus system and transiently in the mammalian cell line COS-7. It was found that after immunoprecipitation of the G11 polypeptides from recombinant baculovirus-infected insect cell lysates or transfected COS-7 cell lysates the immunoprecipitates contained a Mn2+-dependent protein kinase activity that phosphorylated alpha-casein at Ser/Thr residues and histone at Ser residues. Furthermore, mutation of the ATP-binding site by converting the invariant lysine in the catalytic domain (amino acid 317) to a proline resulted in the complete ablation of the enzyme activity. This was consistent with the observation that the G11 polypeptide can be covalently modified by the reactive ATP analogue 5'-p-fluorosulfonylbenzoyladenosine in the absence of ATP, and that this modification is prevented in the presence of 1 mM ATP, indicating that the kinase domain of the G11 polypeptide is capable of binding ATP. Immunofluorescence staining of transfected COS-7 cells transiently expressing G11 revealed that this novel Ser/Thr protein kinase is localized predominantly in the nucleus.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Natl Yang Ming Univ, Sch Med, Dept Immunol & Microbiol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10764, Taiwan; Natl Yang Ming Univ, Sch Med, Immunol Res Ctr, Taipei, Taiwan	University of Oxford; National Yang Ming Chiao Tung University; National Taiwan University; National Yang Ming Chiao Tung University	Campbell, RD (corresponding author), UK HGMP Resource Ctr, Cambridge CB10 1SB, England.		Hsieh, Shie-Liang Edmond/ABA-9184-2021	Lin, Wan Wan/0000-0002-3207-734X				AGUDO B, 1996, HLA MHC GENES MOL FU, P39; CAMPBELL RD, 1997, IMMUNOL TODAY, V18; CHU W, 1994, EUR J BIOCHEM, V225, P695, DOI 10.1111/j.1432-1033.1994.00695.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; Gruen JR, 1996, GENOMICS, V36, P70, DOI 10.1006/geno.1996.0427; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hall F, 1996, HLA MHC GENES MOL FU, P353; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Harlow E., 1988, ANTIBODIES LAB MANUA; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; Khanna A, 1996, BIOCHEM J, V319, P81, DOI 10.1042/bj3190081; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SARGENT CA, 1994, HUM MOL GENET, V3, P481, DOI 10.1093/hmg/3.3.481; SHEN LM, 1994, J BIOL CHEM, V269, P8466; TROWSDALE J, 1996, HLA MHC GENES MOL FU, P23; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; Witters LA, 1990, CURR OPIN CELL BIOL, V2, P212, DOI 10.1016/0955-0674(90)90009-4; YEH NH, 1988, CHIN J MICROBIOL IMM, V21, P210; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	27	21	23	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30954	30960		10.1074/jbc.273.47.30954	http://dx.doi.org/10.1074/jbc.273.47.30954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812991	hybrid			2022-12-25	WOS:000077136900019
J	Lidberg, U; Kannius-Janson, M; Nilsson, J; Bjursell, G				Lidberg, U; Kannius-Janson, M; Nilsson, J; Bjursell, G			Transcriptional regulation of the human carboxyl ester lipase gene in exocrine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-STIMULATED LIPASE; CHOLESTEROL ESTERASE; TRANSGENIC MICE; HUMAN-MILK; BINDING-SITES; DIETARY-REGULATION; ACTIVATED LIPASE; PROLACTIN GENE; COLIPASE GENE; RAT PANCREAS	The human carboxyl ester lipase (CEL) is an important enzyme for the intestinal absorption of dietary lipids. The gene is highly expressed in exocrine pancreas and in the mammary gland during pregnancy and lactation. In this paper, we have focused on its transcriptional regulation in exocrine pancreas. Reporter gene analysis in cell cultures reveals that a high level of tissue-specific expression is established by the proximal 839 base pairs of the 5'-flanking region. This is due to a strong enhancer, located at -672 to -637. Transfections in mammary gland-derived cells reveal that the enhancer is pancreas-specific and does not contribute to the mammary gland expression. This indicates that the expression of the CEL gene in the mammary gland and pancreas, respectively, is due to two different regulatory systems. Further characterizations of the enhancer reveal that it is composed of two closely located cis-elements. The proximal element mediates a positive effect, whereas the distal element exerts a silencing effect on the positive proximal element. The functional enhancer complex is composed of ubiquitously expressed factors, since similar interactions are achieved with nuclear extracts from cells derived from other tissues. However, no enhancer activity is achieved in such cells. Hence, the net enhancer activity is the result of a tissue-specific balance between factors interacting with the two elements. Since none of the described cis-elements show any clear homology to known cis-elements, we propose that the interacting complex is composed of yet unidentified transcription factors.	Chalmers Univ Technol, Dept Mol Biol, Lundbergslab, S-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Mol Biol, S-40530 Gothenburg, Sweden	Chalmers University of Technology; University of Gothenburg	Lidberg, U (corresponding author), Chalmers Univ Technol, Dept Mol Biol, Lundbergslab, Box 462, S-40530 Gothenburg, Sweden.	ulf.lidberg@molbio.gu.se	Nilsson, Jeanette/M-3051-2015; Kannius Janson, Marie/M-3052-2015					AUSUBLE FM, 1994, CURRENT PROTOCOLS MO; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; BRODTEPPLEY J, 1995, BIOCHEM J, V306, P605, DOI 10.1042/bj3060605; BRODTEPPLEY J, 1994, J LIPID RES, V35, P27; BURDON TG, 1994, FEBS LETT, V350, P177, DOI 10.1016/0014-5793(94)00757-8; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; CRAWFORD M A, 1981, Progress in Lipid Research, V20, P31, DOI 10.1016/0163-7827(81)90011-4; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; FREDRIKZON B, 1978, PEDIATR RES, V12, P1048, DOI 10.1203/00006450-197811000-00004; FREED LM, 1986, BIOCHIM BIOPHYS ACTA, V878, P209, DOI 10.1016/0005-2760(86)90148-7; FUKUOKA SI, 1993, J BIOL CHEM, V268, P11312; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; GROSSMAN MI, 1942, AM J PHYSIOL, V138, P676; HAPP B, 1993, J STEROID BIOCHEM, V47, P21, DOI 10.1016/0960-0760(93)90053-Y; HERNELL O, 1974, J LIPID RES, V15, P367; HERNELL O, 1983, J PEDIAT GASTROEN S1, V2, P242; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUANG Y, 1994, BBA-LIPID LIPID MET, V1214, P317; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; Knofler M, 1996, J BIOL CHEM, V271, P21993; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; LopezCandales A, 1996, BIOCHEM CELL BIOL, V74, P257, DOI 10.1139/o96-027; Madeyski K, 1998, MAMM GENOME, V9, P334, DOI 10.1007/s003359900762; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NILSSON J, 1990, EUR J BIOCHEM, V192, P543, DOI 10.1111/j.1432-1033.1990.tb19259.x; Oliveira HCF, 1996, J BIOL CHEM, V271, P31831, DOI 10.1074/jbc.271.50.31831; PATTON JS, 1977, BIOCHIM BIOPHYS ACTA, V486, P322, DOI 10.1016/0005-2760(77)90028-5; Pavlov I. P., 1910, WORK DIGESTIVE GLAND; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RICKETTS J, 1994, J NUTR, V124, P1166, DOI 10.1093/jn/124.8.1166; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHEELE GA, 1989, HDB PHYSL, V3, P477; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMS HF, 1992, BIOCHEMISTRY-US, V31, P7120, DOI 10.1021/bi00146a013; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WICKER C, 1984, EUR J BIOCHEM, V139, P381, DOI 10.1111/j.1432-1033.1984.tb08017.x; WICKER C, 1990, BIOCHEM BIOPH RES CO, V166, P358, DOI 10.1016/0006-291X(90)91953-P; ZOLFAGHARI R, 1992, ARTERIOSCLER THROMB, V12, P295, DOI 10.1161/01.ATV.12.3.295	60	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31417	31426		10.1074/jbc.273.47.31417	http://dx.doi.org/10.1074/jbc.273.47.31417			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813053	hybrid			2022-12-25	WOS:000077136900081
J	Montesinos, ML; Muro-Pastor, AM; Herrero, A; Flores, E				Montesinos, ML; Muro-Pastor, AM; Herrero, A; Flores, E			Ammonium/Methylammonium permeases of a cyanobacterium - Identification and analysis of three nitrogen-regulated amt genes in Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMMONIUM TRANSPORT-SYSTEM; R-2 ANACYSTIS-NIDULANS; SP-STRAIN PCC-7120; P-II PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; METHYLAMMONIUM TRANSPORT; HETEROCYST DEVELOPMENT; GLUTAMINE-SYNTHETASE; SYNECHOCOCCUS	Ammonium is an important nitrogen source for many microorganisms and plants. Ammonium transporters whose activity can be probed with [C-14]methylammonium have been described in several organisms including some cyanobacteria, and amt genes encoding ammonium/methylammonium permeases have been recently identified in yeast, Arabidopsis thaliana, and some bacteria. The unicellular cyanobacterium Synechocystis sp. PCC 6803 exhibited a [C-14]methylammonium uptake activity that was inhibited by externally added ammonium. Three putative amt genes that are found in the recently published complete sequence of the chromosome of strain PCC 6803 were inactivated by insertion of antibiotic resistance-encoding gene-cassettes. The corresponding mutant strains were impaired in uptake of [C-14]methylammonium. Open reading frame sll0108 (amt1) was responsible for a high affinity uptake activity (K-s for methylammonium, 2.7 mu M), whereas open reading frames sll11017 (amt2) and sll0537 (amt3) made minor contributions to uptake at low substrate concentrations. Expression of the three amt genes was higher in nitrogen-starved cells than in cells incubated in the presence of a source of nitrogen (either ammonium or nitrate), but amt1 was expressed at higher levels than the other two amt genes. Transcription of amt1 was found to take place from a promoter bearing the structure of the cyanobacterial promoters activated by the nitrogen control transcription factor, NtcA.	Univ Seville, Ctr Super Invest Cient, E-41092 Seville, Spain	University of Sevilla	Flores, E (corresponding author), Univ Seville, Ctr Invest Cient Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Avda Amer Vespucio S-N, E-41092 Seville, Spain.	flores@cica.es	IBIS, SINAPTICA/C-2547-2016; Muro-Pastor, Alicia M/A-4445-2015; Montesinos, María Luz/H-3251-2015; Flores, Enrique/M-8407-2019; Flores, Enrique/L-2007-2014; Muro-Pastor, Alicia M/Q-3157-2019; Herrero, Antonia/B-7246-2015	Muro-Pastor, Alicia M/0000-0003-2503-6336; Montesinos, María Luz/0000-0003-3525-5874; Flores, Enrique/0000-0001-7605-7343; Flores, Enrique/0000-0001-7605-7343; Muro-Pastor, Alicia M/0000-0003-2503-6336; Herrero, Antonia/0000-0003-1071-6590				APTE SK, 1990, PLANT MOL BIOL, V15, P723, DOI 10.1007/BF00016122; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BOUSSIBA S, 1989, PLANT CELL PHYSIOL, V30, P303, DOI 10.1093/oxfordjournals.pcp.a077743; BOUSSIBA S, 1987, FEMS MICROBIOL LETT, V43, P289; BOUSSIBA S, 1984, J BACTERIOL, V160, P204, DOI 10.1128/JB.160.1.204-210.1984; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; FANIBY JM, 1991, J GEN MICROBIOL, V137, P983; FELLAY R, 1995, MOL MICROBIOL, V16, P657, DOI 10.1111/j.1365-2958.1995.tb02428.x; Flores E., 1994, MOL BIOL CYANOBACTER, VVol 1, P487; FRIAS JE, 1993, J BACTERIOL, V175, P5710; FRIAS JE, 1994, MOL MICROBIOL, V14, P823, DOI 10.1111/j.1365-2958.1994.tb01318.x; Frias JE, 1997, J BACTERIOL, V179, P477, DOI 10.1128/jb.179.2.477-486.1997; Garcia-Dominguez M, 1997, PLANT MOL BIOL, V35, P723, DOI 10.1023/A:1005846626187; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; GOBER JW, 1983, J BACTERIOL, V153, P1196, DOI 10.1128/JB.153.3.1196-1201.1983; HACKETTE SL, 1970, J BIOL CHEM, V245, P4241; Harano Y, 1997, J BACTERIOL, V179, P5744, DOI 10.1128/jb.179.18.5744-5750.1997; IHLENFELDT MJA, 1975, ARCH MICROBIOL, V102, P13, DOI 10.1007/BF00428339; JAYAKUMAR A, 1986, J BACTERIOL, V166, P281, DOI 10.1128/jb.166.1.281-284.1986; JONES R, 1989, MOL GEN GENET, V215, P507, DOI 10.1007/BF00427050; Kaneko T, 1996, DNA Res, V3, P109; KLEINER D, 1993, BIOCHIM BIOPHYS ACTA, V639, P41; Kleiner D., 1993, ALKALI CATION TRANSP, P379; KUNG HF, 1969, J BIOL CHEM, V244, P4136; LUQUE I, 1994, EMBO J, V13, P2862, DOI 10.1002/j.1460-2075.1994.tb06580.x; MacKinney G, 1941, J BIOL CHEM, V140, P315; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; MEEKS JC, 1977, J BIOL CHEM, V252, P7894; Meletzus D, 1998, J BACTERIOL, V180, P3260, DOI 10.1128/JB.180.12.3260-3264.1998; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Montesinos ML, 1997, J BACTERIOL, V179, P853, DOI 10.1128/jb.179.3.853-862.1997; MuroPastor MI, 1996, J BACTERIOL, V178, P4070, DOI 10.1128/jb.178.14.4070-4076.1996; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; PASCHINGER H, 1977, ARCH MICROBIOL, V113, P285, DOI 10.1007/BF00492037; RABOY B, 1978, J BIOL CHEM, V253, P3287; RAI AN, 1984, ARCH MICROBIOL, V137, P241, DOI 10.1007/BF00414551; Reyes JC, 1997, J BACTERIOL, V179, P2678, DOI 10.1128/jb.179.8.2678-2689.1997; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Ritchie RJ, 1996, PLANT CELL ENVIRON, V19, P1307, DOI 10.1111/j.1365-3040.1996.tb00009.x; RITCHIE RJ, 1987, J MEMBRANE BIOL, V95, P131, DOI 10.1007/BF01869158; ROON RJ, 1975, J BACTERIOL, V122, P502, DOI 10.1128/JB.122.2.502-509.1975; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERVINGONZALEZ L, 1984, J GEN MICROBIOL, V130, P3071; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; Siewe RM, 1996, J BIOL CHEM, V271, P5398, DOI 10.1074/jbc.271.10.5398; SMITH FA, 1978, J EXP BOT, V29, P107, DOI 10.1093/jxb/29.1.107; SMITH FA, 1978, J EXP BOT, V29, P121, DOI 10.1093/jxb/29.1.121; Soupene E, 1998, P NATL ACAD SCI USA, V95, P7030, DOI 10.1073/pnas.95.12.7030; STEVENSON R, 1977, BIOCHEM BIOPH RES CO, V75, P1133, DOI 10.1016/0006-291X(77)91501-7; SUZUKI I, 1995, J BACTERIOL, V177, P290, DOI 10.1128/jb.177.2.290-296.1995; Van Dommelen A, 1998, J BACTERIOL, V180, P2652, DOI 10.1128/JB.180.10.2652-2659.1998; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; VEGAPALAS MA, 1992, MOL MICROBIOL, V6, P1853, DOI 10.1111/j.1365-2958.1992.tb01357.x; VEGAPALAS MA, 1990, J BACTERIOL, V172, P643, DOI 10.1128/jb.172.2.643-647.1990; WEI TF, 1994, J BACTERIOL, V176, P4473, DOI 10.1128/JB.176.15.4473-4482.1994; WRAY LV, 1994, J BACTERIOL, V176, P108, DOI 10.1128/JB.176.1.108-114.1994; YOCH DC, 1983, ARCH MICROBIOL, V134, P45, DOI 10.1007/BF00429405	60	94	99	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31463	31470		10.1074/jbc.273.47.31463	http://dx.doi.org/10.1074/jbc.273.47.31463			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813059	hybrid			2022-12-25	WOS:000077136900087
J	Daum, JR; Gorbsky, GJ				Daum, JR; Gorbsky, GJ			Casein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase II alpha which is recognized by the 3F3/2 phosphoepitope antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; CELL-CYCLE; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODIES; BETA-SUBUNIT; IN-VITRO; PHASE; IDENTIFICATION; LOCALIZATION; CHROMOSOMES	The 3FS/2 antibody recognizes a phosphoepitope that is implicated in the mitotic checkpoint regulating the metaphase-to-anaphase transition. Immunoprecipitation and Western blotting revealed that the 3F3/2 antibody binds to human DNA topoisomerase II alpha (HsTII alpha) hom mitotic but not interphase HeLa cells. Extracts from mitotic cells efficiently catalyzed the formation of the 3F3/2 phosphoepitope on fragments of HsTII alpha expressed in bacteria. Expression and site-directed mutagenesis of various HsTII alpha protein fragments mapped the 3F3/2 phosphoepitope to the region of HsTII alpha containing phosphorylated threonine 1342. This threonine lies within a consensus sequence for phosphorylation by casein kinase II (CKII). CKII is present in cellular extracts and is associated with isolated mitotic chromosomes. The 3F3/2 phosphoepitope kinase present in mitotic cell extracts was able to create the epitope using GTP and was inhibited by heparin. A kinase associated with the isolated chromosomes also generated the 3F3/2 phosphoepitope on HsTII alpha. Recombinant CKII catalyzed the formation of the 3F3/2 phosphoepitope on fragments of HsTII alpha containing threonine 1342. These results indicate that the mitotic 3F3/2 phosphoepitope kinase activity is attributable to CKII. We suggest that the 3F3/2 phosphoepitope reflects a CKII-catalyzed phosphorylation of threonine 1342 that may regulate mitotic functions of HsTII alpha.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Gorbsky, GJ (corresponding author), Univ Virginia, Dept Cell Biol, Box 439, Charlottesville, VA 22908 USA.	gig5y@virginia.edu		Gorbsky, Gary/0000-0003-3076-4725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050412] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM50412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1990, J CELL SCI, V96, P439; CARDENAS ME, 1993, J CELL SCI, V104, P533; CHRESTA CM, 1995, LEUKEMIA, V9, P1373; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Larsen A K, 1996, Prog Cell Cycle Res, V2, P229; Li XT, 1997, J CELL SCI, V110, P537; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; PROSPERI E, 1992, ANTICANCER RES, V12, P2093; RAMACHANDRAN C, 1995, BIOCHEM PHARMACOL, V49, P545, DOI 10.1016/0006-2952(94)00443-P; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Renzi L, 1997, J CELL SCI, V110, P2013; RITTSCHOF D, 1982, EUR J BIOCHEM, V123, P333, DOI 10.1111/j.1432-1033.1982.tb19772.x; ROBINSON RG, 1993, HYBRIDOMA, V12, P407, DOI 10.1089/hyb.1993.12.407; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WHALEN AM, 1991, J CELL BIOL, V112, P203, DOI 10.1083/jcb.112.2.203; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209	57	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30622	30629		10.1074/jbc.273.46.30622	http://dx.doi.org/10.1074/jbc.273.46.30622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804834	hybrid			2022-12-25	WOS:000077008100081
J	Dolphin, CT; Beckett, DJ; Janmohamed, A; Cullingford, TE; Smith, RL; Shephard, EA; Phillips, IR				Dolphin, CT; Beckett, DJ; Janmohamed, A; Cullingford, TE; Smith, RL; Shephard, EA; Phillips, IR			The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION AMINE OXIDASE; PIG-LIVER-MICROSOMES; FISH-ODOR SYNDROME; RABBIT LUNG; MULTIPLE FORMS; SUBSTRATE-SPECIFICITY; PRIMARY ALKYLAMINES; ESCHERICHIA-COLI; PRIMARY SEQUENCE; MESSENGER-RNA	Flavin-containing monooxygenases (FMOs) are NADPH-dependent flavoenzymes that catalyze the oxidation of heteroatom centers in numerous drugs and xenobiotics. FMO2, or "puhnonary" FMO, one of five forms of the enzyme identified in mammals, is expressed predominantly in lung and differs from other FMOs in that it can catalyze the N-oxidation of certain primary alkylamines. We describe here the isolation and characterization of cDNAs for human FMO2. Analysis of the sequence of the cDNAs and of a section of the corresponding gene revealed that the major FMO2 allele of humans encodes a polypeptide that, compared with the orthologous protein of other mammals, lacks 64 amino acid residues from its C terminus. Heterologous expression of the cDNA revealed that the truncated polypeptide was catalytically inactive. The nonsense mutation that gave rise to the truncated polypeptide, a C -->T transition in codon 472, is not present in the FMO2 gene of closely related primates, including gorilla and chimpanzee, and must therefore have arisen in the human lineage after the divergence of the Homo and Pan clades. Possible mechanisms for the fixation of the mutation in the human population and the potential significance of the loss of functional FMO2 in humans are discussed.	Univ London Queen Mary & Westfield Coll, Dept Biochem, Mol Biol Lab, London E1 4NS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, London W2 1PG, England	University of London; Queen Mary University London; University of London; University College London; Imperial College London	Phillips, IR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Biochem, Mol Biol Lab, Mile End Rd, London E1 4NS, England.	I.R.Phillips@qmw.ac.uk	Phillips, Ian R/A-7337-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKRAWI M, 1993, BIOCHEM PHARMACOL, V45, P1583, DOI 10.1016/0006-2952(93)90298-B; ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; BEND JR, 1985, ANNU REV PHARMACOL, V25, P97, DOI 10.1146/annurev.pharmtox.25.1.97; Bhagwat SV, 1996, NEUROPSYCHOPHARMACOL, V15, P133, DOI 10.1016/0893-133X(95)00175-D; BHAMRE S, 1995, BRAIN RES, V672, P276, DOI 10.1016/0006-8993(94)01135-5; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DEVEREUX TR, 1974, CHEM-BIOL INTERACT, V8, P91, DOI 10.1016/0009-2797(74)90055-6; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; Dolphin CT, 1997, GENOMICS, V46, P260, DOI 10.1006/geno.1997.5031; Dolphin CT, 1996, EUR J BIOCHEM, V235, P683, DOI 10.1111/j.1432-1033.1996.00683.x; Dolphin CT, 1997, NAT GENET, V17, P491, DOI 10.1038/ng1297-491; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOTH H, 1995, CRIT REV TOXICOL, V25, P165, DOI 10.3109/10408449509021612; Fourney R.M., 1988, FOCUS, V10, P5; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HLAVICA P, 1979, BIOCHEM J, V182, P109, DOI 10.1042/bj1820109; KIMURA M, 1970, GENET RES, V15, P131, DOI 10.1017/S0016672300001439; KIMURA T, 1983, BIOCHEM BIOPH RES CO, V110, P640, DOI 10.1016/0006-291X(83)91197-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LAWTON MP, 1994, P 10 INT S MICR DRUG, P438; LEE MY, 1995, CHEM-BIOL INTERACT, V96, P75, DOI 10.1016/0009-2797(94)03584-U; LEE MY, 1993, ARCH BIOCHEM BIOPHYS, V302, P332, DOI 10.1006/abbi.1993.1219; LITTLE PFR, 1987, DNA CLONING, V3, P1; LOMRI N, 1992, P NATL ACAD SCI USA, V89, P1685, DOI 10.1073/pnas.89.5.1685; MAQUAT LE, 1995, RNA, V1, P453; McCombie RR, 1996, GENOMICS, V34, P426, DOI 10.1006/geno.1996.0308; Nei M., 1987, MOL EVOLUTIONARY GEN; NIKBAKHT KN, 1992, PHARMACOGENETICS, V2, P207, DOI 10.1097/00008571-199210000-00003; OHMIYA Y, 1981, PHARMACOLOGY, V22, P172, DOI 10.1159/000137487; OHMIYA Y, 1982, BIOCHEM PHARMACOL, V31, P157; OVERBY L, 1992, EXP LUNG RES, V18, P131, DOI 10.3109/01902149209020656; OVERBY LH, 1995, ARCH BIOCHEM BIOPHYS, V317, P275, DOI 10.1006/abbi.1995.1163; OZOLS J, 1994, BIOCHEMISTRY-US, V33, P3751, DOI 10.1021/bi00178a035; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PELTZ SW, 1993, GENE DEV, V7, P5778; PHILLIPS IR, 1995, CHEM-BIOL INTERACT, V96, P17, DOI 10.1016/0009-2797(94)03580-2; POULSEN LL, 1986, MOL PHARMACOL, V30, P680; SABOURIN PJ, 1984, INT J BIOCHEM, V16, P713, DOI 10.1016/0020-711X(84)90180-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEHINJOHNSON SE, 1995, J PHARMACOL EXP THER, V272, P1293; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; SHEPHARD EA, 1993, GENOMICS, V16, P85, DOI 10.1006/geno.1993.1144; TYNES RE, 1986, ARCH BIOCHEM BIOPHYS, V251, P654, DOI 10.1016/0003-9861(86)90375-9; TYNES RE, 1985, ARCH BIOCHEM BIOPHYS, V240, P77, DOI 10.1016/0003-9861(85)90010-4; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; TYNES RE, 1987, MOL PHARMACOL, V31, P569; WILLIAMS DE, 1985, MOL PHARMACOL, V28, P381; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; WILLIAMS DE, 1990, P 8 INT S MICR DRUG, P173; Wyatt MK, 1996, DRUG METAB DISPOS, V24, P1320; Yueh MF, 1997, BBA-GENE STRUCT EXPR, V1350, P267, DOI 10.1016/S0167-4781(97)00004-3; ZIEGLER DM, 1972, ARCH BIOCHEM BIOPHYS, V150, P116, DOI 10.1016/0003-9861(72)90017-3; ZIEGLER DM, 1993, ANNU REV PHARMACOL, V33, P179, DOI 10.1146/annurev.pharmtox.33.1.179; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	66	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30599	30607		10.1074/jbc.273.46.30599	http://dx.doi.org/10.1074/jbc.273.46.30599			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804831	hybrid			2022-12-25	WOS:000077008100078
J	Liu, JS; Kuo, SR; Makhov, AM; Cyr, DM; Griffith, JD; Broker, TR; Chow, LT				Liu, JS; Kuo, SR; Makhov, AM; Cyr, DM; Griffith, JD; Broker, TR; Chow, LT			Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEIN; ATPASE ACTIVITY; J-DOMAIN; MOLECULAR CHAPERONE; T-ANTIGEN; TRANSCRIPTION FACTOR; SECONDARY STRUCTURE; SUBSTRATE-BINDING; POLYMERASE-ALPHA	Human papillomavirus replication initiator, the E1 helicase, binds weakly to the origin of DNA replication. Purified human chaperone proteins Hsp70 and Hsp40 (HDJ-1 and HDJ-2) independently and additively enhanced E1 binding to the origin. The interaction between E1 and Hsp70 was transient and required ATP hydrolysis, whereas Hsp40 bound to E1 directly and remained in the complex. A peptide of 20 residues spanning the HPD loop and helix II of the J domain of YDJ-1 also stimulated E1 binding to the origin, alone or in combination with Hsp70 or Hsp40. A mutated peptide (H34Q) had a reduced activity, while an adjacent or an overlapping peptide had no effect. Neither Hsp70 nor the J peptide altered the E1/DNA ratio in the complex. Electron microscopy showed that E1 mainly bound to DNA as a hexamer. In the presence of Hsp40, E1 primarily bound to DNA as a dihexamer. Preincubation of chaperones with viral E1 and template shortened the lag time and increased replication in a cell-free system. Since two helicases are essential for bidirectional replication of human papillomavirus DNA, these results demonstrate that, as in prokaryotes, chaperones play an important role in the assembly of preinitiation complexes on the origin.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 510 MCLM Bldg, Birmingham, AL 35294 USA.	ltchow@uab.edu		Cyr, Douglas/0000-0002-4928-3414	NCI NIH HHS [CA36200, CA19014] Funding Source: Medline; NIGMS NIH HHS [R01 GM056981, GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200, P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANG D, 1991, J BIOL CHEM, V266, P24233; AUBORN KJ, 1994, P NATL ACAD SCI USA, V91, P7340, DOI 10.1073/pnas.91.15.7340; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BUKAU B, 1993, J GEN MICROBIOL, V139, P95, DOI 10.1099/00221287-139-1-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEAN FB, 1992, J BIOL CHEM, V267, P14129; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GRIFFITH JD, 1995, J MOL BIOL, V246, P576, DOI 10.1016/S0022-2836(05)80107-X; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hassell J, 1996, DNA REPLICATION EUKA, P639; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; Jenkins O, 1996, J GEN VIROL, V77, P1805, DOI 10.1099/0022-1317-77-8-1805; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAWASAKI Y, 1992, J BIOL CHEM, V267, P11520; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KUO SR, 1994, J BIOL CHEM, V269, P24058; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee KY, 1998, J VIROL, V72, P4911, DOI 10.1128/JVI.72.6.4911-4917.1998; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU JS, 1995, J BIOL CHEM, V270, P27283, DOI 10.1074/jbc.270.45.27283; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MULLER F, 1994, J BIOL CHEM, V269, P17086; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; POLISSI A, 1995, FEMS MICROBIOL REV, V17, P159; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; STENLUND A, 1996, DNA REPLICATION EUKA, P679; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TAYLOR K, 1995, FEMS MICROBIOL REV, V17, P109; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YAMANE M, 1995, CELL STRUCT FUNCT, V20, P157, DOI 10.1247/csf.20.157; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025	66	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30704	30712		10.1074/jbc.273.46.30704	http://dx.doi.org/10.1074/jbc.273.46.30704			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804845	hybrid, Green Published			2022-12-25	WOS:000077008100092
J	Saaf, A; Monne, M; de Gier, JW; von Heijne, G				Saaf, A; Monne, M; de Gier, JW; von Heijne, G			Membrane topology of the 60-kDa Oxalp homologue from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; ALKALINE-PHOSPHATASE; LEADER PEPTIDASE; PROTEIN TOPOLOGY; ATP SYNTHASE; NUCLEAR GENE; N-TERMINI; SEQUENCE	We have characterized the membrane topology of a 60-kDa inner membrane protein from Escherichia coli that is homologous to the recently identified Oxalp protein in Saccharomyces cerevisiae mitochondria implicated in the assembly of mitochondrial inner membrane proteins. Hydrophobicity and alkaline phosphatase fusion analyses suggest a membrane topology with six transmembrane segments, including an N-terminal signal-anchor sequence not present in mitochondrial Oxalp. In contrast to partial N-terminal fusion protein constructs, the full-length protein folds into a protease-resistant conformation, suggesting that important folding determinants are present in the C-terminal part of the molecule.	Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	von Heijne, G (corresponding author), Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden.	gunnar@biokemi.su.se	von Heijne, Gunnar/AAH-9389-2019; Monné, Magnus/D-5642-2012; von Heijne, Gunnar/F-5576-2011	Monné, Magnus/0000-0003-2344-3878; von Heijne, Gunnar/0000-0002-4490-8569				Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; LEE E, 1994, J BIOL CHEM, V269, P28822; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	26	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30415	30418		10.1074/jbc.273.46.30415	http://dx.doi.org/10.1074/jbc.273.46.30415			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804807	Green Published, hybrid			2022-12-25	WOS:000077008100054
J	van der Vliet, A; Hoen, PAC; Wong, PSY; Bast, A; Cross, CE				van der Vliet, A; Hoen, PAC; Wong, PSY; Bast, A; Cross, CE			Formation of S-nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; NITRIC-OXIDE SYNTHASE; CARBON-DIOXIDE; CATALYZED OXIDATION; ENDOTHELIAL-CELLS; CYCLIC-GMP; SUPEROXIDE; MECHANISM; GLUTATHIONE; KINETICS	Peroxynitrite (ONOO-), a potent oxidant formed by reaction of nitric oxide (NO.) with superoxide anion, can activate guanylyl cyclase and is able to induce vasodilation or inhibit platelet aggregation and leukocyte adhesion, via thiol-dependent formation of NO.. Reaction of ONOO- with thiols is thought to proceed through formation of a S-nitrothiol (thionitrate; RSNO2) intermediate and yields low levels of S-nitrosothiols (thionitrites; RSNO), both of which are theoretical sources of NO.. Kinetic analysis of NO. production after reaction of ONOO- with GSH established that NO. originates exclusively from the thionitrite GSNO. Further mechanistic investigations indicated that GSNO formation by ONOO- does not occur via one-electron oxidation mechanisms. Nitrosation of GSH could theoretically proceed via intermediate formation of the thionitrate GSNO(2), which, after rearrangement to the corresponding sulfenyl nitrite (GSONO), can react with GSH to form GSNO and GSOH, However, no evidence for such a mechanism was found in experiments with NO2. or with the stable nitrothiol tert-butylthionitrate. Using high performance liquid chromatography with chemiluminescence detection, formation of H2O2 was observed after reaction of ONOO- with GSH under both aerobic and anaerobic conditions, at levels similar to the yield of GSNO, indicative of a direct nucleophilic nitrosation mechanism with elimination of HOO-. Our results indicate that ONOO- may contribute to S-nitrosation in vivo and that direct nitrosation of thiols or other nucleophilic substrates by ONOO- may represent an important and often overlooked component of NO. biochemistry.	Univ Calif Davis, Dept Internal Med, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands	University of California System; University of California Davis; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	van der Vliet, A (corresponding author), Univ Calif Davis, Dept Internal Med, Ctr Comparat Resp Biol & Med, 1121 Surge I, Davis, CA 95616 USA.		Hoen, Peter A 't/D-3950-2018; Bast, Aalt/I-7809-2013	Hoen, Peter A 't/0000-0003-4450-3112; Bast, Aalt/0000-0002-5383-2789	NHLBI NIH HHS [HL57452] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057452] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aleryani S, 1998, J BIOL CHEM, V273, P6041, DOI 10.1074/jbc.273.11.6041; Artz JD, 1996, CHEM COMMUN, P927, DOI 10.1039/cc9960000927; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Beckman Joseph S., 1995, Methods (Orlando), V7, P35, DOI 10.1006/meth.1995.1005; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; Butler AR, 1997, ANAL BIOCHEM, V249, P1; CAMERON DR, 1995, CAN J CHEM, V73, P1627, DOI 10.1139/v95-202; Davidson CA, 1996, AM J PHYSIOL-HEART C, V270, pH1038, DOI 10.1152/ajpheart.1996.270.3.H1038; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FEELISCH M, 1991, J CARDIOVASC PHAR S3, V17, P25; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; HUGHES MN, 1971, J CHEM SOC A, P3722, DOI 10.1039/j19710003722; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Lefer DJ, 1997, J CLIN INVEST, V99, P684, DOI 10.1172/JCI119212; LEMERCIER JN, 1995, ARCH BIOCHEM BIOPHYS, V321, P31, DOI 10.1006/abbi.1995.1364; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; Liu ZG, 1998, J PHARMACOL EXP THER, V284, P526; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NEWTON GL, 1981, ANAL BIOCHEM, V114, P383, DOI 10.1016/0003-2697(81)90498-X; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; OAE S, 1980, B CHEM SOC JPN, V53, P775, DOI 10.1246/bcsj.53.775; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; POU S, 1992, J BIOL CHEM, V267, P24173; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, METHOD ENZYMOL, V269, P354; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SOKOLOVSKY M, 1969, BIOCHEMISTRY-US, V8, P4740, DOI 10.1021/bi00840a013; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; White CR, 1997, BIOCHEM J, V328, P517, DOI 10.1042/bj3280517; Williams DLH, 1997, NITRIC OXIDE-BIOL CH, V1, P522, DOI 10.1006/niox.1997.0159; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WU MD, 1994, AM J PHYSIOL, V266, pH2108, DOI 10.1152/ajpheart.1994.266.5.H2108; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863	67	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30255	30262		10.1074/jbc.273.46.30255	http://dx.doi.org/10.1074/jbc.273.46.30255			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804785	hybrid			2022-12-25	WOS:000077008100032
J	Zhang, X; Davis, JQ; Carpenter, S; Bennett, V				Zhang, X; Davis, JQ; Carpenter, S; Bennett, V			Structural requirements for association of neurofascin with ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; X-LINKED HYDROCEPHALUS; BINDING-ACTIVITY; ANION-EXCHANGER; L1 FAMILY; RANVIER; SITES; PHOSPHORYLATION; IDENTIFICATION; MUTATIONS	This paper presents the first structural analysis of the cytoplasmic domain of neurofascin, which is highly conserved among the L1CAM family of cell adhesion molecules, and describes sequence requirements for neurofascin-ankyrin interactions in living cells. The cytoplasmic domain of neurofascin dimerizes in solution, has an asymmetric shape, and exhibits a reversible temperature-dependent beta-structure. Residues Ser(56)-Tyr(81) are necessary for ankyrin binding but do not contribute to either dimerization or formation of structure. Transfected neurofascin recruits GFP-tagged 270-kDa ankyrin, to the plasma membrane of human embryo kidney 293 cells. Deletion mutants demonstrate that the sequence Ser(56)-Tyr(81) contains the major ankyrin-recruiting activity of neurofascin, Mutations of the FIGQY tyrosine (Y81H/A/E) greatly impair neurofascin-ankyrin interactions. Mutation of human L1 at the equivalent tyrosine (Y1229H) is responsible for certain cases of mental retardation (Van Camp, G,, Fransen, E., Vits, L,, Raes, G,, and Willems, P, J, (1996) Hum. Mutat. 8, 391). Mutations F77A and E73Q greatly impair ankyrin binding activity, whereas mutation D74N and a triple mutation of D57N/D58N/D62N result in less loss of ankyrin binding activity. These results provide evidence for a highly specific interaction between ankyrin and neurofascin and suggest that ankyrin association with L1 is required for L1 function in humans.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	enne0l2@mc.duke.edu						Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bennett V, 1997, SOC GEN PHY, V52, P107; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Itoh K, 1997, J NEUROBIOL, V33, P735, DOI 10.1002/(SICI)1097-4695(19971120)33:6<735::AID-NEU3>3.0.CO;2-A; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; VanCamp G, 1996, HUM MUTAT, V8, P391, DOI 10.1002/(SICI)1098-1004(1996)8:4<391::AID-HUMU19>3.0.CO;2-Y; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; Zhang X, 1996, J BIOL CHEM, V271, P31391, DOI 10.1074/jbc.271.49.31391	21	105	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30785	30794		10.1074/jbc.273.46.30785	http://dx.doi.org/10.1074/jbc.273.46.30785			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804856	hybrid			2022-12-25	WOS:000077008100103
J	Marini, AM; Rabin, SJ; Lipsky, RH; Mocchetti, I				Marini, AM; Rabin, SJ; Lipsky, RH; Mocchetti, I			Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CEREBELLAR GRANULE CELLS; BDNF MESSENGER-RNA; TRK PROTOONCOGENE PRODUCT; FACTOR FAMILY; TYROSINE PHOSPHORYLATION; RECEPTOR ACTIVATION; SIGNALING PATHWAYS; MOLECULAR-CLONING; NEURONAL DEATH	The molecular mechanism(s) of N-methyl-D-aspartate (NMDA) neuroprotective properties were investigated in primary cultures of cerebellar granule cell neurons. Granule cells express the neurotrophin receptor TrkB but not TrkA or TrkC. In these cells, the TrkB ligand brain-derived neurotrophic factor (BDNF) prevents glutamate toxicity. Therefore, we have tested the hypothesis that NMDA activates synthesis and release of BDNF, which may prevent glutamate toxicity by an autocrine loop. Exposure of granule cells for 2 and 5 min to a subtoxic concentration of NMDA (100 mu M) evoked an accumulation of BDNF in the medium without concomitant changes in the intracellular levels of BDNF protein or mRNA The increase in BDNF in the medium is followed by enhanced TrkB tyrosine phosphorylation, suggesting that NMDA increases the release of BDNF and therefore the activity of TrkB receptors. To examine whether BDNF and TrkB signaling play a role in the NMDA-mediated neuroprotective properties, neurons were exposed to soluble trkB receptor-IgG fusion protein, which is known to inhibit the activity of extracellular BDNF, and to K252a, a tyrosine kinase inhibitor. Both compounds blocked the NMDA-mediated TrkB tyrosine phosphorylation and subsequently its neuroprotective properties. We suggest that NMDA activates the TrkB receptor via a BDNF autocrine loop, resulting in neuronal survival.	Georgetown Univ, Dept Cell Biol, Div Neurobiol, Washington, DC 20007 USA; Walter Reed Army Med Ctr, Dept Neurol, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Clin Invest, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; NIAAA, Lab Human Neurogenet, NIH, Rockville, MD 20852 USA	Georgetown University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Mocchetti, I (corresponding author), Georgetown Univ, Dept Cell Biol, Div Neurobiol, Med Dent Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.	Moccheti@gunet.georgetown.edu		Lipsky, Robert/0000-0001-7753-1473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029664, R01NS032671, K04NS001675] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 29664, NS 01675, NS 32671] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; Brandoli C, 1998, J NEUROSCI, V18, P7953; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FAVARON M, 1993, NEUROREPORT, V4, P1171; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FOLLESA P, 1993, MOL PHARMACOL, V43, P132; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANEV H, 1990, J PHARMACOL EXP THER, V252, P419; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Marini AM, 1997, ANN NY ACAD SCI, V825, P209, DOI 10.1111/j.1749-6632.1997.tb48431.x; MATTSON MP, 1989, J NEUROSCI, V9, P3728; Mocchetti I, 1996, J NEUROSCI, V16, P2141; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOVELLI A, 1988, BRAIN RES, V451, P206; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; RABIN SJ, 1995, J NEUROCHEM, V65, P347; Rabin SJ, 1998, MOL BRAIN RES, V56, P273, DOI 10.1016/S0169-328X(98)00020-5; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGAL RA, 1995, J NEUROSCI, V15, P4970; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; ZIRRGIEBEL U, 1995, J NEUROCHEM, V65, P2241	48	176	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29394	29399		10.1074/jbc.273.45.29394	http://dx.doi.org/10.1074/jbc.273.45.29394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792641	hybrid			2022-12-25	WOS:000076798300018
J	Safran, JB; Butler, WT; Farach-Carson, MC				Safran, JB; Butler, WT; Farach-Carson, MC			Modulation of osteopontin post-translational state by 1,25-(OH)(2)-vitamin D-3 - Dependence on Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT OSTEOSARCOMA CELLS; VITAMIN-D METABOLITES; OSTEOBLAST-LIKE CELLS; 1,25-DIHYDROXYVITAMIN D-3; BONE SIALOPROTEIN; IN-VITRO; CALCIUM CURRENTS; SKELETAL-MUSCLE; SARCOMA CELLS	In osteoblastic ROS 17/2.8 cells, 1,25-(OH)(2)-vitamin D-3 stimulates transcription of the extracellular matrix phosphoprotein osteopontin (OPN). We now show posttranslational regulation of OPN production by 1,25(OH)(2)D-3. Prior to transcriptional up-regulation of OPN, 1,25-(OH)(2)D-3 induces a shift in OPN isoelectric point (pI) from 4.6 to 5.1. Loading equal amounts of OPN recovered from ROS 17/2.8 cells exposed to 1,25-(OH)(2)D-3 or carrier for 3 h reveals that the pi shift represents reduced phosphorylation. Trypsin cleavage patterns of OPN produced after 1,25-(OH)(2)D-3 treatment indicates phosphorylation changes in the resulting peptides. Using structural analogs to 1,25-(OH)(2)D-3, we found that analog AT (25-(OH)-16-ene-23-yne-D-3), which triggers Ca2+ influx but does not bind to the vitamin D receptor, mimicked the OPN pI shift, whereas analog BT (1,25-(OH)(2)-22-ene-24-cyclopropyl-D-3), which binds to the vitamin D receptor without triggering Ca2+ influx, did not. Likewise, inclusion of the Ca2+ channel blocker nifedipine blocks the charge conversion of OPN. Isolation of OPN from rat femurs and tibiae demonstrates the existence of two OPN charge forms in vivo. We conclude that 1,25(OH)(2)D-3 regulates OPN not only at the transcriptional level, but also modulates OPN phosphorylation state. The latter involves a short term (<3 h) treatment and is associated with membrane-initiated Ca2+ influx.	Univ Texas, Dent Branch, Dept Basic Sci, Houston, TX 77030 USA	University of Texas System	Safran, JB (corresponding author), Univ Delaware, Dept Biol Sci, 117 Wolf Hall, Newark, DE 19716 USA.			Farach-Carson, Mary/0000-0002-4526-3088	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039273] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39273] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; BISSONNETTE M, 1995, J CLIN INVEST, V95, P2215, DOI 10.1172/JCI117911; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; Butler William T., 1996, P167; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CARSON DD, 1985, CELL, V41, P639, DOI 10.1016/S0092-8674(85)80036-2; CHANG PL, 1991, CANCER RES, V51, P2144; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUTT A, 1986, ENDOCRINOLOGY, V118, P661, DOI 10.1210/endo-118-2-661; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FARACHCARSON MC, 1993, AM J PHYSIOL, V265, pF705, DOI 10.1152/ajprenal.1993.265.5.F705; Furman I, 1996, J NEUROSCI RES, V46, P360, DOI 10.1002/(SICI)1097-4547(19961101)46:3<360::AID-JNR9>3.0.CO;2-I; Giachelli CM, 1998, AM J PATHOL, V152, P353; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HWANG S, 1994, J BIOL CHEM, V269, P711; KHOURY R, 1994, ENDOCRINOLOGY, V135, P2446, DOI 10.1210/en.135.6.2446; KOHRI K, 1993, J BIOL CHEM, V268, P15180; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MASSHEIMER V, 1992, BIOCHEM J, V281, P349, DOI 10.1042/bj2810349; MERRILL AH, 1992, NUTR REV, V50, P78; Neame PJ, 1996, CONNECT TISSUE RES, V35, P145, DOI 10.3109/03008209609029185; NEMERE I, 1990, MINER ELECTROL METAB, V16, P109; NEMIR M, 1989, J BIOL CHEM, V264, P18202; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PANNABECKER TL, 1995, BIOCHEM BIOPH RES CO, V213, P499, DOI 10.1006/bbrc.1995.2159; PRINCE CW, 1987, COLLAGEN REL RES, V7, P305; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; QIN XZ, 1994, BIOCHEM BIOPH RES CO, V204, P807, DOI 10.1006/bbrc.1994.2531; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749-6632.1995.tb44633.x; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; Sylvia VL, 1996, J CELL PHYSIOL, V167, P380, DOI 10.1002/(SICI)1097-4652(199606)167:3<380::AID-JCP2>3.0.CO;2-L; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; vanLeeuwen JPTM, 1996, BBA-MOL CELL RES, V1312, P55, DOI 10.1016/0167-4889(96)00016-X; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; WALI RK, 1995, J CELL PHYSIOL, V162, P172, DOI 10.1002/jcp.1041620203; WU CB, 1995, CALCIFIED TISSUE INT, V57, P285, DOI 10.1007/BF00298884; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; YUKIHIRO S, 1994, J BIOL CHEM, V269, P23889; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617	52	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29935	29941		10.1074/jbc.273.45.29935	http://dx.doi.org/10.1074/jbc.273.45.29935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792712	hybrid			2022-12-25	WOS:000076798300089
J	Duthie, SJ; Hawdon, A				Duthie, SJ; Hawdon, A			DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro	FASEB JOURNAL			English	Article						DNA breaks; misincorporated uracil; DNA repair; oxidized pyrimidines; comet assay	FACTORS INFLUENCING MUTATION; HAMSTER OVARY CELLS; FOLATE-DEFICIENCY; ULCERATIVE-COLITIS; HPRT LOCUS; VITAMIN-C; DAMAGE; CANCER; SUPPLEMENTATION; DYSPLASIA	Folic acid is essential for the synthesis and repair of DNA. We report the effects of folate depletion on DNA stability in normal human lymphocytes in vitro. DNA strand breakage, uracil misincorporation, oxidative DNA base damage, and DNA repair capability were determined using variants of the comet assay (single cell gel electrophoresis), Lymphocyte proliferation was measured as an indicator of normal replication. Lymphocytes isolated from human venous blood were stimulated to grow in either complete medium containing folic acid (1 ng/ml-2 mu g/ml) or medium deficient in folic acid for up to 10 days. Cells prepared for comet analysis were treated either with the bacterial DNA repair enzyme endonuclease III to determine the level of oxidized pyrimidines in lymphocyte DNA or with uracil DNA glycosylase, which detects misincorporated uracil, Cell number and viability were measured. Normal human lymphocyte DNA contained detectable amounts of misincorporated uracil (estimated as approximately 1000 per cell). DNA strand breakage and uracil misincorporation increased in a time- and concentration-dependent manner after lymphocytes were cultured with decreasing amounts: of folic acid. DNA damage was induced at folic acid concentrations routinely observed in plasma from the human population (1-10 ng/ml), Lymphocytes cultured under folate-deficient conditions failed to grow normally compared with control cells. However, all lymphocytes remained viable as measured by Trypan blue exclusion. Cells deprived of folate were unable to efficiently repair oxidative DNA damage induced by hydrogen peroxide. Inhibition of repair was maximal after 8 days in culture. Folate supply had no effect on the level of oxidized pyrimidines in lymphocyte DNA, even after 10 days in culture, suggesting that folate deficiency increases uracil misincorporation relatively specifically. These in vitro results: help to determine the mechanism(s) through which folic acid maintains DNA stability.	Rowett Res Inst, Bucksburn AB21 9SB, Aberdeen, Scotland	University of Aberdeen	Duthie, SJ (corresponding author), Rowett Res Inst, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.	sd@rri.sari.ac.uk		Duthie, Susan/0000-0002-7990-4437				BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; BLOUNT BC, 1995, BAILLIERE CLIN HAEM, V8, P461, DOI 10.1016/S0950-3536(05)80216-1; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BRANDA RF, 1993, CANCER RES, V53, P5401; BRANDA RF, 1992, ENVIRON MOL MUTAGEN, V19, P274, DOI 10.1002/em.2850190403; BRANDA RF, 1991, CANCER RES, V51, P6603; BUTTERWORTH CE, 1982, AM J CLIN NUTR, V35, P73, DOI 10.1093/ajcn/35.1.73; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; DOETSCH PW, 1987, MOL CELL BIOL, V7, P26, DOI 10.1128/MCB.7.1.26; Duthie SJ, 1996, CANCER RES, V56, P1291; Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V393, P223, DOI 10.1016/S1383-5718(97)00107-1; Duthie SJ, 1997, CARCINOGENESIS, V18, P1709, DOI 10.1093/carcin/18.9.1709; EVERSON RB, 1988, JNCI-J NATL CANCER I, V80, P525, DOI 10.1093/jnci/80.7.525; Fang JY, 1997, J GASTROENTEROL, V32, P171, DOI 10.1007/BF02936363; FENECH M, 1994, CARCINOGENESIS, V15, P1405, DOI 10.1093/carcin/15.7.1405; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HEIMBURGER DC, 1988, JAMA-J AM MED ASSOC, V259, P1525; JAMES S J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P16; JAMES SJ, 1994, CANCER RES, V54, P5075; Lashner BA, 1997, GASTROENTEROLOGY, V112, P29, DOI 10.1016/S0016-5085(97)70215-4; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; MACGREGOR JT, 1990, P NATL ACAD SCI USA, V87, P9962, DOI 10.1073/pnas.87.24.9962; MILLER AB, 1990, REV ONCOL, V3, P87; NEGRI E, 1991, INT J CANCER, V48, P350, DOI 10.1002/ijc.2910480307; POGRIBNY IP, 1995, CANCER RES, V55, P1894; REIDY JA, 1987, MUTAT RES, V192, P217, DOI 10.1016/0165-7992(87)90059-5; WAINFAN E, 1992, CANCER RES, V52, pS2071	31	244	252	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1491	1497		10.1096/fasebj.12.14.1491	http://dx.doi.org/10.1096/fasebj.12.14.1491			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806758				2022-12-25	WOS:000076749500008
J	Kiang, JG; Gist, ID; Tsokos, GC				Kiang, JG; Gist, ID; Tsokos, GC			Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47-D cells: role of [Ca2+](i) and protein kinases	FASEB JOURNAL			English	Article						viability; heat; protein kinase C; protein kinase A	HUMAN EPIDERMOID-A-431 CELLS; HSP-72 SYNTHESIS; A-431 CELLS; ACTIVATION; INCREASES; INDUCTION; CA2+; RESISTANCE; DAMAGE; GENE	Overexpression of heat shock protein 70 kDa alters the susceptibility of tumor cells to chemotherapeutic agents. We conducted experiments to study the regulation of expression of heat shock proteins (HSPs) in heat shock-treated T47-D cells, a human breast cancer cell line that expresses estrogen receptors, Cells exposed to heat shock at 44 degrees C displayed increased expression of heat shock protein 72 kDa (HSP-72), glucose-regulated protein 78 kDa (GRP-78), and GRP-94 in a time-dependent manner, as shown by [S-35]methionine incorporation and Western blotting experiments, The maximal rate of synthesis occurred between 2 and 4 h after heat shock. Removal of external Ca2+ inhibited the synthesis of the heat shock-induced GRP-78 but not of HSP-72 and GRP-94, whereas treatment of cells with BAPTA (a Ca2+ chelator) inhibited HSP-72 and GRP-78, Treatment with H89 (a protein kinase A inhibitor) blocked the heat shock-induced GRP-78 synthesis, whereas GF-109203X (a protein kinase C inhibitor) attenuated the heat shock-induced HSP-72 synthesis and com pletely blocked synthesis of GRP-78 but not of GRP-94, These results indicate that protein kinase C is involved in regulation of the heat shock-induced synthesis of HSP-72, whereas PKA and PKC are involved in the regulation of GRP-78 synthesis. Cells overexpressing HSP-72 and GRPs after heat shock displayed resistance against lethal temperature (47 degrees C for 50 min) -induced death, which was diminished after removal of external Ca2+ and treatment with GF-109203X, Heat shock increased intracellular free Ca2+ concentration ([Ca2+](i)) in a temperature- and heating duration-dependent fashion, and the increase was inhibited in the absence of external [Ca2+](i) and significantly reduced by pretreatment with H89 and GF-109203X, The results suggest that different pathways are involved in the induction of synthesis of HSP-72, GRP-78, and GRP-94 by heat shock. It is highly likely that only HSP-72 and GRP-78 are involved in the process of cytoprotection from the thermal injury.	Walter Reed Army Inst Res, Dept Clin Physiol, Div Med, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Kiang, JG (corresponding author), Walter Reed Army Inst Res, Dept Clin Physiol, Div Med, Bldg 40,Rm 3117A, Washington, DC 20307 USA.	Dr._Juliann-Kiang@WRSMTP-ccmail.army.mil	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				ADAMS DJ, 1983, ENDOCRINOLOGY, V113, P415, DOI 10.1210/endo-113-1-415; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CIOCCA DR, 1991, BREAST CANCER RES TR, V20, P33, DOI 10.1007/BF01833355; CIOCCA DR, 1982, CANCER RES, V42, P4256; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; Ding XZ, 1996, J INVEST MED, V44, P144; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; Edwards D P, 1981, Breast Cancer Res Treat, V1, P209, DOI 10.1007/BF01806261; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FUCHER C, 1993, J BIOL CHEM, V268, P15168; FUHR JE, 1976, J NATL CANCER I, V56, P89; Hahn G., 1982, HYPERTHERMIA CANC; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; HAHN GM, 1983, RATIONAL BASIS CHEMO, P427; KHANNA A, 1995, ENDOCRINOLOGY, V136, P1775, DOI 10.1210/en.136.4.1775; Kiang JG, 1996, J INVEST MED, V44, P53; KIANG JG, 1994, TOXICOL APPL PHARM, V127, P173, DOI 10.1006/taap.1994.1151; KIANG JG, 1992, AM J PHYSIOL, V263, pC30, DOI 10.1152/ajpcell.1992.263.1.C30; KIANG JG, 1991, BIOCHEM J, V276, P683, DOI 10.1042/bj2760683; Kiang JG, 1996, THYROID, V6, P475, DOI 10.1089/thy.1996.6.475; KIANG JG, 1994, AM J PHYSIOL, V267, pC104, DOI 10.1152/ajpcell.1994.267.1.C104; KIANG JG, 1998, IN PRESS PHARMACOL; Kiang Juliann G., 1997, Chinese Journal of Physiology, V40, P213; Kiang Juliann Gong, 1996, Journal of Biomedical Science, V3, P379, DOI 10.1007/BF02258043; Liossis SNC, 1997, J IMMUNOL, V158, P5668; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKAMURA K, 1991, GASTROENTEROLOGY, V101, P161, DOI 10.1016/0016-5085(91)90473-X; PERDRIZET GA, 1990, TRANSPLANT P, V22, P460; POLLA BS, 1987, AM J PHYSIOL, V252, pC640, DOI 10.1152/ajpcell.1987.252.6.C640; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RICE GC, 1987, CANCER CHEMOTH PHARM, V20, P183, DOI 10.1007/BF00570481; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHER E, 1981, BIOCHEM J, V200, P315, DOI 10.1042/bj2000315; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STOJADINOVIC A, 1995, GASTROENTEROLOGY, V109, P505, DOI 10.1016/0016-5085(95)90339-9; Stojadinovic A, 1997, CRIT CARE MED, V25, P309, DOI 10.1097/00003246-199702000-00020; VILLAR J, 1994, CRIT CARE MED, V22, P914; WALLNER K, 1986, INT J RADIAT ONCOL, V12, P829, DOI 10.1016/0360-3016(86)90043-X; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	43	23	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1571	1579		10.1096/fasebj.12.14.1571	http://dx.doi.org/10.1096/fasebj.12.14.1571			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806766				2022-12-25	WOS:000076749500016
J	Graversen, JH; Lorentsen, RH; Jacobsen, C; Moestrup, SK; Sigurskjold, BW; Thogersen, HC; Etzerodt, M				Graversen, JH; Lorentsen, RH; Jacobsen, C; Moestrup, SK; Sigurskjold, BW; Thogersen, HC; Etzerodt, M			The plasminogen binding site of the C-type lectin tetranectin is located in the carbohydrate recognition domain, and binding is sensitive to both calcium and lysine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-TETRANECTIN; GENE-EXPRESSION; PROTEIN; KRINGLE-4; AFFINITY; IMMUNOREACTIVITY; MINERALIZATION; MUTAGENESIS; ANTIBODY; CRYSTAL	Tetranectin, a homotrimeric protein belonging to the family of C-type lectins and structurally highly related to corresponding regions of the mannose-binding proteins, is known specifically to bind the plasminogen kringle 4 protein domain, an interaction sensitive to lysine. Surface plasmon resonance and isothermal calorimetry binding analyses using single-residue and deletion mutant tetranectin derivatives produced in Escherichia coli showed that the kringle 4 binding site resides in the carbohydrate recognition domain and includes residues of the putative carbohydrate binding site. Furthermore, the binding analysis revealed that the interaction is sensitive to calcium in addition to lysine.	Aarhus Univ, Dept Biol Mol & Struct, Gene Express Lab, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen, Denmark	Aarhus University; Aarhus University; University of Copenhagen	Etzerodt, M (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	met@biobase.dk	Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Graversen, Jonas Heilskov/0000-0002-2411-9933; Graversen, Jonas Heilskov/0000-0001-7119-2108				Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BERGLUND L, 1992, FEBS LETT, V309, P15, DOI 10.1016/0014-5793(92)80729-Z; BETTLER B, 1992, J BIOL CHEM, V267, P185; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; CHRISTENSEN L, 1991, HISTOCHEMISTRY, V95, P427, DOI 10.1007/BF00315737; CLEMMENSEN I, 1989, SCAND J CLIN LAB INV, V49, P719, DOI 10.3109/00365518909091550; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; CLEMMENSEN I, 1991, EUR J BIOCHEM, V195, P735, DOI 10.1111/j.1432-1033.1991.tb15761.x; deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T; Ewart KV, 1998, BIOCHEMISTRY-US, V37, P4080, DOI 10.1021/bi972503w; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; HEARN MTW, 1987, METHOD ENZYMOL, V135, P102; HOGDALL CK, 1993, CANCER, V72, P2415; Holtet TL, 1997, PROTEIN SCI, V6, P1511, DOI 10.1002/pro.5560060715; IBA K, 1995, FEBS LETT, V373, P1, DOI 10.1016/0014-5793(95)00992-I; Kamper EF, 1997, J RHEUMATOL, V24, P262; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; KLUFT C, 1989, BIOCHEM BIOPH RES CO, V161, P427, DOI 10.1016/0006-291X(89)92616-8; KLUFT C, 1989, THROMB RES, V55, P233, DOI 10.1016/0049-3848(89)90440-4; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; NIELSEN H, 1993, SCAND J IMMUNOL, V37, P39, DOI 10.1111/j.1365-3083.1993.tb01662.x; NIELSEN PR, 1993, BIOCHEMISTRY-US, V32, P13019, DOI 10.1021/bi00211a010; Rheinnecker M, 1996, J IMMUNOL, V157, P2989; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; WEWER UM, 1992, LAB INVEST, V67, P253; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	31	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29241	29246		10.1074/jbc.273.44.29241	http://dx.doi.org/10.1074/jbc.273.44.29241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786936	hybrid			2022-12-25	WOS:000076691800097
J	Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ				Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ			Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs	ONCOGENE			English	Article						breast cancer; ovarian cancer; monoclonal antibody; HER-2/neu; cisplatin; doxorubicin	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; MAMMARY EPITHELIAL-CELLS; OVARIAN-CARCINOMA CELLS; INTERSTRAND CROSS-LINKS; PROTEIN-KINASE-C; TYROSINE KINASE; TUMOR-CELLS; C-ERBB-2 EXPRESSION; SIGNAL-TRANSDUCTION	HER-2 oncogene encodes a transmembrane growth factor receptor that is overexpressed in 25-30% of patients with primary breast and ovarian cancer, A murine monoclonal antibody, 4D5, to the extracellular domain of HER-2 receptor elicits cytostatic growth inhibition of tumor cells overexpressing HER-2 protein, but clinical use of this antibody is limited by genesis of human anti-mouse antibodies, To avoid this problem, a recombinant humanized 4D5 monoclonal antibody (rhuMAb HER-2) was developed and tested using a human tumor xenograft model, Human breast and ovarian cancer cells which overexpress HER-2 were inhibited in vivo by the rhuMAb HER-2 antibody, Tumor growth relative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition was directly related to dose of rhuMAb HER-2, Tumor growth resumed on termination of antibody therapy, indicating a cytostatic effect, To elicit a cytotoxic response, human breast tumor xenografts were treated with a combination of antibody and antitumor drugs, cisplatin or doxorubicin, The combination of antibody with either cisplatin or doxorubicin resulted in significantly greater growth inhibition, with the cisplatin combination demonstrating a greater response, In addition, therapy with cisplatin and antireceptor antibody elicited complete tumor remissions after 2-3 cycles of therapy, The schedule of administration of antireceptor antibody and cisplatin was critical for occurrence of antibody-induced potentiation in cisplatin cytotoxicity. Enhanced killing of tumor cells was found only if antibody and drug were given in close temporal proximity, Since interference with DNA repair pathways may contribute to this receptor-enhanced chemosensitivity, repair of cisplatin-damaged reporter DNA (pCMV-beta) was determined in human breast cells, As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA. only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA, An alternative measure of DNA repair, unscheduled DNA synthesis, was also assessed, Treatment with either cisplatin or doxorubicin led to an increase in unscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to HER-2-overexpressing breast cancer cells, Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatin-induced DNA adducts. Expression of p21/WAF1, an important mediator of DNA repair, was disrupted in breast cancer cells with HER-2 overexpression, but not in control cells, after treatment with HER-2 antibody, thus suggesting cross-communication between the HER-2 signaling and DNA repair pathways, These data demonstrate an in vivo antiproliferative effect of rhuMAb HER-2 on tumors that overexpress HER-2 receptor and a therapeutic advantage in the administration of the antireceptor antibody in combination with chemotherapeutic agents.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 90078 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [P01-CA32737, R01-CA60835, R01-CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABOUDPIRAK E, 1989, P NATL ACAD SCI USA, V86, P3778, DOI 10.1073/pnas.86.10.3778; ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANDREWS PA, 1988, CANCER RES, V48, P68; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Boven E, 1996, EUR J CANCER, V32A, P1382, DOI 10.1016/0959-8049(96)00110-4; CAMPBELL RC, 1976, STAT BIOL; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; CHU G, 1994, J BIOL CHEM, V269, P787; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cutts SM, 1996, J BIOL CHEM, V271, P5422, DOI 10.1074/jbc.271.10.5422; DESANTES K, 1992, CANCER RES, V52, P1916; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; DREBIN JA, 1988, ONCOGENE, V2, P387; ELDIERY WS, 1993, CELL, V75, P817; FENDLY BM, 1990, CANCER RES, V50, P1550; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOFMANN J, 1988, INT J CANCER, V42, P382, DOI 10.1002/ijc.2910420313; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISONISHI S, 1991, CANCER RES, V51, P5903; ISONISHI S, 1990, J BIOL CHEM, V265, P3623; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASTAN MB, 1991, CANCER RES, V51, P6304; KINZEL V, 1990, CANCER RES, V50, P7932; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kurbacher CM, 1996, CANCER LETT, V103, P183, DOI 10.1016/0304-3835(96)04212-7; LEMOINE NR, 1990, ONCOGENE, V5, P237; Lewis GD, 1996, CANCER RES, V56, P1457; Liu Y, 1996, CANCER RES, V56, P31; Lofts F J, 1992, Cancer Treat Res, V61, P161; MANEVAL DC, 1991, J NUCL MED, V32, P1837; MARTE BM, 1995, ONCOGENE, V10, P167; McDonald E, 1996, CANCER RES, V56, P2250; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pauletti G, 1996, ONCOGENE, V13, P63; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PUREWAL M, 1993, CANCER CHEMOTH PHARM, V33, P239, DOI 10.1007/BF00686222; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RO J, 1989, CANCER RES, V49, P6941; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6479; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; Tsai CM, 1996, CANCER RES, V56, P1068; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VANDIEST PJ, 1992, PATHOL RES PRACT, V188, P344, DOI 10.1016/S0344-0338(11)81215-X; WAMPLER GL, 1992, CANCER CHEMOTH PHARM, V31, P111, DOI 10.1007/BF00685096; Wu GS, 1996, CLIN CANCER RES, V2, P623; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; Zhang LS, 1996, ONCOGENE, V12, P571; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	85	314	349	1	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2235	2249		10.1038/sj.onc.1202132	http://dx.doi.org/10.1038/sj.onc.1202132			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811454				2022-12-25	WOS:000076698200009
J	Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD				Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD			Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors	ONCOGENE			English	Article						N-myc; indolent B cell lymphoma; retroviral insertion; tumor progression	E-MU-MYC; PUTATIVE ONCOGENE PIM-1; FOLLICULAR LYMPHOMA; C-MYC; BCL-2 GENE; DIFFERENTIAL EXPRESSION; HUMAN NEUROBLASTOMAS; PROVIRAL INSERTION; LYMPHOCYTES-B; MICE BEARING	Little is known about stepwise deregulation of specific genes leading to lymphoid malignancy. Aberrant myc gene expression in transgenic mice is correlated with B cell lymphomagenesis. We generated a unique transgenic mouse model in which deregulated murine E mu-N-myc transgene expression leads to development of indolent B cell lymphoma. Tumor cells were monoclonal, morphologically mature and surface immunoglobulin expressing B cells. Tumors arose in a disease course and exhibited a cytoarchitectural appearance reminiscent of human follicular lymphoma. Yet tumor cells were staged as preB since they failed to rearrange the immunoglobulin light chain genes. Retroviral insertion mutagenesis analyses of adult transgenic mice infected as newborns with murine leukemia virus revealed decreased disease latency, increased lymphoma incidence and a histologically more mature tumor type. Proviral insertion sites were not equivalent when accelerated E mu-N-myc indolent lymphomas were compared to accelerated c-myc preB cell lymphomas. The bcl-2 gene was not disrupted in either spontaneous or provirally accelerated E mu-N-myc lymphomas. These findings suggest that tumor progression in N-myc-associated indolent B cell lymphoma can proceed along diverse pathways involving distinctly different combinations of deregulated and/or intact genes than those pathways described in highly aggressive forms of myc-related murine preB cell disease.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA	Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sheppard, RD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Lindhurst, Marjorie/AHD-3412-2022		NATIONAL CANCER INSTITUTE [R01CA039192] Funding Source: NIH RePORTER; NCI NIH HHS [CA39192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALEXANDER WS, 1989, ONCOGENE, V4, P575; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BERNS A, 1989, INT J CANCER, P22; BREUER M, 1991, CANCER RES, V51, P958; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOLCETTI R, 1989, ONCOGENE, V4, P1009; FINKE J, 1993, J CLIN ONCOL, V11, P1668, DOI 10.1200/JCO.1993.11.9.1668; FRIZZERA G, 1991, AM J CLIN PATHOL, V95, P684, DOI 10.1093/ajcp/95.5.684; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOATES JJ, 1994, AM J SURG PATHOL, V18, P37, DOI 10.1097/00000478-199401000-00004; GRAY DA, 1991, CANCER INVEST, V9, P295; HAMILTON MS, 1991, LEUKEMIA, V5, P768; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Harris NL, 1992, NEOPLASTIC HEMATOPAT, P645; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HILKENS J, 1986, SOMAT CELL MOLEC GEN, V12, P81, DOI 10.1007/BF01560730; HILLION J, 1991, ONCOGENE, V6, P169; HIRVONEN H, 1991, BLOOD, V78, P3012; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; INGHIRAMI G, 1992, NEOPLASTIC HEMATOPAT, P27; JAFFE ES, 1985, SURF PATH LYMPH ORGA; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; Kincade Paul W., 1993, P43; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Kung H. T., 1991, Computation and Cognition. Proceedings of the First NEC Research Symposium, P1; KURIE JM, 1990, ONCOGENE, V5, P577; LADANYI M, 1992, BLOOD, V79, P2124; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee W M, 1989, Cancer Treat Res, V47, P37; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEVINE PH, 1992, CANCER RES, V52, pS5425; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARIN MC, 1994, ONCOGENE, V9, P3107; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MITANI S, 1993, JPN J CANCER RES, V84, P37, DOI 10.1111/j.1349-7006.1993.tb02781.x; Mizukami Y, 1995, ANTICANCER RES, V15, P2899; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MOROY T, 1991, ONCOGENE, V6, P1941; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; NADEAU JH, 1987, GENETICS, V117, P533; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Osmond D G, 1990, Semin Immunol, V2, P173; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; RIMOKH R, 1993, BLOOD, V81, P136; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; RONCALLI M, 1994, CANCER-AM CANCER SOC, V74, P134, DOI 10.1002/1097-0142(19940701)74:1<134::AID-CNCR2820740122>3.0.CO;2-M; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SHEPPARD RD, 1991, MAMM GENOME, V1, P104, DOI 10.1007/BF02443786; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SOLE F, 1994, CANCER GENET CYTOGEN, V75, P72, DOI 10.1016/0165-4608(94)90219-4; STRAKA C, 1993, LEUKEMIA, V7, P268; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAO S, 1991, Kobe Journal of Medical Sciences, V37, P227; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WANG J, 1993, LEUKEMIA, V7, P1834; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WEISS RA, 1985, RNA TUMOR VIRUSES, V1; WETHERALL NT, 1992, PATHOBIOLOGY, V60, P87, DOI 10.1159/000163704; WLODARSKA I, 1994, GENE CHROMOSOME CANC, V10, P171, DOI 10.1002/gcc.2870100304; YANO T, 1992, BLOOD, V80, P758; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	97	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2073	2085		10.1038/sj.onc.1202125	http://dx.doi.org/10.1038/sj.onc.1202125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798678				2022-12-25	WOS:000076540900006
J	Weinstein, EJ; Grimm, S; Leder, P				Weinstein, EJ; Grimm, S; Leder, P			The oncogene heregulin induces apoptosis in breast epithelial cells and tumors	ONCOGENE			English	Article						heregulin; apoptosis; Bcl-2; caspase; breast cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; CANCER CELLS; C-MYC; PROTEIN; EXPRESSION; DEATH; INHIBITION; LIGAND	The products of a growing number of genes have been shown to display seemingly contradictory functions; namely, the induction of tumorigenesis and the induction of apoptosis, Heregulin's involvement in oncogenesis occurs through its interactions with members of the EGF receptor tyrosine kinase family, Recently one isoform of heregulin, beta 2b, was isolated in an in vitro screen for dominant, apoptosis-inducing genes in kidney epithelial cells. Here we show that heregulin is also capable of mediating apoptosis in human and murine mammary tumor cell lines and murine tumors. Furthermore, through transfection of the human breast cancer cell line MCF-7 with the truncated transmembrane/cytoplasmic segment of the heregulin gene, we show that the intracellular region of the heregulin precursor is sufficient for induction of apoptosis, Through the use of DNA fragmentation assays me also show that apoptosis occurs in cell lines established from heregulin-induced mammary gland tumors. TdT addition of digoxigenin labeled nucleotides to 3' OH ends of DNA breaks recapitulated these results in the actual tumors. Finally, over-expression of heregulin is shown to lead to the down-regulation of Bcl-2, an inhibitor of apoptosis. Conversely, the transfection of Bcl-2 into MCF-7 cells inhibits heregulin-mediated programmed cell death.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ADAM L, 1995, CANCER RES, V55, P5156; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Amundadottir LT, 1996, ONCOGENE, V13, P757; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GOLD R, 1994, LAB INVEST, V71, P219; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GRIMM S, 1998, IN PRESS J EXP MED; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAATTELA M, 1995, ONCOGENE, V10, P2297; Krane IM, 1996, ONCOGENE, V12, P1781; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MAKAR AP, 1990, ACTA ONCOL, V29, P931, DOI 10.3109/02841869009096392; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Shimizu S, 1996, ONCOGENE, V12, P2251; SHUM L, 1994, J CELL BIOL, V125, P906; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; THIRY M, 1992, J HISTOCHEM CYTOCHEM, V40, P411, DOI 10.1177/40.3.1552179; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	45	33	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2107	2113		10.1038/sj.onc.1202428	http://dx.doi.org/10.1038/sj.onc.1202428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798682				2022-12-25	WOS:000076540900010
J	Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M				Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M			Secretory Type II Phospholipase A(2) (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa	ONCOGENE			English	Article						secretory phospholipase A(2); PLA2G2A; Mom1; Min; FAP; 1p; colorectal cancer	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; MAJOR MODIFIER; MOM1 LOCUS; CANCER; GENE; IDENTIFICATION; MUTATION; MOUSE; COLI	There is good evidence now that the secretory, type II phospholipase A(2) (Pla2g2a) gene represents the Mom1 locus, a genetic modifier of tumor resistance in the multiple intestinal neoplasia (Min) mouse. Previously we have mapped the human homolog PLA2G2A to 1p35-36.1 within a region that is the target of frequent deletions in sporadic colorectal tumors. Here we show 64% loss of heterozygosity (LOH) at the PLA2G2A locus in primary tumors. We studied PLA2G2A expression in both colorectal tumor cell lines and normal mucosa. Most of the lines lacked detectable PLA2G2A transcripts by Northern analysis. Large differences in expression were seen among normal mucosa of different patients with sporadic tumors. We analysed the coding region of PLA2G2A in eight colorectal cancer cell lines with hemizygous deletion at 1p35-36/PLA2G2A, in none we did detect a mutation. Biallelic expression of PLA2G2A was observed in a cell line heterozygous for an exon 3 polymorphism, rendering unlikely that imprinting is a pathway participating in the loss of PLA2G2A function. It remains uncertain if PLA2G2A, in particular its apparent lack of expression in tumor cells, might be a factor in human colorectal tumorigenesis.	Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Humboldt Univ, Abt Chirurg & Chirurg Onkol, Robert Rossle Klin, Max Delbruck Ctr,Virchow Klinikum, D-13125 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dihlmann S, 1997, ONCOL RES, V9, P119; Dobbie Z, 1996, HUM GENET, V98, P386, DOI 10.1007/s004390050226; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NEVALAINEN TJ, 1995, LAB INVEST, V72, P201; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PRAML C, 1995, ONCOGENE, V11, P1357; PRAML C, 1995, CANCER RES, V55, P5504; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tomlinson IPM, 1996, J MED GENET, V33, P268, DOI 10.1136/jmg.33.4.268; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x	27	26	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2009	2012		10.1038/sj.onc.1202121	http://dx.doi.org/10.1038/sj.onc.1202121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788445				2022-12-25	WOS:000076423500015
J	Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS				Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS			Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy	ONCOGENE			English	Article						myeloid leukemia; transcription factor; target gene	MYELOID-TRANSFORMING GENE; ACUTE MYELOGENOUS LEUKEMIAS; DNA-BINDING PROTEINS; TRANSCRIPTIONAL REGULATION; CONSENSUS SEQUENCE; CELL-LINES; EXPRESSION; PROTOONCOGENE; ACTIVATION; RECEPTOR	We have sought to identify and isolate target genes for the zinc finger protein, EVI-1, which has been implicated in the genesis of myelogenous leukemia both in mouse and human. We have approached this with a two-step selection: we first selected for genomic fragments of mouse DNA that bind to the protein with high affinity; second, we employed cDNA hybrid selection to identify gene sequences contained within these fragments. We show that we have constructed a sublibrary of genomic fragments that contains a significant fraction of the EVI-1-binding sites in the mouse genome, Our data has allowed us to estimate that there are approximately 4300 binding sites per haploid genome in the mouse. We further demonstrate that by using cDNA hybrid selection, it is relatively straightforward to isolate cDNAs that correspond to genes embedded in the EVI-1-binding sublibrary. Several of these are novel, but are represented in databases of anonymous human or mouse cDNAs (expressed sequence tags), One selected gene is Itpr2, encoding the inositol trisphosphate type two receptor, which is transcriptionally regulated during myelopoiesis. Finally, using a chimeric EVI-1-VP16-fusion protein under the control of a tetracycline-regulated system, we have shown that this chimeric activator can directly regulate Itpr2.	Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University	Perkins, AS (corresponding author), Yale Univ, Dept Pathol, POB 208023, New Haven, CT 06520 USA.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUGI T, 1995, ONCOGENE, V11, P191; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MOHLER JD, 1977, GENETICS, V85, P259; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PARIMOO S, 1993, METHODS MOL GENETICS, V1, P23; Peeters P, 1997, CANCER RES, V57, P564; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Perkins AS, 1996, J BIOL CHEM, V271, P1104, DOI 10.1074/jbc.271.2.1104; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; Summers MD, 1987, TEXAS AGR EXPT STATI; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	49	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1527	1538		10.1038/sj.onc.1202331	http://dx.doi.org/10.1038/sj.onc.1202331			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794230				2022-12-25	WOS:000076089900005
J	Kobayashi, T; Imokawa, G; Bennett, DC; Hearing, VJ				Kobayashi, T; Imokawa, G; Bennett, DC; Hearing, VJ			Tyrosinase stabilization by Tyrp1 (the brown locus protein)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAT-COLOR MUTANTS; MAMMALIAN TYROSINASE; DOPACHROME TAUTOMERASE; MELANIN BIOSYNTHESIS; MOUSE MUTATION; WILD-TYPE; MELANOCYTES; GENE; MELANOGENESIS; GLYCOPROTEIN	Mammalian melanogenesis is regulated directly or indirectly by over 85 distinct loci. The Tyr/albino locus, in which mutations cause a lack of pigmentation, encodes tyrosinase (Tyr), the critical and rate-limiting melanogenic enzyme. Other melanogenic enzymes include Tyrp1 (or TRP1) and 3,4-dihydroxyphenylalaninechrome tautomerase (Dct or TRP2) encoded at the Tyrp1/brown and Dct/slaty loci, respectively. Murine Tyrp1 can oxidize 5,6-dihydroxyindole-2-carboxylic acid (DHICA) produced by Dct, but mutations in Tyrp1 also affect the catalytic functions of Tyr. All three enzymes are membrane-bound melanosomal proteins with similar structural features and are thought to interact within and stabilize a melanogenic complex. We have now further investigated the effect of a Tyrp1(b) mutation on Tyr stability. Pulse/chase labeling experiments show that Tyr is degraded more quickly in Tyrp1(b) mutant melanocytes than in melanocytes wild type at that locus. This reduced stability of Tyr can be partly rescued by infection with the wild type Tyrp1 gene, and this is accompanied by phenotypic rescue of infected melanocytes. In sum, these results suggest that, in addition to its catalytic function in oxidizing DHICA, Tyrp1 may play an important role in stabilizing Tyr, a second potential role in the regulation of melanin formation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; St George Hosp, Sch Med, Dept Anat, London SW17 0RE, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Georges University London	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527; Kobayashi, Takeshi/0000-0002-4372-5285				AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DC, 1990, DEVELOPMENT, V110, P471; Boissy RE, 1996, AM J HUM GENET, V58, P1145; BOISSY RE, IN PRESS EXP DERMATO; DOOLITTLE DP, 1996, CATALOG MUTANT GENES, P17; FOSTER M, 1967, GENETIC ASPECTS MAMM, P467; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1973, J ULTRA MOL STRUCT R, V43, P88, DOI 10.1016/S0022-5320(73)90072-5; HEARING VJ, 1992, FUNCTIONAL PROPERTIE, P264; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; *MOUS GEN DAT, 1998, MOUS GEN INF; MOYER FH, 1966, AM ZOOL, V6, P43; MOYER FH, 1963, ANN NY ACAD SCI, V100, P584, DOI 10.1111/j.1749-6632.1963.tb42916.x; ORLOW SJ, 1992, PIGM CELL RES, V5, P113, DOI 10.1111/j.1600-0749.1992.tb00007.x; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; OZEKI H, 1995, J INVEST DERMATOL, V105, P361, DOI 10.1111/1523-1747.ep12320792; PROTA G, 1995, PIGM CELL RES, V8, P153, DOI 10.1111/j.1600-0749.1995.tb00657.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; TAI T, 1983, CANCER RES, V43, P2773; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VALVERDE P, 1992, ARCH BIOCHEM BIOPHYS, V297, P221, DOI 10.1016/0003-9861(92)90665-J; VIJAYASARADHI S, 1991, INT J CANCER, V47, P298, DOI 10.1002/ijc.2910470221; WINDER A, 1994, CELL MOL BIOL RES, V40, P613; WINDER AJ, 1993, J CELL SCI, V106, P153; ZDARSKY E, 1990, GENETICS, V126, P443	42	149	155	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31801	31805		10.1074/jbc.273.48.31801	http://dx.doi.org/10.1074/jbc.273.48.31801			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822646	hybrid			2022-12-25	WOS:000077207000028
J	Gurvitz, A; Mursula, AM; Firzinger, A; Hamilton, B; Kilpelainen, SH; Hartig, A; Ruis, H; Hiltunen, JK; Rottensteiner, H				Gurvitz, A; Mursula, AM; Firzinger, A; Hamilton, B; Kilpelainen, SH; Hartig, A; Ruis, H; Hiltunen, JK; Rottensteiner, H			Peroxisomal Delta 3-cis-Delta 2-trans-enoyl-CoA isomerase encoded by ECI1 is required for growth of the yeast Saccharomyces cerevisiae on unsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL 3,2-TRANS-ENOYL-COA ISOMERASE; CHAIN DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; TRANSCRIPTION FACTORS PIP2P; ENOYL-COA HYDRATASE; BETA-OXIDATION; RAT-LIVER; 3-CIS-2-TRANS-ENOYL-COA ISOMERASE; 3-HYDROXYACYL-COA DEHYDROGENASE; 2,4-DIENOYL-COA REDUCTASE; 2-ENOYL-COA HYDRATASE	We have identified the Saccharomyces cerevisiae gene ECI1 encoding Delta(3)-cis-L-Delta(2)-trans-enoyl-CoA isomerase that acts as an auxiliary enzyme in the beta-oxidation of (poly)unsaturated fatty acids. A mutant devoid of Eci1p was unable to grow on media containing unsaturated fatty acids such as oleic acid but was proficient for growth when a saturated fatty acid such as palmitic acid was the sole carbon source. Levels of ECI1 transcript were elevated in cells grown on oleic acid medium due to the presence in the ECI1 promoter of an oleate response element that bound the transcription factors Pip2p and Oaf1p. Eci1p was heterologously expressed in Escherichia coli and purified to homogeneity. It was found to be a hexameric protein with a subunit of molecular mass 32,000 Da that converted 3-hexenoyl-CoA to trans-2-hexenoyl-CoA Eci1p is the only known member of the hydratase/isomerase protein family with isomerase and/or 2-enoyl-CoA hydratase 1 activities that does not contain a conserved glutamate at its active site. Using a green fluorescent protein fusion, Eci1p was shown to be located in peroxisomes of wild-type yeast cells. Rat peroxisomal multifunctional enzyme type I containing Delta(3)-cis-Delta(2)-trans-enoyl-CoA isomerase activity was expressed in ECI1-deleted yeast cells, and this restored growth on oleic acid.	Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria; Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Oulu, Bioctr, Dept Biochem, FIN-90570 Oulu, Finland	University of Vienna; Ludwig Boltzmann Institute; Finland National Institute for Health & Welfare; University of Oulu	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Bioctr, FIN-90570 Linnanmaa, Finland.			Hartig, Andreas/0000-0003-3334-2763; Mursula, Anu/0000-0001-7975-7505				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; ENGELAND K, 1991, EUR J BIOCHEM, V196, P699, DOI 10.1111/j.1432-1033.1991.tb15868.x; EULERBERTRAM S, 1990, BIOL CHEM H-S, V371, P603, DOI 10.1515/bchm3.1990.371.2.603; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; IGUAL JC, 1991, YEAST, V7, P379, DOI 10.1002/yea.320070408; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSSEN U, 1994, GENOMICS, V23, P223, DOI 10.1006/geno.1994.1480; JONES EW, 1977, GENETICS, V85, P23; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KILPONEN JM, 1994, BIOCHEM J, V300, P1; KILPONEN JM, 1993, FEBS LETT, V322, P299, DOI 10.1016/0014-5793(93)81590-V; KILPONEN JM, 1990, BIOCHEM J, V269, P223, DOI 10.1042/bj2690223; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; RICHTER K, 1980, J BIOL CHEM, V255, P8019; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STOFFEL W, 1978, H-S Z PHYSIOL CHEM, V359, P1777, DOI 10.1515/bchm2.1978.359.2.1777; STOFFEL W, 1993, FEBS LETT, V333, P119, DOI 10.1016/0014-5793(93)80387-A; STRUIJK CB, 1966, BIOCHIM BIOPHYS ACTA, V116, P12, DOI 10.1016/0005-2760(66)90088-9; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wu WJ, 1997, BIOCHEMISTRY-US, V36, P2211, DOI 10.1021/bi962549+	59	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31366	31374		10.1074/jbc.273.47.31366	http://dx.doi.org/10.1074/jbc.273.47.31366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813046	hybrid			2022-12-25	WOS:000077136900074
J	Na, SY; Choi, HS; Kim, JW; Na, DS; Lee, JW				Na, SY; Choi, HS; Kim, JW; Na, DS; Lee, JW			Bcl3, an I kappa B protein, as a novel transcription coactivator of the retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TATA-BINDING PROTEIN; CANDIDATE PROTOONCOGENE BCL-3; ACTIVATION FUNCTION AF-2; NUCLEAR-RECEPTOR; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; CRYSTAL-STRUCTURE; CO-REPRESSOR; DNA-BINDING	We have recently shown that the I kappa B protein I kappa B beta interacted with the retinoid X receptor (RXR) and inhibited the g-cis-retinoic acid (RA)-dependent transactivations (Na, S.-Y., Kim, H.-J,, Lee, S.-H., Choi, H.-S., Na, D. S., Lee, M.-O., Chung, M., Moore, D. D., and Lee, J. W. (1998) J. Biol. Chem. 6, 3212-3215). Herein, we show that a distinct I kappa B protein Bcl3 also interacts with RXR, as shown in the yeast two-hybrid tests and glutathione S-transferase pull-down assays. The Bcl3 interaction involved two distinct subregions of RXR, Le. constitutive interactions of the N-terminal ABC domains and 9-cis-RA-dependent interactions of the C-terminal DEF domains. In contrast to I kappa B beta, Bcl3 did not interact with the AF2 domain of RXR. Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIE alpha in the GST pull-down assays. TBP and TFIIA,however, were not able to interact with I kappa B beta. Accordingly, Bcl3 coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of I kappa B beta. In addition, coexpression of SRC-1 but not p300 further stimulated the Bcl3-mediated enhancement of the g-cis-RA-induced transactivations of RXR. These results suggest that distinct I kappa B proteins differentially modulate the 9-cis-RA-induced transactivations of RXR in vivo.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Paichai Univ, Dept Biochem, Daejeon 302735, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138040, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Pai Chai University; University of Ulsan	Lee, JW (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Moore DD, 1995, GLOB MOB SURV; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ONATE SA, 1995, SCIENCE, V270, P1354; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Weil R, 1997, J BIOL CHEM, V272, P9942; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	71	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30933	30938		10.1074/jbc.273.47.30933	http://dx.doi.org/10.1074/jbc.273.47.30933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812988	hybrid			2022-12-25	WOS:000077136900016
J	Stephens, JM; Lumpkin, SJ; Fishman, JB				Stephens, JM; Lumpkin, SJ; Fishman, JB			Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STAT3 SERINE PHOSPHORYLATION; COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; DNA-BINDING; CULTURED ADIPOCYTES; GENE-EXPRESSION; FACTOR RECEPTOR; PROTEIN-KINASE; PATHWAY	We have recently demonstrated that signal transducers and activators of transcription (STATs) 1, 3, 5A, 5B, and 6 are expressed in both cultured and native adipocytes. Our current studies have focused on the activation of STATs 1 and 3 by leukemia inhibitory factor (LIF), oncostatin-M (OSM), and interferon-gamma (IFN gamma) in 3T3-L1 adipocytes. IFN gamma is shown to be a potent activator of STAT 1 as indicated by both tyrosine phosphorylation and nuclear translocation. However, LIF and OSM, which are potent inducers of STAT 3, are less potent activators of STAT 1 as measured by both tyrosine phosphorylation and nuclear translocation. Both STATs 1 and 3 were translocated to the nucleus in a time-dependent fashion following LIF treatment. In addition, IFN gamma resulted in a time- and dose-dependent effect on STATs 1 and 3 nuclear translocation. Growth hormone, a potent activator of STATs 5A and 5B, had a minimal effect on STAT 1 and STAT 3 tyrosine phosphorylation. Preincubation with either insulin or growth hormone had no detectable effects on the tyrosine phosphorylation or nuclear translocation of STATs 1 and 3 induced by LIF, OSM, or IFN gamma. The effects of LIF and IFN gamma on STAT 1 and 3 tyrosine phosphorylation and nuclear translocation were confirmed in native rat adipocytes. In 3T3-L1 adipocytes, a low level of serine phosphorylation of STAT 3 on residue 727 was observed and was markedly enhanced by insulin, LIF, or OSM. This increase in STAT 3 Ser(727) phosphorylation was dependent upon the activation of MAPK, since the MAPK kinase inhibitor (PD98059) reduced STAT 3 Ser727 phosphorylation to basal levels. The inhibition of MAPK had no effect on the ability of STATs 1 and 3 to be tyrosine-phosphorylated or translocate to the nucleus. These studies demonstrate the highly specific and quantitative activation of STATs 1 and 3 by LIF, OSM, and IFN gamma in adipocytes and indicate that STAT 3 is a substrate for MAPK in adipocytes.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Qual Controlled Biochem Inc, Hopkinton, MA 01748 USA	Louisiana State University System; Louisiana State University	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.		Stephens, Jacqueline M/R-5217-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052968, R56DK052968, R55DK052968] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK52968-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; GREGOIRE F, 1992, J CELL PHYSIOL, V151, P300, DOI 10.1002/jcp.1041510211; Jenab S, 1998, ENDOCRINOLOGY, V139, P1883, DOI 10.1210/en.139.4.1883; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7386; Senturk LM, 1998, AM J REPROD IMMUNOL, V39, P144; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; THOMA B, 1994, J BIOL CHEM, V269, P6215; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	41	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31408	31416		10.1074/jbc.273.47.31408	http://dx.doi.org/10.1074/jbc.273.47.31408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813052	hybrid, Green Published			2022-12-25	WOS:000077136900080
J	Feron, O; Dessy, C; Opel, DJ; Arstall, MA; Kelly, RA; Michel, T				Feron, O; Dessy, C; Opel, DJ; Arstall, MA; Kelly, RA; Michel, T			Modulation of the endothelial nitric-oxide synthase caveolin interaction in cardiac myocytes - Implications for the autonomic regulation of heart rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; PROTEIN; DOMAIN; CELLS; IDENTIFICATION; EXPRESSION; RECEPTOR; GENE	The endothelial isoform of nitric oxide synthase (eNOS) is dually acylated and thereby targeted to signal transducing microdomains termed caveolae. In endothelial cells, eNOS interacts with caveolin-1, which represses eNOS enzyme activity. In cardiac myocytes, eNOS associates with the muscle-specific caveolin-3 isoform, but whether this interaction affects NO production and regulates myocyte function is unknown. We isolated neonatal cardiac myocytes from mutant mice with targeted disruption of the eNOS gene and transfected them with wild-type (WT) eNOS or myristoylation-deficient (myr(-)) eNOS mutant cDNA. In myocytes expressing WT eNOS, the muscarinic cholinergic agonist carbachol completely abrogated the spontaneous beating rate and induced a 4-fold elevation of the cGMP level. By contrast, in the myr(-) eNOS myocytes, carbachol failed to exert its negative chronotropic effect and to increase cGMP levels. We then used a reversible permeabilization protocol to load intact neonatal rat myocytes with an oligopeptide corresponding to the caveolin-3 scaffolding domain. This peptide completely and specifically inhibited the carbachol-induced negative chronotropic effect and the accompanying cGMP elevation. Thus, our results suggest that acylated eNOS may couple muscarinic receptor activation to heart rate control and indicate a key role for eNOS/caveolin interactions in the cholinergic modulation of cardiac myocyte function.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston Biomed Res Inst, Boston, MA 02114 USA; Natl Fund Sci Res, Brussels, Belgium; Amer Heart Assoc, Dallas, TX 75231 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Fonds de la Recherche Scientifique - FNRS	Feron, O (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.		FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286; Arstall, Margaret/0000-0003-0760-6382				BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Han XQ, 1998, P NATL ACAD SCI USA, V95, P6510, DOI 10.1073/pnas.95.11.6510; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; OGAWA S, 1992, J CLIN INVEST, V89, P1085, DOI 10.1172/JCI115688; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; SASE K, 1997, TRENDS CARDIOVAS MED, V7, P25; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	29	160	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30249	30254		10.1074/jbc.273.46.30249	http://dx.doi.org/10.1074/jbc.273.46.30249			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804784	hybrid			2022-12-25	WOS:000077008100031
J	George, SR; Lee, SP; Varghese, G; Zeman, PR; Seeman, P; Ng, GYK; O'Dowd, BF				George, SR; Lee, SP; Varghese, G; Zeman, PR; Seeman, P; Ng, GYK; O'Dowd, BF			A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADRENERGIC-RECEPTORS; SF9 CELLS; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; ALPHA-HELICES; DIMERIZATION; PHOSPHORYLATION; EXPRESSION; PALMITOYLATION	In this study, we show that a peptide based on the sequence of transmembrane domain 6 of the D1 dopamine receptor (D1DR) specifically inhibited D1DR binding and function, without affecting receptor oligomerization. It has been shown that an analogous peptide from the beta 2-adrenergic receptor disrupted dimerization and adenylyl cyclase activation in the PS-adrenergic receptor (Hebert, T. E., Moffett, S., Morello, J. P., Loisel, T. P., Bichet, D. G., Barret, C., and Bouvier, M. (1996) J. Biol. Chem. 221, 16384-16392). Treatment of D1DR with the D1DR transmembrane 6 peptide resulted in a dose-dependent, irreversible inhibition of D1DR antagonist binding, an effect not seen in D1DR with peptides based on transmembrane domains of other G protein-coupled receptors. Incubation with the D1DR transmembrane 6 peptide also resulted in a dose-dependent attenuation of both dopamine-induced [S-35]guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) binding and receptor-mediated dopamine stimulation of adenylyl cyclase activity. Notably, GTP gamma S binding and cAMP production were reduced to levels below baseline, indicating blockade of ligand-independent, intrinsic receptor activity. Immunoblot analyses of the D1DR revealed the receptor existed as monomers, dimers, and higher order oligomers and that these oligomeric states were unaffected after incubation with the D1DR transmembrane 6 peptide. These findings represent the first demonstration that a peptide based on the transmembrane 6 of the D1DR may represent a novel category of noncompetitive D1DR antagonists.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada; Addict Res Fdn, Toronto, ON M5S 2S1, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Rm 4358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		soler, martha maricel m gomez/L-6025-2014; George, Susan R/P-9669-2018; George, Susan/W-7494-2019	soler, martha maricel m gomez/0000-0002-4412-8108; 				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRINKMANN AO, 1994, J PEDIATR ENDOCRINOL, V7, P275; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fukushima Y, 1997, FEBS LETT, V409, P283, DOI 10.1016/S0014-5793(97)00531-0; Gouldson PR, 1997, BIOCHEM SOC T, V25, P1066, DOI 10.1042/bst0251066; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; HAWES BE, 1994, J BIOL CHEM, V269, P15776; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Javitch J A, 1998, Adv Pharmacol, V42, P412; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marti T, 1998, J BIOL CHEM, V273, P9312, DOI 10.1074/jbc.273.15.9312; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TROGADIS JE, 1995, J HISTOCHEM CYTOCHEM, V43, P497, DOI 10.1177/43.5.7730588	37	105	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30244	30248		10.1074/jbc.273.46.30244	http://dx.doi.org/10.1074/jbc.273.46.30244			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804783	hybrid			2022-12-25	WOS:000077008100030
J	Monlauzeur, L; Breuza, L; Le Bivic, A				Monlauzeur, L; Breuza, L; Le Bivic, A			Putative O-glycosylation sites and a membrane anchor are necessary for apical delivery of the human neurotrophin receptor in Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; INTESTINAL EPITHELIAL-CELLS; DECAY-ACCELERATING FACTOR; CANINE KIDNEY-CELLS; HUMAN NGF RECEPTOR; MDCK CELLS; CYTOPLASMIC DOMAIN; AMINOPEPTIDASE-N; SORTING SIGNAL; BIOGENETIC PATHWAYS	We have expressed the human neurotrophin receptor p75 (p75(NTR)) in the intestinal epithelial cell line Caco-2 as a model to study intracellular transport and subcellular sorting signals in intestinal cells. p75(NTR) was localized at the apical membrane of Caco-2 cells and reached this membrane mainly via an indirect pathway. Apical localization, intracellular routing, and basolateral to apical transcytosis were not affected by truncation of the cytoplasmic domain or replacement of the transmembrane domain by a glycosyl phosphatidylinositol anchor. Removal of membrane anchoring resulted in basolateral secretion of the ectodomain of p75(NTR) in Caco-2 cells but in apical secretion in Madin-Darby canine kidney (MDCK) cells. Substitution of potential O-glycosylation sites present in the stalk of p75NTR led to intracellular cleavage and secretion of the ectodomain into the basolateral medium both in Caco-2 and MDCK cells. These results suggest that the stalk of p75NTR carries an apical sorting information that is recognized efficiently by Caco-2 cells only when attached to the membrane. This apical sorting information is linked to the presence of predicted O-glycosylation sites in that region. These putative O-glycosylation sites also play a role in the regulation of p75NTR transport to the cell surface and in the prevention of rapid degradation by cleavage of the stalk domain.	Univ Mediterranee, Fac Sci Luminy, IBDM, UMR6545,Lab Genet & Physiol Dev, F-13288 Marseille 09, France	UDICE-French Research Universities; Aix-Marseille Universite	Le Bivic, A (corresponding author), Univ Mediterranee, Fac Sci Luminy, IBDM, UMR6545,Lab Genet & Physiol Dev, Case 907, F-13288 Marseille 09, France.			Breuza, Lionel/0000-0002-8075-8625				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BERGER J, 1988, J BIOL CHEM, V263, P10016; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; ELLIS JA, 1995, J BIOL CHEM, V270, P20717, DOI 10.1074/jbc.270.35.20717; FIEDLER K, 1995, CELL, V81, P1; GARCIA M, 1993, J CELL SCI, V104, P1281; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; REDDY P, 1989, J BIOL CHEM, V264, P17329; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551	43	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30263	30270		10.1074/jbc.273.46.30263	http://dx.doi.org/10.1074/jbc.273.46.30263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804786	hybrid			2022-12-25	WOS:000077008100033
J	Towler, DA; Bidder, M; Latifi, T; Coleman, T; Semenkovich, CF				Towler, DA; Bidder, M; Latifi, T; Coleman, T; Semenkovich, CF			Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; EXPRESSION; ATHEROSCLEROSIS; CALCIFICATION; EVOLUTION; MELLITUS; LIPASE; BONE	Vascular calcification is common in people with diabetes and its presence predicts premature mortality. To clarify the underlying mechanisms, we used low density lipoprotein receptor-deficient (LDLR -/-) mice to study vascular calcification in the ascending aorta. LDLR -/- mice on a chow diet did not develop obesity, diabetes, atheroma, or vascular calcification. In contrast, LDLR -/- mice on high fat diets containing cholesterol developed obesity, severe hyperlipidemia, hyperinsulinemic diabetes, and aortic atheroma, A high fat diet without cholesterol also induced obesity and diabetes, but caused only moderate hyperlipidemia and did not result in significant aortic atheroma formation. Regardless of cholesterol content, high fat diets induced mineralization of the proximal aorta (assessed by von Kossa staining) and promoted aortic expression of Msx2 and Msx1, genes encoding homeodomain transcription factors that regulate mineralization and osseous differentiation programs in the developing skull. Osteopontin (Opn), an osteoblast matrix protein gene also expressed by activated macrophages, was up-regulated in the aorta by these high fat diets. In situ hybridization showed that peri-aortic adventitial cells in high fat-fed mice express Msx2. Opn was also detected in this adventitial cell population, but in addition was expressed by aortic vascular smooth muscle cells and macrophages of the intimal atheroma, High fat diets associated with hyperinsulinemic diabetes activate an aortic osteoblast transcriptional regulatory program that is independent of intimal atheroma formation. The spatial pattern of Msx2 and Opn gene expression strongly suggests that vascular calcification, thought to be limited to the media, is an active process that can originate from an osteoprogenitor cell population in the adventitia.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Box 8046, St Louis, MO 63110 USA.	dtowler@pharmdec.wustl.edu; semenkov@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker CVH, 1997, MECH DEVELOP, V69, P13, DOI 10.1016/S0925-4773(97)00129-9; Barnard RJ, 1998, J APPL PHYSIOL, V84, P1311, DOI 10.1152/jappl.1998.84.4.1311; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Bujan J, 1996, ATHEROSCLEROSIS, V122, P141, DOI 10.1016/0021-9150(95)05727-7; Butler William T., 1996, P167; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; DAOUD AS, 1976, ARCH PATHOL LAB MED, V100, P372; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DETRANO RC, 1994, AM HEART J, V127, P1526, DOI 10.1016/0002-8703(94)90381-6; Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FITZPATRICK LA, 1993, J CLIN INVEST, V92, P2814; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MEYER WW, 1977, ADV EXP MED BIOL, V82, P783; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; OXLUND H, 1989, DIABETOLOGIA, V32, P748, DOI 10.1007/BF00274536; Pitsavos C, 1998, AM HEART J, V135, P604, DOI 10.1016/S0002-8703(98)70274-1; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Rodan SB, 1997, J ENDOCRINOL, V154, pS47; ROSENBLUM IY, 1977, CALC TISS RES, V23, P151, DOI 10.1007/BF02012781; SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; Semenkovich CF, 1998, J LIPID RES, V39, P1141; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Srivatsa SS, 1997, J CLIN INVEST, V99, P996, DOI 10.1172/JCI119265; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; VIRCHOW R, 1856, WIEN MED WOCHENSCHR, V6, P825; Zuanetti G, 1997, CIRCULATION, V96, P4239	37	210	218	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30427	30434		10.1074/jbc.273.46.30427	http://dx.doi.org/10.1074/jbc.273.46.30427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804809	hybrid			2022-12-25	WOS:000077008100056
J	Abu-Amer, Y; Ross, FP; McHugh, KP; Livolsi, A; Peyron, JF; Teitelbaum, SL				Abu-Amer, Y; Ross, FP; McHugh, KP; Livolsi, A; Peyron, JF; Teitelbaum, SL			Tumor necrosis factor-alpha activation of nuclear transcription factor-kappa B in marrow macrophages is mediated by c-Src tyrosine phosphorylatiola of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; INDUCIBLE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; BONE-RESORPTION; KINASE; TNF; PROTEINS; MICE	Tumor necrosis factor-alpha (TNF) exerts its transcriptional effects via activation of nuclear transcription factor-kappa B (NF-kappa B), NF-kappa B is sequestered in the cytosol by I kappa B alpha and, in most cells, released upon serine phosphorylation of this inhibitory protein which then undergoes rapid, ubiquitin-dependent degradation. In contrast, we find TNF induction of NF-kappa B in murine bone marrow macrophages (BMMs), is mediated, by c-Src, in a cell, and cytokine specific manner. The non-receptor tyrosine kinase is rapidly mobilized and activated upon TNF exposure. Within the same time frame, TNF induced c-Src associates with I kappa B alpha in a long lived complex. The proto-oncogene, when associated with I kappa B alpha phosphorylates the inhibitory protein on tyrosine 42. Consistent with the pivotal role played by c-Src in TNF-induced I kappa B alpha tyrosine phosphoryhtion, NF-kappa B activation, by the cytokine, is markedly delayed and reduced in c-src-/-BMMs. Underscoring the physiological significance of c-Src activation of NF-kappa B, TNF induction of IL-6, which is an NF-kappa B mediated event, is substantially diminished in c-src-/-BMMs.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Fac Med Pasteur, INSERM, CJF 95 05, F-06107 Nice 2, France	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp N, Dept Pathol, 216 S Kingshighway, St Louis, MO 63110 USA.	abuamery@medicine.wustl.edu	Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X; Teitelbaum, Steven/0000-0002-4054-6679				AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLOHISY DR, 1989, J BIOL CHEM, V264, P5370; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DROUET C, 1991, J IMMUNOL, V147, P1694; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOONG AC, 1994, CANCER RES, V54, P5273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebleu B, 1996, TRENDS BIOTECHNOL, V14, P109, DOI 10.1016/0167-7799(96)30005-X; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; PASSERI G, 1994, BONE MINER, V24, P109, DOI 10.1016/S0169-6009(08)80149-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TEITELBAUM SL, 1995, J CELL BIOCHEM, V59, P1, DOI 10.1002/jcb.240590102; Teitelbaum Steven L., 1996, P61; Tetsuka T, 1996, BIOCHEM BIOPH RES CO, V218, P808, DOI 10.1006/bbrc.1996.0144; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEBER C, 1995, J IMMUNOL, V155, P445; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yanagihara Y, 1996, J ALLERGY CLIN IMMUN, V98, pS224, DOI 10.1016/S0091-6749(96)70070-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	61	127	128	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29417	29423		10.1074/jbc.273.45.29417	http://dx.doi.org/10.1074/jbc.273.45.29417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792645	hybrid			2022-12-25	WOS:000076798300022
J	Deora, AA; Win, T; Vanhaesebroeck, B; Lander, HM				Deora, AA; Win, T; Vanhaesebroeck, B; Lander, HM			A redox-triggered Ras-effector interaction - Recruitment of phosphatidylinositol 5 '-kinase to Ras by redox stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; FREE-RADICALS; KINASE; 3-KINASE; ACTIVATION; P21(RAS); TRANSFORMATION; TRANSCRIPTION	Reactive free radical species are known to trigger biochemical events culminating in transcription factor activation and modulation of gene expression. The cytosolic signaling events triggered by free radicals that result in nuclear responses are largely unknown. Here we identify a signaling cascade triggered immediately upon redox activation of Ras. We examined two physiologically relevant models of redox signaling: 1) nitric oxide in human T cells, and 2) advanced glycation end product in rat pheochromocytoma cells. Reactive free radical species generated by nitric oxide donors and the interaction of advanced glycation end product with its receptor led to the recruitment of p85/p110 phosphatidylinositol 3'-kinase (PI3K) to the plasma membrane, where it associated directly with the effector domain of Ras and became activated. Only the p110 beta and p110 delta (but not p110 alpha) catalytic subunits were recruited by redox-activated Ras. Activation of downstream targets of PI3K such as protein kinase B/Akt and mitogen-activated protein kinase was found to be PI3K dependent. Our study demonstrates that nitrosative and oxidative stressors trigger Ras-dependent and PI3K-regulated events in cells and define a biochemical pathway that is triggered by redox signaling.	Cornell Univ, Dept Biochem, Coll Med, New York, NY 10021 USA; Ludwig Inst Canc Res, London W1P 8BT, England	Cornell University; Ludwig Institute for Cancer Research	Lander, HM (corresponding author), Cornell Univ, Dept Biochem, Coll Med, New York, NY 10021 USA.	hmlander@mail.med.cornell.edu			NIAID NIH HHS [AI37637] Funding Source: Medline; NIGMS NIH HHS [GM55509] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055509] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yanagihara Y, 1997, CELL IMMUNOL, V176, P66, DOI 10.1006/cimm.1996.1071; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	34	158	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29923	29928		10.1074/jbc.273.45.29923	http://dx.doi.org/10.1074/jbc.273.45.29923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792710	hybrid			2022-12-25	WOS:000076798300087
J	Gama, L; Breitwieser, GE				Gama, L; Breitwieser, GE			A carboxyl-terminal domain controls the cooperativity for extracellular Ca2+ activation of the human calcium sensing receptor - A study with receptor green fluorescent protein fusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PUTATIVE PHEROMONE RECEPTORS; CA2+-SENSING RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; COUPLED RECEPTORS; MULTIGENE FAMILY; RAT; CELLS; PHOSPHORYLATION	Calcium sensing receptors are part of a growing G protein coupled receptor family, which includes metabotropic glutamate, gamma-aminoisobutyric acid, and pheromone receptors. The distinctive structural features of this family include large extracellular domains that bind agonist and large intracellular, carboxyl-terminal domains of as yet undefined function(s). We have explored the contribution(s) of the carboxyl terminus of the human calcium sensing receptor (CaR) by assessing extracellular Ca2+-mediated changes in intracellular Ca2+ in individual HEK-293 cells transfected with CaR clones. In-frame fusion of EGFP to the carboxyl terminus of CaR had no effect on either the dose response for extracellular Ca2+ activation or CaR desensitization. Carboxyl-terminal truncations, fused in-frame with EGFP (CaR Delta 1024-EGFP, CaR Delta 908-EGFP, CaR Delta 886-EGFP, and CaR Delta 868-EGFP), were assessed for alterations in Ca2+-dependent activation or desensitization. Significant effects on the dose-response relation for extracellular Ca2+ were observed only for the CaR Delta 868 truncation, which exhibited a decreased affinity for extracellular Ca2+ and a decrease in the apparent cooperativity for Ca2+-dependent activation. The alterations in extracellular Ca2+ affinity and cooperativity observed with CaR Delta 868 were recapitulated by a point mutation, T876D, in the full-length CaR-EGFP background. All truncations with wild type dose-response relations exhibited desensitization time courses that were comparable to the full-length CaR, whereas the CaR Delta 868 receptor desensitized completely after two exposures to 10 mM Ca2+. Interestingly, the CaR point mutation T876D exhibited desensitization comparable to wild type CaR, suggesting that this mutation specifically modifies CaR cooperativity. In conclusion, these studies suggest that amino acid residues between 868 and 886 are critical to the apparent cooperativity of Ca2+-mediated activation of G proteins and to CaR desensitization.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Breitwieser, GE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	gbreitwi@welchlink.welch.jhu.edu		Breitwieser, Gerda/0000-0001-9081-0362; Gama, Lucio/0000-0001-9511-012X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1988, J GEN PHYSL S, V44, P251; Chattopadhyay N, 1997, DEV BRAIN RES, V100, P13, DOI 10.1016/S0165-3806(97)00009-6; Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; Ferguson SSG, 1997, NEWS PHYSIOL SCI, V12, P145; Flor PJ, 1996, J NEUROCHEM, V67, P58; Gama L, 1997, AM J PHYSIOL-CELL PH, V273, pC1168, DOI 10.1152/ajpcell.1997.273.4.C1168; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Grady EF, 1997, AM J PHYSIOL-GASTR L, V273, pG586, DOI 10.1152/ajpgi.1997.273.3.G586; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hinson TK, 1997, GENOMICS, V45, P279, DOI 10.1006/geno.1997.4943; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; Kallay E, 1997, BIOCHEM BIOPH RES CO, V232, P80, DOI 10.1006/bbrc.1997.6225; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Nakahara K, 1997, J NEUROCHEM, V69, P1467; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Shui Z, 1998, J PHYSIOL-LONDON, V507, P325, DOI 10.1111/j.1469-7793.1998.325bt.x; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; TOTA MR, 1990, MOL PHARMACOL, V37, P996; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178	47	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29712	29718		10.1074/jbc.273.45.29712	http://dx.doi.org/10.1074/jbc.273.45.29712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792684	hybrid			2022-12-25	WOS:000076798300061
J	Mesonero, JE; Gloor, SM; Semenza, G				Mesonero, JE; Gloor, SM; Semenza, G			Processing of human intestinal prolactase to an intermediate form by furin or by a furin-like proprotein convertase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; SUBTILISIN-LIKE PROTEASE; PHLORIZIN HYDROLASE; ENDOPLASMIC-RETICULUM; MICROVILLAR PROTEINS; PROTEOLYTIC CLEAVAGE; LACTOSE-INTOLERANCE; SUCRASE-ISOMALTASE; EPITHELIAL-CELLS; MOUSE FURIN	Human lactase-phlorizin hydrolase (human-LPH) is synthesized as a large precursor (prepro-LPH), then cleaved to a pro-LPH of 220 kDa which is further cut to a "mature-like LPH" of a size close to that of mature LPH, i.e. about 150 kDa (in the processing of rabbit pro-LPH the intermediate has a mass of approximately 180 kDa). By coexpression of human prepro-LPH with furin in COS-7 cells we show that furin generates a mature-like LPH. Radioactive amino acid sequence analysis reveals that furin recognizes the motif R-T-P-R-832, a protein convertase consensus, to generate a NH2 terminus located 36 amino acids upstream of the NH2 terminal found in vivo at Ala(869). This intermediate is ultimately cleaved to the mature LPH form by other proteases including the pancreatic ones. These data demonstrate that human pro-LPH, like the rabbit enzyme, is processed to the mature enzyme by furin or furin-like enzymes through at least an intermediate form that has, however, an apparent mass close to that of the mature enzyme.	Univ Milan, Dipartimento Chim & Biochim Med, I-20133 Milan, Italy; ETH Zentrum, Swiss Fed Inst Technol, Dept Biochem, CH-8092 Zurich, Switzerland	University of Milan; Swiss Federal Institutes of Technology Domain; ETH Zurich	Semenza, G (corresponding author), Univ Milan, Dipartimento Chim & Biochim Med, I-20133 Milan, Italy.		Mesonero, Jose Emilio J.E./A-2172-2009	Mesonero, Jose Emilio J.E./0000-0003-4758-3998				ALPERS DH, 1975, BIOCHIM BIOPHYS ACTA, V401, P28, DOI 10.1016/0005-2736(75)90338-7; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANIELSEN EM, 1990, BIOCHEMISTRY-US, V29, P305, DOI 10.1021/bi00453a042; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DULUC I, 1991, GENE, V103, P275, DOI 10.1016/0378-1119(91)90286-K; GRUNBERG J, 1995, ARCH BIOCHEM BIOPHYS, V323, P367, DOI 10.1006/abbi.1995.9952; HADDAD P, 1993, CYTOTOXIC CELLS RECO, P251; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jacob R, 1996, EUR J BIOCHEM, V236, P789, DOI 10.1111/j.1432-1033.1996.t01-1-00789.x; KELLER P, 1995, AM J PHYSIOL-GASTR L, V268, pG41, DOI 10.1152/ajpgi.1995.268.1.G41; KELLER P, 1995, J BIOL CHEM, V270, P25722, DOI 10.1074/jbc.270.43.25722; KELLER P, 1992, FEBS LETT, V313, P265, DOI 10.1016/0014-5793(92)81206-2; KELLER P, 1995, FEBS LETT, V368, P563, DOI 10.1016/0014-5793(95)00679-4; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MANTEI N, 1988, EMBO J, V7, P2075; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; Naim HY, 1996, EUR J CELL BIOL, V70, P198; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROSSI M, 1993, FEBS LETT, V336, P299, DOI 10.1016/0014-5793(93)80824-E; ROSSI M, 1992, FEBS LETT, V313, P260, DOI 10.1016/0014-5793(92)81205-Z; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WACKER H, 1992, J BIOL CHEM, V267, P18744; Wuthrich M, 1996, ARCH BIOCHEM BIOPHYS, V336, P27, DOI 10.1006/abbi.1996.0528; Wuthrich M, 1997, FEBS LETT, V405, P321, DOI 10.1016/S0014-5793(97)00206-8; Zecca L, 1998, FEBS LETT, V435, P225, DOI 10.1016/S0014-5793(98)01076-X; ZECCA L, 1997, THESIS SWISS FEDERAL	54	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29430	29436		10.1074/jbc.273.45.29430	http://dx.doi.org/10.1074/jbc.273.45.29430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792647	Green Published, hybrid			2022-12-25	WOS:000076798300024
J	Ozawa, M				Ozawa, M			Identification of the region of alpha-catenin that plays an essential role in cadherin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; PLAKOGLOBIN GAMMA-CATENIN; BETA-CATENIN; ACTIN-BINDING; F-ACTIN; POSSIBLE INVOLVEMENT; CYTOPLASMIC DOMAIN; COMPLEX; ASSOCIATION; EXPRESSION	alpha-Catenin is an intrinsic component of the cadherin adhesion complex and is a 102-kDa protein with multiple interaction sites, including homodimerization sites, and binding sites for beta- and gamma-catenin (plakoglobin), alpha-actinin, and actin. Besides the binding to beta- or gamma-catenin, it is unknown, however, which interaction is critical for the function of cadherins, By expressing a series of E-cadherin-alpha-catenin chimeric molecules on leukemia cells (K562), we have identified the region of alpha-catenin that confers aggregation inducing activity to nonfunctional tail-less E-cadherin, The region has been mapped to the carboxyl-terminal 295 amino acids of alpha-catenin, Consistent with this result, expression in alpha-catenin-deficient cells (DLD-1/Delta alpha) of a mutant alpha-catenin molecule consisting of the amino-terminal beta-/gamma-catenin-binding site and the carboxyl-terminal cell adhesion region identified in the above experiments induced E-cadherin-mediated cell aggregation and compaction. Cells expressing E-cadherin chimeric molecules with the homologous carboxyl-terminal region of vinculin, which contains the actin-binding site of vinculin, did not, however, aggregate as strongly as ones expressing E-cadherin-alpha-catenin chimeric molecules.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan.	mozawa@med2.kufm.kagoshima-u.ac.jp		Ozawa, Masayuki/0000-0002-7887-8441				ABERLE H, 1994, J CELL SCI, V107, P3655; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1992, J CELL SCI, V103, P719; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Huber O, 1997, J CELL SCI, V110, P1759; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nieset JE, 1997, J CELL SCI, V110, P1013; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Obama H, 1997, J BIOL CHEM, V272, P11017; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1995, J BIOCHEM-TOKYO, V118, P1077, DOI 10.1093/jb/118.5.1077; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247	38	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29524	29529		10.1074/jbc.273.45.29524	http://dx.doi.org/10.1074/jbc.273.45.29524			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792660	hybrid			2022-12-25	WOS:000076798300037
J	Suzuki, F; Goto, M; Sawa, C; Ito, S; Watanabe, H; Sawada, J; Handa, H				Suzuki, F; Goto, M; Sawa, C; Ito, S; Watanabe, H; Sawada, J; Handa, H			Functional interactions of transcription factor human GA-binding protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY LATEX-PARTICLES; FACTOR E4TF1; HUMAN-CHROMOSOME; 2 SUBUNITS; ETS; PROMOTER; GENE; PURIFICATION; ACTIVATION; IDENTIFICATION	The transcription factor human GA-binding protein (hGABP) is composed of two subunits, the Ets-related hGABP alpha, which binds to a specific DNA sequence, and either one of two hGABP alpha-associated subunits, hGABP beta or hGABP gamma, The DNA-binding protein hGABP alpha cannot affect transcription by itself, but can modify hGABP-dependent transcription in vitro and in vivo in the presence of its associated subunits. In this study, co-transfection assays showed that the ratio of hGABP beta to hGABP gamma affected transcription from a promoter containing hGABP binding sites. Biochemical analysis showed that they bind to hGABP alpha competitively, indicating that the ratio of hGABP beta to hGABP gamma is important for hGABP complex formation, Kinetic analysis of the protein-protein interaction using the surface plasmon resonance system showed that hGABP alpha binds to hGABP beta or hGABP gamma with similar equilibrium constants. Kinetic analysis of the DNA-hGABP interaction showed that the binding of hGABP gamma to hGABP alpha stabilized the interaction of hGABP alpha with its DNA binding site. In addition, the kinetic analysis revealed that this was due to a slower dissociation of the protein complex from the DNA. These results suggest that hGABP alpha-associated subunits influence the DNA binding stability of hGABP alpha and regulate hGABP-mediated transcription by competing with each other.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021	Watanabe, Hajime/0000-0001-9657-6554				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bachman NJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P152, DOI 10.1006/abbi.1996.0376; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; Goto M, 1995, GENE, V166, P337, DOI 10.1016/0378-1119(95)00575-7; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; INOMATA Y, 1994, J BIOMAT SCI-POLYM E, V5, P293, DOI 10.1163/156856294X00031; INOSTROZA JA, 1992, CELL, V70, P477; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; MERNO A, 1994, NATURE, V365, P227; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SAWADA J, 1995, JPN J CANCER RES, V86, P10, DOI 10.1111/j.1349-7006.1995.tb02981.x; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	32	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29302	29308		10.1074/jbc.273.45.29302	http://dx.doi.org/10.1074/jbc.273.45.29302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792629	hybrid			2022-12-25	WOS:000076798300006
J	Natter, S; Seiberler, S; Hufnagl, P; Binder, BR; Hirschl, AM; Ring, J; Abeck, D; Schmidt, T; Valent, P; Valenta, R				Natter, S; Seiberler, S; Hufnagl, P; Binder, BR; Hirschl, AM; Ring, J; Abeck, D; Schmidt, T; Valent, P; Valenta, R			Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients	FASEB JOURNAL			English	Article						IgE autoimmunity; cDNA cloning; expression in Escherichia coli	BIRCH POLLEN ALLERGEN; FC-EPSILON-RI; II KERATIN; CELLS; PROFILIN; SEQUENCE; IDENTIFICATION; PROTEINS; ACTIN; GENE	Recently we demonstrated that a high percentage of atopic dermatitis (AD) patients displayed specific immunoglobulin E reactivity to human proteins. Here we show that IgE autoreactivity is found predominantly in AD patients with severe skin manifestations and reveal the molecular mature of four IgE autoantigens, An expression cDNA library constructed from a human epithelial cell line (A 431) was screened with serum IgE from two AD patients. DNA sequence analysis of three IgE-reactive domes identified the alpha-chain of the nascent polypeptide-associated complex, cytokeratin type II, and the BCL7B oncogen as atopy-related IgE; autoantigens (ara). The fourth cDNA coded for an IgE autoantigen containing a typical calcium binding motif that occurred in histogenetically different cells and tissues (keratinocytes, muscle, brain). Recombinant Escherichia coli-expressed IgE autoantigens bound IgE from AD but not from patients with other immunologically mediated disorders (graft vs. host disease, systemic lupus erythematosus) and elicited immediate type skin reactions in AD patients. In serum samples collected from an AD patient over a period of 5 years, IgE anti-ara NAC antibody levels peaked during disease exacerbation. Our finding that ara BCL7B was detected in serum bound to ISE antibodies suggests that intracellular IgE autoantigens can become released after tissue damage and may occur as IgE immune complexes, Via binding to antigen presenting cells as well as to effector cells, IgE autoantigen immune complexes may contribute to exacerbation and/or perpetuation of severe atopic diseases even in the absence of exogenous allergens.	Univ Vienna, AKH, Dept Gen & Expt Pathol, Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Clin Microbiol, A-1090 Vienna, Austria; Tech Univ Munich, GSF, Dermatol Clin, D-8000 Munich, Germany; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Vienna	Valenta, R (corresponding author), Univ Vienna, AKH, Dept Gen & Expt Pathol, Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, Test/Y-7921-2019; Ring, Johannes/GLN-4341-2022; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Ring, Johannes/0000-0001-8236-3152; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365				Ausubel FM., 1988, CURRENT PROTOCOLS MO; Battey, 1986, BASIC METHODS MOL BI; Berrens L, 1970, Prog Allergy, V14, P259, DOI 10.1159/000289384; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; COOPER KD, 1989, IMMUNE MECHANISMS CU, P247; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GLASS C, 1985, J CELL BIOL, V101, P2366, DOI 10.1083/jcb.101.6.2366; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; HANIFIN JM, 1986, J AM ACAD DERMATOL, V15, P703, DOI 10.1016/S0190-9622(86)80097-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LEUNG DYM, 1993, CURR OPIN IMMUNOL, V5, P956, DOI 10.1016/0952-7915(93)90112-6; Leung DYM, 1993, DERMATOLOGY GEN MED, P1543; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Ring J, 1996, ALLERGY, V51, P206, DOI 10.1111/j.1398-9995.1996.tb04595.x; RUZICKA T, 1991, HDB ATOPIC ECEMA; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; Simon F, 1944, J ALLERGY, V15, P338, DOI DOI 10.1016/S0021-8707(44)90143-7; SIMON FA, 1947, J INVEST DERMATOL, V9, P329, DOI 10.1038/jid.1947.106; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VALENTA R, 1993, J BIOL CHEM, V268, P22777; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	48	103	110	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1559	1569		10.1096/fasebj.12.14.1559	http://dx.doi.org/10.1096/fasebj.12.14.1559			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806765				2022-12-25	WOS:000076749500015
J	Itoh, S; Landstrom, M; Hermansson, A; Itoh, F; Heldin, CH; Heldin, NE; ten Dijke, P				Itoh, S; Landstrom, M; Hermansson, A; Itoh, F; Heldin, CH; Heldin, NE; ten Dijke, P			Transforming growth factor beta 1 induces nuclear export of inhibitory Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; RECEPTOR; SUPERFAMILY; ANTAGONIST; ACTIVATION; SMAD4/DPC4; MEMBRANE; DNA	Transforming growth factor beta (TGF-beta) signals from membrane to nucleus through serine/threonine kinase receptors and their downstream effector molecules, termed Smad proteins. Recently, Smad6 and Smad7 were identified, which antagonize TGF-beta family signaling by preventing the activation of signal-transducing Smad complexes. Here we report that Smad7, but not Smad6, inhibits TGF-beta 1-induced growth inhibition and the expression of immediate early response genes, including Smad7, Interestingly, in the absence of ligand, Smad7 was found to be predominantly localized in the nucleus, whereas Smad7 accumulated in the cytoplasm upon TGF-beta receptor activation. The latter is in accordance with the physical association of Smad7 with the ligand-activated TGF-beta receptor complex in the cell membrane. Whereas the ectopically expressed C-terminal domain of Smad7 was also exported from the nucleus to the cytoplasm upon TGF-beta challenge, a Smad7 mutant with a small deletion at the C terminus or only the N-terminal domain of Smad7 was localized mainly in the cytoplasm in the absence or presence of ligand, This suggests that an intact Mad homology 2 domain is important for nuclear localization of Smad7, The nuclear localization of Smad7 suggests a functional role distinct from its antagonistic effect in receptor-mediated Smad activation.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden; Univ Uppsala Hosp, Dept Genet & Pathol, Unit Pathol, S-75185 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital	ten Dijke, P (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Fumiko/0000-0002-6134-5331; Landstrom, Marene/0000-0001-6737-7230; Itoh, Susumu/0000-0002-7967-0730				Afrakhte M, 1996, INT J CANCER, V68, P802; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MASSAGUE J, 1998, IN PRESS ANN REV BIO; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	209	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29195	29201		10.1074/jbc.273.44.29195	http://dx.doi.org/10.1074/jbc.273.44.29195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786930	hybrid			2022-12-25	WOS:000076691800091
J	Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA				Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA			hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG	ONCOGENE			English	Article						PTTG; oncogene; transcription; tumorigenesis	SECONDARY-STRUCTURE; IMMUNE PRIVILEGE; PROTEINS; YEAST; GENE; DOMAINS; LIGAND; BRCA1	We have isolated a human cDNA clone encoding a novel protein of 22 kDa that is a human counterpart of the rat oncoprotein PTTG. We show that the corresponding gene (hpttg) is overexpressed in Jurkat cells (a human T lymphoma cell line) and in samples from patients with different kinds of hematopoietic malignancies. Analysis of the sequence showed that hPTTG has an aminoterminal basic domain and a carboxyl-terminal! acidic domain, and that it is a proline-rich protein with several putative SH3-binding sites, Subcellular fractionation studies show that, although hPTTG is mainly a cytosolic protein, it is partially localized in the nucleus. In addition we demonstrate that the acidic carboxyl-terminal region of hPTTG acts as a transactivation domain when fused to a heterologous DNA binding domain, both in yeast and in mammalian cells.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain; Hop Cochin, Hematol Serv, F-75015 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); University of Sevilla; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Romero, Francisco/K-2101-2014; Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; rios, rosa m/G-5742-2015	Romero, Francisco/0000-0002-9588-6881; Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; rios, rosa m/0000-0001-5778-6946				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RamosMorales F, 1997, BIOCHEM BIOPH RES CO, V237, P735, DOI 10.1006/bbrc.1997.7221; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SETH A, 1992, J BIOL CHEM, V267, P24796; Sherman F., 1986, METHODS YEAST GENETI; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	39	163	185	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2187	2193		10.1038/sj.onc.1202140	http://dx.doi.org/10.1038/sj.onc.1202140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811450				2022-12-25	WOS:000076698200005
J	Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R				Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R			Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein	ONCOGENE			English	Article						BRCA1; breast cancer; RING domain; BRCT domain; tumor suppressor	CANCER SUSCEPTIBILITY GENE; BREAST-CANCER; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; EXPRESSION PATTERN; FAMILIAL BREAST; MESSENGER-RNA; MURINE BRCA1; DNA-DAMAGE; SEQUENCE	The BRCA1 gene encodes a tumor suppressor that has been implicated in hereditary forms of breast and ovarian cancer. During S phase of the cell cycle, BRCA1 polypeptides are found in discrete nuclear bodies ('BRCA1 nuclear dots') together with HsRad51, a human homolog of the E. coli recA protein, and BARD1, a protein that interacts with BRCA1 to form a stable heterodimer. BARD1 is structurally similar to BRCA1 in that both molecules harbor an amino-terminal RING domain and two carboxy-terminal BRCT domains. Here we describe the amino acid sequence and expression pattern of murine Bard1. A comparison of the mouse and human sequences reveals that the recognizable protein motifs of BARD1 are well conserved, including the RING domain, the three tandem ankyrin repeats, and, to a lesser extent, the two BRCT domains. However, the remaining sequences of BARD1 display a markedly lower degree of phylogenetic conservation, comparable to those reported for BRCA1 and BRCA2. Moreover, murine Bard1 retains the ability to associate in vivo with BRCA1, and its expression pattern in adult mice mirrors that of Brca1, with elevated levels of RNA transcripts found in the testes and spleen. These data suggest that BRCA1 and BARD1 have co-evolved to participate in a common pathway of tumor suppression.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Baer, R (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Bowcock, Anne/0000-0001-8691-9090	NATIONAL CANCER INSTITUTE [R01CA076334, R01CA060650] Funding Source: NIH RePORTER; NCI NIH HHS [CA76334, CA60650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bertwistle D, 1997, CANCER RES, V57, P5485; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zabludoff SD, 1996, ONCOGENE, V13, P649	48	33	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2143	2148		10.1038/sj.onc.1202123	http://dx.doi.org/10.1038/sj.onc.1202123			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798686				2022-12-25	WOS:000076540900014
J	Dong, JF; Gao, S; Lopez, JA				Dong, JF; Gao, S; Lopez, JA			Synthesis, assembly, and intracellular transport of the platelet glycoprotein Ib-IX-V complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER-SYNDROME; VON-WILLEBRAND-FACTOR; ACTIN-BINDING PROTEIN; CELL ANTIGEN RECEPTOR; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; BETA-CHAINS; ALPHA; EXPRESSION; IDENTIFICATION	The platelet glycoprotein lb-M-V complex plays critical roles in adhering platelets to sites of blood vessel injury and in platelet aggregation under high fluid shear stress. The complex is composed of four membrane-spanning polypeptides: glycoprotein (GP) Ib alpha, GP lb beta, GP IX, and GP V, Glycoprotein lb alpha contains a binding site for von Willebrand factor through which it mediates platelet adhesion; GP V is required for the complex to bind thrombin with high affinity; and both GP Ib beta and GP IX are necessary for efficient plasma membrane expression of the complex. To further define the roles of the individual polypeptide subunits in the biosynthesis and intracellular transport of the GP fb-M-V complex, we studied full and partial complexes expressed in heterologous mammalian cells. We found that the full complex was formed within minutes in the endoplasmic reticulum before being transported into the Golgi cisternae, Approximately 160 min were required for the complex to be fully processed and to appear on the plasma membrane. About 25% of GP Iba expressed as part of either a GP Ib-IX complex or a GP Ib-M-V complex was degraded through a nonlysosomal pathway, Over 60% of GP Ib alpha, however, was degraded when it was expressed in partial complexes with only GP Ib beta or GP IX, The increased degradation was blocked by treating cells either with brefeldin A to prevent the transport of proteins from the endoplasmic reticulum to the Golgi or with lysosomal inhibitors, indicating that GP Iba expressed in partial complexes was targeted to the lysosomes for degradation. These results indicate that the presence of both GP Ib beta and GP IX, but not the presence of GP V, is required for efficient processing and targeting of GP Iba to the plasma membrane. Absence of either GP Ib beta or GP IX increased the rate of GP Ib alpha degradation, providing an explanation for why mutation of their genes leads to deficient GP Iba expression and platelet adhesion in Bernard-Soulier syndrome, the deficiency disorder of the complex.	Vet Affairs Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Internal Med, Div Hematol Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Baylor College of Medicine	Dong, JF (corresponding author), Vet Affairs Med Ctr, Res 151,2002 Holcombe Blvd,Bldg 110,Rm 160, Houston, TX 77030 USA.				NHLBI NIH HHS [HL46416] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALBERTS B, 1989, MOL BIOL CELL, P201; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; BUDARF ML, 1995, HUM MOL GENET, V4, P763, DOI 10.1093/hmg/4.4.763; CALVERLEY DC, 1995, BLOOD, V86, P1361, DOI 10.1182/blood.V86.4.1361.bloodjournal8641361; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CLEMETSON JM, 1994, BLOOD, V84, P1124; CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P51; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; DU XP, 1987, BLOOD, V69, P1524; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FOX JEB, 1989, J BIOL CHEM, V264, P9520; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KOIDE N, 1974, J BIOL CHEM, V249, P4897; KORREL SAM, 1984, EUR J BIOCHEM, V140, P571, DOI 10.1111/j.1432-1033.1984.tb08140.x; Kroll MH, 1996, BLOOD, V88, P1525; Kunishima S, 1997, BLOOD, V89, P2404, DOI 10.1182/blood.V89.7.2404; LANZA F, 1993, J BIOL CHEM, V268, P20801; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MADOFF MA, 1964, J CLIN INVEST, V43, P870, DOI 10.1172/JCI104972; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SOLUM NO, 1980, BIOCHIM BIOPHYS ACTA, V597, P235, DOI 10.1016/0005-2736(80)90102-9; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; Tsuji S, 1996, BLOOD, V88, P3854, DOI 10.1182/blood.V88.10.3854.bloodjournal88103854; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WRIGHT SD, 1993, BLOOD, V81, P2339	47	52	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31449	31454		10.1074/jbc.273.47.31449	http://dx.doi.org/10.1074/jbc.273.47.31449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813057	hybrid			2022-12-25	WOS:000077136900085
J	Taylor, R; Burgner, JW; Clifton, J; Cramer, WA				Taylor, R; Burgner, JW; Clifton, J; Cramer, WA			Purification and characterization of monomeric Escherichia coli vitamin B-12 receptor with high affinity for colicin E3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC ENTEROBACTIN RECEPTOR; CIRCULAR DICHROIC ANALYSIS; OUTER-MEMBRANE; POLYACRYLAMIDE GELS; TRANSPORT; PROTEIN; BINDING; BTUB; TONB; CHANNEL	The btuB gene product from Escherichia coli is a 66.5-kDa integral outer membrane protein required for high-affinity uptake of cyanocobalamin and the translocation of E group colicins and colicin A. Efficient purification of overexpressed BtuB containing stoichiometric levels of bound lipopolysaccharide has been achieved through the extraction of the outer membrane with nonionic detergent followed by ion-exchange chromatography. Analysis of far UV circular dichroism spectra indicates a predominantly beta-sheet secondary structure (76 +/- 4%) with a low alpha-helical content (15 +/- 3%), providing the first direct evidence for secondary structure models derived from sequence and hydropathy analysis. Characterization of the octylglucoside-solubilized receptor by sedimentation equilibrium and sedimentation velocity analysis reveals a monodisperse protein-detergent complex of approximately 89 kDa with a sedimentation coefficient of 4.7 S which, after correction for bound detergent, indicates that BtuB is purified as a monomer. BtuB binds vitamin B-12 with a stoichiometry of approximately 1:1, as observed by a shift in the sedimentation profile of the vitamin to the much faster velocity observed for the protein-detergent complex. The preincubation of colicin E3 with stoichiometric levels of BtuB protects susceptible strains from the lethal effects of the colicin and results in a complex with a sedimentation coefficient appropriate for a BtuB-detergent-colicin E3 complex, demonstrating that monomeric BtuB retains high affinity for this particular ligand after isolation.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Brandeis University	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, 1392 Lilly Hall, W Lafayette, IN 47907 USA.		Clifton, James/C-7289-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045756, R01GM018457] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-08296, GM 45756, GM-18457] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1996, CIRCULAR DICHROISM C; APICELLA MA, 1994, METHOD ENZYMOL, V235, P242; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BRADBEER C, 1990, J BACTERIOL, V172, P4919, DOI 10.1128/jb.172.9.4919-4926.1990; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CAVARD D, 1994, FEMS MICROBIOL LETT, V116, P37; CAVARD D, 1981, FEMS MICROBIOL LETT, V12, P311; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLIFTON J, 1991, THESIS YALE U; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; GUDMUNDSDOTTIR A, 1988, J BIOL CHEM, V263, P14224; HELLER K, 1985, J BACTERIOL, V161, P896, DOI 10.1128/JB.161.3.896-903.1985; HUFTON SE, 1995, MOL MICROBIOL, V15, P381, DOI 10.1111/j.1365-2958.1995.tb02251.x; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; IMAJOH S, 1982, J BIOL CHEM, V257, P6481; JAKES KS, 1974, P NATL ACAD SCI USA, V71, P3380, DOI 10.1073/pnas.71.9.3380; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; Locher KP, 1997, EUR J BIOCHEM, V247, P770, DOI 10.1111/j.1432-1033.1997.t01-1-00770.x; LUDWIG B, 1982, J BIOL CHEM, V257, P5576; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MANENTI S, 1988, FEBS LETT, V233, P148, DOI 10.1016/0014-5793(88)81373-5; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NIKAIDO H, 1993, J BIOENERG BIOMEMBR, V25, P581; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROCQUE WJ, 1987, J BACTERIOL, V169, P4003, DOI 10.1128/jb.169.9.4003-4010.1987; SABET SF, 1973, J BIOL CHEM, V248, P1797; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VENYAMINOV SY, 1993, ANAL BIOCHEM, V214, P17, DOI 10.1006/abio.1993.1450; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	47	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31113	31118		10.1074/jbc.273.47.31113	http://dx.doi.org/10.1074/jbc.273.47.31113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813013	hybrid			2022-12-25	WOS:000077136900041
J	Tong, YZ; Liu-Chen, XY; Ercikan-Abali, EA; Zhao, SC; Banerjee, D; Maley, F; Bertino, JR				Tong, YZ; Liu-Chen, XY; Ercikan-Abali, EA; Zhao, SC; Banerjee, D; Maley, F; Bertino, JR			Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis - Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROFOLATE-REDUCTASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; LACTOBACILLUS-CASEI; INHIBITORS; MECHANISM; DESIGN; EXPRESSION; SUBSTRATE; 1843U89	Human thymidylate synthase (TS) contains three highly conserved residues Ile-108, Leu-221, and Phe-225 that have been suggested to be important for cofactor and antifolate binding. To elucidate the role of these residues and generate drug-resistant human TS mutants, 14 variants with multiple substitutions of these three hydrophobic residues were created by site-directed mutagenesis and transfected into mouse TS-negative cells for complementation assays and cytotoxicity studies, and the mutant proteins expressed and characterized, The I108A mutant confers resistance to raltitrexed and Thymitaq with respective IC50 values 54- and 80-fold greater than wild-type but less resistance to BW1843U89 (6-fold). The F225W mutant displays resistance to BW1843U89 (17-fold increase in IC50 values), but no resistance to raltitrexed and Thymitaq, It also confers 8-fold resistance to fluorodeoxyuridine. Both the kinetic characterization of the altered enzymes and formation of antifolate-resistant colonies in mouse bone marrow cells that express mutant TS are in accord with the IC50 values for cytotoxicity noted above. The human TS mutants (I108A and F225W), by virtue of their desirable properties, including good catalytic function and resistance to antifolate TS inhibitors, confirm the importance of amino acid residues Ile-108 and Phe-225 in the binding of folate and its analogues, These novel mutants may be useful for gene transfer experiments to protect hematopoietic progenitor cells from the toxic effects of these drugs.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; New York State Dept Hlth, Albany, NY 12201 USA	Memorial Sloan Kettering Cancer Center; Cornell University; State University of New York (SUNY) System	Bertino, JR (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, 1275 York Ave,Box 78, New York, NY 10021 USA.	bertinoj@mskcc.org			NCI NIH HHS [CA 08010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008010, R37CA008010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; AYUSAWA D, 1981, SOMAT CELL GENET, V7, P523, DOI 10.1007/BF01549656; BANERJEE D, 1994, CANCER GENE THER, V1, P181; BANERJEE D, 1994, STEM CELLS, V14, P5; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CIESLA J, 1995, BBA-GENE STRUCT EXPR, V1261, P233, DOI 10.1016/0167-4781(95)00008-5; DEV IK, 1994, J BIOL CHEM, V269, P1873; DUCH DS, 1993, CANCER RES, V53, P810; FAUMAN EB, 1994, BIOCHEMISTRY-US, V33, P1502, DOI 10.1021/bi00172a029; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; GALIVAN JH, 1976, BIOCHEMISTRY-US, V15, P356, DOI 10.1021/bi00647a018; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; JACKMAN AL, 1991, ADV ENZYME REGUL, V31, P13, DOI 10.1016/0065-2571(91)90006-8; Jackman AL, 1995, ANN ONCOL, V6, P871, DOI 10.1093/oxfordjournals.annonc.a059353; JACKMAN AL, 1991, CANCER RES, V51, P5579; JACKMAN AL, 1991, ADV EXP MED BIOL, V309, P19; JODRELL DI, 1991, BRIT J CANCER, V64, P833, DOI 10.1038/bjc.1991.409; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; Kittler ELW, 1997, BLOOD, V90, P865, DOI 10.1182/blood.V90.2.865.865_865_872; Koc ON, 1996, SEMIN ONCOL, V23, P46; LI M, 1992, HUM GENE THER, V3, P381, DOI 10.1089/hum.1992.3.4-381; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; NAKANO T, 1994, BIOCHEMISTRY-US, V33, P9945, DOI 10.1021/bi00199a017; Nord L. Dee, 1993, Current Opinion in Oncology, V5, P1017, DOI 10.1097/00001622-199311000-00012; PedersenLane J, 1997, PROTEIN EXPRES PURIF, V10, P256, DOI 10.1006/prep.1997.0750; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; REICH SH, 1992, J MED CHEM, V35, P847, DOI 10.1021/jm00083a007; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; Stout TJ, 1996, STRUCTURE, V4, P67, DOI 10.1016/S0969-2126(96)00010-X; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Touroutoglou N, 1996, CLIN CANCER RES, V2, P227; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WEBBER SE, 1993, J MED CHEM, V36, P733, DOI 10.1021/jm00058a010; WEICHSEL A, 1995, P NATL ACAD SCI USA, V92, P3493, DOI 10.1073/pnas.92.8.3493; WEICHSEL A, 1995, NAT STRUCT BIOL, V2, P1095, DOI 10.1038/nsb1295-1095	43	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31209	31214		10.1074/jbc.273.47.31209	http://dx.doi.org/10.1074/jbc.273.47.31209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813027	hybrid			2022-12-25	WOS:000077136900055
J	Adams, CM; Snyder, PM; Price, MP; Welsh, MJ				Adams, CM; Snyder, PM; Price, MP; Welsh, MJ			Protons activate brain Na+ channel 1 by inducing a conformational change that exposes a residue associated with neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN DEGENERIN MDEG; CAENORHABDITIS-ELEGANS; ION CHANNELS; SUBUNIT; CLONING; FAMILY; MECHANOSENSATION; EXPRESSION; MEMBER	BNC1 is a mammalian neuronal cation channel in the novel DEG/ENaC ion channel family. BNC1 channels are transiently activated by extracellular protons and are constitutively activated by insertion of large residues, such as valine, in place of Gly-430; residue 430 is a site where analogous mutations in some Caenorhabditis elegans family members cause a swelling neurodegeneration. Mutation of Gly-430 to a small amino acid, cysteine, neither generated constitutive currents nor allowed modification of this residue by sulfhydryl-reactive methanethiosulfonate (MTS) compounds. However, when protons activated the channel, Cys-430 became accessible to extracellular MTS reagents, which modified Cys-430 to generate constitutive currents. Fluorescent MTS reagents also labeled Cys-430 in activated channels. These data indicate that protons induce a reversible conformational change that activates BNC1 thereby exposing residue 430 to the extracellular solution. Once Cys-430 is modified with a large chemical group, the channel is prevented from relaxing back to the inactive state. These results link ligand-dependent activation and activation by mutations that cause neurodegeneration.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.			Adams, Christopher/0000-0002-5795-7212; Welsh, Michael/0000-0002-1646-6206				Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0	23	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30204	30207		10.1074/jbc.273.46.30204	http://dx.doi.org/10.1074/jbc.273.46.30204			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804777	hybrid			2022-12-25	WOS:000077008100024
J	LaCount, MW; Handy, G; Lebioda, L				LaCount, MW; Handy, G; Lebioda, L			Structural origins of L(+)-tartrate inhibition of human prostatic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; REFINEMENT; SUBSTRATE	Acid phosphatase activity in the blood serum is usually separated into tartrate-resistant and tartrate-refractory, which is reported as the prostatic acid phosphatase level, Human prostatic acid phosphatase crystals soaked in N-propyl-L-tartramate were used to collect x-ray diffraction data to 2.9 Angstrom resolution under cryogenic conditions. Positive difference electron density, corresponding to the inhibitor, was found. The quality of the electron density maps clearly shows the orientation of the carboxylate and N-propyl-substituted amide groups. The hydroxyl group attached to C3 forms two crucial hydrogen bonds with Arg-79 and His-257, Previous crystallographic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex (Lindqvist, Y., Schneider, G., and Vihko, P. (1993) J. Biol. Chem, 268, 20744-20746) erroneously positioned D-tartrate into the active site. Modeling studies have shown that the C3 hydroxyl group on the D(-)-stereoisomer of tartrate, which does not significantly inhibit prostatic acid phosphatase, does not form strong hydrogen bonds with Arg-79 or His-257. The structure of human prostatic acid phosphatase, noncovalently bound in N-propyl-L-tartramate, is used to develop inhibitors with higher specificity and potency than L(+)-tartrate.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Lebioda, L (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.							APOSTOL I, 1985, ACTA BIOCHIM POL, V32, P187; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; GUTMAN ETHEL BENEDICT, 1936, AMER JOUR CANCER, V28, P485; KILSHEIMER GS, 1957, J BIOL CHEM, V227, P879; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; LINDQVIST Y, 1993, J BIOL CHEM, V268, P20744; LOVELACE L, 1997, POLISH J BIOCH, V44, P673; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; RONNBERG L, 1981, INT J ANDROL, V4, P372, DOI 10.1111/j.1365-2605.1981.tb00721.x; ROY AV, 1971, CLIN CHEM, V17, P1093; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Shetty S D, 1992, Henry Ford Hosp Med J, V40, P93; *TRIP INC, 1991, SYBYL VERS 6 3 MAN; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1978, CLIN CHEM, V24, P1525; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27	20	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30406	30409		10.1074/jbc.273.46.30406	http://dx.doi.org/10.1074/jbc.273.46.30406			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804805	hybrid			2022-12-25	WOS:000077008100052
J	Rhoads, DM; Umbach, AL; Sweet, CR; Lennon, AM; Rauch, GS; Siedow, JN				Rhoads, DM; Umbach, AL; Sweet, CR; Lennon, AM; Rauch, GS; Siedow, JN			Regulation of the cyanide-resistant alternative oxidase of plant mitochondria - Identification of the cysteine residue involved in alpha-keto acid stimulation and intersubunit disulfide bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN COTYLEDON; CYTOCHROME; RESPIRATION; ACTIVATION; PATHWAYS; PYRUVATE; SUGGESTS; PROTEIN; GENE	The cyanide-resistant alternative oxidase of plant mitochondria is a homodimeric protein whose activity can be regulated by a redox-sensitive intersubunit sulfhydryl/disulfide system and by alpha-keto acids. After determining that the Arabidopsis alternative oxidase possesses the redox-sensitive sulfhydryl/disulfide system, site-directed mutagenesis of an Arabidopsis cDNA clone was used to individually change the two conserved Cys residues, Cys-128 and Cys-78, to Ala. Using diamide oxidation and chemical cross-linking of the protein expressed in Escherichia coli, Cys-78 was shown to be: 1) the Cys residue involved in the sulfhydryl/disulfide system; and 2) not required for subunit dimerization. The C128A mutant was stimulated by pyruvate, while the C78A mutant protein had little activity and displayed no stimulation by pyruvate. Mutating Cys-78 to Glu produced an active enzyme which was insensitive to pyruvate, consistent with alpha-keto acid activation occurring through a thiohemiacetal, These results indicate that Cys-78 serves as both the regulatory sulfhydryl/disulfide and the site of activation by alpha-keto acids. In light of these results, the previously observed effects of sulfhydryl reagents on the alternative oxidase of isolated soybean mitochondria were re-examined and were found to be in agreement with a single sulfhydryl residue being the site both of alpha-keto acid activation and of the regulatory sulfhydryl/disulfide system.	Duke Univ, Dev Cell & Mol Biol Bot Dept, Durham, NC 27708 USA	Duke University	Siedow, JN (corresponding author), Duke Univ, Dev Cell & Mol Biol Bot Dept, Durham, NC 27708 USA.	jsiedow@duke.edu						Berthold DA, 1998, BBA-BIOENERGETICS, V1364, P73, DOI 10.1016/S0005-2728(98)00015-2; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; Hiser C, 1996, PLANT PHYSIOL, V110, P277, DOI 10.1104/pp.110.1.277; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; Ito Y, 1997, GENE, V203, P121, DOI 10.1016/S0378-1119(97)00502-7; KUMAR AM, 1992, P NATL ACAD SCI USA, V89, P10842, DOI 10.1073/pnas.89.22.10842; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERS H, 1982, PHYSIOL PLANTARUM, V55, P478, DOI 10.1111/j.1399-3054.1982.tb04530.x; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LENNON AM, 1995, PLANT PHYSIOL, V107, P925, DOI 10.1104/pp.107.3.925; MEEUSE BJD, 1975, ANNU REV PLANT PHYS, V26, P117, DOI 10.1146/annurev.pp.26.060175.001001; MILLAR AH, 1993, FEBS LETT, V329, P259, DOI 10.1016/0014-5793(93)80233-K; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; PALMER JM, 1976, ANNU REV PLANT PHYS, V27, P133, DOI 10.1146/annurev.pp.27.060176.001025; RHOADS DM, 1994, P NATL ACAD SCI USA, V91, P8253, DOI 10.1073/pnas.91.17.8253; Ribas-Carbo M, 1997, PLANT PHYSIOL, V113, P903, DOI 10.1104/pp.113.3.903; RIBAS-CARBO M, 1995, PLANT PHYSIOL, V109, P829, DOI 10.1104/pp.109.3.829; Saisho D, 1997, PLANT MOL BIOL, V35, P585, DOI 10.1023/A:1005818507743; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASARMAN S, 1968, J BACTERIOL, V96, P570; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; Umbach AL, 1996, J BIOL CHEM, V271, P25019, DOI 10.1074/jbc.271.40.25019; Vanlerberghe GC, 1998, PLANT CELL, V10, P1551, DOI 10.1105/tpc.10.9.1551; VANLERBERGHE GC, 1995, PLANT PHYSIOL, V109, P353, DOI 10.1104/pp.109.2.353; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; WILSON SB, 1988, BIOCHEM J, V249, P301, DOI 10.1042/bj2490301	28	131	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30750	30756		10.1074/jbc.273.46.30750	http://dx.doi.org/10.1074/jbc.273.46.30750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804851	hybrid			2022-12-25	WOS:000077008100098
J	Terayama, K; Seiki, T; Nakamura, A; Matsumori, K; Ohta, S; Oka, S; Sugita, M; Kawasaki, T				Terayama, K; Seiki, T; Nakamura, A; Matsumori, K; Ohta, S; Oka, S; Sugita, M; Kawasaki, T			Purification and characterization of a glucuronyltransferase involved in the biosynthesis of the HNK-1 epitope on glycoproteins from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; L2/HNK-1 CARBOHYDRATE EPITOPE; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONIC-ACID; NEURAL CREST MIGRATION; ADHESION MOLECULE NCAM; NERVOUS-SYSTEM; ALPHA-2->3 SIALYLTRANSFERASE; EXPRESSION; GLUCURONOSYLTRANSFERASE	The glucuronyltransferase involved in the biosynthesis of the HNK-1 epitope on glycoproteins was purified to an apparent homogeneity from the Nonidet P-40 extract of 2-week postnatal rat forebrain by sequential chromatographies on CM-Sepharose CL GB, UDP-GlcA-Sepharose 4B, asialo orosomucoid-Sepharose 4B, Matrex gel Blue A, Mono Q, HiTrap chelating, and HiTrap heparin columns. The purified enzyme migrated as a 45-kDa protein upon SDS-polyacrylamide gel electrophoresis under reducing conditions, but eluted as a 90-kDa protein upon Superose gel filtration in the presence of Nonidet P-40, suggesting that the enzyme forms homodimers under non-denatured conditions. The enzyme transferred glucuronic acid to various glycoprotein accepters bearing terminal N-acetyllactosamine structure such as asialo-orosomucoid, asialo-fetuin, and asialo-neural cell adhesion molecule, whereas little activity was detected to paragloboside, a precursor glycolipid of the HNK-1 epitope on glycolipids, These results suggested that the enzyme is specifically associated with the biosynthesis of the HNK-1 epitope on glycoproteins. Sphingomyelin was specifically required for expression of the enzyme activity. Stearoyl-sphingomyelin (18:0) was the most effective, followed by palmitoyl-sphingomyelin (16:0) and lignoceroyl-sphingomyelin (24:0), Interestingly, activity was demonstrated only for sphingomyelin with a saturated fatty acid, i.e. not for that with an unsaturated fatty acid, regardless of the length of the acyl group.	Kyoto Univ, Fac Pharmaceut Sci, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Pharmaceut Sci, Japan Sci & Technol Corp, CREST, Kyoto 6068501, Japan; Shiga Univ, Fac Educ, Dept Chem, Otsu, Shiga 5200862, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Shiga University	Kawasaki, T (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan.			Terayama, Koji/0000-0002-0740-9074				ABE T, 1974, J NEUROCHEM, V23, P1025, DOI 10.1111/j.1471-4159.1974.tb10755.x; ANTTINEN H, 1976, BIOCHIM BIOPHYS ACTA, V429, P750, DOI 10.1016/0005-2744(76)90322-3; ARIGA T, 1987, J BIOL CHEM, V262, P848; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BRONNERFRASER M, 1987, DEV BIOL, V123, P321, DOI 10.1016/0012-1606(87)90390-3; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FOLCH J, 1951, J BIOL CHEM, V191, P833; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HARA A, 1983, J BIOCHEM-TOKYO, V94, P1715; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; ILYAS AA, 1988, CANCER RES, V48, P1512; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KALLER H, 1961, BIOCHEM Z, V334, P451; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KOPACZYK KC, 1965, J LIPID RES, V6, P140; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MITRANIC MM, 1983, J BIOL CHEM, V258, P8630; NILSSON OS, 1977, BIOCHIM BIOPHYS ACTA, V464, P453, DOI 10.1016/0005-2736(77)90019-0; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OKA S, 1992, J BIOL CHEM, V267, P22711; ONO K, 1992, NEUROSCI RES, V15, P221, DOI 10.1016/0168-0102(92)90008-Z; PUKAZHENTHI BS, 1993, J BIOL CHEM, V268, P6445; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAITO T, 1971, J LIPID RES, V12, P257; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WESTCOTT KR, 1985, J BIOL CHEM, V260, P3109; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731; ZAKIM D, 1988, J BIOL CHEM, V263, P5164	41	38	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30295	30300		10.1074/jbc.273.46.30295	http://dx.doi.org/10.1074/jbc.273.46.30295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804790	hybrid			2022-12-25	WOS:000077008100037
J	Anai, O; Ono, H; Funaki, M; Fukushima, Y; Inukai, K; Ogihara, T; Sakoda, H; Onishi, Y; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T				Anai, O; Ono, H; Funaki, M; Fukushima, Y; Inukai, K; Ogihara, T; Sakoda, H; Onishi, Y; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T			Different subcellular distribution and regulation of expression of insulin receptor substrate (IRS)-3 from those of IRS-1 and IRS-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							60-KDA PHOSPHOTYROSINE PROTEIN; RAT ADIPOSE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; ADIPOCYTES; TRANSLOCATION; MEMBRANE; GLUT4; PHOSPHORYLATION; RESISTANCE	Adipocytes contain three major substrate proteins of the insulin receptor, termed IRS-1, IRS-2, and IRS-3. We demonstrated that IRS-1 and IRS-2 are located mainly in the low density microsome (LDM) fraction and are tyrosine phosphorylated in response to insulin stimulation, leading to phosphatidylinositol (PI) 3-kinase activation. In contrast, IRS-3 is located mainly in the plasma membrane (PM) fraction and contributes to PI 3-kinase activation in the PM fraction. The different cellular localizations of IRS proteins may account for the mechanism of insulin resistance induced by a high fat diet, considering that PI 3-kinase activation in the LDM fraction is reportedly essential for the translocation of GLUT4 in adipocytes. High fat feeding in rats increased both protein and mRNA levels of IRS-3 but decreased those of IRS-1 and IRS-2 in epididymal adipocytes. As a result, selective impairment of insulin-induced PI 3-kinase activation was observed in the LDM fraction, whereas PI 3-kinase activation was conserved in the PM fraction. This is the first report showing that different IRS proteins function in different subcellular compartments, which may contribute to determining the insulin sensitivity in adipocytes.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 116, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 755, Japan	University of Tokyo; Asahi Life Foundation; Yamaguchi University	Asano, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Onishi, Yukiko/AAU-9057-2021	Onishi, Yukiko/0000-0003-1180-5982				Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Camp HS, 1997, J BIOL CHEM, V272, P10811; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; GRUNDLEGER ML, 1982, DIABETES, V31, P232, DOI 10.2337/diabetes.31.3.232; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HISSIN PJ, 1982, DIABETES, V31, P589, DOI 10.2337/diabetes.31.7.589; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; PEDERSEN O, 1991, ENDOCRINOLOGY, V129, P771, DOI 10.1210/endo-129-2-771; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Remesar X, 1997, FEBS LETT, V402, P9, DOI 10.1016/S0014-5793(96)01477-9; ROBDELL M, 1964, J BIOL CHEM, V239, P375; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; Terasaki J, 1998, DIABETOLOGIA, V41, P400, DOI 10.1007/s001250050922; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	28	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29686	29692		10.1074/jbc.273.45.29686	http://dx.doi.org/10.1074/jbc.273.45.29686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792680	hybrid			2022-12-25	WOS:000076798300057
J	Fang, M; Wu, HY				Fang, M; Wu, HY			Suppression of leu-500 mutation in topA+ Salmonella typhimurium strains - The promoter relay at work	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA TOPOISOMERASES; UPSTREAM; PROTEIN; LRP; TRANSCRIPTION; ACTIVATION; EXPRESSION; PLASMID; GYRASE	Suppression of leu-500 mutation in Salmonella typhimurium topA(-) strains has been one of the most fascinating examples for the DNA supercoiling effect on transcription initiation control. Previous studies have indicated possible involvement of transcription-driven DNA supercoiling in the activation of the leu-500 promoter in topA(-) strains. Our recent studies have shown that ilvIH transcription activity located 1.9 kilobase pairs upstream is the initial supercoiling signal for leu-500 activation via a promoter relay mechanism. In the present communication, we show that the ilvIH transcription activity-initiated promoter relay can result in leu-500 activation in topA(+) strains. In addition, suppression of the chromosomal leu-500 mutation correlates with the transcription activities of ilvIH and leuO rather than the TopA level in the topA(+) strain. It appears that the leu-500 suppression in a topA(-) strain is due to the constant ilvIH transcription activity.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA.				NIGMS NIH HHS [GM53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053617, R01GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1997, CURRENT PROTOCOL MOL; CALVO JM, 1969, J BACTERIOL, V97, P1272, DOI 10.1128/JB.97.3.1272-1282.1969; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Chen DR, 1998, J BIOL CHEM, V273, P653, DOI 10.1074/jbc.273.1.653; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DUBANAU E, 1972, MOL GEN GENET, V117, P91; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; MARGOLIN P, 1963, GENETICS, V48, P441; Miller JH., 1972, EXPT MOL GENETICS; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WNG JC, 1979, MOL GENETICS 3, P65; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6	29	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29929	29934		10.1074/jbc.273.45.29929	http://dx.doi.org/10.1074/jbc.273.45.29929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792711	hybrid			2022-12-25	WOS:000076798300088
J	Min, DS; Kim, EC; Exton, JH				Min, DS; Kim, EC; Exton, JH			Involvement of tyrosine phosphorylation and protein kinase C in the activation of phospholipase D by H2O2 in Swiss 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; HYDROGEN-PEROXIDE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; INTACT-CELLS; INSULIN-RECEPTOR; VANADATE; MECHANISMS; PHOSPHATIDYLCHOLINE; HYDROPEROXIDE	We have investigated the mechanisms involved in H2O2-mediated phospholipase D (PLD) activation in Swiss 3T3 fibroblasts. In the presence of vanadate, H2O2 induced tyrosine phosphorylation of PLD as well as the platelet-derived growth (PDGF) factor receptor, protein kinase C alpha (PKC alpha), and a 62-kDa protein in rat brain PLD1 (rPLD1) immune complexes. PDGF also induced tyrosine phosphorylation of PLD, but this was abolished by catalase, indicating that it was mediated by H2O2 generation, Interestingly, PLD was found to be constitutively associated with the PDGF receptor and PKC alpha. Stimulation by H2O2 showed a concentration- and time-dependent tyrosine phosphorylation of the proteins in rPLD1 immunoprecipitates and activation of PLD in the cells. Pretreatment of the cells with the protein-tyrosine kinase inhibitors genistein and herbimycin A resulted in a concentration-dependent inhibition of H2O2-induced tyrosine phosphorylation and PLD activation. Activation of PLD by H2O2 was also inhibited dose-dependently by the PKC inhibitors Ro 31-8220 and calphostin C. Down-regulation of PKC by prolonged treatment with 4 beta-phorbol 12-myristate 13-acetate also abolished H2O2-stimulated PLD activity. H2O2 or vanadate alone did not induce tyrosine phosphorylation of proteins in the rPLD1 immune complex or PLD activation. Reduction of intracellular H2O2 levels by pretreatment of the cells with catalase dramatically abrogated tyrosine phosphorylation of proteins in the rPLD1 immune complex and PLD activation, suggesting the potential role of intracellular H2O2 in H2O2-mediated PLD signaling. Taken together, these results suggest that both protein-tyrosine kinase(s) and protein kinase C participate in H2O2-induced PLD activation in Swiss 3T3 cells.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047418] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 RO1 DK 47418] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; CANTLEY LC, 1979, J BIOL CHEM, V254, P1781; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROST SC, 1987, J BIOL CHEM, V262, P9872; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; HOWARTH OW, 1997, J CHEM SOC DA, P1388; INAZU T, 1990, BIOCHEM BIOPH RES CO, V170, P259, DOI 10.1016/0006-291X(90)91268-W; Ito Y, 1997, J NEUROCHEM, V69, P729; KISS Z, 1994, ARCH BIOCHEM BIOPHYS, V311, P430, DOI 10.1006/abbi.1994.1258; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; KUMADA T, 1993, BIOCHEM BIOPH RES CO, V191, P1363, DOI 10.1006/bbrc.1993.1367; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Natarajan V, 1996, CHEM PHYS LIPIDS, V80, P103, DOI 10.1016/0009-3084(96)02548-0; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NECHAY BR, 1986, FASEB J, V45, P123; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGLEN PO, 1981, J BIOL CHEM, V256, P7699; SIZEMORE DR, 1995, SCIENCE, V270, P296; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	47	150	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29986	29994		10.1074/jbc.273.45.29986	http://dx.doi.org/10.1074/jbc.273.45.29986			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792719	hybrid			2022-12-25	WOS:000076798300096
J	Pierrat, B; Correia, JD; Mary, JL; Tomas-Zuber, M; Lesslauer, W				Pierrat, B; Correia, JD; Mary, JL; Tomas-Zuber, M; Lesslauer, W			RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38 alpha mitogen-activated protein kinase (p38 alpha(MAPK))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; LONG-TERM POTENTIATION; P38 MAP KINASE; DUAL PHOSPHORYLATION; INDUCED APOPTOSIS; MAMMALIAN-CELLS; UV-LIGHT; IN-VIVO; STRESS	A novel ribosomal S6 kinase (RSK) family member, RSK-B, was identified in a p38 alpha(MAPK)-baited intracellular interaction screen. RSK-B presents two catalytic domains typical for the RSK family. The protein kinase C-like N-terminal and the calcium/calmodulin kinaselike C-terminal domains both contain conserved ATP-binding and activation consensus sequences. RSK-B is a p38 alpha(MAPK) substrate, and activated by p38 alpha(MAPK) and, more weakly, by ERK1. RSK-B phosphorylates the cAMP response element-binding protein (CREB) and c-Fos peptides. In intracellular assays, RSK-B drives cAMP response element- and AP1-dependent reporter expression. RSK-B locates to the cell nucleus and co-translocates p38 alpha(MAPK). In conclusion, RSK-B is a novel CREB kinase under dominant p38 alpha(MAPK) control, also phosphorylating additional substrates.	F Hoffmann La Roche & Co Ltd, Dept Preclin Res, CH-4070 Basel, Switzerland	Roche Holding	Lesslauer, W (corresponding author), F Hoffmann La Roche & Co Ltd, Dept PRPN D, Bldg 68-65, CH-4070 Basel, Switzerland.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FRESHNEY NW, 1994, CELL, V78, P1030; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JOHNS SW, 1988, P NATL ACAD SCI USA, V85, P3377; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Maroney AC, 1998, J NEUROSCI, V18, P104; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MOLLER DE, 1994, AM J PHYSIOL, V266, P351; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watson A, 1998, J NEUROSCI, V18, P751; Wilk-Blaszczak MA, 1998, J NEUROSCI, V18, P112; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	72	139	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29661	29671		10.1074/jbc.273.45.29661	http://dx.doi.org/10.1074/jbc.273.45.29661			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792677	hybrid			2022-12-25	WOS:000076798300054
J	Zobel-Thropp, P; Gary, JD; Clarke, S				Zobel-Thropp, P; Gary, JD; Clarke, S			delta-N-methylarginine is a novel posttranslational modification of arginine residues in yeast proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; METHYLTRANSFERASE; METHYLATION; ENZYMES; MOTIFS	We have found a novel modification of protein arginine residues in the yeast Saccharomyces cerevisiae, Intact yeast cells lacking RIMT1, the gene encoding the protein omega N-G-arginine methyltransferase, were labeled with the methyl donor S-adenosyl-L-[methyl-H-3]methionine, The protein fraction was acid-hydrolyzed to free amino acids, which were then fractionated on a high resolution sulfonated polystyrene cation exchange column at pH 5.27 and 55 degrees C, In the absence of the omega-N-G,(NL)-L-G-[H-3]dimethylarginine product of the RIMT1 methyltransferase, we were able to detect a previously obscured H-3-methylated species that migrated in the region of methylated arginine derivatives. The [H-3]methyl group(s) of this unknown species were not volatilized by treatment with 2 M NaOH at 55 degrees C for up to 48 h, suggesting that they were not modifications of the terminal omega-guanidino nitrogen atoms. However, this base treatment did result in the formation of a new H-3 methylated derivative that co-chromatographed with delta-N-methylornithhine on high resolution cation exchange chromatography, on reverse phase high pressure liquid chroma tography, and on thin layer chromatography, From these data, we suggest that the identity of the original unknown methylated residue is delta-N-monomethylarginine. The presence of this methylated residue in yeast cells defines a novel type of protein modification reaction in eukaryotes.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; [Anonymous], 1997, NATURE, V387, pS; BENOITON L, 1964, CAN J CHEM, V42, P2043, DOI 10.1139/v64-301; BORDERS CL, 1994, PROTEIN SCI, V3, P541; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Ellington WR, 1998, FEBS LETT, V425, P75, DOI 10.1016/S0014-5793(98)00204-X; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GILBERTSON TJ, 1967, J AM CHEM SOC, V89, P7085, DOI 10.1021/ja01002a043; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, V2, P1612; INUKAI F, 1968, ANN M AGR CHEM SOC J, P183; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MATSUOKA Y, 1969, BIOCHIM BIOPHYS ACTA, V192, P136, DOI 10.1016/0304-4165(69)90019-1; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; NAKAJIMA T, 1971, BIOCHIM BIOPHYS ACTA, V230, P212, DOI 10.1016/0304-4165(71)90206-6; Paik W. K., 1980, PROTEIN METHYLATION; PAIK WK, 1970, BIOCHEM BIOPH RES CO, V40, P224, DOI 10.1016/0006-291X(70)91070-3; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PAIK WK, 1970, J BIOL CHEM, V245, P88; PAIK WK, 1980, BIOCHEM BIOPH RES CO, V97, P8, DOI 10.1016/S0006-291X(80)80126-4; PAIK WK, 1990, PROTEIN METHYLATION; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SHIMONI L, 1995, PROTEIN SCI, V4, P65; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tojo A, 1997, KIDNEY INT, V52, P1593, DOI 10.1038/ki.1997.490	29	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29283	29286		10.1074/jbc.273.45.29283	http://dx.doi.org/10.1074/jbc.273.45.29283			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792625	hybrid			2022-12-25	WOS:000076798300002
J	Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ				Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ			RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer	ONCOGENE			English	Article						mouse model; p53; RB; Ret; thyroid cancer	GERMLINE MUTATIONS; MICE; RB; TUMORS; SYSTEM; P53	Mice bred to carry germline Rb and p53 null alleles are associated with a tumor spectrum that overlaps with the inherited multiple endocrine neoplasia-1 (MEN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC). To study the genetic basis for these tumors, we microdissected MTC specimens or obtained fresh MTC tissue from nine independent Rb+/- p53(+/-) mice, amplified the region of the Ret gene known to be mutated in human MTC, and detected acquired missense Ret mutations in four different mice, These mutations were Localized to a group of tandem cysteines which are analogous to activating germline mutations observed in human MEN2A and familial MTC (FMTC), To determine whether the remaining wild type Rb allele was inactivated in these murine MTC samples, we subjected tumor tissue to immunohistochemical staining with an Rb antibody, and demonstrated the absence of RE staining in murine MTC, while normal tissue retained RE nuclear staining. These findings demonstrate the ability of the gene knockout model to recapitulate somatic multi-step tumorigenesis and suggest that the development of a murine neuroendocrine tumor requires mutational dysregulation within both receptor tyrosine kinase and nuclear tumor suppressor gene pathways.	NCI, Dept Genet, Bethesda, MD 20889 USA; Natl Naval Med Ctr, Bethesda, MD 20889 USA; Div Basic Sci, Anim Sci Branch, Vet & Tumor Pathol Sect, Frederick, MD 21702 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Kaye, FJ (corresponding author), Naval Hosp, NCI, Bldg 8-Rm 5101, Bethesda, MD 20889 USA.		kaye, frederic/E-2437-2011					Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; ERLANDSON RA, 1994, ULTRASTRUCT PATHOL, V18, P149, DOI 10.3109/01913129409016286; HARVEY M, 1995, CANCER RES, V55, P1146; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kloppel G, 1994, Ann N Y Acad Sci, V733, P19; LARSSON C, 1994, ANN NY ACAD SCI, V733, P453, DOI 10.1111/j.1749-6632.1994.tb17295.x; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMITH DP, 1994, J CELL SCI, P43; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	12	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1625	1628		10.1038/sj.onc.1202381	http://dx.doi.org/10.1038/sj.onc.1202381			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794240				2022-12-25	WOS:000076089900015
J	Naumann, U; Durka, S; Weller, M				Naumann, U; Durka, S; Weller, M			Dexamethasone-mediated protection from drug cytotoxicity: association with p21(WAF1/CIP1) protein accumulation?	ONCOGENE			English	Article						steroid; chemotherapy; cell cycle; apoptosis; glioma	HUMAN-MALIGNANT GLIOMA; CELL-CYCLE ARREST; HUMAN NEUTROPHILS; INDUCED APOPTOSIS; BCL-2 EXPRESSION; CARCINOMA CELLS; IMMUNE-SYSTEM; GENE-TRANSFER; P53; P21	Dexamethasone (DEX)-mediated inhibition of drug-induced, but not CD95 ligand-induced, apoptosis in malignant glioma cells correlates with wild-type p53 status. Here, we examined mechanisms underlying DEX-mediated protection from apoptosis, DEX did not induce p53 expression in two p53 wild-type cell lines (U87MG, LN-229) and did not alter drug-induced p53 accumulation. Forced expression of temperature-sensitive p53val(135) in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecin-induced p21(WAF1/CIF1) expression, p53val(135)-transfected cells retained responsiveness to DEX at restrictive temperature, suggesting that p53 activity is not required for cytoprotection, Forced expression of wild-type p53val(135) abrogated the protective effect of DEX, suggesting redundant cytoprotective effects of DEX and p53, Indeed, DEX induced moderate accumulation of p21(WAF1/CIP1) in U87MG, LN-229 and p53 mutant LN-18 cells, but not in p53 mutant LN-308 or T98G cells. LN-18 is also the p53 mutant cell line with the best cytoprotective response to DEX, p21(WAF1/CIP1) accumulation occurred in the absence of changes in p21(WAF1\CIP1) mRNA expression, Wild-type p53 was not required for this DEX effect since DEX induced p21(WAF1/CIP1) accumulation in p53val(135)-transfected LN-229 cells, too. DEX failed to induce p21(WAF1/CIP1) expression or cytoprotection in untransformed rat astrocytes, The same lack of modulation of p21(WAF1/CIP1) expression and drug toxicity was observed in p21(+/+), p21(+/-) and p21(-/-) human colon carcinoma cells. Paradoxically, while only p21(+/+) and p21(+/-) mouse embryonic fibroblasts showed enhance p21(WAF1/CIP1) levels after exposure to DEX, only p21(-/-) fibroblasts were protected from drug toxicity by DEX, The present study links DEX-mediated protection from cancer chemotherapy to a p53-independent pathway of regulating p21(WAF1/CIP1) expression in glioma cells but this effect appears to cell type-specific.	Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chen J, 1996, ONCOGENE, V13, P1395; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; EASTHAM JA, 1995, CANCER RES, V55, P5151; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; Kondo S, 1996, ONCOGENE, V13, P1279; Li XS, 1996, CANCER RES, V56, P5055; NAUMANN U, 1998, IN PRESS INT J CANC; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; TREPEL M, 1998, IN PRESS J NEUROONCO; VAN MEIR EG, 1994, CANCER RES, V54, P649; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wolff JEA, 1996, ANTICANCER RES, V16, P805; Wullner U, 1996, NEUROREPORT, V7, P921; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	34	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1567	1575		10.1038/sj.onc.1202071	http://dx.doi.org/10.1038/sj.onc.1202071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794234				2022-12-25	WOS:000076089900009
J	Burks, DJ; Wang, J; Towery, H; Ishibashi, O; Lowe, D; Riedel, H; White, MF				Burks, DJ; Wang, J; Towery, H; Ishibashi, O; Lowe, D; Riedel, H; White, MF			IRS pleckstrin homology domains bind to acidic motifs in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHOTYROSINE-DEPENDENT INTERACTION; 2-HYBRID SYSTEM; HIGH-AFFINITY; NPEY MOTIF; ASSOCIATION; NUCLEOLIN; DYNAMIN; REGION; KINASE	Using a yeast two-hybrid system, we identified several proteins that interact with the PH domains in IRS-1 and IRS-2, including Lon protease, myeloblast protein, and nucleolin, Although the roles of these molecules in insulin action are not yet known, each protein contained an acidic motif that interacted with the PH domain of IRS-2. However, only the acidic motif in nucleolin bound to IRS-1, suggesting that the PH domain in IRS-1 and IRS-2 are not identical. Moreover, synthetic peptides based on the acidic motif in Lon protease and myeloblast protein inhibited the binding of nucleolin to the PH domain of IRS-2 but not to the PH domain of IRS-1, confirming the selectivity of these PH domains. The ability to bind acidic motifs may be a specific function of the PH domain in IRS proteins, because the PH domains in beta ARK, phospholipase C gamma, or spectrin did not bind nucleolin. In 32D cells, nucleolin bound to both IRS-1 and IRS-2, and expression of the acidic motif of nucleolin inhibited insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-2, These results suggest that the binding of acidic motifs to the PH domain of IRS-1 and IRS-2 disrupts coupling to the activated insulin receptor. Our results are consistent with the hypothesis that the PH domain in the IRS proteins may ordinarily bind acidic peptide motifs in membrane proteins or other acidic membrane elements that couple IRS proteins to activated membrane receptors.	Harvard Univ, Joslin Diabet Ctr, Sch Med, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Wayne State Univ, Sch Med, Dept Biol Sci, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48202 USA; Toyama Med & Pharmaceut Univ, Dept Med 1, Toyama 93001, Japan	Harvard University; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Toyama	White, MF (corresponding author), Harvard Univ, Joslin Diabet Ctr, Sch Med, Howard Hughes Med Inst, 1 Joslin Pl, Cambridge, MA 02138 USA.				NIDDK NIH HHS [DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	40	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31061	31067		10.1074/jbc.273.47.31061	http://dx.doi.org/10.1074/jbc.273.47.31061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813005	hybrid			2022-12-25	WOS:000077136900033
J	Shinkai, A; Ito, M; Anazawa, H; Yamaguchi, S; Shitara, K; Shibuya, M				Shinkai, A; Ito, M; Anazawa, H; Yamaguchi, S; Shitara, K; Shibuya, M			Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; FLT-1 RECEPTOR; CELLS SECRETE; BINDING; VEGF; IDENTIFICATION; ANGIOGENESIS; KDR	The kinase insert domain containing receptor (HDR) for vascular endothelial growth factor (VEGF) has been shown to be involved in vasculogenesis and angiogenesis. This receptor is characterized by seven immunoglobulin (Ig)-like domains within its extracellular region. To identify the domains involved in VEGF binding, we constructed Various deletion mutants of the extracellular region fused with the crystallizable fragment portion of an IgG and then examined the binding affinity with VEGF by means of the BIAcore biosensor assay. Deletion of the COOH-terminal two or three Ig-like domains out of a total of seven affected ligand dissociation rather than association. Further deletion of the fourth domain caused a drastic decrease in the association rate. Binding ability was abolished completely with removed of the third domain. The mutant KDR proteins lacking the NH2-terminal Ig-like domain exhibited a slightly higher association rate compared with those of the mutants having this domain. Deletion of the first two NH2-terminal Ig-like domains caused a drastic reduction in the association rate, but affinity to VEGF was retained, These results suggest that the third Ig-like domain is critical for ligand binding, the second and fourth domains are important for ligand association, and the fifth and sixth domains are required for retention of the ligand bound to the receptor molecule. The first Ig-like domain may regulate the ligand binding.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo, Japan	Kyowa Kirin Ltd; University of Tokyo	Shitara, K (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 1948533, Japan.		Shinkai, Akeo/E-8354-2013	Shinkai, Akeo/0000-0002-9867-0832				Barleon B, 1997, J BIOL CHEM, V272, P10382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; KABAT EA, 1971, ANN NY ACAD SCI, V190, P382, DOI 10.1111/j.1749-6632.1971.tb13550.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yago T, 1997, J IMMUNOL, V158, P707	30	122	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31283	31288		10.1074/jbc.273.47.31283	http://dx.doi.org/10.1074/jbc.273.47.31283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813036	hybrid			2022-12-25	WOS:000077136900064
J	Taketani, S; Adachi, Y; Kohno, H; Ikehara, S; Tokunaga, R; Ishii, T				Taketani, S; Adachi, Y; Kohno, H; Ikehara, S; Tokunaga, R; Ishii, T			Molecular characterization of a newly identified heme-binding protein induced during differentiation of urine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; GLUTATHIONE S-TRANSFERASES; MESSENGER-RNA; 5-AMINOLEVULINATE SYNTHASE; BENZODIAZEPINE RECEPTORS; RABBIT RETICULOCYTES; LIVER-FERROCHELATASE; POSSIBLE INVOLVEMENT; ERYTHROID-CELLS; HEPATOMA-CELLS	A heme-binding protein with a molecular mass of 22 kDa, termed p22 HBP, was purified from mouse liver cytosol, using blue Sepharose CL-6B. We identified a cDNA encoding p22 HBP, and sequence analysis revealed that p22 HBP comprises 190 amino acid residues (M-x 21,063) and has no homology to any other known heme-binding protein. The p22 HEP mRNA (similar to 1.0 kilobases) is ubiquitously expressed in various tissues and is extremely abundant in the liver. cDNA allows for ex pression of active p22 HBP, with a high affinity for Fe-55-hemin, with a K-d of 26 +/- 1.8 nM. The B-max of hemin binding to p22 HBP was 0.55 +/- 0.021 mol/mol of protein, a value consistent with one heme molecule binding per molecule of protein. The order of potency of different ligands to compete against 55Fe-hemin binding to p22 HBP was hemin = protoporphyrin IX > coproporphyrin III > bilirubin > palmitic acid > all-trans-retinoic acid. Treatment of mouse erythroleukemia (MEL) cells with dimethyl sulfoxide or hemin resulted in an increase in p22 HBP mRNA The immunoblot analysis showed that p22 HBP increased with time in dimethyl sulfoxide- and hemin-induced MEL cells. Conversely, transfer of antisense oligonucleotides to p22 HBP cDNA resulted in a decrease of p22 I-TSP in dimethyl sulfoxide-treated MEL cells, and the heme content in these cells decreased to 66-71% of sense oligonucleotides-transferred cells. Thus, this newly identified heme-binding protein, p22 HBP, may be involved in heme utilization for hemoprotein synthesis and even be coupled to hemoglobin synthesis during erythroid differentiation.	Kansai Med Univ, Dept Hyg, Osaka 5708506, Japan; Kansai Med Univ, Dept Pathol 1, Osaka 5708506, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaragi 3058575, Japan	Kansai Medical University; Kansai Medical University; University of Tsukuba	Taketani, S (corresponding author), Kansai Med Univ, Dept Hyg, Osaka 5708506, Japan.							ALAM J, 1989, J BIOL CHEM, V264, P6371; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BERTRAM J, 1994, BIOCHEM BIOPH RES CO, V200, P661, DOI 10.1006/bbrc.1994.1499; BHARGAVA MM, 1981, TRENDS BIOCHEM SCI, V6, P131, DOI 10.1016/0968-0004(81)90049-9; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FURUKAWA T, 1995, BIOCHEM J, V310, P533, DOI 10.1042/bj3100533; Granick S, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P33; HARVEY JW, 1982, BLOOD, V60, P1227; HRKAL Z, 1992, BIOMED CHROMATOGR, V6, P212, DOI 10.1002/bmc.1130060412; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; IBRAHIM NG, 1978, BIOCHEM BIOPH RES CO, V80, P722, DOI 10.1016/0006-291X(78)91304-9; IMMENSCHUH S, 1995, BIOCHEMISTRY-US, V34, P13407, DOI 10.1021/bi00041a018; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; ISHII T, 1993, J BIOL CHEM, V268, P18633; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; KETTERER B, 1976, BIOCHIM BIOPHYS ACTA, V428, P683, DOI 10.1016/0304-4165(76)90198-7; KOHNO H, 1993, J BIOL CHEM, V268, P21359; KOLLER ME, 1977, BIOCHIM BIOPHYS ACTA, V461, P283, DOI 10.1016/0005-2728(77)90178-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1986, J BIOL CHEM, V261, P411; Mainwaring GW, 1996, BIOCHEM J, V318, P297, DOI 10.1042/bj3180297; MAY BK, 1990, MOL BIOL MED, V7, P405; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; NEUWIRT J, 1972, BIOCHIM BIOPHYS ACTA, V264, P235, DOI 10.1016/0304-4165(72)90287-5; OLSEN KW, 1980, ANAL BIOCHEM, V109, P250, DOI 10.1016/0003-2697(80)90644-2; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PONKA P, 1973, BIOCHIM BIOPHYS ACTA, V304, P715, DOI 10.1016/0304-4165(73)90217-1; Ponka P, 1997, BLOOD, V89, P1; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SELF AJ, 1995, METHOD ENZYMOL, V258, P3; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIN WS, 1994, BIOCHEM J, V304, P81, DOI 10.1042/bj3040081; STOUT DL, 1986, CANCER RES, V46, P2756; TAKETANI S, 1994, J BIOL CHEM, V269, P7527; TAKETANI S, 1982, EUR J BIOCHEM, V127, P443; TAKETANI S, 1995, J BIOCHEM-TOKYO, V117, P875, DOI 10.1093/oxfordjournals.jbchem.a124790; TAKETANI S, 1995, EUR J BIOCHEM, V230, P760, DOI 10.1111/j.1432-1033.1995.0760h.x; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TIPPING E, 1976, BIOCHEM J, V157, P461, DOI 10.1042/bj1570461; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALKER CJ, 1991, BIOCHEM J, V276, P691, DOI 10.1042/bj2760691; XU X, 1994, J BIOL CHEM, V269, P30268; YAMAMOTO M, 1988, J BIOL CHEM, V263, P15973; [No title captured]	54	98	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31388	31394		10.1074/jbc.273.47.31388	http://dx.doi.org/10.1074/jbc.273.47.31388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813049	hybrid			2022-12-25	WOS:000077136900077
J	Bouin, AP; Grandvaux, N; Vignais, PV; Fuchs, A				Bouin, AP; Grandvaux, N; Vignais, PV; Fuchs, A			p40(phox) is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase - Implication of a protein kinase C type kinase in the phosphorylation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; CELL-FREE SYSTEM; SH3 DOMAIN; CYTOSOLIC COMPONENTS; HUMAN NEUTROPHILS; 2-HYBRID SYSTEM; P47(PHOX); P67(PHOX); COMPLEX; TRANSLOCATION	The superoxide generating NADPH oxidase complex of phagocytic cells is a multicomponent system containing a membrane-bound flavocytochrome b and a small G protein Rac as well as cytosolic factors p67(phox) (phagocyte oxidase), p47(phox), and p40(phox) which translocate to the membrane upon activation, In a previous paper, we reported that p40(phox) undergoes phosphorylation on multiple sites upon stimulation of the NADPH oxidase by either phorbol 12-myristate 13-acetate or by formyl peptide with a time course that is strongly correlated with that of superoxide production (Fuchs, A, Bouin, A. P,, Rabilloud, T., and Vignais, P. V, (1997) Eur J, Biochem. 249, 531-5S9). In this study, through phosphoamino acid and tryptic peptide maps of in vivo and in vitro phosphorylated p40(phox), we show that p40(phox) is phosphorylated on serine and threonine residues during activation of the NADPH oxidase in dimethyl sulfoxide-differentiated HL60 promyelocytes as well as in isolated human neutrophils, In vitro phosphorylation studies using casein kinase II and protein kinase C (PKC) as well as the effect of various protein kinase inhibitors on the isoelectric focusing pattern of p40(phox) whole cell lysates point to a role of a PKC type kinase in the phosphorylation of p40(phox) Directed mutagenesis of all PKC consensus sites enable us to conclude that Thr(154) and Ser(315) in p40(phox) are phosphorylated during activation of the NADPH oxidase.	CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim & Biophys Syst Integres, UMR 314,CNRS, F-38054 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Fuchs, A (corresponding author), CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim & Biophys Syst Integres, UMR 314,CNRS, 17 Rue Martyrs, F-38054 Grenoble 9, France.		bouin, anne pascale/M-2734-2013	bouin, anne pascale/0000-0002-9616-6173; Fuchs, Alexandra/0000-0001-5536-8716				Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; Fuchs A, 1997, EUR J BIOCHEM, V249, P531, DOI 10.1111/j.1432-1033.1997.00531.x; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MOREL F, 1992, INFLAMMATION, V16, P325, DOI 10.1007/BF00917625; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	24	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30097	30103		10.1074/jbc.273.46.30097	http://dx.doi.org/10.1074/jbc.273.46.30097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804763	hybrid			2022-12-25	WOS:000077008100010
J	Mao, SS; Przysiecki, CT; Krueger, JA; Cooper, CM; Lewis, SD; Joyce, J; Lellis, C; Garsky, VM; Sardana, M; Shafer, JA				Mao, SS; Przysiecki, CT; Krueger, JA; Cooper, CM; Lewis, SD; Joyce, J; Lellis, C; Garsky, VM; Sardana, M; Shafer, JA			Selective inhibition of factor Xa in the prothrombinase complex by the carboxyl-terminal domain of antistasin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; LEECH-DERIVED INHIBITOR; COAGULATION FACTOR-XA; FACTOR-VA; RECOMBINANT ANTISTASIN; PHOSPHOLIPID-VESICLES; STUART FACTOR; IDENTIFICATION; ACTIVATION; THROMBIN	Studies of antistasin, a potent factor Xa inhibitor with anticoagulant properties, were performed wherein the properties of the full-length antistasin polypeptide (ATS-119) were compared with the properties of forms of antistasin truncated at residue 116 (ATS-116) and residue 112 (ATS-112), ATS-119 was 40-fold more potent than ATS-112 in prolonging the activated partial thromboplastin time (APTT), whereas ATS-119 inhibited factor Xa 2.2-fold less avidly and about B-fold more slowly than did ATS-112, The decreased reactivity of ATS-119 suggests that the carboxyl-terminal domain of ATS-119 stabilizes an ATS conformation with a reduced reactivity toward factor Xa, The observation that calcium ion increases the reactivity of ATS-119 but not that of ATS-112 suggests that calcium ion may disrupt interactions involving the carboxyl terminus of ATS-119. Interestingly, ATS-119 inhibited factor Xa in the prothrombinase complex 2-6-fold more potently and 2-3-fold faster than ATS-112. These differences in affinity and reactivity might well account for the greater effectiveness of ATS-119 in prolonging the APTT and suggest that the carboxyl-terminal domain of ATS-119 disrupts interactions involving phospholipid, factor Va, and prothrombin in the prothrombinase complex. The peptide RPKRRLIPRLS, corresponding to the carboxyl domain of ATS-119 prolonged the APTT and inhibited prothrombinase-catalyzed processing of prothrombin, but it failed to inhibit the catalytic activity of isolated factor Xa, Thus, this novel inhibitor appears to exert its inhibitory effects at a site removed hom the active site of factor Xa.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Mao, SS (corresponding author), Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA.							AMES BN, 1960, J BIOL CHEM, V235, P769; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAUER KA, 1991, SEMIN HEMATOL, V28, P10; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; KIESIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MAO SS, 1995, BIOCHEMISTRY-US, V34, P5098, DOI 10.1021/bi00015a021; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NUTT E, 1988, J BIOL CHEM, V263, P10162; NUTT EM, 1991, ARCH BIOCHEM BIOPHYS, V285, P37, DOI 10.1016/0003-9861(91)90325-D; OWEN WG, 1974, J BIOL CHEM, V249, P594; PRZYSIECKI CT, 1992, PROTEIN EXPRES PURIF, V3, P185, DOI 10.1016/1046-5928(92)90014-N; ROSING J, 1980, J BIOL CHEM, V255, P274; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Williams J W, 1979, Methods Enzymol, V63, P437	25	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30086	30091		10.1074/jbc.273.46.30086	http://dx.doi.org/10.1074/jbc.273.46.30086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804761	hybrid			2022-12-25	WOS:000077008100008
J	Schroering, A; Carey, DJ				Schroering, A; Carey, DJ			Sensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL PROLIFERATION; NECROSIS-FACTOR-ALPHA; DIFFERENTIATION FACTOR; GROWTH-FACTOR; HEPARAN-SULFATE; FIBROBLAST GROWTH; NEUREGULIN; SURFACE; BINDING; PROTEOGLYCAN	The beta-heregulin sensory and motor neuron-derived factor (SMDF) has been suggested to be an important regulator of Schwann cell development and proliferation. In the present study, human SMDF was expressed in cultured cell lines. The cells and the recombinant protein were used to examine the membrane association and biological activity of the growth factor. Transfection of cells with SMDF cDNA constructs bearing FLAG epitope tags at either the amino- or carboxyl-terminal ends of the polypeptide resulted in expression of anti-FLAG immunoreactive polypeptides of approximately 44 and 83 kDa. The 83-kDa polypeptide was the major form expressed on the cell surface, as demonstrated by sensitivity to proteolysis in intact cells and surface biotinylation. SMDF was tightly associated with membranes isolated from transfected cells but was solubilized by Triton X-100. Immunofluorescent staining and immunoprecipitation experiments using cells expressing amino- or carboxyl-terminal tagged SMDF revealed that only the carboxyl-terminal end of the protein is exposed on the cell surface. Membranes from SMDF-transfected cells stimulated tyrosine phosphorylation of the beta-heregulin receptor ErbB3 in Schwann cells. Conditioned medium from transfected cells contained a similar activity, suggesting that SMDF is subject to proteolytic release from the plasma membrane. In contrast with other beta-heregulin isoforms, SMDF failed to bind heparin. Stimulation of Schwann cell ErbB3 receptor phosphorylation by SMDF was not affected by inhibition of Schwann cell heparan sulfate proteoglycan synthesis. These results demonstrate that SMDF is a type II transmembrane protein. This orientation places the active epidermal growth factor homology domain, which is located near the carboxyl-terminal end of the polypeptide, on the cell surface, where it can function as a membrane-anchored growth factor.	Penn State Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Carey, DJ (corresponding author), Penn State Coll Med, Weis Ctr Res, 100 Acad Ave, Danville, PA 17822 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GREVE H, 1988, J BIOL CHEM, V263, P12886; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Meyer D, 1997, DEVELOPMENT, V124, P3575; MORISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REISE DJ, 1995, MOL CELL BIOL, V15, P5770; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; Sudhalter J, 1996, GLIA, V17, P28, DOI 10.1002/(SICI)1098-1136(199605)17:1<28::AID-GLIA3>3.0.CO;2-3; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	29	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30643	30650		10.1074/jbc.273.46.30643	http://dx.doi.org/10.1074/jbc.273.46.30643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804837	hybrid			2022-12-25	WOS:000077008100084
J	Nobe, Y; Kawaguchi, S; Ura, H; Nakai, T; Hirotsu, K; Kato, R; Kuramitsu, S				Nobe, Y; Kawaguchi, S; Ura, H; Nakai, T; Hirotsu, K; Kato, R; Kuramitsu, S			The novel substrate recognition mechanism utilized by aspartate aminotransferase of the extreme thermophile Thermus thermophilus HB8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ASPARTATE; AMINO-ACID AMINOTRANSFERASE; COMPLETE GENOME SEQUENCE; ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS; ACTIVE-SITE; RHIZOBIUM-MELILOTI; CRYSTAL-STRUCTURES; CLOSED-FORM; 3 FORMS; PURIFICATION	Aspartate aminotransferase (AspAT) is a unique enzyme that can react with two types of substrate with quite different properties, acidic substrates, such as aspartate and glutamate, and neutral substrates, although the catalytic group Lys-258 acts on both types of substrate. The dynamic properties of the substrate-binding site are indispensable to the interaction with hydrophobic substrates (Kawaguchi, S., Nobe, Y., Yasuoka, J., Wakamiya, T., Kusumoto, S., and Kuramitsu, S. (1997) J. Biochem. (Tokyo) 122, 55-63). AspATs from various organisms are classified into two subgroups, Ia and Ib. The former includes AspATs from Escherichia coli and higher eukaryotes, whereas the latter includes those from Thermus thermophilus and many prokaryotes. The AspATs belonging to subgroup Ia each have an Arg-292 residue, which interacts with the distal carboxyl groups of dicarboxylic (acidic) substrates, but the functionally similar residue of subgroup Ib AspATs has not been identified. In view of the x-ray crystallographic structure of T. thermophilus AspAT, we expected Lys-109 to be this residue in the subgroup Ib AspATs and constructed K109V and K109S mutants. Replacing Lys-109 with Val or Ser resulted in loss of activity toward acidic substrates but increased that toward the neutral substrate, alanine, considerably. These results indicate that Lys-109 is a major determinant of the acidic substrate specificity of subgroup Tb AspATs. Kinetic analysis of the interactions with neutral substrates indicated that T. thermophilus AspAT is subject to less steric hindrance and its substrate-binding pocket has a more flexible conformation than E. coli AspAT. A flexible active site in the rigid T. thermophilus AspAT molecule may explain its high activity even at room temperature.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Osaka City Univ, Grad Sch Sci, Dept Chem, Sumiyoshi Ku, Osaka 5588585, Japan	Osaka University; Osaka Metropolitan University	Kuramitsu, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp	Nakai, Tadashi/F-8047-2010	Nakai, Tadashi/0000-0001-9770-8168; Kato, Ryuichi/0000-0003-2087-2896				ALFANO JR, 1993, J BACTERIOL, V175, P4186, DOI 10.1128/JB.175.13.4186-4196.1993; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bartsch K, 1996, APPL ENVIRON MICROB, V62, P3794, DOI 10.1128/AEM.62.10.3794-3799.1996; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; Fan YX, 1996, BIOCHEM J, V315, P97, DOI 10.1042/bj3150097; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; HAYASHI H, 1989, BIOCHEM BIOPH RES CO, V159, P337, DOI 10.1016/0006-291X(89)92443-1; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; INOUE Y, 1989, J BIOL CHEM, V264, P9673; IWASAKI M, 1994, J BIOCHEM-TOKYO, V115, P156, DOI 10.1093/oxfordjournals.jbchem.a124293; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; JENKINS WT, 1985, TRANSAMINASES, P216; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; JHEE KH, 1995, J BIOCHEM-TOKYO, V118, P101, DOI 10.1093/oxfordjournals.jbchem.a124863; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KALLEN RG, 1985, TRANSAMINASES, P37; Kaneko T, 1996, DNA Res, V3, P109; KARMEN A, 1955, J CLIN INVEST, V34, P126, DOI 10.1172/JCI103055; Katayama M, 1996, GENE, V171, P135, DOI 10.1016/0378-1119(96)00067-4; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MARINO G, 1988, J BIOL CHEM, V263, P12305; MATSUSHIMA Y, 1994, J BIOCHEM-TOKYO, V115, P108, DOI 10.1093/oxfordjournals.jbchem.a124283; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; MIYAZAWA K, 1994, J BIOCHEM, V115, P568, DOI 10.1093/oxfordjournals.jbchem.a124377; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; NAKAI T, 1998, IN PRESS ACTA CRYS D; OFarrell PA, 1997, BIOCHEM BIOPH RES CO, V239, P810, DOI 10.1006/bbrc.1997.7559; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1743, DOI 10.1002/pro.5560040909; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; Singh J., 1992, ATLAS PROTEIN SIDE C, VII; Singh J., 1992, ATLAS PROTEIN SIDE C, VI; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; SUNG MH, 1990, J BACTERIOL, V172, P1345, DOI 10.1128/jb.172.3.1345-1351.1990; SUNG MH, 1991, J BIOL CHEM, V266, P2567; TANIZAWA K, 1989, J BIOL CHEM, V264, P2445; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; VELICK SF, 1962, J BIOL CHEM, V237, P2109; WATSON RJ, 1993, J BACTERIOL, V175, P1919, DOI 10.1128/JB.175.7.1919-1928.1993; Weaver T, 1996, BIOCHEMISTRY-US, V35, P13955, DOI 10.1021/bi9614702; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220	66	28	35	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29554	29564		10.1074/jbc.273.45.29554	http://dx.doi.org/10.1074/jbc.273.45.29554			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792664	hybrid			2022-12-25	WOS:000076798300041
J	Sheppard, KA; Phelps, KM; Williams, AJ; Thanos, D; Glass, CK; Rosenfeld, MG; Gerritsen, ME; Collins, T				Sheppard, KA; Phelps, KM; Williams, AJ; Thanos, D; Glass, CK; Rosenfeld, MG; Gerritsen, ME; Collins, T			Nuclear integration of glucocorticoid receptor and nuclear factor-kappa B signaling by CREB-binding protein and steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; MEDIATED REPRESSION; CBP; IMMUNOSUPPRESSION; INHIBITION; INDUCTION; COMPLEX; ALPHA; P300	The p65 (RelA) component of nuclear factor-kappa B (NF-kappa B) and the glucocorticoid receptor (GR) mutually repress each other's ability to activate transcription. Both of these transcriptional activators depend upon the coactivators CREB-binding protein (CBP) and steroid re ceptor coactivator-1 (SRC-1) for maximal activity. Here we show that increased levels of CBP relieves the inhibition of glucocorticoid-mediated repression of NF-kappa B activity and the NF-kappa B-mediated repression of GR activity. SRC-1 can relieve the NF-kappa B-mediated repression of GR activity. We propose that cross-talk between the p65 component of NF-kappa B and glucocorticoid receptors is due, at least in part, to nuclear competition for limiting amounts of the coactivators CBP and SRC-1, thus providing a novel mechanism for decreasing expression of genes involved in the inflammatory response.	Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Roche Holding; Genentech	Collins, T (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, 221 Longwood Ave, Boston, MA 02115 USA.	tcollins@bustoff.bwh.harvard.edu	Glass, Christopher/AAI-3933-2021; Thanos, Dimitris/AAE-5720-2019	Glass, Christopher/0000-0003-4344-3592; 				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brostjan C, 1997, J IMMUNOL, V158, P3836; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	30	253	261	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29291	29294		10.1074/jbc.273.45.29291	http://dx.doi.org/10.1074/jbc.273.45.29291			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792627	hybrid			2022-12-25	WOS:000076798300004
J	VanRenterghem, B; Morin, M; Czech, MP; Heller-Harrison, RA				VanRenterghem, B; Morin, M; Czech, MP; Heller-Harrison, RA			Interaction of insulin receptor substrate-1 with the sigma 3A subunit of the adaptor protein complex-3 in cultured adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; SORTING SIGNALS; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; AP-2 COMPLEXES; RAT ADIPOCYTES	Signaling through the insulin receptor tyrosine kinase involves its autophosphorylation in response to insulin and the subsequent tyrosine phosphorylation of substrate proteins such as insulin receptor substrate-1 (IRS-1). In basal 3T3-L1 adipocytes, IRS-1 is predominantly membrane-bound, and this localization may be important in targeting downstream signaling elements that mediate insulin action. Since IRS-1 localization to membranes may occur through its association with specific membrane proteins, a 3T3-F442A adipocyte cDNA expression library was screened with non-tyrosine-phosphorylated, baculovirus-expressed IRS-1 in order to identify potential IRS-1 receptors. A cDNA clone that encodes sigma 3A, a small subunit of the AP-3 adaptor protein complex, was demonstrated to bind IRS-1 utilizing this cloning strategy. The specific interaction between IRS-1 and sigma 3A was further verified by in vitro binding studies employing baculovirus-expressed IRS-1 and a glutathione S-transferase (GST)-sigma 3A fusion protein. IRS-1 and sigma 3A were found to co-fractionate in a detergent-resistant population of low density membranes isolated from basal 3T3-L1 adipocytes. Importantly, the addition of exogenous purified GST-sigma 3A to low density membranes caused the release of virtually all of the IRS-1 bound to these membranes, while GST alone had no effect. These results are consistent with the hypothesis that sigma 3A serves as an IRS-1 receptor that may dictate the subcellular localization and the signaling functions of IRS-1.	Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Heller-Harrison, RA (corresponding author), Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, 373 Plantat St, Worcester, MA 01605 USA.							AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark Sharon F., 1996, Molecular Biology of the Cell, V7, p9A; CONWAY B, 1996, EXP CLIN ENDOCR S2, V104, P35; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HELLERHARRISON R, 1996, EXP CLIN ENDOCR S2, V14, P22; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ooi CE, 1997, EMBO J, V16, P4508; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RIORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P214, DOI 10.1159/000134341; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	67	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29942	29949		10.1074/jbc.273.45.29942	http://dx.doi.org/10.1074/jbc.273.45.29942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792713	hybrid			2022-12-25	WOS:000076798300090
J	Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP				Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP			Delayed involution of the mammary epithelium in BALB/c-p53(null) mice	ONCOGENE			English	Article						p53; mice; mammary involution; p21(WAF1) apoptosis	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; BASEMENT-MEMBRANE; GLAND INVOLUTION; P53; APOPTOSIS; TISSUE; DIFFERENTIATION; SUPPRESSION; STROMELYSIN-1	In mammals, weaning of neonates and subsequent milk stasis initiates removal of the secretory epithelium of the mammary gland by apoptosis, The p53 tumor suppressor gene is induced rapidly following weaning of neonates, but its role in the process of involution has not been defined. Therefore, experiments were performed to identify the cell types in which the p53 gene is expressed during involution and determine the consequences of its absence in BALB/c-p53(null) mice. Both p53 mRNA and protein were detected in the mammary epithelium within 48 h following meaning and resulted in an eightfold increase in levels of p21(WAF1) mRNA, Induction of p21(WAF1) mRNA was absent in BALB/c-p53(null) mice, and therefore, was shown to be p53-dependent, The BALB/c-p53(null) mice exhibited delayed involution of the mammary epithelium, as measured by 60% greater epithelial area compared to BALB/c-p53(wt) mice through 5 days postweaning, The delay was transient with no differences being apparent at 7 days post-weaning. Expression of the stromal protease stromelysin-1 was unaffected by the absence of p53 suggesting that stromal responses were intact. These data demonstrate that p53 participates in the first stage of involution initiated by the epithelium itself, but does not affect the second phase during which stromal proteases are induced.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Baystate Med Ctr, Dept Pathol, Springfield, MA 01199 USA	University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.				NATIONAL CANCER INSTITUTE [R29CA066670] Funding Source: NIH RePORTER; NCI NIH HHS [CA66670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; ATWOOD CS, 1995, BIOCHEM BIOPH RES CO, V207, P860, DOI 10.1006/bbrc.1995.1265; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COLOMBEL M, 1995, ONCOGENE, V10, P1269; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HENSON DE, 1994, CANCER, V74, P424, DOI 10.1002/cncr.2820741330; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MacCallum DE, 1996, ONCOGENE, V13, P2575; MUNFORD RE, 1963, J ENDOCRINOL, V28, P17, DOI 10.1677/joe.0.0280017; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Petersen SL, 1996, ENDOCRINOLOGY, V137, P234, DOI 10.1210/en.137.1.234; Pullan S, 1996, J CELL SCI, V109, P631; QUARRIE LH, 1995, CELL TISSUE RES, V281, P413, DOI 10.1007/BF00417859; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WITTY JP, 1995, CANCER RES, V55, P1401	32	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2305	2312		10.1038/sj.onc.1202157	http://dx.doi.org/10.1038/sj.onc.1202157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811461				2022-12-25	WOS:000076723300004
J	Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR				Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR			Interaction of abl and raf with IL-7 signaling pathway and transformation of pre-B cells from resistant mice	ONCOGENE			English	Article						pre-B lymphomagenesis; JAK-STAT signaling; raf/myc retrovirus; abl/myc retrovirus; IL-7 signal transduction	T-CELLS; MURINE PLASMACYTOMAGENESIS; LEUKEMIA-VIRUS; MYC ONCOGENES; V-ABL; EXPRESSION; ABROGATION; MOUSE; DEPENDENCE; RETROVIRUS	After in vivo inoculation with abl/myc- and raf/myc-containing retroviruses, BALB/c mice predominantly develop late stage B cell tumors (plasmacytomas) and less frequently develop earlier B-lineage tumors while DBA/2 mice do not develop B-lineage tumors. We have investigated the in vitro tumorigenic potential of these viruses using cultured normal pre-B cell lymphocytes from both BALB/c and DBA/2 mice. Interestingly, both viruses infect cultured pre-B lymphocytes from both mouse strains. Following infection, IL-7 dependent pre-B cells become independent of normal in vitro growth requirements within 24 h and can rapidly form in vivo pre-B lymphomas in both mouse strains, Mechanisms mediating loss of IL-7 dependence are different depending on whether the I nf or abl gene is present in myc-containing viruses. IL-7 JAK-STAT signaling is constitutively active in abl/myc induced pre-B cell tumors, In contrast, IL-7 JAK-STAT signaling is not constitutive in raf/myc induced pre-B cell tumors, demonstrating that subversion of this component of IL-7 signal transduction is not obligatory for pre-B cell transformation or loss of IL-7 dependence.	US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Rockville, MD 20852 USA; NCI, Genet Lab, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bauer, SR (corresponding author), US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bldg 29B,2E16 HFM-521,1401 Rockville Pike, Rockville, MD 20852 USA.		Bauer, Steven/G-5559-2012	Bauer, Steven/0000-0003-2831-846X				ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; ANDERSON SM, 1990, ONCOGENE, V5, P317; BENDER TP, 1987, J IMMUNOL, V139, P3822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEAN M, 1987, ONCOGENE RES, V1, P279; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; HILBERT DM, 1993, ONCOGENE, V8, P1993; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIN AY, 1996, NEOPLASTIC DIS BLOOD; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; OKABE T, 1992, EUR J IMMUNOL, V22, P31, DOI 10.1002/eji.1830220106; POPLACK DG, 1989, CANC PRINCIPLES PRAC, P1671; Potter M, 1995, Curr Top Microbiol Immunol, V194, P83; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; ROLINK A, 1993, BLOOD, V81, P2290; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1991, BIOCHEM SOC T, V19, P275, DOI 10.1042/bst0190275; ROSE FV, 1992, VIROLOGY, V188, P650, DOI 10.1016/0042-6822(92)90519-U; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Sambrook J., 1989, MOL CLONING; SCHEUERMANN RH, 1993, METHOD ENZYMOL, V218, P446; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; Smith MR, 1996, CURR PROB CANCER, V20, P6, DOI 10.1016/S0147-0272(96)80303-5; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; WEISSINGER EM, 1993, MOL CELL BIOL, V13, P2578, DOI 10.1128/MCB.13.4.2578; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; WIERNIK PH, 1996, NEOPLASTIC DIS BLOOD	38	5	5	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2125	2135		10.1038/sj.onc.1202134	http://dx.doi.org/10.1038/sj.onc.1202134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798684				2022-12-25	WOS:000076540900012
J	Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F				Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F			Role of Gas1 down-regulation in mitogenic stimulation of quiescent NIH3T3 cells by v-Src	ONCOGENE			English	Article						v-Src; proliferation; gas1; PI 3-kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; MAP KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASES; TRANSFORMATION; PROTEINS; ACTIVATION; INHIBITOR; 3-KINASE; GENES	Quiescent mammalian fibroblasts can be induced to reenter the cell cycle by growth factors and oncoproteins, We studied the pathway(s) through which v-Src, the oncogenic tyrosine kinase encoded by the v-src oncogene of Rous sarcoma virus, forces serum-starved NIH3T3 cells to enter S-phase, To this purpose, we isolated and characterized a polyclonal population of NIH3T3 cells transformed by the MR31 retroviral vector, encoding G418 resistance and the v-src temperature-sensitive allele from the mutant ts LA31 PR-A, NIH(MR31! cells displayed a temperature-conditional transformed phenotype and could be made quiescent by serum deprivation at the restrictive temperature, Serum stimulation or thermolabile v-Src reactivation induced entry into S-phase to a comparable extent, although with different kinetics. The data suggest that v-Src mitogenic activity involves early activation of the Erk1/Erk2 MAP kinases with very little tyrosine phosphorylation of the Shc adaptor proteins at least during the early stages of v-Src reactivation and that v-Src-induced S-phase entry was strongly inhibited by drugs affecting MEK or PI 3-kinase, Our results also suggest that down-regulation of gas1 gene expression plays an important role in regulating the efficiency of entry into S-phase triggered by reactivated v-Src and that Gas1 down-regulation does not require PI 3-kinase dependent signals.	Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Lab Nazl Consorzio Interuni Biotecnol, I-34012 Trieste, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Tato, F (corresponding author), Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, Vie Apuli, I-00185 Rome, Italy.		la rocca, severina anna/D-8028-2011; Grossi, Milena/D-2955-2009					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CATLING AD, 1993, ONCOGENE, V8, P1875; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Haefner B, 1997, BIOCHEM J, V328, P649, DOI 10.1042/bj3280649; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCLADE J, 1992, P NATL ACAD SCI USA, V89, P8869; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1990, ONCOGENE, V5, P161; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	33	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1629	1638		10.1038/sj.onc.1202090	http://dx.doi.org/10.1038/sj.onc.1202090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796692				2022-12-25	WOS:000076200100001
J	Pasyk, EA; Morin, XK; Zeman, P; Garami, E; Galley, K; Huan, LJ; Wang, YC; Bear, CE				Pasyk, EA; Morin, XK; Zeman, P; Garami, E; Galley, K; Huan, LJ; Wang, YC; Bear, CE			A conserved region of the R domain of cystic fibrosis transmembrane conductance regulator is important in processing and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; CHLORIDE CHANNEL; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; ATP-BINDING; CFTR; PROTEINS; MODEL; SIMILARITIES; HYDROLYSIS	The R domain of cystic fibrosis transmembrane conductance regulator (CFTR) connects the two halves of the protein, each of which possess a transmembrane-spanning domain and a nucleotide binding domain. Phosphorylation of serine residues, which reside mostly within the C-terminal two-thirds of the R domain, is required for nucleotide-dependent activation of CFTR chloride channel activity. The N terminus of the R domain is also likely to be important in CFTR function, since this region is highly conserved among CFTRs of different species and exhibits sequence similarity with the "linker region" of the related protein, P glycoprotein, To date, however, the role of this region in CFTR channel function remains unknown. In this paper, we report the effects of five disease-causing mutations within the N terminus of the CFTR-R domain. All five mutants exhibit defective protein processing in mammalian HEK-293 cells, suggesting that they are mislocalized and fail to reach the cell surface. However, in the Xenopus oocyte, three mutants reached the plasma membrane. One of these mutants, L619S, exhibits no detectable function, whereas the other two, D614G and I618T, exhibit partial activity as chloride channels. Single channel analysis of these latter two mutants revealed that they possess defective rates of channel opening, consistent with the hypothesis that the N terminus of the R domain participates in ATP-dependent channel gating, These findings support recent structural models that include this region within extended boundaries of the first nucleotide binding domain.	Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Morin, Xenia/0000-0003-3847-0385; Garami, Elizabeth/0000-0003-1295-4007				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Annereau JP, 1997, FEBS LETT, V407, P303, DOI 10.1016/S0014-5793(97)00363-3; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1991, J BIOL CHEM, V266, P19142; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; COLE SP, 1992, SCIENCE, V260, P879; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Hoedemaeker FJ, 1998, PROTEINS, V30, P275, DOI 10.1002/(SICI)1097-0134(19980215)30:3<275::AID-PROT7>3.3.CO;2-L; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; MORIN XK, 1995, J PHYSIOL-LONDON, V486, P707, DOI 10.1113/jphysiol.1995.sp020846; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TABCHARANI JA, 1993, NATURE, V366, P188; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	31	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31759	31764		10.1074/jbc.273.48.31759	http://dx.doi.org/10.1074/jbc.273.48.31759			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822639	hybrid			2022-12-25	WOS:000077207000021
J	Bouvier, F; Backhaus, RA; Camara, B				Bouvier, F; Backhaus, RA; Camara, B			Induction and control of chromoplast-specific carotenoid genes by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HYDROGEN-PEROXIDE; CAPSICUM-ANNUUM; SINGLET OXYGEN; BETA-CAROTENE; XANTHOPHYLL BIOSYNTHESIS; MOLECULAR-CLONING; PHAFFIA-RHODOZYMA; ANTIOXIDANT; EXPRESSION; PLANTS	The differentiation of chloroplasts into chromoplasts involves a series of biochemical changes that culminate with the intense accumulation of long chain chromophore carotenoids such as lycopene, rhodoxanthin, astaxanthin, anhydroeschsoltzxanthin, capsanthin, and capsorubin. The signal pathways mediating these transformations are unknown. Chromoplast carotenoids are known to accumulate in green tissues experiencing stress conditions, and studies indicate that they provide efficient protection against oxidative stress. We tested the role of reactive oxygen species (ROS) as regulators of chromoplast carotenoid biosynthesis in vivo. The addition of ROS progenitors, such as menadione, tert-butylhydroperoxide, or paraquat and prooxidants such as diamide or buthionine sulfoximine to green pericarp discs of pepper fruits rapidly and dramatically induce the simultaneous expression of multiple carotenogenic gene mRNAS that give rise to capsanthin. Similarly, down-regulation of catalase by amitrole induces expression of carotenogenic gene mRNAs leading to the synthesis of capsanthin in excised green pericarp discs. ROS signals from plastids and mitochondria also contribute significantly to this process. Analysis of the capsanthin-capsorubin synthase promoter in combination with a P-glucuronidase reporter gene reveals strong activation in transformed pepper protoplasts challenged with the above ROS. Collectively these data demonstrate that ROS act as a novel class of second messengers that mediate intense carotenoid synthesis during chromoplast differentiation.	CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France; Arizona State Univ, Dept Bot, Tempe, AZ 85287 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Arizona State University; Arizona State University-Tempe	Camara, B (corresponding author), CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.							Asada K., 1987, PHOTOINHIBITION, P227; BABA A, 1981, J BIOL CHEM, V256, P3679; BABBS CF, 1989, PLANT PHYSIOL, V90, P1267, DOI 10.1104/pp.90.4.1267; BALLACH H-J, 1992, Angewandte Botanik, V66, P14; BATRA PP, 1967, J BIOL CHEM, V242, P5630; BEJARANO ER, 1989, PHYTOCHEMISTRY, V28, P1623, DOI 10.1016/S0031-9422(00)97812-9; Bouvier F, 1997, ARCH BIOCHEM BIOPHYS, V346, P53, DOI 10.1006/abbi.1997.0278; BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; Bouvier F, 1996, J BIOL CHEM, V271, P28861, DOI 10.1074/jbc.271.46.28861; BOUVIER F, 1996, THESIS U L PASTEUR; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRENNAN T, 1977, PLANT PHYSIOL, V59, P411, DOI 10.1104/pp.59.3.411; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Camara B, 1995, INT REV CYTOL, V163, P175, DOI 10.1016/S0074-7696(08)62211-1; CAMARA B, 1985, METHOD ENZYMOL, V111, P544; CAMARA B, 1985, METHOD ENZYMOL, V110, P274; CARDE JP, 1988, PLANTA, V173, P1, DOI 10.1007/BF00394480; CARRIERE EA, 1884, REV HORT, V553; Chandra S, 1996, PLANT PHYSIOL, V110, P979, DOI 10.1104/pp.110.3.979; CHAUDIERE J, 1994, FREE RADICAL DAMAGE, P25; CHEN GX, 1990, J BIOL CHEM, V265, P2775; COOPER TG, 1969, J BIOL CHEM, V244, P3507; Corona V, 1996, PLANT J, V9, P505, DOI 10.1046/j.1365-313X.1996.09040505.x; COSTES C, 1969, Bulletin de la Societe Francaise de Physiologie Vegetale, V15, P55; COWAN AK, 1992, J EXP BOT, V43, P1535, DOI 10.1093/jxb/43.12.1535; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DAHLIN C, 1986, PHYSIOL PLANTARUM, V68, P39, DOI 10.1111/j.1399-3054.1986.tb06593.x; Dempsey D A, 1994, Trends Cell Biol, V4, P334, DOI 10.1016/0962-8924(94)90235-6; DERUERE J, 1994, PLANT CELL, V6, P119, DOI 10.1105/tpc.6.1.119; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIAZ M, 1990, PLANT PHYSIOL BIOCH, V28, P679; Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4; Elstner E. F., 1988, Current Topics in Plant Biochemistry and Physiology, V7, P159; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EYSTER HC, 1950, PLANT PHYSIOL, V25, P630, DOI 10.1104/pp.25.4.630; Faludi-Daniel A., 1966, Biochemistry of chloroplasts. Proceedings of a NATO Advanced Study Institute held at Aberystwyth, August 1965., P269; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; FRYER MJ, 1992, PLANT CELL ENVIRON, V15, P381, DOI 10.1111/j.1365-3040.1992.tb00988.x; GALLIARD T, 1978, BIOCH WOUNDED PLANT, P155; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GIULIANO G, 1993, PLANT CELL, V5, P379, DOI 10.1105/tpc.5.4.379; Griffith O W, 1981, Methods Enzymol, V77, P59; GRUMBACH KH, 1984, PHYSIOL PLANTARUM, V60, P389, DOI 10.1111/j.1399-3054.1984.tb06081.x; GUILLOT-SALOMON T, 1967, Bulletin de la Societe des Sciences Veterinaires et de Medecine Comparee de Lyon, V13, P63; HARVEY BMR, 1982, HERBICIDE RESISTANCE, P215; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HAVIR EA, 1992, PLANT PHYSIOL, V99, P533, DOI 10.1104/pp.99.2.533; HIRAYAMA O, 1994, LIPIDS, V29, P149, DOI 10.1007/BF02537155; HSIEH LK, 1974, J BACTERIOL, V118, P385, DOI 10.1128/JB.118.2.385-393.1974; HUGUENEY P, 1992, EUR J BIOCHEM, V209, P399, DOI 10.1111/j.1432-1033.1992.tb17302.x; Hugueney P, 1996, PLANT PHYSIOL, V111, P619, DOI 10.1104/pp.111.2.619; HUGUENEY P, 1995, PLANT J, V8, P417, DOI 10.1046/j.1365-313X.1995.08030417.x; HUGUENEY P, 1994, THESIS U PARIS SUD O; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEREBZOFFQUINTIN S, 1975, PHYSIOL VEG, V13, P55; KOBAYASHI M, 1993, APPL ENVIRON MICROB, V59, P867, DOI 10.1128/AEM.59.3.867-873.1993; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649; KRUGERLEBUS S, 1987, PLANT MOL BIOL REP, V5, P289; KUNTZ M, 1992, PLANT J, V2, P25; LARRINUA IM, 1989, PLANT PHYSL ROCKV, V91, P1226; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIEDVOGEL B, 1976, CYTOBIOLOGIE, V12, P155; LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178; Lippmaa T, 1926, CR HEBD ACAD SCI, V182, P1040; MATTON DP, 1993, PLANT MOL BIOL, V22, P279, DOI 10.1007/BF00014935; MORDI RC, 1991, TETRAHEDRON LETT, V32, P4203, DOI 10.1016/S0040-4039(00)79905-9; MORELAND DE, 1980, ANNU REV PLANT PHYS, V31, P597, DOI 10.1146/annurev.pp.31.060180.003121; OHL S, 1990, PLANT CELL, V9, P49; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PAL DK, 1987, J HORTIC SCI, V62, P117, DOI 10.1080/14620316.1987.11515759; PALOZZA P, 1992, METHOD ENZYMOL, V213, P403; PARKER ML, 1983, PLANTA, V159, P512, DOI 10.1007/BF00409140; POLLE A, 1992, NEW PHYTOL, V121, P89, DOI 10.1111/j.1469-8137.1992.tb01096.x; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; RAU W, 1967, BIOCHIM BIOPHYS ACTA, V136, P589, DOI 10.1016/0304-4165(67)90026-8; RAYMUNDO LC, 1967, PHYTOCHEMISTRY, V6, P1527, DOI 10.1016/S0031-9422(00)82946-5; RICHARDS HM, 1897, ANN BOT, V10, P29; Ridley S.M., 1982, CAROTENOID CHEM BIOC, P353, DOI 10.1016/B978-0-08-026224-6.50029-2; Rogiers SY, 1998, ANN BOT-LONDON, V81, P203, DOI 10.1006/anbo.1997.0543; ROMER S, 1993, BIOCHEM BIOPH RES CO, V196, P1414, DOI 10.1006/bbrc.1993.2410; RUDIGER W, 1976, Z PFLANZENPHYSIOL, V80, P131; RUSHING JW, 1985, J AM SOC HORTIC SCI, V110, P316; Sambrook J, 1989, MOL CLONING LABORATO, P545; SCANDALIOS JG, 1993, PLANT PHYSIOL, V101, P7, DOI 10.1104/pp.101.1.7; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHROEDER WA, 1995, J BIOL CHEM, V270, P18374, DOI 10.1074/jbc.270.31.18374; Schroeder WA, 1996, MICROBIOL-UK, V142, P2923, DOI 10.1099/13500872-142-10-2923; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAISH A, 1993, PLANTA, V190, P363; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SKRIVER K, 1991, P NATL ACAD SCI USA, V88, P7266, DOI 10.1073/pnas.88.16.7266; THEIMER RR, 1972, PLANTA, V106, P331, DOI 10.1007/BF00384770; THEIMER RR, 1970, PLANTA, V92, P129, DOI 10.1007/BF00385205; THOMPSON JE, 1987, NEW PHYTOL, V105, P317, DOI 10.1111/j.1469-8137.1987.tb00871.x; TOYAMA S, 1971, BOT MAG TOKYO, V84, P123; TZENG DD, 1993, ADV PLANT PATHOL, V10, P1; ULRICH R, 1950, CR HEBD ACAD SCI, V230, P567; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VONMOHL H, 1838, ANN SCI NAT BOT BIOL, V9, P212; WRIGHT BJ, 1980, PHYTOCHEMISTRY, V19, P61, DOI 10.1016/0031-9422(80)85013-8; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259; YURELA I, 1996, J BIOL CHEM, V271, P27408; ZITO F, 1995, PHYSIOL PLANTARUM, V94, P535, DOI 10.1111/j.1399-3054.1995.tb00965.x	107	167	189	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30651	30659		10.1074/jbc.273.46.30651	http://dx.doi.org/10.1074/jbc.273.46.30651			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804838	hybrid			2022-12-25	WOS:000077008100085
J	Gerber, HP; McMurtrey, A; Kowalski, J; Yan, MH; Keyt, BA; Dixit, V; Ferrara, N				Gerber, HP; McMurtrey, A; Kowalski, J; Yan, MH; Keyt, BA; Dixit, V; Ferrara, N			Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3 '-kinase Akt signal transduction pathway - Requirement for Flk-1/KDR activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; BLOOD-VESSEL GROWTH; FACTOR VEGF; IN-VIVO; PROTEIN; APOPTOSIS; ANGIOGENESIS; FLT-1; 3-KINASE; INSULIN	Vascular endothelial growth factor (VEGF) has been found to have various functions on endothelial cells, the most prominent of which is the induction of proliferation and differentiation. In this report we demonstrate that VEGF or a mutant, selectively binding to the Flk-1/KDR receptor, displayed high levels of survival activity, whereas Flt-1-specific ligands failed to promote survival of serum-starved primary human endothelial cells. This activity was blocked by the phosphatidylinositol 3'-kinase (PI3-kinase)-specific inhibitors wortmannin and LY294002. Endothelial cells cultured in the presence of VEGF and the Flk-1/KDR-selective VEGF mutant induced phosphorylation of the serine-threonine kinase Akt in a PI3-kinase-dependent manner. Akt activation was not detected in response to stimulation with placenta growth factor or an Flt-1-selective VEGF mutant. Furthermore, a constitutively active Akt was sufficient to promote survival of serum-starved endothelial cells in transient transfection experiments. In contrast, overexpression of a dominant-negative form of Akt blocked the survival effect of VEGF. These findings identify the Flk-1/HDR receptor and the PI3-kinase/Akt signal transduction pathway as crucial elements in the processes leading to endothelial cell survival induced by VEGF. Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium.	Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, San Francisco, CA 94080 USA.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V172, P1081, DOI 10.1016/0006-291X(90)91557-9; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; AUGUSTIN HG, 1995, AM J PATHOL, V147, P339; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BORASIO GD, 1989, NEURON, V2, P1087; Borgstrom P, 1998, PROSTATE, V35, P1; BUCHMAN TG, 1993, AM J PHYSIOL, V265, pH165, DOI 10.1152/ajpheart.1993.265.1.H165; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li YG, 1997, BIOTECHNIQUES, V23, P1026, DOI 10.2144/97236bm12; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Minshall C, 1996, J IMMUNOL, V156, P939; Modlich U, 1996, LAB INVEST, V74, P771; Moore A, 1998, METHOD CELL BIOL, V57, P265; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parrizas M, 1997, J BIOL CHEM, V272, P154; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROBBINS SL, 1981, BASIC PATHOLOGY, P51; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1991, ONCOGENE, V6, P1677; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALKER NI, 1987, J PATHOL, V153, P333, DOI 10.1002/path.1711530407; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	73	1675	1754	1	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30336	30343		10.1074/jbc.273.46.30336	http://dx.doi.org/10.1074/jbc.273.46.30336			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804796	hybrid			2022-12-25	WOS:000077008100043
J	Pastuszak, I; Ketchum, C; Hermanson, G; Sjoberg, EJ; Drake, R; Elbein, AD				Pastuszak, I; Ketchum, C; Hermanson, G; Sjoberg, EJ; Drake, R; Elbein, AD			GDP-L-fucose pyrophosphorylase - Purification, cDNA cloning, and properties of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEX; CARBOHYDRATE LIGAND; CELL-ADHESION; L-SELECTIN; LEWIS; OLIGOSACCHARIDE; DETERMINANTS; RECOGNITION; CONVERSION; RECEPTOR	The enzyme that catalyzes the formation of GDP-L-fucose from GTP and beta-L-fucose-1-phosphate (i.e. GDP-beta-L-fucose pyrophosphorylase, GFPP) was purified about 560-fold from the cytosolic fraction of pig kidney. At this stage, there were still a number of protein bands on SDS gels, but only the 61-kDa band became specifically labeled with the photoaffinity substrate, azido-GDP-L- [P-32]fucose, Several peptides from this 61-kDa band were sequenced and these sequences were used for cloning the gene. The cDNA clone yielded high levels of GFPP activity when expressed in myeloma cells and in a baculovirus system, demonstrating that the 61-kDa band is the authentic GFPP, The porcine tissue with highest specific activity for GFPP was kidney, with lung, liver, and pancreas being somewhat lower. GFPP was also found in Chinese hamster ovary, but not Madin-Darby canine kidney cells. Northern analysis showed the mRNA in human spleen, prostate, testis, ovary, small intestine, and colon. GFPP was stable at 4 degrees C in buffer containing 50 mM sucrose, with little loss of activity over a g-day period. GTP was the best nucleoside triphosphate substrate but significant activity was also observed with ITP and to a lesser extent with ATP, The enzyme was reasonably specific for beta-L-fucose-1-P, but could also utilize alpha-D arabinose-1-P to produce GDP-alpha-D-arabinose, The product of the reaction with GTP and alpha-L-fucose-1-P was characterized as GDP-beta-L-fucose by a variety of chemical and chromatographic methods.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Calbiochem Nova Biochem, San Diego, CA 92121 USA; Cytel Corp, San Diego, CA 92121 USA	University of Arkansas System; University of Arkansas Medical Sciences	Elbein, AD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.				NHLBI NIH HHS [HL 17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMANO J, 1991, J BIOL CHEM, V266, P11461; ASHWELL G, 1957, METHOD ENZYMOL, V3, P73, DOI 10.1016/S0076-6879(57)03350-9; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BULET P, 1984, EUR J BIOCHEM, V144, P255, DOI 10.1111/j.1432-1033.1984.tb08458.x; BUTLER W, 1985, BIOCHIM BIOPHYS ACTA, V829, P238, DOI 10.1016/0167-4838(85)90193-1; COFFEY JW, 1964, J BIOL CHEM, V239, P4011; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; GENG JG, 1992, J BIOL CHEM, V267, P19846; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; IMAI Y, 1993, NATURE, V361, P555; ISHIHARA H, 1968, J BIOL CHEM, V243, P1103; ISHIHARA H, 1968, J BIOL CHEM, V243, P1110; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGER M, 1990, GENE TRANSFER EXPRES, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; MUNRO JR, 1975, ARCH BIOCHEM BIOPHYS, V169, P269, DOI 10.1016/0003-9861(75)90341-0; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Park S, 1997, ANAL BIOCHEM, V244, P321, DOI 10.1006/abio.1996.9906; Park SH, 1998, J BIOL CHEM, V273, P5685, DOI 10.1074/jbc.273.10.5685; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PROHASKA R, 1975, ANAL BIOCHEM, V69, P536, DOI 10.1016/0003-2697(75)90158-X; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; Vries T., 1993, FEBS LETT, V330, P243; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1	38	50	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30165	30174		10.1074/jbc.273.46.30165	http://dx.doi.org/10.1074/jbc.273.46.30165			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804772	hybrid			2022-12-25	WOS:000077008100019
J	Satoh, H; Nakayama, K; Okada, M				Satoh, H; Nakayama, K; Okada, M			Molecular cloning and functional expression of a water-soluble chlorophyll protein, a putative carrier of chlorophyll molecules in cauliflower	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRASSICA-NAPUS LEAVES; A/B-BINDING-PROTEIN; GREEN-ALGA; BRYOPSIS-MAXIMA; PHOTOSYSTEM-II; HIGHER-PLANTS; LIGHT; DROUGHT; COMPLEXES; STRESS	A cDNA for a water-soluble chlorophyll (Chl) protein (WSCP) from cauliflower (Brassica oleracea L. var botrys) was cloned and sequenced. The cDNA contained an open reading frame encoding 19 residues for a signal peptide and 199 residues for the mature form of WSCP. The sequence showed extensive homology to drought-stress-related, 22-kDa proteins in some Brassicaceae plants. Functional WSCP was expressed in Escherichia coli as a fusion protein with a maltose-binding protein (MBP). When the recombinant MBP-WSCP was incubated with thylakoid membranes, the MBP-WSCP removed Chls from these membranes. During this process, the monomer of the apo-MEP-WSCP successfully bound Chls and was converted into tetrameric holo-MBP-WSCP. The reconstituted MBP-WSCP exhibited absorption and fluorescent spectra identical to those of the native WSCP purified from cauliflower leaves. The Chi alb ratio in native WSCP indicates a high content of Chi a, which was mainly due to the higher affinity of MBP-WSCP for Chi a. WSCP is the first example of a hydrophilic protein that can transfer Chls from thylakoid hydrophobic proteins. Possible functions of WSCP are discussed.	Toho Univ, Dept Biomol Sci, Chiba 2748510, Japan	Toho University	Satoh, H (corresponding author), Toho Univ, Dept Biomol Sci, 2-2-1 Miyama, Chiba 2748510, Japan.	hsatoh@biomol.sci.toho-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMIRSHAPIRA D, 1986, PLANT SCI, V43, P201, DOI 10.1016/0168-9452(86)90018-X; ARGYROUDIAKOYUNOGLOU JH, 1982, PLANT PHYSIOL, V70, P1242, DOI 10.1104/pp.70.5.1242; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTELS D, 1992, EMBO J, V11, P2771, DOI 10.1002/j.1460-2075.1992.tb05344.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWNING WL, 1992, PLANT J, V2, P685, DOI 10.1046/j.1365-313X.1992.t01-11-00999.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARCIA AL, 1991, PHOTOSYNTHETICA, V25, P105; GOSTI F, 1995, MOL GEN GENET, V246, P10, DOI 10.1007/BF00290128; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; Ilami G, 1997, PHYTOCHEMISTRY, V45, P1, DOI 10.1016/S0031-9422(96)00788-1; ITOH R, 1982, PLANT CELL PHYSIOL, V23, P557, DOI 10.1093/oxfordjournals.pcp.a076381; Kamimura Y, 1997, PLANT CELL PHYSIOL, V38, P133, DOI 10.1093/oxfordjournals.pcp.a029143; Katayama Nobuyasu, 1994, Japanese Journal of Phycology, V42, P71; KISHORE R, 1993, P NATL ACAD SCI USA, V90, P11845, DOI 10.1073/pnas.90.24.11845; KOBAYASHI M, 1988, BIOCHIM BIOPHYS ACTA, V936, P81, DOI 10.1016/0005-2728(88)90254-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ F, 1994, PHYSIOL PLANTARUM, V91, P605, DOI 10.1111/j.1399-3054.1994.tb02995.x; MARKWELL JP, 1979, P NATL ACAD SCI USA, V76, P1233, DOI 10.1073/pnas.76.3.1233; Matile P, 1996, PLANT PHYSIOL, V112, P1403, DOI 10.1104/pp.112.4.1403; Matile P, 1997, PLANTA, V201, P96, DOI 10.1007/BF01258685; MORAN JF, 1994, PLANTA, V194, P346, DOI 10.1007/BF00197534; MURATA T, 1971, BIOCHIM BIOPHYS ACTA, V245, P208, DOI 10.1016/0005-2728(71)90023-5; MURATA T, 1981, BIOCHIM BIOPHYS ACTA, V635, P341, DOI 10.1016/0005-2728(81)90032-3; Murata T, 1971, CARNEGIE I WASH YB, V70, P504; MURATA T, 1986, THESIS KYUSHU U FUKU; NAKAYAMA K, 1986, PLANT CELL PHYSIOL, V27, P311; NAKAYAMA K, 1994, BBA-BIOENERGETICS, V1184, P103, DOI 10.1016/0005-2728(94)90159-7; Nishio N, 1997, PLANT PHYSIOL, V115, P841, DOI 10.1104/pp.115.2.841; Nooden LD, 1997, PHYSIOL PLANTARUM, V101, P746, DOI 10.1111/j.1399-3054.1997.tb01059.x; Ohtsuka T, 1997, PLANT PHYSIOL, V113, P137, DOI 10.1104/pp.113.1.137; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; REVIRON MP, 1992, PLANT PHYSIOL, V100, P1486, DOI 10.1104/pp.100.3.1486; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SORENSEN AB, 1992, PLANT PHYSIOL, V98, P1538, DOI 10.1104/pp.98.4.1538; SUGIYAMA KI, 1978, BIOCHIM BIOPHYS ACTA, V503, P107, DOI 10.1016/0005-2728(78)90165-2; SULLI C, 1995, J BIOL CHEM, V270, P13084, DOI 10.1074/jbc.270.22.13084; TABATA K, 1983, PLANT CELL PHYSIOL, V24, P987; Tanaka A, 1997, PLANT CELL PHYSIOL, V38, P17, DOI 10.1093/oxfordjournals.pcp.a029080; TANAKA A, 1982, BIOCHIM BIOPHYS ACTA, V680, P265, DOI 10.1016/0005-2728(82)90138-4; TANAKA A, 1991, PLANT CELL PHYSIOL, V32, P195, DOI 10.1093/oxfordjournals.pcp.a078064; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	45	60	66	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30568	30575		10.1074/jbc.273.46.30568	http://dx.doi.org/10.1074/jbc.273.46.30568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804827	hybrid			2022-12-25	WOS:000077008100074
J	Tsuboi, S; Fukuda, M				Tsuboi, S; Fukuda, M			Overexpression of branched O-linked oligosaccharides on T cell surface glycoproteins impairs humoral immune responses in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; GERMINAL CENTER FORMATION; CD40 LIGAND; L-SELECTIN; CARBOHYDRATE ANTIGENS; EXPRESSION CLONING; LYMPHOCYTES; BIOSYNTHESIS; LEUKEMIA; GLYCANS	The aberrant expression of core 2 O-glycans on T cell surface glycoproteins has been associated with various immunodeficient syndromes such as Wiskott-Aldrich syndrome and AIDS. To determine the effect of this aberrant expression of core 2 O-glycans on immune responses, we previously generated transgenic mice overexpressing core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT) in T cells, and demonstrated that T cell primary immune responses mediated through interaction between T cells and antigen-presenting cells are impaired in the transgenic mice (Tsuboi, S., and Fukuda, M. (1991) EIMBO J. 16, 6364-6373). In this study, we determined whether overexpression of core 2 oligosaccharides on T cells leads to impaired humoral immune responses by B cells using the same transgenic mice. When T cells were activated, both T and B cells from the transgenic and control mice expressed an equivalent amount of CD40L and CD40, which are, respectively, the receptor and counter-receptor for the interaction between T and B cells. However, activated T cells from the transgenic mice induced B cell proliferation less efficiently than those from control mice, regardless of whether B cells were isolated from control or the transgenic mice. This suggests that overexpression of core 2 O-glycans on T cell surface glycoproteins renders T cell-B cell interaction inefficient. Moreover, in the transgenic mice both immunoglobulin isotype switching and germinal center formation were also impaired. Taken together, these results indicate that aberrant expression of core 2 O-glycans on T cell surface glycoproteins results in impaired humoral immune responses due to an impaired interaction between T and B cells.	Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [R37CA33000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BARRAN P, 1997, GLYCOBIOLOGY, V7, P121; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BINZ H, 1975, J EXP MED, V142, P1231, DOI 10.1084/jem.142.5.1231; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GRANOVSKY M, 1997, GLYCOBIOLOGY, V7, P1048; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HYMAN R, 1986, CELL IMMUNOL, V101, P320, DOI 10.1016/0008-8749(86)90145-0; KATO T, 1994, J IMMUNOL, V152, P2130; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEE N, 1990, J BIOL CHEM, V265, P20476; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; OCHS HD, 1980, BLOOD, V55, P243; PERRILO NL, 1995, NATURE, V378, P736; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROY M, 1993, J IMMUNOL, V151, P2497; SAITOH O, 1991, BLOOD, V77, P1491; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Xu JC, 1996, J EXP MED, V183, P589, DOI 10.1084/jem.183.2.589; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	50	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30680	30687		10.1074/jbc.273.46.30680	http://dx.doi.org/10.1074/jbc.273.46.30680			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804842	hybrid			2022-12-25	WOS:000077008100089
J	Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE				Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE			Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						CGH; Ki-ras; gene amplification; MAP kinase; mammary gland tumor; transgenic mice; Ras-bound GTP and GDP	LARGE T-ANTIGEN; HUMAN-BREAST CARCINOMAS; C-MYC; ONCOGENE AMPLIFICATION; PROTO-ONCOGENE; GENE; CELLS; EXPRESSION; CANCER; TUMORIGENESIS	We have previously documented that transgenic mice expressing SV40 Tag regulated by the rat prostatic steroid-binding protein C3(1) 5'-flanking region display multistage mammary tumorigenesis. To delineate genetic changes associated with mammary tumor progression, comparative genomic hybridization (CGH) was performed. CGH revealed a consistent gain of the telomeric region of chromosome 6, This region contains the Ki-ras proto-oncogene, Analyses of genomic DNA by Southern blot demonstrated up to 40-fold amplification of the Ki-ras gene. Ki-ras amplification was detected in 12, 46 and 68% of tumors from 4, 5 and 6 month old mice, respectively, whereas no amplifications were found in any preneoplastic mammary tissues. Tumors bearing Ki-ras gene amplification exhibited high levels of Ki-ras RNA and protein, The over-expressed Ki-Ras protein in these tumors appeared functionally active as indicated by the elevated MAP kinase activity, These data demonstrate that while Ki-ras amplification might not be an early event, there is a strong association between Ki-ras amplification and over-expression and mammary tumor progression in this model. This study also shows that CGH is a powerful and useful technique for identifying chromosomal copy number changes during tumor progression, and that this model may provide a predictable in vivo system for studying gene amplification.	NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bldg 41 Room C619, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				ALDAZ CM, 1993, CANCER RES, V53, P5339; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CZERNIAK B, 1989, CANCER, V63, P2008, DOI 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO;2-D; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARCIA I, 1989, CANCER RES, V49, P6675; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Jenkins RB, 1997, CANCER RES, V57, P524; Jones KA, 1995, CANCER SURV, V25, P315; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; RIED T, 1995, CANCER RES, V55, P5415; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEKHAR PVM, 1994, INVAS METAST, V14, P27; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1996, CANCER RES, V56, P4894; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; THEILLET C, 1986, CANCER RES, V46, P4776; VARLEY JM, 1987, ONCOGENE, V1, P423; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2403	2411		10.1038/sj.onc.1202456	http://dx.doi.org/10.1038/sj.onc.1202456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811472				2022-12-25	WOS:000076723300015
J	Costa, C; Solanes, G; Visa, J; Bosch, F				Costa, C; Solanes, G; Visa, J; Bosch, F			Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus	FASEB JOURNAL			English	Article						bovine growth hormone; IGF; PEPCK; hyperglycemia	FUSION GENES; FACTOR-I; MICE; HISTOPATHOLOGY; EXPRESSION; METABOLISM; ACID; GH	Transgenic rabbits expressing the bovine growth hormone (bGH) gene in liver and kidney were obtained to study the long-term effects of chronic exposure to GH in nonrodent animals, These rabbits presented high levels of bGH and insulin-like growth factor I in serum. In spite of chronic exposure to bGH, transgenic rabbits had similar body weight to controls. However, enlargement of the head and limbs and reduction of visceral fat were observed in these animals. They also showed marked hyperinsulinemia, hyperglycemia, and hypertriglyceridemia, indicating that they developed insulin resistance, Furthermore, serious histopathological alterations, including marked fibrosis, were observed in liver, kidney, and skeletal muscle. These anatomical, metabolic, and histological alterations closely resemble those found in patients with acromegaly, Thus, transgenic rabbits overexpressing GH may be a good model of the human disease.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra, Spain	Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra, Spain.		costa, cristina/P-5924-2014; Costa, Cristina/AAP-4005-2020	costa, cristina/0000-0002-6549-4553; Costa, Cristina/0000-0002-1837-4268; BOSCH, FATIMA/0000-0002-7705-5515				BODEN G, 1968, METABOLISM, V17, P1, DOI 10.1016/S0026-0495(68)80002-2; BUHLER TA, 1990, BIO-TECHNOL, V8, P140, DOI 10.1038/nbt0290-140; CHANGDEMORANVILLE BM, 1992, ENDOCRIN METAB CLIN, V21, P649, DOI 10.1016/S0889-8529(18)30207-X; CHEN NY, 1995, ENDOCRINOLOGY, V136, P660, DOI 10.1210/en.136.2.660; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOUGLAS RG, 1990, BRIT J SURG, V77, P785, DOI 10.1002/bjs.1800770722; FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175; GANDA OP, 1993, DIABETES REV, V1, P286; JADRESIC A, 1982, Q J MED NS L1, V202, P189; MASTAGLIA FL, 1973, ACTA NEUROPATHOL, V24, P273, DOI 10.1007/BF00685584; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MERIMEE TJ, 1995, PRINCIPLES PRACTICE; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; OSULLIVAN AJ, 1994, J CLIN ENDOCR METAB, V78, P381, DOI 10.1210/jc.78.2.381; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PICKETT JBE, 1975, NEUROLOGY, V25, P638, DOI 10.1212/WNL.25.7.638; PINKERT CA, 1994, TRANSGENIC RES, V3, P401, DOI 10.1007/BF01976771; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; Pursel V G, 1990, J Reprod Fertil Suppl, V40, P235; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RIEN M, 1982, J CLIN ENDOCR METAB, V55, P147; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SHEA BT, 1990, GENET RES, V56, P21, DOI 10.1017/S0016672300028846; Steele FR, 1996, NAT MED, V2, P369, DOI 10.1038/nm0496-369; THORNER MO, 1992, TXB ENDOCRINOLOGY; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; WASS JAH, 1980, CLIN ENDOCRINOL, V12, P53, DOI 10.1111/j.1365-2265.1980.tb03132.x; WIEGHART M, 1990, J REPROD FERTIL S, V41, P89; YUN JS, 1990, P SOC EXP BIOL MED, V194, P308	32	34	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1455	1460		10.1096/fasebj.12.14.1455	http://dx.doi.org/10.1096/fasebj.12.14.1455			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806754				2022-12-25	WOS:000076749500004
J	Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV				Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV			Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis	ONCOGENE			English	Article						Ras; Met; HGF/SF; tumorigenesis; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; PROTOONCOGENE PRODUCT; ONCOGENE ACTIVATION; FACTOR RECEPTOR; NIH/3T3 CELLS; HUMAN CANCER; EXPRESSION; TRANSFORMATION; TUMORIGENICITY	Aberrations in Met-hepatocyte growth factor/scatter factor (HGF/SF) signaling have been implicated in the acquisition of tumorigenic and metastatic phenotypes, Here we show that murine NIH3T3 and C127 cells transformed by the Ras oncogene overexpress the Met receptor, resulting in enhanced HGF/SF-mediated responses in vitro including invasion through basement membrane. Accompanying the increase in Met in ras-transformed NIH3T3 cells, there is a decrease in endogenous HGF/SF expression as previously observed in cells exogenously overexpressing Met. However, subcutaneously grown tumors and experimental lung metastases derived from these cells express significantly higher levels of endogenous HGF/SF together with high levels of Met, These results suggest Met-HGF/SF signaling enhances tumor growth and metastasis of Ras-transformed NIH3T3 cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, POB B, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012		OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BONDY GP, 1985, CANCER RES, V45, P6005; BOS JL, 1989, CANCER RES, V49, P4682; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; GALANG CK, 1994, ONCOGENE, V9, P2913; Gambarotta G, 1996, ONCOGENE, V13, P1911; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	31	66	70	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2019	2025		10.1038/sj.onc.1202135	http://dx.doi.org/10.1038/sj.onc.1202135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798673				2022-12-25	WOS:000076540900001
J	Habano, W; Nakamura, S; Sugai, T				Habano, W; Nakamura, S; Sugai, T			Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: Evidence for mismatch repair systems in mitochondrial genome	ONCOGENE			English	Article						genomic instability; mitochondrial DNA; colorectal carcinoma	CRYPT-ISOLATION TECHNIQUE; II RECEPTOR GENE; CANCER-CELLS; NUCLEAR-DNA; MUTATIONS; DISEASES; COLON; CARCINOGENESIS; DEFICIENCY; EXPRESSION	The role, if any, that alterations play in the carcinogenic process remains unclear. To determine whether mtDNA instability occurs in cancers, nine microsatellite sequences in the mtDNA mere examined in 45 sporadic colorectal carcinomas. Alteration in a polycytidine (C)n tract within a noncoding displacement-loop (D-loop) region was detected in 20 carcinomas (44%), three of which also exhibited frameshift mutations in a polyadenosine (A)8 or polycytidine (C)6 tract within NADH dehydrogenase (ND) genes. Interestingly, all three mutant genes were predicted to encode truncated ND proteins, which lacked a large portion of the C-terminus. These results suggested that certain repair systems, like the mismatch repair systems in the nuclear genome, are required for mtDNA maintenance and that defects in these systems can lead to target mitochondrial gene mutations in colorectal carcinomas.	Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 020, Japan	Iwate University	Nakamura, S (corresponding author), Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Uchimaru, Morioka, Iwate 020, Japan.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BERNARDI G, 1979, TRENDS BIOCHEM SCI, V4, P197, DOI 10.1016/0968-0004(79)90079-3; BISHOP JM, 1993, CELL, V75, P235; BOYER JC, 1995, CANCER RES, V55, P6063; BURGART LJ, 1995, AM J PATHOL, V147, P1105; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; FUKUDA M, 1985, J MOL BIOL, V186, P257, DOI 10.1016/0022-2836(85)90102-0; Habano W, 1996, LAB INVEST, V74, P933; Habano W, 1998, ONCOGENE, V16, P1259, DOI 10.1038/sj.onc.1201651; HEERDT BG, 1994, CANCER RES, V54, P3912; HEERDT BG, 1990, CANCER RES, V50, P1596; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JONASSON J, 1977, J CELL SCI, V24, P255; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; NAKAMURA S, 1993, GUT, V34, P1240, DOI 10.1136/gut.34.9.1240; OBERLEY LW, 1979, CANCER RES, V39, P1141; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; PARSONS R, 1995, CANCER RES, V55, P5548; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; REENAN RAG, 1992, GENETICS, V132, P975; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WILKIE D, 1983, INT REV CYTOL, P157; Yoshida T, 1996, J SURG ONCOL, V63, P9	41	135	154	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1931	1937		10.1038/sj.onc.1202112	http://dx.doi.org/10.1038/sj.onc.1202112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788436				2022-12-25	WOS:000076423500006
J	Nikiforov, YE; Nikiforova, M; Fagin, JA				Nikiforov, YE; Nikiforova, M; Fagin, JA			Radiation-induced post-Chernobyl pediatric thyroid carcinomas	ONCOGENE			English	Article						minisatellites; microsatellites; radiation; thyroid tumors; Chernobyl; genomic instability	INDUCED GENOMIC INSTABILITY; POLYMERASE CHAIN-REACTION; HUMAN MINISATELLITE; HYPERVARIABLE LOCI; IONIZING-RADIATION; MUTATION PROCESSES; SOMATIC MUTATIONS; RET PROTOONCOGENE; NUCLEAR ACCIDENT; VNTR-LOCUS	Exposure to ionizing radiation induces different forms of genomic instability in cultured cells and experimental animals. A higher rate of germline mutations at human hypervariable minisatellite loci was reported in children born from parents exposed to radiation after Chernobyl, implicating genome destabilization as a possible mechanism responsible for late radiation effects in humans. To test if radiation-induced carcinogenesis in the thyroid gland may be associated with somatic minisatellite instability or microsatellite instability, we utilized a PCR-based approach to study normal and tumor DNA from 17 pediatric post-Chernobyl papillary thyroid carcinomas for mutations at three different minisatellite loci (D1S80, D17S30, ApoB), and 27 microsatellite loci of di-, tri-, or tetranucleotide repeats. Minisatellite instability was found in three (18%) tumors, with one of them exhibiting mutations in all three minisatellite loci, whereas two others showed mutations in one of two informative markers. By contrast, none of 20 sporadic thyroid cancers from patients with no history of radiation exposure was positive for minisatellite instability. Microsatellite analysis of post-Chernobyl tumors revealed a mutation in one (6%) tumor only at the locus of D10S1412, whereas all other 26 microsatellite markers showed identical patterns in each normal/tumor pair. Our results suggest that somatic cell microsatellite instability does not contribute to radiation-induced thyroid carcinogenesis. However, somatic minisatellite mutation events are present in a subset of radiation-induced, but not sporadic, thyroid cancers, suggesting that this type of genomic instability may play a role in radiation-induced tumorigenesis in the thyroid gland.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA072597, R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50706, CA 72597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BOGDANOVA T, 1995, THYROID S1, V5, P28; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FELBER M, 1994, CANCER BIOCHEM BIOPH, V14, P163; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; IVEY JN, 1994, J FORENSIC SCI, V39, P52; JEFFREYS AJ, 1995, ELECTROPHORESIS, V16, P1577, DOI 10.1002/elps.11501601261; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KARRAN P, 1995, SCIENCE, V268, P1857, DOI 10.1126/science.7604258; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; PAQUETTE B, 1994, CANCER RES, V54, P3173; PASINI B, 1995, ONCOGENE, V11, P1737; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SINGH L, 1995, ELECTROPHORESIS, V16, P1586, DOI 10.1002/elps.11501601262; STSJAZHKO VA, 1995, BMJ-BRIT MED J, V310, P801, DOI 10.1136/bmj.310.6982.801; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7; ZEDENIUS J, 1995, HUM GENET, V96, P27, DOI 10.1007/BF00214182	37	24	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1983	1988		10.1038/sj.onc.1202120	http://dx.doi.org/10.1038/sj.onc.1202120			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788442				2022-12-25	WOS:000076423500012
J	Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM				Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM			The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins	ONCOGENE			English	Article						Crk; CRKL; SH3; HPK1; KHS; kinase; adapter	N-TERMINAL KINASE; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAINS; CELL ANTIGEN RECEPTOR; SH3 DOMAIN; C-CRK; GROWTH-FACTOR; EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; JUN KINASE	Adapter proteins function by mediating the rapid and specific assembly of multi-protein complexes during the signal transduction which guards proliferation, differentiation and many functions of higher eukaryotic cells, To understand their functional roles in different cells it is important to identify the selectively interacting proteins in these cells. Two novel candidates for signalling partners of Crk family adapter proteins, the hematopoietic progenitor kinase 1 (HPK1) and the kinase homologous to SPS1/STE20 (KHS), were found to bind with great selectivity to the first SH3 domains of c-Crk and CRKL. While KHS bound exclusively to Crk family proteins, HPK1 also interacted with both SH3 domains of Grb2 and weakly with Nck, but not with more than 25 other SH3 domains tested. The interaction of HPK1 with c-Crk and CRKL was studied in more detail. HPK1-binding to the first SH3 domain of CRKL is direct and occurs via proline-rich motifs in the C-terminal, non-catalytic portion of HPK1. In vitro complexes were highly stable and in vivo complexes of c-Crk and CRKL with HPK1 were detectable by co-immnnoprecipitation with transiently transfected cells but also with endogenous proteins. Furthermore, c-Crk II and, to a lesser extent, CRKL were substrates for HPK1, These results make it likely that HPK1 and KHS participate in the signal transduction of Crk family adapter proteins in certain cell types.	Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany; Lower Saxony Inst Peptide Res, IPF, D-30625 Hannover, Germany; Childrens Hosp, Dept Mol Pathol, Los Angeles, CA 90027 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Wurzburg; Children's Hospital Los Angeles; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine	Feller, SM (corresponding author), Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Heisterkamp, Nora/C-1698-2012	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Sattler M, 1996, ONCOGENE, V12, P839; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, ONCOGENE, V13, P381; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Torres M, 1996, ONCOGENE, V12, P77; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V13, P1379; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	58	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1893	1901		10.1038/sj.onc.1202108	http://dx.doi.org/10.1038/sj.onc.1202108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788432				2022-12-25	WOS:000076423500002
J	Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL				Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL			TNF-alpha activates at least two apoptotic signaling cascades	ONCOGENE			English	Article						apoptosis; caspase; mitochondria; ROS	TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; REDOX REGULATION; NEURONAL DEATH; BCL-2	Apoptosis, the process whereby cells activate an intrinsic death program, can be induced in HeLa cells by TNF-alpha treatment. The aims of the present study were (i) to examine the precise role and the origin of Reactive Oxygen Species (ROS) in the TNF-alpha-induced programmed cell death, (ii) to characterize and order the morphological and mitochondrial changes associated with this process and (iii) to link these events with the activation of caspases, Analyses were performed on TNF-alpha-treated cells in the presence of an anti-oxidant, or of a general caspase inhibitor, To assess the role of mitochondria in the cell death signal transduction, these studies were also realized on HeLa-variant cell lines lacking functional mitochondrial respiratory chain. We show that at least two separate signaling cascades, both mediated by Z-VAD-sensitive caspase(s), contribute to the TNF-alpha-induced apoptosis of HeLa cells, One signaling pathway involves an early mitochondria-dependent ROS production, the other being ROS-independent.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Versailles St Quentin Yvelines, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.		Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HSU H, 1995, CELL, V8145, P495; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, CANCER RES, V56, P2033; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO N, 1995, J IMMUNOL, V154, P3194; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUSIN SA, 1996, J EXP MED, V184, P1; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	73	126	128	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1639	1651		10.1038/sj.onc.1202094	http://dx.doi.org/10.1038/sj.onc.1202094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796693	Green Published			2022-12-25	WOS:000076200100002
J	Niederreither, K; Harbers, M; Chambon, P; Dolle, P				Niederreither, K; Harbers, M; Chambon, P; Dolle, P			Expression of T: G mismatch-specific thymidine-DNA glycosylase and DNA methyl transferase genes during development and tumorigenesis	ONCOGENE			English	Article						in situ hybridization; DNA repair; mouse mammary tumor virus; p53; transgenic mice	SIGNALING PATHWAY; P53 GENE; METHYLTRANSFERASE; CANCER; CELLS; MICE; TUMORS; HYPERMETHYLATION; HYPOMETHYLATION; PROGRESSION	In situ hybridization was used to characterize the expression pattern of the T:G mismatch-specific thymidine-DNA glycosylase (TDG) gene, encoding a DNA repair enzyme which corrects G:T mismatches that result from the hydrolytic deamination of 5-methyl cytosines, TDG transcripts were uniformly and ubiquitously expressed from 7.5-13.5 days post-coitum, but were then markedly enriched in specific tissues of the developing fetus. At 14.5 gestational days, TDG was strongly expressed in the developing nervous system, thymus, lung, liver, kidney and intestine, At later stages, high levels of expression were detected in the thymus, brain, nasal epithelium and within proliferating regions of the intestine, skin, kidney, teeth and bone, This pattern of expression strongly correlated with those of the methyl transferase (MTase) gene, coding for the enzyme which specifically methylates CpG dinucleotides, and the p53 tumour suppressor gene. However, TDG and MTase were differentially expressed during maturation of the male and female germline, We also report that tumors occuring in mice which overexpress MMTV-v-Ha-ras or MMTV-c-myc transgenes or mice heterozygous for p53 gene disruption, all show elevated TDG and MTase expression specific to the transformed tissue.	ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dolle, P (corresponding author), ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.		Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; Harbers, Matthias/0000-0002-5613-7220				Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BENOIT G, 1994, BIOL REPROD, V50, P1312, DOI 10.1095/biolreprod50.6.1312; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Heby O, 1995, INT J DEV BIOL, V39, P737; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JacksonGrusby L, 1996, SEMIN CANCER BIOL, V7, P261, DOI 10.1006/scbi.1996.0034; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Niederreither K, 1998, METH MOL B, V89, P247; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robertson KD, 1997, AM J HUM GENET, V61, P1220, DOI 10.1086/301658; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SZYF M, 1991, J BIOL CHEM, V266, P10027; TORNALETTI S, 1995, ONCOGENE, V10, P1493; WALTER CA, 1994, SOMAT CELL MOLEC GEN, V20, P451, DOI 10.1007/BF02255837; WIND N, 1995, CELL, V82, P321; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016	43	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1577	1585		10.1038/sj.onc.1202072	http://dx.doi.org/10.1038/sj.onc.1202072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794235				2022-12-25	WOS:000076089900010
J	Arnold, WV; Fertala, A; Sieron, AL; Hattori, H; Mechling, D; Bachinger, HP; Prockop, DJ				Arnold, WV; Fertala, A; Sieron, AL; Hattori, H; Mechling, D; Bachinger, HP; Prockop, DJ			Recombinant procollagen II: Deletion of D period segments identifies sequences that are required for helix stabilization and generates a temperature-sensitive N-proteinase cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN TRIPLE-HELIX; CHICK-EMBRYO TENDONS; AMINO-ACID-SEQUENCE; ALPHA-1(I) CHAIN; COIL TRANSITION; FIBRILS; PURIFICATION; MONOMERS; CONFORMATION; TELOPEPTIDE	A cDNA cassette system was used to synthesize recombinant versions of procollagen II in which one of the four blocks of 234 amino acids that define a repeating D periods of the collagen triple helix were deleted, All the proteins were triple helical and all underwent a helix-to-coil transition between 25 and 42 degrees C as assayed by circular dichroism, However, the details of the melting curves varied. The procollagen lacking the DI period unfolded 3 degrees C lower than a full-length molecule. With the procollagen lacking the D4 period, the first 25% of unfolding occurred at a lower temperature than the full-length molecule, but the rest of the structure unfolded at the same temperature. With the procollagen lacking the terminal D0.4 period, the protein unfolded 3 degrees C lower than the full-length molecule and a smaller fraction of the protein was secreted by stably transfected clones than with the other recombinant procollagens. The results confirmed previous suggestions that the collagen triple helix contains regions of varying stability and they demonstrated that the two D periods at the end of the molecule contain sequences that serve as clamps for folding and for stabilizing the triple helix. Reaction of the recombinant procollagens with procollagen N-proteinase indicated that in the procollagen lacking the sequences, the D1 period assumed an unusual temperature-sensitive conformation at 35 degrees C that allowed cleavage at an otherwise resistant Gly-Ala bond between residues 394 and 395 of the alpha 1(II) chain.	Allegheny Univ Hlth Sci, Ctr Gene Therapy, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Biol, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Oregon Hlth Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Drexel University; Jefferson University; Oregon Health & Science University; Oregon Health & Science University	Prockop, DJ (corresponding author), Allegheny Univ Hlth Sci, Ctr Gene Therapy, 245 N 15 St,Rm 10118 NCB,Mail Stop 421, Philadelphia, PA 19102 USA.		Sieron, Aleksander L/G-1700-2013	Sieron, Aleksander L./0000-0002-3894-9508	NIAMS NIH HHS [AR39740] Funding Source: Medline; PHS HHS [R043366] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arnold WV, 1997, MATRIX BIOL, V16, P105, DOI 10.1016/S0945-053X(97)90039-1; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BERGER J, 1985, BIOCHEMISTRY-US, V24, P600, DOI 10.1021/bi00324a009; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; Bhatnagar RS, 1997, J BIOMOL STRUCT DYN, V14, P547, DOI 10.1080/07391102.1997.10508155; BROWN RA, 1977, BIOCHEM BIOPH RES CO, V74, P1102, DOI 10.1016/0006-291X(77)91632-1; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Byers Peter H., 1993, P317; Coyne KJ, 1997, SCIENCE, V277, P1830, DOI 10.1126/science.277.5333.1830; DAVIS JM, 1993, J BIOL CHEM, V268, P25965; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Fertala A, 1997, J BIOL CHEM, V272, P6457, DOI 10.1074/jbc.272.10.6457; FERTALA A, 1994, J BIOL CHEM, V269, P11584; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FIETZEK PP, 1976, INT REV CONNECT TISS, V1, P1; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; KADLER KE, 1988, J BIOL CHEM, V263, P10517; Kadler KE, 1996, BIOCHEM J, V316, P1; KUHN K, 1966, BIOCHEM Z, V344, P418; KUIVANIEMI H, 1991, FASEB J, V5, P2082; MANN K, 1992, EUR J BIOCHEM, V210, P839, DOI 10.1111/j.1432-1033.1992.tb17487.x; MOULD AP, 1982, J MOL BIOL, V195, P543; NAGAN N, 1994, J BIOL CHEM, V269, P22366; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V32, P1; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; RYHANEN L, 1983, ARCH BIOCHEM BIOPHYS, V223, P562, DOI 10.1016/0003-9861(83)90621-5; SIERON AL, 1993, J BIOL CHEM, V268, P21232; SOKOLOV B P, 1989, Medical Science Research, V17, P911; SOKOLOV BP, 1987, BIOKHIMIYA, V53, P1828; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; VITAGLIANO L, 1995, J MOL BIOL, V247, P69, DOI 10.1006/jmbi.1994.0123; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	44	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31822	31828		10.1074/jbc.273.48.31822	http://dx.doi.org/10.1074/jbc.273.48.31822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822649	hybrid			2022-12-25	WOS:000077207000031
J	Cotten, JF; Welsh, MJ				Cotten, JF; Welsh, MJ			Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; CFTR CHLORIDE CHANNEL; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; CL CHANNELS; FUNCTIONAL SIMILARITIES; STRUCTURAL MODEL; PROTEINS; HYDROLYSIS; PYROPHOSPHATE	The cytosolic nucleotide binding domains of cystic fibrosis transmembrane conductance regulator (NBD1 and NBD2) mediate ATP-dependent opening and closing of the Cl- channel pore. To learn more about NBD structure and function, we introduced a cysteine residue into the Walker A motif or the LSGGQ motif of each NBD and examined modification by N-ethylmaleimide (NEM). Covalent modification of either Walker A motif partially inhibited cystic fibrosis transmembrane conductance regulator channel activity, decreasing the open state probability by prolonging the long closed duration. An increase in cytosolic ATP concentration slowed the rate of modification. The data suggest that both NBDs interact with ATP to influence channel opening and that inhibition by NEM modification was in part due to decreased ATP binding. When cysteine was placed in the NBD2 Walker A motif, it was modified more rapidly than when it was placed in NBD1, suggesting that the NBDs are not structurally or functionally identical. Modification of a cysteine inserted in the LSGGQ motif of either NBD1 or NBD2 also inhibited channel activity. The rate of modification was comparable with that of a thiol in free solution, suggesting that the LSGGQ motif resides in a surface-exposed position in both NBDs.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu		Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Annereau JP, 1997, FEBS LETT, V407, P303, DOI 10.1016/S0014-5793(97)00363-3; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; EPENSON JH, 1981, CHEM KINETICS REACTI; GLYNN IM, 1971, J PHYSIOL-LONDON, V218, P239, DOI 10.1113/jphysiol.1971.sp009612; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; Muller M, 1996, J BIOL CHEM, V271, P1877; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0	42	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31873	31879		10.1074/jbc.273.48.31873	http://dx.doi.org/10.1074/jbc.273.48.31873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822656	hybrid			2022-12-25	WOS:000077207000038
J	Komano, H; Seeger, M; Gandy, S; Wang, GT; Krafft, GA; Fuller, RS				Komano, H; Seeger, M; Gandy, S; Wang, GT; Krafft, GA; Fuller, RS			Involvement of cell surface glycosyl-phosphatidylinositol-linked aspartyl proteases in alpha-secretase-type cleavage and ectodomain solubilization of human Alzheimer beta-amyloid precursor protein in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SACCHAROMYCES-CEREVISIAE; KEX2 PROTEASE; PEPTIDE; YAP3; GENE; METALLOPROTEINASE; DISINTEGRIN; EXPRESSION; MEMBRANE	Human beta-amyloid precursor protein (APP) introduced into yeast undergoes alpha-secretase-type cleavage, suggesting that yeast have alpha-secretase-like protease(s). Here we report that two structurally and functionally related glycosyl-phosphatidylinositol-linked yeast aspartyl proteases, Mkc7p and Yap3p (collectively termed yapsin), are responsible for alpha-secretase-type cleavage of APP expressed in yeast, resulting in release of soluble APP into the extracellular space. Disruption of MKC7 and YAP3 in a vacuolar protease-deficient strain abolished this APP cleavage/release, and APP cleavage/release could be restored by introduction of MKC7 or YAP3 on a single copy plasmid. Purified Mkc7p cleaved an internally quenched fluorogenic APP peptide substrate at the alpha-secretase cleavage site. Measurement of proteolytic activity either in yeast homogenates or on the yeast cell surface revealed that most Mkc7p and Yap3p activities were localized at the cell surface. These results establish a molecular basis for alpha-secretase-type cleavage in yeast and support the generally held concept that alpha-secretase cleavage of APP occurs at the cell surface.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Rockefeller Univ, New York, NY 10021 USA; NYU, Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Northwestern Univ, Sch Med, Evanston, IL 60201 USA; NW Healthcare Res Inst, Evanston, IL 60201 USA	University of Michigan System; University of Michigan; Rockefeller University; Nathan Kline Institute for Psychiatric Research; New York University; Abbott Laboratories; Northwestern University	Fuller, RS (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				NIA NIH HHS [AG10791, AG13780, AG11508] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R55AG011508, R01AG013780, R01AG010791, R01AG011508] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1997, HDB PROTEOLYTIC ENZY, P901; Greenfield J., 1997, Society for Neuroscience Abstracts, V23, P3; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HINES V, 1994, CELL MOL BIOL RES, V40, P273; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; LADROR US, 1994, J BIOL CHEM, V269, P18422; Le Brocque D. S., 1996, Neurobiology of Aging, V17, pS98, DOI 10.1016/S0197-4580(96)80396-4; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; OHYA Y, 1991, J BIOL CHEM, V266, P12356; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; ZHANG HY, 1994, J BIOL CHEM, V269, P27799; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7	30	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31648	31651		10.1074/jbc.273.48.31648	http://dx.doi.org/10.1074/jbc.273.48.31648			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822624	hybrid			2022-12-25	WOS:000077207000006
J	Kumar, J; Erickson, HP; Sheetz, MP				Kumar, J; Erickson, HP; Sheetz, MP			Ultrastructural and biochemical properties of the 120-kDa form of chick kinectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-BINDING PROTEIN; MICROTUBULES INVITRO; VESICLE MOTILITY; CELLS; MOTOR	Kinectin, an integral membrane protein (160 kDa), was identified as a kinesin-binding protein. Analysis of the predicted amino acid sequence of kinectin cDNA indicated an alpha-helical coiled-coil structure from amino acid 320 to 1310, A 120-kDa kinectin has been observed consistently, and N-terminal sequencing showed that 232 amino acids were missing from the N terminus of full-length kinectin, 120-kDa kinectin was distributed in the supernatant and a low density fraction of vesicles, whereas both forms were in the high density fraction of vesicles. In the electron microscope, the 120-kDa form appeared as a linear molecule of 133 nn in length. In hydrodynamic studies, the cytosolic 120-kDa kinectin was a dimer, Monoclonal antibody molecules (anti-kinectin BR160.9) bound asymmetrically to kinectin often with two antibodies/kinectin, indicative of a parallel coiled-coil. Metabolic labeling with [H-3]myristic acid showed that both the 120- and 160-kDa kinectin are myristoylated in chick embryo fibroblasts, The myristoylation of 120-kDa kinectin may provide a mechanism for linking it to a low density fraction of vesicles. Immunoprecipitation with a 160-kDa kinectin-specific antibody brought down the 120-kDa kinectin, Thus, we suggest that kinectin is an extended parallel coiled-coil dimer, often a heterodimer.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Sheetz, MP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	m.sheetz@cellbio.duke.edu			NINDS NIH HHS [NS-23345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; BURKHARDT JK, 1993, J CELL SCI, V104, P151; Burkhardt JK, 1996, TRENDS CELL BIOL, V6, P127, DOI 10.1016/0962-8924(96)20002-9; BURKHARDT JK, 1994, NATO ASI SERIES H, V91, P212; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAKAGAWA S, 1989, ANAL BIOCHEM, V168, P48; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SAMBROOK E, 1989, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171	22	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31738	31743		10.1074/jbc.273.48.31738	http://dx.doi.org/10.1074/jbc.273.48.31738			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822636	hybrid			2022-12-25	WOS:000077207000018
J	Michel, F; Grimaud, L; Tuosto, L; Acuto, O				Michel, F; Grimaud, L; Tuosto, L; Acuto, O			Fyn and ZAP-70 are required for Vav phosphorylation in T cells stimulated by antigen-presenting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; B7-2 REGULATION; FAMILY KINASES; RHO-FAMILY; SH2 DOMAIN; C-CBL; RECEPTOR	In T cells, triggering of the T cell antigen receptor or of the co-stimulatory receptor CD28 can direct tyrosine phosphorylation of the signaling protein Vav. We investigated the role played by the protein tyrosine kinases Fyn, Lck, and ZAP-70 in these processes in a T cell hybridoma after physiological stimulation of the T cell receptor (TCR) and CD28. A dominant-negative mutant approach based on overexpression of catalytically inactive alleles of these kinases showed that CD28-induced Vav phosphorylation preferentially requires Fyn, whereas ZAP-70 had no role. Consistently, Vav was strongly phosphorylated in Lck-deficient JCAM-1 cells after CD28 ligation. In contrast, ZAP-70 appeared to control TCR-directed Vav phosphorylation. However, overexpression of ZAP-70 carrying a mutated Tyr(315), contained within a motif previously suggested to be a Vav Src homology 2 domain binding site, had little or no effect. Immunoprecipitation assays showed that phosphorylated Vav associated with Fyn after CD28 triggering and that this interaction, likely to involve binding of Fyn Src homology 2 domain to Vav, was more strongly detectable after concomitant CD28 and TCR stimulation. These data suggest that Fyn plays a major role in controlling Vav phosphorylation upon T cell activation and that the mechanism implicating ZAP-70 in this process may be more complex than previously anticipated.	Inst Pasteur, Dept Immunol, Mol Immunol Unit, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Acuto, O (corresponding author), Inst Pasteur, Dept Immunol, Mol Immunol Unit, 25 Rue Dr Roux, F-75724 Paris 15, France.	oacuto@pasteur.fr	Tuosto, Loretta/F-7017-2011	Tuosto, Loretta/0000-0001-9056-4077; Michel, Frederique/0000-0002-3524-2232				August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BLANK U, 1993, EUR J IMMUNOL, V23, P3057, DOI 10.1002/eji.1830231203; BonnefoyBerard N, 1996, STEM CELLS, V14, P250, DOI 10.1002/stem.140250; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Grazioli L, 1998, J BIOL CHEM, V273, P8916, DOI 10.1074/jbc.273.15.8916; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUPTA S, 1994, J BIOL CHEM, V269, P17349; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; King PD, 1997, J IMMUNOL, V158, P580; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; KLOHE E, 1993, HUM IMMUNOL, V37, P51, DOI 10.1016/0198-8859(93)90142-N; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Michel F, 1996, CELL IMMUNOL, V173, P165, DOI 10.1006/cimm.1996.0264; Mimura T, 1997, J IMMUNOL, V158, P2977; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; OERS NSC, 1996, IMMUNITY, V5, P429; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TUOSTO L, 1995, EUR J IMMUNOL, V25, P2917, DOI 10.1002/eji.1830251031; Tuosto L, 1998, EUR J IMMUNOL, V28, P2131, DOI 10.1002/(SICI)1521-4141(199807)28:07<2131::AID-IMMU2131>3.0.CO;2-Q; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31932	31938		10.1074/jbc.273.48.31932	http://dx.doi.org/10.1074/jbc.273.48.31932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822663	Green Published, hybrid			2022-12-25	WOS:000077207000045
J	Moore, KP; Holt, SG; Patel, RP; Svistunenko, DA; Zackert, W; Goodier, D; Reeder, BJ; Clozel, M; Anand, R; Cooper, CE; Morrow, JD; Wilson, MT; Darley-Usmar, V; Roberts, LJ				Moore, KP; Holt, SG; Patel, RP; Svistunenko, DA; Zackert, W; Goodier, D; Reeder, BJ; Clozel, M; Anand, R; Cooper, CE; Morrow, JD; Wilson, MT; Darley-Usmar, V; Roberts, LJ			A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RADICAL-CATALYZED MECHANISM; LIPID-PEROXIDATION; NITRIC-OXIDE; RAT; OXIDATION; INJURY; NONCYCLOOXYGENASE; F-2-ISOPROSTANES; HYDROPEROXIDES	Muscle injury (rhabdomyolysis) and subsequent deposition of myoglobin in the kidney causes renal vasoconstriction and renal failure. We tested the hypothesis that myoglobin induces oxidant injury to the kidney and the formation of F-2-isoprostanes, potent renal vasoeonstrictors formed during lipid peroxidation. In low density lipoprotein (LDL), myoglobin induced a 30-fold increase in the formation of F-2-isoprostanes by a mechanism involving redox cycling between ferric and ferryl forms of myoglobin, In an animal model of rhabdomyolysis, urinary excretion of F-2-isoprostanes increased by 7.3-fold compared with controls. Administration of alkali, a treatment for rhabdomyolysis, improved renal function and significantly reduced the urinary excretion of F-2-isoprostanes by similar to 80%, EPR and UV spectroscopy demonstrated that myoglobin was deposited in the kidneys as the redox competent ferric myoglobin and that it's concentration was not decreased by alkalinization, Kinetic studies demonstrated that the reactivity of ferryl myoglobin, which is responsible for inducing lipid peroxidation, is markedly attenuated at alkaline pH. This was further supported by demonstrating that myoglobin-induced oxidation of LDL was inhibited at alkaline pH. These data strongly support a causative role for oxidative injury in the renal failure of rhabdomyolysis and suggest that the protective effect of alkalinization may be attributed to inhibition of myoglobin-induced lipid peroxidation.	UCL Royal Free & Univ Coll, Sch Med, Joint Dept Med, London NW3 2QG, England; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35243 USA; Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Div, Birmingham, AL 35243 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Hoffmann La Roche AG, Preclin Res, CH-4070 Basel, Switzerland; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	University of London; University College London; UCL Medical School; Vanderbilt University; Vanderbilt University; Roche Holding; University of Essex	Moore, KP (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Joint Dept Med, Rowland Hill St, London NW3 2QG, England.	kmoore@rfhsm.ac.uk	Holt, Stephen/AAU-7808-2020; Cooper, Chris/AAK-9729-2020; Reeder, Brandon/AAI-1450-2020; Darley-Usmar, Victor/F-7656-2010	Holt, Stephen/0000-0001-5004-5539; Cooper, Chris/0000-0003-0381-3990; Reeder, Brandon/0000-0001-7474-2611; Darley-Usmar, Victor/0000-0001-8921-7086; Holt, Steve/0000-0001-6936-9736; Patel, Rakesh/0000-0002-1526-4303; Svistunenko, Dimitri/0000-0001-8060-2738	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABULEZZ SR, 1991, P NATL ACAD SCI USA, V88, P9833, DOI 10.1073/pnas.88.21.9833; ANTONINI E, 1997, FRONT BIOL, P13; AYER G, 1971, CIRC RES, V29, P128, DOI 10.1161/01.RES.29.2.128; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P3367; BETTER OS, 1990, NEW ENGL J MED, V322, P825; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; COOPER CE, 1994, FREE RADICAL RES, V20, P219, DOI 10.3109/10715769409147518; DEE G, 1991, FEBS LETT, V294, P38, DOI 10.1016/0014-5793(91)81338-9; DUBOSE TD, 1979, J CLIN INVEST, V64, P476, DOI 10.1172/JCI109485; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; GROSSMAN RA, 1974, NEW ENGL J MED, V291, P807, DOI 10.1056/NEJM197410172911601; HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P39, DOI 10.1006/abbi.1994.1409; KARAM H, 1995, J PHARMACOL EXP THER, V274, P481; KURTZ TW, 1976, CIRC RES, V38, P30, DOI 10.1161/01.RES.38.1.30; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MAREE A, 1994, NEPHROL DIAL TRANSPL, V9, P78; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; NATH KA, 1994, LAB INVEST, V71, P209; PALLER MS, 1988, AM J PHYSIOL, V255, pF539, DOI 10.1152/ajprenal.1988.255.3.F539; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; Patel RP, 1996, J LIPID RES, V37, P2361; ROBERTS LJ, 1997, BIOCHIM BIOPHYS ACTA, V1453, P121; RodriguezMalaver AJ, 1997, FEBS LETT, V406, P37, DOI 10.1016/S0014-5793(97)00233-0; Salahudeen AK, 1996, NEPHROL DIAL TRANSPL, V11, P635, DOI 10.1093/oxfordjournals.ndt.a027352; SHAH SV, 1988, AM J PHYSIOL, V255, pF438, DOI 10.1152/ajprenal.1988.255.3.F438; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; VENKATACHALAM MA, 1976, CIRC RES, V38, P267, DOI 10.1161/01.RES.38.4.267; ZAGER RA, 1989, LAB INVEST, V60, P619; ZAGER RA, 1992, J CLIN INVEST, V89, P989, DOI 10.1172/JCI115682; Zager RA, 1997, KIDNEY INT, V51, P728, DOI 10.1038/ki.1997.104; ZAGER RA, 1992, J CLIN INVEST, V90, P711, DOI 10.1172/JCI115942	42	209	219	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31731	31737		10.1074/jbc.273.48.31731	http://dx.doi.org/10.1074/jbc.273.48.31731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822635	hybrid			2022-12-25	WOS:000077207000017
J	Pope, AJ; Lapointe, J; Mensah, L; Benson, N; Brown, MJB; Moore, KJ				Pope, AJ; Lapointe, J; Mensah, L; Benson, N; Brown, MJB; Moore, KJ			Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus - I: Kinetic mechanism of the substrate activation reaction studied by transient and steady-state techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; PSEUDOMONIC ACID; ESCHERICHIA-COLI; OXAZOLE DERIVATIVES; CHEMISTRY; SIMULATION; RESISTANCE; MUPIROCIN; FAMILY	The kinetic mechanism for the amino acid activation reaction of Staphylococcus aureus isoleucyl-tRNA synthetase (IleRS; E) has been determined from stopped-flow measurements of the tryptophan fluorescence associated with the formation of the enzyme-bound aminoacyl adenylate (E.Ile-AMP; Scheme 1). Isoleucine (Ile) binds to the E.ATP complex (K-4 = 1.7 +/- 0.9 mu M) similar to 35-fold more tightly than to E (K-1 = 50-100 mu M), primarily due to a reduction in the Be dissociation rate constant (k(-1) approximate to 100-150 s(-1), cf. k(-4) = 3 +/- 1.5 s(-1)). Similarly, ATP binds more tightly to E.Ile (K-3 = similar to 70 mu M) than to E (K-2 = similar to 2.5 mM). The formation of the E.isoleucyl adenylate intermediate, E.Ile-AMP, resulted in a further increase in fluorescence allowing the catalytic step to be monitored (k(+5) = similar to 60 s(-1)) and the reverse rate constant (k(-5) = similar to 150-200 s(-1)) to be determined from pyrophosphorolysis of a pre-formed E.Ile-AMP complex (K-6 = similar to 0.25 mM). Scheme 1 was able to globally predict all of the observed transient kinetic and steady-state PPi/ATP exchange properties of IleRS by simulation. A modification of Scheme 1 could also provide an adequate description of the kinetics of tRNA aminoacylation (k(cat,tr) = similar to 0.35 s(-1)) thus providing a framework for understanding the kinetic mechanism of aminoacylation in the presence of tRNA and of inhibitor binding to IleRS.	SmithKline Beecham Pharmaceut, Dept Mol Recognit, Harlow CM19 5AW, Essex, England; Univ Laval, Fac Sci & Genie, Dept Biochim, Quebec City, PQ G1K 7P4, Canada	GlaxoSmithKline; Laval University	Pope, AJ (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Recognit, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.							BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Broom NJP, 1996, J MED CHEM, V39, P3596, DOI 10.1021/jm950882q; BROOM NJP, 1995, J ANTIBIOT, V48, P1336, DOI 10.7164/antibiotics.48.1336; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CASSIO D, 1967, BIOCHEMISTRY-US, V6, P827, DOI 10.1021/bi00855a024; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; Cleland W.W., 1970, ENZYMES, P1; CRIMMIN MJ, 1989, J CHEM SOC PERK T 1, P2059, DOI 10.1039/p19890002059; DYKE KGH, 1991, FEMS MICROBIOL LETT, V77, P195, DOI 10.1111/j.1574-6968.1991.tb04346.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FARMER TH, 1992, J ANTIMICROB CHEMOTH, V30, P587, DOI 10.1093/jac/30.5.587; Fersht A., 1984, ENZYME STRUCTURE MEC; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; Francklyn C, 1997, RNA, V3, P954; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GUTFREUND H, 1975, ENZYMES PHYSICAL PRI, P157; Gutfreund H, 1995, KINETICS LIFE SCI; HUGHES J, 1978, J ANTIBIOT, V31, P330, DOI 10.7164/antibiotics.31.330; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Meinnel Thierry, 1995, P251; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; MOE JG, 1979, BIOCHEMISTRY-US, V18, P2804, DOI 10.1021/bi00580a018; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; NAGEL GM, 1995, J MOL EVOL, V40, P487; NUREKI O, 1997, AMINOACYL TRNA SYNTH; PLATEAU P, 1994, ADV MICROB PHYSIOL, V36, P81, DOI 10.1016/S0065-2911(08)60177-0; Pope AJ, 1998, J BIOL CHEM, V273, P31702, DOI 10.1074/jbc.273.48.31702; Pope AJ, 1998, J BIOL CHEM, V273, P31691, DOI 10.1074/jbc.273.48.31691; RAUHUT R, 1986, BIOSYSTEMS, V19, P173, DOI 10.1016/0303-2647(86)90038-9; SEGAL IH, 1975, ENZYME KINETICS BEHA; Walker G., 1993, P106	36	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31680	31690		10.1074/jbc.273.48.31680	http://dx.doi.org/10.1074/jbc.273.48.31680			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822629	hybrid			2022-12-25	WOS:000077207000011
J	Pope, AJ; Moore, KJ; McVey, M; Mensah, L; Benson, N; Osbourne, N; Broom, N; Brown, MJB; O'Hanlon, P				Pope, AJ; Moore, KJ; McVey, M; Mensah, L; Benson, N; Osbourne, N; Broom, N; Brown, MJB; O'Hanlon, P			Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; ESCHERICHIA-COLI; ANTIBACTERIAL ACTIVITY; MUPIROCIN RESISTANCE; OXAZOLE DERIVATIVES; CHEMISTRY; BINDING; SIMULATION; SYSTEMS; ASSAY	The interactions of isoleucyl-tRNA synthetase (IleRS, E) from Staphylococcus aureus with both intermediate analogues and pseudomonic acid (PS-A) have been investigated using transient and steady-state techniques. Non-hydrolyzable analogues of isoleucyl-AMP (I) were simple competitive inhibitors (Ile-ol-AMP, K-i = 50 nM and Ile-NHSO2-AMP, K-i = 1 nM;), PS-A (J) inhibits IleRS via a slow-tight binding competitive mechanism where E.J (K-j = similar to 2 nM), undergoes an isomerization to form a stabilized E.*J complex (K-j* = 50 pM). To overcome tight-binding artifacts when K-j* much less than [E], K-j* values were estimated from PPi/ATP exchange where [S] much greater than K-m, thus raising K-J,K-app* well above [E]. Using [H-3]PS-A, it was confirmed that binding occurs with 1:1 stoichiometry and is reversible, Formation of inhibitor complexes was monitored directly through changes in enzyme tryptophan fluorescence. For Ile-ol-AMP and Ile-NHSO2-AMP, the fluorescence intensity of E.I was identical to that when E.Ile-AMP forms catalytically. Binding of PS-A induced only a small change in IleRS fluorescence that was characterized using transient kinetic competition. SB-205952, a PS-A analogue, produced a 37% quenching of IleRS fluorescence upon binding as a result of radiationless energy transfer, Inhibitor reversal rates were obtained by measuring relaxation between spectroscopically different complexes, Together, these data represent a comprehensive solution to the kinetics of inhibition by these compounds.	SmithKline Beecham Pharmaceut, Mol Interact & New Assay Technol, Dept Mol Recognit, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Med Chem, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Pope, AJ (corresponding author), SmithKline Beecham Pharmaceut, Mol Interact & New Assay Technol, Dept Mol Recognit, New Frontiers Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.							BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Broom NJP, 1996, J MED CHEM, V39, P3596, DOI 10.1021/jm950882q; BROOM NJP, 1995, J ANTIBIOT, V48, P1336, DOI 10.7164/antibiotics.48.1336; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CASSIO D, 1967, BIOCHEMISTRY-US, V6, P827, DOI 10.1021/bi00855a024; CASSOBIANCO JO, 1989, ANTIMICROB AGENTS CH, V33, P156; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; CHANG GG, 1983, ANAL BIOCHEM, V130, P171, DOI 10.1016/0003-2697(83)90665-6; CRIMMIN MJ, 1989, J CHEM SOC PERK T 1, P2059, DOI 10.1039/p19890002059; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOBSON RL, 1985, BACTROBAN; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; FARMER TH, 1992, J ANTIMICROB CHEMOTH, V30, P587, DOI 10.1093/jac/30.5.587; Fersht A., 1984, ENZYME STRUCTURE MEC; Francklyn C, 1997, RNA, V3, P954; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; HUGHES J, 1978, J ANTIBIOT, V31, P330, DOI 10.7164/antibiotics.31.330; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; JANSSEN DA, 1993, ANTIMICROB AGENTS CH, V37, P2003, DOI 10.1128/AAC.37.9.2003; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANDES C, 1995, BIOCHIMIE, V77, P194, DOI 10.1016/0300-9084(96)88125-9; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; NUREKI O, 1997, AMINOACYL TRNA SYNTH; Pope AJ, 1998, J BIOL CHEM, V273, P31680, DOI 10.1074/jbc.273.48.31680; RATKITZIS ET, 1984, BIOCHEM J, V217, P341; SCHAECHTER M, 1987, ESCHERICHIA COLI SAL, V1; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; SLOCOMBE B, 1991, J HOSP INFECT, V19, P19, DOI 10.1016/0195-6701(91)90198-H; SOUTHGATE CCB, 1978, BIOCHEM J, V175, P461, DOI 10.1042/bj1750461; Walker G., 1993, P106; WARD A, 1986, DRUGS, V32, P425, DOI 10.2165/00003495-198632050-00002; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WILSON M, 1995, ANTIMICROB AGENTS CH, V39, P1925; YANIGASAWA T, 1994, J BIOL CHEM, V269, P24304	38	54	55	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31691	31701		10.1074/jbc.273.48.31691	http://dx.doi.org/10.1074/jbc.273.48.31691			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822630	hybrid			2022-12-25	WOS:000077207000012
J	La Fontaine, S; Firth, SD; Camakaris, J; Englezou, A; Theophilos, MB; Petris, MJ; Howie, M; Lockhart, PJ; Greenough, M; Brooks, H; Reddel, RR; Mercer, JFB				La Fontaine, S; Firth, SD; Camakaris, J; Englezou, A; Theophilos, MB; Petris, MJ; Howie, M; Lockhart, PJ; Greenough, M; Brooks, H; Reddel, RR; Mercer, JFB			Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE GENE; DISEASE GENE; PROTEIN; MUTATIONS; BINDING; MOUSE; ENCODES; EFFLUX; CELLS; ATP7A	Menkes' disease is a fatal, X-linked, copper deficiency disorder that results hom defective copper efflux from intestinal cells and inadequate copper delivery to other tissues, leading to deficiencies of critical copper-dependent enzymes. Wilson's disease is an autosomally inherited, copper toxicosis disorder resulting from defective biliary excretion of copper, which leads to copper accumulation in the liver. The ATP7A and ATP7B genes that are defective in patients with Menkes' and Wilson's diseases, respectively, encode transmembrane, P-type ATPase proteins (ATP7A or MNK and ATP7B or WND, respectively) that function to translocate copper across cellular membranes. In this study, the cDNAs derived from a normal human ATP7A gene and the murine ATP7B homologue, Atp7b, were separately transfected into an immortalized fibroblast cell line obtained from a Menkes' disease patient. Both MNK and WND expressed from plasmid constructs were able to correct the copper accumulation and copper retention phenotype of these cells. However, the two proteins responded differently to elevated extracellular copper levels, Although MNK showed copper-induced trafficking from the trans-Golgi network. to the plasma membrane, in the same cell line the intracellular location of WND did not appear to be affected by elevated copper.	Royal Childrens Hosp, Murdoch Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Childrens Med Res Inst, Wentworthville 2145, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Children's Medical Research Institute - Australia	Mercer, JFB (corresponding author), Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Burwood Campus,221 Burwood Hwy, Clayton, Vic 3125, Australia.	jmercer@deakin.edu.au	Greenough, Mark/AAK-1615-2021; La Fontaine, Sharon/G-7113-2018; Mercer, Julian/R-8583-2019; Lockhart, Paul J/E-7753-2011; Reddel, Roger R/A-6635-2014	La Fontaine, Sharon/0000-0002-9948-074X; Lockhart, Paul J/0000-0003-2531-8413; Reddel, Roger R/0000-0002-6302-6107; Greenough, Mark/0000-0001-6767-0584				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAMAKARIS J, 1980, BIOCHEM GENET, V18, P117, DOI 10.1007/BF00504364; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Danks D. M, 1995, METABOLIC BASIS INHE, VI, P2211; DAS S, 1994, AM J HUM GENET, V55, P883; De Silva R., 1995, Methods in Cell Science, V17, P75; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; DIJKSTRA M, 1995, J CLIN INVEST, V95, P412, DOI 10.1172/JCI117670; GOKA TJ, 1976, P NATL ACAD SCI USA, V73, P604, DOI 10.1073/pnas.73.2.604; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; La Fontaine S, 1998, PLASMID, V39, P245, DOI 10.1006/plas.1997.1334; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Monaco AP, 1995, ADV GENET, V33, P233, DOI 10.1016/S0065-2660(08)60335-1; Nagano K, 1998, HEPATOLOGY, V27, P799, DOI 10.1002/hep.510270323; PAYNTER JA, 1990, EUR J BIOCHEM, V190, P149, DOI 10.1111/j.1432-1033.1990.tb15558.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Sambrook J., 2002, MOL CLONING LAB MANU; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Tumer Z, 1997, AM J HUM GENET, V60, P63; Tumer Z, 1997, J MED GENET, V34, P265, DOI 10.1136/jmg.34.4.265; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Yang XL, 1997, BIOCHEM J, V326, P897, DOI 10.1042/bj3260897; [No title captured]	36	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31375	31380						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813047				2022-12-25	WOS:000077136900075
J	Lindquist, JM; Rehnmark, S				Lindquist, JM; Rehnmark, S			Ambient temperature regulation of apoptosis in brown adipose tissue - Erk1/2 promotes norepinephrine-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; UNCOUPLING PROTEIN; MAP KINASE; PRIMARY CULTURE; FAT-CELLS; CAMP; ADIPOCYTES; EXPRESSION; DEATH; RAS	Brown adipose tissue hyperplasia is a fundamental response to low ambient temperature. We show here that cold exposure of an animal markedly increased the phosphorylation of mitogen-activated protein kinase (p42/p44) Erk1 and Erk2 in brown adipose tissue, and protected cells in the tissue from apoptosis, We also show that cessation of the sympathetic stimulus, by transferring cold-adapted animals to 28 degrees C, caused an increased rate of apoptosis in the tissue. In primary cultures of brown adipose tissue, norepinephrine (NE) stimulated both the phosphorylation and the activity of Erk1/2 via the Erk kinase MEK, and protected the cells form apoptosis. Similarly, agonist stimulation of alpha(1)- and beta-adrenergic receptors and increases in the intracellular level of Ca2+ and cAMP stimulated the phosphorylation of Erk1/2, Agonist stimulation of alpha(1) and beta-adrenergic receptors, and increased intracellular cAMP level also promoted the cell survival. Furthermore, NE stimulated the expression and secretion of basic fibroblast growth factor (bFGF), which further promoted the cell survival via MEK-dependent activation of Erk1/2. In essence, we show that Erk1/2 has a critical role in promoting NE- and bFGF dependent survival of brown adipocytes, and propose that NE- and bFGF-dependent regulation of the cell survival is involved in the cold-induced hyperplasia of brown adipose tissue.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, Dept Metab Res, S-10691 Stockholm, Sweden	Stockholm University	Rehnmark, S (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, Dept Metab Res, S-10691 Stockholm, Sweden.							ACKERMAN RC, 1993, PROSTAG OTH LIPID M, V45, P475, DOI 10.1016/0090-6980(93)90123-O; BARGE RM, 1988, AM J PHYSIOL, V254, pE323, DOI 10.1152/ajpendo.1988.254.3.E323; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bengtsson T, 1996, J BIOL CHEM, V271, P33366, DOI 10.1074/jbc.271.52.33366; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; Cannon B, 1996, INT J OBESITY, V20, pS36; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DESAUTELS M, 1986, BIOCHEM CELL BIOL, V64, P1125, DOI 10.1139/o86-148; DOWNS TR, 1983, ANAL BIOCHEM, V131, P538, DOI 10.1016/0003-2697(83)90212-9; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FURUTA I, 1994, BIOL REPROD, V51, P1315, DOI 10.1095/biolreprod51.6.1315; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HERRON D, 1990, FEBS LETT, V268, P296, DOI 10.1016/0014-5793(90)81031-I; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HUNT TE, 1967, ANAT REC, V157, P537, DOI 10.1002/ar.1091570313; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KikuchiUtsumi K, 1997, BIOCHEM J, V322, P417, DOI 10.1042/bj3220417; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MENTZ F, 1995, EUR J IMMUNOL, V25, P1798, DOI 10.1002/eji.1830250648; MICHEL PP, 1995, EUR J NEUROSCI, V7, P251, DOI 10.1111/j.1460-9568.1995.tb01061.x; MOHELL N, 1989, BIOCHEM J, V261, P401, DOI 10.1042/bj2610401; NARAYANSINGH T, 1972, COMP BIOCHEM PHYSIOL, V42, P889, DOI 10.1016/0300-9629(72)90395-7; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; Nedergaard J, 1995, INT J DEV BIOL, V39, P827; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Porras A, 1997, FEBS LETT, V416, P324, DOI 10.1016/S0014-5793(97)01204-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; Sassone CP., 1998, INT J BIOCHEM CELL B, V30, P27; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMSON JF, 1969, J CELL BIOL, V41, P312, DOI 10.1083/jcb.41.1.312; THONBERG H, 1994, J BIOL CHEM, V269, P33179; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WEST DC, 1985, ANAL BIOCHEM, V147, P289, DOI 10.1016/0003-2697(85)90274-X; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMASHITA H, 1995, CELL GROWTH DIFFER, V6, P1457; Yamazaki T, 1997, CIRCULATION, V95, P1260; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	66	87	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30147	30156		10.1074/jbc.273.46.30147	http://dx.doi.org/10.1074/jbc.273.46.30147			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804770	hybrid			2022-12-25	WOS:000077008100017
J	de Santa Barbara, P; Moniot, B; Poulat, F; Boizet, B; Berta, P				de Santa Barbara, P; Moniot, B; Poulat, F; Boizet, B; Berta, P			Steroidogenic factor-1 regulates transcription of the human anti-mullerian hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEXUAL-DIFFERENTIATION; DUCT SYNDROME; EXPRESSION; FAMILY; GENE	Anti-mullerian hormone type II receptor (AMHRII) is a serine/threonine receptor and a member of type II receptors of the transforming growth factor beta superfamily, AMHRII has been recently identified in humans, mice, rats, and rabbits. In the male embryo, the AMHRII gene has been shown to be expressed in Sertoli's cells, in Leydig's cells and in the mesenchymal cells surrounding the mullerian duct. To determine the functional region of the AMHRII promoter as well as the factors controlling AMHRII gene expression, we used a 1.1-kilobase DNA fragment from the 5'-flanking region of the human AMHRII gene to generate a series of deletion or mutation and analyzed the resulting transcriptional activities after transfection of the NT2/D1 teratocarcinoma cell line, Our results indicate that maximal expression of the AMHRII promoter in this particular cell line, a cell line positive for endogenous AMHRII expression, requires a conserved estrogen receptor half-site element (AGGTCA) identical to the binding element for steroidogenic factor-1 (SF-1). Studies of this SF-1 binding element using gel mobility shift, antibody supershift assays, and transient transfections of reporter constructs indicate that SF-1 can bind and transactivate the AMHRII promoter. Finally, SF-1 protein expression in human male embryos was shown to display a good coincidence with the previously reported AMHRII expression profile. We then propose that SF-1 may be a key transcriptional regulator of AMHRII gene expression during early human development.	Inst Genet Humaine, Human Mol Genet Grp, CNRS, UPR 1142, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Berta, P (corresponding author), Inst Genet Humaine, Human Mol Genet Grp, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.	berta@igh.cnrs.fr	de Santa Barbara, Pascal/AAO-5969-2021; POULAT, FRANCIS/AAV-2170-2020; de Santa Barbara, Pascal/N-6426-2015	de Santa Barbara, Pascal/0000-0001-9040-2481; POULAT, FRANCIS/0000-0003-2070-1296; de Santa Barbara, Pascal/0000-0001-9040-2481				BAARENDS WM, 1994, DEVELOPMENT, V120, P189; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIULI G, 1997, DEVELOPMENT, V124, P1799; GROOTEGORD JA, 1994, MOL CELL ENDOCRINOL, V100, P29, DOI 10.1016/0303-7207(94)90274-7; GUERRIER D, 1989, J CLIN ENDOCR METAB, V68, P46, DOI 10.1210/jcem-68-1-46; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JOSSO N, EARLY HUM DEV, V33, P91; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; ORAHILLY R, 1983, ANAT EMBRYOL, V166, P247, DOI 10.1007/BF00305086; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1996, J ANDROL, V17, P336; TSUJI M, 1992, ENDOCRINOLOGY, V131, P1481, DOI 10.1210/en.131.3.1481; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; Zimmermann S, 1998, MOL ENDOCRINOL, V12, P706, DOI 10.1210/me.12.5.706	27	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29654	29660						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792676				2022-12-25	WOS:000076798300053
J	Devidas, S; Yue, HW; Guggino, WB				Devidas, S; Yue, HW; Guggino, WB			The second half of the cystic fibrosis transmembrane conductance regulator forms a functional chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR GENE; LINING RESIDUES; CL CHANNEL; MUTATIONS; IDENTIFICATION; FAMILY; BLOCK	The cystic fibrosis transmembrane conductance regulator (CFTR) consists of two transmembrane domains (TMDs), TMD1 and TMD2, two cytoplasmic nucleotide binding domains (NBDs), NBD1 and NBD2, and a regulatory domain. To elucidate the complex function of the CFTR, deletion constructs encompassing the second half of the CFTR distal to the first transmembrane domain were expressed in Xenopus oocytes and IB3 cells (a cystic fibrosis cell line). Constructs containing the regulatory domain, the second transmembrane domain, and the second nucleotide binding domain formed constitutively active channels, which were further stimulated upon the addition of cAMP. On the other hand, a construct encompassing the second transmembrane domain and the second nucleotide binding domain was stimulated to a small but noticeable extent upon the addition of cAMP, The selectivity of the second-half construct was the same for iodide and chloride, in contrast to the selectivity of wild-type CFTR, which is Cl- > I-. However, both constructs displayed single-channel conductances that were significantly smaller than those displayed by the first half of the CFTR, We conclude that regions of the second transmembrane domain may contribute to the overall channel of the pore, although the first half of the CFTR may confer its selectivity.	Johns Hopkins Univ, Sch Med, Dept Physiol & Pediat, Baltimore, MD 21205 USA	Johns Hopkins University	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol & Pediat, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051811, R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK048977] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122, HL 51811] Funding Source: Medline; NIDDK NIH HHS [DK 48977] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; CARROLL TP, 1995, J BIOL CHEM, V270, P11941, DOI 10.1074/jbc.270.20.11941; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; FEREC C, 1992, NAT GENET, V1, P188, DOI 10.1038/ng0692-188; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; SAVOV A, 1994, HUM MOL GENET, V3, P57; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SIEBERT FS, 1996, J BIOL CHEM, V271, P27493; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5	24	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29373	29380		10.1074/jbc.273.45.29373	http://dx.doi.org/10.1074/jbc.273.45.29373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792638	hybrid			2022-12-25	WOS:000076798300015
J	Li, Y; Smith, T; Grabski, S; DeWitt, DL				Li, Y; Smith, T; Grabski, S; DeWitt, DL			The membrane association sequences of the prostaglandin endoperoxide synthases-1 and -2 isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; H SYNTHASE-1; ENDOPLASMIC-RETICULUM; EXPRESSION; GENE; CYCLOOXYGENASE-2; MOBILITY; CANCER; CELLS	Based on the crystal structures of the prostaglandin endoperoxide H synthases-1 and -2 (PGHS-1 and PGHS-2), four short amphipathic helices near the amino termini of these proteins have been proposed to act as membrane binding domains. me constructed a series of plasmids coding for amino-terminal sequences of the PGHS-1 and PGHS-8 joined to the green fluorescent protein from Aequorea victoria, and we examined the subcellular distribution of the fusion proteins expressed from these plasmids using confocal microscopy of intact cells and Western blot analysis. DNA sequences coding for amino acids 1-139 and 1-136 of PGHS-1 and PGHS-2, respectively, which include the signal peptides, epidermal growth factor homology domains, glycosylation sites, and the putative membrane-binding helices of these two isozymes, were required for targeting the PGHS-green fluorescent protein fusion proteins to the endoplasmic reticulum and nuclear membranes when expressed in NIH 3T3 cells. Chimeric proteins that did not contain the putative membrane binding domains are targeted to the endoplasmic reticulum, but are not associated with membrane structures, and are present only in soluble cell fractions. These are the first experiments to directly confirm that the amphipathic helices present near the amino terminus of the PGHS-1 and PGHS-2 isozymes act as membrane anchors,	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	DeWitt, DL (corresponding author), Michigan State Univ, Dept Biochem, 519 Biochem, E Lansing, MI 48824 USA.		Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X	NIGMS NIH HHS [GM4073] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1212; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; KARGMAN SL, 1995, CANCER RES, V55, P2556; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; SANO H, 1995, CANCER RES, V55, P3785; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Song I, 1996, ARCH BIOCHEM BIOPHYS, V334, P67, DOI 10.1006/abbi.1996.0430; SWAISGOOD M, 1989, EXP CELL RES, V180, P529, DOI 10.1016/0014-4827(89)90079-7; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	24	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29830	29837		10.1074/jbc.273.45.29830	http://dx.doi.org/10.1074/jbc.273.45.29830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792699	hybrid			2022-12-25	WOS:000076798300076
J	Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D				Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D			Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase	ONCOGENE			English	Article						Bcr-Abl; SHPTP1; SAP kinase transformation	C-ABL; DNA-DAMAGE; IONIZING-RADIATION; STRESS-RESPONSE; ADAPTER PROTEIN; ONCOGENE; GROWTH; FIBROBLASTS; ACTIVATION; PATHWAY	The oncogenic Bcr-Abl variant of the c-Abl tyrosine kinase transforms cells by a mechanism dependent on activation of the stress-activated protein kinase (SAPK). Other work has shown that c-Abl interacts with the SHPTP1 protein tyrosine phosphatase in induction of SAPK activity by genotoxic stress. The present studies demonstrate that Bcr-Abl binds constitutively to SHPTP1. We show that Bcr-Abl phosphorylates SHPTP1 on C-terminal Y536 and Y564 sites. The functional significance of the Bcr-Abl/SHPTP1 interaction is supported by the finding that SHPTP1 regulates Bcr-Abl-induced SAPK activity. Importantly, SHPTP1 also decreases Bcr-Abl-dependent transformation of fibroblasts. These findings indicate that SHPTP1 functions as a tumor suppressor in cells transformed by Bcr-Abl.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Liedtke, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GOGA A, 1995, ONCOGENE, V11, P791; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; YAN MH, 1994, NATURE, V372, P798; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	26	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1889	1892		10.1038/sj.onc.1202117	http://dx.doi.org/10.1038/sj.onc.1202117			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788431	Bronze			2022-12-25	WOS:000076423500001
J	Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC				Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC			A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas	ONCOGENE			English	Article						sarcoma; SSX; KRAB; transcription	ZINC-FINGER PROTEINS; KRUPPEL-ASSOCIATED BOX; HUMAN SYNOVIAL SARCOMA; SYT; TRANSLOCATION; FUSION; FAMILY; CHROMOSOME; ACTIVATOR; MEMBERS	SSX genes show extensive nucleotide sequence conservation but little is known of their function. Disruption of SSX1 or SSX2, by chromosome translocation and 'in-frame' fusion to SYT, is a consistent feature of synovial sarcomas, The resulting SYT-SSX1/SSX2 proteins are activators of transcription; transactivation function is located in SYT, Unrearranged SSX1 can repress transcription, and this has been attributed to a putative Kruppel associated box (KRAB) repression domain at the N-terminus. Here we isolated SSX-KRAB domains to specifically measure repression activity, using a previously characterized KOX1-KRAB domain as a control. In our repressor assay SSX1- and SSX2-KRAB domains down-modulated the transactivation of reporter gene by threefold, compared with 83-fold repression achieved by KOX1-KRAB in the assay. Yeast two-hybrid analysis showed that SSX1-KRAB, unlike KOX1-KRAB, fails to interact with the KRAB co-repressor TIF1 beta. These results raise questions about the evolutionary and functional relationship of SSX-KRAB and typical KRAB domains of Kruppel zinc finger genes. We found that full-length SSX1 showed potent (74-fold) repression in our repressor assay, indicating the existence of a repression domain distinct from SSX-KRAB. By assaying deletion constructs of SSX1 we localized repression activity to 33 amino acids at the C-terminus. This novel domain is conserved between SSX family members, and, unlike the KRAB-related domain, is retained on fusion with SYT, This has important implications in understanding the mechanism by which the SYT-SSX fusion protein could contribute to neoplasia.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0HS, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0HS, England; Univ Rostock, Inst Immunol, D-18055 Rostock, Germany	Imperial College London; Cancer Research UK; Imperial College London; University of Rostock	Knight, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus, London W12 0HS, England.			Lim, Fei Ling/0000-0002-7744-4836				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THIESEN H-J, 1990, New Biologist, V2, P363; Thiesen Hans-Juergen, 1997, P315; Tureci O, 1996, CANCER RES, V56, P4766; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	26	112	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2013	2018		10.1038/sj.onc.1202122	http://dx.doi.org/10.1038/sj.onc.1202122			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788446				2022-12-25	WOS:000076423500016
J	Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL				Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL			The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors	ONCOGENE			English	Article						rac; ras; G-protein coupled receptor; tyrosine kinase linked receptor; JAK/STAT linked receptor	NIH 3T3 CELLS; HETEROTRIMERIC G-PROTEINS; KINASE KINASE KINASE; C-JUN; MUSCARINIC RECEPTORS; SIGNALING PATHWAY; BINDING PROTEINS; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; HA-RAS	Ras and rac are each members of the superfamily of monomeric GTPases and both function as molecular switches to link cell-surface signals to intracellular responses. Using a novel assay of cellular proliferation called R-SAT(TM) (Receptor Selection and Amplification Technology), we examined the roles of ras and rac in mediating the proliferative responses to a variety of cell-surface receptors, Activated, wild-type and dominant-negative mutants of rac and ras were tested for their effects on cellular proliferation either alone or in combination with receptors, Activated rac (rac Q61L, henceforth rac*) and ras (ras G12V, henceforth ras*) each induced strong proliferative responses. Dominant-negative rac (rac T17N, henceforth rac(-)) dramatically suppressed proliferative responses to G-protein coupled receptors (GPCR's) including the m5 muscarinic receptor and the alpha 1B adrenergic receptor. In contrast, rac(-) had little or no effect upon responses to the tyrosine kinase receptor TrkC, and only partially suppressed responses to the Janus kinase (JAK/STAT) linked granulocyte macrophage colony stimulating factor (GM-CSF) receptor. Dominant-negative ras (ras T17N, henceforth ras(-)) blocked the proliferative responses to all of the tested receptors, Compared to rac(-) and ras(-), wild-type rac and ras had only modest effects on the tested receptors, Overall these results demonstrate that rac mediates the proliferative effects of G-protein coupled receptors through a pathway that is distinct from the proliferative signaling pathway utilized by tyrosine kinase linked and JAK-linked receptors.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; NIDR, Mol Signaling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAN MH, 1994, NATURE, V372, P798	58	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1617	1623		10.1038/sj.onc.1202067	http://dx.doi.org/10.1038/sj.onc.1202067			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794239				2022-12-25	WOS:000076089900014
J	Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD				Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD			Mutation analysis of the PTEN/MMAC1 gene in lung cancer	ONCOGENE			English	Article						homozygous deletion; loss of heterozygosity; chromosome 10q23	TUMOR-SUPPRESSOR GENE; COWDEN-DISEASE; PROSTATE-CANCER; PTEN; CARCINOMAS; PHOSPHATASE; DELETIONS; FREQUENT; BREAST; IDENTIFICATION	We studied PTEN/MMAC1, a newly discovered candidate tumor suppressor gene at 10q23.3, for mutations in lung cancer. One hundred and thirty-six lung cancer cell line DNAs (66 small cell lung cancers, SCLC, 61 non-small cell lung cancers, NSCLC, four mesotheliomas, five extrapulmonary small cell cancers) were analysed for PTEN/MMAC1 homozygous deletions and five (8%) SCLC lines showed homozygous deletions interrupting the PTEN/MMAC1 gene. Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations. Northern blot analysis revealed that expression of the PTEN/MMAC1 gene was considerably lower in all the tumor cell lines with point mutations while no expression was detected for cell lines with PTEN/MMAC1 homozygous deletions. Mutation analysis of 22 uncultured, microdissected, primary SCLC tumors and metastases showed two silent mutations, and two apparent homozygous deletions. We also discovered a processed pseudogene (PTEN2) which has 98.5% nt identity to PTEN/MMAC1, that needs to be accounted for in cDNA mutation analysis, Our findings suggest that genetic abnormalities of the PTEN/MMAC1 gene are only involved in a relatively small subset of lung cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Fong, Kwun M/G-6369-2010; Sekido, Yoshitaka/P-9756-2015; Muneer, Sowbiya/S-5382-2019	Fong, Kwun/0000-0002-6507-1403; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; Bostrom J, 1998, CANCER RES, V58, P29; Dahia PLM, 1997, CANCER RES, V57, P4710; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Li DM, 1997, ENG FRACT MECH, V57, P1, DOI 10.1016/S0013-7944(97)00023-4; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maniatis T., 1982, MOL CLONING LAB MANU; Marsh DJ, 1997, CANCER RES, V57, P500; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; RIED T, 1997, BRIT J CANCER, V75, P79; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; VIRMANI A, 1998, IN PRESS GENES CHROM; Wechsler DS, 1996, GENOMICS, V32, P466, DOI 10.1006/geno.1996.0144	29	166	175	7	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1557	1565		10.1038/sj.onc.1202070	http://dx.doi.org/10.1038/sj.onc.1202070			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794233				2022-12-25	WOS:000076089900008
J	Anderson, KA; Means, RL; Huang, QH; Kemp, BE; Goldstein, EG; Selbert, MA; Edelman, AM; Fremeau, RT; Means, AR				Anderson, KA; Means, RL; Huang, QH; Kemp, BE; Goldstein, EG; Selbert, MA; Edelman, AM; Fremeau, RT; Means, AR			Components of a calmodulin-dependent protein kinase cascade - Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; GENE-EXPRESSION; T-LYMPHOCYTES; CDNA CLONING; I CASCADE; CALCIUM; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION	Ca2+/calmodulin-dependent protein kinases I and IV (CaMKI and CaMKIV, respectively) require phosphorylation on an equivalent single Thr in the activation loop of subdomain MI for maximal activity. Two distinct CaMHI/IV kinases, CaMKK alpha and CaMKK beta, were purified from rat brain and partially sequenced (Edelman, A. M., Mitchelhill, K., Selbert, M. A., Anderson, K. A., Hook, S. S., Stapleton, D., Goldstein, E. G., Means, A. R., and Kemp, B. E. (1996) J. Biol. Chem. 271, 10806-10810). We report here the cloning and sequencing of cDNAs for human and rat CaMKK beta, tissue and regional brain localization of CaMKK beta protein, and mRNA and functional characterization of recombinant CaMKK beta in vitro and in Jurkat T cells. The sequences of human and rat CaMKK beta demonstrate 65% identity and 80% similarity with CaMKK alpha and 30-40% identity with CaMKI and CaMKIV themselves. CaMKK beta is broadly distributed among rat tissues with highest levels in CaMKIV-expressing tissues such as brain, thymus, spleen, and testis. In brain, CaMKK beta tracks more closely with CaMKIV than does CaMKK alpha. Bacterially expressed CaMKK beta undergoes intramolecular autophosphorylation, is regulated by Ca2+/CaM, and phosphorylates CaMKI and CaMKIV on Thr(177) and Thr(200), respectively. CaMKK beta activates both CaMKI and CaMKIV when coexpressed in Jurkat T cells as judged by phosphorylated cAMP response element-binding protein-dependent reporter gene expression. CaMKK beta activity is enhanced by elevation of intracellular Ca2+, although substantial activity is observed at the resting Ca2+ concentration. The strict Ca2+ requirement of CaMKIV-dependent phosphorylation of cAMP response element-binding protein, is therefore controlled at the level of CaMKIV rather than CaMKK.	Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	Duke University; St. Vincent's Institute of Medical Research; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Means, AR (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline; NINDS NIH HHS [NS-24738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTS MJ, 1992, MOL CELL NEUROSCI, V3, P461, DOI 10.1016/1044-7431(92)90057-9; Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHAFOULEAS JG, 1979, J BIOL CHEM, V254, P262; Chatila T, 1997, J VIROL, V71, P6560, DOI 10.1128/JVI.71.9.6560-6567.1997; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FREMEAU RT, 1990, EMBO J, V9, P3533, DOI 10.1002/j.1460-2075.1990.tb07562.x; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; Means AR, 1997, RECENT PROG HORM RES, V52, P389; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Sawamura Y, 1996, BRAIN RES, V706, P259, DOI 10.1016/0006-8993(95)01161-7; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166	52	207	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31880	31889		10.1074/jbc.273.48.31880	http://dx.doi.org/10.1074/jbc.273.48.31880			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822657	hybrid			2022-12-25	WOS:000077207000039
J	Ogawa, S; Oku, A; Sawano, A; Yamaguchi, S; Yazaki, Y; Shibuya, M				Ogawa, S; Oku, A; Sawano, A; Yamaguchi, S; Yazaki, Y; Shibuya, M			A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/FlK-1 receptor and carries a potent mitotic activity without heparin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLT TYROSINE KINASE; POXVIRUS ORF VIRUS; SIGNAL-TRANSDUCTION; FACTOR FAMILY; ANGIOGENESIS; KDR; IDENTIFICATION; VASCULOGENESIS; EXPRESSION; PROTEIN	Vascular endothelial growth factor (VEGF) mediates endothelial cell proliferation, angiogenesis, and vascular permeability via the endothelial cell receptors, KDR/FLk-1 and Flt-1. Recently, a gene encoding a polypeptide with about 25% amino acid identity to mammalian VEGF was identified in the genome of Orf virus (OV), a parapoxvirus that affects sheep and goats and occasionally, humans, to generate lesions with angiogenesis. In this study, we examined the biological activities and receptor of OV-derived NZ-7 VEGF (VEGF-E). VEGF-E was found to be a dimer of about 20 kDa with no basic domain nor affinity for heparin column, similar to VEGF(121) subtype. VEGF(121) has 10-100-fold less endothelial cell mitotic activity than VEGF(165) due to lack of a heparin-binding basic region. Interestingly, however, VEGF-E showed almost equal levels of mitotic activity on primary endothelial cells and vascular permeability activity as VEGF(165). Furthermore, VEGF-E bound KDR/Flk-1 (VEGFR-2) and induced its autophosphorylation to almost the same extent as VEGF(165), but did not bind Flt-1 (VEGFR-1) nor induce autophosphorylation of Flt-1. These results indicate that VEGF-E is a novel type of endothelial growth factor, utilizing only one of the VEGF receptors, and carrying a potent mitogenic activity without affinity to heparin.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Med, Dept Internal Med 3, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Sakaue-Sawano, Asako/0000-0002-6975-0390				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ANTONIADES HN, 1983, SCIENCE, V220, P963, DOI 10.1126/science.6844921; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Fleming SB, 1997, J VIROL, V71, P4857, DOI 10.1128/JVI.71.6.4857-4861.1997; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joukov V, 1996, EMBO J, V15, P290; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MCKEEVER DJ, 1988, J COMP PATHOL, V99, P317, DOI 10.1016/0021-9975(88)90052-7; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Robinson A. J., 1981, Veterinary Bulletin, V51, P771; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMANE A, 1994, ONCOGENE, V9, P2683; YEH HP, 1974, ARCH DERMATOL, V109, P390, DOI 10.1001/archderm.109.3.390	45	306	335	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31273	31282		10.1074/jbc.273.47.31273	http://dx.doi.org/10.1074/jbc.273.47.31273			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813035	hybrid			2022-12-25	WOS:000077136900063
J	Sahay, N; Guy, HI; Liu, X; Evans, DR				Sahay, N; Guy, HI; Liu, X; Evans, DR			Regulation of an Escherichia coli mammalian chimeric carbamoyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; ACETYL-L-GLUTAMATE; COOH-TERMINAL DOMAIN; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; EHRLICH ASCITES-CARCINOMA; BINDING-SITE; REVERSIBLE DISSOCIATION; CONTROLLED PROTEOLYSIS; DIHYDROOROTASE DOMAIN	Carbamoyl-phosphate synthetase (CPSase) consists of a 120-kDa synthetase domain (CPS) that makes carbamoyl phosphate from ATP, bicarbonate, and ammonia usually produced by a separate glutaminase domain. CPS is composed of two subdomains, CPS.A and CPS.B. Although CPS.A and CPS.B have specialized functions in intact CPSase, the separately cloned subdomains can catalyze carbamoyl phosphate synthesis. This report describes the construction of a 58-kDa chimeric CPSase composed of Escherichia coli CPS.A catalytic subdomains and the mammalian regulatory subdomain. The catalytic parameters are similar to those of the E. coli enzyme, but the activity is regulated by the mammalian effecters and protein kinase A phosphorylation. The chimera has a single site that binds phosphoribosyl 5'-pyrophosphate (PRPP) with a dissociation constant of 25 mu M. The dissociation constant for UTP of 0.23 mM was inferred from its effect on PRPP binding. Thus, the regulatory subdomain is an exchangeable ligand binding module that can control both CPS.A and CPS.B domains, and the pathway for allosteric signal transmission is identical in E. coli and mammalian CPSase. A deletion mutant that truncates the polypeptide within a postulated regulatory sequence is as active as the parent chimera but is insensitive to effecters. PRPP and UTP bind to the mutant, suggesting that the carboxyl half of the subdomain is essential for transmitting the allosteric signal but not for ligand binding.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO E, 1992, J BIOL CHEM, V267, P4524; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1976, COMP BIOCHEM PHYS B, V54, P261, DOI 10.1016/0305-0491(76)90154-1; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BEIN K, 1991, J BIOL CHEM, V266, P3791; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CARREY EA, 1988, EUR J BIOCHEM, V171, P583, DOI 10.1111/j.1432-1033.1988.tb13828.x; CERVERA J, 1993, J BIOL CHEM, V268, P12504; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; CZERWINSKI RM, 1995, BIOCHEMISTRY-US, V34, P13920, DOI 10.1021/bi00042a025; DAVIDSON JN, 1994, ADV EXP MED BIOL, V370, P591; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; DENISDUPHIL M, 1990, EUR J BIOCHEM, V193, P581, DOI 10.1111/j.1432-1033.1990.tb19376.x; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1998, J BIOL CHEM, V273, P14172, DOI 10.1074/jbc.273.23.14172; Guy HI, 1997, J BIOL CHEM, V272, P29255, DOI 10.1074/jbc.272.46.29255; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Hanahan D, 1985, DNA CLONING PRACTICA; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KHORANA HG, 1958, J BIOL CHEM, V230, P941; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LIM F, 1988, J BIOL CHEM, V263, P11493; LIU X, 1994, J BIOL CHEM, V269, P27747; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING LAB MANU; MAREYA SM, 1995, BIOORGAN MED CHEM, V3, P525, DOI 10.1016/0968-0896(95)00042-F; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PAULUS TJ, 1979, J BACTERIOL, V137, P82, DOI 10.1128/JB.137.1.82-91.1979; Penefsky H S, 1979, Methods Enzymol, V56, P527; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUMSBY PC, 1984, BIOCHEM J, V217, P435, DOI 10.1042/bj2170435; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SHOAF WT, 1971, BIOCHEM BIOPH RES CO, V45, P796; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Switzer R L, 1978, Methods Enzymol, V51, P3; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	78	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31195	31202		10.1074/jbc.273.47.31195	http://dx.doi.org/10.1074/jbc.273.47.31195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813025	hybrid			2022-12-25	WOS:000077136900053
J	Knepper-Nicolai, B; Savill, J; Brown, SB				Knepper-Nicolai, B; Savill, J; Brown, SB			Constitutive apoptosis in human neutrophils requires synergy between calpains and the proteasome downstream of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FC-GAMMA-RIII; THYMOCYTE APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; SYMPATHETIC NEURONS; CYTOPLASMIC DOMAIN; DNA FRAGMENTATION; ALPHA-FODRIN; ACTIVATION; PROTEINS	Programmed cell death invariably requires the activation of proteolytic cascades that are not yet well defined but are initiated after apical caspase activation. We provide evidence that calpains and the proteasome function synergistically downstream of caspases to assist the constitutive apoptotic program of aging neutrophils, which plays an important role in resolution of inflammatory responses. Inhibitor studies indicated that "tetherrng" of preapoptotic senescent neutrophils to human macrophages required caspase activity. However, the development of morphological features characteristic of apoptosis, including nuclear morphology, PS exposure, surface protein shedding, and the capacity to be ingested:by macrophages, required the downstream action of either calpains or the proteasome. Calpain activities were constitutively active in freshly isolated neutrophils and responsible for rearrangements in the protein composition and structure of the plasmalemmal cytoskeleton as they aged in culture and underwent apoptosis. This included a dissociation of protein(s) from F-actin, a candidate mechanism for increased susceptibility to cleavage, and a loss in immunodetectable alpha-actinin and ezrin, two actin-binding, membrane-anchoring proteins. These results clarify roles for different classes of proteases in a physiologically important form of constitutive apoptosis.	Univ Hosp, Dept Med, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England	Nottingham University Hospital NHS Trust; University of Nottingham	Brown, SB (corresponding author), Univ Edinburgh, Dept Med RIE, Inflammat Repair Grp, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Brown, Simon/B-3006-2009					Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; BRUNO S, 1992, LEUKEMIA, V6, P1113; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dick LR, 1997, J BIOL CHEM, V272, P182; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; HASLETT C, 1985, AM J PATHOL, V119, P101; HOMBURG CHE, 1995, BLOOD, V85, P532; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kouchi Z, 1997, APOPTOSIS, V2, P84, DOI 10.1023/A:1026443926962; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Mampuru LJ, 1996, EXP CELL RES, V226, P372, DOI 10.1006/excr.1996.0238; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MUSSON RA, 1983, AM J PATHOL, V111, P331; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; REDELMAN D, 1980, J IMMUNOL, V124, P870; REN Y, 1995, J IMMUNOL, V154, P2366; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sambrano GR, 1997, ARTERIOSCL THROM VAS, V17, P3442, DOI 10.1161/01.ATV.17.12.3442; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SAVILL JS, 1989, J CLIN INVEST, V84, P1518, DOI 10.1172/JCI114328; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Squier MKT, 1996, CELL DEATH DIFFER, V3, P275; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; Villa PG, 1998, J CELL SCI, V111, P713; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437; ZHU W, 1995, BIOCHEM BIOPH RES CO, V214, P1130, DOI 10.1006/bbrc.1995.2403	61	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30530	30536		10.1074/jbc.273.46.30530	http://dx.doi.org/10.1074/jbc.273.46.30530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804822	hybrid			2022-12-25	WOS:000077008100069
J	Chattopadhyay, S; Whitehurst, CE; Chen, JZ				Chattopadhyay, S; Whitehurst, CE; Chen, JZ			A nuclear matrix attachment region upstream of the T cell receptor beta gene enhancer binds Cux/CDP and SATB1 and modulates enhancer-dependent reporter gene expression but not endogenous gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CUT HOMEODOMAIN PROTEIN; DNA-BINDING; V(D)J RECOMBINATION; CHAIN ENHANCER; TCR-BETA; TRANSGENIC MICE; DECAMER MOTIF; PROMOTER; TRANSCRIPTION	We have previously identified a DNase I-hypersensitive site in the T cell receptor beta locus, designated HS1, that is located 400 base pairs upstream of the transcriptional enhancer E-beta and is induced during CD4(-)CD8(-) to CD4(+)CD8(+) thymocyte differentiation. Using electrophoretic mobility shift assays, we show that HS1 induction correlates with increased binding of two nuclear factors, Cux/CDP and SATB1, to a 170-hase pair DNA sequence within HS1. Furthermore, we demonstrate that HS1 is a nuclear matrix attachment region, referred to as MAR(beta). These findings demonstrate that an analogous organization of cis-regulatory elements in which a nuclear matrix attachment region is in close proximity to an enhancer is conserved in the immunoglobulin and T cell receptor loci. In addition, we show that MAR(beta) represses E-beta-dependent reporter gene expression in transient transfection assays. However, the targeted deletion of MAR(beta) from the endogenous locus does not change T cell receptor beta gene transcription in developing T cells. These contrasting results suggest a potential pitfall of functional studies of nuclear matrix attachment regions outside of their natural chromosomal context.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Chen, JZ (corresponding author), MIT, Ctr Canc Res, E17-128,40 Ames St, Cambridge, MA 02139 USA.	JChen@mit.edu		Whitehurst, Charles/0000-0003-3112-5458	NCI NIH HHS [CA14051] Funding Source: Medline; NIAID NIH HHS [AI07463, AI40146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040146, T32AI007463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVAREZ JD, 1995, J IMMUNOL, V155, P1191; ANDERSON SJ, 1989, MOL CELL BIOL, V9, P4835, DOI 10.1128/MCB.9.11.4835; ANDERSON SJ, 1988, P NATL ACAD SCI USA, V85, P3551, DOI 10.1073/pnas.85.10.3551; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Avitahl N, 1996, INT IMMUNOL, V8, P1359, DOI 10.1093/intimm/8.9.1359; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLASQUEZ VC, 1989, GENOME, V31, P503, DOI 10.1139/g89-098; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; Chattopadhyay S, 1998, J IMMUNOL, V160, P1256; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; HARADA R, 1994, J BIOL CHEM, V269, P2062; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LEE MR, 1992, J IMMUNOL, V148, P1906; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; Levelt CN, 1995, IMMUNITY, V3, P667, DOI 10.1016/1074-7613(95)90056-X; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MCDOUGALL S, 1988, SCIENCE, V241, P205, DOI 10.1126/science.2968651; MOMBAERTS P, 1995, P NATL ACAD SCI USA, V92, P7420, DOI 10.1073/pnas.92.16.7420; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NASHIMOTO Y, 1989, J EXP MED, V169, P2097; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; Oancea AE, 1997, MOL CELL BIOL, V17, P2658, DOI 10.1128/MCB.17.5.2658; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WHITEHURST C, 1992, NUCLEIC ACIDS RES, V20, P4929, DOI 10.1093/nar/20.18.4929; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4; ZONG RT, 1995, J BIOL CHEM, V270, P24040	63	59	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29838	29846		10.1074/jbc.273.45.29838	http://dx.doi.org/10.1074/jbc.273.45.29838			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792700	hybrid			2022-12-25	WOS:000076798300077
J	Dyer, JR; Pepio, AM; Yanow, SK; Sossin, WS				Dyer, JR; Pepio, AM; Yanow, SK; Sossin, WS			Phosphorylation of eIF4E at a conserved serine in Aplysia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; INITIATION-FACTOR EIF-4E; PROTEIN-KINASE-C; MESSENGER-RNA; TRANSLATION INITIATION; BINDING PROTEINS; PHORBOL ESTERS; ISOZYME FORM; SYNAPSE; STIMULATION	We have cloned eIF4E from the marine mollusk, Aplysia californica. The sequence of eIF4E from Aplysia is more similar to vertebrate eIF4Es than to other invertebrate sequences. Aplysia eIF4E is encoded by two tissue-specific RNAs, Antibodies raised to the carboxyl ter minus of eIF4E recognize a 29-kDa protein that can bind to 7-methyl-GTP caps, The phosphorylation site identified in mammalian eIF4E is conserved in the Aplysia homologue, and an Aplysia eIF4E fusion protein is phosphorylated well by both Aplysia protein kinase C isoforms. However, protein kinase C phosphorylates both Ser-207 and Thr-208 in vitro, while only Ser-207 is phosphorylated in vivo. We have confirmed that Ser-207 is phosphorylated in vivo by raising a phosphopeptide antibody to this site. This antibody will be useful in determining the signal transduction pathways leading to eIF4E phosphorylation in Aplysia.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.	mdws@musica.mcgill.ca						ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BU X, 1993, J BIOL CHEM, V268, P4975; Byrne JH, 1996, J NEUROSCI, V16, P425; Dyer JR, 1997, DNA CELL BIOL, V16, P347, DOI 10.1089/dna.1997.16.347; Dyer JR, 1996, J NEUROCHEM, V67, P932; FEIG S, 1993, J NEUROSCI, V13, P1010; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Lavoie CA, 1996, J BIOL CHEM, V271, P16393, DOI 10.1074/jbc.271.27.16393; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Marin P, 1997, J NEUROSCI, V17, P3445; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Sossin WS, 1996, TRENDS NEUROSCI, V19, P215; Sossin WS, 1996, J NEUROSCI, V16, P10; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; WAKIYAMA M, 1995, FEBS LETT, V360, P191, DOI 10.1016/0014-5793(95)00081-J; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEILER IJ, 1994, PROG BRAIN RES, V100, P189; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; Yanow SK, 1998, J NEUROCHEM, V70, P572	44	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29469	29474		10.1074/jbc.273.45.29469	http://dx.doi.org/10.1074/jbc.273.45.29469			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792652	hybrid			2022-12-25	WOS:000076798300029
J	Kitmitto, A; Mustafa, AO; Holzenburg, A; Ford, RC				Kitmitto, A; Mustafa, AO; Holzenburg, A; Ford, RC			Three-dimensional structure of higher plant photosystem I determined by electron crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL CRYSTALS; THYLAKOID MEMBRANES; SYNECHOCOCCUS SP; GRANA MARGINS; RESOLUTION; COMPLEXES; RECONSTITUTION; HETEROGENEITY; MICROSCOPY; TOPOLOGY	We describe the three-dimensional structure of higher plant photosystem I (PSI) as obtained by electron microscopy of two-dimensional crystals formed at the grana margins of thylakoid membranes. The negatively stained crystalline areas displayed unit cell dimensions a = 26.6 nm, b = 27.7 nm, and gamma = 90 degrees, and p22(1)2(1) plane group symmetry consisting of two monomers facing upward and two monomers facing downward with respect to the membrane plane. Higher plant PSI shows several structural similarities to the cyanobacterial PSI complex, with a prominent ridge on the stromal side of the complex. The stromal ridge is resolved into at least three separate domains that are interpreted as representing the three well characterized stromal subunits, the psa C, D, and E gene products. The lumenal surface is relatively flat but exhibits a distinct central depression that may be the binding site for plastocyanin. Higher plant PSI is of dimensions 15-16 x 11-12.5 nm, and thus leaves a larger footprint in the membrane than its cyanobacterial equivalent (13 x 10.5 nm). It is expected that additional membrane-bound polypeptides will be present in the higher plant PSI. Both higher plant and cyanobacterial complexes span about 8-9 nm in the direction orthogonal to the membrane. This report represents the first three-dimensional structure for the higher plant PSI complex.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Manchester; University of Leeds; University of Leeds	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	R.FORD@UMIST.AC.UK		Ford, Robert/0000-0002-0958-1505				ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDREASSON E, 1993, BIOCHIM BIOPHYS ACTA, V1141, P175, DOI 10.1016/0005-2728(93)90040-M; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P49, DOI 10.1016/0005-2728(90)90177-6; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; BRYANT DA, 1991, CURRENT TOPICS PHOTO, V11, P1; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; DUNAHAY TG, 1985, PLANT PHYSIOL, V78, P606, DOI 10.1104/pp.78.3.606; FISH LE, 1985, J BIOL CHEM, V260, P1413; FORD RC, 1987, EMBO J, V6, P1581, DOI 10.1002/j.1460-2075.1987.tb02403.x; FORD RC, 1988, EMBO J, V7, P2287, DOI 10.1002/j.1460-2075.1988.tb03071.x; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; FROMME P, 1994, BIOCHIM BIOPHYS ACTA, V1141, P175; HEFTI A, 1992, FEBS LETT, V296, P29, DOI 10.1016/0014-5793(92)80396-X; HLADIK J, 1991, PHOTOSYNTH RES, V29, P171, DOI 10.1007/BF00036220; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Karrasch S, 1996, J MOL BIOL, V262, P336, DOI 10.1006/jmbi.1996.0517; Kitmitto A, 1997, J BIOL CHEM, V272, P19497, DOI 10.1074/jbc.272.31.19497; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; MAXWYNN R, 1988, BIOCHEMISTRY-US, V27, P5863; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; STOYLOVA S, 1996, PHOTOSYNTHESIS LIGHT, V3, P333; WITT I, 1988, BER BUNSEN PHYS CHEM, V92, P1503, DOI 10.1002/bbpc.198800358; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	30	21	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29592	29599		10.1074/jbc.273.45.29592	http://dx.doi.org/10.1074/jbc.273.45.29592			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792668	hybrid			2022-12-25	WOS:000076798300045
J	Knutzon, DS; Thurmond, JM; Huang, YS; Chaudhary, S; Bobik, EG; Chan, GM; Kirchner, SJ; Mukerji, P				Knutzon, DS; Thurmond, JM; Huang, YS; Chaudhary, S; Bobik, EG; Chan, GM; Kirchner, SJ; Mukerji, P			Identification of Delta 5-desaturase from Mortierella alpina by heterologous expression in bakers' yeast and canola	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MICROSOMAL PREPARATIONS; CYTOCHROME B(5); FATTY-ACIDS; DESATURASE; GENE; ARABIDOPSIS; CLONING; CDNA; BIOSYNTHESIS	A DNA fragment with homology to Delta 6-desaturases from borage and cyanobacteria was isolated after polymerase chain reaction amplification of Mortierella alpina cDNA with oligonucleotide primers corresponding to the conserved regions of known Delta 6-desaturase genes. This fragment was used as a probe to isolate a cDNA clone with an open reading frame encoding 446 amino acids from a M. alpina library, Expression of this open reading frame from an inducible promoter in Saccharomyces ces cerevisiae in the presence of various substrates revealed that the recombinant product had Delta 5-desaturase activity. The effects of growth and induction conditions as well as host strain on activity of the recombinant Delta 5-desaturase in S. cerevisiae were evaluated. Expression of the M. alpina Delta 5-desaturase cDNA in transgenic canola seeds resulted in the production of taxoleic acid (Delta 5,9-18:2) and pinolenic acid (Delta 5,9,12-18: 3), which are the Delta 5-desaturation products of oleic and linoleic acids, respectively.	Abbott Labs, Ross Prod Div, Columbus, OH 43215 USA; Calgene Inc, LLC, Davis, CA 95616 USA	Abbott Laboratories	Mukerji, P (corresponding author), Abbott Labs, Ross Prod Div, 625 Cleveland Ave, Columbus, OH 43215 USA.	pradip.mukerji@rossnutrition.com						ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; BROWSE J, 1993, J BIOL CHEM, V268, P16345; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Cadena DL, 1997, BIOCHEMISTRY-US, V36, P6960, DOI 10.1021/bi970091l; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Gunstone FD, 1994, LIPID HDB; HAVELAND P, 1989, GENE AMST, V83, P57; HOGE JHC, 1982, EXP MYCOL, V6, P225, DOI 10.1016/0147-5975(82)90114-1; HORROBIN DF, 1992, PROG LIPID RES, V31, P163, DOI 10.1016/0163-7827(92)90008-7; HUANG YS, 1991, BIOCHIM BIOPHYS ACTA, V1082, P319, DOI 10.1016/0005-2760(91)90208-Y; JAREONKITMONGKOL S, 1992, J GEN MICROBIOL, V138, P997, DOI 10.1099/00221287-138-5-997; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Murata Norio, 1996, P22; Napier JA, 1998, BIOCHEM J, V330, P611; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; RADKE SE, 1988, THEOR APPL GENET, V75, P685, DOI 10.1007/BF00265588; REDDY AS, 1993, PLANT MOL BIOL, V22, P293, DOI 10.1007/BF00014936; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHINMEN Y, 1989, APPL MICROBIOL BIOT, V31, P11, DOI 10.1007/BF00252518; SMITH MA, 1994, PLANT MOL BIOL, V25, P527, DOI 10.1007/BF00043880; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; Spychalla JP, 1997, P NATL ACAD SCI USA, V94, P1142, DOI 10.1073/pnas.94.4.1142; STEARNS T, 1990, METHOD ENZYMOL, V185, P280; TAKAGI T, 1982, LIPIDS, V17, P716, DOI 10.1007/BF02534657; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; Wolff R. L., 1997, INFORM - International News on Fats, Oils and Related Materials, V8, P116; YAMADA H, 1987, AGR BIOL CHEM TOKYO, V51, P785, DOI 10.1080/00021369.1987.10868119; YOO M, 1988, BIOCHEM BIOPH RES CO, V156, P576, DOI 10.1016/S0006-291X(88)80881-7	33	122	169	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29360	29366		10.1074/jbc.273.45.29360	http://dx.doi.org/10.1074/jbc.273.45.29360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792636	hybrid			2022-12-25	WOS:000076798300013
J	Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M				Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions	ONCOGENE			English	Article						Epstein-Barr virus; LMP-1; NF-kappa B; CD54; CD40; TNF-R	NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; TRANSIENT EXPRESSION; EPITHELIAL-CELLS; BINDING-SITES; ACTIVATION; GENE; INDUCTION; TRAF2; MEMBRANE-PROTEIN-1	The Epstein-Barr virus (EBV) encoded Latent Membrane Protein-1 (LMP1) mimics a constitutively active receptor molecule, and has been shown to activate NF-kappa B and the MAPK and JNK pathways, Two regions within the cytosolic domain of LMP1 have been found to effect cell signalling. One of these, the carboxy-terminal activation region-1 (CTAR1), binds members of the TRAF family of proteins, and the other (CTAR2) binds TRADD, suggesting that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor family of receptors, The ability to bind TRAFs, to activate NF-kappa B and the JNK pathway, to upregulate cellular genes such as CD54 (ICAM-1 adhesion molecule), and to affect cell growth and apoptosis has led to the suggestion that LMP1 signalling is similar to, or even identical to CD40, However, we now show that while ligand-induced CD40 signalling is impaired in the Jurkat T cell line, LMP1 was fully functional; therefore demonstrating that LMP1 and CD40 signalling differ, Mutated LMP1 genes, in which one or other of the CTAR1 and CTAR2 domains was non-functional, behaved more like CD40 in being unable to upregulate the CD54 cell surface marker in Jurkat cells, However, the CTAR1 domain of LMP1, which shared a TRAF-binding sequence motif with CD40, differed from CD40 in being unable to activate NF-kappa B in Jurkat, Cotransfection experiments with LMP1 mutants demonstrated that CTAR1 can cooperative with CTAR2 on separate LMP1 molecules, provided that they exist within the same oligomeric complex.	Cardiff Univ, Dept Med, Cardiff CF4 4XX, S Glam, Wales; Univ Birmingham, Sch Med, Inst Canc Studies, Birmingham B15 2TJ, W Midlands, England	Cardiff University; University of Birmingham	Rowe, M (corresponding author), Cardiff Univ, Dept Med, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENRIQUEZ N, 1998, UNPUB; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	46	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2383	2392		10.1038/sj.onc.1202144	http://dx.doi.org/10.1038/sj.onc.1202144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811470				2022-12-25	WOS:000076723300013
J	Franco, L; Guida, L; Bruzzone, S; Zocchi, E; Usai, C; De Flora, A				Franco, L; Guida, L; Bruzzone, S; Zocchi, E; Usai, C; De Flora, A			The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes	FASEB JOURNAL			English	Article						proteoliposomes; intracellular calcium homeostasis; transmembrane enzymes; catalytic channels	HUMAN-ERYTHROCYTES; NAD+ GLYCOHYDROLASE; SELF-AGGREGATION; CYCLASE ACTIVITY; OUTER SURFACE; ANTIGEN CD38; HYDROLYSIS; PROTEIN; CELLS; INVOLVEMENT	CD38 is a type II transmembrane glycoprotein expressed in many vertebrate cells. It is a bifunctional ectoenzyme that catalyzes both the synthesis of Cyclic ADP-ribose (cADPR) from NAD(+) and the degradation of cADPR to ADP-ribose by means of its ADP-ribosyl cyclase and cADPR-hydrolase activities, respectively. The cyclase also converts NGD(+) to cyclic GDP-ribose (cGDPR), which is refractory to cADPR-hydrolase, cADPR, but not cGDPR, is a potent calcium mobilizer from intracellular stores. It has been demonstrated to be a new second messenger involved in the regulation of calcium homeostasis in many cell types, from plants to mammals. The number of physiological processes shown to be regulated by cADPR is steadily increasing. A topological paradox exists because ectocellularly generated cADPR acts intracellularly. Here we demonstrate that the catalytic functioning of CD38 is accompanied by a cADPR (cGDPR) -transporting activity across natural and artificial membranes. In resealed membranes from CD38(+) human erythrocytes, transport of catalytically generated cADPR or cGDPR was saturation dependent and occurred against a concentration gradient. Likewise, CD38-reconstituted proteoliposomes were active in concentrating NAD(+) (NGD(+))-derived cADPR (cGDPR) inside the vesicle compartment. Moreover, the cADpR-transporting activity in CD38 proteoliposomes prevented the hydrolase-catalyzed degradation to ADPR that occurs conversely with detergent-solubilized CD38, resulting in selective influx of cADPR. In the CD38 proteoliposomes, catalytically active CD38 exhibited monomeric, dimeric, and tetrameric structures. In CD38 sense- but not in antisense-transfected HeLa cells, externally added NAD+ resulted in significant, transient increases in cytosolic calcium. These data suggest that transmembrane juxtaposition of two or four CD38 monomers can generate a catalytically active channel for selective formation and influx of cADPR (cGDPR) to reach cADPR-responsive intracellular calcium stores.	Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; CNR, Inst Cybernet & Biophys, I-16149 Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	De Flora, A (corresponding author), Univ Genoa, Inst Biochem, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1984, J BIOL CHEM, V259, P150; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DEFLORA A, 1981, ACTA BIOL MED GER, V40, P563; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; FRANCO L, 1994, BIOCHEM BIOPH RES CO, V202, P1710, DOI 10.1006/bbrc.1994.2132; FUNARO A, 1990, J IMMUNOL, V145, P2390; Funaro A, 1998, J IMMUNOL, V160, P2238; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; Hoshino S, 1997, J IMMUNOL, V158, P741; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM UH, 1993, BIOCHIM BIOPHYS ACTA, V1178, P121, DOI 10.1016/0167-4889(93)90001-6; KONDO T, 1989, METHOD ENZYMOL, V171, P217; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; MARSH JB, 1966, J LIPID RES, V7, P574; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MULLER HM, 1987, BIOCHEM J, V246, P319, DOI 10.1042/bj2460319; NANRI H, 1983, J BIOL CHEM, V258, P5985; PLAGEMANN PGW, 1982, J BIOL CHEM, V257, P2069; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SALHANY JM, 1983, J BIOL CHEM, V258, P245; SHAHID U, 1996, J BIOL CHEM, V271, P15922; STECK TL, 1974, METHOD ENZYMOL, V31, P176; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHGO A, 1994, J BIOL CHEM, V269, P28555; WIDDAS WF, 1989, METHODS ENZYMOLOGY, V173, P231; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZATMAN LJ, 1953, J BIOL CHEM, V200, P197; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; ZOCCHI E, 1995, FEBS LETT, V359, P35, DOI 10.1016/0014-5793(95)00005-T; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	51	101	117	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1507	1520						14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806760				2022-12-25	WOS:000076749500010
J	Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T				Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T			Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers	ONCOGENE			English	Article						17p13.3; LOH; p53; tumor suppressor gene; lung cancer	DINUCLEOTIDE REPEAT POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; SHORT ARM; CHROMOSOME 17P13.3; BREAST-CANCER; HUMAN GENOME; ALLELE LOSS; MUTATIONS; DISTINCT; 17P	The short arm of chromosome 17 is one of the most frequently affected chromosomal regions in lung cancers, while there is solid evidence that the p53 gene at 17p13.1 is a target for frequent 17p deletions. In the present study, we re-evaluated 17p deletions in lung cancers by conducting a detailed analysis of the minimum deleted region(s) on 17p with reference to the p53 gene status in each 100 primary lung cancer cases. In addition to the p53 locus at 17p13.1, the presence of an independent, commonly deleted region(s) at 17p13.3 was identified, Furthermore, loss of heterozygosity (LOH) at 17p13.3 was shown to be even more frequent than that at 17p13.1 and it appeared to occur in the absence of p53 mutation and/or 17p13.1 deletion. These results suggest that in addition to the p53 gene at 17p13.1, an as yet unidentified tumor suppressor gene(s) residing at 17p13.3 might play a role in lung carcinogenesis possibly in an earlier phase than the p53 gene. This would warrant future studies to identify the putative tumor suppressor gene at 17p13.3 in order to gain a better understanding of the molecular pathogenesis of this fatal disease.	Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 464, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 500, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 467, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Osaka University; Gifu University; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 464, Japan.		Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Konishi, Hiroyuki/0000-0003-1131-4905; Mitsudomi, Tetsuya/0000-0001-9860-8505				BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BIEGEL JA, 1992, CANCER RES, V52, P3391; CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; CHIBA I, 1990, ONCOGENE, V5, P1603; Chung GTY, 1995, ONCOGENE, V11, P2591; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haataja L, 1997, CANCER RES, V57, P32; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1994, ONCOGENE, V9, P1231; HORIO Y, 1993, CANCER RES, V53, P1; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondo M, 1996, ONCOGENE, V12, P1365; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; OLIPHANT AR, 1991, NUCLEIC ACIDS RES, V19, P4794; PARK SY, 1995, CANCER GENET CYTOGEN, V79, P74, DOI 10.1016/0165-4608(94)00103-I; Phillips NJ, 1996, CANCER RES, V56, P606; RADFORD DM, 1995, CANCER RES, V55, P3399; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Todd S, 1997, CANCER RES, V57, P1344; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	49	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2095	2100		10.1038/sj.onc.1202128	http://dx.doi.org/10.1038/sj.onc.1202128			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798680				2022-12-25	WOS:000076540900008
J	Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK				Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK			The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5 ' regulatory region and chromosomal breakpoints distant from the gene	ONCOGENE			English	Article						BCL6 mutation; 3q27 translocation; NHL	B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; FINGER ENCODING GENE; C-MYC; 3Q27 TRANSLOCATION; MALIGNANT-LYMPHOMA; BURKITT-LYMPHOMA; ABNORMALITIES; LAZ3/BCL6; PROTEIN	The BCL6 gene, mapped at the chromosomal band 3q27, encodes a POZ/Zinc finger transcription repressor protein, It is frequently activated in Non-Hodgkin's lymphomas (NHL) by translocations with breakpoints clustering in the 5' major breakpoint region (MBR) as well as by mutations in the same region, The translocations lead to BCL6 activation by substitution of promoters of rearranging genes derived from the reciprocal chromosomal partners such as IG. We report the molecular genetic analysis of a novel t(2;3)(q21;q27) translocation subset in NHL comprising three cases without apparent BCL6 involvement in the translocation, Southern blot analysis of tumor DNAs utilizing BCL6 MBR probes revealed no rearrangement in two cases, Two rearranged bands in the third case resulted from a deletion in one allele and a mutation in the other allele, Southern blot analysis of DNA from one of the two tumors without BCL6 rearrangement, using a probe derived from the recently identified alternative breakpoint region (ABR), showed a rearrangement,The ABR is located 200-270 kb telomeric to MBR, Mutations were identified in the previously reported hypermutable region of BCL6 in all three tumors, In one, the mutant allele alone was found to be expressed by RT-PCR analysis of RNA, These results demonstrate the presence of 3q27 translocation breakpoints at a distance from BCL6 suggesting distant breaks that deregulate the gene or involvement of other genes that may be subject to rearrangement.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Div Oncol, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA044029, R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [CA44029, CA66999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1997, CANCER RES, V57, P7; AXELSON H, 1994, INT J CANCER, V56, P418, DOI 10.1002/ijc.2910560322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BASTARD C, 1992, BLOOD, V79, P2527; BENITEZ J, 1992, CANCER GENET CYTOGEN, V59, P68, DOI 10.1016/0165-4608(92)90161-Z; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; Butler M., 1997, Blood, V90, p316A; CHAGANTI SR, 1998, IN PRESS GENES CHROM; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLERY E, 1995, ONCOGENE, V10, P2171; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GaliegueZouitina S, 1995, CR ACAD SCI III-VIE, V318, P1125; JOOS S, 1992, CANCER RES, V52, P6547; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KONISHI H, 1990, CANCER RES, V50, P2698; KORNBLAU SM, 1991, HEMATOL ONCOL, V9, P63; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Seyfert VL, 1996, ONCOGENE, V12, P2331; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TWEEDDALE ME, 1987, BLOOD, V69, P1307; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1717	1722		10.1038/sj.onc.1202098	http://dx.doi.org/10.1038/sj.onc.1202098			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796700	Green Accepted			2022-12-25	WOS:000076200100009
J	Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P				Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P			Homozygous deletions at 3p12 in breast and lung cancer	ONCOGENE			English	Article						DUTT1/Hrobo-1; lung cancer; U2020 deletion; tumour suppressor gene; familial non-specific dementia	YEAST ARTIFICIAL CHROMOSOMES; MOLECULAR-GENETIC CHANGES; CELL-LINE U2020; SHORT ARM; CLONING; CARCINOMA; SEQUENCES; TUMORS; PCR; DNA	We have constructed a physical map of the region homozygously deleted in the U2020 cell line at 3p12, including the location of putative CpG islands. Adjacent to one of these islands, we have identified and cloned a new gene (DUTT1) and used probes from this gene to detect two other homozygous deletions occurring in lung and breast carcinomas: the smallest deletion is within the gene itself and would result in a truncated protein. The DUTT1 gene is a member of the neural cell adhesion molecule family, although its widespread expression suggests it plays a less specialized role compared to other members of the family.	Med Res Council Ctr, Macclesfield SK10 4TG, Cheshire, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; NCI, Frederick Canc Res Facil, Immunobiol Lab, Frederick, MD 21701 USA; Univ Uppsala, Akad Sjukhuset, Dept Oncol, S-75185 Uppsala, Sweden	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Rabbitts, P (corresponding author), Med Res Council Ctr, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.		Sekido, Yoshitaka/P-9756-2015	Bergh, Jonas/0000-0001-5526-1847; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABURENT H, 1994, AM J HUM GENET S, V55, P269; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BROWN J, 1995, HUM MOL GENET, V4, P1625, DOI 10.1093/hmg/4.9.1625; BUTLER R, 1992, GENOMICS, V12, P42, DOI 10.1016/0888-7543(92)90404-G; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GEMMILL RM, 1995, NATURE, V377, P299; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HEPPELLPARTON AC, 1994, CYTOGENET CELL GENET, V66, P42, DOI 10.1159/000133661; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LERMAN MI, 1991, HUM GENET, V86, P567; OGILVIE D, 1993, METHOD MOL BIOL, V54, P131; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; SUNDARESAN V, 1995, ANN ONCOL, V6, pS27; TASSONE F, 1995, HUM MOL GENET, V4, P1509, DOI 10.1093/hmg/4.9.1509; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODD S, 1995, GENOMICS, V25, P19, DOI 10.1016/0888-7543(95)80105-U; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377	31	89	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1723	1729		10.1038/sj.onc.1202103	http://dx.doi.org/10.1038/sj.onc.1202103			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796701				2022-12-25	WOS:000076200100010
J	Cao, ZJ; Huang, K; Horwitz, AF				Cao, ZJ; Huang, K; Horwitz, AF			Identification of a domain on the integrin alpha(5) subunit implicated in cell spreading and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING AFFINITY; BETA-PROPELLER DOMAIN; FOCAL ADHESION KINASE; AMINO-ACID-RESIDUES; CYTOPLASMIC DOMAINS; PLATELET INTEGRIN; CONFORMATIONAL-CHANGES; VITRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY	The alpha(5)beta(1) integrin is a cell surface receptor for fibronectin implicated in several cellular activities including cell proliferation, differentiation, and migration. The primary site at which the alpha(5)beta(1) integrin interacts with fibronectin is the RGD (Arg-Gly-Asp) amino acid sequence. In general, the sites on the integrin alpha subunits involved in ligand binding are not well characterized. Eased on previous cross-linking studies, sequence alignment, predicted conformation, and intron-exon boundaries, we identified a 144-residue region (positions 223-567) on the alpha(5) subunit as a putative binding region and divided it into four subdomains named domains I, II, III, and IV. Chimeric receptors were prepared in which sequences on the alpha(5) subunit were exchanged with the corresponding sequences on the alpha(6) subunit, which is specific for laminin and does not bind via an RGD sequence. The mutated human alpha(5) integrin gene was transfected into CHO B2 cells, which are deficient in alpha(5) expression. Only chimeras of domain III or IV express on the cell surface. Both of these chimeras decreased the adhesion, spreading, focal adhesion assembly, and migration on fibronectin, The adhesion of the chimeric receptors to fibronectin remained sensitive to the RGD peptide, and antibodies that inhibit interaction with the fibronectin synergy site and RGD loop remain inhibitory for the chimeras, indicating that our chimeras do not inhibit binding to either the RGD or synergy sites. Finally, the affinity of soluble fibronectin to cells via the alpha(5)beta(1) receptor decreased only about S-fold, This decrease is substantially less than the observed effects on migration and spreading, which were not altered by changes in substrate concentration. Thus, the alteration in binding sites does not easily account for the changes in cell spreading and focal adhesion assembly, The tyrosine phosphorylation and focal adhesion assembly that are seen when cells expressing the wild type alpha(5) receptor adhere to fibronectin mere inhibited in cells expressing the chimeric receptors, Therefore, our results suggest that the chimeras of these domains likely interrupt alpha(5)-mediated conformational signaling.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Horwitz, AF (corresponding author), Univ Illinois, Dept Cell & Struct Biol, B107 CLSL,601 S Goodwin Ave, Urbana, IL 61801 USA.	afh@uiuc.edu			NIGMS NIH HHS [GM23244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023244, R37GM023244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4482; AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Briesewitz R, 1996, MOL BIOL CELL, V7, P1499, DOI 10.1091/mbc.7.10.1499; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; GAMIER J, 1978, J MOL BIOL, V120, P97; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOGG N, 1993, AM REV RESPIR DIS, V148, P55; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; MA L, 1995, J BIOL CHEM, V270, P18401, DOI 10.1074/jbc.270.31.18401; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, BIOCH SOC T S, V23, P395; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PAULA S, 1994, EMBO J, V13, P1790; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	58	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31670	31679		10.1074/jbc.273.48.31670	http://dx.doi.org/10.1074/jbc.273.48.31670			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822628	hybrid			2022-12-25	WOS:000077207000010
J	Pope, AJ; McVey, M; Fantom, K; Moore, KJ				Pope, AJ; McVey, M; Fantom, K; Moore, KJ			Effects of substrate and inhibitor binding on proteolysis of isoleucyl-tRNA synthetase from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PSEUDOMONIC ACID; ESCHERICHIA-COLI; CLEAVAGE	Binding of ligands to isoleucyl-tRNA synthetase (IleRS; E) from Staphylococcus aureus was investigated through effects on proteolytic digestion. Approximately 50-fold higher concentrations of protease (trypsin or chymotrypsin) were required to inactivate IleRS after incubation with substrates and formation of the E.Ile-AMP intermediate compared with free E, Binding of pseudomonic acid A (PS-A) or isoleucynol adenylate (Ile-ol-AMP) also induced resistance to proteolysis and altered the patterns of IleRS cleavage fragments in an inhibitor-class specific manner. The determinants for PS-A binding mere investigated via proteolysis of E.[H-3]PS-A. Limited proteolysis of E.[H-3]PS-A (excising residues 186-407) could be achieved without significant loss of bound inhibitor, eliminating this region as contributing to inhibitor binding. Assays were developed which allowed IleRS proteolysis to be readily followed using fluorescence polarization. Inhibitor-protected IleRS was labeled with fluorescein isothiocyanate with only a small effect upon catalytic activity (Fl-IleRS). The (pseudo) kinetics of proteolytic cleavage of F1-IleRS could be measured at low nanomolar FI-IleRS concentrations in 96/384-well microtiter plates, allowing realtime monitoring of dose-dependent protection from proteolysis. Thus, inhibitor (and substrate) binding could be reproducibly assessed in the absence of measurements of catalytic acitvity. This could potentially form the basis of novel screening assays for ligands to other proteins.	SmithKline Beecham Pharmaceut, Dept Mol Recognit, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Pope, AJ (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Recognit, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.	Andrew_J_Pope@SBPHRD.COM						BOLGER R, 1994, BIOTECHNIQUES, V17, P585; Broom NJP, 1996, J MED CHEM, V39, P3596, DOI 10.1021/jm950882q; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CARREY EA, 1989, PROTEIN STRUCTURE PR, P117; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; DIGNAM JD, 1991, EUR J BIOCHEM, V198, P201, DOI 10.1111/j.1432-1033.1991.tb16002.x; Haugland R., 1996, HDB FLUORESCENT PROB; HUGHES J, 1978, J ANTIBIOT, V31, P330, DOI 10.7164/antibiotics.31.330; Jolley M. E., 1996, J BIOMOL SCREEN, V1, P33; KALOGERAKOS T, 1980, BIOCHEMISTRY-US, V19, P3712, DOI 10.1021/bi00557a012; LEATHERBARROW RJ, 1992, GRAFIT VER 3 0; Meinnel Thierry, 1995, P251; MORRISON JF, 1988, ADV ENZYMOL RELATED, V33, P14565; Pope AJ, 1998, J BIOL CHEM, V273, P31691, DOI 10.1074/jbc.273.48.31691; Pope AJ, 1998, J BIOL CHEM, V273, P31680, DOI 10.1074/jbc.273.48.31680; SOUTHAN C, 1994, J PROTEIN CHEM, V13, P461; YANIGASAWA T, 1994, J BIOL CHEM, V39, P24304	18	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31702	31706		10.1074/jbc.273.48.31702	http://dx.doi.org/10.1074/jbc.273.48.31702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822631	hybrid			2022-12-25	WOS:000077207000013
J	Krementsova, E; Giffin, MJ; Pincus, D; Baker, TA				Krementsova, E; Giffin, MJ; Pincus, D; Baker, TA			Mutational analysis of the Mu transposase - Contributions of two distinct regions of domain II to recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND-TRANSFER; BACTERIOPHAGE-MU; BINDING DOMAIN; B-PROTEIN; ACTIVE-SITE; TARGET DNA; TRANSPOSITIONAL RECOMBINATION; ESCHERICHIA-COLI; HIV-1 INTEGRASE; CLEAVAGE	Mu transposase is a member of a protein family that includes many transposases and the retroviral integrases. These recombinases catalyze the DNA cleavage and joining reactions essential for transpositional recombination. Here we demonstrate that, consistent with structural predictions, aspartate 336 of Mu transposase is required for catalysis of both DNA cleavage and DNA joining. This residue, although located 55 rather than 35 residues NH2-terminal of the essential glutamate, is undoubtedly the analog of the second aspartate of the Asp-Asp-35-Glu motif found in other family members, The core domain of Mu transposase consists of two subdomains:the NH2-terminal subdomain (IIA) contains the conserved Asp-Asp-Glu motif residues, whereas the smaller COOH-terminal subdomain (IIB) contains a large positively charged region exposed on its surface. To probe the function of domain HB, we constructed mutant proteins carrying deletion or substitution mutations within this region. The activity of the deletion proteins revealed that domains IIA and HB can be provided by different subunits in the transposase tetramer. Substitution mutations at two pairs of exposed lysine residues within the positively charged surface of domain IIB render transposase defective in transposition at a reaction step after DNA cleavage but prior to DNA joining. The severity of tl;is defect depends on the structure of the DNA flanking the cleavage site. Thus, these data suggest that domain IIB is involved in manipulating the DNA near the cleavage site and that this function is important during the transition between the DNA cleavage and the DNA joining steps of recombination.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05401 USA.	tabaker@mit.edu			NIGMS NIH HHS [GM49924] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; Clubb RT, 1997, J MOL BIOL, V273, P19, DOI 10.1006/jmbi.1997.1312; Clubb RT, 1996, P NATL ACAD SCI USA, V93, P1146, DOI 10.1073/pnas.93.3.1146; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Junop MS, 1997, EMBO J, V16, P2646, DOI 10.1093/emboj/16.10.2646; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; Namgoong SY, 1998, J MOL BIOL, V275, P221, DOI 10.1006/jmbi.1997.1466; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Schumacher S, 1997, EMBO J, V16, P7532, DOI 10.1093/emboj/16.24.7532; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1992, J BIOL CHEM, V267, P9552; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	45	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31358	31365		10.1074/jbc.273.47.31358	http://dx.doi.org/10.1074/jbc.273.47.31358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813045	hybrid			2022-12-25	WOS:000077136900073
J	Meksuriyen, D; Fukuchi-Shimogori, T; Tomitori, H; Kashiwagi, K; Toida, T; Imanari, T; Kawai, G; Igarashi, K				Meksuriyen, D; Fukuchi-Shimogori, T; Tomitori, H; Kashiwagi, K; Toida, T; Imanari, T; Kawai, G; Igarashi, K			Formation of a complex containing ATP, Mg2+, and spermine - Structural evidence and biological significance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL UPTAKE SYSTEM; ESCHERICHIA-COLI; ADENOSINE 5'-TRIPHOSPHATE; POLYAMINE BINDING; BOVINE LYMPHOCYTES; PROTEIN-SYNTHESIS; P-31 NMR; NUCLEOTIDES; STIMULATION; CONSTANTS	The conformation of ATP in the presence of Mg2+ and/or spermine was studied by P-31 and H-1 NMR, to clarify how polyamines interact with ATP, Spermine predominantly interacted with the beta- and gamma-phosphates of ATP in the presence of Mg2+. A conformational change of the beta- and gamma-phosphate of ATP with spermine could not be observed in the absence of Mg2+ by P-31 NMR, It was found by H-1 NMR that the conformation of adenosine moiety of ATP was not influenced significantly by spermine. The binding of Mg2+ to ATP was slightly inhibited by spermine and vice versa, The results indicate that the binding sites of Mg2+ and spermine on ATP only partially overlap. The PotA protein, an ATP-dependent enzyme, was used as a model system to study the biological role of the ATP-Mg2+-spermine complex. The ATPase activity of PotA was greatly enhanced by spermine. Double reciprocal plots at several concentrations of spermine as an activator indicate that spermine interacts with ATP, but not with PotA The activity of protein kinase A was also stimulated about 2-fold by spermine. The results suggest that a ternary complex of ATP-Mg2+-spermine may play an important Pole in some ATP-dependent reactions in vivo and in the physiological effects of endogenous polyamines.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Fac Engn, Dept Ind Chem, Chiba 2758588, Japan	Chiba University; Chiba Institute of Technology	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.		Shimogori, Tomomi/L-2893-2013	Shimogori, Tomomi/0000-0002-6931-5401; Igarashi, Kazuei/0000-0003-3751-3187				ALTONA C, 1973, J AM CHEM SOC, V95, P2333, DOI 10.1021/ja00788a038; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BISHOP EO, 1981, BIOCHIM BIOPHYS ACTA, V635, P63, DOI 10.1016/0005-2728(81)90007-4; Clarke K, 1996, J BIOL CHEM, V271, P21142, DOI 10.1074/jbc.271.35.21142; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DIXSON M, 1979, ENZYME, P381; ERNST RR, 1987, PRINCIPLES NUCL MAGN, P336; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GUNTHER T, 1994, BBA-BIOMEMBRANES, V1192, P281, DOI 10.1016/0005-2736(94)90129-5; IGARASHI K, 1981, EUR J BIOCHEM, V114, P127; IGARASHI K, 1984, CANCER RES, V44, P5332; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; JENKINS WT, 1985, ANAL BIOCHEM, V145, P362, DOI 10.1016/0003-2697(85)90375-6; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; KENNARD O, 1970, NATURE, V225, P333, DOI 10.1038/225333a0; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LED JJ, 1985, J AM CHEM SOC, V107, P6755, DOI 10.1021/ja00310a002; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NAKAI C, 1977, BIOCHEMISTRY-US, V16, P5636, DOI 10.1021/bi00644a039; ORIOLI P, 1980, NATURE, V283, P691, DOI 10.1038/283691a0; PEGG AE, 1988, CANCER RES, V48, P759; Pohjanpelto P, 1996, EMBO J, V15, P1193, DOI 10.1002/j.1460-2075.1996.tb00458.x; Shimogori T, 1996, BIOCHEM BIOPH RES CO, V223, P544, DOI 10.1006/bbrc.1996.0931; SIGEL H, 1987, EUR J BIOCHEM, V165, P65, DOI 10.1111/j.1432-1033.1987.tb11194.x; SON TD, 1977, BIOCHIM BIOPHYS ACTA, V500, P405, DOI 10.1016/0304-4165(77)90031-9; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; SUGIYAMA S, 1996, J BIOL CHEM, V271, P95619; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WATANABE S, 1991, J BIOL CHEM, V266, P20803	33	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30939	30944		10.1074/jbc.273.47.30939	http://dx.doi.org/10.1074/jbc.273.47.30939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812989	hybrid			2022-12-25	WOS:000077136900017
J	Stangl, H; Cao, GQ; Wyne, KL; Hobbs, HH				Stangl, H; Cao, GQ; Wyne, KL; Hobbs, HH			Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low density lipoproteins, and nonlipoprotein cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPROTEIN-A-I; SR-BI; PLASMA-MEMBRANE; ADRENAL-GLAND; COENZYME-A; CELLS; EXPRESSION; RAT; CAVEOLAE; DELIVERY	Scavenger receptor, class B, type I (SR-BI) is a cell surface glycoprotein that mediates selective uptake and efflux of sterols from high density lipoproteins (HDL) to cells. A Chinese hamster ovary cell line that is deficient in functional LDL receptors, but has high expression levels of recombinant SR-BI (IdlA7-SR-BI), was used to examine the effect of SR-BI on the trafficking of sterols between lipoproteins and cells. To monitor the fate of sterols transported by SR-BI into cells, we measured the incorporation of [C-14]oleate into cholesterol esters by acyl-CoA:cholesteryl acyltransferase in the endoplasmic reticulum, We show that incubation of IdlA7-SRBI cells with either LDL or HDL resulted in an equally dramatic increase in the formation of [C-14]oleate-labeled cholesterol esters, The lipoprotein-stimulated, SR-BI-dependent increase in cholesterol esterification was inhibited by chloroquine, The uptake of sterols and their incorporation into cholesterol esters by SR-BI from LDL was largely a selective process. The addition of free cholesterol to IdlA7-SRBI cells also stimulated cholesterol ester formation in a chloroquine-sensitive fashion. We also show that SR-BI mediates the efflux of endogenously synthesized sterols from the cell membrane. From these studies we conclude that, in the absence of the LDL receptor, overexpression of SR-BI can mediate significant transport of sterols between lipoproteins and the endoplasmic reticulum of cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Stangl, Herbert/R-9441-2019; Eckhardt, Erik/G-1567-2010; Stangl, Herbert/AAT-4379-2021	Stangl, Herbert/0000-0002-7288-7320; 	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1976, BIOCHEM BIOPH RES CO, V72, P880, DOI 10.1016/S0006-291X(76)80214-8; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; AZHAR S, 1988, J LIPID RES, V29, P869; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BALASUBRAMANIAM S, 1977, J BIOL CHEM, V252, P1771; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P7854; GREENWALT DE, 1992, BLOOD, V80, P1105; HERZ J, 1990, J BIOL CHEM, V265, P21355; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Medicherla S, 1996, BIOCHEMISTRY-US, V35, P6243, DOI 10.1021/bi952137l; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MIMEO C, 1996, EXP CELL RES, V224, P237; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Xu SZ, 1997, J LIPID RES, V38, P1289	41	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31002	31008		10.1074/jbc.273.47.31002	http://dx.doi.org/10.1074/jbc.273.47.31002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812997	hybrid			2022-12-25	WOS:000077136900025
J	Dua, R; Levy, DL; Campbell, JL				Dua, R; Levy, DL; Campbell, JL			Role of the putative zinc finger domain of Saccharomyces cerevisiae DNA polymerase epsilon in DNA replication and the S/M checkpoint pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; S-PHASE CHECKPOINT; PROTEIN-KINASE; CHROMOSOMAL REPLICATION; DAMAGE RESPONSE; BUDDING YEAST; GENE; REPAIR; SUBUNIT; SYSTEM	It has been proposed that C-terminal motifs of the catalytic subunit of budding yeast polymerase (pol) epsilon (POL2) couple DNA replication to the S/M checkpoint (Navas, T, A., Zheng, Z,, and Elledge, S, J, (1995) Cell 80, 29-39). Scanning deletion analysis of the C terminus reveals that 20 amino acid residues between two putative C-terminal zinc fingers are essential for DNA replication and for an intact S/M cell cycle checkpoint. All mutations affecting the inter-zinc finger amino acids or the zinc fingers themselves are sensitive to methylmethane sulfonate and have reduced ability to induce RNR3, showing that the mutants are defective in the transcriptional response to DNA damage as well as the cell cycle response, The mutations affect the assembly of the pol epsilon holoenzyme, Two-hybrid assays show that the POL2 subunit interacts with itself, and that the replication and checkpoint mutants are specifically defective in the interaction, suggesting (but not proving) that direct or indirect dimerization may be important for the normal functions of pol epsilon, The POL2 C terminus is sufficient for interaction with DPB2, the essential and phylogenetically conserved subunit of pol epsilon, but not for interaction with DPB3. Neither Dpb3p nor Dpb2p homodimerizes in the two-hybrid assay.	CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA.	jcampbel@cco.caltech.edu	Levy, Daniel/AAA-7205-2019	Levy, Daniel/0000-0002-7853-3275	NIGMS NIH HHS [GM25508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; HUMPHREY T, 1995, CURR BIOL, V5, P376, DOI 10.1016/S0960-9822(95)00077-7; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; James P, 1996, GENETICS, V144, P1425; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Marini F, 1997, EMBO J, V16, P639, DOI 10.1093/emboj/16.3.639; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SRIENC F, 1986, CYTOMETRY, V7, P132, DOI 10.1002/cyto.990070203; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; TOYN JH, 1995, MOL CELL BIOL, V15, P5312; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	41	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					30046	30055		10.1074/jbc.273.45.30046	http://dx.doi.org/10.1074/jbc.273.45.30046			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792727	Green Submitted, hybrid			2022-12-25	WOS:000076798300104
J	Masuda, MO; Levin, M; de Oliveira, SF; dos Santos Costa, PC; Bergami, PL; dos Santos Almeida, NA; Pedrosa, RC; Ferrari, I; Hoebeke, J; de Carvalho, CC				Masuda, MO; Levin, M; de Oliveira, SF; dos Santos Costa, PC; Bergami, PL; dos Santos Almeida, NA; Pedrosa, RC; Ferrari, I; Hoebeke, J; de Carvalho, CC			Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens	FASEB JOURNAL			English	Article						immunoglobulin; heart block; ribosomal P proteins; muscarinic receptor	IDIOPATHIC DILATED CARDIOMYOPATHY; PROTEIN-COUPLED RECEPTORS; RIBOSOMAL-P-PROTEIN; HEART-DISEASE; AUTOANTIBODIES; IDENTIFICATION; DETERMINANTS; EXPRESSION; EPITOPES; BINDING	Antibodies of chronic chagasic patients have been shown to interfere with electric and mechanical activities of cardiac embryonic myocytes in culture and with whole mammalian hearts. A mechanism proposed for this effect involves interaction of the antibodies with G-protein-linked membrane receptors, thus leading to activation of beta adrenergic and muscarinic receptors; more specifically, IgG of chagasic patients would interact with the negatively charged regions of the second extracellular loop of these receptors. We performed competition experiments to test this hypothesis. We evaluated the effect of sera/IgG from patients previously known to depress electrogenesis and/or atrioventricular conduction in isolated rabbit hearts after incubation with live and lysed parasites, the peptide corresponding to the second extracellular loop (O2) of the M2 receptor, and different peptides derived from two ribosomal proteins of T. cruzi: PO and P2 beta. Our results indicate that I) the antigenic factor inducing the functionally active IgGs in the chagasic patients is probably an intracellular T. cruzi antigen; 2) IgG/serum is interacting with the O2 region of the M2 receptor in the rabbit heart; and 3) the negative charges present in the ribosomal proteins of T. cruzi are important in mediating the interaction between the patients' serum/IgG and the receptor.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, CCS, Hosp Clementino Fraga Filho, Rio de Janeiro, Brazil; Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; CNRS, Lab Enzymol & Chim Prot, F-37032 Tours, France	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Centre National de la Recherche Scientifique (CNRS)	de Carvalho, CC (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, Bloco G,Ilha Fundao, BR-21949900 Rio De Janeiro, Brazil.	acarlos@ibccf.biof.ufrj.br	de Carvalho, Antonio Carlos Campos/A-3152-2008	de Carvalho, Antonio Carlos Campos/0000-0002-0062-3043; dos Santos Costa, Patricia Cristina/0000-0003-0111-6980				AFFRANCHINO JL, 1989, MOL BIOCHEM PARASIT, V34, P221, DOI 10.1016/0166-6851(89)90050-9; ANDRADE ZA, 1983, CIBA F SYMP, V99, P214; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER Z, 1994, SCI PUBLICATION, V547, P30; Chagas C., 1909, Memorias do Instituto Oswaldo Cruz, V1; CHIALE PA, 1995, J AM COLL CARDIOL, V26, P864, DOI 10.1016/0735-1097(95)00262-2; COTRIM PC, 1990, J CLIN MICROBIOL, V28, P519, DOI 10.1128/JCM.28.3.519-524.1990; deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031; Dias J. C. P., 1984, Memorias do Instituto Oswaldo Cruz, V79, P85, DOI 10.1590/S0074-02761984000500017; Elies R, 1996, J IMMUNOL, V157, P4203; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Ferrari I, 1997, LANCET, V350, P262, DOI 10.1016/S0140-6736(05)62226-X; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Hoebeke J, 1995, M S-MED SCI, V11, P1661, DOI 10.4267/10608/2366; HOEBEKE J, 1995, REV ARGENT CARDIOL, V63, P221; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; LAFAILLE JJ, 1989, MOL BIOCHEM PARASIT, V35, P127, DOI 10.1016/0166-6851(89)90115-1; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LEVIN MJ, 1990, IMMUNOL LETT, V24, P69, DOI 10.1016/0165-2478(90)90038-R; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVIN MJ, 1991, FEMS MICROBIOL IMMUN, V89, P11, DOI 10.1111/j.1574-6968.1991.tb04965.x; LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530; LOPES ER, 1975, REV SOC BRAS MED TRO, V6, P269; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; Mijares A, 1996, FEBS LETT, V399, P188, DOI 10.1016/S0014-5793(96)01321-X; PEREZ MA, 1984, BRAZ J MED BIOL RES, V17, P189; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8	32	46	51	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1551	1558		10.1096/fasebj.12.14.1551	http://dx.doi.org/10.1096/fasebj.12.14.1551			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806764				2022-12-25	WOS:000076749500014
J	Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI				Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI			C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer	ONCOGENE			English	Article						c-erbB3; c-erbB4; ER; EGFR; cell proliferation; endocrine response; RT-PCR	EPIDERMAL GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; ESTROGEN-RECEPTOR; MONOCLONAL-ANTIBODY; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; FAMILY MEMBERS; HEREGULIN; DIFFERENTIATION	We examined c-erbB3 and c-erbB4 mRNA expression in 47 primary breast cancer samples by simultaneous RT-PCR and have investigated correlations between these parameters and the expression of both ER and EGFR mRNA and protein as measured by RT-PCR and ICA and with Ki67 immunostaining, A direct association was found between c-erbB3 and c-erbB4 mRNA and ER marker status measured by either RT-PCR (c-erbB3 P = 0.0003; c-erbB4 P = 0.02) or ICA (c-erbB-3 P = 0.002; c-erbB4 P = 0.01). Inverse associations were seen between c-erbB3 and c-erbB4 mRNA marker status and EGFR membrane protein (c-erbB3: P = 0.003; c-erbB4: P = 0.003) and mRNA (c-erbB4: P = 0.009) status. These associations were reinforced by Spearman Rank Correlation Tests. A significant relationship was seen between Ki67 and c-erbB4 mRNA status and level. Measurements of c-erbB3 protein levels in tumour samples removed from a further 89 patients of known response to endocrine therapy: (i) confirmed the relationship between c-erbB3 and ER and (ii) identified that patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to benefit from endocrine measures. A non-significant trend was recorded between c-erbB3 levels and Ki67 immunostaining, These results clearly demonstrate that increased c-erbB3 and c-erbB4 expression appears to be associated with the prognostically-favourable ER phenotype.	Univ Wales, Coll Med, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales; Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0NN, England; City Hosp, Dept Histopathol, Nottingham NG5 1PB, England; City Hosp, Dept Surg, Nottingham NG5 1PB, England	Cardiff University; Cancer Research UK; Imperial College London; University of Nottingham; University of Nottingham	Knowlden, JM (corresponding author), Univ Wales, Coll Med, Tenovus Canc Res Ctr, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		Gee, Julia MW/N-3995-2014	Gee, Julia MW/0000-0001-6483-2015; Ellis, Ian/0000-0001-5292-8474				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Brotherick I, 1995, CANCER IMMUNOL IMMUN, V41, P280, DOI 10.1007/BF01517215; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; DAFFADA AAI, 1994, J MOL ENDOCRINOL, V13, P265, DOI 10.1677/jme.0.0130265; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYE RA, 1989, ONCOGENE, V4, P1153; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GEE JMW, 1996, HORMONE DEPENDENT CA, P169; GERDES J, 1984, J IMMUNOL, V133, P1710; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Gullick WJ, 1996, CANCER SURV, V27, P339; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; JORDAN VC, 1993, BRIT J PHARMACOL, V110, P507, DOI 10.1111/j.1476-5381.1993.tb13840.x; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Knowlden JM, 1997, CLIN CANCER RES, V3, P2165; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LONARDO F, 1990, New Biologist, V2, P992; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON RI, 1991, EUR J CANCER, V27, P908, DOI 10.1016/0277-5379(91)90145-4; NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1; NICHOLSON RI, 1992, RECENT ADV ENDOCRINO, P150; NICHOLSON RI, 1996, HORMONES CANC, P227; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; RAJKUMAR T, 1995, BREAST, V4, P84, DOI 10.1016/0960-9776(95)90001-2; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191	49	106	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1949	1957		10.1038/sj.onc.1202107	http://dx.doi.org/10.1038/sj.onc.1202107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788438				2022-12-25	WOS:000076423500008
J	Lee, JM				Lee, JM			Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation	ONCOGENE			English	Article						p53; KIT; Steel; mitochondria; apoptosis; oxygen	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C; STEEL FACTOR; P53-MEDIATED APOPTOSIS; LYMPHOCYTE APOPTOSIS; MAST-CELLS; W/C-KIT; BCL-2; P53	The KIT protein is a receptor tyrosine kinase of the platelet derived growth factor (PDGF) receptor family which regulates haematopoiesis, melanogenesis and gut and germ cell development. KIT regulates these diverse processes, at least in part, by inhibiting apoptosis. We have previously found that KIT can suppress p53-mediated apoptosis. The mechanism by which KIT suppresses apoptosis is, however, uncharacterized. Neither is it clear how p53 induces apoptosis. In this report me find that p53-dependent apoptosis proceeds through a pathway involving depolarization of the mitochondrial electropotential gradient (Delta Psi(m)) and the generation of reactive oxygen species (ROS). KIT activation suppresses p53-induced apoptosis in the mouse DP16 Friend erythroleukemia cell line by preventing Delta Psi(m) depolarization and ROS generation, Thus, the KIT kinase prevents apoptosis by regulating mitochondrial function and cellular redox state.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Lee, JM (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNSTEIN A, 1990, CIBA F SYMP, V148, P158; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Castedo M, 1996, J IMMUNOL, V157, P512; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; delPeso L, 1997, SCIENCE, V278, P687; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Henkart PA, 1996, J EXP MED, V183, P1293, DOI 10.1084/jem.183.4.1293; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; HUNTER TV, 1994, ANN REV CELL BIOL, V10, P251; IEMURA A, 1994, AM J PATHOL, V144, P321; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEV S, 1992, J BIOL CHEM, V267, P15970; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1993, NATURE, V362, P849; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NETA R, 1993, BLOOD, V81, P324; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shimizu S, 1996, ONCOGENE, V13, P21; SHUI CX, 1995, CANCER RES, V55, P3431; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Um HD, 1996, J IMMUNOL, V156, P3469; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	73	34	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1653	1662		10.1038/sj.onc.1202102	http://dx.doi.org/10.1038/sj.onc.1202102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796694				2022-12-25	WOS:000076200100003
J	Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A				Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A			NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity	ONCOGENE			English	Article						NF1; N-ras proto-oncogene; lymphoma; Erk; Ras-GTPase	NEUROFIBROMATOSIS TYPE-1 GENE; INDUCED MALIGNANT PHENOTYPE; TRANSGENIC MICE; CELL-LINES; MUTATIONS; GROWTH; PROTOONCOGENE; PATHWAY; NEUROBLASTOMA; TUMORIGENESIS	We crossed transgenic mice overexpressing the N-ras proto-oncogene (RasTg) with mice carrying one inactivated copy of the NF1 tumor suppressor gene (NF1+/-)to assess their possible cooperation in tumorigenesis. We have found a significant increase in the incidence of lymphomas in animals with both lesions (RasTg NF1+/-), as compared with animals with single lesions, The mechanism of this cooperation appears to be independent of the NF1 GTPase activating activity since the level of Ras-GTP in primary cultures of tumor tissue do not differ among animals with double and with single lesions. Nevertheless, the finding of significantly higher levels of Erk-1 and Erk-2 activation in lymphomas in the RasTg NF1+/- than in the RasTg group suggests that this cooperative effect may be in part explained by increased signaling through the Erk pathways. Consistent with a role for Erk activation in transformation is the additional observation that Erk-1 and Erk-2 activation is significantly increased in lymphomas as compared with normal spleen. This activation is likely to occur by phosphorylation of previously synthesized and inactive Erk proteins since, despite differences in activation, Erk-1 and:Erk-2 expression is similar in normal and lymphoid tissue in all groups. The observed cooperation in in vivo lymphomagenesis between N-ras overexpression and NF1 inactivation emphasizes the importance of searching for additional functions for the NF1 protein and of intensifying the screening for NF1 mutations in human lymphomas.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mangues, Ramon/J-6396-2014	Mangues, Ramon/0000-0003-2661-9525; Pellicer, Angel/0000-0002-5062-0692; Corral, Teresa/0000-0003-2959-9910	NATIONAL CANCER INSTITUTE [R37CA036327, T32CA009161, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434, CA36327, 5T32 CA09161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; HEIM RA, 1995, HUM MOL GENET, V4, P975, DOI 10.1093/hmg/4.6.975; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KALRA R, 1994, BLOOD, V84, P3435; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; Li Y, 1996, CANCER RES, V56, P2872; Malumbres M, 1997, BIOTECHNIQUES, V22, P1114, DOI 10.2144/97226st03; MANGUES R, 1994, CANCER RES, V54, P6395; MANGUES R, 1995, MOL CARCINOGEN, V14, P94, DOI 10.1002/mc.2940140205; Mangues R, 1996, ONCOGENE, V13, P1053; MANGUES R, 1992, ONCOGENE, V7, P2073; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIYAUCHI J, 1994, BLOOD, V83, P2248; NEUBAUER A, 1991, BLOOD, V77, P594; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shen MH, 1996, J MED GENET, V33, P2, DOI 10.1136/jmg.33.1.2; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	39	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1705	1716		10.1038/sj.onc.1202097	http://dx.doi.org/10.1038/sj.onc.1202097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796699				2022-12-25	WOS:000076200100008
J	Beeckmans, S; Van Driessche, E				Beeckmans, S; Van Driessche, E			Pig heart fumarase contains two distinct substrate-binding sites differing in affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIAL; ESCHERICHIA-COLI; ACTIVE-SITE; DIRECTED MUTAGENESIS; CYTOSOLIC FUMARASES; ASPARTASE; PURIFICATION; ACTIVATION; SEQUENCES; GENE	A eukaryotic fumarase is for the first time unequivocally shown to contain two distinct substrate-binding sites. Pig heart fumarase is a tetrameric enzyme consisting of four identical subunits of 50 kDa each. Besides the true substrates L-malate and fumarate, the active sites (sites A) also bind their analogs D-malate and oxaloacetate, as well as the competitive inhibitor glycine, The additional binding sites (sites B) on the other hand also bind the substrates and their analogs D-malate and oxaloacetate, as well as L-aspartate which is not an inhibitor. Depending on the pH, the affinity of sites B for ligands (K-d being in the millimolar range) is 1-2 orders of magnitude lower than the affinity of sites A (of which hh is in the micromolar range). However, saturating sites B results in an increase in the overall activity of the enzyme. The benzenetetracarboxyl compound pyromellitic acid displays very special properties. One molecule of this ligand is indeed able to bind into a site A and a site B at the same time, Four molecules of pyromellitic acid were found to bind per molecule fumarase, and the affinity of the enzyme for this ligand is very high (K-d = 0.6 to 2.2 mu M, depending on the pH). Experiments with this ligand turned out to be crucial in order to explain the results obtained. An essential tyrosine residue is found to be located in site A, whereas an essential methionine residue resides in or near site B, Upon limited proteolysis, a peptide of about 4 kDa is initially removed, probably at the C-terminal side; this degradation results in inactivation of the enzyme. Small local conformational changes in the enzyme are picked up by circular dichroism measurements in the near-UV region. This spectrum is built up of two tryptophanyl triplets, the first one of which is modified upon saturating the active sites (A), and the second one upon saturating the low affinity binding sites (B).	Free Univ Brussels, Dept Prot Chem, Inst Mol Biol & Biotechnol, B-1640 Rhode St Genese, Belgium		Beeckmans, S (corresponding author), Free Univ Brussels, Dept Prot Chem, Inst Mol Biol & Biotechnol, Paardenstr 65, B-1640 Rhode St Genese, Belgium.							ALBERTY RA, 1959, ENZYMES, V5, P531; ANDERSEN B, 1980, BIOCHEM J, V189, P653, DOI 10.1042/bj1890653; BEECKMANS S, 1982, INT J BIOCHEM, V14, P453, DOI 10.1016/0020-711X(82)90112-4; BEECKMANS S, 1977, EUR J BIOCHEM, V78, P437, DOI 10.1111/j.1432-1033.1977.tb11756.x; BEECKMANS S, 1982, INT J BIOCHEM, V14, P965, DOI 10.1016/0020-711X(82)90056-8; BEECKMANS S, 1993, J MOL RECOGNIT, V6, P195, DOI 10.1002/jmr.300060408; BEECKMANS S, 1983, BIOCHIM BIOPHYS ACTA, V743, P370, DOI 10.1016/0167-4838(83)90395-3; BEECKMANS S, 1984, PROTIDES BIOL FLUIDS, V32, P1013; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; FASMAN GD, 1963, METHOD ENZYMOL, V6, P928, DOI 10.1016/0076-6879(63)06266-2; HANSEN JN, 1969, J BIOL CHEM, V244, P6270; HASINOFF BB, 1986, BIOCHEM J, V235, P891, DOI 10.1042/bj2350891; Hill R. L., 1971, ENZYMES, V5, P539; HILL ROBERT L., 1964, BROOKHAVEN SYMP BIOL, V17, P80; IDA N, 1985, J BIOCHEM-TOKYO, V98, P35, DOI 10.1093/oxfordjournals.jbchem.a135269; KARSTEN WE, 1986, BIOCHEMISTRY-US, V25, P1299, DOI 10.1021/bi00354a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURASE S, 1991, BIOCHEM BIOPH RES CO, V177, P414, DOI 10.1016/0006-291X(91)91999-S; MURASE S, 1993, J BIOCHEM-TOKYO, V114, P735, DOI 10.1093/oxfordjournals.jbchem.a124246; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; OVADI J, 1995, CELL ARCHITECTURE ME; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; ROGERS GA, 1976, J BIOL CHEM, V251, P5711; ROSE IA, 1992, BIOCHEMISTRY-US, V31, P9993, DOI 10.1021/bi00156a019; Rose IA, 1997, BIOCHEMISTRY-US, V36, P12346, DOI 10.1021/bi971258d; ROSE IA, 1993, BIOCHEMISTRY-US, V32, P8504, DOI 10.1021/bi00084a016; SACCHETTINI JC, 1988, BIOCHEM BIOPH RES CO, V153, P435, DOI 10.1016/S0006-291X(88)81243-9; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; TEIPEL JW, 1968, J BIOL CHEM, V243, P5679; Weaver T, 1996, BIOCHEMISTRY-US, V35, P13955, DOI 10.1021/bi9614702; Weaver T, 1997, PROTEIN SCI, V6, P834; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; WEAVER TM, 1993, J MOL BIOL, V231, P141, DOI 10.1006/jmbi.1993.1264; WHARTON CW, 1982, BIOCHEM J, V203, P351, DOI 10.1042/bj2030351; WOODS SA, 1986, BIOCHEM J, V237, P547, DOI 10.1042/bj2370547; WU M, 1987, J BIOL CHEM, V262, P12275	38	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31661	31669		10.1074/jbc.273.48.31661	http://dx.doi.org/10.1074/jbc.273.48.31661			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822627	hybrid			2022-12-25	WOS:000077207000009
J	Gao, B; Kunos, G				Gao, B; Kunos, G			Cell type-specific transcriptional activation and suppression of the alpha(1B) adrenergic receptor gene middle promoter by nuclear factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; DNA-BINDING; NF-I; RAT; PROTEINS; LIVER; ELEMENT; DOMAIN; BETA; REPLICATION	Nuclear factor 1 (NF1) has been reported to be a transcriptional activator for some genes and a transcriptional silencer for others, Here we report that in Hep3B cells, cotransfection of NF1/L, NF1/Red1, or NF1/X with the alpha(1B) adrenergic receptor (alpha(1B)AR) gene middle (P2) promoter increases P2 activity to more or less the same degree, whereas in DDT1 MF-2 cells cotransfection of NF1/L or NF1/Red1 causes a small but statistically significant decrease in the P2 promoter activity, and NF1/X causes a greater, 70% inhibition. Further experiments using truncated NF1/X mutants indicate that NF1/X contains both positive and negative regulatory domains. The positive domain, located between amino acids 416 and 505, is active in Hep3B cells, whereas the negative domain, located between amino acids 243 and 416, is active in DDT1 MF-2 cells, These functional domains are also capable of regulating transcription when isolated from their natural context and fused into the GAL4 binding domain. Furthermore, NF1 affinity purified from rat liver nuclear extracts copurified with a non-DNA binding protein, which can bind to the P2 promoter of the alpha(1B)AR gene via interacting with NF1, Taken together, these findings indicate that NF1/X contains both activation and suppression domains that may be recognized and modulated by cell type-specific cofactors, This may be one of the mechanisms whereby NF1 can activate or suppress the expression of different genes, and it may also underlie the tissue-specific regulation of the alpha(1B) AR gene.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Gao, B (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.	BGAO@HSC.VCU.EDU			NATIONAL CANCER INSTITUTE [R29CA072681] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA-72681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gao B, 1997, MOL PHARMACOL, V52, P1019, DOI 10.1124/mol.52.6.1019; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; Gao B, 1996, MOL CELL BIOL, V16, P5997; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GAO B, 1994, J BIOL CHEM, V269, P15762; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAJIYAMA Y, 1994, BIOCHEM J, V303, P313, DOI 10.1042/bj3030313; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM TK, 1993, J BIOL CHEM, V268, P20866; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; MATSUMOTO K, 1989, BIOCHEM BIOPH RES CO, V164, P1212, DOI 10.1016/0006-291X(89)91798-1; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROY RJ, 1993, ANN NY ACAD SCI, V684, P207, DOI 10.1111/j.1749-6632.1993.tb32286.x; ROY RJ, 1994, EUR J BIOCHEM, V219, P799, DOI 10.1111/j.1432-1033.1994.tb18560.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; SHI YH, 1995, MOL CELL BIOL, V15, P4309; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; Tarapore P, 1997, NUCLEIC ACIDS RES, V25, P3895, DOI 10.1093/nar/25.19.3895; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31784	31787		10.1074/jbc.273.48.31784	http://dx.doi.org/10.1074/jbc.273.48.31784			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822643	hybrid			2022-12-25	WOS:000077207000025
J	Huang, Y; Takahashi, M; Tanazawa, K; Putney, JW				Huang, Y; Takahashi, M; Tanazawa, K; Putney, JW			Effect of adenophostin A on Ca2+ entry and calcium release-activated calcium current (I-crac) in rat basophilic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIUM-BREVICOMPACTUM; POTENT AGONISTS; MAST-CELLS; DEPLETION; RECEPTOR; INOSITOL-1,4,5-TRISPHOSPHATE; INACTIVATION; FEEDBACK; INFLUX; STORES	In most non-excitable cells, calcium influx is signaled by depletion of intracellular calcium stores, a process known as capacitative calcium entry. Adenophostin A, a potent activator of the inositol 1,4,5-trisphosphate receptor, has been reported to activate Ca2+ entry in Xenopus oocytes to a greater extent than expected on the basis of its ability to release calcium stores. In this study, we compared the abilities of adenophostin A and inositol 2,4,5-trisphosphate ((2,4,5)IP3) to release Ca2+ from intracellular stores, to activate Ca2+ entry, and to activate calcium release-activated calcium current (I-crac) in rat basophilic leukemia cells. Under conditions of low intracellular Ca2+ buffering (0.1 mM BAPTA), adenophostin A-induced Ca2+ release and activation of I-crac could be monitored simultaneously. However, other reagents that would be expected to deplete Ca2+ stores ((2,4,5)IP3, 3-fluoro-inositol 1,4,5-trisphosphate, thapsigargin, and ionomycin) were unable to activate I-crac under this low Ca2+ buffering condition. Adenophostin A activated I-crac after a significant delay, longer than the delay for Ca2+ release. Thus, adenophostin A activates I-crac as a consequence of release of intracellular Ca2+, rather than directly acting on store-operated channels. The unique ability of adenophostin A to activate I-crac under conditions of low intracellular Ca2+ buffering suggests an additional site of action, perhaps in preventing or reducing rapid Ca2+-dependent inactivation of store-operated Ca2+ channels.	NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Sankyo Co Ltd, Biol Res Labs, Tokyo 140, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Daiichi Sankyo Company Limited	Putney, JW (corresponding author), NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; DeLisle S, 1997, J BIOL CHEM, V272, P9956; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KWAN CY, 1990, J BIOL CHEM, V265, P678; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; Marchant JS, 1997, BIOCHEM J, V321, P573, DOI 10.1042/bj3210573; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; TAKAHASHI M, 1993, J ANTIBIOT, V46, P1643, DOI 10.7164/antibiotics.46.1643; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; VANDERKOOI JM, 1971, ARCH BIOCHEM BIOPHYS, V144, P99, DOI 10.1016/0003-9861(71)90458-9; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	23	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31815	31821		10.1074/jbc.273.48.31815	http://dx.doi.org/10.1074/jbc.273.48.31815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822648	hybrid			2022-12-25	WOS:000077207000030
J	Yarema, KJ; Mahal, LK; Bruehl, RE; Rodriguez, EC; Bertozzi, CR				Yarema, KJ; Mahal, LK; Bruehl, RE; Rodriguez, EC; Bertozzi, CR			Metabolic delivery of ketone groups to sialic acid residues - Application to cell surface glycoform engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; SELECTIN-CARBOHYDRATE INTERACTIONS; O-GLYCANS; MAMMALIAN-CELLS; RAT-LIVER; OLIGOSACCHARIDES; ACETYLMANNOSAMINE; BIOSYNTHESIS; GLYCOSYLTRANSFERASE; GLYCOPROTEIN	The development of chemical strategies for decorating cells with defined carbohydrate epitopes would greatly facilitate studies of carbohydrate-mediated cell surface interactions. This report describes a general strategy for engineering the display of chemically defined oligosaccharides on cell surfaces that combines the concepts of metabolic engineering and selective chemical reactivity, Using a recently described method (Mahal, L, K., Yarema, K. J., and Bertozzi, C, R. (1997) Science 276, 1125-1128), we delivered a uniquely reactive ketone group to endogenous cell surface sialic acid residues by treating cells with the ketone-bearing metabolic precursor N-levulinoylmannosamine (ManLev), The ketone undergoes highly selective condensation reactions with complementary nucleophiles such as aminooxy and hydrazide groups. The detailed quantitative parameters of ManLev metabolism in human and nonhuman-derived cell lines were determined to establish a foundation for the modification of cell surfaces with novel epitopes at defined cell-surface densities. Ketones within the glycoconjugates on ManLev-treated cells were then reacted with synthetic aminooxy and hydrazide-functionalized carbohydrates, The remodeled cells were endowed with novel lectin binding profiles as determined by flow cytometry analysis. The simplicity and generality of this method make it well suited for use in the study of carbohydrate-mediated cell surface interactions.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Mahal, Lara/GRY-7287-2022	Mahal, Lara/0000-0003-4791-8524				ANGELINO NJ, 1995, CARBOHYD RES, V276, P99, DOI 10.1016/0008-6215(95)00154-L; ATKINSON PH, 1980, ALTERATIONS GLYCOPRO; BAUMANN H, 1982, GLYCOCONJUGATES, V4; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; BERNACKI RJ, 1982, GLYCOCONJUGATES, V4, P245; BROWN AE, 1982, BIOCHIM BIOPHYS ACTA, V714, P217, DOI 10.1016/0304-4165(82)90327-0; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; CARVER JP, 1993, PURE APPL CHEM, V65, P763, DOI 10.1351/pac199365040763; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; DUNN WA, 1980, J BIOL CHEM, V255, P5971; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; ELBIEN AD, 1987, ANNU REV BIOCHEM, V56, P497; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FERWERDA W, 1981, J NEUROCHEM, V36, P1492, DOI 10.1111/j.1471-4159.1981.tb00591.x; GAHMBERG CG, 1994, METHOD ENZYMOL, V230, P32; GORELIK E, 1995, CANCER RES, V55, P4168; HARMS E, 1974, CANCER RES, V34, P3165; Herrmann M, 1997, J VIROL, V71, P5922, DOI 10.1128/JVI.71.8.5922-5931.1997; HUGHES RC, 1977, EUR J BIOCHEM, V72, P265, DOI 10.1111/j.1432-1033.1977.tb11249.x; HYNES RO, 1974, CELL, V1, P147, DOI 10.1016/0092-8674(74)90105-6; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IVANOV S, 1985, INT J BIOCHEM, V17, P1125, DOI 10.1016/0020-711X(85)90047-3; JENCKS WP, 1959, J AM CHEM SOC, V81, P475, DOI 10.1021/ja01511a053; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kahne D, 1997, CURR OPIN CHEM BIOL, V1, P130, DOI 10.1016/S1367-5931(97)80119-6; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LEMIEUX GA, 1998, IN PRESS TRENDS BIOT; Liang R, 1997, P NATL ACAD SCI USA, V94, P10554, DOI 10.1073/pnas.94.20.10554; LIN TTS, 1980, EUR J BIOCHEM, V105, P453; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Mahal LK, 1997, CHEM BIOL, V4, P415, DOI 10.1016/S1074-5521(97)90193-9; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PILLER V, 1990, J BIOL CHEM, V265, P9264; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; PRIETO PA, 1995, J BIOL CHEM, V270, P29515, DOI 10.1074/jbc.270.49.29515; Rodriguez EC, 1997, J AM CHEM SOC, V119, P9905, DOI 10.1021/ja971633p; ROTENBERG SA, 1991, P NATL ACAD SCI USA, V88, P2490, DOI 10.1073/pnas.88.6.2490; RUMP JA, 1986, BIOL CHEM H-S, V367, P425, DOI 10.1515/bchm3.1986.367.1.425; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; RYLL T, 1994, BIOTECHNOL BIOENG, V44, P184, DOI 10.1002/bit.260440207; RYLL T, 1991, J CHROMATOGR-BIOMED, V570, P77, DOI 10.1016/0378-4347(91)80202-N; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; SAYER JM, 1973, J AM CHEM SOC, V95, P4277, DOI 10.1021/ja00794a600; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULTZ AM, 1975, CARBOHYD RES, V40, P119, DOI 10.1016/S0008-6215(00)82674-9; SCHWARTZ EL, 1983, BIOCHIM BIOPHYS ACTA, V762, P489, DOI 10.1016/0167-4889(83)90051-4; Sears P, 1996, P NATL ACAD SCI USA, V93, P12086, DOI 10.1073/pnas.93.22.12086; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SLAMENOVA D, 1980, MUTAT RES, V71, P253, DOI 10.1016/0027-5107(80)90077-9; SRIVASTAVA G, 1992, J BIOL CHEM, V267, P22356; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; THOMAS GH, 1985, BIOCHIM BIOPHYS ACTA, V846, P37, DOI 10.1016/0167-4889(85)90107-7; TOLVANEN M, 1986, J BIOL CHEM, V261, P9546; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Yarema KJ, 1998, CURR OPIN CHEM BIOL, V2, P49, DOI 10.1016/S1367-5931(98)80035-5; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	71	154	168	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31168	31179		10.1074/jbc.273.47.31168	http://dx.doi.org/10.1074/jbc.273.47.31168			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813021	hybrid			2022-12-25	WOS:000077136900049
J	Khalil, EM; De Angelis, J; Cole, PA				Khalil, EM; De Angelis, J; Cole, PA			Indoleamine analogs as probes of the substrate selectivity and catalytic mechanism of serotonin N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; METABOLISM; CLONING; CSK	Serotonin N-acetyltransferase (arylallrylamine N-acetyltransferase (AANAT)) catalyzes the reaction of serotonin (or tryptamine) with acetyl-CoA to form N acetyl serotonin (or N-acetyltryptamine) and is responsible for the melatonin circadian rhythm in vertebrates. This study evaluates a series of indoleamine analogs as alternate substrates of AANAT, 3-Indolepropylamine and 3-indolebutylamine were chemically synthesized and found to be processed by AANAT, although 20- and 60-fold less efficiently compared with the natural substrate serotonin, respectively. Racemic alpha-methyltryptamine and N-omega-methyltryptamine were also shown to be substrates for AANAT, again with reduced k(cat) and k(cat)/K-m compared with serotonin, The enzyme did exhibit similar to 9:1 stereoselectivity for the R-enantiomer of a methyltryptamine versus the S-enantiomer, By measuring the enzymatic rates versus increasing buffer microviscosity, it was demonstrated that diffusional release of product is most likely the principal rate-determining step for the enzymatic transformation of tryptamine (which has similar k(cat) and k(cat)/K-m compared with serotonin), Analysis of k(cat) and k(cat)/K-m versus pH for the poor substrate N-omega-methyltryptamine showed that an ionizable group on the enzyme with pK(a) similar to 7, required to be in its deprotonated form, may be important in catalysis, The alpha-methyltryptamine analog alpha-trifluoromethyltryptamine was not processed by the enzyme, but served as a modest competitive inhibitor. Taken together with the ps-rate analysis, these results favor a model in which the serotonin substrate binds to the enzyme as the positively charged ammonium salt, and nucleophilicity of the amine is important in enzyme-catalyzed acetyl transfer.	Rockefeller Univ, Bioorgan Chem Lab, New York, NY 10021 USA	Rockefeller University	Cole, PA (corresponding author), Rockefeller Univ, Bioorgan Chem Lab, 1230 York Ave, New York, NY 10021 USA.							BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; BUDAVARI S, 1996, MERCK INDEX, P1454; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dixon M., 1964, ENZYMES, V2nd; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; JENCKS WP, 1960, J AM CHEM SOC, V82, P1778, DOI 10.1021/ja01492a058; KAYUMOV V, 1973, ZH VSES KHIM OVA+, V18, P342; KITAGUCHI H, 1989, J AM CHEM SOC, V111, P3094, DOI 10.1021/ja00190a070; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; Preobrazhenskaya MN, 1998, TETRAHEDRON LETT, V39, P109, DOI 10.1016/S0040-4039(97)10461-0; REPKE DB, 1976, J HETEROCYCLIC CHEM, V13, P775, DOI 10.1002/jhet.5570130417; WALSH C, 1983, ADV ENZYMOL RAMB, V55, P197; Xiao GY, 1997, J AM CHEM SOC, V119, P9325, DOI 10.1021/ja972608m; ZIMMER R, 1992, J ORG CHEM, V57, P339, DOI 10.1021/jo00027a058	21	28	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30321	30327		10.1074/jbc.273.46.30321	http://dx.doi.org/10.1074/jbc.273.46.30321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804794	Green Published, hybrid			2022-12-25	WOS:000077008100041
J	Laudanna, C; Mochly-Rosen, D; Liron, T; Constantin, G; Butcher, EC				Laudanna, C; Mochly-Rosen, D; Liron, T; Constantin, G; Butcher, EC			Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; MYRISTOYLATED PSEUDOSUBSTRATE PEPTIDE; XENOPUS-LAEVIS OOCYTES; BREAST-CANCER CELLS; ADP-RIBOSYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; PKC-ZETA; MULTIDRUG-RESISTANCE	Classical chemoattractants and chemokines trigger integrin-dependent adhesion of blood leukocytes to vascular endothelium and also direct subsequent extravasation and migration into tissues. In studies of human polymorphonuclear neutrophil responses to formyl peptides and to interleukin 8, we show evidence of involvement of the atypical zeta protein kinase C in the signaling pathway leading to chemoattractant-triggered actin assembly, integrin-dependent adhesion, and chemotaxis. Selective inhibitors of classical and novel protein kinase C isozymes do not prevent chemoattractant-induced neutrophil adhesion and chemotaxis. In contrast, chelerythrine chloride and synthetic myristoylated peptides with sequences based on the endogenous zeta protein kinase C pseudosubstrate region block agonist-induced adhesion to fibrinogen, chemotaxis and F-actin accumulation. Biochemical analysis shows that chemoattractants trigger rapid translocation of zeta protein kinase C to the plasma membrane accompanied by rapid but transient increase of the kinase activity. Moreover, pretreatment with C3 transferase, a specific inhibitor of Rho small GTPases, blocks zeta but not alpha protein kinase C plasma membrane translocation. Synthetic peptides from zeta protein kinase C also inhibit phorbol ester-induced integrin-dependent adhesion but not NADPH-oxidase activation, and C3 transferase pretreatment blocks phorbol ester-triggered translocation of zeta but not a! protein kinase C. These data suggest the involvement of zeta protein kinase C in chemoattractant-induced leukocyte integrin-dependent adhesion and chemotaxis. Moreover, they highlight a potential link between atypical protein kinase C isozymes and Rho signaling pathways leading to integrin-activation.	Stanford Univ, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Affairs Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; Univ Verona, Inst Gen Biol, I-37134 Verona, Italy; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Verona; Stanford University	Laudanna, C (corresponding author), Univ Verona, Inst Gen Biol, Strada Le Grazie 4, I-37134 Verona, Italy.	clauda@borgoroma.univr.it		Mochly-Rosen, Daria/0000-0002-6691-8733; Constantin, Gabriela/0000-0001-8978-3539	NIDDK NIH HHS [DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aktories K, 1997, J CLIN INVEST, V100, pS11; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bergman PJ, 1997, CANCER CHEMOTH PHARM, V40, P453, DOI 10.1007/s002800050686; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Gomez J, 1997, J IMMUNOL, V158, P1516; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Gupta KP, 1996, J BIOL CHEM, V271, P2102, DOI 10.1074/jbc.271.4.2102; HARRIS TE, 1995, BIOCHEM SOC T, V23, pS187, DOI 10.1042/bst023187s; Harris TE, 1996, MOL CELL ENDOCRINOL, V121, P133, DOI 10.1016/0303-7207(96)03858-0; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kent JD, 1996, J IMMUNOL, V157, P4641; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH G, 1994, BIOCHEM J, V299, P775, DOI 10.1042/bj2990775; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; LEY K, 1993, J IMMUNOL, V151, P6347; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MACHESKY L, 1997, J CELL BIOL, V4, P913; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; Milligan G, 1995, Adv Pharmacol, V32, P1, DOI 10.1016/S1054-3589(08)61010-8; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PATARROYO M, 1982, INT J CANCER, V30, P707, DOI 10.1002/ijc.2910300606; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TURNER RS, 1985, PHOSPHOLIPIDS CELLUL, P75; VALMU L, 1991, EUR J IMMUNOL, V21, P2857, DOI 10.1002/eji.1830211130; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; WHEELERJONES CPD, 1995, BIOCHEM SOC T, V23, pS205, DOI 10.1042/bst023205s; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	66	209	216	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30306	30315		10.1074/jbc.273.46.30306	http://dx.doi.org/10.1074/jbc.273.46.30306			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804792	hybrid			2022-12-25	WOS:000077008100039
J	Zentner, MD; Lin, HH; Wen, X; Kim, KJ; Ann, DK				Zentner, MD; Lin, HH; Wen, X; Kim, KJ; Ann, DK			The amiloride-sensitive epithelial sodium channel alpha-subunit is transcriptionally down-regulated in rat parotid cells by the extracellular signal-regulated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; NA+ CHANNEL; GENE-EXPRESSION; GROWTH-FACTOR; NEURONAL DIFFERENTIATION; CAENORHABDITIS-ELEGANS; TRANSDUCTION PATHWAY; HOMOLOGOUS SUBUNITS; ONCOGENIC RAF-1; ION CHANNELS	Previous studies have shown that an inducible Raf-1 kinase protein, Delta Raf-1:ER, activates the mitogen-activated protein kinase/extracellular signal-regulated protein kinase (ERK)-signaling pathway, which is required for the transformation of the rat salivary epithelial cell line, Pa-4. Differential display polymerase chain reaction was employed to search for mRNAs repressed by Delta Raf-1:ER activation. Through this approach, the gene encoding the cu-subunit of the amiloride-sensitive epithelial sodium channel (alpha-ENac) was identified as a target of activated Raf-1 kinases. alpha-ENaC down-regulation could also be seen in cells treated with 12-O-tetradecanoyl-1-phorbol-13-acetate (TPA), indicating that the repression of steady-state alpha-ENaC mRNA level was dependent upon the activity of protein kinase C, the target of TPA, as well. Pretreatment of cells with a specific inhibitor of the ERK kinase pathway, PD 98059, markedly abolished the down-regulation of alpha-ENaC expression, consistent with the hypothesis that the ERR kinase-signaling pathway is involved in TPA-mediated repression. Moreover, through the use of transient transfection assays with alpha-ENaC-reporter and activated Raf expression construct(s), we provide the first evidence that activation of the ERR pathway down-regulates alpha-ENaC expression at the transcriptional level. Elucidating the molecular programming that modulates the expression of the alpha-subunit may provide new insights into the modulation of sodium reabsorption across epithelia.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Med Physiol & Biophys & Biomed Engn, Will Rogers Inst, Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 210B, Los Angeles, CA 90033 USA.				NHLBI NIH HHS [HL 38658, HL 46943] Funding Source: Medline; NIDCR NIH HHS [DE 07211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046943, R01HL046943, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen RH, 1996, ONCOGENE, V12, P1493; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI D, 1997, THESIS U SO CALIFORN; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIN HH, 1991, GENOMICS, V10, P102, DOI 10.1016/0888-7543(91)90490-6; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Ludwig M, 1998, HUM GENET, V102, P576, DOI 10.1007/s004390050743; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rossier B C, 1994, Curr Opin Nephrol Hypertens, V3, P487, DOI 10.1097/00041552-199409000-00003; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	64	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30770	30776		10.1074/jbc.273.46.30770	http://dx.doi.org/10.1074/jbc.273.46.30770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804854	hybrid			2022-12-25	WOS:000077008100101
J	Bebok, Z; Mazzochi, C; King, SA; Hong, JS; Sorscher, EJ				Bebok, Z; Mazzochi, C; King, SA; Hong, JS; Sorscher, EJ			The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61 beta and a cytosolic, deglycosylated intermediary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; RNA-POLYMERASE; CROSS-LINKING; GENE-PRODUCT; CFTR; DEGRADATION; EXPRESSION; SYSTEM; CELLS; RECONSTITUTION	Endoplasmic reticulum (ER) degradation pathways can selectively route proteins away from folding and maturation. Both soluble and integral membrane proteins can be targeted from the ER to proteasomal degradation in this fashion. The cystic fibrosis transmembrane conductance regulator (CFTR) is an integral, multidomain membrane protein localized to the apical surface of epithelial cells that functions to facilitate Cl(-)transport. CFTR was among the first membrane proteins for which a role of the proteasome in ER-related degradation was described. However, the signals that route CFTR to ubiquitination and subsequent degradation are not known. Moreover, limited information is available concerning the subcellular localization of polyubiquitinated CFTR or mechanisms underlying ret regrade dislocation of CFTR from the ER membrane to the proteasome either before or after ubiquitination. In the present study, we show that proteasome inhibition with clasto-lactacystin beta-lactone (4 mu M, 1 h) stabilizes the presence of a deglycosylated CFTR intermediate for up to 5 h without increasing the core glycosylated (band B) form of CFTR, Deglycosylated CFTR is present under the same conditions that result in accumulation of polyubiquitinated CFTR, Moreover, the deglycosylated form of both wild type and Delta F508 CFTR can be found in the cytosolic fraction. Both the level and stability of cytosolic, deglycosylated CFTR are increased by proteasome blockade. During retrograde translocation from the ER to the cytosol, CFTR associates with the Sec61 trimeric complex. Sec61 is the key component of the mammalian co-translational protein translocation system and has been proposed to function as a two way channel that transports proteins both into the ER and back to the cytosol for degradation. We show that the level of the Sec61.CFTR complexes are highest when CFTR degradation proceeds at the greatest rate (approximately 90 min after pulse labeling). Quantities of Sec61.CFTR complexes are also increased by inhibition of the proteasome, Based on these results, we propose a model in which complex membrane proteins such as CFTR are transported through the Sec61 trimeric complex back to the cytosol, escorted by the beta subunit of Sec61, and degraded by the proteasome or by other proteolytic systems.	Univ Alabama, Dept Med, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sorscher, EJ (corresponding author), Univ Alabama, Dept Med, Gregory Fleming James Cyst Fibrosis Res Ctr, 1918 Univ Blvd,Rm 798 BHSB, Birmingham, AL 35294 USA.			Sorscher, Eric J./0000-0001-9341-3354				Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; RIORDAN JR, 1989, SCIENCE, V245, P1066; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	36	97	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29873	29878		10.1074/jbc.273.45.29873	http://dx.doi.org/10.1074/jbc.273.45.29873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792704	hybrid			2022-12-25	WOS:000076798300081
J	Cervino, V; Benaim, G; Carafoli, E; Guerini, D				Cervino, V; Benaim, G; Carafoli, E; Guerini, D			The effect of ethanol on the plasma membrane calcium pump is isoform-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CA2+ PUMP; HUMAN-ERYTHROCYTES; CA-2+ PUMP; LIMITED PROTEOLYSIS; PROTEIN-KINASE; ATPASE; EXPRESSION; ENZYME; TRANSDUCTION	The effect of ethanol has been studied on four different isoforms of the plasma membrane Ca2+-ATPase expressed in Sf9 cells with the help of the baculovirus system. The PMCA2CI protein was maximally activated by 0.5% ethanol, a concentration 8-10 times lower than that needed to obtain the same effect on the PMCA4 protein or on the pump of erythrocyte membranes, which is a mixture of isoforms 1 and 4. Experiments performed with truncated pumps indicated that the stimulation by ethanol was lost if the C-terminal region between Lys(1065) and Lys(1161), encompassing the calmodulin binding domain, was removed. These observations indicate that the stimulation is the result of a direct interaction of ethanol with the C terminal regulatory domain of the Ca2+ pump.	Swiss Fed Inst Technol, Biochem Lab, CH-8092 Zurich, Switzerland; Cent Univ Venezuela, Fac Ciencias, Inst Expt Biol, Caracas, Venezuela	ETH Zurich; University of Central Venezuela	Guerini, D (corresponding author), ETH Zentrum, Univ Str 16, CH-8092 Zurich, Switzerland.		Carafoli, Ernesto/K-5192-2016; Benaim, Gustavo/H-5552-2019	Carafoli, Ernesto/0000-0002-7826-0094; Benaim, Gustavo/0000-0002-9359-5546				ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BANAIM G, 1996, MOL IMMUNE MECHANISM, P89; BENAIM G, 1994, BBA-BIOMEMBRANES, V1195, P141, DOI 10.1016/0005-2736(94)90020-5; BENAIM G, 1984, J BIOL CHEM, V259, P8471; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GOPINATH RM, 1981, AM J HEMATOL, V7, P303; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; JAMES P, 1988, J BIOL CHEM, V263, P2905; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PAN B, 1995, THESIS SWISS FEDERAL; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1980, CELL CALCIUM, V1, P287, DOI 10.1016/0143-4160(80)90031-7; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; Stauffer TP, 1997, BRAIN RES, V748, P21, DOI 10.1016/S0006-8993(96)01282-6; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Suju M, 1996, BIOCHEM J, V317, P933, DOI 10.1042/bj3170933; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; Verma AK, 1996, J BIOL CHEM, V271, P3714; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	34	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29811	29815		10.1074/jbc.273.45.29811	http://dx.doi.org/10.1074/jbc.273.45.29811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792696	hybrid			2022-12-25	WOS:000076798300073
J	Di Cunto, F; Calautti, E; Hsiao, J; Ong, L; Topley, G; Turco, E; Dotto, GP				Di Cunto, F; Calautti, E; Hsiao, J; Ong, L; Topley, G; Turco, E; Dotto, GP			Citron Rho-interacting kinase, a novel tissue-specific Ser/Thr kinase encompassing the Rho-Rac-binding protein citron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; SERINE/THREONINE KINASE; MYOSIN PHOSPHATASE; ACTIN CYTOSKELETON; MOLECULAR-CLONING; PUTATIVE TARGET; COILED-COIL; CELL-SHAPE; IDENTIFICATION; GTPASES	We have identified a novel serine/threonine kinase belonging to the myotonic dystrophy kinase family. The kinase can be produced in at least two different isoforms: a similar to 240-kDa protein (Citron Rho-interacting kinase, CRIK), in which the kinase domain is followed by the sequence of Citron, a previously identified Rho/Rac binding protein; a similar to 54-kDa protein (CRIK-short kinase (SK)), which consists mostly of the kinase domain. CRIK and CRIK-SK proteins are capable of phosphorylating exogenous substrates as well as of autophosphorylation, when tested by in vitro kinase assays after expression into COS7 cells. CRIK kinase activity is increased severalfold by coexpression of costitutively active Rho, while active Rac has more limited effects. Kinase activity of endogenous CRIK is indicated by in vitro kinase assays after immunoprecipitation with antibodies recognizing the Citron moiety of the protein. When expressed in keratinocytes, full-length CRIK but not CRIK-SK, localizes into corpuscular cytoplasmic structures and elicits recruitment of actin into these structures. The previously reported Rho-associated kinases ROCK I and II are ubiquitously expressed. In contrast, CRIK exhibits a restricted pattern of expression, suggesting that this kinase may fulfill a more specialized function in specific cell types.	Massachusetts Gen Hosp, Cutaneous biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Turin, Dept Genet Biol & Med Chem, Turin, Italy	Harvard University; Massachusetts General Hospital; Harvard University; University of Turin	Dotto, GP (corresponding author), Massachusetts Gen Hosp, Cutaneous biol Res Ctr, 13th St, Charlestown, MA 02129 USA.		Calautti, Enzo/M-8283-2018; Di Cunto, Ferdinando/K-5575-2016	Calautti, Enzo/0000-0002-4439-9709; di cunto, ferdinando/0000-0001-9367-6357	NCI NIH HHS [CA73796, CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RONCO LV, 1994, J BIOL CHEM, V269, P277; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Zhao YM, 1997, J BIOL CHEM, V272, P10013	27	88	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29706	29711		10.1074/jbc.273.45.29706	http://dx.doi.org/10.1074/jbc.273.45.29706			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792683	hybrid			2022-12-25	WOS:000076798300060
J	Giulian, D; Haverkamp, LJ; Yu, JH; Karshin, M; Tom, D; Li, J; Kazanskaia, A; Kirkpatrick, J; Roher, AE				Giulian, D; Haverkamp, LJ; Yu, JH; Karshin, M; Tom, D; Li, J; Kazanskaia, A; Kirkpatrick, J; Roher, AE			The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MONONUCLEAR PHAGOCYTES; MASS-SPECTROMETRY; MAMMALIAN BRAIN; MICROGLIA; PEPTIDES; PROTEIN; DEPOSITION; MECHANISM; SEQUENCE	The beta-amyloid peptide 1-42 (A beta 1-42), a major component of neuritic and core plaques found in Alzheimer's disease, activates microglia to kill neurons. Selective modifications of amino acids near the N terminus of A beta showed that residues 13-16, the HHQK domain, bind to microglial cells. This same cluster of basic amino acids is also known as a domain with high binding affinity for heparan sulfate. Both A beta binding to microglia and A beta induction of microglial killing of neurons were sensitive to heparitinase cleavage and to competition with heparan sulfate, suggesting membrane-associated heparan sulfate mediated plaque-microglia interactions through the HHQK domain, Importantly, small peptides containing HHQK inhibited A beta 1-42 cell binding as well as plaque induction of neurotoxicity in human microglia. In vivo experiments confirmed that the HHQK peptide reduces rat brain inflammation elicited after infusion of A beta peptides or implantation of native plaque fragments. Strategies which exploit HHQK-like agents may offer a specific therapy to block plaque-induced microgliosis and, in this way, slow the neuronal loss and dementia of Alzheimer's disease.	Baylor Coll Med, Alzheimers Dis Res Ctr, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Alzheimers Dis Res Ctr, Dept Pathol, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Sun Hlth Res Inst, Halderman Lab Alzheimers Dis Res, Sun City, AZ 85351 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Banner Research; Banner Health; Banner Sun Health Research Institute	Giulian, D (corresponding author), Baylor Coll Med, Alzheimers Dis Res Ctr, Dept Neurol, 1 Baylor Plaza, Houston, TX 77030 USA.	dgiulian@bcm.tmc.edu						Armbrustmacher V W, 1979, Pathol Annu, V14 Pt 1, P145; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOLSI DINO, 1927, RIV PAT NERV E MENT, V32, P65; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Davies Peter, 1994, P327; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Giulian D., 1992, CURR TOP NEUROL, V12, P23; Hunter M J, 1972, Methods Enzymol, V25, P585, DOI 10.1016/S0076-6879(72)25058-3; KONDO Y, 1995, NEUROSCI RES, V22, P123, DOI 10.1016/0168-0102(95)00878-W; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LUCCA U, 1994, BIOL PSYCHIAT, V36, P854, DOI 10.1016/0006-3223(94)90598-3; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; Miles E W, 1977, Methods Enzymol, V47, P431; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; PATTHY L, 1975, J BIOL CHEM, V250, P557; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Riordan J F, 1972, Methods Enzymol, V25, P515, DOI 10.1016/S0076-6879(72)25048-0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SCHRODE J, 1978, J BIOL CHEM, V253, P4837; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Terry Robert D., 1994, P179; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894	39	129	156	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29719	29726		10.1074/jbc.273.45.29719	http://dx.doi.org/10.1074/jbc.273.45.29719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792685	hybrid			2022-12-25	WOS:000076798300062
J	Gulino, D; Delachanal, E; Concord, E; Genoux, Y; Morand, B; Valiron, MO; Sulpice, E; Scaife, R; Alemany, M; Vernet, T				Gulino, D; Delachanal, E; Concord, E; Genoux, Y; Morand, B; Valiron, MO; Sulpice, E; Scaife, R; Alemany, M; Vernet, T			Alteration of endothelial cell monolayer integrity triggers resynthesis of vascular endothelium cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; BETA-CATENIN; ALPHA-CATENIN; ADHESION MOLECULE; STRUCTURAL BASIS; VE-CADHERIN; IN-VIVO; PROTEIN; COMPLEX; DOMAIN	Although cadherins appear to be necessary for proper cell-cell contacts, the physiological role of VE-cadherin (vascular endothelium cadherin) in adult tissue has not been clearly determined. To shed some light on this question, we have disturbed the adhesive function of VE-cadherin in human endothelial cell culture using a polyclonal anti-VE cadherin antibody. This antibody disrupts confluent endothelial cell monolayers in vitro and transiently generates numerous gaps at cell-cell junctions. The formation of these gaps correlates with a reversible increase in the monolayer permeability. We present evidence that destruction of the homotypic interactions between the extracellular domains of VE-cadherin induces a rapid resynthesis of VE-cadherin, leading to restoration of endothelial cell-cell contacts. The expression of new molecules of VE-cadherin correlates with a modest but significant increase in VE-cadherin mRNA synthesis, Altogether, these results establish a critical role for VE-cadherin in the maintenance and restoration of endothelium integrity.	CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; CEA, Dept Biol Mol & Struct, Hematol Lab, F-38054 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Gulino, D (corresponding author), CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, 41 Ave Martyrs, F-38027 Grenoble, France.	gulino@ibs.fr	Vernet, Thierry/G-1118-2012	Sulpice, Eric/0000-0001-7695-0561				ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gotsch U, 1997, J CELL SCI, V110, P583; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GULINO D, 1992, J BIOL CHEM, V267, P1001; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIM L, 1995, MOL CELL BIOL, V15, P4553; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LIAW CW, 1990, EMBO J, V9, P2701, DOI 10.1002/j.1460-2075.1990.tb07456.x; Matsumura T, 1997, J IMMUNOL, V158, P3408; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SALOMON D, 1992, J CELL SCI, V102, P1; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TACHEICHI M, 1991, SCIENCE, V251, P1451; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; TANIHARA H, 1994, J CELL SCI, V107, P1697; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Zondag GCM, 1996, J CELL BIOL, V134, P1513, DOI 10.1083/jcb.134.6.1513	52	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29786	29793		10.1074/jbc.273.45.29786	http://dx.doi.org/10.1074/jbc.273.45.29786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792693	hybrid			2022-12-25	WOS:000076798300070
J	Lo, B; Silverman, M				Lo, B; Silverman, M			Cysteine scanning mutagenesis of the segment between putative transmembrane helices IV and V of the high affinity Na+/glucose cotransporter SGLT1 - Evidence that this region participates in the Na+ and voltage dependence of the transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; STATE CURRENTS; EXPRESSION; KINETICS; BINDING; CLAMP; MECHANISM; CHANNELS	Site-directed mutagenesis and chemical modification of specific cysteine amino acid side chains by methanethiosulfonate (MTS) derivatives were combined to elucidate structure/function relationships of the cloned rabbit Na+/glucose cotransporter, SGLT1, Each amino acid in the region (residues 162-173) between putative transmembrane helices IV and V of SGLT1 was replaced individually with Cys, Mutant proteins were expressed in Xenopus laevis oocytes and studied using the two-electrode voltage clamp method. At certain key positions, Cys substitution resulted in 1) a change in the apparent affinity for sugar, 2) an alteration in the voltage dependence of the transient currents, and 3) a sensitivity to inhibition by either the ethylamine (MTSEA) or the ethylsulfonate MTS derivatives. For the three Cys mutants inhibited by MTSEA (F163C, A166C, and L173C), inhibition of steady state transport is related to changes in membrane potential-dependent transitions within the Na+/glucose transport cycle. MTSEA shifted the transient currents of these Cys mutants toward more negative membrane potentials (Delta V-0.5 = -18 mV for F163C and A166C, -12 mV for L173C), When the mutations were combined to produce double and triple Cys mutants, the degree to which the transient currents were shifted along the membrane potential axis by MTSEA correlated with the number of cysteines, In this way it was possible to manipulate the voltage dependence of the transient currents over a range spanning 91 mV. Examination of the Na+ dependence of the transient currents indicates that a 91-mV shift is equivalent to that caused by a 10-fold reduction in the external Na+ concentration. We conclude that this region has a role in determining the Na+ binding and voltage-sensing properties of SGLT1 and that it forms an alpha-helix with one surface possibly lining a Na+ pore within SGLT1.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto	Silverman, M (corresponding author), Univ Toronto, Dept Med, Med Sci Bldg,Rm 7207, Toronto, ON M5S 1A8, Canada.	melvin.silverman@utoronto.ca						Bennett E, 1996, BIOPHYS J, V70, P1676, DOI 10.1016/S0006-3495(96)79730-8; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Chen XZ, 1996, BIOPHYS J, V71, P2544, DOI 10.1016/S0006-3495(96)79447-X; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1966, ANN NY ACAD SCI, V779, P136; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; KIMMICH GA, 1978, AM J PHYSIOL, V235, pC73, DOI 10.1152/ajpcell.1978.235.3.C73; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; LAUGER P, 1986, J MEMBRANE BIOL, V91, P275, DOI 10.1007/BF01868820; LEE WS, 1994, J BIOL CHEM, V269, P12032; Lo B, 1998, J BIOL CHEM, V273, P903, DOI 10.1074/jbc.273.2.903; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mager S, 1996, J NEUROSCI, V16, P5405; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Rakowski RF, 1997, J MEMBRANE BIOL, V155, P105, DOI 10.1007/s002329900162; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	36	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29341	29351		10.1074/jbc.273.45.29341	http://dx.doi.org/10.1074/jbc.273.45.29341			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792634	hybrid			2022-12-25	WOS:000076798300011
J	Oka, M; Nakai, M; Endo, T; Lim, CR; Kimata, Y; Kohno, K				Oka, M; Nakai, M; Endo, T; Lim, CR; Kimata, Y; Kohno, K			Loss of hsp70-hsp40 chaperone activity causes abnormal nuclear distribution and aberrant microtubule formation in M-phase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; EUKARYOTIC DNAJ HOMOLOG; T-COMPLEX POLYPEPTIDE-1; TUBULIN-LIKE TUB4P; GAMMA-TUBULIN; MOLECULAR CHAPERONES; SPINDLE ORIENTATION; CELL-CYCLE; IN-VIVO; CYTOPLASMIC CHAPERONIN	The 70-kDa heat shock proteins, hsp70, are highly conserved among both prokaryotes and eukaryotes, and function as chaperones in diverse cellular processes. To elucidate the function of the yeast cytosolic hsp70 Ssa1p in vivo, we characterized a Saccharomyces cerevisiae ssa1 temperature-sensitive mutant (ssa1-134), After shifting to the restrictive temperature (37 degrees C), ssa1-134 mutant cells showed abnormal distribution of nuclei and accumulated as large-budded cells with a 2 N DNA content, We observed more prominent mutant phenotypes using nocodazole-synchronized cells: when cells were incubated at the restrictive temperature following nocodazole treatment, viability was rapidly lost and abnormal arrays of bent microtubules were formed. Chemical cross-linking and immunoprecipitation analyses revealed that the interaction of mutant Ssa1p with Ydj1p (cytosolic DnaJ homologue in yeast) was much weaker compared with wild-type Ssa1p, These results suggest that Ssa1p and Ydj1p chaperone activities play important roles in the regulation of microtubule formation in M phase. In support of this idea, a ydj1 null mutant at the restrictive temperature was found to exhibit more prominent phenotypes than ssa1-134. Furthermore, both ssa1-134 and ydj1 null mutant cells exhibited greater sensitivity to anti-microtubule drugs. Finally, the observation that SSA1 and YDJ1 interact genetically with a gamma-tubulin, TUB4, supports the idea that they play a role in the regulation of microtubule formation.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Nagoya Univ, Fac Sci, Chikusa Ku, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Nara Institute of Science & Technology; Nagoya University; Japan Science & Technology Agency (JST)	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.	kkouno@bs.aist-nara.ac.jp	Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				AHMAD S, 1990, MOL CELL BIOL, V10, P5160, DOI 10.1128/MCB.10.10.5160; Baxter BK, 1996, MOL CELL BIOL, V16, P6444; Becker J, 1996, MOL CELL BIOL, V16, P4378; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BLOCH MA, 1995, J CELL SCI, V108, P3541; Brown CR, 1996, J BIOL CHEM, V271, P824, DOI 10.1074/jbc.271.2.824; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CRAIG EA, 1992, MOL CELLULAR BIOL YE, V2, P501; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DEBEC A, 1990, J CELL SCI, V96, P403; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Endo T, 1996, J BIOL CHEM, V271, P4161; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; GUPTA RS, 1984, J BIOL CHEM, V259, P1882; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KARASEV AV, 1992, FEBS LETT, V304, P12, DOI 10.1016/0014-5793(92)80578-5; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LI WZ, 1994, J BIOL CHEM, V269, P18616; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Liang P, 1997, J CELL SCI, V110, P1431; LIM L, 1984, BIOCHEM J, V224, P677, DOI 10.1042/bj2240677; Lin P, 1997, P NATL ACAD SCI USA, V94, P10780, DOI 10.1073/pnas.94.20.10780; MARCHESI VT, 1993, P NATL ACAD SCI USA, V90, P3028, DOI 10.1073/pnas.90.7.3028; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MUKAI H, 1993, GENE, V132, P57; NELSON RJ, 1992, GENETICS, V131, P277; Oka M, 1997, J BIOCHEM, V121, P578; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PERRET E, 1995, J CELL SCI, V108, P711; RATTNER JB, 1991, EXP CELL RES, V195, P110, DOI 10.1016/0014-4827(91)90505-O; Rose MD., 1990, METHODS YEAST GENETI; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANCHEZ C, 1994, ARCH BIOCHEM BIOPHYS, V310, P428, DOI 10.1006/abbi.1994.1188; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SIKORSKI RS, 1989, GENETICS, V122, P19; Sobel SG, 1995, J CELL BIOL, V131, P1775, DOI 10.1083/jcb.131.6.1775; Spang A, 1996, J CELL BIOL, V134, P429, DOI 10.1083/jcb.134.2.429; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; UZAWA M, 1995, DEV BIOL, V171, P51, DOI 10.1006/dbio.1995.1259; VIDAIR CA, 1993, J CELL PHYSIOL, V154, P443, DOI 10.1002/jcp.1041540302; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEATHERBEE JA, 1980, BIOCHEMISTRY-US, V19, P4116, DOI 10.1021/bi00558a033; WELLER NK, 1988, BIOL CELL, V63, P307, DOI 10.1016/0248-4900(88)90121-9; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Williams NE, 1997, J CELL SCI, V110, P1665; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAZOV P, 1997, J CELL SCI, V110, P1879; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; [No title captured]	75	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29727	29737		10.1074/jbc.273.45.29727	http://dx.doi.org/10.1074/jbc.273.45.29727			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792686	hybrid			2022-12-25	WOS:000076798300063
J	Esteller, M; Levine, R; Baylin, SB; Ellenson, LH; Herman, JG				Esteller, M; Levine, R; Baylin, SB; Ellenson, LH; Herman, JG			MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas	ONCOGENE			English	Article						MLH1; hypermethylation; endometrial carcinoma; microsatellite instability	MISMATCH REPAIR GENES; NONPOLYPOSIS COLORECTAL-CANCER; CPG ISLAND METHYLATION; COLON-CANCER; MUTATIONAL ANALYSIS; DNA METHYLATION; HOMOLOG; TUMORS; HMLH1; HMSH2	Microsatellite instability (MSI) has been detected in endometrial carcinomas occurring in women affected by hereditary nonpolyposis colorectal carcinoma (HNPCC) as well as in 20% of presumably sporadic endometrial tumors. While the MSI+ phenotype observed in endometrial tumors from HNPCC patients is attributed to germ line mutations in mismatch repair (MMR) genes, somatic mutations of known MMR genes are infrequent in MSI+ sporadic endometrial carcinomas, Recently, cytosine methylation of the MLH1 promoter region has been identified in a subset of MSI+ colon primary carcinomas and cell lines. We studied the MLH1 and MSH2 promoter methylation status in 29 presumably sporadic uterine endometrioid carcinomas (UECs), which had previously been characterized for the MSI phenotype and a subset for DNA MMR gene mutational status. We found that 13 (45%) of 29 cases of EC were hypermethylated in the 5' CpG island of MLH1. Hypermethylation of MSH2 was not observed, MLH1 was hypermethylated in 12 (92%) of 13 MSI+ tumors, while only 1 (6%) of 16 MSI- tumors (Fischer's exact test P < 0.0001). Other tumor types we tested did not demonstrate MLH1 promoter hypermethylation, Our data suggest that hypermethylation of MLH1, but not of MSH2, is associated with the MSI phenotype in sporadic endometrial carcinomas.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA43318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1997, CANCER RES, V57, P3370; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; Caduff RF, 1996, AM J PATHOL, V148, P1671; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kane MF, 1997, CANCER RES, V57, P808; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kobayashi K, 1996, JPN J CANCER RES, V87, P141, DOI 10.1111/j.1349-7006.1996.tb03151.x; KOBAYASHI K, 1995, GENE CHROMOSOME CANC, V14, P128, DOI 10.1002/gcc.2870140207; KOLODNER RD, 1995, CANCER RES, V55, P242; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lim PC, 1996, CLIN CANCER RES, V2, P1907; LIU B, 1994, CANCER RES, V54, P4590; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Risinger JI, 1997, CANCER RES, V57, P4736; RISINGER JI, 1993, CANCER RES, V53, P1; Tashiro H, 1997, CANCER RES, V57, P3935; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	32	392	401	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2413	2417		10.1038/sj.onc.1202178	http://dx.doi.org/10.1038/sj.onc.1202178			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811473				2022-12-25	WOS:000076723300016
J	Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN				Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN			Mapping of chromosome 3p deletions in human epithelial ovarian tumors	ONCOGENE			English	Article						ovarian; chromosome 3p; loss of heterozygosity; tumor suppressor	SUPPRESSOR GENE; RECEPTOR GENE; HUMAN GENOME; CELL-LINES; FHIT GENE; LOW-GRADE; CANCER; CARCINOMAS; MAP; IDENTIFICATION	Epithelial ovarian tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of tumor suppressor genes within the deleted regions. We have recently established a primary tissue culture system as a model to investigate the genetic events associated with ovarian cancer. The frequencies of loss of heterozygosity (LOH) at 16 loci representative of chromosome 3p in 33 tumor biopsies and 47 ovarian primary cultures derived from unselected ovarian cancers were examined, This repertoire also included benign and borderline tumors as well as malignant ovarian ascites, LOH was observed in 25 (31%) samples for at least one marker: 21 of 58 malignant, two of 12 borderline and two of 10 benign specimens, Chromosome 3p loss was not restricted to ovarian tumors of high grade and stage. LOH was observed in both cultured and non cultured tumors and ascites, A spontaneously immortalized cell line derived from a malignant ovarian ascites, OV-90, displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p, The pattern of deletion displayed by these 25 samples enabled the determination of at least two distinct regions of overlapping deletions on chromosome 3p extending from D3S1270 to D3S1597 and from D3S1293 to D3S1283, In addition, a region proximal to D3S1300 was deleted in a subset of samples. Although loss of loci overlapping these three regions (Regions I, II and III) were observed in malignant and benign tumors, in borderline tumors loss was observed of markers representative of Region III only. While RAR beta is presently included in Region II, the minimal regions of deletion exclude VHL, TGFBR2, PTPasey and FHIT as candidate tumor suppressors in ovarian tumorigenesis.	CHUM Campus Notre Dame, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J2, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM Campus Notre Dame, Inst Canc Montreal, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aebi S, 1996, CANCER RES, V56, P3087; BUICK RN, 1985, CANCER RES, V45, P3668; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DODSON MK, 1993, CANCER RES, V53, P4456; EHLEN T, 1990, ONCOGENE, V5, P219; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Hendricks DT, 1997, CANCER RES, V57, P2112; HOULE B, 1994, CANCER RES, V54, P365; JONES MH, 1992, ONCOGENE, V7, P1631; KRUK PA, 1990, LAB INVEST, V63, P132; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; MANNING A, 1998, UNPUB MOL CARCINOGEN; MATHEW S, 1994, GENOMICS, V20, P114, DOI 10.1006/geno.1994.1134; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; Nakashima R, 1996, ONCOL REP, V3, P887; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARSONS R, 1995, CANCER RES, V55, P5548; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Phillips NJ, 1996, CANCER RES, V56, P606; RIMESSI P, 1994, ONCOGENE, V9, P3467; Schuler GD, 1996, SCIENCE, V274, P547; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sun HS, 1996, MAMM GENOME, V7, P128, DOI 10.1007/s003359900032; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG JC, 1998, UNPUB CANC GENET CYT; WARY KK, 1993, CANCER RES, V53, P1498; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHITMAN G, 1993, NORMAL OVARIAN DEV F; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; ZHENG JP, 1991, CANCER RES, V51, P4045	37	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2359	2365		10.1038/sj.onc.1202152	http://dx.doi.org/10.1038/sj.onc.1202152			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811467				2022-12-25	WOS:000076723300010
J	Biebermann, H; Schoneberg, T; Schulz, A; Krause, G; Gruters, A; Schultz, G; Gudermann, T				Biebermann, H; Schoneberg, T; Schulz, A; Krause, G; Gruters, A; Schultz, G; Gudermann, T			A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G-protein coupling	FASEB JOURNAL			English	Article						G-protein-coupled receptor; molecular modeling; receptor conformation; thyroid; TSH receptor allele	LUTROPIN CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; TSH RECEPTOR; CONGENITAL HYPOTHYROIDISM; CONSTITUTIVE ACTIVITY; AMINO-ACID; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION	In the human thyroid, the wild-type thyrotropin receptor (TSHR) couples to adenylyl cyclase and phospholipase C and constitutively increases intracellular cAMP levels. The first human TSHR sequence submitted differs from subsequently cloned wild-type receptors by an exchange of a conserved Y residue within transmembrane domain 5 (TM5) for an H residue. We did not detect the Y601H mutant in 263 European individuals, but confirmed the homozygous occurrence of TSHR-Y601. Expression of TSHR-Y601H in COS-7 cells revealed a loss of constitutive cAMP production and selective lack of TSH-induced phosphoinositide hydrolysis, whereas agonist-induced cAMP formation remained unaltered. Analysis of several mutant receptors (Y601A, Y601D, Y601F, Y601K, Y601P, Y601S, Y601W, Y601 Delta) did not show restoration of constitutive activity and dual signaling, thus suggesting a functional role of a properly spaced hydroxyl group at position 601. Molecular modeling revealed that the formation of a hydrogen bond between the hydroxyl group of Y601 in TM5 and the carbonyl oxygen of A623 in the peptide backbone of TM6 is critical for the receptor to adopt active conformations that impart wild-type signaling properties. Our finding indicate that multiple active receptor states underlie coupling of a G-protein-coupled receptor to different G-proteins.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Humboldt Univ, Klin & Poliklin Kinderheilkunde, Klinikum Rudolf Virchow, Berlin, Germany; Inst Mol Pharmakol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	guderman@zedat.fu-berlin.de		Biebermann, Heike/0000-0002-2024-7778				Abramowicz MJ, 1997, J CLIN INVEST, V99, P3018, DOI 10.1172/JCI119497; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Arey BJ, 1997, MOL ENDOCRINOL, V11, P517, DOI 10.1210/me.11.5.517; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Biebermann H, 1997, J CLIN ENDOCR METAB, V82, P3471, DOI 10.1210/jc.82.10.3471; Biebermann H, 1997, NEW ENGL J MED, V336, P1390, DOI 10.1056/NEJM199705083361914; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CliftonBligh RJ, 1997, J CLIN ENDOCR METAB, V82, P1094, DOI 10.1210/jc.82.4.1094; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fernandez LM, 1996, BIOCHEMISTRY-US, V35, P3986, DOI 10.1021/bi952421c; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Higuchi R., 1989, PCR TECHNOLOGY, P61; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; JOHNSTONE AP, 1994, MOL CELL ENDOCRINOL, V105, pR1, DOI 10.1016/0303-7207(94)90175-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1995, ENDOCR J, V42, P587, DOI 10.1507/endocrj.42.587; KRAUSE G, 1995, QSAR MOL MODELLING, P530; Kristinsdottir BP, 1996, ENG OPTIMIZ, V26, P1, DOI 10.1080/03052159608941107; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SAMANA P, 1993, J BIOL CHEM, V288, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; TAKESHITA A, 1994, THYROID, V4, P255, DOI 10.1089/thy.1994.4.255; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a	53	79	80	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1461	1471		10.1096/fasebj.12.14.1461	http://dx.doi.org/10.1096/fasebj.12.14.1461			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806755				2022-12-25	WOS:000076749500005
J	Gupta, RW; Mayer, BJ				Gupta, RW; Mayer, BJ			Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus	ONCOGENE			English	Article						SH2/SH3 adapters; MAPK; FGF; mesoderm induction	FIBROBLAST GROWTH-FACTOR; PC12 CELL-DIFFERENTIATION; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE; FGF-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; POINT MUTATION; SH3 DOMAINS; PATHWAY	The SH2/SH3 adapters Nck, Grb2 and Crk promote the assembly of signaling complexes by binding to tyrosine phosphorylated proteins using their SH2 domains and to proline-rich sequences on effector molecules using their SH3 domains. FGF, which activates a receptor tyrosine kinase, induces mesoderm formation in Xenopus embryos through activation of the Ras/Raf/MAPK signaling pathway. We present evidence that dominant-negative mutants of Nck and Grb2, but not Crk1, can inhibit mesoderm-specific gene induction by eFGF in Xenopus animal cap explants. We also show that dominant-negative mutants of Grb2 and Nck can inhibit eFGF-induced Erk1 activation in Xenopus animal caps, and that targeting the first two SH3 domains of Nck to the membrane can activate Erk1 in the absence of eFGF.. Furthermore, combinations of the dominant-negative Grb2 mutants with the inhibitory Nck mutant synergistically inhibited Erk1 activation by eFGF in Xenopus animal caps, suggesting that the dominant-negative Nck and Grb2 mutants inhibit Erk1 activation by binding to different proteins. By contrast only Grb2 mutants could inhibit eFGF-induced Erk1 activation in human 293 cells, demonstrating diversity in the specific mechanisms of signaling from FGF to MAP kinases in different cells.	Harvard Med Sch, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1995, ONCOGENE, V10, P1465; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HU G, 1995, MOL CELL BIOL, V15, P1169; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MUSLIN AJ, 1994, MOL CELL BIOL, V14, P3006, DOI 10.1128/MCB.14.5.3006; NAKEILNY S, 1992, EMBO J, V11, P2123; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	61	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2155	2165		10.1038/sj.onc.1202158	http://dx.doi.org/10.1038/sj.onc.1202158			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811447				2022-12-25	WOS:000076698200002
J	Cipriano, SC; Chen, YQ				Cipriano, SC; Chen, YQ			Insensitivity to growth inhibition by TGF-beta 1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells	ONCOGENE			English	Article						TGF-beta; G(1) arrest; cell cycle; p15(INK4B); p21(WAF1/Cip1/Sdi1); p27(KIP1); prostate cancer	DEPENDENT KINASE INHIBITOR; TGF-BETA; CANCER-CELLS; CYCLE ARREST; POTENTIAL MEDIATOR; SMAD PROTEINS; GENE; PROLIFERATION; DPC4; SUPPRESSION	TGF-beta is a potent growth inhibitor of epithelial cells. However, many transformed cells have lost their sensitivity to this growth inhibitory effect. The molecular mechanism of such insensitivity is not get understood, Here, we have studied the TGF-beta 1 effect on normal human prostate and carcinoma cells. Our results showed that normal cells were sensitive to growth inhibition, whereas tumor cells were not or only minimally inhibited regardless of the concentration of TGF-beta 1 (20 to 80 pM) or time of exposure (1-5 days). p21(WAF/Cip1/Sdi1) and p15(INK4B) but not p27(KIP1) were detectable by Western blotting in normal and tumor cells, TGF-beta 1 treatment increased the association of p21(WAF1/Cip1/Sdi1) with the Cdk2/cyclin E complex in both normal and prostate tumor cells. However, there was no increase in the association of p15(INK4B) nor p27(Kip1) with the Cdk/cyclin complexes, In normal cells, the increase in the association of p21(WAF1/Cip1/Sdi1). With th, Cdk2/cyclin E complex resulted in inhibition of the Cdk2 activity. In contrast, although there was an increase in the association of p21(WAF1/Cip1/Sdi1) With th, Cdk2/cyclin E complex in tumor cells, there was no inhibition of the Cdk2 activity, These results indicate that a lack of inhibition of the Cdk2 activity correlates with insensitivity to TGF-beta 1 in prostate tumor cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Chen, YQ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; GAO X, 1995, ONCOGENE, V11, P1395; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUBECKLOBENSTE.B, 1989, J CLIN INVEST, V8, P764; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herman JG, 1996, CANCER RES, V56, P722; HUGGETT AC, 1990, CANCER RES, V50, P7468; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; IVARONE A, 1997, NATURE, V387, P417; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schutte M, 1996, CANCER RES, V56, P2527; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	22	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1549	1556		10.1038/sj.onc.1202069	http://dx.doi.org/10.1038/sj.onc.1202069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794232				2022-12-25	WOS:000076089900007
J	Villani, G; Greco, M; Papa, S; Attardi, G				Villani, G; Greco, M; Papa, S; Attardi, G			Low reserve of cytochrome c oxidase capacity in vivo in the respiratory chain of a variety of human cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; IN-VIVO; H+/E STOICHIOMETRY; MUSCLE-FIBERS; FLUX CONTROL; RAT MUSCLE; DNA; DISEASES; CYTOSKELETON; CARCINOMA	The question of whether and to what extent the in vivo cytochrome c oxidase (COX) capacity in mammalian cells exceeds that required to support respiration is still unresolved. In the present work, to address this question, a newly developed approach for measuring the rate of COX activity, either as an isolated step or as a respiratory chain-integrated step, has been applied to a variety of human cell types, including several tumor-derived semidifferentiated cell lines, as well as specialized cells removed from the organism. KCN titration assays, carried out on intact uncoupled cells, have clearly shown that the COX capacity is in low excess (16-40%) with respect to that required to support the endogenous respiration rate. Furthermore, measurements of O-2 consumption rate supported by 0.4 mM tetramethyl-p-phenylenediamine in antimycin-inhibited uncoupled intact cells have given results that are fully consistent with those obtained in the KCN titration experiments. Similarly, KCN titration assays on distonin-permeabilized cells have revealed a COX capacity that is nearly limiting (7-22% excess) for ADP + glutamate/malate-dependent respiration. The present observations, therefore, substantiate the conclusion that the in vivo control of respiration by COX is much tighter than has been generally assumed on the basis of experiments carried out on isolated mitochondria, This conclusion has important implications for understanding the role of physiological or pathological factors in affecting the COX threshold.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Bari, Inst Med Biochem & Chem, I-70124 Bari, Italy	California Institute of Technology; Universita degli Studi di Bari Aldo Moro	Villani, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Papa, Sergio/0000-0002-4417-1763	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND MD, 1994, EUR J BIOCHEM, V226, P819, DOI 10.1111/j.1432-1033.1994.00819.x; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; CAPITANIO N, 1991, FEBS LETT, V288, P179, DOI 10.1016/0014-5793(91)81029-8; Capitanio N, 1996, BIOCHEMISTRY-US, V35, P10800, DOI 10.1021/bi9606509; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; Geromel V, 1997, BIOCHEM BIOPH RES CO, V236, P643, DOI 10.1006/bbrc.1997.7024; Gnaiger E, 1998, J EXP BIOL, V201, P1129; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; JONES DP, 1979, BIOCHIM BIOPHYS ACTA, V576, P17, DOI 10.1016/0005-2795(79)90480-X; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KADENBACH B, 1995, BBA-MOL BASIS DIS, V1271, P103, DOI 10.1016/0925-4439(95)00016-W; Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KUNZ D, 1995, BIOCHEM MOL MED, V54, P105, DOI 10.1006/bmme.1995.1015; KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F; Kuznetsov AV, 1996, J BIOL CHEM, V271, P283, DOI 10.1074/jbc.271.1.283; Kuznetsov AV, 1997, BBA-MOL BASIS DIS, V1360, P142, DOI 10.1016/S0925-4439(96)00072-5; Kuznetsov AV, 1998, J CELL BIOL, V140, P1091, DOI 10.1083/jcb.140.5.1091; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LIU X, 1986, CELL, V86, P147; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; OLSSON L, 1980, P NATL ACAD SCI-BIOL, V77, P5429, DOI 10.1073/pnas.77.9.5429; PAPA S, 1991, FEBS LETT, V288, P183, DOI 10.1016/0014-5793(91)81030-C; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; SAGIEISENBERG R, 1979, EUR J BIOCHEM, V97, P127, DOI 10.1111/j.1432-1033.1979.tb13093.x; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wiedemann FR, 1998, FEBS LETT, V422, P33, DOI 10.1016/S0014-5793(97)01586-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	46	182	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31829	31836		10.1074/jbc.273.48.31829	http://dx.doi.org/10.1074/jbc.273.48.31829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822650	Green Accepted, hybrid			2022-12-25	WOS:000077207000032
J	Yang, XD; Yu, L; He, DY; Yu, CA				Yang, XD; Yu, L; He, DY; Yu, CA			The quinone-binding site in succinate-ubiquinone reductase from Escherichia coli - Quinone-binding domain and amino acid residues involved in quinone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-II SUCCINATE; HYDROPHOBIC SUBUNITS; FUMARATE REDUCTASE; OXIDOREDUCTASE; PROTEIN; IDENTIFICATION; DEHYDROGENASE; CLONING; HEART; QPS3	When purified ubiquinone (Q)-depleted succinate-ubiquinone reductase from Escherichia coli is photoaffinity-labeled with 3-azido-2-methyl-5-methoxy-[H-3] 6-geranyl-1,4-benzoquinone ([H-3]azido-Q) followed by SDS-polyacrylamide gel electrophoresis, radioactivity is found in the SdhC subunit, indicating that this subunit is responsible for ubiquinone binding, An [H-3]azido-Q-linked peptide, with a retention time of 61.7 min, is obtained by high performance liquid chromatography of the protease It digest of [H-3]azido-Q-labeled SdhC obtained from preparative SDS-polyacrylamide gel electrophoresis on labeled reductase, The partial N-terminal amino acid sequence of this peptide is NH2-TIRFPITAIASILHRVS-, corresponding to residues 17-33, The ubiquinone-binding domain in the proposed structural model of SdhC, constructed based on the hydropathy plot of the deduced amino acid sequence of this protein, is located at the N-terminal end toward the transmembrane helix I. To identify amino acid residues responsible for ubiquinone binding, substitution mutations at the putative ubiquinone-binding region of SdhC were generated and characterized. E, coli NM256 lacking genomic succinate-Q reductase genes was constructed and used to harbor the mutated succinate-Q reductase genes in a low copy number pRKD418 plasmid, Substitution of serine 27 of SdhC with alanine, cysteine, or threonine or substitution of arginine 31 with alanine, lysine, or histidine yields cells unable to grow aerobically in minimum medium with succinate as carbon source. Furthermore, little succinate-ubiquinone reductase activity and [H-3]azido-Q uptake are detected in succinate-ubiquinone reductases prepared from these mutant cells grown aerobically in LB medium. These results indicate that the hydroxyl group, the size of the amino acid side chain at position 27, and the guanidino group at position 31 of SdhC are critical for succinate-ubiquinone reductase activity, perhaps by formation of hydrogen bonds with carbonyl groups of the 1,4-benzoquinone ring of the quinone molecule. The hydroxyl group, but not the size of the amino acid side chain, at position 33 of SdhC is also important, because Ser-33 can be substituted with threonine but not with alanine.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.				NIGMS NIH HHS [GM 30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; ELKABBANI O, 1991, BIOCHEMISTRY-US, V30, P5361, DOI 10.1021/bi00236a006; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; KITA K, 1989, J BIOL CHEM, V264, P2672; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Lee GY, 1998, BBA-BIOENERGETICS, V1363, P35, DOI 10.1016/S0005-2728(97)00089-3; MATHER MW, 1995, GENE, V156, P85, DOI 10.1016/0378-1119(95)00074-G; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; *PROMEGA, 1996, ALT SIT 228 IN VITR; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Shenoy SK, 1996, FASEB J, V10, P2837; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SPENCER ME, 1974, J BACTERIOL, V117, P947, DOI 10.1128/JB.117.3.947-953.1974; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WILSON DF, 1964, J BIOL CHEM, V239, P2683; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Yang XD, 1997, J BIOL CHEM, V272, P9683; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU CA, 1993, J BIOENERG BIOMEMBR, V23, P259	28	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31916	31923		10.1074/jbc.273.48.31916	http://dx.doi.org/10.1074/jbc.273.48.31916			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822661	hybrid			2022-12-25	WOS:000077207000043
J	Sullivan, DJ; Matile, H; Ridley, RG; Goldberg, DE				Sullivan, DJ; Matile, H; Ridley, RG; Goldberg, DE			A common mechanism for blockade of heme polymerization by antimalarial quinolines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; MALARIA PARASITES; HEMOZOIN; CHLOROQUINE; INHIBITION; PIGMENT; CULTURE	The antimalarial quinolines are believed to work by blocking the polymerization of toxic heme released during hemoglobin proteolysis in intraerythrocytic Plasmodium falciparum. In the presence of free heme, chloroquine and quinidine associate with the heme polymer. We, have proposed that this association of the quinolineheme complex with polymer caps the growing heme polymer, preventing further sequestration of additional heme that then accumulates to levels that kill the parasite. In this work results of binding assays demonstrate that the association of quinoline-heme complex with heme polymer is specific, saturable, and high affinity and that diverse quinoline analogs can compete for binding. The relative quinoline binding affinity for heme polymer rather than free heme correlates with disruption of heme polymerization. Mefloquine, another important antimalarial quinoline, associated with polymer in a similar fashion, both in cultured parasites and in the test tube. In parasite culture, blocking heme release with protease inhibitor was antagonistic to mefloquine action, as it is to chloroquine action. These data suggest a common mechanism for quinoline antimalarial action dependent on drug interaction with both heme and heme polymer.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Pharma Res Preclin, CH-4070 Basel, Switzerland; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Johns Hopkins University; Roche Holding; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Sullivan, DJ (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER; PHS HHS [A1-31615] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASAWAMAHASAKDA W, 1994, MOL BIOCHEM PARASIT, V67, P183, DOI 10.1016/0166-6851(94)00128-6; BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P727, DOI 10.1016/S0006-2952(97)00510-8; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P737, DOI 10.1016/S0006-2952(97)00509-1; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; Flores MVC, 1997, PARASITOL RES, V83, P734, DOI 10.1007/s004360050330; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Hawley SR, 1998, ANTIMICROB AGENTS CH, V42, P682, DOI 10.1128/AAC.42.3.682; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x; Pandey AV, 1997, FEBS LETT, V402, P236, DOI 10.1016/S0014-5793(96)01536-0; Ridley RG, 1997, ANN TROP MED PARASIT, V91, P559, DOI 10.1080/00034989760932; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	21	147	148	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31103	31107		10.1074/jbc.273.47.31103	http://dx.doi.org/10.1074/jbc.273.47.31103			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813011	hybrid			2022-12-25	WOS:000077136900039
J	Horvath, G; Serru, V; Clay, D; Billard, M; Boucheix, C; Rubinstein, E				Horvath, G; Serru, V; Clay, D; Billard, M; Boucheix, C; Rubinstein, E			CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION MOLECULE; MHC CLASS-II; B-LYMPHOCYTES; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; CELL-LINE; ANTIPROLIFERATIVE ANTIBODY-1; HOMOTYPIC ADHESION; COMPLEX; SURFACE	The CD19-CD21-CD81 complex regulates signal transduction events critical for B lymphocyte development and humoral immunity. CD81, a molecule with 4 trans membrane domains, member of the tetraspan superfamily, is engaged, together with other tetraspans such as CD9, CD53, CD63, and CD82, in multimolecular complexes containing beta(1) integrins and major histocompatibility complex antigens, Here we demonstrate that two other tetraspans, CD82 and the early B cell marker CD9, are coimmunoprecipitated with CD19 from Brij97 lysates of B cell lines. Moreover, CD9 was coprecipitated from lysates of purified CD10(+) early B cells. These associations were confirmed by the cocapping of CD19 with CD9 or CD82. The CD9/CD19 association was disrupted in the presence of digitonin, contrary to the CD81/CD19 association, indicating that CD9 and CD81 interact with CD19 in different ways. The CD9/CD81 association is also disrupted in the presence of digitonin, suggesting that CD9 associates with CD19 only through CD81. To characterize the regions involved in the CD81/CD19 association, two reciprocal CD9/CD81 chimeric molecules were tested for the association with CD19, but none of them could be coprecipitated with CD19 in digitonin, indicating that the domain of CD81 responsible for its association with CD19 is complex. Finally, engagement of CD9 could induce the tyrosine phosphorylation of different proteins, including CD19 itself, suggesting that the CD9/CD19 association is functionally relevant. Thus, a physical and functional link is formed between the CD19-CD21-CD81 complex and the integrin-tetraspan complexes, which is dynamically modulated in the process of B cell differentiation.	Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rubinstein, E (corresponding author), Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France.	erubin@infobiogen.fr	Rubinstein, Eric/B-4650-2019	Rubinstein, Eric/0000-0001-7623-9665; Boucheix, Claude/0000-0003-4184-7008				ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BOUCHEIX C, 1985, LEUKEMIA RES, V9, P597, DOI 10.1016/0145-2126(85)90139-0; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; IMAI T, 1993, J IMMUNOL, V151, P6470; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; ODUM N, 1991, EUR J IMMUNOL, V21, P2121, DOI 10.1002/eji.1830210921; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; RYAN DH, 1992, J IMMUNOL, V149, P3759; SATO S, 1995, P NATL ACAD SCI USA, V92, P11558, DOI 10.1073/pnas.92.25.11558; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; Szollosi J, 1996, J IMMUNOL, V157, P2939; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tsitsikov EN, 1997, P NATL ACAD SCI USA, V94, P10844, DOI 10.1073/pnas.94.20.10844; Xiao J, 1996, J BIOL CHEM, V271, P7659, DOI 10.1074/jbc.271.13.7659	38	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30537	30543		10.1074/jbc.273.46.30537	http://dx.doi.org/10.1074/jbc.273.46.30537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804823	hybrid			2022-12-25	WOS:000077008100070
J	Jahraus, A; Tjelle, TE; Berg, T; Habermann, A; Storrie, B; Ullrich, O; Griffiths, G				Jahraus, A; Tjelle, TE; Berg, T; Habermann, A; Storrie, B; Ullrich, O; Griffiths, G			In vitro fusion of phagosomes with different endocytic organelles from J774 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; MOUSE PERITONEAL-MACROPHAGES; GTP-BINDING-PROTEINS; MEMBRANE-FUSION; EARLY ENDOSOMES; HORSERADISH-PEROXIDASE; GDP/GTP EXCHANGE; VESICLE FUSION; RAB PROTEINS; LYSOSOMES	We describe novel biochemical and electron microscopy assays to investigate in vitro fusion of latex bead phagosomes with three different endocytic organelle fractions from J774 macrophages. After formation, early phagosomes fuse avidly with early and late endosomes and for a longer period of time with lysosomes, but they subsequently become fusion-incompetent. The fusion of early, but not late, phagosomes with all three endocytic fractions could be significantly stimulated by Rab5. In contrast to other cell types investigated, this Rab is uniquely enriched on both early and late endosomes in J774 macrophages. Moreover, exogenous Rab5 stimulates homotypic fusion between both sets of organelles. This was shown by a quantitative electron microscopy fusion assay that can directly assay fusion between any combination of morphologically defined organelles. By the same approach, we discovered an unexpected Rab5-stimulatable fusion between early and late endosomes in J774, but not in BHK cells. Thus, in J774 cells both Rab5 and the endocytic pathway seem to have evolved additional functions not yet seen in nonphagocytic cells.	European Mol Biol Lab, Cell Biol Programme, D-69012 Heidelberg, Germany; Univ Oslo, MCB, N-0136 Oslo, Norway; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany	European Molecular Biology Laboratory (EMBL); University of Oslo; Virginia Polytechnic Institute & State University; Johannes Gutenberg University of Mainz	Griffiths, G (corresponding author), European Mol Biol Lab, Cell Biol Programme, Postfach 102209, D-69012 Heidelberg, Germany.	griffiths@embl-heidelberg.de		Habermann, Anja/0000-0003-3686-9050				ALMERS W, 1994, NATURE, V367, P682; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; Blocker A, 1996, J BIOL CHEM, V271, P3803; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; Desjardins M, 1997, J CELL SCI, V110, P2303; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Diakonova M, 1997, J CELL SCI, V110, P1199; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Emans N, 1996, FEBS LETT, V398, P37, DOI 10.1016/S0014-5793(96)01213-6; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GABAY JE, 1986, BIOCHEM SOC T, V14, P256, DOI 10.1042/bst0140256; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Greenberg Steven, 1993, P941; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; GRIFFITHS G, 1991, TRENDS CELL BIOL, V1, P1; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HARDING CV, 1995, TRENDS CELL BIOL, V5, P105, DOI 10.1016/S0962-8924(00)88959-X; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; KIELIAN MC, 1980, J CELL BIOL, V85, P754, DOI 10.1083/jcb.85.3.754; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSZYCKI SS, 1994, SCIENCE, V263, P678; Laurent O, 1998, J BIOL CHEM, V273, P793, DOI 10.1074/jbc.273.2.793; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERESSE S, 1995, J CELL SCI, V108, P3349; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MULLER WA, 1980, J CELL BIOL, V86, P292, DOI 10.1083/jcb.86.1.292; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; Oh YK, 1996, J CELL BIOL, V132, P585, DOI 10.1083/jcb.132.4.585; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PITT A, 1992, J BIOL CHEM, V267, P126; RABINOVITCH M, 1995, TRENDS CELL BIOL, V5, P85, DOI 10.1016/S0962-8924(00)88955-2; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; RUSSELL DG, 1995, CURR OPIN IMMUNOL, V7, P479, DOI 10.1016/0952-7915(95)80092-1; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SHONN MA, 1995, MOL BIOL CELL S, V6, P272; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STOORVOGEL W, 1993, BIOCHEM SOC T, V21, P711, DOI 10.1042/bst0210711; STORRIE B, 1988, INT REV CYTOL, V111, P53, DOI 10.1016/S0074-7696(08)61731-3; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; SUNG SSJ, 1983, J CELL PHYSIOL, V116, P21, DOI 10.1002/jcp.1041160105; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; Tjelle TE, 1996, J CELL SCI, V109, P2905; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; WANG YL, 1987, J CELL BIOL, V104, P1749, DOI 10.1083/jcb.104.6.1749; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	85	96	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30379	30390		10.1074/jbc.273.46.30379	http://dx.doi.org/10.1074/jbc.273.46.30379			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804802	hybrid			2022-12-25	WOS:000077008100049
J	Jansen, G; Mauritz, R; Drori, S; Sprecher, H; Kathmann, I; Bunni, M; Priest, DG; Noordhuis, P; Schornagel, JH; Pinedo, HM; Peters, GJ; Assaraf, YG				Jansen, G; Mauritz, R; Drori, S; Sprecher, H; Kathmann, I; Bunni, M; Priest, DG; Noordhuis, P; Schornagel, JH; Pinedo, HM; Peters, GJ; Assaraf, YG			A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL LINE; BREAST-CANCER CELLS; THYMIDYLATE SYNTHASE; METHOTREXATE TRANSPORT; MAMMALIAN-CELLS; L1210 CELLS; MEMBRANE-TRANSPORT; MURINE L1210; ACQUIRED-RESISTANCE; LEUCOVORIN RESCUE	CEM/MTX is a subline of human CCRF-CEM leukemia cells which displays >200-fold resistance to methotrexate (MTX) due to defective transport via the reduced folate carrier (RFC). CEM/MTX-low folate (LF) cells, derived by a gradual deprivation of folic acid from 2.3 mu M to 2 nM (LF) in the cell culture medium of CEM/MTX cells, resulted in a >20-fold overexpression of a structurally altered RFC featuring; 1) a wild type K-m value for MTX transport but a 31-fold and 9-fold lower K-m values for folic acid and leucovorin, respectively, relative to wild type RFC; 2) a 10-fold RFC1 gene amplification along with a >20-fold increased expression of the main 3.1-kilobase RFC1 mRNA; 3) a marked stimulation of MTX transport by anions (i.e. chloride); and 4) a G --> A mutation at nucleotide 227 of the RFC cDNA in both CEM/MTX-LF and CEM/MTX, resulting in a lysine for glutamate substitution at amino acid residue 45 predicted to reside within the first transmembrane domain of the human RFC. Upon transfer of CEM/MTX-LF cells to folate replete medium (2.3 mu M folic acid), the more efficient folic acid uptake in CEM/MTX-LF cells resulted in a 7- and 24-fold elevated total folate pool compared with CEM and CEM/MTX cells, respectively (500 versus 69 and 21 pmol/mg of protein, respectively). This markedly elevated intracellular folate pool conferred a novel mechanism of resistance to polyglutamatable (e.g. ZD1694, DDATHF, and AG2034) and lipophilic antifolates (e.g. trimetrexate and pyrimethamine) by abolishing their polyglutamylation and circumventing target enzyme inhibition.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Free Univ Amsterdam Hosp, Dept Oncol, NL-1081 HV Amsterdam, Netherlands; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Netherlands Canc Inst, Dept Internal Med, NL-1066 CX Amsterdam, Netherlands	Technion Israel Institute of Technology; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical University of South Carolina; Netherlands Cancer Institute	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il	; Peters, Godefridus J/C-7562-2013	Jansen, Gerrit/0000-0001-8190-8368; Peters, Godefridus J/0000-0002-5447-2877				ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BOARMAN DM, 1992, CANCER RES, V52, P36; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; BRAAKHUIS BJM, 1993, BIOCHEM PHARMACOL, V46, P2155, DOI 10.1016/0006-2952(93)90604-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; BUNNI MA, 1994, CANCER CHEMOTH PHARM, V34, P455, DOI 10.1007/BF00685654; DIXON KH, 1994, J BIOL CHEM, V269, P17; DUCH DS, 1993, CANCER RES, V53, P810; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREISHEIM JH, 1992, ADV ENZYME REGUL, V32, P17; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; Hanlon MH, 1996, CANCER RES, V56, P3301; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1986, CANCER RES, V46, P1633; Jackman AL, 1995, ANN ONCOL, V6, P871, DOI 10.1093/oxfordjournals.annonc.a059353; Jackman AL, 1997, CLIN CANCER RES, V3, P911; JACKMAN AL, 1995, BRIT J CANCER, V71, P914, DOI 10.1038/bjc.1995.178; JANSEN G, 1992, ONCOL RES, V4, P299; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1991, CANCER CHEMOTH PHARM, V28, P115, DOI 10.1007/BF00689699; JANSEN G, 1990, J BIOL CHEM, V265, P18272; Jansen G, 1998, DRUG RESIST UPDATE, V1, P211, DOI 10.1016/S1368-7646(98)80042-3; JANSEN G, 1997, PTERIDINES, V8, P116; JOLIVET J, 1994, BIOCHEM PHARMACOL, V47, P659, DOI 10.1016/0006-2952(94)90128-7; LIN JT, 1991, CANCER INVEST, V9, P159, DOI 10.3109/07357909109044227; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MATHERLY LH, 1995, DRUG TRANSPORT ANTIM, P453; MCGUIRE JJ, 1993, LEUKEMIA, V7, P1996; MINI E, 1985, CANCER RES, V45, P325; MOLTHOFF CF, 1992, J NUCL MED, V33, P2000; MOSCOW JA, 1995, CANCER RES, V55, P3790; OCONNOR BM, 1991, CANCER RES, V51, P3874; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAVLOVIC M, 1993, ADV EXP MED BIOL, V338, P775; Pavlovic Mirjana, 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P21; Peters GJ, 1996, EXPERT OPIN INV DRUG, V5, P637; Pinard MF, 1996, CANCER CHEMOTH PHARM, V38, P281, DOI 10.1007/s002800050483; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRIEST DG, 1991, J NATL CANCER I, V83, P1806, DOI 10.1093/jnci/83.24.1806; Ratnam M., 1990, FOLIC ACID METABOLIS, P91; RHEE MS, 1994, MOL PHARMACOL, V45, P783; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; Sharif KA, 1998, BIOCHEM PHARMACOL, V55, P1683, DOI 10.1016/S0006-2952(98)00039-2; Shemer G., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P431; SHEN DW, 1986, MOL CELL BIOL, V6, P4039, DOI 10.1128/MCB.6.11.4039; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, NATL CANCER I MONOGR, V5, P127; SPRECHER H, 1995, J BIOL CHEM, V270, P20668, DOI 10.1074/jbc.270.35.20668; SPRECHER H, 1996, P AM ASSOC CANC RES, V37, P2601; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; VANDERWILT CL, 1992, CANCER RES, V52, P4922; WEITMAN SD, 1992, CANCER RES, V52, P3396; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; WESTERHOF GR, 1995, CANCER RES, V55, P3795; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Wong SC, 1998, BIOCHEM PHARMACOL, V55, P1135, DOI 10.1016/S0006-2952(97)00639-4; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	79	143	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30189	30198		10.1074/jbc.273.46.30189	http://dx.doi.org/10.1074/jbc.273.46.30189			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804775	hybrid			2022-12-25	WOS:000077008100022
J	Lea, SM; Powell, RM; McKee, T; Evans, DJ; Brown, D; Stuart, DI; van der Merwe, PA				Lea, SM; Powell, RM; McKee, T; Evans, DJ; Brown, D; Stuart, DI; van der Merwe, PA			Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; BINDING; COMPLEMENT; RHINOVIRUS; DOMAINS; ICAM-1; BIOSENSOR; PROTEIN; CLONING	The biochemical properties of the molecular interactions mediating viral-cell recognition are poorly characterized. In this study, we use surface plasmon resonance to study the affinity and kinetics of the interaction of echovirus 11 with its cellular receptor decay-accelerating factor (CD55). As reported for interactions between cell-cell recognition molecules, the interaction has a low affinity (K-D similar to 3.0 mu m) as a result of a very fast dissociation rate constant (k(on) similar to 10(5) m(-1). s(-1), k(off) -0.3 s(-1)). This contrasts with the interaction of soluble ICAM-1 (sICAM-1, CD54) with human rhinovirus 3 which has been reported to have a similar affinity but 10(2)-10(3)-fold slower kinetics (Casasnovas, J. M., and Springer, T. A (1995) J. Biol. Chem. 270, 13216-13224). The extracellular portion of decay-accelerating factor comprises four short consensus repeat domains (domains 1-4) and a mucin-like stalk. By comparison of the binding affinity for echovirus 11 of various fragments of decay-accelerating factor, we are able to conclude that short consensus repeat domain 3 contributes similar to 80% of the binding energy.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Reading, Sch Anim & Microbial Sci, Virol Res Grp, Reading RG6 5AJ, Berks, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Oxford Ctr Mol Sci, New Chem Lab, Oxford OX1 3QT, England; Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England	University of Oxford; University of Reading; University of Cambridge; University of Oxford; University of Oxford	Lea, SM (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	susan@biop.ox.ac.uk	van der Merwe, P. Anton/F-8539-2011; Evans, David/C-7553-2012; Lea, Susan M/B-7678-2009	Lea, Susan M/0000-0001-9287-8053; McKee, Thomas/0000-0002-2147-3136; Stuart, David/0000-0002-3426-4210; Evans, David J./0000-0002-1315-4258	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BERNHARDT G, 1994, VIROLOGY, V203, P344, DOI 10.1006/viro.1994.1493; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; COYNE KE, 1992, J IMMUNOL, V149, P2906; Daniels GL, 1998, TRANSFUSION, V38, P332, DOI 10.1046/j.1537-2995.1998.38498257370.x; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Melnick J.L, 1996, FIELDS VIROLOGY; NICHOLSONWELLER A, 1994, J LAB CLIN MED, V123, P485; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Schuck P, 1996, BIOPHYS J, V70, P1230, DOI 10.1016/S0006-3495(96)79681-9; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x	24	62	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30443	30447		10.1074/jbc.273.46.30443	http://dx.doi.org/10.1074/jbc.273.46.30443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804811	hybrid			2022-12-25	WOS:000077008100058
J	Weitzmann, MN; Woodford, KJ; Usdin, K				Weitzmann, MN; Woodford, KJ; Usdin, K			The mouse Ms6-hm hypervariable microsatellite forms a hairpin and two unusual tetraplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INSULIN GENE; DNA-STRUCTURE; SECONDARY STRUCTURES; MINISATELLITE LOCUS; SOMATIC MUTATION; QUADRUPLEX DNA; TANDEM ARRAYS; HUMAN-DISEASE; SEQUENCE; PROTEIN	The mouse Ms6-hm microsatellite consists of a tandem array of the pentamer d(CAGGG)(n). This microsatellite is extremely hypervariable, showing a germ line mutation rate of 2.5%/gamete. The mechanism responsible for this instability is not known. The ability to form intrastrand structures is a conserved feature of many hypervariable sequences, and it has been suggested that the formation of such structures might account for instability by affecting DNA replication, repair, or recombination. Here we show that this microsatellite is able to form intrastrand structures as well. Under physiological conditions, the Ms6-hm microsatellite forms a hairpin as well as two different unusual intrastrand tetraplexes. The hairpin forms in the absence of monovalent cation and contains G.A, G.C, and G.G base pairs in a 1:1:1 ratio. In the presence of K+, a tetraplex is formed in which the adenines are unpaired and extrahelical, and the cytosines are involved in C.C pairs. In Na+, a tetraplex forms that contains C.C+ pairs, with the adenines being intrahelical and hydrogen-bonded to guanines. Tetraplex formation in the presence of Na+ requires both cytosines and adenines and might reflect the altered internal dimensions of this tetraplex, perhaps resulting from the ability of the C.C+ pairs to become intercalated in this sequence context. Our demonstration of the stabilization of tetraplexes by hydrogen bonding between adenines and guanines expands the hydrogen-bonding possibilities for tetraplexes and suggests that the category of sequences with tetraplex-forming potential may be larger than previously appreciated.	NIDDK, Sect Genom Struct & Funct, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Usdin, K (corresponding author), NIDDK, Sect Genom Struct & Funct, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 202,8 Ctr Dr,MSC 0830, Bethesda, MD 20892 USA.	ku@helix.nih.gov						AHMED S, 1994, NAT STRUCT BIOL, V1, P83, DOI 10.1038/nsb0294-83; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; Boulard Y, 1997, J MOL BIOL, V268, P331, DOI 10.1006/jmbi.1997.0975; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; HAMMONDKOSACK MCU, 1993, J MOL ENDOCRINOL, V10, P121, DOI 10.1677/jme.0.0100121; HAMMONDKOSACK MCU, 1992, J MOL ENDOCRINOL, V9, P221, DOI 10.1677/jme.0.0090221; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HORN GT, 1991, NUCLEIC ACIDS RES, V19, P4772, DOI 10.1093/nar/19.17.4772; Howell R, 1997, MOL BIOL EVOL, V14, P144, DOI 10.1093/oxfordjournals.molbev.a025747; Howell RM, 1996, J BIOL CHEM, V271, P5208; Hud NV, 1996, BIOCHEMISTRY-US, V35, P15383, DOI 10.1021/bi9620565; KELLY R, 1991, P ROY SOC B-BIOL SCI, V245, P235, DOI 10.1098/rspb.1991.0115; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; LEE JS, 1980, NUCLEIC ACIDS RES, V8, P4305, DOI 10.1093/nar/8.18.4305; LEONARD NJ, 1971, BIOCHEMISTRY-US, V10, P3335, DOI 10.1021/bi00794a003; LEONARD NJ, 1984, CRC CR REV BIOCH MOL, V15, P125, DOI 10.3109/10409238409102299; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; NAGESH N, 1995, J BIOCHEM BIOPH METH, V30, P1, DOI 10.1016/0165-022X(94)00057-K; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEELA F, 1987, BIOCHEMISTRY-US, V26, P2232, DOI 10.1021/bi00382a024; SEELA F, 1989, BIOCHEMISTRY-US, V28, P6193, DOI 10.1021/bi00441a010; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Usdin K, 1998, NUCLEIC ACIDS RES, V26, P4078, DOI 10.1093/nar/26.17.4078; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WEISMANSHOMER P, 1994, BIOCHEM BIOPH RES CO, V205, P305, DOI 10.1006/bbrc.1994.2665; Weitzmann MN, 1996, J BIOL CHEM, V271, P20958, DOI 10.1074/jbc.271.34.20958; Weitzmann MN, 1997, J BIOL CHEM, V272, P9517; WILLARD HF, 1989, GENOME, V31, P737, DOI 10.1139/g89-132; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029	41	24	25	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30742	30749		10.1074/jbc.273.46.30742	http://dx.doi.org/10.1074/jbc.273.46.30742			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804850	hybrid			2022-12-25	WOS:000077008100097
J	Yuan, T; Vogel, HJ				Yuan, T; Vogel, HJ			Calcium-calmodulin-induced dimerization of the carboxyl-terminal domain from petunia glutamate decarboxylase - A novel calmodulin-peptide interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; 2-DIMENSIONAL NMR-SPECTROSCOPY; PULSED-FIELD GRADIENTS; NITRIC-OXIDE SYNTHASE; BINDING DOMAIN; PHOSPHORYLASE-KINASE; CENTRAL HELIX; CA2+ BINDING; CALDESMON; RECOGNITION	The acidic, bilobed protein calmodulin (CaM; molecular mass of 16.7 kDa) can activate some 40 distinct proteins in a calcium-dependent manner. The majority of the CaM-binding domain regions of the target proteins are basic and hydrophobic in nature, are devoid of multiple negatively charged residues, and have a propensity to form an alpha-helix. The CaM-binding domain in the C-terminal region of petunia glutamate decarboxylase (PGD) is atypical because it contains five negatively charged residues. Therefore, we chose to study the binding of calcium-CaM to a as-residue synthetic peptide encompassing the C-terminaI region of PGD. Gel band shift assays, fluorescence spectroscopy, and NMR titration studies showed that a single unique complex of calcium-CaM with two PGD peptides is formed. The formation of a 1:2 protein-peptide complex is unusual; normally, calcium-CaM forms 1:1 complexes with the majority of its target proteins. Circular dichroism spectroscopy showed that the bound PGD peptides have an alpha-helical structure. NMR studies of biosynthetically [methyl-C-13]methionine-labeled CaM revealed that all the Met side chains in CaM are involved in the binding of the PGD peptides. Analysis of fluorescence spectra showed that the single Trp residue of the two peptides becomes bound to the N- and C-terminal lobes of CaM. These results predict that binding of calcium-CaM to PGD will give rise to dimerization of the protein, which may be necessary for activation. Possible models for the structure of the protein-peptide complex, such as a dimeric peptide structure, are discussed.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.							ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAUM G, 1993, J BIOL CHEM, V268, P19610; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAVIS AL, 1991, J MAGN RESON, V94, P637, DOI 10.1016/0022-2364(91)90154-L; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Graether SP, 1997, BIOCHEMISTRY-US, V36, P364, DOI 10.1021/bi962008k; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; Huber PAJ, 1996, BIOCHEM J, V316, P413, DOI 10.1042/bj3160413; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JUMINAGA D, 1994, J BIOL CHEM, V269, P1660; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kuhlman B, 1997, J MOL BIOL, V270, P640, DOI 10.1006/jmbi.1997.1146; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MAYR GW, 1984, EUR J BIOCHEM, V143, P513, DOI 10.1111/j.1432-1033.1984.tb08400.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P1179, DOI 10.1021/bi00004a011; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Sackett DL, 1996, J BIOL CHEM, V271, P9987, DOI 10.1074/jbc.271.17.9987; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; Smith JS, 1998, BIOCHEMISTRY-US, V37, P33, DOI 10.1021/bi972026h; SNEDDEN WA, 1995, PLANT PHYSIOL, V108, P543, DOI 10.1104/pp.108.2.543; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; Sorensen BR, 1998, BIOCHEMISTRY-US, V37, P4244, DOI 10.1021/bi9718200; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WIDER G, 1993, J MAGN RESON SER B, V102, P239, DOI 10.1006/jmrb.1993.1092; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YUAN T, 1995, BIOCHEMISTRY-US, V34, P10690, DOI 10.1021/bi00033a045; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P10883, DOI 10.1021/bi00202a006; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; Zhang MJ, 1997, PROTEIN PEPTIDE LETT, V4, P291; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; Zhou N, 1997, BIOCHEMISTRY-US, V36, P2817, DOI 10.1021/bi9625713	59	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30328	30335		10.1074/jbc.273.46.30328	http://dx.doi.org/10.1074/jbc.273.46.30328			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804795	hybrid			2022-12-25	WOS:000077008100042
J	George, CH; Kendall, JM; Campbell, AK; Evans, WH				George, CH; Kendall, JM; Campbell, AK; Evans, WH			Connexin-aequorin chimerae report cytoplasmic calcium environments along trafficking pathways leading to gap junction biogenesis in living COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED RECOMBINANT AEQUORIN; ENDOPLASMIC-RETICULUM; INTERCELLULAR COMMUNICATION; HELA-CELLS; CA2+ CONCENTRATION; PROTEIN; MEMBRANE; EXPRESSION; PERMEABILITY; TRANSPORT	The cytoplasmic calcium environments along membrane trafficking pathways leading to gap junction intercellular communication channels at the plasma membrane were studied. Connexins, the constitutive proteins of gap junctions, were fused at their carboxyl terminus to the calcium-sensitive photoprotein aequorin. The cellular location of the chimeric proteins was determined by immunolocalization and subcellular fractionation. The generation of functional gap junctions by the connexin chimerae was monitored by the ability of the cells to exchange small dyes. Although aequorin fused to connexin-26 was nonfunctional, its ability to report Ca2+ and to form functional gap junctions was rescued by replacement of its cytoplasmic carboxyl tail with that of connexin-43. In COS-7 cells expressing these connexin-aequorin chimerae, calcium levels below the plasma membrane were higher (similar to 5 mu M) than those in the cytoplasm (similar to 100 nM); gap junctions were able to transfer dyes under these conditions. Cytoplasmic levels of free calcium surrounding the ERGIC/Golgi reported by connexin-43 chimera (similar to 420 nM) were twice those measured by connexin-32 chimera (similar to 200 nM); both chimerae measured calcium levels substantially higher than those reported by a connexin-26 chimera (similar to 130 nM). Dispersion of the ERGIC and Golgi complex by brefeldin A led to a marked reduction in calcium levels. The results show that the various connexin chimerae were located in spatially different subcellular stores and that the ERGIC/Golgi regions of the cell maintain heterogeneous cytoplasmic domains of calcium. The implications of the subplasma-membrane Ca2+ levels on the gating of gap junctions are discussed.	Univ Wales Coll Med, Dept Biochem Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	George, CH (corresponding author), Univ Wales Coll Med, Dept Biochem Med, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Campbell, Anthony K/N-5855-2014	Campbell, Anthony K/0000-0002-2506-5500; George, Christopher/0000-0001-9852-1135				Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BECKER DL, 1995, J CELL SCI, V108, P1455; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Blinks J.R., 1978, Methods in Enzymology, V57, P292; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Bolsover SR, 1996, CELL CALCIUM, V20, P373, DOI 10.1016/S0143-4160(96)90043-3; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRUZZONE R, 1994, J CELL SCI, V107, P955; BUDUNOVA IV, 1994, CANCER J - FRANCE, V7, P228; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Cao FL, 1998, J CELL SCI, V111, P31; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CROW JM, 1994, INVEST OPHTH VIS SCI, V35, P3332; DAGUZAN C, 1995, INT J DEV BIOL, V39, P653; Diez JA, 1998, GAP JUNCTIONS, P130; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; George CH, 1998, BIOCHEM BIOPH RES CO, V247, P785, DOI 10.1006/bbrc.1998.8835; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HIGH S, 1997, MOL B INT U, P119; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; Kendall JM, 1998, TRENDS BIOTECHNOL, V16, P216, DOI 10.1016/S0167-7799(98)01184-6; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; LAZRAK A, 1993, BIOPHYS J, V65, P2002, DOI 10.1016/S0006-3495(93)81242-6; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; Peracchia C, 1996, PFLUG ARCH EUR J PHY, V431, P379, DOI 10.1007/BF02207275; Ponnambalam S, 1996, J CELL SCI, V109, P675; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; Pouli AE, 1998, BIOCHEM J, V330, P1399; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Torok K, 1997, BIOCHEM J, V326, P479; UNWIN PNT, 1983, J CELL BIOL, V97, P1459, DOI 10.1083/jcb.97.5.1459; WAHL M, 1992, J CELL PHYSIOL, V150, P593, DOI 10.1002/jcp.1041500321; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	61	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29822	29829		10.1074/jbc.273.45.29822	http://dx.doi.org/10.1074/jbc.273.45.29822			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792698	Green Accepted, hybrid			2022-12-25	WOS:000076798300075
J	Hendricks, SP; Mathews, CK				Hendricks, SP; Mathews, CK			Allosteric regulation of vaccinia virus ribonucleotide reductase, analyzed by simultaneous monitoring of its four activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; RECOMBINANT MOUSE; BACTERIOPHAGE-T4; PURIFICATION; EFFECTORS; MUTANTS; CELLS; GENE	As determined by simultaneous monitoring of its four activities, vaccinia virus-coded ribonucleoside diphosphate (rNDP) reductase shows responses to individual nucleoside triphosphate effectors-ATP, dATP, dGTP, and dTTP-similar to those previously reported for rNDP reductase of mouse, which the viral enzyme closely resembles. This investigation uses the vaccinia enzyme as a readily available and convenient model for understanding the cellular enzyme. As previously reported for T4 phage aerobic rNDP reductase, we found the relative activities of ADP, CDP, GDP, and UDP reduction to be reasonably close to the proportions of the four deoxyribonucleotides in the vaccinia virus genome, but only when the four substrates and the four allosteric effecters were all provided at their approximate intracellular concentrations. GDP reductase levels were somewhat higher, proportionately, than the representation of dGMP in vaccinia virus DNA. To understand this behavior and also to evaluate possible relationships between ribonucleotide reductase control and the very low dGTP pools seen in eukaryotic cells, we carried out substrate saturation experiments with a "bioproportional" mixture containing the four rNDP substrates at their relative in vivo concentrations as determined from rNDP pool measurements. Reduction of the two purine substrates was inhibited at high concentrations of this mixture, and data suggest that ADP acts as a specific inhibitor of its own reduction and that of GDP. Use of the four-substrate assay revealed also that a mixture of vaccinia virus R1 protein and mouse R2 protein is catalytically active, making this the first reported chimeric rNDP reductase to show biological activity.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@ucs.orst.edu			NIGMS NIH HHS [GM-55234] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; CHANG CH, 1979, CANCER RES, V39, P5081; CORY JG, 1985, J BIOL CHEM, V260, P2001; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; Hauschka P V, 1973, Methods Cell Biol, V7, P361; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; Hendricks SP, 1998, J BIOL CHEM, V273, P29519, DOI 10.1074/jbc.273.45.29519; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HOWELL ML, 1993, J BIOL CHEM, V268, P7155; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; SJOBERG BM, 1997, STRUCT BOND, V88, P140; SLABAUGH M, 1988, J VIROL, V62, P519, DOI 10.1128/JVI.62.2.519-527.1988; SLABAUGH MB, 1993, J BIOL CHEM, V268, P17803; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; TENGELSON LA, 1988, VIROLOGY, V164, P7426; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	26	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29512	29518		10.1074/jbc.273.45.29512	http://dx.doi.org/10.1074/jbc.273.45.29512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792658	hybrid			2022-12-25	WOS:000076798300035
J	Jones, PC; Fillingame, RH				Jones, PC; Fillingame, RH			Genetic fusions of subunit c in the F-0 sector of H+-transporting ATP synthase - Functional dimers and trimers and determination of stoichiometry by cross-linking analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+/ATP COUPLING RATIO; ESCHERICHIA-COLI F1F0; PROTON TRANSLOCATION; MOLECULAR MACHINE; COMPLEX; F1-ATPASE; ROTATION; DUPLICATION; MICROSCOPY; EVOLUTION	The multicopy c subunit of the H+-transporting ATP synthase of Escherichia coli folds through the transmembrane F-0 sector as a hairpin of two hydrophobic alpha-helices with the proton-translocating aspartyl-61 side chain centered in the second transmembrane helix. The number of subunits c in the F-0 complex, which is thought to determine the H+-pumping/ATP stoichiometry, was previously not determined with exactness but thought to range from 9-12. The studies described here indicate that the exact number is 12. Based upon the precedent of the subunit c in vacuolar-type ATPases, which are composed of four transmembrane helices and seem to have evolved by gene duplication of an F-0-type progenitor gene, we constructed genetically fused dimers and trimers off. coli subunit c. Both the dimeric and trimeric forms proved to be functional. These results indicate that the total number of subunit c in F-0 should be a multiple of 2 and 3. Based upon a previous study in which the oligomeric organization of c subunits in F-0 was determined by cross-linking of Cys-substituted subunits (Jones, P. C., Jiang, W., and Fillingame, R. H. (1998) J. Biol. Chem. 273, 17178-17185), we introduced Cys into the first and last transmembrane helices of subunit c monomers, dimers, and trimers and attempted to generate cross-linked products by oxidation with Cu(II)-(1,10-phenanthroline)(2). Double Cys substitutions at two sets of positions gave rise to extensive cross linked multimers. Multimers of the monomer that extended up to the position of c(12) were correlated and calibrated with distinct cross-linked species of the appropriate doubly Cys-substituted dimers (i.e. c(2), c(4)...c(12)) and doubly Cys-substituted trimers (i.e. c(3), c(6), c(9), c(12)). The results show that there are 12 copies of subunit c per F-0 in E. coli, the exact number having both mechanistic and structural significance.	Univ Wisconsin, Dept Biolmol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biolmol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Berry S, 1996, BBA-BIOENERGETICS, V1276, P51, DOI 10.1016/0005-2728(96)00031-X; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Nicholls DG., 1992, BIOENERGETICS 2; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VanWalraven HS, 1996, FEBS LETT, V379, P309, DOI 10.1016/0014-5793(95)01536-1; VIK SB, 1994, J BIOL CHEM, V269, P30364; von Meyenburg K, 1982, Tokai J Exp Clin Med, V7 Suppl, P23; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	34	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29701	29705		10.1074/jbc.273.45.29701	http://dx.doi.org/10.1074/jbc.273.45.29701			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792682	hybrid			2022-12-25	WOS:000076798300059
J	Schwientek, T; Almeida, R; Levery, SB; Holmes, EH; Bennett, E; Clausen, H				Schwientek, T; Almeida, R; Levery, SB; Holmes, EH; Bennett, E; Clausen, H			Cloning of a novel member of the UDP-galactose :beta-N-acetylglucosamine beta 1,4-galactosyltransferase family, beta 4Gal-T4, involved in glycosphingolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; OLIGOSACCHARIDE SYNTHESIS; ACCEPTOR SPECIFICITY; GENOMIC STRUCTURE; GENE; LACTALBUMIN; EXPRESSION; ACETYLGALACTOSAMINYLTRANSFERASE	A novel putative member of the human UDP-galactose:beta-N-acetylglucosamine beta 1,4-galactosyltransferase family, designated beta 4Gal-T4, was identified by BLAST analysis of expressed sequence tags. The sequence of beta 4Gal-T4 encoded a type II membrane protein with significant sequence similarity to other beta 1,4-galactosyltransferases. Expression of the full coding sequence and a secreted form of beta 4Gal-T4 in insect cells showed that the gene product had beta 1,4 galactosyltransferase activity. Analysis of the substrate specificity of the secreted form revealed that the enzyme catalyzed glycosylation of glycolipids with terminal beta-GlcNAc; however, in contrast to beta 4Gal-T1, -T2, and -T3, this enzyme did not transfer galactose to asialo-agalacto-fetuin, asialo-agalactotransferrin, or ovalbumin. The catalytic activity of beta 4Gal-T4 with monosaccharide acceptor substrates, N-acetylglucosamine as well as glucose, was markedly activated in the presence of alpha-lactalbumin. The genomic organization of the coding region of beta 4Gal-T4 was contained in six exons. All intron/exon boundaries were similarly positioned in beta 4Gal-T1, -T2, and -T3. beta 4Gal-T4 represents a new member of the beta 4-galactosyltransferase family. Its kinetic parameters suggest unique functions in the synthesis of neolactoseries glycosphingolipids.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Porto, Portugal; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Northwest Hosp, Seattle, WA 98125 USA	University of Copenhagen; Universidade do Porto; University System of Georgia; University of Georgia	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	henrik.clausen@odont.ku.dk	Almeida, Raquel/B-9647-2012; Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021	Almeida, Raquel/0000-0002-5622-1633; Bennett, Eric/0000-0002-4976-0647; 	NATIONAL CANCER INSTITUTE [R01CA070740, R01CA066234, R01CA041521] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA70740, 1 RO1 CA66234, R01 CA41521] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; [Anonymous], 1977, Lipids, V12, P455; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BELL JE, 1976, J BIOL CHEM, V251, P3003; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BEYER TA, 1979, J BIOL CHEM, V254, P2531; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; DO KY, 1994, J BIOL CHEM, V269, P23456; GROBLER JA, 1994, J BIOL CHEM, V269, P5106; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P1069, DOI 10.1021/bi00119a016; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Neeleman AP, 1996, P NATL ACAD SCI USA, V93, P10111, DOI 10.1073/pnas.93.19.10111; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POWELL JT, 1976, J BIOL CHEM, V251, P3653; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; RODEN L, 1966, J BIOL CHEM, V241, P5949; RODEN L, 1981, BIOCH GLYCOPROTEINS, P267; Sato T, 1998, BIOCHEM BIOPH RES CO, V244, P637, DOI 10.1006/bbrc.1998.8327; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; Shaper NL, 1997, J BIOL CHEM, V272, P31389, DOI 10.1074/jbc.272.50.31389; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHUR BD, 1982, J BIOL CHEM, V257, P6871; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TORRES CR, 1984, J BIOL CHEM, V259, P3308; VandenEijnden DH, 1997, BIOCHEM SOC T, V25, P887, DOI 10.1042/bst0250887; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YET MG, 1988, J BIOL CHEM, V263, P111	57	82	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29331	29340		10.1074/jbc.273.45.29331	http://dx.doi.org/10.1074/jbc.273.45.29331			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792633	hybrid			2022-12-25	WOS:000076798300010
J	Wang, SG; Farley, RA				Wang, SG; Farley, RA			Valine 904, tyrosine 898, and cysteine 908 in Na,K-ATPase alpha subunits are important for assembly with beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE COMPLEXES; GASTRIC H+,K+-ATPASE; OUABAIN BINDING; FUNCTIONAL EXPRESSION; DISTAL COLON; AMINO-ACIDS; IDENTIFICATION; NA+,K+-ATPASE; KIDNEY; YEAST	A 26-amino acid sequence in an extracellular loop of the Na,K-ATPase cy subunit between membrane-spanning segments 7 and 8 has been shown to bind to the beta subunit of Na,K-ATPase and to promote alpha beta assembly (Lemas, M.V., Hamrick, M., Takeyasu, K, and Fambrough, D. M. (1994) J. Biol. Chem. 269, 8255-8259) When this as-amino acid sequence of the rat Na,K-ATPase alpha 3 subunit was replaced by the corresponding sequence of the rat gastric H,K-ATPase alpha subunit, the chimeric alpha subunit assembled preferentially with the rat gastric H,K-ATPase beta subunit (Wang, S.-G., Eakle, K. A., Levenson, R., and Farley, R. A. (1997) Am. J. Physiol. 272, C923-C930). In the present study, these 26 amino acids (Asn(886)-Ala(911)) of rat Na,K-ATPase alpha 3 were replaced by the corresponding amino acids Asn(908)-Ala(933) of rat distal colon H,K-ATPase. Site-directed mutagenesis of the chimeric alpha subunits and Na,K-ATPase alpha 3 showed that Val(904), Tyr(898), and Cys(908) in the Na,K-ATPase alpha 3 subunit are key residues in cup subunit interactions. The V904Q mutation in Na,IF-ATPase alpha 3 reduced the B-max for ouabain binding and the ATPase activity of alpha 3 beta 1 complexes by similar to 95%, and Y898R reduced the B-max and ATPase activity by similar to 60%. The complementary mutations Q904V and R898Y increased the amount of ouabain bound by yeast membranes expressing the chimera with the colon H,K-ATPase sequence. The amount of ouabain bound by complexes assembled between Na,K-ATPase alpha 3 containing the Y898R, C908G mutations and gastric H,K-ATPase beta was less than 10% of wild type Na,K-ATPase alpha 3 expressed with the same beta subunit. The R898Y,G908C mutations in the chimeric alpha subunits also increased ouabain binding.	Univ So Calif, Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Farley, RA (corresponding author), Univ So Calif, Sch Med, Dept Physiol & Biophys, 1333 San Pablo St,MMR 250, Los Angeles, CA 90033 USA.				NIGMS NIH HHS [GM-28673] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; Wang SG, 1997, AM J PHYSIOL-CELL PH, V272, pC923, DOI 10.1152/ajpcell.1997.272.3.C923	21	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29400	29405		10.1074/jbc.273.45.29400	http://dx.doi.org/10.1074/jbc.273.45.29400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792642	hybrid			2022-12-25	WOS:000076798300019
J	Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M				Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M			AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene	ONCOGENE			English	Article						transcription factor; hematopoiesis; AML1; PEBP2 beta/CBF beta; PU.1; RT-PCR; gene targeting	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FACTOR-RECEPTOR PROMOTER; DNA-BINDING; AML1 GENE; FUSION TRANSCRIPT; C-MYB	The AML1 and PEBP2 beta/CBF beta genes encode the DNA-binding and non-binding subunits, respectively, of the heterodimeric transcription factor, PEBP2/CBF. Targeting each gene results in an almost identical phenotype, namely the complete lack of definitive hematopoiesis in the fetal liver on embryonic day 11.5 (E11.5). We examined and compared the expression levels of various hematopoiesis-related genes in wild type embryos and in embryos mutated for AML1 or PEBP2 beta/CBF beta. The RNAs were prepared from the yolk sacs of E9.5 embryos, from the aorta-gonad- mesonephros regions of E11.5 embryos and from the livers of E11.5 embryos and RT-PCR was performed to detect various gene transcripts. Transcripts were detected for most of the hematopoiesis-related genes that encode transcription factors, cytokines and cytokine receptors, even in tissues from homozygously targeted embryos. On the other hand, PU.1 transcripts were never detected in any tissue of AML1(-/-) or PEBP2 beta/CBF beta(-/-) embryos. In addition, transcripts for the Vav, flk-2/flt-3, M-CSF receptor, G-CSF receptor and c-Myb genes were not detected in certain tissues of the (-/-) embryos. The results suggest that the expression of a particular set of hematopoiesis-related genes is closely correlated with the PEBP2/CBF function.	Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 108, Japan; Human Genome Sci Inc, Rockville, MD 20850 USA; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 606, Japan	Tohoku University; Tohoku University; Japanese Foundation for Cancer Research; University of Tokyo; GlaxoSmithKline; Human Genome Sciences Inc; Kyoto University	Satake, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLANAHAN T, 1993, BLOOD, V81, P2903; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	53	108	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2287	2293		10.1038/sj.onc.1202151	http://dx.doi.org/10.1038/sj.onc.1202151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811459				2022-12-25	WOS:000076723300002
J	Inoue, K; Sherr, CJ; Shapiro, LH				Inoue, K; Sherr, CJ; Shapiro, LH			Regulation of the CD13/aminopeptidase N gene by DMP1, a transcription factor antagonized by D-type cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS PROTEINS COOPERATE; HUMAN AMINOPEPTIDASE-N; NOCICEPTIN/ORPHANIN FQ; ESTROGEN-RECEPTOR; CELL-CYCLE; MYB; ACTIVATION; BINDING; METABOLISM; CD13	The binding of the Myb-like DMP1 transcription factor to DNA consensus sequences [CCCG(G/T)ATGT] in artificial promoters is antagonized by D-type cyclins with no requirement for their catalytic partners, cyclin-dependent kinase (CDK) 4 and CDK6. The subset of DMP1 binding sites containing the GGA core can bind Ets family transcription factors Ets-l and Ets-a. Screening of a series of natural promoters revealed that the CD13/aminopeptidase N (APN; EC 3.4.11.2) promoter could bind and be activated by DMP1. Activation of CD13/APN required both the intact DNA binding and transactivation domains of DMP1 and was inhibited by D-type cyclins, but not by cyclins A, B, C, or H, in a CDK-independent manner, CD13/APN is transactivated by a cooperative interaction between c-Myb bound to its cognate site and Ets-l tethered to one of three GGA core-containing sites located 30-50 base pairs downstream. DMP1 binds to one of the Ets binding sites (designated Ets C) and synergizes with c-Myb in activating CD13/APN expression. Analysis of nuclear lysates from KG1a early myeloid cells using an oligonucleotide probe containing only the DMP1/Ets C binding site indicated that endogenous DMP1 and a putative Ets family member bind this element in vivo. DMP1-DNA complexes were significantly more stable than those containing the Ets factor. These data indicate that two different Myb family proteins collaborate in regulating APN gene expression and point to a role for DMP1 in normal myeloid cell development.	St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital	Shapiro, LH (corresponding author), St Jude Childrens Res Hosp, Dept Expt Oncol, 332 N Lauderdale, Memphis, TN 38105 USA.	linda.shapiro@stjude.org	Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206	NCI NIH HHS [CA-70909, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070909, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHMUN RA, 1995, LEUHOCYTE TYPING, V5, P771; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FALK K, 1994, IMMUNOGENETICS, V39, P230; FUJII H, 1995, CLIN EXP METASTAS, V13, P337; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HOGG N, 1987, LEUCOCYTE TYPING, V3, P576; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; KATO J, 1993, GENE DEV, V7, P331; Konkoy CS, 1996, EUR J PHARMACOL, V297, P47, DOI 10.1016/0014-2999(95)00827-6; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LUCIUS R, 1995, J NEUROCHEM, V64, P1841; MATSAS R, 1984, FEBS LETT, V175, P124, DOI 10.1016/0014-5793(84)80583-9; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; MENRAD A, 1993, CANCER RES, V53, P1450; Montiel JL, 1997, J NEUROCHEM, V68, P354; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Noble F, 1997, FEBS LETT, V401, P227, DOI 10.1016/S0014-5793(96)01476-7; Ptashne M, 1997, NAT MED, V3, P1069, DOI 10.1038/nm1097-1069; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rohrer J, 1998, BLOOD, V91, P214, DOI 10.1182/blood.V91.1.214.214_214_221; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TURNER AJ, 1987, MAMMALIAN ECTOENZYME, P211; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	47	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29188	29194		10.1074/jbc.273.44.29188	http://dx.doi.org/10.1074/jbc.273.44.29188			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786929	hybrid			2022-12-25	WOS:000076691800090
J	Chen, L; Zhang, WJ; Fregien, N; Pierce, M				Chen, L; Zhang, WJ; Fregien, N; Pierce, M			The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products	ONCOGENE			English	Article						neu/her-2; oncogene; glycosyltransferase; glycosylation	HAMSTER-KIDNEY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-1-6 BRANCHED OLIGOSACCHARIDES; DISTINCT METASTATIC POTENTIALS; BREAST-CANCER; NEU-ONCOGENE; TRANSGENIC MICE; MEMBRANE-GLYCOPROTEINS; EPITHELIAL-CELLS; PROTO-ONCOGENE	Malignant transformation is associated with changes in the glycosylation of cell surface proteins. For example, the N-linked oligosaccharides containing the [GlcNAc beta(1,6)Man] branch are increased after transformation of many cell types by a number of tumor viruses and oncogenes which induce the expression of N-acetylglucosaminyl-transferase V (GlcNAc-T V), the enzyme that adds this branch, A large percentage of human breast carcinomas have increased N-linked beta(1,6) branches on glycoproteins, while up to 30% of breast carcinomas have amplified the oncogene her-2/neu (erb-B2), We tested the hypothesis that expression of her-2/neu stimulates GlcNAc-T V gene expression and increases the beta(1,6) branching of N-linked oligosaccharides, We found that neu-transformed NIH3T3 cells have a threefold increase in GlcNAc-T V enzyme activity and increased beta(1,6) branching on a specific set of glycoproteins. Promoter/reporter experiments showed that her-2/neu stimulates transcription from the human GlcNAc-T V promoter and that the her-2/neu response element was located about 400 bp 5' of the transcription initiation site and includes three Ets transcription factor binding sequences, Co-transfections with dominant-negative Raf and Ets expression plasmids demonstrated that the transcriptional activation of the GlcNAc-T V promoter by neu is mediated by the Ras-Raf-Ets signal transduction pathway.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Shanghai Jaio Tung Univ, Dept Biochem & Mol Biol, Inst Mol Biol, Shanghai, Peoples R China; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Shanghai Jiao Tong University; University of Miami	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.				NCRR NIH HHS [RR5351] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BORG A, 1991, ONCOGENE, V6, P137; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DO KY, 1994, J BIOL CHEM, V269, P23456; FERNANDES B, 1991, CANCER RES, V51, P718; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayes D F, 1996, Recent Results Cancer Res, V140, P101; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; Li WP, 1997, INT J CANCER, V71, P483, DOI 10.1002/(SICI)1097-0215(19970502)71:3<483::AID-IJC29>3.3.CO;2-P; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; Tan M, 1997, CANCER RES, V57, P1199; TIKANNEN S, 1992, J CLIN ONCOL, V10, P1044; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	47	81	82	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2087	2093		10.1038/sj.onc.1202124	http://dx.doi.org/10.1038/sj.onc.1202124			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798679				2022-12-25	WOS:000076540900007
J	Dore, JJE; Edens, M; Garamszegi, N; Leof, EB				Dore, JJE; Edens, M; Garamszegi, N; Leof, EB			Heteromeric and homomeric transforming growth factor-beta receptors show distinct signaling and endocytic responses in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; II RECEPTOR; GM-CSF; REVEALS; CLONING; DOMAIN; DIFFERENTIATION; INTERNALIZATION; EXPRESSION	Transforming growth factor-beta (TGF-beta) induces distinct responses dependent upon the cellular context. It is unclear whether the initial receptor interactions identified in one cell type will be operative in another. Utilizing a chimeric receptor strategy we have examined the signaling and endocytic activity of both heteromeric (type I/type II) and homomeric (type I/type I or type II/type II) TGF-beta R interactions in Mv1Lu epithelial cells. In agreement with that observed in mesenchymal cells, all TGF-beta R signaling in Mv1Lu cells required the formation of a heteromeric type I-type II receptor complex. However, the initial endocytic response to TGF-beta R oligomerization was distinctly regulated in the two cell types. While heteromeric TGF-beta receptors were internalized and down-regulated, homomeric TGF-beta R interactions showed diminished endocytic activity in Mv1Lu cells. This contrasts to that observed in mesenchymal cultures where ligand bound to TGF-beta R homomers was internalized, yet the receptors were not down-regulated. Moreover, while previous reports have suggested that mutations at serine 172 or threonine 176 in the type I TGF-beta R separated transcriptional from proliferative responses, we found no separation of pathways or effect on initial endocytic activity when the analogous mutations were made in the chimeric receptors.	Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Guggenheim 6, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054200, R01GM055816, R37GM055816] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55816, GM-54200] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1985, CANCER CELL, V3, P73; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; ROVATI GE, 1988, ANAL BIOCHEM, V174, P636, DOI 10.1016/0003-2697(88)90067-X; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	42	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31770	31777		10.1074/jbc.273.48.31770	http://dx.doi.org/10.1074/jbc.273.48.31770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822641	hybrid			2022-12-25	WOS:000077207000023
J	Kupfer, C; Lee, S; Kemper, B				Kupfer, C; Lee, S; Kemper, B			Binding of endonuclease VII to cruciform DNA - Visualization in the electron microscope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-SEDIMENTING DNA; GENE-49-CONTROLLED ENDONUCLEASE; T4-HEAD MATURATION; T4; JUNCTION; BACTERIOPHAGE-T4; CLEAVAGE; GENE-49; ENZYME	The binding of Holliday structure resolving endonuclease VII to cruciform DNA was studied in the electron microscope. The protein was found to bind either to the junction or to one of the arms or an end of one of the arms of the construct. The amount of bound protein was determined by measuring the size of the complexes. On average, one complex containing three dimers was found per one molecule of cruciform DNA.	Univ Cologne, Genet Inst, D-50674 Cologne, Germany; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Cologne; University of North Carolina; University of North Carolina Chapel Hill	Kemper, B (corresponding author), Univ Cologne, Genet Inst, Zulpicher Str 47, D-50674 Cologne, Germany.				NIGMS NIH HHS [GM 31819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; Birkenbihl RP, 1998, J MOL BIOL, V280, P73, DOI 10.1006/jmbi.1998.1851; Birkenbihl RP, 1998, EMBO J, V17, P4527, DOI 10.1093/emboj/17.15.4527; Christoph A, 1998, J MOL BIOL, V277, P529, DOI 10.1006/jmbi.1998.1628; FLEMMING M, 1993, VIROLOGY, V196, P910, DOI 10.1006/viro.1993.1557; FRANKEL FR, 1971, J MOL BIOL, V62, P439, DOI 10.1016/0022-2836(71)90147-1; GiraudPanis MJE, 1997, EMBO J, V16, P2528, DOI 10.1093/emboj/16.9.2528; Golz S, 1997, EUR J BIOCHEM, V245, P573, DOI 10.1111/j.1432-1033.1997.00573.x; Golz S, 1995, DNA Res, V2, P277, DOI 10.1093/dnares/2.6.277; Golz S, 1998, NUCLEIC ACIDS RES, V26, P1132, DOI 10.1093/nar/26.4.1132; Greger B, 1998, NUCLEIC ACIDS RES, V26, P4432, DOI 10.1093/nar/26.19.4432; KEMPER B, 1976, J VIROL, V18, P1000, DOI 10.1128/JVI.18.3.1000-1015.1976; KEMPER B, 1981, EUR J BIOCHEM, V115, P133; KEMPER B, 1981, EUR J BIOCHEM, V115, P123; KEMPER B, 1997, BIOCH GENETICS CELL, P179; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Pohler JRG, 1996, J MOL BIOL, V260, P678; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671	21	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31637	31639		10.1074/jbc.273.48.31637	http://dx.doi.org/10.1074/jbc.273.48.31637			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822621	hybrid			2022-12-25	WOS:000077207000003
J	Jiang, DH; Yang, H; Willson, JKV; Liang, JR; Humphrey, LE; Zborowska, E; Wang, D; Foster, J; Fan, R; Brattain, MG				Jiang, DH; Yang, H; Willson, JKV; Liang, JR; Humphrey, LE; Zborowska, E; Wang, D; Foster, J; Fan, R; Brattain, MG			Autocrine transforming growth factor alpha provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON-CARCINOMA; TRANSGENIC MICE; TGF-ALPHA; C-MYC; FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; GENE-EXPRESSION; MAMMARY-GLAND; EGF-RECEPTOR	CBS human colon carcinoma cells are poorly tumorigenic in athymic nude mice, whereas FET colon carcinoma cells are non-tumorigenic, Both cell lines have well differentiated properties in tissue culture. Transforming growth factor alpha (TGF-alpha) was ectopically expressed by stable transfection of a TGF-alpha cDNA under repressible tetracycline control. The TGF-alpha-transfected cells showed enhanced clonal initiation and shortened lag phase growth in tissue culture without an alteration in doubling time in exponential phase relative to untransfected cells. Furthermore, the TGF-alpha transfectants showed increased independence from exogenous growth factors in clonal growth assays and induction of DNA synthesis after release from quiescence. Growth factor independence was associated with sustained epidermal growth factor receptor activation in quiescent TGF-alpha-transfected cells and the requirement of exogenous insulin for stimulation of quiescent cells to reenter the cell cycle. Higher cloning, reduced lag time in tissue, and the acquisition of growth factor independence for DNA synthesis without a change in doubling time of TGF-alpha-transfected cells indicate that autocrine TGF-alpha functions by facilitating re-entry into the cell cycle from sub-optimal growth states rather than promoting or controlling the proliferation of actively cycling cells, The modulation of growth regulation by autocrine TGF-alpha was associated with increased malignant properties as TGF-alpha transfectants showed increased tumorigenicity in athymic nude mice. The administration of tetracycline reversed the effects of TGF-alpha expression in these cells both in vivo and in vitro, indicating that the alterations of the biological properties were due to the expression of TGF-alpha. Since these cells are continuously grown in a completely chemically defined medium without serum supplementation, it was possible to assign the mechanism underlying the generation of growth factor independence to the replacement of a requirement for exogenous insulin in parental cells by autocrine TGF-alpha.	Univ Texas, Hlth Sci Ctr, Dept Surg & Biochem, San Antonio, TX 78284 USA; Med Coll Ohio, Dept Biochem, Toledo, OH 43699 USA; Med Coll Ohio, Dept Mol Biol, Toledo, OH 43699 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; Case Western Reserve University	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg & Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Jiang, Dianhua/B-1421-2009; Liang, Carol Jiurong/AAI-4963-2021	Jiang, Dianhua/0000-0002-4508-3829; Liang, Jiurong/0000-0001-5179-5016	NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, R01CA068316] Funding Source: NIH RePORTER; NCI NIH HHS [CA68316, CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; COFFEY RJ, 1994, CANCER RES, V54, P1678; COFFEY RJ, 1987, CANCER RES, V47, P4590; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1985, CANCER CELL, V3, P79; DIMARCO E, 1989, ONCOGENE, V4, P831; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; MULDER KM, 1991, CANCER RES, V51, P2256; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURAKAMI H, 1993, CANCER RES, V53, P1719; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TAKAGI H, 1993, CANCER RES, V53, P4329; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAN CW, 1988, CANCER LETT, V43, P139, DOI 10.1016/0304-3835(88)90226-1; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Wu GF, 1997, ONCOGENE, V15, P1555, DOI 10.1038/sj.onc.1201329; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	43	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31471	31479		10.1074/jbc.273.47.31471	http://dx.doi.org/10.1074/jbc.273.47.31471			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813060	hybrid			2022-12-25	WOS:000077136900088
J	Lacourciere, GM; Stadtman, TC				Lacourciere, GM; Stadtman, TC			The NIFS protein can function as a selenide delivery protein in the biosynthesis of selenophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SELENOCYSTEINE LYASE; SYNTHETASE; ENZYME; GENE; PURIFICATION; MECHANISM; LIVER; RAT	The NIFS protein from Azobacter vinelandii is a pyridoxal phosphate-containing homodimer that catalyzes the formation of equimolar amounts of elemental sulfur and L-alanine from the substrate L-cysteine (Zheng, L,, White, R, H,, Cash, V, L,, Jack, R, F,, and Dean, D. R, (1993) Proc. Natl, Acad Sci, U.S.A. 90, 2754-2758), A sulfur transfer role of NIFS in which the enzyme donates sulfur for iron sulfur center formation in nitrogenase was suggested. The fact that NIFS also can catalyze the decomposition of L-selenocysteine to elemental selenium and L-alanine suggested the possibility that this enzyme might serve as a selenide delivery protein for the in vitro biosynthesis of selenophosphate. In agreement with this hypothesis, we have shown that replacement of selenide with NIFS and L-selenocysteine in the in vitro selenophosphate synthetase assay results in an increased rate of formation of selenophosphate. These results thus support the view that a selenocysteine specific enzyme similar to NIFS may be involved as an in vivo selenide delivery protein for selenophosphate biosynthesis. A kinetic characterization of the two NIFS catalyzed reactions carried out in the present study indicates that the enzyme favors L-cysteine as a substrate compared with its selenium analog. A specific activity for L-cysteine of 142 nmol/min/mg compared with 55 nmol/min/mg for L-selenocysteine was determined. This level of enzyme activity on the selenoamino acid substrate is adequate to deliver selenium to selenophosphate synthetase in the in vitro assay system described.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Stadtman, TC (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 103,9000 Rockville Pike, Bethesda, MD 20892 USA.							ESAKI N, 1981, BIOCHEMISTRY-US, V20, P4492, DOI 10.1021/bi00518a039; ESAKI N, 1982, J BIOL CHEM, V257, P4386; ESAKI N, 1988, J BACTERIOL, V170, P751, DOI 10.1128/jb.170.2.751-756.1988; Flint DH, 1996, J BIOL CHEM, V271, P16068; GLASS RS, 1993, BIOCHEMISTRY-US, V532, P12255; KICE JL, 1980, J AM CHEM SOC, V102, P4448, DOI 10.1021/ja00533a025; KIM IY, 1992, J BIOL CHEM, V267, P19650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SLIWKOWSKI MX, 1985, J BIOL CHEM, V260, P3140; STADTMAN TC, 1979, P 3 INT S ORG SEL TE, P115; VERES Z, 1994, J BIOL CHEM, V269, P10597; WASCHULEWSKI IH, 1988, J NUTR, V118, P367, DOI 10.1093/jn/118.3.367; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	18	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30921	30926		10.1074/jbc.273.47.30921	http://dx.doi.org/10.1074/jbc.273.47.30921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812986	hybrid			2022-12-25	WOS:000077136900014
J	Pfister, SL; Spitzbarth, N; Nithipatikom, K; Edgemond, WS; Falck, JR; Campbell, WB				Pfister, SL; Spitzbarth, N; Nithipatikom, K; Edgemond, WS; Falck, JR; Campbell, WB			Identification of the 11,14,15- and 11,12,15-trihydroxyeicosatrienoic acids as endothelium-derived relaxing factors of rabbit aorta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE CORONARY-ARTERIES; ARACHIDONIC-ACID; DEPENDENT RELAXATIONS; BLOOD-VESSELS; ACETYLCHOLINE; METABOLISM; CYTOCHROME-P-450; 15-LIPOXYGENASE; TRANSFORMATION; HYDROPEROXIDE	A number of endothelium-derived relaxing factors have been identified including nitric oxide, prostacyclin, and the epoxyeicosatrienoic acids. Previous work showed that in rabbit aortic endothelial cells, arachidonic acid was metabolized by a lipoxygenase to vasodilatory eicosanoids. The identity was determined by the present study. Aortic homogenates were incubated in the presence of [U-C-14]arachidonic acid, [U-C-14]arachidonic acid plus 15-lipoxygenase (soybean lipoxidase), or [U-C-14]15-hydroxyeicosatetraenoic acid (15-HPETE) and analyzed by reverse phase high pressure liquid chromatography (RP-HPLC). Under both experimental conditions, there was a radioactive metabolite that migrated at 17.5-18.5 min on RP-HPLC. When the metabolite was isolated from aortic homogenates, it relaxed precontracted aortas in a concentration-dependent manner. Gas chromatography/mass spectrometry (GC/MS) of the derivatized metabolite indicated the presence of two products; 11,12,15-trihydroxyeicosatrienoic acid (THETA) and 11,14,15-THETA. A variety of chemical modifications of the metabolite supported these structures and confirmed the presence of a carboxyl group, double bonds, and hydroxyl groups. With the combination of 15-lipoxygenase, arachidonic acid, and aortic homogenate, an additional major radioactive peak was observed. This fraction was analyzed by GC/MS. The mass spectrum was consistent with this peak, containing both the 11-hydroxy-14,15-epoxyeicosatrienoic acid (11-H-14,15-EETA) and 15-H-11,12-EETA. The hydroxyepoxyeicosatrienoic acid (HEETA) fraction also relaxed precontracted rabbit aorta. Microsomes derived from rabbit aortas also synthesized 11,12,15- and 11,14,15-THETAs from 15-HPETE, and pretreatment with the cyctochrome P450 inhibitor, miconazole, blocked the formation of these products. The present studies suggest that arachidonic acid is metabolized by 15-lipoxygenase to 15-HPETE, which undergoes an enzymatic rearrangement to 11-H-14,15-EETA and 15-H-11,12-EETA. Hydrolysis of the epoxy group results in the formation of 11,14,15- and 11,12,15-THETA, which relaxed rabbit aorta. Thus, the 15-series THETAs join prostacyclin, nitric oxide, and epoxyeicosatrienoic acids as new members of the family of endothelium-derived relaxing factors.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Medical College of Wisconsin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Campbell, WB (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL-37981] Funding Source: Medline; NIGMS NIH HHS [GM-31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT R W, 1981, Progress in Lipid Research, V20, P279, DOI 10.1016/0163-7827(81)90055-2; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; COWAN CL, 1993, J PHARMACOL EXP THER, V266, P1482; DALARCAO M, 1987, BRIT J PHARMACOL, V91, P627, DOI 10.1111/j.1476-5381.1987.tb11256.x; DEMEY JG, 1982, J PHARMACOL EXP THER, V222, P166; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; FALCK JR, 1983, TETRAHEDRON LETT, V24, P5715, DOI 10.1016/S0040-4039(00)94181-9; Fujimoto S, 1997, EUR J PHARMACOL, V330, P177, DOI 10.1016/S0014-2999(97)00180-5; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; HENRIKSSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P272, DOI 10.1016/0005-2760(85)90166-3; LANEUVILLE O, 1991, BIOCHIM BIOPHYS ACTA, V1084, P60, DOI 10.1016/0005-2760(91)90056-N; LANEUVILLE O, 1992, BRIT J PHARMACOL, V105, P297, DOI 10.1111/j.1476-5381.1992.tb14249.x; MONCADA S, 1978, PHARMACOL REV, V30, P293; Murphy ME, 1995, J PHYSIOL-LONDON, V489, P723, DOI 10.1113/jphysiol.1995.sp021086; NARUMIYA S, 1981, J BIOL CHEM, V256, P9583; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PACEASCIAK CR, 1989, FREE RADICAL BIO MED, V7, P409, DOI 10.1016/0891-5849(89)90125-1; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; Pfister SL, 1996, AM J PHYSIOL-HEART C, V270, pH1021, DOI 10.1152/ajpheart.1996.270.3.H1021; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PFISTER SL, 1992, HYPERTENSION, V20, P682, DOI 10.1161/01.HYP.20.5.682; PFISTER SL, 1988, PROSTAGLANDINS, V36, P515, DOI 10.1016/0090-6980(88)90047-0; PINTO A, 1986, J PHARMACOL EXP THER, V236, P445; PINTO A, 1987, J PHARMACOL EXP THER, V240, P856; PINTO A, 1987, J PHARMACOL EXP THER, V241, P763; Rosolowsky M, 1996, BBA-LIPID LIPID MET, V1299, P267, DOI 10.1016/0005-2760(95)00216-2; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; RUBANYI GM, 1985, J PHARMACOL EXP THER, V235, P81; SAEZ JM, 1975, J BIOL CHEM, V250, P1683; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SINGER HA, 1983, J PHARMACOL EXP THER, V226, P796; SINGER HA, 1983, J PHARMACOL EXP THER, V226, P790; VANDIEST MJ, 1991, J PHARMACOL EXP THER, V256, P194; WEISS RH, 1987, ARCH BIOCHEM BIOPHYS, V252, P334, DOI 10.1016/0003-9861(87)90039-7	35	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30879	30887		10.1074/jbc.273.47.30879	http://dx.doi.org/10.1074/jbc.273.47.30879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812980	hybrid			2022-12-25	WOS:000077136900008
J	Wang, JC; Stafford, JM; Granner, DK				Wang, JC; Stafford, JM; Granner, DK			SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; GENE-TRANSCRIPTION; FACTOR-1-ALPHA GENE; YOUNG MODY1; ACTIVATION; P300; CBP; COMPLEX; PROTEIN	Hepatocyte nuclear factor-4 (HNF4), a member of the nuclear receptor superfamily, plays an important role in tissue-specific gene expression, including genes involved in hepatic glucose metabolism. In this study, we show that SRC-1 and GRIP1, which act as coactivators for various nuclear receptors, associate with HNF4 in vivo and enhance its transactivation potential, The AF-2 domain of HNF4 is required for this interaction and for the potentiation of transcriptional activity by these coactivators, p300 can also serve as a coactivator with HNF4, and it synergizes with SRC-1 to further augment the activity of HNF4, HNF4 is also a key regulator of the expression of hepatocyte nuclear factor-1 (HNF1), The overexpression of SRC-I or GRIP1 enhances expression from a HNF1 gene promoter-reporter in HepG2 hepatoma cells, and this requires an intact HNF4-binding site in the HNF1 gene promoter. Type I maturity onset diabetes of young (MODY), which is characterized by abnormal glucose-mediated insulin secretion, is caused by mutations of the HNF4 gene. A mutation of the HNF4-binding site in the HNF1 gene promoter has also been associated with MODY, Thus, HNF4 is involved in the regulation of glucose homeostasis at several levels and along with the SRC-1, GRIP1, and p300 may play an important role in the pathophysiology of non-insulin-dependent diabetes mellitus.	Vanderbilt Univ, Ctr Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Ctr Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020; Stafford, John/K-7763-2017	Wang, Jen-Chywan/0000-0001-6030-6886; Stafford, John/0000-0001-6527-959X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593, R37DK035107, R01DK035107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25107, R37 DK035107, DK 20593] Funding Source: Medline; NIGMS NIH HHS [GM07347, T32 GM007347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN WS, 1994, GENES DEV; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; MIURA N, 1993, NUCLEIC ACIDS RES, V21, P3731, DOI 10.1093/nar/21.16.3731; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SLADEK FM, 1994, LIVER GENE EXPRESSIO, V11, P207; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	43	112	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30847	30850		10.1074/jbc.273.47.30847	http://dx.doi.org/10.1074/jbc.273.47.30847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812974	Green Accepted, hybrid			2022-12-25	WOS:000077136900002
J	Basu, S; Bayoumy, S; Zhang, Y; Lozano, J; Kolesnick, R				Basu, S; Bayoumy, S; Zhang, Y; Lozano, J; Kolesnick, R			BAD enables ceramide to signal apoptosis via Ras and Raf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; NUCLEOTIDE EXCHANGE FACTORS; PROGRAMMED CELL-DEATH; FAS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; KSR-1 GENE ENCODES; BCL-2 HOMOLOG; CYTOCHROME-C; FREE SYSTEM	Prior investigations document that proliferative signaling cascades, under some circumstances, initiate apoptosis, although mechanisms that dictate the final outcome are largely unknown. In COS-7 cells, ceramide signals Raf-1 activation through Bus (Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X.H., Basu, S., McGinley, M., Chan-Hui, P. Y., Lichenstein, H., and Kolesnick, R. (1997) Cell 89, 63-72), but not apoptosis. However, expression of small amounts of the pro apoptotic Bcl-2 family member, BAD, conferred ceramide induced apoptosis onto COS-7 cells. Ceramide signaled apoptosis in BAD expressing cells by a pathway involving sequentially kinase suppressor of Ras (KSR)/ceramide-activated protein kinase, Pas, c-Raf-1, and MEK1. Downstream, this pathway linked to BAD dephosphorylation at serine 136 by prolonged inactivation of Akt/PKB. Further, mutation of BAD at serine 136 abrogated ceramide signaling of apoptosis. The present study indicates that when ceramide signals through the Ras/Raf cascade, the availability of a single target, BAD, may dictate an apoptotic outcome.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, Sloan Kettering Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.		Lozano, José/C-2760-2014	Lozano, José/0000-0002-8187-2833	NCI NIH HHS [CA42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Castedo M, 1996, J IMMUNOL, V157, P512; CHEN CY, 1995, ONCOGENE, V11, P1487; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decaudin D, 1997, CANCER RES, V57, P62; delPeso L, 1997, SCIENCE, V278, P687; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GUILLOT E, 1997, P NATL ACAD SCI USA, V94, P3302; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; Karim FD, 1998, DEVELOPMENT, V125, P1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitada S, 1998, AM J PATHOL, V152, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU J, 1994, J BIOL CHEM, V269, P3047; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTAVI ZN, 1993, CELL, V74, P609; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	72	152	156	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30419	30426		10.1074/jbc.273.46.30419	http://dx.doi.org/10.1074/jbc.273.46.30419			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804808	hybrid			2022-12-25	WOS:000077008100055
J	Kavran, JM; Klein, DE; Lee, A; Falasca, M; Isakoff, SJ; Skolnik, EY; Lemmon, MA				Kavran, JM; Klein, DE; Lee, A; Falasca, M; Isakoff, SJ; Skolnik, EY; Lemmon, MA			Specificity and promiscuity in phosphoinositide binding by Pleckstrin homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; ADRENERGIC-RECEPTOR KINASE; HIGH-AFFINITY BINDING; PROTEIN-KINASE; PH DOMAIN; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; INOSITOL PHOSPHATES; MOLECULAR-CLONING; PHOSPHOLIPASE-C	Pleckstrin homology (PH) domains are small protein modules involved in recruitment of signaling molecules to cellular membranes, in some cases by binding specific phosphoinositides. We describe use of a convenient "dot-blot"' approach to screen 10 different PH domains for those that recognize particular phosphoinositides. Each PH domain bound phosphoinositides in the assay, but only two (from phospholipase C-delta(1) and Grp1) showed clear specificity for a single species. Using soluble inositol phosphates, we show that the Grp1 PH domain (originally cloned on the basis of its phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) binding) binds specifically to D-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) (the PtdTns(3,4,5)P-3 headgroup) with K-D = 27.3 nM, but binds D-myo-inositol 1,3,4-trisphosphate (Ins(1,3,4)P-3) or D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) over 80-fold more weakly. We show that this specificity allows localization of the Grp1 PH domain to the plasma membrane of mammalian cells only when phosphatidylinositol 3-kinase (PI 3-K) is activated. The presence of three adjacent equatorial phosphate groups was critical for inositol phosphate binding by the Grp1 PH domain. By contrast, another PH domain capable of PI 3-K-dependent membrane recruitment (encoded by EST684797) does not distinguish Ins(1,3,4)P-3 from Ins(1,3,4,5)P-3 (binding both with very high affinity), despite selecting strongly against Ins(1,4,5)P-3. The remaining PH domains tested appear significantly less specific for particular phosphoinositides. Together with data presented in the literature, our results suggest that many PH domains bind similarly to multiple phosphoinositides (and in some cases phosphatidylserine), and are likely to be regulated in vivo by the most abundant species to which they bind. Thus, using the same simple approach to study several PH domains simultaneously, our studies suggest that highly specific phosphoinositide binding is a characteristic of relatively few cases.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro CH, Italy; NYU, Sch Med, Skirball Inst Biomol Med, Dept Pharmacol, New York, NY 10016 USA	University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; New York University	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, A606 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu	Isakoff, Steven/ABE-3566-2020; Falasca, Marco/S-4020-2016	Falasca, Marco/0000-0002-9801-7235; Klein, Daryl/0000-0002-7188-0450; Lemmon, Mark/0000-0002-3379-5319	Fondazione Telethon Funding Source: Custom; NIDDK NIH HHS [DK49207] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049207] Funding Source: NIH RePORTER	Fondazione Telethon(Fondazione Telethon); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; AUSUBEL FM, 1997, CURENT PROTOCOLS MOL; BELLACOSA A, 1993, ONCOGENE, V8, P745; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hinchliffe K, 1997, NATURE, V390, P123, DOI 10.1038/36458; HU RJ, 1992, J BIOL CHEM, V267, P18715; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MARGOLIS B, 1995, DNA CLONING, V2, P1; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RON D, 1992, BIOTECHNIQUES, V13, P866; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TORTORELLA D, 1994, ANAL BIOCHEM, V217, P176, DOI 10.1006/abio.1994.1106; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	78	365	372	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30497	30508		10.1074/jbc.273.46.30497	http://dx.doi.org/10.1074/jbc.273.46.30497			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804818	hybrid			2022-12-25	WOS:000077008100065
J	Masuda, Y; Bennett, RAO; Demple, B				Masuda, Y; Bennett, RAO; Demple, B			Dynamics of the interaction of human apurinic endonuclease (Ape1) with its substrate and product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; EXONUCLEASE-III; POLYMERASE-BETA; EXOCYCLIC ADDUCT; ACTIVE-SITE; BINDING; IDENTIFICATION	We investigated the interaction dynamics of human abasic endonuclease, the Ape1 protein (also called Ref1, Hap1, or Apex), with its DNA substrate and incised product using electrophoretic assays and site-specific amino acid substitutions. Changing aspartate 283 to alanine (D283A) left 10% residual activity, contrary to a previous report, but complementation of repair-deficient bacteria by the D283A Ape1 protein was consistent with its activity in vitro. The D308A, D283/D308A double mutant, and histidine 309 to asparagine proteins had 22, 1, and similar to 0.02% of wild-type Ape1 activity, respectively. Despite this range of enzymatic activities, all the mutant proteins had near-wild-type binding affinity specific for DNA containing a synthetic abasic site. Thus, substrate recognition and cleavage are genetically separable steps. Both the wild-type and mutant Ape1 proteins bound strongly to the enzyme incision product, an incised abasic site, which suggested that Ape1 might exhibit product inhibition. The use of human DNA polymerase beta to increase Ape1 activity by eliminating the incision product supports this conclusion. Notably, the complexes of the D283A, D308A, and D283A/D308A double mutant proteins with both intact and incised abasic DNA were significantly more stable than complexes containing wild-type Ape1, which may contribute to the lower turnover numbers of the mutant enzymes. Wild-type Ape1 protein bound tightly to DNA containing a one-nucleotide gap but not to DNA with a nick, consistent with the proposal that substrate recognition by Ape1 involves a space bracketed by duplex DNA, rather than mere flexibility of the DNA.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988	NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993] Funding Source: Medline; NIEHS NIH HHS [ES03926] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GU LY, 1994, J BIOL CHEM, V269, P32685; Hang B, 1996, P NATL ACAD SCI USA, V93, P13737, DOI 10.1073/pnas.93.24.13737; Hang B, 1997, BIOCHEMISTRY-US, V36, P15411, DOI 10.1021/bi971367s; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HUPP TR, 1993, J BIOL CHEM, V268, P13128; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Rothwell DG, 1996, NUCLEIC ACIDS RES, V24, P4217, DOI 10.1093/nar/24.21.4217; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P891; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992; WEISS B, 1976, J BIOL CHEM, V251, P1896; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XU YJ, 1998, IN PRESS J BIOL CHEM, V273	49	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30352	30359		10.1074/jbc.273.46.30352	http://dx.doi.org/10.1074/jbc.273.46.30352			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804798	hybrid			2022-12-25	WOS:000077008100045
J	Pomes, A; Melen, E; Vailes, LD; Retief, JD; Arruda, LK; Chapman, MD				Pomes, A; Melen, E; Vailes, LD; Retief, JD; Arruda, LK; Chapman, MD			Novel allergen structures with tandem amino acid repeats derived from German and American cockroach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE ANTIBODY-RESPONSES; INNER-CITY CHILDREN; HOUSE-DUST MITE; BLATTELLA-GERMANICA; ANOPHELES-GAMBIAE; MAJOR ALLERGEN; BLOOD MEAL; TRYPSIN; ASTHMA; HYPERSENSITIVITY	Cockroaches produce potent allergens that are an important cause of asthma. The two principal domiciliary cockroach species, Blattella germanica and Periplaneta americana, secrete major allergens, Bla g 1 and Per a 1. Here, we report the molecular cloning of three Bla g 1 cDNA clones, which showed 70% amino acid sequence identity with Per a 1. Plaque immunoassays with human IgE antibodies or murine monoclonal antibodies showed that these allergens were antigenically cross-reactive. The Bla gl sequences also showed homology to five previously undefined cockroach allergen sequences. An unusual feature of all these sequences was that they contained multiple tandem amino acid repeats of similar to 100 amino acid residues. Between one and seven repeat units were identified by dot-plot matrix analysis. The sequences also showed homology to a mosquito protein involved in digestion (ANG12 precursor) and to mitochondrial energy transfer proteins. High levels of Bla g 1 were found in cockroach hindgut and proventriculus. Amino acid sequencing of natural Ela g 1 and Per a 1 suggested that these allergens are cleaved by trypsin-like enzymes following secretion into the digestive tract. The repeat sequences appear to have evolved by duplication of an ancestral amino acid domain, which may have arisen from the mitochondrial energy transfer proteins.	Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, ITC Hlth Sci, Charlottesville, VA 22908 USA; USP, Dept Parasitol Microbiol Imunol, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil	University of Virginia; University of Virginia; Universidade de Sao Paulo	Pomes, A (corresponding author), Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Med, Box 225, Charlottesville, VA 22908 USA.	ap8d@avery.med.virginia.edu	Pomés, Anna/H-7010-2019; Arruda, L. Karla/D-5845-2013	Pomés, Anna/0000-0002-8729-1829; Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 32557, AI 34601] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034601, R01AI032557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BELL WJ, 1981, LAB COCKROACH EXPT C, P33; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chapman MD, 1997, ALLERGY, V52, P374, DOI 10.1111/j.1398-9995.1997.tb01014.x; CHAPMAN MD, 1997, ALLERGY ALLERGIC DIS, P942; CHAPMAN MD, 1998, ENCY IMMUNOLOGY, V1, P64; Esch RE, 1991, REGULATORY CONTROL S, P171; GRAF R, 1991, EXPERIENTIA, V47, P603, DOI 10.1007/BF01949885; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; MELEN E, 1998, J ALLERGY CLIN IMMUN, V101, P156; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; MULLER HM, 1993, EMBO J, V12, P2891, DOI 10.1002/j.1460-2075.1993.tb05951.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4; Wu CH, 1997, ALLERGY, V52, P411, DOI 10.1111/j.1398-9995.1997.tb01020.x; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7; [No title captured]	32	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30801	30807		10.1074/jbc.273.46.30801	http://dx.doi.org/10.1074/jbc.273.46.30801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804858	hybrid			2022-12-25	WOS:000077008100105
J	Reggiori, F; Conzelmann, A				Reggiori, F; Conzelmann, A			Biosynthesis of inositol phosphoceramides and remodeling of glycosylphosphatidylinositol anchors in Saccharomyces cerevisiae are mediated by different enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM LOCALIZATION; VARIANT SURFACE GLYCOPROTEIN; GOLGI-APPARATUS; SECRETORY PATHWAY; MEMBRANE ANCHORS; SPHINGOLIPID SYNTHESIS; TRANSMEMBRANE DOMAIN; MYRISTATE EXCHANGE; PROTEIN-TRANSPORT; TRYPANOSOMA-CRUZI	Metabolic labeling of cells with [H-3]dihydrosphingosine ([H-3]DHS) allows us to follow the incorporation of this tracer into ceramides (Cer), inositol phosphoceramides (IPCs), and mannosylated IPCs and at the same time to assess the remodeling of glycosylphosphatidylinositol proteins during which preexisting anchor lipid moieties are replaced by [H-3]Cer-containing anchors. The results indicate that the remodelases in the endoplasmic reticulum and Golgi use as their substrate Cers that are not generated by the breakdown of IPCs but are newly synthesized. Aureobasidin A, an inhibitor of the IPC synthase Aur1p completely blocks IPC biosynthesis at 0.5 mu g/ml but does not block remodeling of glycosylphosphatidylinositol anchors even at concentrations up to 10 mu g/ml. In addition, a synthetic Cer analogue, N-hexanoyl-[H-3]DHS, is used as a substrate by Aur1p but not by the remodelases. Thus, remodeling is not mediated by Aur1p although remodeling presumably proceeds by an analogous reaction. Studies with secretion mutants deficient in COPII or COPI coat proteins show that all COPII mutants are unable to introduce [H-3]Cer by the Golgi remodelase at the restrictive temperature. This suggests that Cer has to be transported by a COPII-dependent way from the endoplasmic reticulum to Golgi for Golgi remodeling to occur. Golgi remodeling is also not operating in the erd2 mutant and is significantly reduced in COPI mutants, suggesting a dependence of Golgi remodeling on retrotransport.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Conzelmann, A (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.		Reggiori, Fulvio/U-8327-2019	Reggiori, Fulvio/0000-0003-2652-2686				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Buxbaum LU, 1996, P NATL ACAD SCI USA, V93, P1178, DOI 10.1073/pnas.93.3.1178; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUNN T, 1994, J BIOL CHEM, V269, P7273; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GATT S, 1968, BIOCHEM BIOPH RES CO, V32, P588, DOI 10.1016/0006-291X(68)90277-5; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MERILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; REGGIORI F, 1998, IN PRESS METHODS MOL; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P294, DOI 10.1016/0005-2760(76)90172-7; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Sutterlin C, 1997, J CELL SCI, V110, P2703; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5414; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Wuestehube LJ, 1996, GENETICS, V142, P393; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	84	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30550	30559		10.1074/jbc.273.46.30550	http://dx.doi.org/10.1074/jbc.273.46.30550			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804825	hybrid			2022-12-25	WOS:000077008100072
J	Wilkening, G; Linke, T; Sandhoff, K				Wilkening, G; Linke, T; Sandhoff, K			Lysosomal degradation on vesicular membrane surfaces - Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDASE; SAPOSIN-C; PHOSPHATIDYLSERINE LIPOSOMES; PROTEIN; BIS(MONOACYLGLYCERO)PHOSPHATE; GLUCOCEREBROSIDASE; SPHINGOLIPIDS; TOPOLOGY; STORAGE; LIVER	According to a recent hypothesis (Sandhoff, K., and Kolter, T. (1996) Trends Cell Biol. 6, 98-103), glycolipids, which originate from the plasma membrane, are exposed to lysosomal degradation on the surface of intralysosomal vesicles. Taking the interaction of membrane-bound lipid substrates and lysosomal hydrolases as an experimental model, we studied the degradation of glucosylceramides with different acyl chain lengths by purified glucocerebrosidase in a detergent-free liposomal assay system. Our investigation focused on the stimulating effect induced by lysosomal components such as sphingolipid activator protein C (SAP-C or saposin C), anionic lysosomal lipids, bis(monoacylglycero)phosphate, and dolichol phosphate, as well as degradation products of lysosomal lipids, e.g, dolichols and free fatty acids. The size of the substrate-containing liposomal vesicles was varied in the study. Enzymatic hydrolysis of glucosylceramide carried by liposomes made of phosphatidylcholine and cholesterol was rather slow and only weakly accelerated by the addition of SAP-C. However, the incorporation of anionic lipids such as bis(monoacylglycero)phosphate, dolichol phosphate, and phosphatidylinositol into the substrate carrying liposomes stimulated glucosylceramide hydrolysis up to 30-fold. Dolichol was less effective. SAP-C activated glucosylceramide hydrolysis under a variety of experimental conditions and was especially effective for the increase of enzyme activity when anionic lipids were inserted into the liposomes. Glucosylceramides with short acyl chains were found to be degraded much faster than the natural substrates. Dilution experiments indicated that the added enzyme molecules associate at least partially with the membranes and act there. Surface plasmon resonance experiments demonstrated binding of SAP C at concentrations up to 1 mu M to liposomes. At higher concentrations (2.5 mu M SAP C), liposomal lipids were released from the liposome coated chip. A model for lysosomal glucosylceramide hydrolysis is discussed.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Bonn	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany.	sandhoff@uni-bonn.de						Amidon B, 1996, BIOCHEMISTRY-US, V35, P13995, DOI 10.1021/bi961164o; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; Cooper MA, 1997, CHEM COMMUN, P1625, DOI 10.1039/a703943c; CULLIS PR, 1996, BIOCH LIPIDS LIPOPRO, P9; DANG QQ, 1982, LIPIDS, V17, P798, DOI 10.1007/BF02535356; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HUTERER S, 1979, J LIPID RES, V20, P966; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; PATRICK AD, 1965, BIOCHEM J, V97, pC17, DOI 10.1042/bj0970017C; PETERS SP, 1977, J BIOL CHEM, V252, P563; PRENCE EM, 1995, BIOCHEM J, V310, P571, DOI 10.1042/bj3100571; QI XY, 1994, J BIOL CHEM, V269, P16746; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; VABBRO D, 1991, J BIOL CHEM, V266, P15021; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	30	125	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30271	30278		10.1074/jbc.273.46.30271	http://dx.doi.org/10.1074/jbc.273.46.30271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804787	hybrid			2022-12-25	WOS:000077008100034
J	Born, TL; Thomassen, E; Bird, TA; Sims, JE				Born, TL; Thomassen, E; Bird, TA; Sims, JE			Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-INDUCING FACTOR; INTERFERON-GAMMA; MOLECULAR-CLONING; ACCESSORY PROTEIN; KAPPA-B; FAMILY; MEMBER; IRAK; PURIFICATION; EXPRESSION	We have identified a novel member of the interleukin-1 (IL-1) receptor family, which we have termed AcPL. In transient transfection assays, we were unable to demonstrate a role for AcPL in IL-1-induced activation of NF kappa B. Interleukin-18 (interferon-gamma-inducing factor) is another member of the IL-1 family of cytokines, and it has recently been shown that IL-18 has a weak affinity for IL-1R-rp1. We examined whether AcPL might function alone or in concert with IL-1R-rp1 to mediate IL-18 signaling. We found that both IL-1R-rp1 and AcPL expression were required for induction of NF kappa B activity and for activation of c-Jun N-terminal kinase in response to IL-18. Furthermore, a dominant negative version of AcPL specifically inhibited IL-18 signaling. In vitro immunoprecipitation assays demonstrated that AcPL alone was unable to bind IL-18 with any appreciable affinity. We propose that although IL-1R-rp1 binds the cytokine, IL-1R-rp1 and AcPL proteins are both required for IL-18 signaling, analogous to the requirement for both IL-1R and IL-1RAcP in IL-1-mediated responses.	Immunex Corp, Seattle, WA 98101 USA	Immunex Corporation	Born, TL (corresponding author), Immunex Corp, 51 Univ St, Seattle, WA 98101 USA.			Sims, John/0000-0002-5667-9185				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; BIRD TA, 1994, J BIOL CHEM, V269, P31836; Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HAMMERSCHMDIT W, 1995, J VIROL, V69, P2968; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Parnet P, 1996, J BIOL CHEM, V271, P3967; Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; TOMINAGA S, 1989, FEBS LETT, V318, P83; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Ushio S, 1996, J IMMUNOL, V156, P4274; Wesche H, 1996, FEBS LETT, V391, P104, DOI 10.1016/0014-5793(96)00713-2	36	288	311	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29445	29450		10.1074/jbc.273.45.29445	http://dx.doi.org/10.1074/jbc.273.45.29445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792649	hybrid			2022-12-25	WOS:000076798300026
J	Chen, BC; Chou, CF; Lin, WW				Chen, BC; Chou, CF; Lin, WW			Pyrimidinoceptor-mediated potentiation of inducible nitric-oxide synthase induction in J774 macrophages - Role of intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; RAW-264.7 MURINE MACROPHAGES; PHOSPHOLIPASE-C; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; PERITONEAL-MACROPHAGES; FUNCTIONAL EXPRESSION; NUCLEOTIDE RECEPTOR; SIGNAL-TRANSDUCTION	We have shown that, in murine J774 macrophages, binding of UTP to pyrimidinoceptors stimulates phosphoinositide (PI) breakdown and an increase in [Ca2+](i). In this study, UTP modulation of the expression of inducible nitric-oxide synthase (iNOS) was investigated. Although UTP alone had no effect, stimulation of J774 cells with a combination of UTP (10-300 mu M) and LPS (0.1-3 mu g/ml) resulted in a potentiated increase in nitrite levels. In parallel, the amount of iNOS protein induced by LPS was also potentiated by UTP treatment. The UTP potentiating effect was attenuated by U73122, suggesting involvement of the downstream signaling pathways of phosphatidylinositide turnover. The tyrosine kinase inhibitor genistein inhibited both the LPS-induced nitrite response and the UTP potentiation. Conversely, two protein kinase C inhibitors, Ro 31-8220 and Go 6976, and a phosphatidylcholine-specific phospholipase C inhibitor, D609, inhibited LPS-stimulated nitrite induction, but did not affect the potentiating effect of UTP, which was also unaffected by pretreatment with phorbol 12-myristate 13-acetate for 8 h. Furthermore, the UTP-induced potentiation was abolished by BAPTA/AM or KN-93 (a selective inhibitor of Ca2+/calmodulin-dependent protein kinase (CaMK)). Nitrite potentiation and iNOS induction were prominent when UTP was added simultaneously with LPS, with the potentiating effect being lost when UTP was added 3 h after treatment with LPS. Pyrrolidinedithiocarbamate (3-30 mu M), an inhibitor of NF-kappa B, caused a concentration-dependent reduction in the nitrite response to LPS and UTP. In electrophoretic mobility shift assays, LPS produced marked activation of NF-kappa B and AP-1, which was potentiated by UTP. LPS-induced degradation of I kappa B-alpha as well as the phosphorylation of I kappa B-alpha were also increased by UTP. Moreover, the UTP-potentiated activation of NF-kappa B and AP-1 and the degradation and phosphorylation of I kappa B-alpha were inhibited by KN-93. Taken together, these data demonstrate that nucleotides, especially UTP, can potentiate the LPS-induced activation of NF-kappa B and AP-1 and of iNOS induction via a CaMK-dependent pathway and suggest that the UTP-dependent up-regulation of iNOS may constitute a novel element in the inflammatory process.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei, Taiwan; Natl Yang Ming Univ, Immunol Res Ctr, Taipei, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University	Lin, WW (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1 Jen Ai Rd,Sec 1, Taipei, Taiwan.			Lin, Wan Wan/0000-0002-3207-734X				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Chen BC, 1996, BRIT J PHARMACOL, V119, P1628, DOI 10.1111/j.1476-5381.1996.tb16082.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fredholm BB, 1996, DRUG DEVELOP RES, V39, P461, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<461::AID-DDR28>3.0.CO;2-2; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lin WW, 1997, BRIT J PHARMACOL, V121, P1749, DOI 10.1038/sj.bjp.0701300; Lin WW, 1997, EUR J PHARMACOL, V321, P121, DOI 10.1016/S0014-2999(96)00930-2; Lin WW, 1996, BRIT J PHARMACOL, V119, P261, DOI 10.1111/j.1476-5381.1996.tb15980.x; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; Mullet D, 1997, J Immunol, V158, P897; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Park YC, 1996, IMMUNOLOGY, V87, P296, DOI 10.1046/j.1365-2567.1996.456544.x; PAUL A, 1995, BRIT J PHARMACOL, V114, P482, DOI 10.1111/j.1476-5381.1995.tb13252.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SANDS WA, 1994, BIOCHEM BIOPH RES CO, V199, P461, DOI 10.1006/bbrc.1994.1251; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SODHI A, 1994, INT J IMMUNOPATH PH, V7, P65; SOWA G, 1994, EUR J PHARM-MOLEC PH, V266, P125, DOI 10.1016/0922-4106(94)90101-5; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TONETTI M, 1994, BIOCHEM BIOPH RES CO, V203, P430, DOI 10.1006/bbrc.1994.2200; TONETTI M, 1995, BIOCHEM BIOPH RES CO, V214, P125, DOI 10.1006/bbrc.1995.2265; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	56	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29754	29763		10.1074/jbc.273.45.29754	http://dx.doi.org/10.1074/jbc.273.45.29754			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792689	hybrid			2022-12-25	WOS:000076798300066
J	Denning, MF; Wang, YH; Nickoloff, BJ; Wrone-Smith, T				Denning, MF; Wang, YH; Nickoloff, BJ; Wrone-Smith, T			Protein kinase C delta is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40-TRANSFORMED HUMAN KERATINOCYTES; GROWTH-FACTOR RECEPTOR; B-INDUCED APOPTOSIS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; DIFFERENTIATION MARKERS; SIGNAL-TRANSDUCTION; IONIZING-RADIATION; GENE-EXPRESSION; IN-VITRO; CELLS	The elimination of ultraviolet (UV) radiation-damaged keratinocytes via apoptosis is an important mechanism for the protection of the skin from sunlight, an ubiquitous environmental carcinogen. Due to the pleiotropic nature of UV radiation, the molecular mechanisms of UV-induced apoptosis are poorly understood. Protein kinase C (PKC) is a family of enzymes critically involved in the regulation of differentiation in the epidermis, and is associated with the induction of apoptosis by ionizing radiation in other cell types. In normal human keratinocytes, the induction of apoptosis by UV exposure correlated with generation of the catalytic domain of PKC delta in the soluble fraction. In contrast, phorbol ester 12-O-tetradecanoylphorbol-13-acetate caused translocation of PKC delta from the soluble to the particulate fraction without inducing apoptosis. The effect of UV radiation on PKC delta was isoform specific, as UV exposure did not stimulate the cleavage, or effect the subcellular distribution of any other PKC isoform. The soluble, catalytic domain of PKC delta induced by UV exposure was associated with an increase in soluble PKC delta activity. Proteases of the caspase family are activated duping W-induced apoptosis. Inhibition of caspases blocked the W-induced cleavage of PKC delta and apoptosis. In addition, inhibition of PKC activity specifically inhibited UV-induced apoptosis of keratinocytes, without affecting the G(0)/G(1) cell cycle block induced by UV exposure. These results indicate that PKC activation is involved in the W-induced death effector pathway of keratinocytes undergoing apoptosis, and defines a novel role for this enzyme in epidermal homeostasis.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; Courtois SJ, 1997, EXP CELL RES, V233, P135, DOI 10.1006/excr.1997.3537; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Haake AR, 1997, EXP CELL RES, V231, P83, DOI 10.1006/excr.1996.3441; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; LICHTI U, 1988, CANCER RES, V48, P74; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MITRA R, 1994, KERATINOCYTE METHODS, P17; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Pena JC, 1998, CANCER RES, V58, P2111; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; SMITH MD, 1994, J INVEST DERMATOL, V102, P433, DOI 10.1111/1523-1747.ep12372958; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; Takahashi H, 1997, BIOCHEM BIOPH RES CO, V236, P194, DOI 10.1006/bbrc.1997.6931; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	207	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29995	30002		10.1074/jbc.273.45.29995	http://dx.doi.org/10.1074/jbc.273.45.29995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792720	hybrid			2022-12-25	WOS:000076798300097
J	Lindsey, DF; Amerik, A; Deery, WJ; Bishop, JD; Hochstrasser, M; Gomer, RH				Lindsey, DF; Amerik, A; Deery, WJ; Bishop, JD; Hochstrasser, M; Gomer, RH			A deubiquitinating enzyme that disassembles free polyubiquitin chains is required for development but not growth in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-SENSING FACTOR; SIGNAL TRANSDUCTION PATHWAYS; DE-UBIQUITINATING ENZYME; PROTEIN-DEGRADATION; GENE-EXPRESSION; CELL-DENSITY; DISCOIDEUM; CLONING; ISOPEPTIDASE; RECEPTOR	Although cell differentiation usually involves synthesis of new proteins, little is known about the role of protein degradation. In eukaryotes, conjugation to ubiquitin polymers often targets a protein for destruction. This process is regulated by deubiquitinating enzymes, which can disassemble ubiquitin polymers or ubiquitin-substrate conjugates, We find that a deubiquitinating enzyme, UbpA, is required for Dictyostelium development. ubpA cells have normal protein profiles on gels, grow normally, and show normal responses to starvation such as differentiation and secretion of conditioned medium factor. However, ubpA cells have defective aggregation, chemotaxis, cAMP relay, and cell adhesion, These defects result from low expression of cAMP pulse-induced genes such as those encoding the cAR1 cAMP receptor, phosphodiesterase, and the gp80 adhesion protein. Treatment of ubpA cells with pulses of exogenous cAMP allows them to aggregate and express these genes like wild-type cells, but they still fail to develop fruiting bodies. Unlike wild type, ubpA cells accumulate ubiquitin-containing species that comigrate with ubiquitin polymers, suggesting a defect in polyubiquitin metabolism. UbpA has sequence similarity with yeast Ubp14, which disassembles free ubiquitin chains. Yeast ubp14 cells have a defect in proteolysis, due to excess ubiquitin chains competing for substrate binding to proteasomes, Cross-species complementation and enzyme specificity assays indicate that UbpA and Ubp14 are functional homologs, We suggest that specific developmental transitions in Dictyostelium require the degradation of specific proteins and that this process in turn requires the disassembly of polyubiquitin chains by UbpA.	Howard Hughes Med Inst, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; Rice University; University of Chicago	Gomer, RH (corresponding author), Howard Hughes Med Inst, Houston, TX 77030 USA.	richard@bioc.rice.edu	Amerik, Alexander/AAM-4167-2020	Hochstrasser, Mark/0000-0002-1131-5484; Gomer, Richard/0000-0003-2361-4307	NIGMS NIH HHS [GM53586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Clark A, 1997, MOL BIOL CELL, V8, P1989, DOI 10.1091/mbc.8.10.1989; Clay JL, 1995, DEV BIOL, V172, P665, DOI 10.1006/dbio.1995.8045; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DOTTIN RP, 1991, DEV GENET, V12, P2, DOI 10.1002/dvg.1020120103; FALQUET L, 1995, FEBS LETT, V376, P233, DOI 10.1016/0014-5793(95)01287-7; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FAURE M, 1990, MOL CELL BIOL, V10, P1921, DOI 10.1128/MCB.10.5.1921; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FROHMAN MA, 1990, RACE RAPID AMPLIFICA, P28; GOMER RH, 1991, DEVELOPMENT, V112, P269; GOMER RH, 1987, STRATEGY STUDY DEV P, P471; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HADARI T, 1992, J BIOL CHEM, V267, P719; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, BIOTECHNIQUES, V12, P58; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MULLERTAUBENBERGER A, 1988, FEBS LETT, V229, P273, DOI 10.1016/0014-5793(88)81139-6; OHMACHI T, 1989, BIOCHEMISTRY-US, V28, P5226, DOI 10.1021/bi00438a046; PAMPORI NA, 1995, BIOTECHNIQUES, V18, P588; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; ROBERTSON ADJ, 1981, CELL, V24, P603, DOI 10.1016/0092-8674(81)90087-8; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SCHAAP P, 1991, INTERCELLULAR INTERA, P147; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIU CH, 1990, BIOESSAYS, V12, P357, DOI 10.1002/bies.950120802; SNARRJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; SOLL DR, 1982, DEV BIOL, V91, P183, DOI 10.1016/0012-1606(82)90021-5; SUSSMAN M, 1987, CULTIVATION SYNCHRON, P9; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VANHAASTERT PJM, 1984, J GEN MICROBIOL, V130, P2559; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; WU L, 1990, GENE, V91, P51, DOI 10.1016/0378-1119(90)90161-J; Yuan XQ, 1996, GENETICS, V144, P147; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069	55	43	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29178	29187		10.1074/jbc.273.44.29178	http://dx.doi.org/10.1074/jbc.273.44.29178			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786928	hybrid			2022-12-25	WOS:000076691800089
J	Ozawa, K; Suzuki, S; Asada, M; Tomooka, Y; Li, AJ; Yoneda, A; Komi, A; Imamura, T				Ozawa, K; Suzuki, S; Asada, M; Tomooka, Y; Li, AJ; Yoneda, A; Komi, A; Imamura, T			An alternatively spliced fibroblast growth factor (FGF)-5 mRNA is abundant in brain and translates into a partial agonist/antagonist for FGF-5 neurotrophic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE PROTECTION ASSAY; MESSENGER-RNA; NERVOUS-SYSTEM; FACTOR FAMILY; CLONED GENES; PC12 CELLS; IN-VIVO; EXPRESSION; PROTEIN; MEMBERS	We detected in the brain and then cloned two novel, short forms of human and mouse fibroblast growth factor (FGF)-5 mRNA, which were designated human FGF-5S (hFGF-5S) and mouse FGF-5S (mFGF-5S), respectively. Genomic analysis indicated that mFGF-5S and authentic mFGF-5 mRNAs were transcribed from a single gene; hFGF-5S and mFGF-5S mRNAs were generated by excluding the second exon of the respective FGF-5 genes, and the alternatively spliced mRNAs encoded for 123- and 121-amino acid proteins, respectively. Indeed, a neuron-like cell line expressing mFGF-5S mRNA secreted a protein of the expected size and with FGF-5 antigenicity. In PC12 cells, expression of hFGF-5 or exposure to hFGF-5 protein induced differentiation. Neither expression of hFGF-5S, alone, nor co-expression of hFGF-5S with hFGF-5 induced significant differentiation, At high concentrations, hFGF-5S protein partially antagonized FGF-5 activity, whereas by itself, hFGF-5S exerted very weak neurotrophic activity. hFGF-5S protein binds to FGF receptor (FGFR)-1 on PC12 transfectants and partially inhibits hFGF-5-induced tyrosine phosphorylation of FGFR-1 and an FGFR substrate, but it also induces phosphorylation by itself. These results suggest that FGF-5S is a naturally expressed partial agonist/antagonist of FGF-5 neurotrophic activity in the brain and that its effects are exerted in part at the level of the receptor.	Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tokyo University of Science; Tokyo University of Science	Imamura, T (corresponding author), Natl Inst Biosci & Human Technol, Biosignaling Dept, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		ASADA, MASAHIRO/M-4086-2018	ASADA, MASAHIRO/0000-0001-6092-2080				Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUAN C, 1988, GENE, V67, P21; Hattori Y, 1996, BBA-GENE STRUCT EXPR, V1306, P31, DOI 10.1016/0167-4781(19)60001-1; Hattori Y, 1997, MOL BRAIN RES, V47, P262, DOI 10.1016/S0169-328X(97)00065-X; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HUET C, 1994, CELL BIOL LAB HDB, V2, P291; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; KITAOKA T, 1994, INVEST OPHTH VIS SCI, V35, P3189; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Li AW, 1996, BIOCHEM BIOPH RES CO, V223, P19, DOI 10.1006/bbrc.1996.0839; Lin HY, 1996, J NEUROSCI, V16, P4579; LINDHOLM D, 1994, EUR J NEUROSCI, V6, P244, DOI 10.1111/j.1460-9568.1994.tb00267.x; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; Nakata H, 1996, BIOCHEM BIOPH RES CO, V218, P538, DOI 10.1006/bbrc.1996.0096; NASS SJ, 1995, BIOTECHNIQUES, V19, P772; NISHI R, 1994, SCIENCE, V265, P1052, DOI 10.1126/science.8066443; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozawa K, 1996, MOL BRAIN RES, V41, P279, DOI 10.1016/0169-328X(96)00108-8; Ozawa K., 1996, Molecular Biology of the Cell, V7, p186A; Ozawa K, 1997, BRAIN RES PROTOC, V1, P211, DOI 10.1016/S1385-299X(96)00030-X; Sambrook J., 2002, MOL CLONING LAB MANU; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tomooka Y, 1998, CELL STRUCT FUNCT, V23, P101, DOI 10.1247/csf.23.101; TURNBOW MA, 1993, BIOTECHNIQUES, V15, P267; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WUNDRACK I, 1992, ELECTROPHORESIS, V13, P637, DOI 10.1002/elps.11501301130; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YU YL, 1992, J EXP MED, V175, P1073, DOI 10.1084/jem.175.4.1073; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	51	31	35	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29262	29271		10.1074/jbc.273.44.29262	http://dx.doi.org/10.1074/jbc.273.44.29262			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786939	hybrid			2022-12-25	WOS:000076691800100
J	Chen, RH; Su, YH; Chuang, RLC; Chang, TY				Chen, RH; Su, YH; Chuang, RLC; Chang, TY			Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase Akt-dependent pathway	ONCOGENE			English	Article						TGF-beta-induced apoptosis; insulin; PI 3-kinase; Akt	PROGRAMMED CELL-DEATH; PROTEIN-KINASE AKT; FACTOR-II; SIGNALING PATHWAY; RAT HEPATOCYTES; HEPATOMA-CELLS; RECEPTORS; EXPRESSION; INDUCTION; SURVIVAL	Insulin and insulin receptor substrate 1 (IRS-1) are capable of protecting liver cells from apoptosis induced by transforming growth factor-beta (TGF-beta), The Ras/mitogen-activated protein kinase (MAP kinase) and the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathways are both activated upon insulin stimulation and can protect against apoptosis under certain circumstances. We investigated which of these pathways is responsible for the protective effect of insulin on TGF-beta-induced apoptosis. An activated Pas, although elicited a strong mitogenic effect, could not protect Hep3B cells from TGF-beta-induced apoptosis, Furthermore, PD98059, a selective inhibitor of MEK, did not suppress the antiapoptotic effect of insulin. In contrast, the PI 3-kinase inhibitor, LY294002, efficiently blocked the effect of insulin. Protection against TGF-beta-induced apoptosis conferred by PI 3-kinase was further verified by stable transfection of an activated PI 3-kinase, Downstream targets of PI 3-kinase involved in this protection was further investigated. An activated Akt mimicked the antiapoptotic effect of insulin, whereas a dominant-negative Akt inhibited such effect. However, rapamycin, the p70(S6) kinase inhibitor, had no effect on the protectivity of insulin against TGF-beta-induced apoptosis, suggesting that the antiapoptotic target of PI 3-kinase/Akt pathway is independent or lies upstream of the p70S6 kinase, The mechanism by which PI 3-kinase/Akt pathway interferes with the apoptotic signaling of TGF-beta was explored. Activation of PI 3-kinase did not lead to a suppression of Smad hetero-oligomerization or nuclear translocation but blocked TGF-beta-induced caspase-3-like activity. In summary, the PI 3-kinase/Akt pathway, but not the Ras/MAP kinase pathway, protects against TGF-beta-induced apoptosis by inhibiting a step downstream of Smad but upstream of caspase-3.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Sci, Inst Biol Chem, Taipei 10764, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Chen, RH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan.		Chen, Ruey-Hwa/G-6121-2019; Su, Yi-Hsien/F-2910-2014	Chen, Ruey-Hwa/0000-0001-8124-5832; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CARIANI E, 1988, CANCER RES, V48, P6844; Chao JR, 1997, ONCOGENE, V14, P721, DOI 10.1038/sj.onc.1200884; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Derynck R, 1994, CYTOKINE HDB, P319; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fan GS, 1996, ONCOGENE, V12, P1909; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; TAKAGI H, 1992, CANCER RES, V52, P5171; TANAKA S, 1996, CANCER RES, V56, P391; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG CY, 1995, CANCER RES, V55, P5101; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG D, 1993, CANCER RES, V53, P2020; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	53	160	170	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1959	1968		10.1038/sj.onc.1202111	http://dx.doi.org/10.1038/sj.onc.1202111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788439				2022-12-25	WOS:000076423500009
J	Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W				Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W			Modulation of endoplasmic reticulum calcium pump by Bcl-2	ONCOGENE			English	Article						Bcl-2; endoplasmic reticulum calcium pump; gene expression	INTRACELLULAR CALCIUM; GENE-EXPRESSION; CELL-GROWTH; APOPTOSIS; CA2+; HOMEOSTASIS; RECEPTOR; CHANNEL; PROTEIN; THAPSIGARGIN	Members of the bcl-2 gene family encode proteins that function either to promote or to inhibit apoptosis. Despite numerous efforts, the mechanism of action of Bcl-2, an anti-apoptotic protein, is still not clear. In particular, the relation between Bcl-2 and the endoplasmic reticulum (ER) calcium store is not well-understood. In the present work, we examined the effect of Bcl-2 on the ER store. We demonstrate that overexpression of Bcl-2 in breast epithelial cells modulates ER store by upregulating calcium pump (SERCA) expression,without affecting the release channel (IP3R). The steady state levels of SERCA2 mRNA and protein were both increased in Bcl-2 expression clones. The increase in SERCA2 protein leads to accelerated calcium uptake and enhanced Ca2+ loading. In addition, we also show the detection of intracellular interaction between Bcl-2 and SERCA molecules by co-immunoprecipitation. Since high lumenal Ca2+ concentration of ER is essential for normal cell functions, the results suggest that Bcl-2 preserves the ER Ca2+ store by upregulating SERCA gene expression as well as by a possible interaction with the pump.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Kuo, TH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.				NCI NIH HHS [CA-64139] Funding Source: Medline; NHLBI NIH HHS [HL-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064139, R01CA064139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CALPHAM DE, 1995, CELL, V80, P259; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; FURUYA Y, 1994, CANCER RES, V54, P6167; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; LIU CM, 1978, J BIOL CHEM, V253, P5892; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Marin MC, 1996, ONCOGENE, V12, P2259; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; UPADHYAY S, 1995, CANCER RES, V55, P4520; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	36	167	168	0	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1903	1910		10.1038/sj.onc.1202110	http://dx.doi.org/10.1038/sj.onc.1202110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788433				2022-12-25	WOS:000076423500003
J	Harder, KW; Moller, NPH; Peacock, JW; Jirik, FR				Harder, KW; Moller, NPH; Peacock, JW; Jirik, FR			Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FOCAL ADHESIONS; C-SRC; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; STABLE ASSOCIATION; V-CRK; PHOSPHORYLATED PROTEINS; MORPHOLOGICAL-CHANGES; ACTIVATED PP60C-SRC	The roles of protein-tyrosine phosphatases (PTPs) in processes such as cell growth and adhesion are poorly understood. To explore the ability of specific PTPs to regulate cell signaling pathways initiated by stimulation of growth factor receptors, we expressed the receptor-like PTP, PTP alpha, in A431 epidermoid carcinoma cells. These cells express high levels of the epidermal growth factor (EGF) receptor and proliferate in response to the autocrine production of transforming growth factor-alpha. Conversely, EGF stimulation of A431 cells in vitro leads to growth inhibit-ion and triggers the rapid detachment of these cells from the substratum. Although PTP alpha expression did not alter the growth characteristics of either unstimulated or EGF-stimulated cells, this phosphatase was associated with increased cell-substratum adhesion. Furthermore, PTP alpha-expressing A431 cells were strikingly resistant to EGF-induced cell rounding. Overexpression of PTP alpha in A431 cells was associated with the dephosphorylation/activation of specific Src family kinases, suggesting a potential mechanism for the observed alteration in A431 cell-substratum adhesion. Src kinase activation was dependent on the D1 catalytic subunit of PTP alpha, and there was evidence of association between PTP alpha and Src kinase(s). PTP alpha expression also led to increased association of Src kinase with the integrin-associated focal adhesion kinase, pp125(FAK). I,addition, paxillin, a Src and/or pp125(FAK) substrate, displayed increased levels of tyrosine phosphorylation in PTP alpha-expressing cells and was associated with elevated amounts of Csk. In view of these alterations in focal adhesion-associated molecules in PTP alpha-expressing A431 cells, as well as the changes in adhesion demonstrated by these cells, we propose that PTP alpha may have a role in regulating cell-substratum adhesion.	Univ British Columbia, Dept Med, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of British Columbia; Novo Nordisk	Jirik, FR (corresponding author), Univ British Columbia, Dept Med, Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	jirikcmmt.@ubc.ca						ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BERNARD G, 1994, J IMMUNOL, V152, P5161; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COBB BS, 1993, ONCOGENE, V8, P2897; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOMBE DR, 1994, BLOOD, V84, P739; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Fashena SJ, 1995, CURR BIOL, V5, P1367, DOI 10.1016/S0960-9822(95)00272-7; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GINSBURG E, 1985, CANCER LETT, V28, P143, DOI 10.1016/0304-3835(85)90069-2; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMATA N, 1986, CANCER RES, V46, P1648; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KING ICL, 1986, BIOCHEM BIOPH RES CO, V140, P837, DOI 10.1016/0006-291X(86)90710-2; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; LUI X, 1993, ONCOGENE, V8, P1119; MACLEOD CL, 1986, J CELL PHYSIOL, V127, P175, DOI 10.1002/jcp.1041270121; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OKADA M, 1993, J BIOL CHEM, V268, P18070; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SANTON JB, 1986, CANCER RES, V46, P4701; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZILTENER HJ, 1987, J IMMUNOL, V138, P1099	76	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31890	31900		10.1074/jbc.273.48.31890	http://dx.doi.org/10.1074/jbc.273.48.31890			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822658	hybrid			2022-12-25	WOS:000077207000040
J	Chen, XS; Zhang, YY; Funk, CD				Chen, XS; Zhang, YY; Funk, CD			Determinants of 5-lipoxygenase nuclear localization using green fluorescent protein 5-lipoxygenase fusion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; INTRACELLULAR-LOCALIZATION; ALVEOLAR MACROPHAGES; MOLECULAR-BIOLOGY; ARACHIDONIC-ACID; HUMAN-LEUKOCYTES; LEUKOTRIENE B-4; 12-LIPOXYGENASE; TRANSLOCATION; PURIFICATION	5-Lipoxygenase catalyzes the first two steps in the biosynthesis of leukotrienes, potent extracellular mediators of inflammation and allergic disorders. The unanticipated observation of 5-lipoxygenase in the nucleus of some cell types including bone marrow-derived mast cells (Chen, X, S., Naumann, T. A., Kurre, U., Jenkins, N. A, Copeland, N, G., and Funk, C. D, (1995) J. Biol, Chem, 270, 17993-17999) has raised speculation about intranuclear actions of leukotrienes or the enzyme itself. To explore the entry of 5-Lipoxygenase into the nucleus we have transfected various cell types with expression vectors encoding native 5-lipoxygenase and green fluorescent protein/5-lipoxygenase (GFP-5LO) fusion proteins. 5-Lipoxygenase and green fluorescent protein/5-lipoxygenase co-localized with the nuclear DNA stain Hoechst 33258 in each cell type. The three main basic regions of 5-lipoxygenase were incapable of acting as "classical" nuclear localization signal sequences. Mutations that abolished enzyme activity/non-heme iron resulted in proteins that would no longer enter the nucleus. An NH2-terminal 5-lipoxygenase fragment of 80 residues was sufficient for directing nuclear localization of green fluorescent protein but not cytosolic pyruvate kinase, The combined data suggest that 5-lipoxygenase enters the nucleus not by a classical nuclear localization signal but by a non-conventional signal located in the predicted beta-barrel domain that may be masked by structural alterations.	Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 805, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 805, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NHLBI NIH HHS [HL58464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Funk CD, 1997, NAT STRUCT BIOL, V4, P966, DOI 10.1038/nsb1297-966; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Hagmann W, 1996, EXP CELL RES, V228, P197, DOI 10.1006/excr.1996.0317; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAM BK, 1989, J BIOL CHEM, V264, P12885; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MAHMUD I, 1993, BIOCHIM BIOPHYS ACTA, V1166, P211, DOI 10.1016/0005-2760(93)90099-U; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; Tan R A, 1998, Curr Opin Pulm Med, V4, P25, DOI 10.1097/00063198-199801000-00005; UEDA N, 1986, J BIOL CHEM, V261, P7982; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; ZHANG YY, 1993, J BIOL CHEM, V268, P2535	43	58	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31237	31244		10.1074/jbc.273.47.31237	http://dx.doi.org/10.1074/jbc.273.47.31237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813031	hybrid			2022-12-25	WOS:000077136900059
J	Kim, YM; Kim, TH; Seol, DW; Talanian, RV; Billiar, TR				Kim, YM; Kim, TH; Seol, DW; Talanian, RV; Billiar, TR			Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; CASPASE FAMILY; CELL-DEATH; PROTEASE; COMPLEX; BAX; MITOCHONDRIA; LIVER	It is now known that caspase-3-like protease activation can promote BcI-2 cleavage and mitochondrial cytochrome c release and that these events can lead to further downstream caspase activation. NO has been proposed as a potent, endogenous inhibitor of caspase-3-like protease activity. Experiments were carried out to determine whether NO could interrupt Bcl-2 cleavage or cytochrome c release by the inhibition of caspase activity linking these events. NO inhibited the capacity of purified caspase-3 to cleave recombinant Bcl-2. Both Bcl-2 cleavage and cytochrome c release were inhibited in tumor necrosis factor alpha- and actinomycin D-treated MCF-7 cells exposed to NO donors. The NO-mediated inhibition of Bcl-2 cleavage and cytochrome c release occurred in association with an inhibition of apoptosis and caspase-3-like activation. Thus, NO suppresses a key step in the positive feedback amplification of apoptotic signaling by preventing Bcl-2 cleavage and cytochrome c release.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Kangwon Natl Univ, Coll Med, Dept Mol & Cellular Biochem, Chunchon 200701, South Korea; BASF Biores Corp, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kangwon National University; BASF	Billiar, TR (corresponding author), Presbyterian Univ Hosp, A1010,200 Lothrop St, Pittsburgh, PA 15213 USA.	billiar@pittsurg.nb.upmc.edu	Park, Sang-Youel/D-5966-2012	Park, Sang-Youel/0000-0003-0575-6045	NIGMS NIH HHS [R01-GM-44100] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Boese M, 1997, J BIOL CHEM, V272, P21767, DOI 10.1074/jbc.272.35.21767; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Crow J P, 1995, Adv Pharmacol, V34, P17; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LEIST M, 1995, AM J PATHOL, V146, P1220; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	36	215	227	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31437	31441		10.1074/jbc.273.47.31437	http://dx.doi.org/10.1074/jbc.273.47.31437			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813055	hybrid			2022-12-25	WOS:000077136900083
J	Bach, TL; Barsigian, C; Yaen, CH; Martinez, J				Bach, TL; Barsigian, C; Yaen, CH; Martinez, J			Endothelial cell VE-cadherin functions as a receptor for the beta 15-42 sequence of fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR STROMA GENERATION; HEPARIN-BINDING DOMAIN; ARG-GLY-ASP; BETA-CHAIN; TERMINAL DOMAIN; TUBE FORMATION; ADHESION; ANGIOGENESIS; RECOGNITION; PROTEIN	The content of fibrin with the apical surface of human umbilical vein endothelial cells (HUVEC) can induce capillary tube formation via the interaction of fibrin beta 15-42 with a putative cell receptor (Chalupowicz, D. G., Chowdhury, Z. A., Bach, T. L., Barsigian, C., and Martinez, J. (1945) J. Cell Biol. 130, 207-215). To characterize this interaction, we studied the binding of the thrombin-cleaved N-terminal disulfide knot of fibrin (NDSK II), a dimeric fragment with exposed beta 15-42, to HUVEC in three separate assay systems. Time-course binding of I-125-NDSK II to HUVEC monolayers or suspensions revealed that binding was specific at 50-60%, as determined by the addition of unlabeled NDSK II. Specific binding of I-125-NDSK II to HUVEC was 70% reversible by dilution or by competition, and was found to be divalent cation-independent. Binding plateaued after 10 min at a saturation of 15-20 nM. Scatchard analysis using the LIGAND computer program defined a single population of receptors with a K-D of 7.7 +/- 1.6 nM and approximately 21,000 +/- 7000 binding sites/cell. N-terminal disulfide knot derivatives in which beta 15-42 was absent (NDSK 325) or unexposed (NDSK, NDSK I) did not show specific binding. Specific binding of I-125-NDSK II could not be inhibited by RGDS or by antibodies to the alpha(v)beta(3) or beta(1) integrins, PECAM-1, ICAM-1, or N-cadherin, In contrast, a synthetic beta 15-42/ovalbumin conjugate inhibited total I-125-NDSK II binding by 47 +/- 19% (corresponding to 95% of specific I-125-NDSK II bound) and a monoclonal antibody to vascular endothelial cadherin (VE-cadherin) inhibited binding by 35 +/- 8% (corresponding to 70% of specific 125I-NDSK II bound). Another assay was based on the capture of cadherins from HUVEC lysates by a polyclonal pan-cadherin antibody immobilized on plastic dishes. Binding of NDSK II to the captured cadherins was 89 +/- 5% specific, while specific binding of NDSK 325 and NDSK was negligible. An immortalized line of human adipose-derived microvascular endothelial cells, which express N-cadherin but not VE-cadherin, demonstrated no specific binding of NDSK II by the capture assay. These data define a novel interaction of fibrin with VE-cadherin, which is mediated by the fibrin N-terminal beta 15-42 sequence, and may contribute to the mechanism through which fibrin induces angiogenesis.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Hematol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Martinez, J (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, 1015 Walnut St, Philadelphia, PA 19107 USA.				NHLBI NIH HHS [HL-20092] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020092] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; Dejana E, 1997, J CLIN INVEST, V100, pS7; DeLisser HM, 1997, AM J PATHOL, V151, P671; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; Famiglietti J, 1997, J CELL BIOL, V138, P1425, DOI 10.1083/jcb.138.6.1425; FLYNN JT, 1997, SHOCK, V7, P1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P5; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; Matsumura T, 1997, J IMMUNOL, V158, P3408; MEH DA, 1995, J LAB CLIN MED, V125, P384; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Newman PJ, 1997, J CLIN INVEST, V100, pS25; Odrljin TM, 1996, ARTERIOSCL THROM VAS, V16, P1544, DOI 10.1161/01.ATV.16.12.1544; Odrljin TM, 1996, BLOOD, V88, P2050, DOI 10.1182/blood.V88.6.2050.bloodjournal8862050; OSTER ZH, 1985, P NATL ACAD SCI USA, V82, P3465, DOI 10.1073/pnas.82.10.3465; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PROCYK R, 1991, BLOOD, V77, P1469; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SALOMON D, 1992, J CELL SCI, V102, P7; SHAINOFF JR, 1990, THROMB HAEMOSTASIS, V63, P193; SMITH JW, 1994, J BIOL CHEM, V269, P960; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VERNON RB, 1995, AM J PATHOL, V147, P873; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; WEIMAR B, 1986, ARTERIOSCLEROSIS, V6, P139, DOI 10.1161/01.ATV.6.2.139	58	104	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30719	30728		10.1074/jbc.273.46.30719	http://dx.doi.org/10.1074/jbc.273.46.30719			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804847	hybrid			2022-12-25	WOS:000077008100094
J	Bennett, EP; Hassan, H; Mandel, U; Mirgorodskaya, E; Roepstorff, P; Burchell, J; Taylor-Papadimitriou, J; Hollingsworth, MA; Merkx, G; van Kessel, AG; Eiberg, H; Steffensen, R; Clausen, H				Bennett, EP; Hassan, H; Mandel, U; Mirgorodskaya, E; Roepstorff, P; Burchell, J; Taylor-Papadimitriou, J; Hollingsworth, MA; Merkx, G; van Kessel, AG; Eiberg, H; Steffensen, R; Clausen, H			Cloning of a human UDP-N-acetyl-alpha-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; MOLECULAR-CLONING; CDNA CLONING; IN-VIVO; HUMAN GENOME; EXPRESSION; GENE; SPECIFICITY; SEQUENCE; CELLS	A fourth human UDP-GalNAc:polypeptide N- acetylgalactosaminyltransferase, designated GalNAc-T4, was cloned and expressed. The genomic organization of GalNAc-T4 is distinct from GalNAc-T1, -T2, and -T3, which contain multiple coding exons, in that the coding region is contained in a single exon. GalNAc-T4 was placed at human chromosome 12q21.3-q22 by in situ hybridization and linkage analysis. GalNAc-T4 expressed in Sf9 cells or in a stably transfected Chinese hamster ovary cell line exhibited a unique acceptor substrate specificity. GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined). Furthermore, GalNAc-T4 showed the best kinetic properties with an O-glycosylation site in the P-selectin glycoprotein ligand-1 molecule. Northern analysis of human organs revealed a wide expression pattern. Immunohistology with a monoclonal antibody showed the expected Golgi-like localization in salivary glands. A single base polymorphism, G1516A (Val to lie), was identified (allele frequency 34%). The function of GalNAc-T4 complements other GalNAc-transferases in O-glycosylation of MUC1 showing that glycosylation of MUC1 is a highly ordered process and changes in the repertoire or topology of GalNAc-transferases will result in altered pattern of O-glycan attachments.	Univ Copenhagen, Sch Dent, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Copenhagen, Fac Hlth Sci, Genet Inst, DK-2200 Copenhagen N, Denmark; Aalborg Hosp, Reg Ctr Blood Transfus, Aalborg, Denmark	University of Copenhagen; University of Southern Denmark; Cancer Research UK; University of Nebraska System; University of Nebraska Medical Center; Radboud University Nijmegen; University of Copenhagen; Aalborg University; Aalborg University Hospital	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Fac Hlth Sci, Norre Allee 20, DK-2200 Copenhagen N, Denmark.		van Kessel, Ad Geurts/A-2810-2010; clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012; Bennett, Eric/AAG-6120-2020	Bennett, Eric/0000-0002-4976-0647; Burchell, Joy/0000-0003-0413-3823	NCI NIH HHS [1 RO1 CA66234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V211, P347, DOI 10.1006/bbrc.1995.1817; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, GLYCOBIOLOGY, V8, P547, DOI 10.1093/glycob/8.6.547; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; CLAUSEN H, 1994, TRANSFUS CLIN BIOL, V1, P79, DOI 10.1016/S1246-7820(94)80001-4; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; deSouza SJ, 1996, P NATL ACAD SCI USA, V93, P14632, DOI 10.1073/pnas.93.25.14632; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EIBERG H, 1989, CLIN GENET, V35, P313; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GUM JR, 1989, J BIOL CHEM, V264, P6480; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; LOWE JB, 1993, BAILLIERE CLIN HAEM, V6, P465, DOI 10.1016/S0950-3536(05)80155-6; MANDEL U, 1998, IN PRESS GLYCOBIOLOG; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; Meurer JA, 1996, GLYCOBIOLOGY, V6, P231, DOI 10.1093/glycob/6.2.231; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Nadir E, 1996, P NATL ACAD SCI USA, V93, P6470, DOI 10.1073/pnas.93.13.6470; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; Nehrke K, 1998, GLYCOBIOLOGY, V8, P367, DOI 10.1093/glycob/8.4.367; Nielsen PA, 1996, J DENT RES, V75, P1820, DOI 10.1177/00220345960750110201; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OTT J, 1976, AM J HUM GENET, V28, P528; OTT J, 1996, AM J HUM GENET, V59, P810; Porchet N, 1995, BIOCHEM SOC T, V23, P800, DOI 10.1042/bst0230800; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; TaylorPapadimitriou J, 1997, IMMUNOL TODAY, V18, P105, DOI 10.1016/S0167-5699(97)01028-1; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156	50	188	210	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30472	30481		10.1074/jbc.273.46.30472	http://dx.doi.org/10.1074/jbc.273.46.30472			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804815	hybrid			2022-12-25	WOS:000077008100062
J	Mowen, K; David, M				Mowen, K; David, M			Role of the STAT1-SH2 domain and STATE in the activation and nuclear translocation of STAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR ISGF-3; MUTANT-CELL LINE; INTERFERON-GAMMA; ALPHA-INTERFERON; IFN-GAMMA; GENE; RECEPTOR; PHOSPHORYLATION	Interferon (IFN) induction of immediate-early response genes is mediated through the signal transducers and activators of transcription (STATs), Activation of STAT1 by IFN alpha or IFN gamma through its tyrosine phosphorylation involves members of the Jak tyrosine kinases, In addition, STAT2 is activated by IFN alpha; and, together with STAT1 and p48/ISGF3 gamma, forms the transcription factor complex ISGF3, Previous findings suggested that the STAT1-SH2 domain, which is required for the homo- or heterodimerization of STAT1, also participates in the recruitment of STAT1 to the IFN-receptors, because mutations in the SH2-domain abolished STAT1 activation by IFN gamma, Furthermore, STATE was reported to be required for the activation of STAT1 by IFN alpha, We were able to induce STAT1 tyrosine phosphorylation by IFN alpha/beta in the absence of STAT2 or a functional STAT1-SH2 domain. In contrast, IFN gamma was unable to cause tyrosine phosphorylation of STAT1-(SH2:Arg --> Gln). Interestingly, although STAT1 was found in the nucleus in STAT2-deficient cells, the nuclear accumulation of the tyrosine phosphorylated SH2-mutant STAT1 was impaired. In summary, our results indicate that the SH2 domain of STAT1 is not required for its ligand-dependent activation by IFN alpha/beta, Moreover, tyrosine phosphorylation is not sufficient to target STAT1 to the nucleus; rather, dimerization appears to play a critical role in the subcellular distribution of STAT1.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,Bonner Hall 3138, La Jolla, CA 92093 USA.				NCI NIH HHS [CA80105] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Bach EA, 1996, MOL CELL BIOL, V16, P3214; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FINBLOOM DS, 1995, ARTHRITIS RHEUM-US, V38, P877, DOI 10.1002/art.1780380702; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HALLEK M, 1992, BLOOD, V80, P1736; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAEHELI P, 1986, MOL CELL BIOL, V6, P4770, DOI 10.1128/MCB.6.12.4770; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; YAN C, 1989, P NATL ACAD SCI USA, V86, P2243, DOI 10.1073/pnas.86.7.2243; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x	46	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30073	30076		10.1074/jbc.273.46.30073	http://dx.doi.org/10.1074/jbc.273.46.30073			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804758	Green Published, hybrid			2022-12-25	WOS:000077008100005
J	Pearce, D; Matsui, W; Miner, JN; Yamamoto, KR				Pearce, D; Matsui, W; Miner, JN; Yamamoto, KR			Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOSITE RESPONSE ELEMENT; ALPHA-FETOPROTEIN GENE; C-JUN; FUNCTIONAL ANTAGONISM; NEGATIVE REGULATION; BINDING DOMAIN; AP-1; FOS; INTERFERENCE; ACTIVATION	The glucocorticoid receptor (GR) displays distinct modes of regulation when bound at glucocorticoid response elements (GREs) bearing different binding sequences and arrangements of binding sites. For example, it has been shown to activate transcription synergistically with itself or with other regulatory factors, such as AP1, when bound to a consensus palindromic element or "simple GRE" that is multimerized or linked tightly with an API site. In contrast, at certain "composite GREs" GR and AP1 bind to nonconsensus sequences, and GR either activates or represses depending on the subunit composition of AP1, To uncouple the contributions to regulatory behavior of binding sequences and binding element arrangements, we examined GR action at "paired elements," combinations of a simple GRE and a consensus AP1 site, separated by different distances. We found that GR synergized with either c-Jun or c-Jun-c-Fos at paired elements with GRE-AP1 site separations of greater than or equal to 26 base pairs. In contrast, paired elements with separations of 14-18 base pairs mimicked the composite GRE, i.e, GR synergized with c-Jun and repressed c-Jun-c-Fos, In DNA binding studies, GR and AP1 cooccupied the paired elements, We conclude that the arrangement of binding sites within a compound response element can be a major determinant of regulatory factor action.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pearce, D (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.		Matsui, William H/C-3383-2009	Matsui, William/0000-0002-3088-0964	NATIONAL CANCER INSTITUTE [R01CA020535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051151] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 20535] Funding Source: Medline; NIDDK NIH HHS [R29-DK51151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate C, 1990, Semin Cancer Biol, V1, P19; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONG JM, 1989, MOL CELL ENDOCRINOL, V66, P109, DOI 10.1016/0303-7207(89)90054-3; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; HERBOMEL P, 1990, New Biologist, V2, P1063; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kerppola TK, 1997, EMBO J, V16, P2907, DOI 10.1093/emboj/16.10.2907; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WH, 1996, MOL ENDOCRINOL, V10, P1399, DOI 10.1210/me.10.11.1399; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MITTAL R, 1994, MOL ENDOCRINOL, V8, P1701, DOI 10.1210/me.8.12.1701; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Petz LN, 1997, J STEROID BIOCHEM, V60, P31, DOI 10.1016/S0960-0760(96)00171-9; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sitlani A, 1996, P NATL ACAD SCI USA, V93, P3248, DOI 10.1073/pnas.93.8.3248; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, V22, P1169; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	30	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30081	30085		10.1074/jbc.273.46.30081	http://dx.doi.org/10.1074/jbc.273.46.30081			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804760	hybrid			2022-12-25	WOS:000077008100007
J	Katsube, T; Takahisa, M; Ueda, R; Hashimoto, N; Kobayashi, M; Togashi, S				Katsube, T; Takahisa, M; Ueda, R; Hashimoto, N; Kobayashi, M; Togashi, S			Cortactin associates with the cell-cell junction protein ZO-1 in both Drosophila and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TYROSINE PHOSPHORYLATION; TIGHT JUNCTION; DNA-BINDING; HEMATOPOIETIC LINEAGE; NEGATIVE REGULATOR; EPITHELIAL-CELLS; CYCLIN D1; EXPRESSION; EXTRAMACROCHAETAE	Cortactin is an actin filament-binding protein localizing at cortical regions of cells and a prominent substrate for Src family protein-tyrosine kinases in response to multiple extracellular stimuli. Human cortactin has been identified as a protein product of a putative oncogene, EMS1. In this report, we describe the identification of a Drosophila homolog of cortactin as a molecule that interacts with Drosophila ZO-1 using yeast two-hybrid screening. Drosophila cortactin is a 559-amino acid protein highly expressed in embryos, larvae, and pupae but relatively underexpressed in adult flies. Deletion and substitution mutant analyses revealed that the SH3 domain of Drosophila cortactin binds to a PXXP motif in the proline-rich domain of Drosophila ZO-1. Colocalization of these proteins at cell-cell junction sites was evident under a confocal laser-scanning microscope. In vivo association was confirmed by coimmunoprecipitation of cortactin and ZO-1 from Drosophila embryo lysates. We also demonstrate an association for each of the murine homologs by immunoprecipitation analyses of mouse tissue lysates. Our previous work has demonstrated the involvement of ZO-1 in a signaling pathway that regulates expression of the emc gene in Drosophila. The potential roles of the cortactin.ZO-1 complex in cell adhesion and cell signaling are discussed.	Mitsubishi Kasei Inst Life Sci, Neurogenet Res Project, Machida, Tokyo 1948511, Japan		Togashi, S (corresponding author), Mitsubishi Kasei Inst Life Sci, Neurogenet Res Project, Minamiooya 11, Machida, Tokyo 1948511, Japan.							ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIURA K, 1995, CELL MOTIL CYTOSKEL, V30, P272, DOI 10.1002/cm.970300405; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KITAMURA D, 1995, BIOCHEM BIOPH RES CO, V208, P1137, DOI 10.1006/bbrc.1995.1452; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; MAA MC, 1992, ONCOGENE, V7, P2429; MIGLARESE MR, 1994, ONCOGENE, V9, P1989; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WONG S, 1992, ONCOGENE, V7, P2407; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457	44	123	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29672	29677		10.1074/jbc.273.45.29672	http://dx.doi.org/10.1074/jbc.273.45.29672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792678	hybrid			2022-12-25	WOS:000076798300055
J	Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M				Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M			Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation	ONCOGENE			English	Article						Cdk3; cell cycle; p27; c-Myc; E2F	DEPENDENT KINASES; THYMIDINE KINASE; C-MYC; PROTEIN-KINASES; RETINOBLASTOMA PROTEIN; GENE; COMPLEXES; FAMILY; E2F; TRANSACTIVATION	The G1-S transition in mammalian cells has been demonstrated to require the cyclin-dependent kinases cdk2, cdk3 and cdk4/6. Here we show that a novel kinase activity associated with cdk3 fluctuates throughout the cell cycle differently from the expression of cyclin D1-, E- and A-associated kinase activities. Cdk3 kinase activity is neither affected by p16 (in contrast to cdk4/6) nor by E2F-1 (in contrast to cdk2), but is downregulated upon transient p27 expression. We found cdk3 to bind to p21 and p27, We provide evidence that p27 could be involved in the regulation of the cell cycle fluctuation of cdk3 activity: cdk3 protein does not fluctuate and interaction of cdk3 with p27, but not with p21, is lost when cdk3 kinase becomes active during the cell cycle. In Myc-overexpressing cells, but not in normal Rat1 cells, constitutive ectopic expression of cdk3 induces specific upregulation of cdk3-associated kinase activity that is still cell cycle phase dependent. Ectopic cdk3, but not cdk2, enhances Myc-induced proliferation and anchorage-independent growth associated with Myc activation, without effects on cyclin D1, E- and A protein expression or kinase activities. High levels of cdk3 in Myc-overexpressing cells trigger up- and deregulation of E2F-dependent transcription without inducing the E2F-DNA binding capacity. In contrast to all other studied positive G1 regulators, cdk3 is unable to cooperate with ras in fibroblast transformation suggesting a function of cdk3 in G1 progression that is different from cyclin Dor E-associated kinase activities. Our data provide first insights into the regulation of cdk3-associated kinase activity and suggest a model how cdk3 participates in the regulation of the G1-S transition.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Klinikum Esses, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Moroy, Tarik/D-9923-2011					BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BULLRICH F, 1995, CANCER RES, V55, P1199; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Sherbet G.V., 1997, GENETICS CANC; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VLACH J, 1996, EMBO J, V15, P6596; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	38	28	30	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2259	2269		10.1038/sj.onc.1202145	http://dx.doi.org/10.1038/sj.onc.1202145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811456				2022-12-25	WOS:000076698200011
J	Du, GG; MacLennan, DH				Du, GG; MacLennan, DH			Functional consequences of mutations of conserved, polar amino acids in transmembrane sequences of the Ca2+ release channel (ryanodine receptor) of rabbit skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; MALIGNANT HYPERTHERMIA; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; PROTEIN ISOFORMS; CELLS; LOCALIZATION; SITES; CA2+-ATPASE; SENSITIVITY	The potential role in Ca2+ release channel function of highly conserved, polar, and small amino acids in predicted transmembrane sequences in the rabbit skeletal muscle ryanodine receptor (RyR1) was investigated through mutagenesis, Acidic amino acids Asp(3987), Glu(4032), Asp(4815), Asp(4917), Asp(4938),and Asp(4969) and amidated residues Asn(4034) Asn(4037) Asn(4574) Asn(4805), Asn(4806), and Gln(4933), and Gly(4033) were mutated to Ala, and Ala(3988) was mutated to Val, When expressed in HEK-293 cells and challenged with either caffeine or 4-chloro-m cresol, mutants E4032A, N4806A, D4815A, and D4917A did not respond, indicating that Ca2+ release channel function was impaired. None of these mutants exhibited specific binding of [H-3]ryanodine. Mutants N4805A and Q4933A showed a diminished response to both caffeine and 4-chloro-m-cresol, but [H-3]ryanodine binding was not altered. Other mutant responses and the responses of mutants E4032D, N4806Q or D, D4815N or E, and D4938N or E were unaltered when compared with RyR1, However, mutants E4032Q, D4917N or E, and Q4933N or E displayed neither caffeine nor 4-chloro-m-cresol response nor [H-3]ryanodine binding. Sedimentation assays indicated that the nonfunctional mutants did contain tetrameric complexes, implying that defects in the assembly of a functional channel did not occur with specific mutations in transmembrane sequences. These results support the view that amino acids Glu(4032) (M2), Asn(4806) (M7), Asp(4815) (M7), Asp(4917) (M10), and Gln(4933) (M10) are involved in channel function and regulation.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						AIREY JA, 1990, J BIOL CHEM, V265, P14187; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GRUNWALD R, 1995, J BIOL CHEM, V270, P11338, DOI 10.1074/jbc.270.19.11338; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARTY I, 1994, BIOCHEM J, V298, P743, DOI 10.1042/bj2980743; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; OTSU K, 1994, J BIOL CHEM, V269, P9413; OTSU K, 1990, J BIOL CHEM, V265, P13472; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUTKO JL, 1996, AM J PHYSIOL, V271, pC1007; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	48	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31867	31872		10.1074/jbc.273.48.31867	http://dx.doi.org/10.1074/jbc.273.48.31867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822655	hybrid			2022-12-25	WOS:000077207000037
J	Lin, BC; Annabi, B; Hiraiwa, H; Pan, CJ; Chou, JY				Lin, BC; Annabi, B; Hiraiwa, H; Pan, CJ; Chou, JY			Cloning and characterization of cDNAs encoding a candidate glycogen storage disease type 1b protein in rodents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATE TRANSPORT-SYSTEM; MICROSOMAL GLUCOSE-6-PHOSPHATASE; ENZYME-DEFICIENT; MESSENGER-RNA; GENE; MUTATIONS; IB; 1A; STIMULATION; MEMBRANE	Glycogen storage disease type 1 (GSD-I) is a group of genetic disorders caused by a deficiency in the activity of the enzyme glucose-6-phosphatase. (G6Pase). GSD-la and GSD-lb, the two major subgroups, have been confirmed at the molecular genetic level. The gene responsible for GSD-lb maps to human chromosome 11q23 and a candidate human GSD-lb cDNA that encodes a microsomal transmembrane protein has been identified. In this study, we show that this cDNA maps to chromosome 11q23; thus it is a strong candidate for GSD-lb. Furthermore, we isolated and characterized candidate murine and rat GSD-lb cDNAs. Both encode transmembrane proteins sharing 93-95% sequence homology to the human GSD-lb protein. The expression profiles of murine GSD-lb and G6Pase differ both in the liver and in the kidney; the GSD-lb transcript appears before the G6Pase mRNA during development. In addition to G6Pase deficiency, GSD-lb patients suffer neutropenia, neutrophil dysfunction, and recurrent bacterial infections. Interestingly, although the G6Pase mRNA is expressed primarily in the liver, kidney, and intestine, the GSD-lb mRNA is expressed in numerous tissues, including human neutrophils/monocytes.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chou@helix.nih.gov	Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785				Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; BUBLITZ C, 1988, J BIOL CHEM, V263, P12849; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coligan JKA, 1991, CURRENT PROTOCOLS IM; FULCERI R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P129, DOI 10.1016/0005-2736(90)90409-H; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; GOLDSMITH PK, 1979, BIOCHIM BIOPHYS ACTA, V583, P133, DOI 10.1016/0304-4165(79)90421-5; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; IGARASHI Y, 1984, BIOCHEM BIOPH RES CO, V119, P593, DOI 10.1016/S0006-291X(84)80290-9; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; KADNER RJ, 1993, J BIOENERG BIOMEMBR, V25, P637; KILPATRICK L, 1990, J CLIN INVEST, V86, P196, DOI 10.1172/JCI114684; KOVEN NL, 1986, PEDIATR RES, V20, P438, DOI 10.1203/00006450-198605000-00012; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; MartinezZaguilan R, 1996, MINER ELECTROL METAB, V22, P318; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; MOSES SW, 1990, J PEDIATR GASTR NUTR, V11, P155, DOI 10.1097/00005176-199008000-00004; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NILSSON OS, 1978, EUR J BIOCHEM, V82, P627, DOI 10.1111/j.1432-1033.1978.tb12059.x; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; ROE TF, 1992, NEW ENGL J MED, V326, P1666, DOI 10.1056/NEJM199206183262504; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; WENDEL U, 1993, EUR J PEDIATR, V152, pS49	37	68	69	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31656	31660		10.1074/jbc.273.48.31656	http://dx.doi.org/10.1074/jbc.273.48.31656			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822626	hybrid			2022-12-25	WOS:000077207000008
J	Lowe, ME; Kaplan, MH; Jackson-Grusby, L; D'Agostino, D; Grusby, MJ				Lowe, ME; Kaplan, MH; Jackson-Grusby, L; D'Agostino, D; Grusby, MJ			Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-STIMULATED LIPASE; CARBOXYL ESTER LIPASE; EXOCRINE PANCREAS; DEFICIENT MICE; TARGET-CELLS; HUMAN-MILK; GENE; GP-3; IDENTIFICATION; ORGANIZATION	The pancreas secretes several different Lipases. The most abundant is pancreatic triglyceride lipase (PTL). The pancreas also synthesizes two homologues of PTL, the pancreatic lipase-related proteins 1 and 2 (PLRP1 and PLRP2), Cytotoxic T-lymphocytes also express PLRP2 under certain conditions. We sought to determine the role of PLRP2 in fat absorption and in T-cell cytotoxicity by creating a PLRP2-deficient mouse. Adult PLRP2-deficient mice had normal fat absorption. In contrast, suckling PLRP2-deficient mice had fat malabsorption evidenced by increased fecal weight, increased fecal fats, and the presence of undigested and partially digested dietary triglycerides in the feces. As a result, the PLRP2-deficient pups had a decreased rate of weight gain. To assess T cell cytotoxicity, we immunized PLRP2-deficient mice with a mastocytoma cell line, P815, and determined the ability of splenocytes from the immunized mice to kill P815 cells in a Cr-51 release assay. PLRP2-deficient cells had deficient killing activity in this assay, and PLRP2-deficient splenocytes released fewer fatty acid from the target cells than did control cells. Our results provide the first evidence of a physiological function for PLRP2, PLRP2 participates in T cell cytotoxicity, and PLRP2 performs a crucial role in the digestion of dietary fats in suckling animals.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Lowe, ME (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116, St Louis, MO 63110 USA.				Intramural NIH HHS [Z01 DK053100] Funding Source: Medline; NCI NIH HHS [CA-56462] Funding Source: Medline; NIDDK NIH HHS [R01 DK053100] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA056462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053100, R01DK053100] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSON JW, 1989, AM J PHYSIOL, V256, pG817, DOI 10.1152/ajpgi.1989.256.5.G817; Andersson L, 1996, BBA-LIPID LIPID MET, V1302, P236, DOI 10.1016/0005-2760(96)00068-9; BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BITMAN J, 1981, J LIQ CHROMATOGR, V4, P1023, DOI 10.1080/01483918108059602; BITMAN J, 1981, J LIQ CHROMATOGR, V4, P1007, DOI 10.1080/01483918108059601; CHEN Q, 1989, BIOCHIM BIOPHYS ACTA, V1004, P372, DOI 10.1016/0005-2760(89)90086-6; COHEN M, 1971, GASTROENTEROLOGY, V60, P1; CYGLER M, 1993, PROTEIN SCI, V2, P366; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FREDIKZON A, 1978, PEDIATR RES, V43, P247; GILLER T, 1992, J BIOL CHEM, V267, P16509; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HERNELL O, 1993, J PEDIATR GASTR NUTR, V16, P426, DOI 10.1097/00005176-199305000-00014; Hernell O., 1992, SEMINARS GASTROINTES, V3, P189; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOFMANN AF, 1971, BILE ACIDS, P103; HOGAN B, 1994, MANIPULATING MOUSE E, P373; JENNENS ML, 1995, J LIPID RES, V36, P2374; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kaplan MH, 1996, GENOMICS, V35, P606, DOI 10.1006/geno.1996.0407; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; Lowe ME, 1997, METHOD ENZYMOL, V284, P285; MILLER PE, 1987, AM J PHYSIOL, V252, pG768, DOI 10.1152/ajpgi.1987.252.6.G768; MORGAN RGH, 1969, Q J EXP PHYSIOL CMS, V54, P228, DOI 10.1113/expphysiol.1969.sp002021; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; RICHIERI GV, 1991, J IMMUNOL, V147, P2809; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; WAGNER ACC, 1994, J BIOL CHEM, V269, P9099; WISHART MJ, 1993, J BIOL CHEM, V268, P10303	33	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31215	31221		10.1074/jbc.273.47.31215	http://dx.doi.org/10.1074/jbc.273.47.31215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813028	Green Accepted, hybrid			2022-12-25	WOS:000077136900056
J	Beeler, T; Bacikova, D; Gable, K; Hopkins, L; Johnson, C; Slife, H; Dunn, T				Beeler, T; Bacikova, D; Gable, K; Hopkins, L; Johnson, C; Slife, H; Dunn, T			The Saccharomyces cerevisiae TSC10/YBR265w gene encoding 3-ketosphinganine reductase is identified in a screen for temperature-sensitive suppressors of the Ca2+-sensitive csg2 Delta mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PALMITOYLTRANSFERASE ACTIVITY; SHORT-CHAIN DEHYDROGENASES; SPHINGOLIPID SYNTHESIS; ENDOPLASMIC-RETICULUM; PROTEIN; STRAINS; YEAST; BIOSYNTHESIS; DISRUPTION; SEQUENCE	Saccharomyces cerevisiae csg2 Delta mutants accumulate the sphingolipid inositolphosphorylceramide, which renders the cells Ca2+-sensitive. Temperature-sensitive mutations that suppress the Ca2+ sensitivity of csg2 Delta mutants were isolated and characterized to identify genes that encode sphingolipid synthesis enzymes. These temperature-sensitive csg2 Delta suppressors (tsc) fall into 15 complementation groups. The TSC10/YBR265w, gene was found to encode 3-ketosphinganine reductase, the enzyme that catalyzes the second step in the synthesis of phytosphingosine, the long chain base found in yeast sphingolipids. 3-Ketosphinganine reductase (Tsc10p) is essential for growth in the absence of exogenous dihydrosphingosine or phytosphingosine, Tsc10p is a member of the short chain dehydrogenase/reductase protein family. The tsc10 mutants accumulate 3-ketosphinganine and microsomal membranes isolated from tsc10 mutants have low 3-ketosphinganine reductase activity. His(6)-tagged Tsc10p was expressed in Escherichia coli and isolated by nickel-nitrilotriacetic acid column chromatography. The recombinant protein catalyzes the NADPH-dependent reduction of 3-ketosphinganine. These data indicate that Tsc10p is necessary and sufficient for catalyzing the NADPH-dependent reduction of 3-ketosphinganine to dihydrosphingosine.	Uniformed Serv Univ Hlth Sci, Dept Biochem, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Bacikova, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem, Bethesda, MD 20814 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HUNG CY, 1995, BIOCHEM J, V307, P107, DOI 10.1042/bj3070107; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1637, DOI 10.1515/bchm2.1968.349.2.1637; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; ZHAO C, 1994, J BIOL CHEM, V269, P21480	24	149	153	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30688	30694		10.1074/jbc.273.46.30688	http://dx.doi.org/10.1074/jbc.273.46.30688			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804843	Green Submitted, hybrid			2022-12-25	WOS:000077008100090
J	Hatzis, P; Al-Madhoon, AS; Jullig, M; Petrakis, TG; Eriksson, S; Talianidis, I				Hatzis, P; Al-Madhoon, AS; Jullig, M; Petrakis, TG; Eriksson, S; Talianidis, I			The intracellular localization of deoxycytidine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE ANALOGS; I-KAPPA-B; CELL-CYCLE; RIBONUCLEOTIDE REDUCTASE; PHOSPHOLIPID PRECURSORS; TRANSCRIPTION FACTORS; THYMIDINE KINASE-1; DNA; EXPRESSION; MOUSE	Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxynucleoside salvage pathway in mammalian cells and plays a key role in the activation of several pharmacologically important nucleoside analogs. Using a highly specific polyclonal antibody raised against a C-terminal peptide of the human dCK, we analyzed its subcellular localization by Western blots of biochemically fractionated nuclear and cytoplasmic fractions as well as by in situ immunochemistry. Native dCK was found to be located mainly in the cytoplasm in several cell types, and the enzyme was more concentrated in the perinuclear and cellular membrane area. In contrast, when dCK was overexpressed in the cells, it was mainly located in the nucleus. The results demonstrate that native dCK is a cytoplasmic enzyme. However, it has the ability to enter the nucleus under certain conditions, suggesting the existence of a cytoplasmic retention mechanism that may have an important function in the regulation of the deoxynucleoside salvage pathway.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece; Biomed Ctr, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Foundation for Research & Technology - Hellas (FORTH)	Talianidis, I (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, POB 1527, Heraklion 71110, Crete, Greece.		Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bianchi V, 1997, J BIOL CHEM, V272, P16118, DOI 10.1074/jbc.272.26.16118; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BOHMAN C, 1990, BIOCH LIFE SCI ADV, V9, P11; CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; JOHANSSON M, 1995, BIOCHEM PHARMACOL, V50, P163, DOI 10.1016/0006-2952(95)00129-N; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; KARLSSON A, 1994, J BIOL CHEM, V269, P24374; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; PLUNKETT W, 1991, PHARMACOL THERAPEUT, V49, P239, DOI 10.1016/0163-7258(91)90057-S; REDDY GPV, 1983, NATURE, V303, P86; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RICHEL DJ, 1990, LEUKEMIA RES, V14, P363, DOI 10.1016/0145-2126(90)90164-5; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; SPASOKOUKOTSKAJA T, 1995, EUR J CANCER, V31A, P202, DOI 10.1016/0959-8049(94)00435-8; SPASOKUKOTSKAJA T, 1991, BIOCHEM BIOPH RES CO, V174, P680, DOI 10.1016/0006-291X(91)91471-N; SPASOKUKOTSKAJA T, 1988, BIOCHEM BIOPH RES CO, V155, P923, DOI 10.1016/S0006-291X(88)80584-9; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SPYROU G, 1989, J BIOL CHEM, V264, P960; STARBORG M, 1995, J CELL SCI, V108, P927; TALLMAN MS, 1995, BLOOD, V86, P2463; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; VANHAPEREN VWTR, 1994, CANCER RES, V54, P4138	35	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30239	30243		10.1074/jbc.273.46.30239	http://dx.doi.org/10.1074/jbc.273.46.30239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804782	hybrid			2022-12-25	WOS:000077008100029
J	Sturgeon, BE; Sipe, HJ; Barr, DP; Corbett, JT; Martinez, JG; Mason, RP				Sturgeon, BE; Sipe, HJ; Barr, DP; Corbett, JT; Martinez, JG; Mason, RP			The fate of the oxidizing tyrosyl radical in the presence of glutathione and ascorbate - Implications for the radical sink hypothesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; REDUCED GLUTATHIONE; PHENOXYL RADICALS; SUPEROXIDE; ANTIOXIDANTS; METABOLISM; OXIDATION; ACID; LACTOPEROXIDASE; ACETAMINOPHEN	Cellular systems contain as much as millimolar concentrations of both ascorbate and GSH, although the GSH concentration is often 10-fold that of ascorbate. It has been proposed that GSH and superoxide dismutase (SOD) act in a concerted effort to eliminate biologically generated radicals. The tyrosyl radical (Tyr(.)) generated by horseradish peroxidase in the presence of hydrogen peroxide can react with GSH to form the glutathione thiyl radical (GS(.)), GS(.) can react with the glutathione anion (GS(-)) to form the disulfide radical anion (GSSG(radical) (anion)). This highly reactive disulfide radical anion will reduce molecular oxygen, forming superoxide and glutathione disulfide (GSSG). In a concerted effort, SOD will catalyze the dismutation of superoxide, resulting in the elimination of the radical. The physiological relevance of this GSH/SOD concerted effort is questionable, In a tyrosyl radical-generating system containing ascorbate (100 mu M) and GSH (8 mM), the ascorbate nearly eliminated oxygen consumption and diminished GS(.) formation. In the presence of ascorbate, the tyrosyl radical will oxidize ascorbate to form the ascorbate radical. When measuring the ascorbate radical directly using fast-flow electron spin resonance, only minor changes in the ascorbate radical electron spin resonance signal intensity occurred in the presence of GSH. These results indicate that in the presence of physiological concentrations of ascorbate and GSH, GSH is not involved in the detoxification pathway of oxidizing free radicals formed by peroxidases.	Hampden Sydney Coll, Dept Chem, Hampden Sydney, VA 23943 USA; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sturgeon, BE (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BIELSKI BHJ, 1982, ADV CHEM SER, P81; BROWN LAS, 1996, ANTIOX HEALTH DIS, V3, P117; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Buettner GR, 1996, HDB ANTIOXIDANTS, P91; DAVIES MJ, 1987, CHEM-BIOL INTERACT, V61, P177, DOI 10.1016/0009-2797(87)90038-X; FISCHER V, 1991, MOL PHARMACOL, V40, P846; FORNI LG, 1983, J CHEM SOC PERK T 2, P961, DOI 10.1039/p29830000961; GADELHA FR, 1992, CHEM-BIOL INTERACT, V85, P35, DOI 10.1016/0009-2797(92)90051-L; GOLDMAN R, 1997, ENV NUTR INTERACT, V1, P97; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; JIN FM, 1993, J CHEM SOC PERK T 2, P1583, DOI 10.1039/p29930001583; KAGAN VE, 1994, BIOCHEMISTRY-US, V33, P9651, DOI 10.1021/bi00198a034; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V14, P91, DOI 10.1016/0891-5849(93)90513-T; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; PICHORNER H, 1995, ARCH BIOCHEM BIOPHYS, V323, P429, DOI 10.1006/abbi.1995.0064; RALSTON I, 1978, CAN J BIOCHEM CELL B, V56, P1115, DOI 10.1139/o78-175; RALSTON IM, 1980, CAN J BIOCHEM CELL B, V58, P1270, DOI 10.1139/o80-170; RAO DNR, 1990, J BIOL CHEM, V265, P844; ROSS D, 1985, J BIOL CHEM, V260, P5028; SCHULER RH, 1977, RADIAT RES, V69, P417, DOI 10.2307/3574655; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; Sipe HJ, 1997, DRUG METAB DISPOS, V25, P468; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; SLADE R, 1985, AM REV RESPIR DIS, V131, P742; TAMBA M, 1991, J CHEM SOC PERK T 2, P1681, DOI 10.1039/p29910001681; WAHLLANDER A, 1979, FEBS LETT, V97, P138, DOI 10.1016/0014-5793(79)80069-1; Ward Paul, 1995, P1; WEST PR, 1984, BIOCHEM PHARMACOL, V33, P2933, DOI 10.1016/0006-2952(84)90222-3; WINTERBOURN CC, 1994, ARCH BIOCHEM BIOPHYS, V314, P284, DOI 10.1006/abbi.1994.1444; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; WINTERBOURN CC, 1995, ANTIOX HEALTH DIS, V2, P117; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183	41	74	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30116	30121		10.1074/jbc.273.46.30116	http://dx.doi.org/10.1074/jbc.273.46.30116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804766	hybrid			2022-12-25	WOS:000077008100013
J	Benowitz, LI; Jing, Y; Tabibiazar, R; Jo, SA; Petrausch, B; Stuermer, CAO; Rosenberg, PA; Irwin, N				Benowitz, LI; Jing, Y; Tabibiazar, R; Jo, SA; Petrausch, B; Stuermer, CAO; Rosenberg, PA; Irwin, N			Axon outgrowth is regulated by an intracellular purine-sensitive mechanism in retinal ganglion cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; CULTURED SYMPATHETIC NEURONS; GOLDFISH OPTIC-NERVE; GUINEA-PIG AORTA; NEURITE OUTGROWTH; ADENOSINE RECEPTORS; REGENERATE AXONS; PC12 CELLS; INHIBITION	Although purinergic compounds are widely involved in the intra- and intercellular communication of the nervous system, little is known of their involvement in the growth and regeneration of neuronal connections. In dissociated cultures, the addition of adenosine or guanosine in the low micromolar range induced goldfish retinal ganglion cells to extend lengthy neurites and express the growth-associated protein GAP-43. These effects were highly specific and did not reflect conversion of the nucleosides to their nucleotide derivatives; pyrimidines, purine nucleotides, and membrane-permeable, nonhydrolyzable cyclic nucleotide analogs were all inactive. The activity of adenosine required its conversion to inosine, because inhibitors of adenosine deaminase rendered adenosine inactive. Exogenously applied inosine and guanosine act directly upon an intracellular target, which may coincide with a kinase described in PC12 cells. In support of this, the effects of the purine nucleosides were blocked with purine transport inhibitors and were inhibited competitively with the purine analog 6-thioguanine (6-TG). In PC12 cells, others have shown that 6-TG blocks nerve growth factor-induced neurite outgrowth and selectively inhibits the activity of protein kinase N, a partially characterized, nerve growth factor-inducible serine-threonine kinase. In both goldfish and rat retinal ganglion cells, 6-TG completely blocked outgrowth induced by other growth factors, and this inhibition was reversed with inosine. These results suggest that axon outgrowth in central nervous system neurons critically involves an intracellular purine-sensitive mechanism.	Childrens Hosp, Labs Neurosci Res Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; Univ Konstanz, Dept Biol, D-78434 Constance, Germany	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Konstanz	Benowitz, LI (corresponding author), Childrens Hosp, Labs Neurosci Res Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA.			Jing, Yun/0000-0003-1800-0650; Benowitz, Larry/0000-0002-0277-7222; Rosenberg, Paul/0000-0002-5185-1118	NATIONAL EYE INSTITUTE [R01EY005690] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 05690] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BENOWITZ LI, 1983, J NEUROSCI, V3, P2153; BRAUMANN T, 1986, J NEUROCHEM, V47, P912; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; COLLIS MG, 1986, EUR J PHARMACOL, V121, P141, DOI 10.1016/0014-2999(86)90404-8; COLLIS MG, 1987, BRIT J PHARMACOL, V92, P69, DOI 10.1111/j.1476-5381.1987.tb11297.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunwiddie TV, 1997, J NEUROSCI, V17, P7673; EDSTROM A, 1992, BRAIN RES, V570, P35, DOI 10.1016/0006-8993(92)90560-V; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; GEIGER JD, 1986, J NEUROSCI, V6, P2702; GREENE LA, 1990, J NEUROSCI, V10, P1479; Gysbers JW, 1996, NEUROSCI LETT, V220, P175, DOI 10.1016/S0304-3940(96)13253-5; Haun SE, 1996, J NEUROCHEM, V67, P2051; HEACOCK AM, 1982, NEUROCHEM RES, V7, P771, DOI 10.1007/BF00965529; JO SA, 1997, IN PRESS NEUROSCIENC; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIMAMUARA K, 1994, J BIOL CHEM, V269, P18961; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller TM, 1997, J BIOL CHEM, V272, P9847; REINHARD E, 1994, DEVELOPMENT, V120, P1757; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SCHAFER KH, 1995, NEUROREPORT, V6, P937, DOI 10.1097/00001756-199504190-00028; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SCHWALB JM, 1995, J NEUROSCI, V15, P5514; Schwalb JM, 1996, NEUROSCIENCE, V72, P901, DOI 10.1016/0306-4522(95)00605-2; SCHWARTZ M, 1981, BRAIN RES, V206, P331, DOI 10.1016/0006-8993(81)90535-7; SNYDER SH, 1985, ANNU REV NEUROSCI, V8, P103; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TOLKOVSKY AM, 1987, NEUROSCIENCE, V23, P1133, DOI 10.1016/0306-4522(87)90187-4; VOLONTE C, 1992, J BIOL CHEM, V267, P21663; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; WAKADE TD, 1995, J PHYSIOL-LONDON, V488, P123, DOI 10.1113/jphysiol.1995.sp020951; WILLIAMS M, 1990, ANN NY ACAD SCI, V603, P93; WOLINSKY EJ, 1985, J NEUROSCI, V5, P1680; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; ZURN AD, 1988, P NATL ACAD SCI USA, V85, P8301, DOI 10.1073/pnas.85.21.8301	46	82	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29626	29634		10.1074/jbc.273.45.29626	http://dx.doi.org/10.1074/jbc.273.45.29626			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792672	Green Published, hybrid			2022-12-25	WOS:000076798300049
J	Cao, HJ; Wang, HS; Zhang, Y; Lin, HY; Phipps, RP; Smith, TJ				Cao, HJ; Wang, HS; Zhang, Y; Lin, HY; Phipps, RP; Smith, TJ			Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression - Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; DENOVO PROTEIN-SYNTHESIS; HUMAN-SKIN FIBROBLASTS; GRAVES OPHTHALMOPATHY; T-CELLS; B-CELLS; GLYCOSAMINOGLYCAN SYNTHESIS; DERMAL FIBROBLASTS; MOLECULAR-CLONING; INTERFERON-GAMMA	Human orbital fibroblasts play a putative role in the pathogenesis of thyroid-associated ophthalmopathy (TAO), We hypothesize that the hyaluronan accumulation and inflammation in TAO derive from enhanced biosynthetic activities of orbital fibroblasts, CD40, a member of the tumor necrosis factor-alpha receptor superfamily, is a critical signaling molecule expressed by B lymphocytes, Engagement of CD40 with CD154 or CD40 ligand results in the activation of target genes. Orbital fibroblasts also display CD40, Here we report that CD40 engagement leads to substantial increases in hyaluronan synthesis in orbital fibroblasts, The increase is approximately 8-fold above control values, is comparable to the induction elicited by IL-1 beta and could be attenuated with dexamethasone but not by SC 58125, a prostaglandin endoperoxide H synthase-2 (PGHS-2)-selective inhibitor. PGHS-2 is also induced by CD40 engagement in a time-dependent manner, and this is mediated through increases in levels of steady-state mRNA, The induction of PGHS-2 leads to a dramatically enhanced prostaglandin E-2 production that can be blocked by SC 58125 and dexamethasone. CD40 ligand up-regulates the synthesis of IL-1 alpha, and blocking this cytokine with exogenous IL-1 receptor antagonist (IL-1ra) or with IL-1 alpha neutralizing antibodies partially attenuates the induction of PGHS-2. In contrast, CD40 ligand up-regulation of hyaluronan synthesis is unaffected by IL-1ra, CD40 cross-linking enhances mitogen-activated protein kinase activation, and interrupting this pathway attenuates the PGHS-2 induction. Thus the CD40/CD40 ligand bridge represents a potentially important activational pathway for orbital fibroblasts that may underlie the cross-talk between these cells and leukocytes. These findings may be relevant to the pathogenesis of TAO and provide insights into previously unrecognized, potential therapeutic targets.	Albany Med Coll, Dept Med, Div Mol & Cellular Med A175, Albany, NY 12208 USA; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA; Yang Ming Univ, Sch Life Sci, Dept Anat, Taipei, Taiwan; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Pediat & Environm Med, Rochester, NY 14642 USA	Albany Medical College; Albany Medical College; National Yang Ming Chiao Tung University; University of Rochester; University of Rochester; University of Rochester	Smith, TJ (corresponding author), Albany Med Coll, Dept Med, Div Mol & Cellular Med A175, 47 New Scotland Ave, Albany, NY 12208 USA.		Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008976, R01EY011708] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11198] Funding Source: Medline; NEI NIH HHS [EY 11708, EY 08976] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARBOGAST B, 1975, BIOCHEM BIOPH RES CO, V67, P376, DOI 10.1016/0006-291X(75)90326-5; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BERENSON CS, 1995, J CLIN ENDOCR METAB, V80, P2668, DOI 10.1210/jc.80.9.2668; CAO HJ, 1995, INVEST OPHTH VIS SCI, V36, P1411; CAO HJ, 1997, THYROID, V7, pS43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECARLI M, 1993, J CLIN ENDOCR METAB, V77, P1120, DOI 10.1210/jc.77.5.1120; FRIES KM, 1995, CLIN IMMUNOL IMMUNOP, V77, P42, DOI 10.1016/0090-1229(95)90135-3; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GALY AHM, 1992, J IMMUNOL, V149, P775; Gaspari AA, 1996, EUR J IMMUNOL, V26, P1371, DOI 10.1002/eji.1830260629; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GRUBECKLOEBENSTEIN B, 1994, J CLIN INVEST, V93, P2738, DOI 10.1172/JCI117289; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HOGG MG, 1995, AM J PHYSIOL-CELL PH, V269, pC359, DOI 10.1152/ajpcell.1995.269.2.C359; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; KABACK LA, 1997, THYROID, V7, pS10; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; Meyer K, 1941, J EXP MED, V73, P309, DOI 10.1084/jem.73.3.309; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PHIPPS RP, 1990, EUR J IMMUNOL, V20, P1723, DOI 10.1002/eji.1830200815; PRUMMEL MF, 1993, LANCET, V342, P949, DOI 10.1016/0140-6736(93)92001-A; Ridley SH, 1997, J IMMUNOL, V158, P3165; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sempowski GD, 1997, J IMMUNOL, V158, P4670; Sempowski GD, 1998, AM J PHYSIOL-CELL PH, V274, pC707, DOI 10.1152/ajpcell.1998.274.3.C707; Sempowski GD, 1997, J PERIODONTOL, V68, P284, DOI 10.1902/jop.1997.68.3.284; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SMITH TJ, 1992, AM J PHYSIOL, V263, pC24, DOI 10.1152/ajpcell.1992.263.1.C24; Smith TJ, 1997, ENDOCRINOLOGY, V138, P5576, DOI 10.1210/en.138.12.5576; SMITH TJ, 1994, P NATL ACAD SCI USA, V91, P5094, DOI 10.1073/pnas.91.11.5094; SMITH TJ, 1993, AM J PHYSIOL, V265, pC138, DOI 10.1152/ajpcell.1993.265.1.C138; SMITH TJ, 1993, J INVEST DERMATOL, V100, P288, DOI 10.1111/1523-1747.ep12469828; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; SMITH TJ, 1995, J CLIN ENDOCR METAB, V80, P2620, DOI 10.1210/jc.80.9.2620; SMITH TJ, 1982, J CLIN INVEST, V70, P1066, DOI 10.1172/JCI110694; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Sutherland CL, 1996, J IMMUNOL, V157, P3381; WANG HS, 1995, J CLIN ENDOCR METAB, V80, P3553, DOI 10.1210/jc.80.12.3553; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; Young DA, 1998, P NATL ACAD SCI USA, V95, P8904, DOI 10.1073/pnas.95.15.8904; Zhang Y, 1998, J IMMUNOL, V160, P1053	73	155	167	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29615	29625		10.1074/jbc.273.45.29615	http://dx.doi.org/10.1074/jbc.273.45.29615			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792671	hybrid			2022-12-25	WOS:000076798300048
J	Garrad, RC; Otero, MA; Erb, L; Theiss, PM; Clarke, LL; Gonzalez, FA; Turner, JT; Weisman, GA				Garrad, RC; Otero, MA; Erb, L; Theiss, PM; Clarke, LL; Gonzalez, FA; Turner, JT; Weisman, GA			Structural basis of agonist-induced desensitization and sequestration of the P2Y(2) nucleotide receptor - Consequences of truncation of the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; EXTRACELLULAR ATP; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; CALCIUM MOBILIZATION; ENDOTHELIAL-CELLS; CYSTIC-FIBROSIS; RELEASE	Molecular determinants of P2Y(2) receptor desensitization and sequestration have been investigated. Wildtype P2Y(2) receptors and a series of five C-terminal truncation cation mutants of the receptor were epitope-tagged and stably expressed in 1321N1 cells. These constructs were used to assess the importance of the intracellular C terminus on 1) UTP stimulated increases in intracellular calcium concentration, 2) homologous desensitization of the receptor, and 3) agonist-induced decreases in cell-surface density (receptor sequestration) of epitope-tagged receptors using fluorescence-activated cell sorting. The potency and efficacy of UTP were similar for the wild-type and all mutant P2Y(2) receptors, Truncation of 18 or more amino acids from the C terminus increased by similar to 30-fold the concentration of UTP necessary to desensitize the receptor. Both the rate and magnitude of UTP-induced receptor sequestration were decreased with progressively larger truncations of the C terminus, Furthermore, the recovery from sequestration was slower for the most extensively truncated receptor. Complete desensitization was obtained with >50% of the original receptor complement remaining on the cell surface. Protein kinase C activation, which desensitizes the P2Y(2) receptor, had no effect on sequestration, consistent with the ideas that desensitization and sequestration are discrete events and that agonist occupancy is required for receptor sequestration.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Univ Missouri, Dept Vet Biomed Sci, Columbia, MO 65212 USA; Univ Missouri, Dept Pharmacol, Columbia, MO 65212 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65212 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Garrad, RC (corresponding author), Univ Missouri, Dept Biochem, M121 Med Sci Bldg, Columbia, MO 65212 USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261; Erb, Laurie/0000-0001-6372-3378	NIDDK NIH HHS [R29 DK048816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GONZALEZ FA, 1989, P NATL ACAD SCI USA, V86, P4530, DOI 10.1073/pnas.86.12.4530; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Koenig JA, 1996, MOL PHARMACOL, V49, P351; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; LIN TA, 1993, J NEUROCHEM, V60, P1115, DOI 10.1111/j.1471-4159.1993.tb03262.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PEARCE B, 1989, J NEUROCHEM, V52, P971, DOI 10.1111/j.1471-4159.1989.tb02549.x; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SASAKAWA N, 1989, J NEUROCHEM, V52, P441, DOI 10.1111/j.1471-4159.1989.tb09140.x; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TURNER JT, 1990, J PHARMACOL EXP THER, V253, P1049; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; WILKINSON GF, 1994, MOL PHARMACOL, V45, P731; YU SS, 1993, J BIOL CHEM, V268, P337	33	70	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29437	29444		10.1074/jbc.273.45.29437	http://dx.doi.org/10.1074/jbc.273.45.29437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792648	hybrid			2022-12-25	WOS:000076798300025
J	Morgunov, I; Srere, PA				Morgunov, I; Srere, PA			Interaction between citrate synthase and malate dehydrogenase - Substrate channeling of oxaloacetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID CYCLE ENZYMES; POLYETHYLENE-GLYCOL; EXCLUDED-VOLUME; FUSION PROTEIN; COMPARTMENTATION; PRECIPITATION; MITOCHONDRIA; ASSOCIATION; MECHANISM; COMPLEXES	The interactions between pig heart citrate synthase and mitochondrial malate dehydrogenase or cytosolic malate dehydrogenase were studied using the frontal analysis method of gel filtration and by precipitation in polyethylene glycol. This method showed that an interaction between citrate synthase and mitochondrial malate dehydrogenase occurred but no interaction between citrate synthase and cytosolic malate dehydrogenase. Channeling of oxaloacetate in the malate dehydrogenase and citrate synthase-coupled systems was tested using polyethylene glycol precipitates of citrate synthase and mitochondrial malate dehydrogenase, and citrate synthase and cytosolic malate dehydrogenase. The effectiveness of large amounts of aspartate aminotransferase and oxaloacetate decarboxylase, as competing enzymes for the intermediate oxaloacetate, was examined. Aspartate aminotransferase and oxaloacetate decarboxylase were less effective competitors for oxaloacetate when precipitated citrate synthase and mitochondrial malate dehydrogenase in polyethylene glycol was used at low ionic strength compared with free enzymes in the absence of polyethylene glycol or with a co-precipitate of citrate synthase and cytosolic malate dehydrogenase. Substrate channeling of oxaloacetate with citrate synthase-mitochondrial malate dehydrogenase precipitate was inefficient at high ionic strength. These effects could be explained through electrostatic interactions of mitochondrial but not cytosolic malate dehydrogenase with citrate synthase.	Dallas Vet Affairs Med Ctr, Res Serv, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Srere, PA (corresponding author), Dallas Vet Affairs Med Ctr, Res Serv, 151B,4500 S Lancaster Rd, Dallas, TX 75216 USA.	pasrere1@airmail.net		Morgunov, Igor/0000-0002-5051-2958				ARAKAWA T, 1985, ANAL BIOCHEM, V144, P267, DOI 10.1016/0003-2697(85)90115-0; ATHA DH, 1981, J BIOL CHEM, V256, P2108; BEECKMANS S, 1989, EUR J BIOCHEM, V183, P449, DOI 10.1111/j.1432-1033.1989.tb14948.x; DATTA A, 1985, J BIOL CHEM, V260, P5008; DIMROTH P, 1981, EUR J BIOCHEM, V115, P353, DOI 10.1111/j.1432-1033.1981.tb05245.x; Elcock AH, 1997, BIOCHEMISTRY-US, V36, P16049, DOI 10.1021/bi971709u; Elcock AH, 1996, BIOCHEMISTRY-US, V35, P12652, DOI 10.1021/bi9614747; Englard S., 1969, METHOD ENZYMOL, V13, P99; HAIRE RN, 1984, BIOPOLYMERS, V23, P2761, DOI 10.1002/bip.360231206; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; HAN JN, 1993, BIOPHYS J, V65, P1155, DOI 10.1016/S0006-3495(93)81145-7; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ITOH H, 1970, ANAL BIOCHEM, V35, P405, DOI 10.1016/0003-2697(70)90202-2; LAURENT TC, 1963, BIOCHEM J, V89, P253, DOI 10.1042/bj0890253; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; MERZ JM, 1987, ARCH BIOCHEM BIOPHYS, V258, P132, DOI 10.1016/0003-9861(87)90330-4; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; OVADI J, 1995, CELL ARCHITECTURE ME; PORPACZY Z, 1987, J BIOL CHEM, V262, P9509; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; SPIVEY HO, 1989, BIOESSAYS, V10, P127, DOI 10.1002/bies.950100409; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1973, P NATL ACAD SCI USA, V70, P2534, DOI 10.1073/pnas.70.9.2534; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Srere PA, 1997, CHANNELING INTERMEDI, P201; TOMPA P, 1987, J BIOL CHEM, V262, P6089; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; TYISKA RL, 1986, NATO SERIES A, V127, P177; Velot C, 1997, BIOCHEMISTRY-US, V36, P14271, DOI 10.1021/bi972011j; WELCH GR, 1977, PROG BIOPHYS MOL BIO, V32, P103; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	33	95	99	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29540	29544		10.1074/jbc.273.45.29540	http://dx.doi.org/10.1074/jbc.273.45.29540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792662	hybrid			2022-12-25	WOS:000076798300039
J	Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K				Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K			Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53	ONCOGENE			English	Article						lovastatin; cell cycle; cyclins; CKIs; CDKs; adaptor molecule	DEPENDENT KINASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; CANCER CELLS; POTENTIAL MEDIATOR; MEVALONATE PATHWAY; RESTRICTION POINT; ACTIVATING KINASE	Previously, we reported that lovastatin, a potent inhibitor of the enzyme HMG CoA reductase also acts as an antimitogenic agent by arresting cells in the G1 phase of the cell cycle resulting in cell cycle-independent alteration of cyclin dependent kinase inhibitors (CKIs), In the present study we have investigated the nature of the CKIs (p21 and p27) alterations resulting in G1 arrest in both normal and tumor breast cell lines by lovastatin, We show that even though lovastatin treatment causes G1 arrest in a wide variety of normal and tumor breast cells irrespective of their p53 or pRb status, the p21 and p27 protein levels are not increased in all cell lines treated suggesting that the increase in p21 and p27 protein expression per se is not necessary for lovastatin mediated G1 arrest. However, the binding of p21 and p27 to CDK2 increases significantly following treatment of cells with lovastatin leading to inhibition of CDK2 activity and a subsequent arrest of cells in G1, The increased CKI binding to CDK2 is achieved by the redistribution of both p21 and p27 from CDK4 to CDK2 complexes subsequent to decreases in CDK4 and cyclin D3 expression following lovastatin treatment, Lastly, we show that lovastatin treatment of 76N-E6 breast cell line with an altered p53 pathway also results in G1 arrest and similar redistribution of CKIs from CDK4 to CDK2 as observed in other breast cell lines examined, These observations suggest that lovastatin induced G1 arrest of breast cell lines is through a p53 independent pathway and is mediated by decreased CDK2 activity through redistribution of CKIs from CDK4 to CDK2.	Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Keyomarsi, K (corresponding author), Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [R29-CA666062] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIGNON J, 1993, ARCH INTERN MED, V153, P1079; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GrayBablin J, 1997, CANCER RES, V57, P604; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Harper JW, 1997, CANCER SURV, V29, P91; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HESSLING JJ, 1980, J IMMUNOL METHODS, V38, P315, DOI 10.1016/0022-1759(80)90280-X; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Jakus J, 1996, ONCOGENE, V12, P2369; JANI JP, 1993, INVAS METAST, V13, P314; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Keyomarsi Khandan, 1996, Methods in Cell Science, V18, P109, DOI 10.1007/BF00122161; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MICHIELI P, 1994, CANCER RES, V54, P3391; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TAM SW, 1994, ONCOGENE, V9, P2663; Thibault A, 1996, CLIN CANCER RES, V2, P483; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P710; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	69	171	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2393	2402		10.1038/sj.onc.1202322	http://dx.doi.org/10.1038/sj.onc.1202322			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811471				2022-12-25	WOS:000076723300014
J	Ungefroren, H; Gellersen, B; Krull, NB; Kalthoff, H				Ungefroren, H; Gellersen, B; Krull, NB; Kalthoff, H			Biglycan gene expression in the human leiomyosarcoma cell line SK-UT-1 - Basal and protein kinase A-induced transcription involves binding of Sp1-like/Sp3 proteins in the proximal promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; VASCULAR SMOOTH-MUSCLE; MESSENGER-RNA LEVELS; ENDOTHELIAL-CELLS; PROLACTIN GENE; GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; CATALYTIC SUBUNIT; UP-REGULATION; HUMAN CERVIX	In this study we demonstrate that the gene encoding the small leucine-rich proteoglycan biglycan is expressed in human myometrial tissue and in the human leiomyosarcoma cell line SK-UT-1. Treatment of SK-UT-1 cells with forskolin or 8-bromo-cAMP strongly increased biglycan mRNA and this effect was transcriptional as shown by transient transfection experiments with biglycan promoter-luciferase reporter fusion genes. The cAMP-mediated induction of the transfected biglycan promoter in SK-UT-1 cells was abolished by coexpression of a specific protein kinase A inhibitor, and was mimicked by overexpression of the catalytic subunit (CP) of protein kinase A. By 5' deletion analysis, part of the cAMP response was localized to the segment from residues -78 to -46 of the biglycan promoter. This region conferred strong cAMP responsiveness to a heterologous promoter. Electrophoretic mobility shift and antibody supershift assays identified two specific complexes that contained nuclear proteins antigenically related to the ubiquitous transcription factors Spl and Sp3, respectively. The binding site of these proteins was mapped to a CT-rich sequence extending from -59 to -49 in the biglycan promoter. Mutating this sequence eliminated complex formation and markedly reduced basal and cAMP-dependent promoter activity of transfected reporter genes. In vitro binding studies using recombinant Spl revealed that the nuclear factor binding to the CT element was not Spl but a Spl-like protein(s). Western blot analysis of SK-UT-1 nuclear proteins confirmed expression of Sp3, Spl and nuclear proteins that crossreacted with Spl antibody but according to their molecular weight were not Spl. These results indicate that all cAMP-dependent as well as some basal biglycan transcription in SK-UT-1 cells is mediated through activated protein kinase A and that both functions are conferred at the promoter level through the interaction of Sp1-like/Sp3 factors with the CT element at -59 in the biglycan promoter.	Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, D-24105 Kiel, Germany; Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany; Med Lab Dr HR Ebersold, CH-3001 Bern, Switzerland	University of Kiel; University of Hamburg	Ungefroren, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, Arnold Heller Str 7, D-24105 Kiel, Germany.		Kalthoff, Holger/B-1618-2010					ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BOHNHOFF A, 1996, ENDOCR J, V5, P241; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DAY RN, 1989, J BIOL CHEM, V264, P431; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Heegaard AM, 1997, J BONE MINER RES, V12, P2050, DOI 10.1359/jbmr.1997.12.12.2050; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOWARD P, 1991, J BIOL CHEM, V266, P10189; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kresse H, 1994, EXS, V70, P73; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; NORMAN M, 1993, OBSTET GYNECOL, V82, P1013; NORMAN M, 1993, OBSTET GYNECOL, V81, P217; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P26; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer H, 1996, EUR J BIOCHEM, V242, P467, DOI 10.1111/j.1432-1033.1996.467rr.x; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1997, BIOCHEM BIOPH RES CO, V235, P413, DOI 10.1006/bbrc.1997.6801; UNGEFROREN H, 1995, BIOL REPROD, V52, P1095, DOI 10.1095/biolreprod52.5.1095; Ungefroren H, 1998, CANCER RES, V58, P1741; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002	56	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29230	29240		10.1074/jbc.273.44.29230	http://dx.doi.org/10.1074/jbc.273.44.29230			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786935	hybrid			2022-12-25	WOS:000076691800096
J	Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H				Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H			Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development	ONCOGENE			English	Article						Eph; Ephrin; dorsalization; secondary axis	PROTEIN-TYROSINE KINASE; NEURAL CREST CELLS; EPH-FAMILY; TRANSMEMBRANE LIGANDS; EXPRESSION CLONING; COMMISSURAL AXONS; SPEMANN ORGANIZER; IN-VITRO; GENE; GUIDANCE	The Eph class is the largest family of receptor tyrosine kinases and has been shown to play various roles in neural development including axon pathfinding and neural crest migration, EphB2 associates with transmembrane ligands Ephrin-B1 and -B2, which leads to tyrosine phosphorylation of both the ligands and receptor and is presumed to regulate cell-to-cell interactions by bidirectional signaling. We have investigated the biological effects of the EphB2-induced signal in the early stage of Xenopus laevis development. Xenopus EphB2 transcripts were detected maternally and were expressed at equal levels between the ventral and dorsal halves of the gastrulae, with expression increasing after the late gastrula stage. EphB2 mRNA expression in dorsal marginal zone explants from gastrulae increases during later development while that in ventral explants does not, We show here that microinjection of RNA encoding EphB2 into a ventral blastomere of embryos induced a partial secondary dorsal axis which consisted of neural tissues, notochord and somites, Analysis with molecular markers verified that the microinjected EphB2 dorsalized the mesoderm of ventral marginal zone explants, These dorsalizing effects of EphB2 in both the whole embryo and ventral explants were inhibited by the coinjection of RNA encoding the soluble form of Ephrin-B1, Furthermore, co-injection of EphB2 and Ephrin-B1 RNAs synergistically enhanced the dorsalization effect, These data show that the interaction between EphB2 and its ligands including Ephrin-B1 causes signaling events which lead to dorsal development, and strongly suggests the existence of proteins which mediate the dorsalization induced by EphB2 in early stage embryos of Xenopus laevis.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 43131, Japan	Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 43131, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X				BRANDLI AW, 1995, DEV DYNAM, V203, P119; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLOW E, 1988, ANTIBODIES; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; JONES CM, 1995, DEVELOPMENT, V121, P3651; Jones TL, 1997, ONCOGENE, V14, P2159, DOI 10.1038/sj.onc.1201082; JONES TL, 1995, ONCOGENE, V10, P1111; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Sambrook J., 1989, MOL CLONING; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCALES JB, 1995, ONCOGENE, V11, P1745; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Weinstein DC, 1996, MECH DEVELOP, V57, P133, DOI 10.1016/0925-4773(96)00536-9; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	41	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1509	1516		10.1038/sj.onc.1202068	http://dx.doi.org/10.1038/sj.onc.1202068			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794228	Bronze			2022-12-25	WOS:000076089900003
J	Bunnell, WL; Pham, HV; Glabe, CG				Bunnell, WL; Pham, HV; Glabe, CG			gamma-secretase cleavage is distinct from endoplasmic reticulum degradation of the transmembrane domain of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; I HEAVY-CHAINS; ALZHEIMERS-DISEASE; BETA-PROTEIN; RAPID DEGRADATION; WILD-TYPE; CELLS; PEPTIDE; INHIBITION; GENERATION	One of the critical cleavage events that generates Alzheimer's amyloid A beta peptide occurs within the transmembrane domain (TMD) of the amyloid precursor protein (APP) and is carried out by a poorly understood enzyme activity known as gamma-secretase. To investigate this processing, a probe molecule, H26-57C, was constructed containing the TMD of APP flanked immediately on each side by unique epitope tags. H26-57C-transfected cells secrete a similar to 2.9-kDa fragment, indicating that the lumenal and cytosolic domains of APP are not required for gamma-secretase processing. Pulse-chase experiments indicate that the probe turns over with a half-life of 8 min. No degradation intermediates are detected during the chase period, indicating that TMD turnover is a highly processive mechanism. The protease inhibitors, ALLN and MG132, cause a dramatic (50-fold) increase in the steady-state amount of the probe. All of the inhibitors that prevent degradation of the probe in the rough endoplasmic reticulum increase the amount of the similar to 2.9-kDa fragment that is secreted into the media and also causes a similar increase the secretion of 4 kDa A beta from APP-transfected cells. These results indicate that the system responsible for the degradation of the probe in the rough endoplasmic reticulum and the intramembrane cleavage by gamma-secretase that produces soluble, secreted A beta are distinct and opposing processes.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline; NINDS NIH HHS [NS-31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BURDICK D, 1992, J BIOL CHEM, V267, P546; Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1992, J BIOL CHEM, V267, P9080; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY AM, 1991, CELL IMMUNOL, V138, P24, DOI 10.1016/0008-8749(91)90129-Y; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WIKSTROM L, 1992, J BIOL CHEM, V268, P5; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	54	35	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31947	31955		10.1074/jbc.273.48.31947	http://dx.doi.org/10.1074/jbc.273.48.31947			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822665	hybrid			2022-12-25	WOS:000077207000047
J	Rajendran, S; Jezewska, MJ; Bujalowski, W				Rajendran, S; Jezewska, MJ; Bujalowski, W			Human DNA polymerase beta recognizes single-stranded DNA using two different binding modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; DIMENSIONAL HOMOGENEOUS LATTICE; NUCLEIC ACID INTERACTIONS; NON-COOPERATIVE BINDING; ABASIC SITE REPAIR; ESCHERICHIA-COLI; LARGE LIGANDS; BOVINE TESTIS; PROTEIN; MACROMOLECULE	Interactions between the human DNA polymerase beta (pol beta) and a single-stranded (ss) DNA have been studied using the quantitative fluorescence titration technique. Examination of the fluorescence increase of the poly(dA) etheno-derivative (poly(d epsilon A)) as a function of the binding density of pol beta-nucleic acid complexes reveals the existence of two binding phases. In the first high affinity phase, pol beta forms a complex with a ssDNA in which 16 nucleotides are occluded by the enzyme. In the second phase, transition to a complex where the polymerase occludes only 5 nucleotides occurs. Thus, human pol beta binds a ssDNA in two binding modes, which differ in the number of occluded nucleotide residues. We designate the first complex as (pol beta)(16) and the second as (pol beta)(5) binding modes. The analyses of the enzyme binding to ssDNA have been performed using statistical thermodynamic models, which account for the existence of the two binding modes of the enzyme, cooperative interactions, and the overlap of potential binding sites. The importance of the discovery that human pol beta binds a ssDNA, using different binding modes, for the possible mechanistic model of the functioning of human pol beta, is discussed.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Bujalowski, W (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Struct Biol, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046679] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P30ES06676] Funding Source: Medline; NIGMS NIH HHS [GM-46679] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BAKER BM, 1978, BIOPOLYMERS, V17, P1361, DOI 10.1002/bip.1978.360170519; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FERRARI ME, 1994, J MOL BIOL, V236, P106, DOI 10.1006/jmbi.1994.1122; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2117, DOI 10.1021/bi952344l; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Kornberg A., 1992, DNA REPLICATION; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LEDNEVA RK, 1977, NUCLEIC ACIDS RES, V5, P4226; LIFSON S, 1964, J CHEM PHYS, V40, P3705, DOI 10.1063/1.1725077; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Mullen GP, 1997, BIOCHEMISTRY-US, V36, P4713, DOI 10.1021/bi962363a; OLMSTED MC, 1989, P NATL ACAD SCI USA, V86, P7766, DOI 10.1073/pnas.86.20.7766; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842	35	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31021	31031		10.1074/jbc.273.47.31021	http://dx.doi.org/10.1074/jbc.273.47.31021			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813000	hybrid			2022-12-25	WOS:000077136900028
J	Christenson, LK; McAllister, JM; Martin, KO; Javitt, NB; Osborne, TF; Strauss, JF				Christenson, LK; McAllister, JM; Martin, KO; Javitt, NB; Osborne, TF; Strauss, JF			Oxysterol regulation of steroidogenic acute regulatory protein gene expression - Structural specificity and transcriptional and posttranscriptional actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; HUMAN GRANULOSA-CELLS; STEROL 27-HYDROXYLASE; PROMOTER ACTIVITY; STAR GENE; CHOLESTEROL; PATHWAY; BINDING; 7-ALPHA-HYDROXYLATION	Oxysterols exert a major influence over cellular cholesterol homeostasis. We examined the effects of oxysterols on the expression of steroidogenic acute regulatory protein (StAR), which increases the delivery of cholesterol to sterol-metabolizing P450s in the mitochondria, 22(R)-hydroxycholesterol (22(R)-OHC), 25-OHC, and 27-OHC each increased steroidogenic factor-1 (SF-1)-mediated StAR gene transactivation by similar to 2-fold in CV-1 cells. In contrast, cholesterol, progesterone, and the 27-OHC metabolites, 27-OHC-5 beta-3-one and 7 alpha,27-OHC, had no effect. Unlike our findings in CV-1 cells, SF-1-dependent StAR promoter activity was not augmented by 27-OHC in COS-1 cells, Y-1 cells, EeWo choriocarcinoma cells, Chinese hamster ovary (CHO) cells, and human granulosa cells. Studies examining the metabolism of 27-OHC indicated that CV-1 cells formed a single polar metabolite, 3 beta-OH-5-cholestenoic acid from radiolabeled 27-OHC, However, this metabolite inhibited StAR promoter activity in CV-1, COS-1 and CHO cells. Because 7 alpha,27-OHC was unable to increase SF-1-dependent StAR promoter activity, we examined 27-OHC 7 alpha-hydroxylase in COS-1 and CHO cells. COS-1 cells contained high 7 alpha-hydroxylase activity, whereas the enzyme was undetectable in CHO cells. The hypothesis that oxysterols act in CV-1 cells to increase StAR promoter activity by reducing nuclear levels of sterol regulatory element binding protein was tested. This notion was refuted when it was discovered that sterol regulatory element binding protein-1a is a potent activator of the StAR promoter in CV-1, COS-1, and human granulosa cells. Human granulosa and theca cells, which express endogenous SF-1, contained more than 5-fold more StAR protein following addition of 27-OHC, whereas StAR mRNA levels remained unchanged. We conclude that 1) there are cell-specific effects of oxysterols on SF-1-dependent transactivation; 2) the ability to increase transactivation is limited to certain oxysterols; 3) there are cell-specific pathways of oxysterol metabolism; and 4) oxysterols elevate StAR protein levels through posttranscriptional actions.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; New York University; University of California System; University of California Irvine	Christenson, LK (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, 415 Curie Blvd, Philadelphia, PA 19104 USA.		Christenson, Lane K/G-6435-2013	Javitt, Norman B/0000-0001-9265-3508	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34449, HD06274] Funding Source: Medline; NIDDK NIH HHS [DK32995] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BRANNIAN JD, 1993, ENDOCRINOLOGY, V132, P591, DOI 10.1210/en.132.2.591; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOLOS TG, 1988, BIOCHEMISTRY-US, V27, P3503, DOI 10.1021/bi00409a056; GOLOS TG, 1987, MOL ENDOCRINOL, V1, P321, DOI 10.1210/mend-1-4-321; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JAVITT NB, 1990, J LIPID RES, V31, P1527; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lee C, 1996, J LIPID RES, V37, P1356; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martin KO, 1997, J LIPID RES, V38, P1053; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; Mellon SH, 1998, ENDOCRINOLOGY, V139, P3026, DOI 10.1210/en.139.6.3026; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pollack SE, 1997, J CLIN ENDOCR METAB, V82, P4243, DOI 10.1210/jc.82.12.4243; Reiss AB, 1997, J LIPID RES, V38, P1254; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; RUDNEY H, 1986, ANNU REV NUTR, V6, P245, DOI 10.1146/annurev.nu.06.070186.001333; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang J, 1997, EUR J BIOCHEM, V247, P129, DOI 10.1111/j.1432-1033.1997.00129.x	37	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30729	30735		10.1074/jbc.273.46.30729	http://dx.doi.org/10.1074/jbc.273.46.30729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804848	hybrid			2022-12-25	WOS:000077008100095
J	Di Fruscio, M; Chen, TP; Bonyadi, S; Lasko, P; Richard, S				Di Fruscio, M; Chen, TP; Bonyadi, S; Lasko, P; Richard, S			The identification of two Drosophila K homology domain proteins - KEP1 and SAM are members of the Sam68 family of GSG domain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; FRAGILE-X SYNDROME; TUMOR-SUPPRESSOR GENE; CAENORHABDITIS-ELEGANS; GERMLINE DEVELOPMENT; NUCLEIC-ACID; FMR-1 GENE; GLD-1; ENCODES; QUAKING	Sam68 is a member of a growing family of RNA-binding proteins that contains an extended K homology (KH) domain embedded in a larger domain called the GSG ((G) under bar RP33, (S) under bar am68, (G) under bar LD1) domain. To identify GSG domain family members, we searched data bases for expressed sequence tags encoding related portions of the Sam68 KH domain. Here we report the identification of two novel Drosophila KH domain proteins, which we termed KEP1 ((K) under bar H (e) under bar ncompassing (p) under bar rotein) and SAM. SAM bears sequence identity with mammalian Sam68 and may be the Drosophila Sam68 homolog, me demonstrate that SARI, KEP1, and the recently identified Drosophila Who/How are RNA-binding proteins that are able to self-associate into homomultimers, The GSG domain of KEP1 and SARI was necessary to mediate the RNA binding and self-association. To elucidate the cellular roles of these proteins, SAM, KEP1, and Who/How were expressed in mammalian and Drosophila S2 cells. KEP1 and Who/How were nuclear and SARI was cytoplasmic. The expression of KEP1 and SARI, but not Who/How, activated apoptotic pathways in Drosophila S2 cells. The identification of KEP1 and SAM implies that a large GSG domain protein family exists and helps redefine the boundaries of the GSG domain. Taken together, our data suggest that KEP1 and SAM may play a role in the activation or regulation of apoptosis and further implicate the GSG domain in RNA binding and oligomerization.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University	Richard, S (corresponding author), Lady Davis Inst Med Res, Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mcrd@musica.mcgill.ca	Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arning S, 1996, RNA, V2, P794; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; BARIAT L, 1997, J BIOL CHEM, V272, P3129; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DOERIG RE, 1988, EMBO J, V7, P2579, DOI 10.1002/j.1460-2075.1988.tb03107.x; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fyrberg C, 1997, GENE, V197, P315, DOI 10.1016/S0378-1119(97)00278-3; Fyrberg C, 1998, BIOCHEM GENET, V36, P51, DOI 10.1023/A:1018700202971; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Jones AR, 1996, DEV BIOL, V180, P165, DOI 10.1006/dbio.1996.0293; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NUSSBAUM RL, 1995, METABOLIC BASIS INHE, P795; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Saffman EE, 1998, MOL CELL BIOL, V18, P4855, DOI 10.1128/MCB.18.8.4855; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Zaffran S, 1997, DEVELOPMENT, V124, P2087; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176; Zorn AM, 1997, GENE, V188, P199, DOI 10.1016/S0378-1119(96)00795-0	49	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30122	30130		10.1074/jbc.273.46.30122	http://dx.doi.org/10.1074/jbc.273.46.30122			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804767	hybrid			2022-12-25	WOS:000077008100014
J	O'Connell, MA; Bennett, BL; Mercurio, F; Manning, AM; Mackman, N				O'Connell, MA; Bennett, BL; Mercurio, F; Manning, AM; Mackman, N			Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; TISSUE FACTOR GENE; RIBOSOMAL S6 KINASE; C-REL/P65 HETERODIMERS; ACTIVATION; ALPHA; PHOSPHORYLATION; DEGRADATION; BETA; INDUCTION	Mononuclear phagocytes play a major role in immune and inflammatory responses. Bacterial lipopolysaccharide (LPS) induces monocytes to express a variety of genes by activating the NF-kappa B/Rel transcription factor family. Recently, we have reported that the tumor necrosis factor and interleukin 1 signaling pathways activate two kinases, IKK1 and IKK2. Phosphorylation of the I kappa B cytoplasmic inhibitors, I kappa B alpha, I kappa B beta, and I kappa B epsilon, by these kinases triggers proteolytic degradation and the release of NF-kappa B/Rel proteins into the nucleus. At present, the role of the IKKs in LPS signaling has not been investigated. Here, we report that LPS induces IKK activity in human monocytes and THP-1 monocytic cells. The kinetics of activation of kinase activity in monocytic cells are relatively slow with maximal activity observed at 60 min, which coincides with the degradation of I kappa Bs and the nuclear translocation of NF-kappa B. In transfection experiments, overexpression of wild type IKK1, a dominant negative mutant IKK1 (K44M), or wild type IKK2 did not affect LPS-induced kappa B-dependent transcription in monocytic cells. In contrast, a dominant negative mutant of IKK2 inhibited LPS induction of kappa B-dependent transcription in a dose-dependent manner. These results indicate that LPS induction of kappa B-dependent gene expression in human monocytic cells requires activation of IKK2.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Signal Pharmaceut Inc, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute	Mackman, N (corresponding author), Scripps Res Inst, Dept Immunol, IMM-17,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			O'Connell, Maria/0000-0002-0267-0951	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MACKMAN N, 1994, J BIOL CHEM, V269, P26363; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weil R, 1997, J BIOL CHEM, V272, P9942; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	30	157	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30410	30414		10.1074/jbc.273.46.30410	http://dx.doi.org/10.1074/jbc.273.46.30410			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804806	hybrid			2022-12-25	WOS:000077008100053
J	Umemura, T; Tatsuno, I; Shibasaki, M; Homma, M; Kawagishi, I				Umemura, T; Tatsuno, I; Shibasaki, M; Homma, M; Kawagishi, I			Intersubunit interaction between transmembrane helices of the bacterial aspartate chemoreceptor homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; ACCEPTING CHEMOTAXIS PROTEINS; SINGLE CYTOPLASMIC DOMAIN; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; MULTIPLE METHYLATION; SERINE CHEMORECEPTOR; SENSORY RECEPTOR; IN-VIVO; TAR	The transmembrane domain that connects the extracellular and intracellular domains of cell-surface receptors must play a critical role in signal transduction. Here, we report studies of the interaction between the transmembrane helices (TM1 and TM2) of the Escherichia coli aspartate chemoreceptor (Tar). Tar exists as a homodimer regardless of its state of ligand occupancy. A particular residue substitution in TM1 (A19K) abolishes the signaling ability of Tar. This signaling defect can be suppressed by single residue substitutions in TM2 (W192R, A198E, V201E, and V202L). We have found that these suppressors can be divided into two groups. A198E and V201E (class 1) almost completely suppress the defects caused by A19R, and this suppression occurs between two subunits of the Tar dimer. In contrast, W192R and V202L (class 2) fail to suppress some signaling defects, and their suppression does not occur between subunits. Because disulfide-crosslinking studies predict that residues 198 and 201 point toward residue 19 of the partner subunit, we propose that the class 1 suppressors form an intersubunit salt bridge with Lys-19. Indeed, A19K was suppressed by several additional aspartate or glutamate substitutions on the same face of TM2 occupied by residues 198 and 201. None of these intersubunit salt bridges perturb signaling function, suggesting that the mechanism of transmembrane signal propagation does not involve large displacements (such as extensive rotation) of the TM1 and TM2 helices relative to each other.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Kawagishi, I (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Tatsuno, Ichiro/GQP-8401-2022	Tatsuno, Ichiro/0000-0003-4053-9695				BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Baumgartner JW, 1996, J BACTERIOL, V178, P4651, DOI 10.1128/jb.178.15.4651-4660.1996; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; CHELSKY D, 1980, P NATL ACAD SCI-BIOL, V77, P2434, DOI 10.1073/pnas.77.5.2434; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DEFRANCO AL, 1980, P NATL ACAD SCI-BIOL, V77, P2429, DOI 10.1073/pnas.77.5.2429; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ENGSTROM P, 1980, CELL, V20, P165, DOI 10.1016/0092-8674(80)90244-5; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; JEFFERY CJ, 1994, BIOCHEMISTRY-US, V33, P3457, DOI 10.1021/bi00178a001; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LI CY, 1993, J BACTERIOL, V175, P2564, DOI 10.1128/JB.175.9.2564-2567.1993; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; Nishiyama SI, 1997, J BACTERIOL, V179, P6573, DOI 10.1128/jb.179.21.6573-6580.1997; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423	47	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30110	30115		10.1074/jbc.273.46.30110	http://dx.doi.org/10.1074/jbc.273.46.30110			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804765	hybrid, Green Submitted			2022-12-25	WOS:000077008100012
J	Valentijn, JA; Fyfe, GK; Canessa, CM				Valentijn, JA; Fyfe, GK; Canessa, CM			Biosynthesis and processing of epithelial sodium channels in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; NA+ CHANNEL; PROTEASOME; ALDOSTERONE; DEGRADATION; EXPRESSION; MEMBRANE; SUBUNITS; PROTEINS; MUTANT	The epithelial sodium channel (ENaC) provides the rate-limiting step in the reabsorption of sodium by many epithelia. The number of channels at the cell surface is tightly regulated; most cells express only a few channels. We have examined the biosynthesis and cell surface expression of ENaC in Xenopus oocytes. The subunits of ENaC are readily synthesized in the endoplasmic reticulum, but most of them remain as immature proteins in pre-Golgi compartments, where they are degraded by the proteasomal pathway without apparent ubiquitination. Even when the three subunits, alpha, beta, and gamma, are expressed in the same cell, only a very small fraction of the total channel population leave the endoplasmic reticulum, acquire complex oligosaccharides, and reach the plasma membrane. Overexpression of subunits does not increase the number of channels in the plasma membrane but results in the appearance of cytoplasmic subunits in a form not membrane bound. The data indicate that maturation and assembly of the subunits are slow and inefficient processes, and constitute limiting steps for the expression of functional ENaC channels in the plasma membrane.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Canessa, CM (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.		Valentijn, Jack/E-5162-2012		NHLBI NIH HHS [5P50HL55007] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055007] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JEENSEN TJ, 1995, CELL, V83, P129; KAHNE T, 1994, J IMMUNOL METHODS, V168, P209, DOI 10.1016/0022-1759(94)90057-4; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; May A, 1997, J AM SOC NEPHROL, V8, P1813; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1982, J MEMBRANE BIOL, V64, P91, DOI 10.1007/BF01870771; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Valentijn JA, 1998, EUR J CELL BIOL, V76, P204, DOI 10.1016/S0171-9335(98)80035-6; WALKER JM, 1996, PROTEIN PROTOCOLS HD; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	33	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30344	30351		10.1074/jbc.273.46.30344	http://dx.doi.org/10.1074/jbc.273.46.30344			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804797	hybrid			2022-12-25	WOS:000077008100044
J	Yu, JH; Wjasow, C; Backer, JM				Yu, JH; Wjasow, C; Backer, JM			Regulation of the p85/p110 alpha Phosphatidylinositol 3 '-kinase - Distinct roles for the N-terminal and C-terminal SH2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PI 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CATALYTIC SUBUNIT; ACTIVATION; BINDING; P85; ASSOCIATION; PI3-KINASE; EXPRESSION	Our previous studies on the p85/p110 alpha phosphatidylinositol 3-kinase showed that the p85 regulatory subunit inhibits the p110 alpha catalytic subunit, and that phosphopeptide activation of p85/p110 alpha dimers reflects a disinhibition of p110 alpha (Yu, J,, Zhang, Y,, McILroy, J,, Rordorf-Nikolic, T., Orr, G. A., and Backer, J. M. (1998) Mol. Cell, Biol, 18, 1379-1387), We now define the domains of p85 required for inhibition of p110 alpha. The iSH2 domain of p85 is sufficient to bind p110 alpha but does not inhibit it. Inhibition of p110 alpha requires the presence of the nSH2 domain linked to the iSH2 domain. Phosphopeptides increase the activity of nSH2/iSH2-p110 alpha dimers, demonstrating that the nSH2 domain mediates both inhibition of p110 alpha and disinhibition by phosphopeptides, In contrast, phosphopeptides did not increase the activity of iSH2/cSH2-p110 alpha dimers, or dimers composed of p110 alpha and an nSH2/iSH2/cSH2 construct containing a mutant nSH2 domain. Phosphopeptide binding to the cSH2 domain increased p110 alpha activity only in the context of an intact p85 containing both the nSH2 domain and residues 1-322 (the SH3, proline-rich and breakpoint cluster region-homolgy domains). These data suggest that the nSH2 domain of p85 is a direct regulator of p110 alpha activity. Regulation of p110 alpha by phosphopeptide binding to the cSH2 domain occurs by a mechanism that requires the additional presence of the nSH2 domain and residues 1-322 of p85.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM55692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	25	138	143	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30199	30203		10.1074/jbc.273.46.30199	http://dx.doi.org/10.1074/jbc.273.46.30199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804776	hybrid			2022-12-25	WOS:000077008100023
J	Gut, A; Balda, MS; Matter, K				Gut, A; Balda, MS; Matter, K			The cytoplasmic domains of a beta(1) integrin mediate polarization in Madin-Darby canine kidney cells by selective basolateral stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; STRUCTURAL REQUIREMENTS; SURFACE POLARITY; FC-RECEPTORS; MEMBRANE; LOCALIZATION; ENDOCYTOSIS; EXPRESSION	In Madin-Darby canine kidney cells, newly synthesized apical and basolateral membrane proteins are gen erally transported directly to their respective cell surface domain due to targeting determinants that mediate sorting in the Golgi complex. In several basolateral membrane proteins, these targeting determinants reside in the cytoplasmic domains. We show here that basolateral expression of the human alpha(5)beta(1) integrin in stably transfected Madin-Darby canine kidney cells is also mediated by the cytoplasmic domains. Distinct regions in both cytoplasmic domains were found to be sufficient to mediate basolateral expression independently from one another. Unexpectedly, newly synthesized wild-type alpha(5)beta(1) and basolaterally expressed chimeras containing the cytoplasmic domain of either alpha(5) or beta(1) were integrated into both cell surface domains, preferentially apically, during biosynthesis, The apical pools of wild-type integrin and chimeric subunits were found to become quickly degraded, whereas the basolateral pools were stabilized. Thus, the cytoplasmic domains of the alpha(5)beta(1) integrin are independently sufficient to mediate sorting by selective basolateral stabilization.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Matter, K (corresponding author), Univ Geneva, Dept Cell Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Matter, Karl/C-4880-2008	Matter, Karl/0000-0001-8026-7220; /0000-0002-8427-6746				Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CONTRERAS RG, 1989, AM J PHYSIOL, V257, pC896, DOI 10.1152/ajpcell.1989.257.5.C896; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GREEN SA, 1985, J BIOL CHEM, V260, P9867; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Keller P, 1997, J CELL SCI, V110, P3001; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; Matter K, 1998, J CELL SCI, V111, P511; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; Montesano R, 1997, J CELL PHYSIOL, V173, P152, DOI 10.1002/(SICI)1097-4652(199711)173:2<152::AID-JCP14>3.0.CO;2-I; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NHIEU GTV, 1996, J BIOL CHEM, V271, P7665; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; OJAKIAN GK, 1994, J CELL SCI, V107, P561; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; SCHWIMMER R, 1995, J CELL SCI, V108, P2487; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215; Vignoud L, 1997, J CELL SCI, V110, P1421; VIGNOUD L, 1994, BIOCHEM BIOPH RES CO, V199, P603, DOI 10.1006/bbrc.1994.1271; WANG AZ, 1990, J CELL SCI, V95, P153; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zuk A, 1996, J CELL SCI, V109, P1875	49	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29381	29388		10.1074/jbc.273.45.29381	http://dx.doi.org/10.1074/jbc.273.45.29381			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792639	hybrid			2022-12-25	WOS:000076798300016
J	Kupprion, C; Motamed, K; Sage, EH				Kupprion, C; Motamed, K; Sage, EH			SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PLATELET FACTOR-IV; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; FACTOR VPF/VEGF; EXPRESSION; PROTEIN; BINDING; ANGIOGENESIS; ACTIVATION	SPARC (secreted protein, acidic and rich in cysteine) is a matricellular protein that modulates cell adhesion and proliferation and is thought to function in tissue remodeling and angiogenesis. In this study, we demonstrate that SPARC inhibits DNA synthesis by >90% in human microvascular endothelial cells (HMEC) stimulated by the endothelial cell mitogen vascular endothelial growth factor (VEGF). Peptides derived from SPARC domain IV, which contains a disulfide-bonded EF-hand sequence and binds to endothelial cells, mimicked the effect of native SPARC, The inhibition was also observed with a peptide from the follistatin-like domain II, whereas peptides from SPARC domains I and III had no effect on VEGF-stimulated DNA synthesis. The inhibition of HMEC proliferation was mediated in part by the binding of VEGF to SPARC, The binding of I-125-VEGF to HMEC was reduced by SPARC and SPARC peptides from domain IV in a concentration-dependent manner, In a radioimmune precipitation assay, peptides from SPARC domains II and IV each competed with native SPARC for its binding to VEGF, It has been reported that VEGF stimulates the tyrosine phosphorylation and activation of mitogen-activated protein kinases Erk1 and Erk2, We now show that SPARC reduces this phosphorylation in VEGF-stimulated HMEC to levels of unstimulated controls. SPARC thus modulates the mitogenic activity of VEGF through a direct binding interaction and reduces the association of VEGF with its cell-surface receptors, Moreover, an additional diminution of VEGF activity by SPARC is accomplished through a reduction in the tyrosine phosphorylation of mitogen-activated protein kinases.	Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Sage, EH (corresponding author), Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIGMS NIH HHS [GM 40711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Barleon B, 1997, CANCER RES, V57, P5421; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Couffinhal T, 1997, AM J PATHOL, V150, P1673; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; IRUELAARISPE ML, 1995, MOL BIOL CELL, V6, P327, DOI 10.1091/mbc.6.3.327; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Melnyk O, 1996, CANCER RES, V56, P921; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Motamed K, 1998, J CELL BIOCHEM, V70, P543, DOI 10.1002/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; PEER J, 1995, LAB INVEST, V72, P638; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; POLVERINI PJ, 1989, CYTOKINES, V1, P54; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Sage E. H., 1996, ADV ONCOL, V12, P17; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sage EH, 1997, NAT MED, V3, P144; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1984, J BIOL CHEM, V259, P3993; Sasaki T, 1997, J BIOL CHEM, V272, P9237; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	60	230	242	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29635	29640		10.1074/jbc.273.45.29635	http://dx.doi.org/10.1074/jbc.273.45.29635			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792673	hybrid			2022-12-25	WOS:000076798300050
J	Wadhwa, R; Takano, S; Robert, M; Yoshida, A; Nomura, H; Reddel, RR; Mitsui, Y; Kaul, SC				Wadhwa, R; Takano, S; Robert, M; Yoshida, A; Nomura, H; Reddel, RR; Mitsui, Y; Kaul, SC			Inactivation of tumor suppressor p53 by Mot-2, a hsp70 family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EMBRYO FIBROBLASTS; CELL-LINES; T-ANTIGEN; IMMORTALIZATION; MORTALIN; IDENTIFICATION; MUTATIONS; BINDING; PROTEIN; ASSOCIATION	The mortalin genes, mot-1 and mot-2, are hsp70 family members that were originally cloned from normal and immortal murine cells, respectively. Their proteins differ by only two amino acid residues but exhibit different subcellular localizations, arise from two distinct genes, and have contrasting biological activities. We report here that the two proteins also differ in their interactions with the tumor suppressor protein p53. The pancytosolic mot-1 protein in normal cells did not show colocalization with p53; in contrast, nonpancytosolic mot-2 and p53 overlapped significantly in immortal cells. Transfection of mot-2 but not mot-1 resulted in the repression of p53-mediated transactivation in p53-responsive reporter assays. Inactivation of p53 by mot-2 was supported by the down-regulation of p53-responsive genes p21(WAF-1) and mdm-2 in mot-2-transfected cells only. Furthermore, NIH 3T3 cells transfected with expression plasmid encoding green fluorescent protein-tagged mot-2 but not mot-1 showed an abrogation of nuclear translocation of wild-type p53. These results demonstrate a novel mechanism of p53 inactivation by mot-2 protein.	Chugai Res Inst Mol Med, Ibaraki 30041, Japan; AIST, Natl Inst Biosci & Human Technol, Ibaraki 3058566, Japan; Childrens Med Res Inst, Sydney, NSW 2145, Australia	National Institute of Advanced Industrial Science & Technology (AIST); Children's Medical Research Institute - Australia; University of Sydney	Wadhwa, R (corresponding author), Chugai Res Inst Mol Med, 153-2 Nagai, Ibaraki 30041, Japan.	renu@tk.chugai-pharm.co.jp	Wadhwa, Renu/L-8898-2018; Takano, Shuichi/I-6512-2013; Robert, Martin/B-3970-2009; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014	Wadhwa, Renu/0000-0001-8248-5192; Robert, Martin/0000-0002-7082-5142; Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; Hall PA, 1996, J PATHOL, V180, P1; Harlow E, 1988, ANTIBODIES LABORATOR, P521; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Kaul SC, 1997, EXP CELL RES, V232, P56, DOI 10.1006/excr.1997.3503; Kaul SC, 1998, ONCOGENE, V17, P907, DOI 10.1038/sj.onc.1202017; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; Kaul Sunil C., 1998, Indian Journal of Experimental Biology, V36, P345; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; Moll UM, 1996, MOL CELL BIOL, V16, P1126; ONeill FJ, 1997, ONCOGENE, V14, P955, DOI 10.1038/sj.onc.1200913; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; OZBUN MA, 1993, CANCER RES, V53, P1646; Reed Michael, 1993, Gene Expression, V3, P95; RITTLING SR, 1992, ONCOGENE, V7, P935; Sadekova S, 1997, INT J RADIAT BIOL, V72, P653, DOI 10.1080/095530097142807; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; Takano S, 1997, EXP CELL RES, V237, P38, DOI 10.1006/excr.1997.3754; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; VERONIQUE G, 1998, MOL CELL BIOL, V18, P1611; Wadhwa R, 1996, EXP CELL RES, V226, P381, DOI 10.1006/excr.1996.0239; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013	36	187	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29586	29591		10.1074/jbc.273.45.29586	http://dx.doi.org/10.1074/jbc.273.45.29586			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792667	hybrid			2022-12-25	WOS:000076798300044
J	Krtolica, A; Krucher, NA; Ludlow, JW				Krtolica, A; Krucher, NA; Ludlow, JW			Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities	ONCOGENE			English	Article						protein phosphatase type 1 (PP1); pRB hypoxia; cyclin-dependent kinase activity; mammalian cell cycle	CYCLIN-DEPENDENT KINASES; PROTEIN PHOSPHATASE-ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SUPPRESSOR PROTEIN; S-PHASE; PHOSPHORYLATION; INHIBITOR; P21; TRANSCRIPTION	Exposure of CV-1P cells to hypoxic conditions results in reversible cell cycle arrest concomitant with accumulation of pRB in the hypophosphorylated, growth suppressive form. Similar to cell cycle arrest induced by serum starvation, we show here that hypoxia-induced arrest is accompanied by a decrease in pRB-directed CDK4 and CDK2 activities, lower cyclin D and E protein levels, and by an increase in p27 protein abundance. Immunoprecipitation studies reveal an increase in p27 association with cyclin E-CDK2 complexes. In contrast to cell cycle arrest induced by serum starvation, hypoxia increases PP1-mediated pRB dephosphorylation. These data reveal that synergy between decreased pRB-directed cyclin/CDK activity and increased pRB-directed phosphatase activity contribute towards inducing and maintaining pRB in its hypophosphorylated, growth suppressive state during hypoxia.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Ludlow, JW (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NCI NIH HHS [T32 CA09363, CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940, T32CA009363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; AMELLEM O, 1991, CELL PROLIFERAT, V24, P127, DOI 10.1111/j.1365-2184.1991.tb01144.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1988, METHOD ENZYMOL, V159, P390; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Geng Y, 1996, ONCOGENE, V12, P1173; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krtolica A, 1996, CANCER RES, V56, P1168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2295	2304		10.1038/sj.onc.1202159	http://dx.doi.org/10.1038/sj.onc.1202159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811460				2022-12-25	WOS:000076723300003
J	Neve, R; Chang, CH; Scott, GK; Wong, A; Friis, RR; Hynes, NE; Benz, CC				Neve, R; Chang, CH; Scott, GK; Wong, A; Friis, RR; Hynes, NE; Benz, CC			The epithelium-specific Ets transcription factor ESX is associated with mammary gland development and involution	FASEB JOURNAL			English	Article						Ets family; ESX promoter; ESX expression and mammary gland differentiation	EPIDERMAL GROWTH-FACTOR; CELL-DEATH; GENE-EXPRESSION; BREAST-CANCER; DIFFERENTIATION; PROLIFERATION; APOPTOSIS; PROTEIN; FAMILY	To study mammary gland expression of the epithelium-restricted Ets factor, ESX, mouse cDNA and genomic sequences were cloned and a similar to 350 bp proximal promoter region with >80% mouse-human homology was identified that mediates ESX induction by serum, heregulin (HRG)I or epidermal growth factor (EGF). ESX mRNA expression progressively increases during embryonic mouse development from day 7 and is detectable in virgin mammary glands; it shows little if any change during pregnancy, then declines to barely detectable levels after 3 days of lactation. Similarly, cultured HC11 cells from midpregnant mouse mammary epithelium show an increase in ESX expression upon reaching lactogenic competency (in the presence of EGF or HRG), with a decline to barely detectable levels upon exposure to lactogenic hormones that induce milk protein (beta-casein) expression. In contrast, involuting mouse and rat mammary glands show maximal ESX expression. High ESX levels are also seen in the involuting ventral prostate gland of rats. These findings, including the persistence of up-regulated ESX in fully regressed mammary glands, suggest that ESX expression can be induced by soluble growth factors and is maximally up-regulated in those partially com mitted epithelial cells destined to survive both the apoptotic and remodeling phases of glandular involution.	Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94143 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Bern, Dept Clin Res, CH-3004 Bern, Switzerland	University of California System; University of California San Francisco; Friedrich Miescher Institute for Biomedical Research; University of Bern	Benz, CC (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, Dept Med, Box 1270,3rd & Parnassus, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, R01-CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chepko G, 1997, TISSUE CELL, V29, P239, DOI 10.1016/S0040-8166(97)80024-9; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Daly JM, 1997, CANCER RES, V57, P3804; Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HROMAS R, 1994, INT J HEMATOL, V59, P257; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Lochter A., 1997, Biological signalling and the mammary gland, 2nd Hannah Symposium, Ayr, UK, 4-6 September 1996., P77; Lund LR, 1996, DEVELOPMENT, V122, P181; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTI A, 1995, CELL DEATH DIFFER, V2, P277; Nishi N, 1996, PROSTATE, V28, P139; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Russo J, 1997, ENDOCR-RELAT CANCER, V4, P7, DOI 10.1677/erc.0.0040007; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; STRANGE R, 1992, DEVELOPMENT, V115, P49; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; VONDERHAAR BK, 1987, J CELL PHYSIOL, V132, P581, DOI 10.1002/jcp.1041320324; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; Wilde C. J., 1997, Biological signalling and the mammary gland, 2nd Hannah Symposium, Ayr, UK, 4-6 September 1996., P103; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766	29	46	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1541	1550		10.1096/fasebj.12.14.1541	http://dx.doi.org/10.1096/fasebj.12.14.1541			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806763				2022-12-25	WOS:000076749500013
J	Colnot, S; Romagnolo, B; Lambert, M; Cluzeaud, F; Porteu, A; Vandewalle, A; Thomasset, M; Kahn, A; Perret, C				Colnot, S; Romagnolo, B; Lambert, M; Cluzeaud, F; Porteu, A; Vandewalle, A; Thomasset, M; Kahn, A; Perret, C			Intestinal expression of the calbindin-D9K gene in transgenic mice - Requirement for a Cdx2-binding site in a distal activator region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; TYROSINE AMINOTRANSFERASE GENE; VITAMIN-D-RECEPTOR; SUCRASE-ISOMALTASE GENE; HORMONE FUSION GENES; CIS-ACTING ELEMENTS; HOMEOBOX GENE; TATA BOX; TRANSCRIPTION; ENHANCER	The calbindin-D9K gene encodes a vitamin D-induced calcium-binding protein that is expressed as a marker of small intestine differentiation. We have shown that 4580 base pairs of its 5' DNA regulatory region can target reporter transgene expression in the intestine and cause this transgene to respond like the endogenous gene to vitamin D active metabolite and that the homeoprotein Cdx2 is bound to the TATA box in the intestine. We now show that the 4580 base pairs construct confers a differentiated pattern of reporter transgene expression in the intestine and that cooperation between the proximal promoter and a distal element located in an opened chromatin structure is responsible for the intestinal expression and vitamin D responsiveness of the transgene, Gel shift and footprinting assays using duodenal nuclear extracts indicate that this distal element contains a Cdx2-binding site. Finally, a mutation in this distal Cdx2-binding site dramatically decreases intestinal expression in transgenic mice. This report, using an in vivo approach, demonstrates the crucial role of Cdx2 for the transcription of an intestinal gene.	Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Hop Robert Debre, INSERM, U458, F-75019 Paris, France; Fac Med Xavier Bichat, Inst Fed Rech 02, INSERM, U246, F-75810 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perret, C (corresponding author), Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Romagnolo, Béatrice/D-5017-2017; Colnot, Sabine/A-9169-2008; Perret-Mayeux, Christine/L-3297-2017	Romagnolo, Béatrice/0000-0001-8772-3604; Colnot, Sabine/0000-0002-3949-9107; perret, christine/0000-0003-4710-7051				Barton MC, 1997, P NATL ACAD SCI USA, V94, P7257, DOI 10.1073/pnas.94.14.7257; BRUNS MEH, 1981, J BIOL CHEM, V256, P4649; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COLNOT S, 1995, MOL CELL ENDOCRINOL, V113, P89, DOI 10.1016/0303-7207(95)03618-H; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GRANGE T, 1989, EXP CELL RES, V180, P220, DOI 10.1016/0014-4827(89)90226-7; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Guy LG, 1997, NUCLEIC ACIDS RES, V25, P4400, DOI 10.1093/nar/25.21.4400; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; JAMES R, 1991, J BIOL CHEM, V266, P3246; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Li YC, 1998, ENDOCRINOLOGY, V139, P847, DOI 10.1210/en.139.3.847; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PERRET C, 1991, GENE, V108, P227, DOI 10.1016/0378-1119(91)90438-H; PERRET C, 1985, EUR J BIOCHEM, V150, P211, DOI 10.1111/j.1432-1033.1985.tb09009.x; PERRET C, 1994, VITAMIN D, P385; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Romagnolo B, 1996, J BIOL CHEM, V271, P16820, DOI 10.1074/jbc.271.28.16820; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSI H, 1995, P NATL ACAD SCI USA, V92, P7197, DOI 10.1073/pnas.92.16.7197; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; THOMASSET M, 1982, AM J PHYSIOL, V243, pE483, DOI 10.1152/ajpendo.1982.243.6.E483; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P176, DOI 10.1210/endo-119-1-176; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	53	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31939	31946		10.1074/jbc.273.48.31939	http://dx.doi.org/10.1074/jbc.273.48.31939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822664	hybrid			2022-12-25	WOS:000077207000046
J	Bourteele, S; Hausser, A; Doppler, H; Horn-Muller, J; Ropke, C; Schwarzmann, G; Pfizenmaier, K; Muller, G				Bourteele, S; Hausser, A; Doppler, H; Horn-Muller, J; Ropke, C; Schwarzmann, G; Pfizenmaier, K; Muller, G			Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid syntheses by caspases in apoptotic Kym-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGANINE N-ACYLTRANSFERASE; NEUTRAL SPHINGOMYELINASE; GOLGI-APPARATUS; SIGNAL; BIOSYNTHESIS; ACTIVATION; EXPRESSION; INDUCTION; RECEPTOR; SURFACE	The role, origin, and mode of action of the lipid messenger ceramide in programmed cell death and its Linkage to receptor-associated apoptotic signal proteins is still unresolved. We show here in Kym-1 rhabdomyosarcoma cells that tumor necrosis factor (TNF)-induced apoptosis is preceded by a multiphasic increase in intracellular ceramide levels, Distinct enzymes were found to contribute to three waves of ceramide, neutral sphingomyelinase, ceramide synthase, and acid sphingomyelinase, with peak activities at 1-2, 40, and around 200 min, respectively the latter coinciding with progression to irreversible damage. In parallel with ceramide generation, TNF-mediated inhibition of glucosylceramide and sphingomyelin (SM) synthase prevents the immediate metabolization of this lipid mediator. In the presence of benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone(Z-VAD-fmk) or benzyloxycarbonyl-Asp-Glu-Val-Asp-chloromethyl ketone (Z-DEVD-cmk), a broad spectrum and a caspase 3-selective inhibitor, respectively, glucosylceramide and SM synthase activity remains unaffected by TNF, and intracellular ceramide accumulation is not observed. Our results show that several lipid enzymes contribute to generation of ceramide in response to TNF and identify glucosylceramide and SM synthase as important regulators of the kinetics and magnitude of intracellular ceramide accumulation. As glucosylceramide and SM synthase activity is caspase-sensitive, our data suggest a novel functional link between caspase(s) and ceramide during apoptotic processes.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Bonn, Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Stuttgart; University of Bonn	Muller, G (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Gertraud.Mueller@po.uni-stuttgart.de	Hausser, Angelika/AAC-4531-2021					AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; GRELL M, 1994, J IMMUNOL, V153, P1963; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kronke M, 1997, Cytokine Growth Factor Rev, V8, P103; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; PUTZ U, 1995, EUR J CELL BIOL, V68, P113; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Zhang P, 1997, J BIOL CHEM, V272, P9609	31	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					31245	31251		10.1074/jbc.273.47.31245	http://dx.doi.org/10.1074/jbc.273.47.31245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9813032	hybrid			2022-12-25	WOS:000077136900060
J	Grundemann, D; Koster, S; Kiefer, N; Breidert, T; Engelhardt, M; Spitzenberger, F; Obermuller, N; Schomig, E				Grundemann, D; Koster, S; Kiefer, N; Breidert, T; Engelhardt, M; Spitzenberger, F; Obermuller, N; Schomig, E			Transport of monoamine transmitters by the organic cation transporter type 2, OCT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER TRANSPORTERS; FUNCTIONAL EXPRESSION; RAT-KIDNEY; NORADRENALINE; CLONING; DISPROCYNIUM24; INHIBITOR; CELLS	The recently cloned apical renal transport system for organic cations (OCT2) exists in dopamine-rich tissues such as kidney and some brain areas (Grundemann, D., Babin-Ebell, J., Martel, F., Ording, N., Schmidt, A., and Schomig, E. (1997) J. Biol. Chem. 272, 10408-10413). The study at hand was performed to answer the question of whether OCT2 accepts dopamine and other monoamine transmitters as substrate. 293 cells were stably transfected with the OCT2r cDNA resulting in the 293(OCT2r) cell line. Expression of OCT2r in 293 cells induces specific transport of tritiated dopamine, noradrenaline, adrenaline, and B-hydroxytryptamine (5-HT). Initial rates of specific H-3-dopamine, H-3-noradrenaline, H-3-adrenaline, and H-3-5-HT transport were saturable, the K-m values being 2.1, 4.4, 1.9, and 3.6 mmol/liter. The corresponding V-max values were 3.9, 1.0, 0.59, and 2.5 nmol min(-1).mg of protein(-1), respectively. 1,1'-diisopropyl-2,4'-cyanine (disprocynium24), a known inhibitor of OCT2 with a potent eukaliuric diuretic activity, inhibited SH-dopamine uptake into 293(OCT2r) cells with an K-i of 5.1 (2.6, 9.9) nmol/liter. In situ hybridization reveals that, within the kidney, the OCT2r mRNA is restricted to the outer medulla and deep portions of the medullary rays indicating selective expression in the S3 segment of the proximal tubule. These findings open the possibility that OCT2r plays a role in renal dopamine handling.	Univ Heidelberg, Dept Pharmacol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schomig, E (corresponding author), Univ Heidelberg, Dept Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Gründemann, Dirk/AAD-2217-2022	Kiefer, Nicholas/0000-0002-2574-7106				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Aperia A, 1994, Curr Opin Nephrol Hypertens, V3, P39, DOI 10.1097/00041552-199401000-00005; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Eisenhofer G, 1996, N-S ARCH PHARMACOL, V354, P287; GIROS B, 1992, MOL PHARMACOL, V42, P383; GOLDSTEIN M, 1972, PHARMACOL REV, V24, P293; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Graefe KH, 1997, N-S ARCH PHARMACOL, V356, P115, DOI 10.1007/PL00005018; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; HAGEGE J, 1985, KIDNEY INT, V27, P3, DOI 10.1038/ki.1985.2; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martel F, 1996, N-S ARCH PHARMACOL, V354, P320; Muhlbauer B, 1997, N-S ARCH PHARMACOL, V356, P846, DOI 10.1007/PL00005126; Obermuller N, 1997, KIDNEY INT, V52, P1584, DOI 10.1038/ki.1997.489; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PARTI R, 1987, J NEUROCHEM, V48, P949, DOI 10.1111/j.1471-4159.1987.tb05609.x; RUSS H, 1993, J MED CHEM, V36, P4208, DOI 10.1021/jm00078a010; RUSS H, 1992, N-S ARCH PHARMACOL, V346, P158, DOI 10.1007/BF00165297; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHUMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; Segel IH, 1975, ENZYME KINETICS BEHA; WILKINSON L, 1989, SYSTAT SYSTEM STAT	28	124	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 20	1998	273	47					30915	30920		10.1074/jbc.273.47.30915	http://dx.doi.org/10.1074/jbc.273.47.30915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	141HG	9812985	hybrid			2022-12-25	WOS:000077136900013
J	Guha, S; Manna, TK; Das, KP; Bhattacharyya, B				Guha, S; Manna, TK; Das, KP; Bhattacharyya, B			Chaperone-like activity of tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; ALPHA-CRYSTALLIN; MOLECULAR CHAPERONE; CYTOPLASMIC CHAPERONIN; PROTEIN; POLYMERIZATION; SUBUNITS; GROEL	Tubulin, a ubiquitous protein of eukaryotic cytoskeleton, is a building block unit of microtubule. Although several cellular processes are known to be mediated through the tubulin-microtubule system, the participation of tubulin or microtubule in protein folding path way has not yet been reported. Here we show that goat brain tubulin has some functions and features similar to many known molecular chaperones. Substoichiometric amounts of tubulin can suppress the non-thermal and thermal aggregation of a number of unrelated proteins such as insulin, equine liver alcohol dehydrogenase, and soluble eye lens proteins containing beta- and gamma-crystallins. This chaperone-like activity of tubulin becomes more pronounced as temperature increases. Aging of tubulin solution at 37 degrees C also enhances its chaperone-like activity. Tubulin loses its chaperone-like activity upon removal of its flexible hydrophilic C-terminal tail. These results suggest that both electrostatic and hydrophobic interactions are important in substrate binding by tubulin and that the negatively charged C-terminal tails play a crucial role for its chaperone-like activity.	Bose Inst, Dept Biochem, Calcutta 700054, W Bengal, India; Bose Inst, Dept Chem, Calcutta 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute	Bhattacharyya, B (corresponding author), Bose Inst, Dept Biochem, Centenary Bldg,P 1-2,CIT Scheme,VIIM, Calcutta 700054, W Bengal, India.	bablu@boseinst.ernet.in		Manna, Tapas/0000-0002-2213-6246; Das, Kali/0000-0001-7686-9077				Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; HAMEL E, 1981, ARCH BIOCHEM BIOPHYS, V209, P29, DOI 10.1016/0003-9861(81)90253-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; PONSTINGL H, 1983, J SUBMICR CYTOL PATH, V15, P359; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P3536, DOI 10.1021/bi00360a010; RAMAN B, 1994, J BIOL CHEM, V269, P27264; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SACKETT DL, 1985, J BIOL CHEM, V260, P43; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WARD LD, 1994, BIOCHEMISTRY-US, V33, P11891, DOI 10.1021/bi00205a027; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	32	66	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 13	1998	273	46					30077	30080		10.1074/jbc.273.46.30077	http://dx.doi.org/10.1074/jbc.273.46.30077			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139BR	9804759	hybrid			2022-12-25	WOS:000077008100006
J	Bursey, EH; Burgess, BK				Bursey, EH; Burgess, BK			The role of methionine 156 in cross-subunit nucleotide interactions in the iron protein of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MYOSIN MOTOR DOMAIN; X-RAY STRUCTURES; CONFORMATIONAL-CHANGES; FE-PROTEIN; MOLYBDENUM COFACTOR; SIGNAL-TRANSDUCTION; CRYSTALLOGRAPHIC STRUCTURE; ADENOSINE 5'-TRIPHOSPHATE; KLEBSIELLA-PNEUMONIAE	A variant Fe protein has been created at the completely conserved residue methionine 156 by changing it to cysteine. The Azotobacter vinelandii strain expressing M156C is unable to grow under nitrogen-fixing conditions, and the purified protein cannot support Substrate reduction in vitro. This mutation has an effect on the Fe protein's ability to undergo the MgATP-induced conformational change as evidenced by the fact that M156C is chelated in the presence of MgATP with a lower observed rate than wild-type. While the electron paramagnetic resonance spectra of this protein are similar to those of the wild-type Fe protein, the circular dichroism spectrum is markedly different in the presence of MgATP, showing that the conformation adopted by M156C following nucleotide binding is different from the wild-type conformation. Although competition activity and chelation assays show that this Fe protein can still form a complex with the MoFe protein, this altered conformation only supports MgATP hydrolysis at 1% the rate of wild-type Fe protein. A model based on x-ray crystallographic information is presented to explain the importance of Met-156 in stabilization of the correct conformation of the Fe protein via critical interactions of the residue with Asp-43 and nucleotide in the other subunit.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN L, 1994, J BIOL CHEM, V269, P3290; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PALMER G, 1972, ARCH BIOCHEM BIOPHYS, V153, P325, DOI 10.1016/0003-9861(72)90452-3; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; Tari LW, 1996, NAT STRUCT BIOL, V3, P355, DOI 10.1038/nsb0496-355; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEHR CT, 1980, NUCL ACID CONSTITUEN; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	46	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29678	29685		10.1074/jbc.273.45.29678	http://dx.doi.org/10.1074/jbc.273.45.29678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792679	hybrid			2022-12-25	WOS:000076798300056
J	Chakravarty, L; Rogers, L; Quach, T; Breckenridge, S; Kolattukudy, PE				Chakravarty, L; Rogers, L; Quach, T; Breckenridge, S; Kolattukudy, PE			Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PLATELET FACTOR-IV; HEPARIN-BINDING; RHEUMATOID-ARTHRITIS; EXPRESSION; MCP-1; IDENTIFICATION; SUBSTITUTION; LIPOPROTEIN; RESOLUTION	Monocytes rolling on the endothelial cell. layer interact with monocyte chemoattractant protein-1 (MCP-1) that is tethered to the proteoglycans on the luminal side of the endothelial cells and consequently initiate adhesion of monocytes in the early phase of immune response. The amino acid residues in MCP-1 involved in tethering to the proteoglycans have not been elucidated. MCP-1 showed binding to [H-3]heparin with a K-D of 1.5 mu M. We substituted lysine or histidine residues at the C-terminal end of MCP-1 with alanine residues and tested these mutants for their ability to bind heparin, heparan sulfate, hyaluronic acid, and chondroitin sulfate-C. Substitution of Lys-58 or His-66 drastically reduced glycosaminoglycan binding. Substitution of Lys-56 or deletion of the five amino acid residues at the C terminus, including Lys-75, did not alter the heparin binding ability, suggesting that the other lysine residues at the C terminus are not involved in glycosaminoglycan binding. MCP-1 and its mutants did not bind hyaluronic acid as strongly as the other subunits of the GAGs. Substitution of Lys-58 or His-66 by alanine that prevented glycosaminoglycan binding did not affect Ca2+ influx, receptor binding, or chemotactic activity elicited by the chemokine on monocytic THP-1 cells. Therefore, we conclude that the Lys-58 and His-66 residues in the C-terminal alpha-helix of MCP-1 are essential for glycosaminoglycan binding and probably for the binding to the endothelial surface proteoglycans.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kolattukudy, PE (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	kolattukudy.2@osu.edu	kolattukudy, pappachan e/A-1350-2012		NHLBI NIH HHS [HL48916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048916] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAHOSHI T, 1993, ARTHRITIS RHEUM-US, V36, P762, DOI 10.1002/art.1780360605; Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Beall CJ, 1996, BIOCHEM J, V313, P633, DOI 10.1042/bj3130633; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; CRISMAN JM, 1998, IN PRESS MOL CELL BI; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; FORRESTER JS, 1991, ANNU REV MED, V42, P35, DOI 10.1146/annurev.med.42.1.35; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; GRAVES DT, 1992, AM J PATHOL, V140, P9; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JONES ML, 1992, J IMMUNOL, V149, P2147; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Koopmann W, 1997, J BIOL CHEM, V272, P10103; KURATSU J, 1993, J NATL CANCER I, V85, P1836, DOI 10.1093/jnci/85.22.1836; Lin YG, 1998, INFECT IMMUN, V66, P2319, DOI 10.1128/IAI.66.5.2319-2322.1998; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MAIONE TE, 1991, CANCER RES, V51, P2077; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Molestina RE, 1998, INFECT IMMUN, V66, P1370, DOI 10.1128/IAI.66.4.1370-1376.1998; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; ROVIN BH, 1994, LAB INVEST, V71, P536; RUSSELL ME, 1993, P NATL ACAD SCI USA, V90, P6086, DOI 10.1073/pnas.90.13.6086; SCHOEN FJ, 1991, TRENDS CARDIOVAS MED, V1, P216, DOI 10.1016/1050-1738(91)90041-C; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TAKEYA M, 1991, EXP MOL PATHOL, V54, P61, DOI 10.1016/0014-4800(91)90044-X; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P110; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VILLIGER PM, 1992, J IMMUNOL, V149, P722; Wang GP, 1997, ATHEROSCLEROSIS, V133, P31, DOI 10.1016/S0021-9150(97)00109-3; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	48	84	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29641	29647		10.1074/jbc.273.45.29641	http://dx.doi.org/10.1074/jbc.273.45.29641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792674	hybrid			2022-12-25	WOS:000076798300051
J	Hatzinikolas, G; Gibson, MA				Hatzinikolas, G; Gibson, MA			The exon structure of the human MAGP-2 gene - Similarity with the MAGP-1 gene is confined to two exons encoding a cysteine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; NF-KAPPA-B; MOLECULAR-CLONING; EXTRACELLULAR MICROFIBRILS; GLYCOPROTEIN-1 MAGP-1; COMPONENT; FIBRILLIN; TRANSCRIPTION; EXPRESSION; TISSUES	A cDNA for human microfibril-associated glycoprotein-a (MAGP-2) was used to screen a human leukocyte genomic DNA library in EMBL-3 vector. One clone, clone H (10 kilobase pairs (kbp)), was isolated that contained most of the MAGP-2 gene. The remainder of the 3' end of the gene was obtained by direct polymerase chain reaction amplification of genomic DNA, The human MAGP-2 gene was found to be about 11 kbp in size and to contain 10 evenly distributed exons, The internal exons range in size from 30 base pairs (bp) to 88 bp with exons 4 and 6 the only exons of equal size (45 bp), All internal intron: exon junctions are defined by canonical splice donor and acceptor sites. Each junction has a 1/2 codon split with the exception of the exon 8/9 junction, which has a 2/1 split. The translation initiation codon is in exon 2, and the final exon contains 110 bp of coding sequence, including 2 cysteine codons, Primer extension experiments identified only one major transcription initiation site, 213 bases upstream of the ATG site. Rapid analysis of cDNA ends-polymerase chain reaction analysis of the 5' end of MAGP-2 mRNA from placenta confirmed this result and did not detect any alternative splicing of transcripts,The putative promoter region of the MAGP-2 gene was found to be AT-rich and it lacked a TATA box and other common regulatory elements. However the sequence surrounding the transcription start site CTCA(+1)TTCC was similar to the consensus CTCA(+1)NTCT (N is any nucleoside) for an initiator element found in terminal deoxynucleotidyltransferase and a number of other highly regulated genes. Comparison with the previously characterized human MAGP-1 gene showed that structural similarity was largely confined to the exact size, sequence, and junction alignment of the two penultimate exons which encode the first six of the seven cysteine residues that are precisely spaced in both proteins. The findings are consistent with the growing evidence that, although MAGP-1 and MAGP-2 are both intimately involved in the biology of fibrillin-containing microfibrils, the MAGPs are structurally, functionally, and developmentally diverse proteins which share one characteristic cysteine-rich motif.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	mgibson@medicine.adelaide.edu.au						ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; DIETZ HC, 1994, ADV HUM GENET, V22, P153; FARACO J, 1995, GENOMICS, V25, P630, DOI 10.1016/0888-7543(95)80004-6; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GRILLI M, 1993, INT REV CYTOL, V143, P1; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Karonen T, 1997, BRIT J DERMATOL, V137, P51, DOI 10.1046/j.1365-2133.1997.17671859.x; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	37	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29309	29314		10.1074/jbc.273.45.29309	http://dx.doi.org/10.1074/jbc.273.45.29309			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792630	hybrid			2022-12-25	WOS:000076798300007
J	Marathe, S; Yu, YG; Turner, GE; Palmier, C; Weiss, RL				Marathe, S; Yu, YG; Turner, GE; Palmier, C; Weiss, RL			Multiple forms of arginase are differentially expressed from a single locus in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; GAGA TRANSCRIPTION FACTOR; RAT-LIVER ARGINASE; NUCLEOTIDE-SEQUENCE; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; MOLECULAR-CLONING; GENE ENCODES; MITOCHONDRIAL; ARGININE	The Neurospora crassa catabolic enzyme, arginase (L-arginine amidinohydrolase, EC 3.5.3.1), exists in multiple forms. Multiple forms of arginase are found in many vertebrates, but this is the only reported example in a microbial organism. The two major forms are structurally similar with subunit sizes of 36 and 41 kDa, respectively. The larger form is produced by mycelia growing in arginines-supplemented medium. Both forms are localized in the cytosol. The structural gene for arginase, aga, has been cloned and sequenced; it contains a 358-codon open reading frame with three in-frame ATGs at the amino terminus. Mutagenesis of these ATGs revealed that the first ATG initiates the 41-kDa protein and the third ATG initiates the 36-kDa protein. Mutation of the second ATG has no effect on translation. Northern analysis demonstrated that a 1.4-kilobase (kb) transcript is synthesized in minimal medium and both a 1.4- and 1.7-kb transcript are produced in arginine-supplemented medium. Primer extension identified the 5' ends of each transcript and demonstrated that the first and third ATG of the open reading frame are the initial AUGs of the 1.7- and 1.4-kb mRNA, respectively. The results suggest that a basal promoter produces the 1.4-kb transcript and an arginine "activated" promoter is responsible for the 1.7-kb transcript. Tandem promoters are rare in eukaryotic organisms, and they often regulate developmental or tissue-specific gene expression. The possibility that arginase has a role in differentiation in N. crassa is being investigated.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Turner, GE (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	turner@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47631] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAMAYO R, 1995, FUNGAL GENET NEWSL, V43, P9; ARCHIBALD RM, 1945, J BIOL CHEM, V157, P507; ATKINSON DE, 1992, PHYSIOL ZOOL, V65, P243, DOI 10.1086/physzool.65.2.30158252; ATKINSON DE, 1984, TRENDS BIOCHEM SCI, V9, P297, DOI 10.1016/0968-0004(84)90293-7; BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BERUTER J, 1978, BIOCHEM J, V175, P449, DOI 10.1042/bj1750449; BORKOVICH KA, 1987, J BACTERIOL, V169, P5510, DOI 10.1128/jb.169.12.5510-5517.1987; BORKOVICH KA, 1987, J BIOL CHEM, V262, P7081; BORKOVICH KA, 1985, THESIS U CALIFORNIA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARTER P, 1987, METHOD ENZYMOL, V154, P382; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHUI MI, 1992, GENETICS, V132, P987; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAMER CL, 1983, ANAL BIOCHEM, V128, P384, DOI 10.1016/0003-2697(83)90390-1; DAVIS RH, 1970, J BACTERIOL, V102, P299, DOI 10.1128/JB.102.2.299-305.1970; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DAVIS RH, 1968, J BACTGERIOL, V97, P383; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GLASS RD, 1973, J BIOL CHEM, V248, P5785; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; GROVE G, 1981, J BIOL CHEM, V256, P463; HARAGUCHI Y, 1987, P NATL ACAD SCI USA, V84, P412, DOI 10.1073/pnas.84.2.412; HAUTALA JA, 1977, J BACTERIOL, V130, P704, DOI 10.1128/JB.130.2.704-713.1977; HIRSCHKOLB H, 1968, J BIOL CHEM, V243, P6123; Ivey FD, 1996, MOL BIOL CELL, V7, P1283, DOI 10.1091/mbc.7.8.1283; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KUBELIK AR, 1991, MOL CELL BIOL, V11, P4022, DOI 10.1128/MCB.11.8.4022; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE PROT; Maniatis T., 1982, MOL CLONING LAB MANU; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; OKAMOTO PM, 1991, MOL GEN GENET, V227, P213, DOI 10.1007/BF00259673; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; OUZOUNIS CA, 1994, J MOL EVOL, V39, P101; PAN SC, 1995, GENE, V154, P115, DOI 10.1016/0378-1119(94)00837-I; PATTERTON D, 1994, J BIOL CHEM, V269, P25328; SACHS MS, 1986, J BIOL CHEM, V261, P869; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRELL A, 1989, EUR J BIOCHEM, V184, P635, DOI 10.1111/j.1432-1033.1989.tb15060.x; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; SUMRADA RA, 1984, J BACTERIOL, V160, P1078, DOI 10.1128/JB.160.3.1078-1087.1984; TARRAB R, 1974, EUR J BIOCHEM, V49, P457, DOI 10.1111/j.1432-1033.1974.tb03850.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANHUFFEL C, 1994, YEAST, V10, P923, DOI 10.1002/yea.320100707; Vann DC, 1995, FUNGAL GENET NEWSL A, V42, P53; VIELLEBREITBURD F, 1972, J BIOL CHEM, V247, P1227; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; WU M, 1987, J BIOL CHEM, V262, P12275; XU QL, 1993, EUR J BIOCHEM, V211, P891, DOI 10.1111/j.1432-1033.1993.tb17622.x; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	63	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29776	29785		10.1074/jbc.273.45.29776	http://dx.doi.org/10.1074/jbc.273.45.29776			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792692	hybrid			2022-12-25	WOS:000076798300069
J	Muise-Helmericks, RC; Grimes, HL; Bellacosa, A; Malstrom, SE; Tsichlis, PN; Rosen, N				Muise-Helmericks, RC; Grimes, HL; Bellacosa, A; Malstrom, SE; Tsichlis, PN; Rosen, N			Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase Akt-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; INITIATION-FACTOR 4E; EPITHELIAL-CELL LINE; PROTEIN-KINASE; GROWTH-FACTOR; GENE-EXPRESSION; MESSENGER-RNA; HERBIMYCIN-A; TRANSLATION INITIATION; SIGNAL-TRANSDUCTION	Cyclin D expression is regulated by growth factors and is necessary for the induction of mitogenesis. Herbimycin A, a drug that binds to Hsp90, induces the destruction of tyrosine kinases and causes the down-regulation of cyclin D and an Rb-dependent growth arrest in the G(1) phase of the cell cycle. We find that the induction of D cyclin expression by serum and its repression by herbimycin A are regulated at the level of mRNA translation. Induction of cyclin D by serum occurs prior to the induction of its mRNA and does not require transcription. Herbimycin A repression is characterized by a decrease in the synthetic rate of D-cyclins prior to changes in mRNA expression and in the absence of changes in the half-life of the protein, This effect on D-cyclin translation is mediated via a phosphatidylinositol 3-kinase (PI 3-kinase)-dependent pathway. PI 3-kinase inhibitors such as wortmannin and LY294002, and rapamycin, an inhibitor of FRAP/TOR, cause a decline in the level of D-cyclins, whereas inhibitors of mitogen-activated protein kinase kinase and farnesyltransferase do not. Cells expressing the activated, myristoylated form of Akt kinase, a target of PI 3-kinase, are refractory to the effects of herbimycin A or serum starvation on D-cyclin expression. These data suggest that serum induction of cyclin D expression results from enhanced translation of its mRNA and that this results from activation of a pathway that is dependent upon PI 3-kinase and Akt kinase.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Fox Chase Cancer Center	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Rosen, Neal/ABF-2677-2020	Grimes, H. Leighton/0000-0001-8162-6758	NCI NIH HHS [P50CA68425-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Altucci L, 1996, ONCOGENE, V12, P2315; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1993, ONCOGENE, V8, P745; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deguchi A, 1996, J BIOCHEM-TOKYO, V120, P1118; delPeso L, 1997, SCIENCE, V278, P687; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAN EKH, 1995, ONCOGENE, V10, P953; HAWLEY RG, 1994, GENE THER, V1, P136; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JIANG W, 1993, ONCOGENE, V8, P3447; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIPPEL A, 1997, MOL CELL BIOL, V17, P338; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MANNIATIS T, 1994, MOL CLONING LAB MANU; MATAKEYAMA M, 1994, GENE DEV, V8, P1759; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SOULE HD, 1990, CANCER RES, V50, P6075; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TAM SW, 1994, ONCOGENE, V9, P2663; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TOMIDA A, 1997, ONCOGENE, P2699; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	74	435	449	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29864	29872		10.1074/jbc.273.45.29864	http://dx.doi.org/10.1074/jbc.273.45.29864			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792703	hybrid			2022-12-25	WOS:000076798300080
J	Zhao, ZJ; Zhao, RX				Zhao, ZJ; Zhao, RX			Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; TERMINAL SH2 DOMAIN; SIGNAL-TRANSDUCTION; STRUCTURAL PROTEIN; CELLS; RECEPTORS; INSULIN; MYELIN; FAMILY; KINASE	Overexpression of a catalytically inactive mutant of tyrosine phosphatase SHP-2 in 293 cells resulted in hyperphosphorylation of a glycoprotein specifically associated with the enzyme. The protein has been purified to near homogeneity, Based on the amino acid sequences of peptides obtained from the protein, a full-length cDNA was isolated. The cDNA encodes a protein with a single transmembrane segment and a signal sequence. The extracellular portion of the protein contains a single immunoglobulin-like domain displaying 46% sequence identity to that of myelin P0, a major structural protein of peripheral myelin. The intracellular segment of the protein shows no significant sequence identity to any known protein except for two immunoreceptor tyrosine-based inhibitory motifs. We name the protein PZR for protein zero related. Transfection of the PZR cDNA in Jurkat cells gave rise to a protein of expected molecular size. Stimulation of cells with pervanadate resulted in tyrosine phosphorylation of PZR and a near-stoichiometric association of PZR with SHP-2. Northern blotting analyses revealed that PZR is widely expressed in human tissues and is particularly abundant in heart, placenta, kidney, and pancreas. As a binding protein and a putative substrate of SHP-2, PZR protein may have an important role in cell signaling.	Vanderbilt Univ, Ctr Canc, Dept Med, Div Hematol, Nashville, TN 37232 USA	Vanderbilt University	Zhao, ZJ (corresponding author), Vanderbilt Univ, Ctr Canc, Dept Med, Div Hematol, 547 MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.	joe.zhao@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57393] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Choe SY, 1996, NEURON, V17, P363, DOI 10.1016/S0896-6273(00)80167-1; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; FILBIN MT, 1992, BIOESSAYS, V14, P541, DOI 10.1002/bies.950140808; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Frearson JA, 1996, EUR J IMMUNOL, V26, P1539, DOI 10.1002/eji.1830260720; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HARDING AE, 1995, BRAIN, V118, P809, DOI 10.1093/brain/118.3.809; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; Jiao HY, 1997, EXP HEMATOL, V25, P592; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Ulyanova T, 1997, IMMUNOL RES, V16, P101, DOI 10.1007/BF02786326; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vely F, 1997, J IMMUNOL, V159, P2075; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO Z, 1995, ADV PROT PHOSPHATASE, V9, P297; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	43	66	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 6	1998	273	45					29367	29372		10.1074/jbc.273.45.29367	http://dx.doi.org/10.1074/jbc.273.45.29367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	135JJ	9792637	hybrid			2022-12-25	WOS:000076798300014
J	Martin, F; Pintor, J; Rovira, JM; Ripoll, C; Miras-Portugal, MT; Soria, B				Martin, F; Pintor, J; Rovira, JM; Ripoll, C; Miras-Portugal, MT; Soria, B			Intracellular diadenosine polyphosphates: a novel second messenger in stimulus-secretion coupling	FASEB JOURNAL			English	Article						K-ATP channel; pancreatic beta-cell; stimulus-secretion coupling; diabetes	MOUSE PANCREATIC-ISLETS; BETA-CELLS; CHROMAFFIN CELLS; INSULIN RELEASE; GLUCOSE; MECHANISM; ATP; OSCILLATIONS; INHIBITION; CHANNELS	In pancreatic beta-cells, stimulatory glucose concentrations increase cytosolic diadenosine polyphosphates ([Ap(n)A](i)) to concentrations sufficient to block ATP-sensitive K+ (K-ATP) channels, High-performance liquid chromatography and patch clamp techniques were used to study the metabolic pathways by which pancreatic beta-cells synthesize Ap(n)A and the mechanism through which Ap(n)A inhibit K-ATP channels, Ap(n)A show a glucose- and time-dependent cytosolic concentration increase parallel, though 30-to 50-fold higher, to changes observed in adenine nucleotides, Other fuel secretagogues, leucine and 2-ketoisocaproate, waise [Ap(n)A](i) as efficiently as 22 mM glucose, Blockade of glycolysis or Krebs cycle decreases glucose-induced [Ap(n)A](i). No significant increase in cytosolic Ap(n)A concentrations is induced by nonnutrient secretagogues or nonmetabolizable nutrient secretagogues. Inorganic pyrophosphatase inhibition with sodium fluoride blocks 22 mM glucose-induced [Ap(n)A](i) increase. Ap(n)A inhibition of K-ATP channel resembles that of ATP in efficacy, but shows clear functional differences, Unlike ATP, Ap(4)A does not restore channel activity after rundown. Furthermore, these compounds do not compete with each other for the same site, These features suggest a prominent role for Ap(4)A in beta-cell function, comparable to ATP, We conclude that nutrient metabolism through pyrophosphatase activation is necessary to induce Ap(n)A synthesis, which in turn constitutes a new, ATP-independent, metabolic regulator of K-ATP channel activity.	Miguel Hernandez Univ, Dept Physiol, Alicante 03550, Spain; Miguel Hernandez Univ, Inst Bioengn, Alicante 03550, Spain; Miguel Hernandez Univ, Dept Sci & Technol, Alicante 03550, Spain; Univ Complutense Madrid, Fac Vet, Dept Biochem, Madrid, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Complutense University of Madrid	Soria, B (corresponding author), Miguel Hernandez Univ, Dept Physiol, Campus San Juan,Apdo 18, Alicante 03550, Spain.	bernat.soria@umh.es	, Bernat/AAL-6470-2021; Ripoll, Cristina/F-3324-2016; Miras-Portugal, Maria Teresa/L-7137-2014; Martin, Franz/K-4197-2014	Ripoll, Cristina/0000-0003-0935-8722; Martin, Franz/0000-0002-5745-8704; Pintor, Jesus/0000-0002-9191-7679; Soria, Bernat/0000-0002-2356-0380				AAS M, 1968, BIOCHIM BIOPHYS ACTA, V164, P157, DOI 10.1016/0005-2760(68)90142-2; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BAYKOV AA, 1992, ARCH BIOCHEM BIOPHYS, V294, P238, DOI 10.1016/0003-9861(92)90163-Q; CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GRUMMT F, 1978, P NATL ACAD SCI USA, V75, P371, DOI 10.1073/pnas.75.1.371; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MARTIN F, 1995, DIABETES, V44, P300, DOI 10.2337/diabetes.44.3.300; MCLENNAN AG, 1992, AP A OTHE DINUCLEOTI; OGILVIE A, 1981, ANAL BIOCHEM, V115, P302, DOI 10.1016/0003-2697(81)90009-9; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1991, LIFE SCI, V48, P2317, DOI 10.1016/0024-3205(91)90268-G; RAMOS A, 1995, BBA-PROTEIN STRUCT M, V1253, P103, DOI 10.1016/0167-4838(95)00154-M; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; Yakovenko I. N., 1993, Biokhimiya, V58, P3; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	31	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1499	1506		10.1096/fasebj.12.14.1499	http://dx.doi.org/10.1096/fasebj.12.14.1499			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806759				2022-12-25	WOS:000076749500009
J	Lamarche-Vane, N; Hall, A				Lamarche-Vane, N; Hall, A			CdGAP, a novel proline-rich GTPase-activating protein for Cdc42 and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; BINDING-PROTEIN; SIGNALING PATHWAY; RHO-GTPASES; SH3 DOMAIN; KAPPA-B; FAMILY; YEAST; FILOPODIA	Cdc42 mediates several signaling pathways leading to actin reorganization, transcriptional activation, and cell cycle control. Mutational analysis of Cdc42 has revealed that actin reorganization and transcriptional activation are induced through independent signaling pathways. The Y40C effector mutant of Cdc42 no longer interacts with many of its known target proteins, such as p65(PAK) and WASP, yet this mutant can still induce filopodia formation. To identify Cdc42 targets involved in actin rearrangements, we have screened a yeast two-hybrid cDNA library using the Y40C mutant of Cdc42 as a bait. We report here the identification of a novel serine- and proline-rich GTPase-activating protein, CdGAP, which is active in vitro on both Cdc42 and Pac, Microinjection of CdGAP into serum starved fibroblasts inhibits both platelet-derived growth factor-induced lamellipodia and bradykinin-induced filopodia mediated by Pac and Cdc42, respectively. CdGAP does not show in vitro activity toward Rho, and it has no effect on lysophosphatidic acid-induced stress fiber formation when microinjected into fibroblasts. The carboxyl terminus of CdGAP reveals potential protein kinase C phosphorylation sites and five SH3 binding motifs. Thus, CdGAP is a novel GAP that is likely to participate in Cdc42- and Pac-induced signaling pathways leading to actin reorganization.	UCL, Med Res Council Lab Mol Cell Biol, CRC, Signal Transduct Grp, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nlamarche@medcor.mcgill.ca						AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHEN WN, 1994, J BIOL CHEM, V269, P820; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YAMAMOTO K, 1993, J BIOL CHEM, V268, P17750; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	42	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29172	29177		10.1074/jbc.273.44.29172	http://dx.doi.org/10.1074/jbc.273.44.29172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786927	hybrid			2022-12-25	WOS:000076691800088
J	Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D				Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D			P21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase PKB, mediated signaling pathways in T lymphocytes	ONCOGENE			English	Article						p21ras; Akt/PKB; signalling pathways; T cells	CELL ANTIGEN RECEPTOR; RAS EFFECTOR PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; NEGATIVE SELECTION; REGULATED KINASE-2; PROTEIN-KINASE; ACTIVATION; DIFFERENTIATION; TRANSFORMATION; P21(RAS)	p21ras is activated by the T cell antigen receptor (TCR) and then co-ordinates important signaling pathways for T lymphocyte activation. Effector pathways for this guanine nucleotide binding protein in T cells are mediated by the serine/threonine kinase Raf-l and the Ras-related GTPase Rac-1. In fibroblasts, an important effector for the Ras oncogene is Phosphatidylinositol 3-kinase (PtdIns 3-kinase). Activation of this lipid kinase is able to induce critical Rac-1 signaling pathways and can couple p21ras to cell survival mechanisms via the serine/threonine kinase Akt/PKB, The role of PtdIns 3-kinase in Ras signaling in T cells has not been explored. In the present study, we examined the ability of PtdIns 3-kinase to initiate the Rac-1 signaling pathways important for T cell activation. We also examined the possibility that Akt/PKB is regulated by Ras signaling pathways in T lymphocytes. The results show that Ras can initiate a Rac-1 mediated pathway that regulates the transcriptional function of AP-1 complexes. PtdIns 3-kinase signals cannot mimic p21ras and induce the Rac mediated responses of AP-1 transcriptional activation. Moreover, neither TCR or Ras activation of AP-I is dependent on PtdIns 3-kinase. PKB is activated in response to triggering of the T cell antigen receptor; PtdIns 3-kinase activity is both required and sufficient for this TCR response. In contrast, p21ras signals are unable to induce Akt/PKB activity in T cell nor is Ras function required for Akt/PKB activation in response to the TCR. The present data thus highlight that PtdIns 3-kinase and Akt/PKB are not universal Ras effector molecules. Ras can initiate Rac-1 regulated signaling pathways in the context of T cell antigen receptor function independently of PtdIns 3-kinase activity.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England; Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England	Cancer Research UK; University of London; University College London	Genot, E (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Immunol, Du Cane Rd, London W12 0NN, England.		Genot, Elisabeth/G-8031-2014; Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIAN.P, 1997, CELL, V89; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; YAN MH, 1994, NATURE, V372, P798	30	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1731	1738		10.1038/sj.onc.1202101	http://dx.doi.org/10.1038/sj.onc.1202101			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796702				2022-12-25	WOS:000076200100011
J	Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L				Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L			Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer	ONCOGENE			English	Article						SCLC chromosome 10; LOH; tumor suppressor	PROSTATE-CANCER; HOMOZYGOUS DELETION; HUMAN GLIOBLASTOMAS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; CARCINOMA; PROTEIN; MXI1; LOCALIZATION	Recent cytogenetic studies indicated that loss of the long arm of chromosome 10 is a frequent event in small cell lung cancer (SCLC) and that a common region of the deletion is at 10q24-qter, which suggests the presence of a tumor-suppressor gene there. To map precise tumor-suppressor loci on the chromosome arm for further positional cloning efforts, we tested 46 primary SCLCs using microsatellite analysis, By analysing 11 highly polymorphic microsatellite markers located in 10q23-q26, we found that at least 78% (36/46) of the tumors exhibited loss of heterozygosity (LOH) at 10q with at least two distinct minimally deleted regions, LOH at one region (10q24) was found in at least 74% (32/43) of informative cases with a minimally deleted region between D10S198 and D10S192 (about 2 cM); LOH at another region (10q24-q25) was observed in at least 66% (29/44) of informative tumors with a minimally deleted region between D10S221 and D10S587 (about 11 cM), LOH at both regions or across both regions was observed in at least 52% (24/46) of the tumors tested, However, no mutations or homozygous deletions were found in the coding region of MXI1, a candidate tumor suppressor gene at 10q24-q25, in a panel of SCLC cell lines. Our data demonstrate that at least two tumor-suppressor loci exist on 10q and that they may play an important role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [CA 16672, CA 70907, U19 CA 68437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437, P30CA016672, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; AYER DE, 1993, CELL, V72, P1; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HOSOE S, 1994, CANCER RES, V54, P1787; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MERLO A, 1994, CANCER RES, V54, P2322; MILLER CW, 1992, CANCER RES, V52, P1695; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORI N, 1990, ONCOGENE, V5, P1713; MORITA R, 1991, CANCER RES, V51, P5817; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; RIED T, 1994, CANCER RES, V54, P1801; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	33	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1749	1753		10.1038/sj.onc.1202073	http://dx.doi.org/10.1038/sj.onc.1202073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796705				2022-12-25	WOS:000076200100014
